[{"internal_id": 50113196, "Award ID": "UM1HL134590", "Award Amount": 31061232.12, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-22", "CFDA Number": "93.310", "Description": "HOUSEHOLD AIR POLLUTION AND HEALTH: A MULTI-COUNTRY LPG INTERVENTION TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_UM1HL134590_7529"}, {"internal_id": 50113190, "Award ID": "UM1HL119073", "Award Amount": 4723243.75, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-29", "CFDA Number": "93.837", "Description": "PROOF OF PRINCIPLE EVALUATION OF IV GALLIUM NITRATE IN PATIENTS WITH CF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_UM1HL119073_7529"}, {"internal_id": 50113186, "Award ID": "UM1HL116886", "Award Amount": 4714263.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-21", "CFDA Number": "93.838", "Description": "SORAFENIB FOR HEPATOPULMONARY SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_UM1HL116886_7529"}, {"internal_id": 50113178, "Award ID": "UM1HL112958", "Award Amount": 3118620.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-07-30", "CFDA Number": "93.838", "Description": "PROSTAGLANDIN INHIBITION FOR EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce6cc294-968c-0136-a2e3-f34319ce4753-C", "generated_internal_id": "ASST_NON_UM1HL112958_7529"}, {"internal_id": 83103969, "Award ID": "UH3HL141797", "Award Amount": 5175444.5, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-08-14", "CFDA Number": "93.350", "Description": "LUNG-ON-A-CHIP DISEASE MODELS FOR EFFICACY TESTING (COVID-19 COMPETITIVE REVISION)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": 928351.0, "Infrastructure Obligations": null, "recipient_id": "3c727a6e-aeb7-b7bb-b622-36f566d604a5-C", "generated_internal_id": "ASST_NON_UH3HL141797_7529"}, {"internal_id": 82469189, "Award ID": "UH3HL141736", "Award Amount": 8338150.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-07-29", "CFDA Number": "93.837", "Description": "1/2 PROSPECT: PRONE AND OSCILLATION PEDIATRIC CLINICAL TRIAL (CCC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_UH3HL141736_7529"}, {"internal_id": 110464736, "Award ID": "UH3HL141722", "Award Amount": 8058480.48, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-09-18", "CFDA Number": "93.837", "Description": "1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_UH3HL141722_7529"}, {"internal_id": 96201493, "Award ID": "UH3HL140177", "Award Amount": 7276223.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-03-20", "CFDA Number": "93.837", "Description": "1/2: AN ANESTHESIA-CENTERED BUNDLE TO REDUCE POSTOPERATIVE PULMONARY COMPLICATIONS: THE PRIME-AIR STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_UH3HL140177_7529"}, {"internal_id": 68564900, "Award ID": "UH3HL137872", "Award Amount": 1702603.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-09-07", "CFDA Number": "93.837", "Description": "1/2 HYDROCORTISONE FOR BPD RESPIRATORY AND DEVELOPMENTAL OUTCOMES STUDY (HYBRID OUTCOMES STUDY): CLINICAL COORDINATING CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_UH3HL137872_7529"}, {"internal_id": 50111386, "Award ID": "UH3HL125119", "Award Amount": 3092822.38, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-07-28", "CFDA Number": "93.837", "Description": "PREVENTION OF SEVERE ACUTE RESPIRATORY FAILURE IN PATIENTS WITH PROOFCHECK - AN E", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_UH3HL125119_7529"}, {"internal_id": 50111384, "Award ID": "UH3HL123886", "Award Amount": 2275408.7, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-01-23", "CFDA Number": "93.837", "Description": "MIR-29 MIMICRY AS A THERAPY FOR PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_UH3HL123886_7529"}, {"internal_id": 50111383, "Award ID": "UH3HL123876", "Award Amount": 3686146.91, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-01-31", "CFDA Number": "93.837", "Description": "PRE-CLINICAL DEVELOPMENT OF A NOVEL ANTI-YKL-40 BIOLOGIC TO TREAT SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_UH3HL123876_7529"}, {"internal_id": 50111382, "Award ID": "UH3HL123827", "Award Amount": 3232814.84, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-05-02", "CFDA Number": "93.837", "Description": "TARGETING RESITIN AND RELM-BETA TO TREAT PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_UH3HL123827_7529"}, {"internal_id": 50111381, "Award ID": "UH3HL123816", "Award Amount": 1042966.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-01-23", "CFDA Number": "93.838", "Description": "PRECLINICAL DEVELOPMENT OF MYOSOLVINS, A NEW CLASS OF MEDICINE FOR ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_UH3HL123816_7529"}, {"internal_id": 50111380, "Award ID": "UH3HL123645", "Award Amount": 2571202.84, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-12-16", "CFDA Number": "93.837", "Description": "SYNTHESIS OF EFFECTIVE AND SAFE MUCOLYTICS FOR PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_UH3HL123645_7529"}, {"internal_id": 50111379, "Award ID": "UH3HL123610", "Award Amount": 3886105.32, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-01-23", "CFDA Number": "93.837", "Description": "THERAPEUTIC TARGETING OF CAROTID BODY CHEMOREFLEX FOR SLEEP DISORDERED BREATHING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_UH3HL123610_7529"}, {"internal_id": 50111378, "Award ID": "UH3HL123502", "Award Amount": 3475211.56, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-11-09", "CFDA Number": "93.837", "Description": "A NEW GENUS OF UBIQUITIN-BASED ANTI-INFLAMMATORIES FOR COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_UH3HL123502_7529"}, {"internal_id": 50111377, "Award ID": "UH3HL123442", "Award Amount": 3283424.53, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.837", "Description": "MUC5B, A NOVEL THERAPEUTIC TARGET FOR IDIOPATHIC PULMONARY FIBROSIS (IPF)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_UH3HL123442_7529"}, {"internal_id": 50111376, "Award ID": "UH3HL123429", "Award Amount": 3349617.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-12-12", "CFDA Number": "93.838", "Description": "PRECLINICAL DEVELOPMENT OF AN ANTI-MUCUS DRUG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_UH3HL123429_7529"}, {"internal_id": 50111375, "Award ID": "UH3HL123423", "Award Amount": 3072783.84, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-13", "CFDA Number": "93.837", "Description": "TREATMENT OF PULMONARY FIBROSIS WITH INHIBITORS OF INTEGRIN ALPHAVBETA1.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_UH3HL123423_7529"}, {"internal_id": 50111241, "Award ID": "UH2HL123610", "Award Amount": 4690158.86, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-09-22", "CFDA Number": "93.837", "Description": "THERAPEUTIC TARGETING OF CAROTID BODY CHEMOREFLEX FOR SLEEP DISORDERED BREATHING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_UH2HL123610_7529"}, {"internal_id": 50111239, "Award ID": "UH2HL123442", "Award Amount": 4514721.0, "Award Type": null, "Base Obligation Date": "2014-09-22", "CFDA Number": "93.838", "Description": "MUC5B, A NOVEL THERAPEUTIC TARGET FOR IDIOPATHIC PULMONARY FIBROSIS (IPF)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_UH2HL123442_7529"}, {"internal_id": 100873768, "Award ID": "UG3HL152323", "Award Amount": 1483792.2, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-07-06", "CFDA Number": "93.837", "Description": "ALPHA-1 ANTITRYPSIN DISEASE COHORT: LONGITUDINAL BIOMARKER  STUDY OF DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_UG3HL152323_7529"}, {"internal_id": 100874228, "Award ID": "UG3HL151865", "Award Amount": 1676934.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-07-17", "CFDA Number": "93.837", "Description": "PRECLINICAL PULMONARY FIBROSIS, AN OPPORTUNE RARE DISEASE COHORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_UG3HL151865_7529"}, {"internal_id": 110464597, "Award ID": "UG3HL147016", "Award Amount": 1343356.55, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-09-14", "CFDA Number": "93.837", "Description": "1/2: AZITHROMYCIN THERAPY IN PRESCHOOLERS WITH A SEVERE WHEEZING EPISODE DIAGNOSED AT THE EMERGENCY DEPARTMENT (AZ-SWED)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_UG3HL147016_7529"}, {"internal_id": 110463769, "Award ID": "UG3HL147011", "Award Amount": 1277244.4, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-09-14", "CFDA Number": "93.837", "Description": "1/2 GANCICLOVIR TO PREVENT REACTIVATION OF CYTOMEGALOVIRUS IN PATIENTS WITH ACUTE RESPIRATORY FAILURE AND SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_UG3HL147011_7529"}, {"internal_id": 86315916, "Award ID": "UG3HL145266", "Award Amount": 923924.8, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-09-20", "CFDA Number": "93.837", "Description": "1/2 PROSPECTIVE TREATMENT EFFICACY IN IPF USLNG GENOTYPE FOR NAC SELECTION (PRECISIONS) TRIAL AND MOLECULAR ENDOPHENOTYPING IN IDIOPATHIC PULMONARY FIBROSIS AND INTERSTITIAL LUNG DISEASES STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_UG3HL145266_7529"}, {"internal_id": 50111008, "Award ID": "UG3HL141797", "Award Amount": 2821656.5, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-24", "CFDA Number": "93.350", "Description": "LUNG-ON-A-CHIP DISEASE MODELS FOR EFFICACY TESTING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c727a6e-aeb7-b7bb-b622-36f566d604a5-C", "generated_internal_id": "ASST_NON_UG3HL141797_7529"}, {"internal_id": 66800464, "Award ID": "UG3HL141736", "Award Amount": 1290681.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-06-11", "CFDA Number": "93.838", "Description": "1/2 PROSPECT: PRONE AND OSCILLATION PEDIATRIC CLINICAL TRIAL (CCC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_UG3HL141736_7529"}, {"internal_id": 86318517, "Award ID": "UG3HL141722", "Award Amount": 1141694.52, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-09-23", "CFDA Number": "93.837", "Description": "1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_UG3HL141722_7529"}, {"internal_id": 78990699, "Award ID": "UG3HL140177", "Award Amount": 485924.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-03-18", "CFDA Number": "93.838", "Description": "1/2: AN ANESTHESIA-CENTERED BUNDLE TO REDUCE POSTOPERATIVE PULMONARY COMPLICATIONS: THE PRIME-AIR STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_UG3HL140177_7529"}, {"internal_id": 50111006, "Award ID": "UG3HL137872", "Award Amount": 278072.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-01", "CFDA Number": "93.838", "Description": "1/2 HYDROCORTISONE FOR BPD RESPIRATORY AND DEVELOPMENTAL OUTCOMES STUDY (HYBRID OUTCOMES STUDY): CLINICAL COORDINATING CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_UG3HL137872_7529"}, {"internal_id": 50110935, "Award ID": "UG1HL139126", "Award Amount": 2436127.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "CLINICAL CENTERS FOR THE NHLBI'S PRECISION INTERVENTIONS FOR SEVERE AND/OR EXACERBATION PRONE ASTHMA (PRECISE) NETWORK (UG1)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_UG1HL139126_7529"}, {"internal_id": 50110934, "Award ID": "UG1HL139125", "Award Amount": 2485530.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "CHICAGO METROPOLITAN ASTHMA CONSORTIUM FOR SEVERE / EXACERBATION-PRONE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_UG1HL139125_7529"}, {"internal_id": 50110933, "Award ID": "UG1HL139124", "Award Amount": 2792447.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "PATINA - PRECISION ADMINISTRATION OF TREATMENT IN NEUTROPHILIC SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_UG1HL139124_7529"}, {"internal_id": 50110932, "Award ID": "UG1HL139123", "Award Amount": 2271973.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "PRECISION INTERVENTIONS FOR SEVERE AND/OR EXACERBATION PRONE ASTHMA (PRECISE)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_UG1HL139123_7529"}, {"internal_id": 50110931, "Award ID": "UG1HL139119", "Award Amount": 2238273.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "WASHINGTON UNIVERSITY'S PRECISION BIOLOGIC INTERVENTIONS FOR SEVERE EXACERBATION PRONE ASTHMA (PRECISE) CLINICAL CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1a1108fb-0099-a708-6def-aa6d101c8ba8-C", "generated_internal_id": "ASST_NON_UG1HL139119_7529"}, {"internal_id": 50110930, "Award ID": "UG1HL139118", "Award Amount": 2224084.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "THE GREAT LAKES PRECISE PARTNERSHIP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_UG1HL139118_7529"}, {"internal_id": 50110929, "Award ID": "UG1HL139117", "Award Amount": 2192315.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "SAN DIEGO TEAM ASTHMA MANAGEMENT USING PHENOTYPES (STAMP)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_UG1HL139117_7529"}, {"internal_id": 50110928, "Award ID": "UG1HL139106", "Award Amount": 2200190.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "SEQUENTIAL, MULTIPLE ASSIGNMENT, RANDOMIZED TRIAL IN SEVERE ASTHMA PROTOCOL (SMART-SA)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_UG1HL139106_7529"}, {"internal_id": 50110927, "Award ID": "UG1HL139098", "Award Amount": 2374766.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "TYPE-2 OR NOT TYPE-2:  THAT IS THE (THERAPEUTIC) QUESTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_UG1HL139098_7529"}, {"internal_id": 50110926, "Award ID": "UG1HL139054", "Award Amount": 2423244.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "PRECISE NETWORK:  ADAPT (ADVANCING SEVERE ASTHMA PRECISION THERAPY)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_UG1HL139054_7529"}, {"internal_id": 68168238, "Award ID": "U54HL147127", "Award Amount": 20542715.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-08-29", "CFDA Number": "93.837", "Description": "INTEGRATED HEALTH, BEHAVIORAL AND ECONOMIC RESEARCH ON CURRENT AND EMERGING TOBACCO PRODUCTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_U54HL147127_7529"}, {"internal_id": 65893729, "Award ID": "U54HL142012", "Award Amount": 7032244.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-04-30", "CFDA Number": "93.837", "Description": "MOLECULAR AND CELLULAR MECHANISMS OF THE FVIII IMMUNE RESPONSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_U54HL142012_7529"}, {"internal_id": 50106180, "Award ID": "U54HL127672", "Award Amount": 3646479.13, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-09-18", "CFDA Number": "93.350", "Description": "RLDC: MOLECULAR PATHWAY-DRIVEN DIAGNOSTICS & THERAPEUTICS FOR RARE LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_U54HL127672_7529"}, {"internal_id": 68171284, "Award ID": "U54HL120163", "Award Amount": 19221825.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-08-31", "CFDA Number": "93.077", "Description": "AMERICAN HEART ASSOCIATION TOBACCO CENTER FOR REGULATORY SCIENCE (A-TRAC) 2.0", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c475e5b-7872-8474-d55d-1dd730c21b78-C", "generated_internal_id": "ASST_NON_U54HL120163_7529"}, {"internal_id": 50106166, "Award ID": "U54HL096458", "Award Amount": 19952851.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2009-08-05", "CFDA Number": "93.350", "Description": "GENETIC DISORDER OF MUCOCILARY CLEARANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_U54HL096458_7529"}, {"internal_id": 83795522, "Award ID": "U24HL148865", "Award Amount": 5581518.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-08-22", "CFDA Number": "93.837", "Description": "THE LUNGMAP DATA COORDINATION CENTER FOR NEXT GEN SYSTEMS BIOLOGY OF RESPIRATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_U24HL148865_7529"}, {"internal_id": 110464295, "Award ID": "U24HL147018", "Award Amount": 1884513.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-09-14", "CFDA Number": "93.837", "Description": "2/2: AZITHROMYCIN THERAPY IN PRESCHOOLERS WITH A SEVERE WHEEZING EPISODE DIAGNOSED AT THE EMERGENCY DEPARTMENT (AZ-SWED)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_U24HL147018_7529"}, {"internal_id": 110463978, "Award ID": "U24HL147012", "Award Amount": 988258.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-09-16", "CFDA Number": "93.837", "Description": "2/2 GANCICLOVIR TO PREVENT REACTIVATION OF CYTOMEGALOVIRUS IN PATIENTS WITH ACUTE RESPIRATORY FAILURE AND SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "569197a4-81d0-b264-5640-e9db4cf71fd0-C", "generated_internal_id": "ASST_NON_U24HL147012_7529"}, {"internal_id": 86316047, "Award ID": "U24HL145265", "Award Amount": 5597583.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-09-20", "CFDA Number": "93.837", "Description": "PROSPECTIVE TREATMENT EFFICACY IN IPF USLNG GENOTYPE FOR NAC SELECTION (PRECISIONS) TRIAL AND MOLECULAR ENDOPHENOTYPING IN IDIOPATHIC PULMONARY FIBROSIS AND INTERSTITIAL LUNG DISEASES STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_U24HL145265_7529"}, {"internal_id": 67833379, "Award ID": "U24HL141762", "Award Amount": 7167310.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-08-13", "CFDA Number": "93.837", "Description": "SPIROMICS GIC SUPPORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_U24HL141762_7529"}, {"internal_id": 85590277, "Award ID": "U24HL141727", "Award Amount": 1437420.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-09-05", "CFDA Number": "93.837", "Description": "2/1 ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_U24HL141727_7529"}, {"internal_id": 66800866, "Award ID": "U24HL141723", "Award Amount": 4727083.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-06-11", "CFDA Number": "93.837", "Description": "2/2 PROSPECT: PRONE AND OSCILLATION PEDIATRIC CLINICAL TRIAL (DCC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_U24HL141723_7529"}, {"internal_id": 78989573, "Award ID": "U24HL140109", "Award Amount": 2311154.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-03-18", "CFDA Number": "93.837", "Description": "2/2: AN ANESTHESIA-CENTERED BUNDLE TO REDUCE POSTOPERATIVE PULMONARY COMPLICATIONS: THE PRIME-AIR STUDY.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_U24HL140109_7529"}, {"internal_id": 50100906, "Award ID": "U24HL138998", "Award Amount": 43989024.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "DATA, MODELING,AND COORDINATION CENTER FOR PRECISE NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_U24HL138998_7529"}, {"internal_id": 50100903, "Award ID": "U24HL137729", "Award Amount": 1986476.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-01", "CFDA Number": "93.837", "Description": "2/2 HYDROCORTISONE FOR BPD RESPIRATORY AND DEVELOPMENTAL OUTCOMES STUDY (HYBRID OUTCOMES STUDY): DATA COORDINATING CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8303ed9b-9fb4-3e90-ca81-50bbcf400948-C", "generated_internal_id": "ASST_NON_U24HL137729_7529"}, {"internal_id": 50100898, "Award ID": "U24HL135691", "Award Amount": 36513772.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-03", "CFDA Number": "93.837", "Description": "DATA COORDINATING CENTER FOR THE PEDIATRIC HEART NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": 2653648.0, "Infrastructure Obligations": null, "recipient_id": "c1f4bd31-f76a-e52f-fc8e-4a835d6c22c0-C", "generated_internal_id": "ASST_NON_U24HL135691_7529"}, {"internal_id": 50096700, "Award ID": "U10HL109257", "Award Amount": 3796356.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.838", "Description": "SEVERE ASTHMA RESEARCH PROGRAM (SARP)-WASHINGTON UNIVERSITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_U10HL109257_7529"}, {"internal_id": 50096699, "Award ID": "U10HL109250", "Award Amount": 3989387.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.838", "Description": "AIRWAY REDOX BIOCHEMISTRY AS A DETERIMINANT OF ASTHMA PHENOTYPE DURING ADOLESCEN*", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_U10HL109250_7529"}, {"internal_id": 50096698, "Award ID": "U10HL109172", "Award Amount": 4190985.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.838", "Description": "AMSA: ALXR/FBR MEDIATED SIGNALING IN SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_U10HL109172_7529"}, {"internal_id": 50096697, "Award ID": "U10HL109168", "Award Amount": 3856295.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-05", "CFDA Number": "93.838", "Description": "STABILITY OF SEVERE ASTHMA PHENOTYPES: IMPACT OF EXACERBATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_U10HL109168_7529"}, {"internal_id": 50096696, "Award ID": "U10HL109164", "Award Amount": 3756105.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.838", "Description": "LONGITUDINAL PHENOMICS AND GENETICS OF SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "623a4232-bd5e-fb60-cf01-48cd08a5a593-C", "generated_internal_id": "ASST_NON_U10HL109164_7529"}, {"internal_id": 50096695, "Award ID": "U10HL109152", "Award Amount": 3887021.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.838", "Description": "IMPLICATIONS AND STABILITY OF CLINICAL AND MOLECULAR PHENOTYPES OF SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U10HL109152_7529"}, {"internal_id": 50096694, "Award ID": "U10HL109146", "Award Amount": 4022468.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.838", "Description": "CLINICAL AND MOLECULAR PHENOTYPES OF SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_U10HL109146_7529"}, {"internal_id": 50096692, "Award ID": "U10HL109086", "Award Amount": 8084758.42, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-11", "CFDA Number": "93.837", "Description": "CLINICAL COORDINATING CENTER FOR THE SEVERE ASTHMA RESEARCH PROGRAM (SARP)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47ed9961-3300-5ed7-bb62-e5359d99eaf9-C", "generated_internal_id": "ASST_NON_U10HL109086_7529"}, {"internal_id": 50096689, "Award ID": "U10HL098177", "Award Amount": 4671718.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2009-09-18", "CFDA Number": "93.838", "Description": "ASTHMANET:  PHENOTYPIC INFLUENCES ON ASTHMA TREATMENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U10HL098177_7529"}, {"internal_id": 50096688, "Award ID": "U10HL098115", "Award Amount": 57619719.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2009-09-18", "CFDA Number": "93.838", "Description": "DATA COORDINATING CENTER FOR THE NHLBI ASTHMA NETWORK (ASTHMANET)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47ed9961-3300-5ed7-bb62-e5359d99eaf9-C", "generated_internal_id": "ASST_NON_U10HL098115_7529"}, {"internal_id": 50096685, "Award ID": "U10HL098103", "Award Amount": 4419494.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2009-09-21", "CFDA Number": "93.838", "Description": "ATLANTIC COAST CONSORTIUM FOR ASTHMA (ACC-A) ASTHMANET CLINICAL SITE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "623a4232-bd5e-fb60-cf01-48cd08a5a593-C", "generated_internal_id": "ASST_NON_U10HL098103_7529"}, {"internal_id": 50096683, "Award ID": "U10HL098098", "Award Amount": 4508512.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2009-09-21", "CFDA Number": "93.838", "Description": "WASHINGTON UNIVERSITY ASTHMANET", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_U10HL098098_7529"}, {"internal_id": 50096682, "Award ID": "U10HL098096", "Award Amount": 4509189.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2009-09-18", "CFDA Number": "93.838", "Description": "CHICAGOLAND METROPOLITAN ASTHMANET CONSORTIUM (CMAC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_U10HL098096_7529"}, {"internal_id": 83115772, "Award ID": "U01HL148867", "Award Amount": 4265244.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-08-17", "CFDA Number": "93.837", "Description": "DECODING THE CELLULAR NICHES CRITICAL FOR LUNG MATURATION AND PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_U01HL148867_7529"}, {"internal_id": 83797250, "Award ID": "U01HL148861", "Award Amount": 6968245.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-08-21", "CFDA Number": "93.837", "Description": "BIOREPOSITORY FOR INVESTIGATION OF DISEASES OF THE LUNG (BRINDL) - PHASE II", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": 1357803.0, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_U01HL148861_7529"}, {"internal_id": 83797276, "Award ID": "U01HL148860", "Award Amount": 4681935.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-08-29", "CFDA Number": "93.837", "Description": "RESEARCH CENTER FOR SPATIOTEMPORAL LUNG IMAGING AND OMICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "74457bb7-b18d-9762-896e-e575e7a4ed82-C", "generated_internal_id": "ASST_NON_U01HL148860_7529"}, {"internal_id": 83115581, "Award ID": "U01HL148857", "Award Amount": 4429595.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-08-18", "CFDA Number": "93.837", "Description": "MULTI-MODAL CHARACTERIZATION OF THREE HUMAN LUNG NICHES AT THE SINGLE CELL LEVEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_U01HL148857_7529"}, {"internal_id": 83796934, "Award ID": "U01HL148856", "Award Amount": 3589240.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-08-21", "CFDA Number": "93.837", "Description": "LUNGMAP PHASE II - BUILDING A MULTIDIMENSIONAL MAP OF DEVELOPING HUMAN LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_U01HL148856_7529"}, {"internal_id": 81395432, "Award ID": "U01HL148692", "Award Amount": 819692.59, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-06-11", "CFDA Number": "93.370", "Description": "GENERATION OF FUNCTIONAL LUNG STEM CELLS FROM HUMAN IPSCS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_U01HL148692_7529"}, {"internal_id": 81396218, "Award ID": "U01HL146408", "Award Amount": 21041809.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-06-12", "CFDA Number": "93.837", "Description": "THE AMERICAN LUNG ASSOCIATION (ALA) LUNG HEALTH COHORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_U01HL146408_7529"}, {"internal_id": 92603059, "Award ID": "U01HL146002", "Award Amount": 17276351.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-09-23", "CFDA Number": "93.837", "Description": "IMMUNOMETABOLIC PHENOTYPES IN ADULT SEVERE ASTHMA AND DISEASE PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": 434002.0, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_U01HL146002_7529"}, {"internal_id": 76737869, "Award ID": "U01HL145567", "Award Amount": 2833817.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-12-21", "CFDA Number": "93.837", "Description": "NORMAL AGING LUNG CELL ATLAS (NALCA)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_U01HL145567_7529"}, {"internal_id": 76738309, "Award ID": "U01HL145561", "Award Amount": 2639923.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-12-27", "CFDA Number": "93.837", "Description": "THE HUMAN DISTAL AIRWAY AGING PROJECT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_U01HL145561_7529"}, {"internal_id": 76738122, "Award ID": "U01HL145560", "Award Amount": 2641513.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-12-21", "CFDA Number": "93.837", "Description": "INTEGRATIVE, AGE-RELATED CHANGES IN GENOME AND EPIGENOME IN HUMAN LUNG IN RELATION TO SMOKING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_U01HL145560_7529"}, {"internal_id": 85589510, "Award ID": "U01HL145550", "Award Amount": 2354168.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-09-18", "CFDA Number": "93.866", "Description": "MAPPING AGE-RELATED CHANGES IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_U01HL145550_7529"}, {"internal_id": 76738090, "Award ID": "U01HL145547", "Award Amount": 2574812.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-12-21", "CFDA Number": "93.837", "Description": "IMMUNOBIOLOGY AND ALVEOLAR PHYSIOLOGY OF THE AGING LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_U01HL145547_7529"}, {"internal_id": 81395136, "Award ID": "U01HL145435", "Award Amount": 7379332.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-06-12", "CFDA Number": "93.837", "Description": "LONG TERM FOLLOW UP OF THE LUNG TRANSPLANT OUTCOMES GROUP COHORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_U01HL145435_7529"}, {"internal_id": 67834056, "Award ID": "U01HL143507", "Award Amount": 1041050.98, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-08-15", "CFDA Number": "93.837", "Description": "EDUCATIONAL STRATEGIES TO PROMOTE POST-EXTUBATION NON-INVASIVE VENTILATION IN PATIENTS WITH ACUTE RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U01HL143507_7529"}, {"internal_id": 67832533, "Award ID": "U01HL143505", "Award Amount": 1072361.17, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-08-15", "CFDA Number": "93.837", "Description": "IMPLEMENTATION OF COMPUTERIZED CLINICAL SUPPORT FOR MECHANICAL VENTILATION OF PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2ec62179-269e-eca7-af13-c17efa73189f-C", "generated_internal_id": "ASST_NON_U01HL143505_7529"}, {"internal_id": 67314368, "Award ID": "U01HL143475", "Award Amount": 1182304.97, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-07-18", "CFDA Number": "93.837", "Description": "PREPARING FOR A HYBRID TRIAL OF PULSE OXIMETRY DE-IMPLEMENTATION IN STABLE INFANTS WITH BRONCHIOLITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_U01HL143475_7529"}, {"internal_id": 67833914, "Award ID": "U01HL143453", "Award Amount": 832128.02, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-08-06", "CFDA Number": "93.837", "Description": "DIGITAL IMPLEMENTATION INTERVENTION TRIALS IN ACUTE LUNG CARE (DIGITAL-C) NETWORK PLANNING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_U01HL143453_7529"}, {"internal_id": 66995383, "Award ID": "U01HL142099", "Award Amount": 4773705.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-06-25", "CFDA Number": "93.837", "Description": "A NURSE-LED INTERVENTION TO EXTEND THE HIV TREATMENT CASCADE FOR CARDIOVASCULAR DISEASE PREVENTION (EXTRA-CVD)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": 822421.0, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_U01HL142099_7529"}, {"internal_id": 66487082, "Award ID": "U01HL139466", "Award Amount": 3925153.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-05-30", "CFDA Number": "93.837", "Description": "A MULTI-SCALE COMPUTATIONAL MODEL OF THE EXTRACELLULAR MATRIX OF THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6bb5676d-1119-4abb-3c6a-1bdba277e0cd-C", "generated_internal_id": "ASST_NON_U01HL139466_7529"}, {"internal_id": 50095242, "Award ID": "U01HL138689", "Award Amount": 8234396.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "AN ASTHMA COLLABORATION TO REDUCE CHILDHOOD ASTHMA DISPARITIES ON THE NAVAJO NATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_U01HL138689_7529"}, {"internal_id": 50095241, "Award ID": "U01HL138687", "Award Amount": 7518277.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "WEST PHILADELPHIA ASTHMA CARE IMPLEMENTATION PLAN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_U01HL138687_7529"}, {"internal_id": 50095240, "Award ID": "U01HL138682", "Award Amount": 5801749.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "RVA BREATHES: A RICHMOND CITY COLLABORATION TO REDUCE PEDIATRIC ASTHMA DISPARITIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_U01HL138682_7529"}, {"internal_id": 50095239, "Award ID": "U01HL138677", "Award Amount": 7999307.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "RHODE ISLAND ASTHMA INTEGRATED RESPONSE PROGRAM (RI-AIR)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f21f887-ca03-f1f2-6e30-1c1498f78b9e-C", "generated_internal_id": "ASST_NON_U01HL138677_7529"}, {"internal_id": 69725816, "Award ID": "U01HL138626", "Award Amount": 9988564.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-09-21", "CFDA Number": "93.837", "Description": "NATURAL HISTORY OF VIRAL INDUCED AIRWAY DYSFUNCTION AND ASTHMA IN MINORITY CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_U01HL138626_7529"}, {"internal_id": 50095233, "Award ID": "U01HL137880", "Award Amount": 27863205.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-14", "CFDA Number": "93.837", "Description": "SPIROMICS II: BIOLOGICAL UNDERPINNINGS OF COPD HETEROGENEITY AND PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_U01HL137880_7529"}, {"internal_id": 50095232, "Award ID": "U01HL137183", "Award Amount": 1817807.45, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-04-15", "CFDA Number": "93.837", "Description": "UNBIASED ANALYSIS OF GENOMIC CORRELATES OF GENE EXPRESSION IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "427ea0fd-a29e-756b-4973-911cb119bc8d-C", "generated_internal_id": "ASST_NON_U01HL137183_7529"}, {"internal_id": 50095231, "Award ID": "U01HL137182", "Award Amount": 1628003.58, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-04-10", "CFDA Number": "93.837", "Description": "SCALABLE AND TRANSLATIONAL ANALYSIS TOOLS ON THE CLOUD FOR DEEP INTEGRATIVE OMICS DATA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_U01HL137182_7529"}, {"internal_id": 50095230, "Award ID": "U01HL137181", "Award Amount": 1845135.68, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-04-07", "CFDA Number": "93.310", "Description": "HIGH-PERFORMANCE MIXED MODEL TOOLSET FOR INTEGRATIVE OMICS ANALYSIS OF BIG DATA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_U01HL137181_7529"}, {"internal_id": 50095229, "Award ID": "U01HL137162", "Award Amount": 1576674.24, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-04-20", "CFDA Number": "93.837", "Description": "FROM GENE REGIONS TO WHOLE CHROMOSOMES: SCALING UP ASSOCIATION-FINDING FOR DISEASE AND OMICS OUTCOMES IN TOPMED", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_U01HL137162_7529"}, {"internal_id": 50095228, "Award ID": "U01HL137159", "Award Amount": 1809411.53, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-04-17", "CFDA Number": "93.837", "Description": "SYSTEMS LEVEL CAUSAL DISCOVERY IN HETEROGENEOUS TOPMED DATA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U01HL137159_7529"}, {"internal_id": 50095224, "Award ID": "U01HL135842", "Award Amount": 2337095.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-03-08", "CFDA Number": "93.837", "Description": "IMAGE-BASED MULTI-SCALE MODELING FRAMEWORK OF THE CARDIOPULMONARY SYSTEM: LONGITUDINAL CALIBRATION AND ASSESSMENT OF THERAPIES IN PEDIATRIC PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_U01HL135842_7529"}, {"internal_id": 50095222, "Award ID": "U01HL134766", "Award Amount": 8051078.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-20", "CFDA Number": "93.837", "Description": "EPITHELIAL STEM/PROGENITOR CELLS AS REPAIR AGENTS IN DIFFUSE ALVEOLAR DAMAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_U01HL134766_7529"}, {"internal_id": 50095220, "Award ID": "U01HL134760", "Award Amount": 8498041.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-20", "CFDA Number": "93.837", "Description": "MODELING, PATHOGENESIS AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_U01HL134760_7529"}, {"internal_id": 50095219, "Award ID": "U01HL134745", "Award Amount": 8334384.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-22", "CFDA Number": "93.837", "Description": "EDITING ALVEOLAR PROGENITOR CELLS FOR CORRECTION OF MONOGENIC DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_U01HL134745_7529"}, {"internal_id": 50095204, "Award ID": "U01HL133708", "Award Amount": 3747774.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-24", "CFDA Number": "93.837", "Description": "PREMATURITY-RELATED VENTILATORY CONTROL: LEADERSHIP DATA AND COORDINATION CENTER (LDCC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_U01HL133708_7529"}, {"internal_id": 50095203, "Award ID": "U01HL133704", "Award Amount": 2610982.99, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-26", "CFDA Number": "93.837", "Description": "INTEGRATED ANALYSIS OF AUTONOMIC BIOMARKERS IN PREMATURITY-RELATED VENTILATORY CONTROL: DETERMINATION OF NEURORESPIRATORY MATURATION AND PREDICTORS O", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_U01HL133704_7529"}, {"internal_id": 50095202, "Award ID": "U01HL133700", "Award Amount": 2384404.08, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-01", "CFDA Number": "93.837", "Description": "PHYSIOLOGIC BIOMARKERS PREDICTING VENTILATORY INSTABILITY AND HYPOXEMIA IN PREMATURE INFANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_U01HL133700_7529"}, {"internal_id": 50095201, "Award ID": "U01HL133689", "Award Amount": 2676936.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.837", "Description": "OXYGENATION INSTABILITY AND MATURATION OF CONTROL OF BREATHING IN EVOLVING BPD.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_U01HL133689_7529"}, {"internal_id": 50095200, "Award ID": "U01HL133643", "Award Amount": 2603383.51, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-25", "CFDA Number": "93.837", "Description": "HIBBS -ASSOCIATION BETWEEN INTERMITTENT HYPOXIA AND LATER RESPIRATORY MORBIDITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_U01HL133643_7529"}, {"internal_id": 50095199, "Award ID": "U01HL133536", "Award Amount": 2437936.46, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-24", "CFDA Number": "93.837", "Description": "PRE-VENT APNEA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_U01HL133536_7529"}, {"internal_id": 50095195, "Award ID": "U01HL133232", "Award Amount": 3783083.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-25", "CFDA Number": "93.837", "Description": "AUTOANTIBODY-TARGETED THERAPY FOR ACUTE EXACERBATIONS OF IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_U01HL133232_7529"}, {"internal_id": 50095190, "Award ID": "U01HL131755", "Award Amount": 3606817.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-20", "CFDA Number": "93.837", "Description": "MULTICENTER INTERVENTIONAL LYMPHANGIOLEIOMYOMATOSIS EARLY DISEASE TRIAL (MILED)-CCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_U01HL131755_7529"}, {"internal_id": 50095186, "Award ID": "U01HL131529", "Award Amount": 1497161.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-20", "CFDA Number": "93.837", "Description": "MULTICENTER INTERVENTIONAL LYMPHANGIOLEIOMYOMATOSIS EARLY DISEASE TRIAL (MILED) - DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ceec5ef7-d6a5-28f0-e23f-ec61155b7078-C", "generated_internal_id": "ASST_NON_U01HL131529_7529"}, {"internal_id": 50095185, "Award ID": "U01HL131072", "Award Amount": 2949071.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.837", "Description": "A MULTI-SCALE SYSTEMS PHARMACOLOGY APPROACH TO TB THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_U01HL131072_7529"}, {"internal_id": 50095182, "Award ID": "U01HL131046", "Award Amount": 1713126.87, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-26", "CFDA Number": "93.837", "Description": "BUILDING MULTILEVEL MODELS OF THERAPEUTIC RESPONSE IN THE LUNGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U01HL131046_7529"}, {"internal_id": 50095180, "Award ID": "U01HL131022", "Award Amount": 5003156.54, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-26", "CFDA Number": "93.837", "Description": "THE MOLECULAR AND GENETIC PATHOGENSIS OF LAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_U01HL131022_7529"}, {"internal_id": 50095172, "Award ID": "U01HL130050", "Award Amount": 4692289.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-04-30", "CFDA Number": "93.837", "Description": "ORBEX: PRIMARY PREVENTION OF ASTHMA AND WHEEZING IN CHILDREN-DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47ed9961-3300-5ed7-bb62-e5359d99eaf9-C", "generated_internal_id": "ASST_NON_U01HL130050_7529"}, {"internal_id": 50095170, "Award ID": "U01HL130045", "Award Amount": 22360710.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-04-29", "CFDA Number": "93.837", "Description": "ORBEX: PRIMARY PREVENTION OF ASTHMA AND WHEEZING IN CHILDREN-CCC LEAD APPLICATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_U01HL130045_7529"}, {"internal_id": 50095169, "Award ID": "U01HL130010", "Award Amount": 2329469.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.310", "Description": "BEYOND PAIRWISE DNA CONTACTS: EXPLORING HIGHER-ORDER GENOME STRUCTURE USING PROXIMITY LIGATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_U01HL130010_7529"}, {"internal_id": 50095168, "Award ID": "U01HL130007", "Award Amount": 3948028.53, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-09-14", "CFDA Number": "93.310", "Description": "NOVEL TOOLS TO COMPREHENSIVELY MAP DYNAMIC ORGANIZATION OF RNA AND DNA IN HIGHER-ORDER NUCLEAR STRUCTURES WITHIN SINGLE CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "74bac010-0a24-8f82-8021-0fa16ab4bc6d-C", "generated_internal_id": "ASST_NON_U01HL130007_7529"}, {"internal_id": 50095167, "Award ID": "U01HL129998", "Award Amount": 4139282.32, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.310", "Description": "ENGINEERING AND VISUALIZING GENOME FOLDING AT HIGH SPATIOTEMPORAL RESOLUTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_U01HL129998_7529"}, {"internal_id": 50095166, "Award ID": "U01HL129971", "Award Amount": 1915399.66, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.310", "Description": "NEW AUTOMATED EXPERIMENTAL AND COMPUTATIONAL PIPELINE FOR HIGH COVERAGE SINGLE-CELL HI-C AND ITS INTEGRATION WITH SINGLE CELL RNA-SEQ: ENABLING 4D NU", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "52a3bc33-b23b-0c54-7fff-2e17fbd7bfb0-C", "generated_internal_id": "ASST_NON_U01HL129971_7529"}, {"internal_id": 50095165, "Award ID": "U01HL129958", "Award Amount": 3579692.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-09-14", "CFDA Number": "93.310", "Description": "DISTANCE-HI-C: CREATING PHOTO ACTIVATED X-LINKERS TO DEFINE NUCLEAR ARCHITECTURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c3617e9-a213-5748-732e-c98dc05d3232-C", "generated_internal_id": "ASST_NON_U01HL129958_7529"}, {"internal_id": 50095164, "Award ID": "U01HL128964", "Award Amount": 1628938.43, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-07-31", "CFDA Number": "93.837", "Description": "STUDY OF CO-TRIMOXAZOLE AND PROTON PUMP INHIBITION USING PRAGMATIC DESIGN IN IDIOPATHIC PULMONARY FIBROSIS - CLEANUP-IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_U01HL128964_7529"}, {"internal_id": 50095163, "Award ID": "U01HL128954", "Award Amount": 16812010.28, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-07-22", "CFDA Number": "93.837", "Description": "NETWORK MANAGEMENT CORE (NEMO) FOR THE PULMONARY TRIALS COOPERATIVE (PTC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U01HL128954_7529"}, {"internal_id": 50095162, "Award ID": "U01HL128952", "Award Amount": 1562097.74, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-09-11", "CFDA Number": "93.837", "Description": "REDEFINING THERAPY IN EARLY COPD: RETHINC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_U01HL128952_7529"}, {"internal_id": 50095161, "Award ID": "U01HL128951", "Award Amount": 1778866.1, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-07-27", "CFDA Number": "93.837", "Description": "EFFECT OF LOSARTAN ON PROGRESSION OF EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_U01HL128951_7529"}, {"internal_id": 50095160, "Award ID": "U01HL128868", "Award Amount": 1186811.03, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-08-05", "CFDA Number": "93.837", "Description": "HEALTH THROUGH OBESITY CARE FOR PATIENTS WITH COPD (HOPE)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "300cc8dc-2af9-357b-0a09-f9b239e5ae53-C", "generated_internal_id": "ASST_NON_U01HL128868_7529"}, {"internal_id": 50095143, "Award ID": "U01HL126088", "Award Amount": 2814166.73, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-08-11", "CFDA Number": "93.837", "Description": "ICOMPARE - DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_U01HL126088_7529"}, {"internal_id": 50095137, "Award ID": "U01HL125307", "Award Amount": 5185505.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-09-04", "CFDA Number": "93.837", "Description": "IMPACT OF TREATMENT OF MILD SLEEP-DISORDERED BREATHING ON CHILDREN'S HEALTH-DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_U01HL125307_7529"}, {"internal_id": 50095136, "Award ID": "U01HL125295", "Award Amount": 7924751.82, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-09-04", "CFDA Number": "93.837", "Description": "IMPACT OF TREATMENT OF MILD SLEEP-DISORDERED BREATHING ON CHILDREN'S HEALTH-CCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_U01HL125295_7529"}, {"internal_id": 50095135, "Award ID": "U01HL125218", "Award Amount": 1487245.98, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-09-18", "CFDA Number": "93.837", "Description": "PVDOMICS DEFINING THE FUTURE FINGERPRINTS OF PULMONARY VASCULAR DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_U01HL125218_7529"}, {"internal_id": 50095134, "Award ID": "U01HL125215", "Award Amount": 1679394.63, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-09-18", "CFDA Number": "93.837", "Description": "INTERGRATED ENDOTHELIAL PHENOTYPING TO REDEFINE PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_U01HL125215_7529"}, {"internal_id": 50095133, "Award ID": "U01HL125212", "Award Amount": 1455901.13, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-09-18", "CFDA Number": "93.837", "Description": "A MOLECULAR PHENOTYPE OF COMBINED PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_U01HL125212_7529"}, {"internal_id": 50095132, "Award ID": "U01HL125208", "Award Amount": 1451447.28, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-09-15", "CFDA Number": "93.837", "Description": "PHENOMIC AND GENOMIC STUDY TO SUBPHENOTYPE HISPANICS WITH PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_U01HL125208_7529"}, {"internal_id": 50095131, "Award ID": "U01HL125205", "Award Amount": 1512703.4, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-09-12", "CFDA Number": "93.837", "Description": "REDEFINING PULMONARY HYPERTENSION THROUGH PULMONARY VASCULAR DISEASE PHENOMICS: CLINICAL CENTERS (CC) (U01).", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_U01HL125205_7529"}, {"internal_id": 50095130, "Award ID": "U01HL125177", "Award Amount": 20020754.35, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-09-12", "CFDA Number": "93.837", "Description": "PULMONARY VASCULAR DISEASE PHENOMICS PROGRAM (PVDOMICS) DATA COORDINATING CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_U01HL125177_7529"}, {"internal_id": 50095129, "Award ID": "U01HL125175", "Award Amount": 1011691.12, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-11-20", "CFDA Number": "93.837", "Description": "HOPKINS CLINICAL CENTER FOR PULMONARY VASCULAR DISEASE PHENOMICS PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_U01HL125175_7529"}, {"internal_id": 50095125, "Award ID": "U01HL123033", "Award Amount": 2396561.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "PREVENTION AND EARLY TREATMENT OF ACUTE LUNG INJURY CLINICAL TRIALS NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_U01HL123033_7529"}, {"internal_id": 50095124, "Award ID": "U01HL123031", "Award Amount": 2605905.86, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "CLINICAL CENTERS (CC) FOR THE NHLBI PREVENTION AND EARLY TREATMENT OF ACUTE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_U01HL123031_7529"}, {"internal_id": 50095123, "Award ID": "U01HL123027", "Award Amount": 1687238.72, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "WAKE FOREST CLINICAL CENTER FOR THE NHLBI PETAL NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "623a4232-bd5e-fb60-cf01-48cd08a5a593-C", "generated_internal_id": "ASST_NON_U01HL123027_7529"}, {"internal_id": 50095122, "Award ID": "U01HL123023", "Award Amount": 1462092.01, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "OHIO CONSORTIUM CLINICAL CENTER FOR THE NHLBI PREVENTION AND EARLY TREATMENT OF A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_U01HL123023_7529"}, {"internal_id": 50095121, "Award ID": "U01HL123022", "Award Amount": 2931714.36, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "CLINICAL CENTERS (CC) FOR THE NHLBI PREVENTION AND EARLY TREATMENT OF ACUTE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_U01HL123022_7529"}, {"internal_id": 50095120, "Award ID": "U01HL123020", "Award Amount": 2124560.79, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "PREVENTIVE AND EARLY TREATMENT OF ACUTE LUNG INJURY CLINICAL TRIALS NETWORK- PGH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": 273199.21, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U01HL123020_7529"}, {"internal_id": 50095119, "Award ID": "U01HL123018", "Award Amount": 2361550.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "INTERMOUNTAIN HEALTHCARE CLINICAL CENTER (CC) FOR THE NHLBI PREVENTION AND EARLY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2ec62179-269e-eca7-af13-c17efa73189f-C", "generated_internal_id": "ASST_NON_U01HL123018_7529"}, {"internal_id": 50095118, "Award ID": "U01HL123010", "Award Amount": 2561997.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.310", "Description": "COLORADO PETAL CLINICAL CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_U01HL123010_7529"}, {"internal_id": 50095117, "Award ID": "U01HL123009", "Award Amount": 67164534.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.838", "Description": "CCC FOR NHLBI PREVENTION AND EARLY TREATMENT OF ACUTE LUNG INJURY PETAL NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": 14758228.0, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_U01HL123009_7529"}, {"internal_id": 50095116, "Award ID": "U01HL123008", "Award Amount": 2262032.08, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "PACIFIC NORTHWEST CLINICAL CENTER FOR THE NHLBI PETAL NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_U01HL123008_7529"}, {"internal_id": 50095115, "Award ID": "U01HL123004", "Award Amount": 2633641.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "PREVENTION AND EARLY TREATMENT OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_U01HL123004_7529"}, {"internal_id": 50095114, "Award ID": "U01HL122998", "Award Amount": 1867642.71, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "EINSTEIN PETAL: CLINICAL CENTER FOR THE PETAL NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_U01HL122998_7529"}, {"internal_id": 50095113, "Award ID": "U01HL122989", "Award Amount": 2128374.09, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "ACUTE LUNG INJURY GROUP NEW ENGLAND PROGRAM TO SUPPORT PETAL NETWORK RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3b77461b-d74c-9784-e800-bb061239d65f-C", "generated_internal_id": "ASST_NON_U01HL122989_7529"}, {"internal_id": 50095110, "Award ID": "U01HL122703", "Award Amount": 4493309.67, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-13", "CFDA Number": "93.837", "Description": "CENTER FOR LUNG DEVELOPMENT IMAGING AND OMICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "74457bb7-b18d-9762-896e-e575e7a4ed82-C", "generated_internal_id": "ASST_NON_U01HL122703_7529"}, {"internal_id": 50095109, "Award ID": "U01HL122700", "Award Amount": 6099986.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-13", "CFDA Number": "93.837", "Description": "BIOREPOSITORY FOR INVESTIGATION OF NEONATAL DISEASES OF LUNG-NORMAL (BRINDL-NL)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_U01HL122700_7529"}, {"internal_id": 50095108, "Award ID": "U01HL122681", "Award Amount": 3818137.64, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-13", "CFDA Number": "93.837", "Description": "MOLECULAR ANATOMY OF HUMAN ALVEOLAR DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c10cf51-1fb6-c52e-c48f-8fcef0f37eff-C", "generated_internal_id": "ASST_NON_U01HL122681_7529"}, {"internal_id": 50095107, "Award ID": "U01HL122642", "Award Amount": 3874945.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-13", "CFDA Number": "93.837", "Description": "\"LUNG MAP\" ATLAS RESEARCH CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_U01HL122642_7529"}, {"internal_id": 50095106, "Award ID": "U01HL122638", "Award Amount": 7391319.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-13", "CFDA Number": "93.838", "Description": "MOLECULAR ATLAS OF LUNG DEVELOPMENT - DATA COORDINATING CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_U01HL122638_7529"}, {"internal_id": 50095105, "Award ID": "U01HL122626", "Award Amount": 3686904.96, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-13", "CFDA Number": "93.837", "Description": "ALVEOLAR DEVMAP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_U01HL122626_7529"}, {"internal_id": 50095097, "Award ID": "U01HL121831", "Award Amount": 3161026.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-26", "CFDA Number": "93.838", "Description": "GENOMIC ANALYSIS OF IMMUNITY AND LUNG INFLAMMATION IN HIV INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_U01HL121831_7529"}, {"internal_id": 50095096, "Award ID": "U01HL121828", "Award Amount": 3673861.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-26", "CFDA Number": "93.838", "Description": "HIV+ ALVEOLAR MACROPHAGE OXIDANT-MEDIATED APOPTOSIS OF PULMONARY ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_U01HL121828_7529"}, {"internal_id": 50095095, "Award ID": "U01HL121827", "Award Amount": 3235187.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-26", "CFDA Number": "93.838", "Description": "HIV AND COPD:IMMUNE MEDIATED MECHANISMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_U01HL121827_7529"}, {"internal_id": 50095094, "Award ID": "U01HL121819", "Award Amount": 3312870.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-26", "CFDA Number": "93.838", "Description": "GENOTYPIC AND FUNCTIONAL PROPERTIES OF HIV-1 NEF CLINICAL ISOLATES IN PAH-HIV", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_U01HL121819_7529"}, {"internal_id": 50095093, "Award ID": "U01HL121816", "Award Amount": 3362932.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-26", "CFDA Number": "93.838", "Description": "INTERACTIONS OF SMOKING, PD-1 AND IL-10 IN HIV-ASSOCIATED LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_U01HL121816_7529"}, {"internal_id": 50095092, "Award ID": "U01HL121814", "Award Amount": 3459314.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-26", "CFDA Number": "93.838", "Description": "IMMUNE MECHANISMS OF HIV-ASSOCIATED COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_U01HL121814_7529"}, {"internal_id": 50095091, "Award ID": "U01HL121812", "Award Amount": 3073007.47, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-26", "CFDA Number": "93.837", "Description": "LUNG AND HIV ANALYTICAL DATA COORDINATING CENTER (LHAD-CC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_U01HL121812_7529"}, {"internal_id": 50095090, "Award ID": "U01HL121807", "Award Amount": 2313235.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-26", "CFDA Number": "93.838", "Description": "THE IMPACT OF OXIDATIVE STRESS ON HIV-INDUCED LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c9476c3-c39d-74de-31b6-2c9a10197e11-C", "generated_internal_id": "ASST_NON_U01HL121807_7529"}, {"internal_id": 50095089, "Award ID": "U01HL121804", "Award Amount": 2833491.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-26", "CFDA Number": "93.838", "Description": "MOLECULAR MECHANISMS OF CHRONIC AIRWAY AND ALVEOLAR DISEASE IN HIV", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_U01HL121804_7529"}, {"internal_id": 50095088, "Award ID": "U01HL121518", "Award Amount": 8925653.83, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2014-06-20", "CFDA Number": "93.865", "Description": "DATA FUSION: A SUSTAINABLE, SCALABLE, OPEN SOURCE REGISTRY ADVANCING PVD RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_U01HL121518_7529"}, {"internal_id": 50095085, "Award ID": "U01HL119963", "Award Amount": 1262281.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-06-17", "CFDA Number": "93.838", "Description": "VITAMIN D TO PREVENT SEVERE ASTHMA EXACERBATIONS IN HIGH-RISK CHILDREN: DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U01HL119963_7529"}, {"internal_id": 50095084, "Award ID": "U01HL119952", "Award Amount": 2865394.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-05-19", "CFDA Number": "93.838", "Description": "VITAMIN D TO PREVENT SEVERE ASTHMA EXACERBATIONS IN HIGH-RISK CHILDREN - CCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U01HL119952_7529"}, {"internal_id": 50095061, "Award ID": "U01HL114623", "Award Amount": 6568823.5, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-12", "CFDA Number": "93.837", "Description": "OPTIMIZE - CCC - LEAD APPLICATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_U01HL114623_7529"}, {"internal_id": 50095060, "Award ID": "U01HL114589", "Award Amount": 3237799.01, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-13", "CFDA Number": "93.837", "Description": "OPTIMIZE - DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_U01HL114589_7529"}, {"internal_id": 50095059, "Award ID": "U01HL114494", "Award Amount": 3148135.97, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-05", "CFDA Number": "93.837", "Description": "AN INTEGRATIVE STATISTICS-GUIDED IMAGE-BASED MULTI-SCALE LUNG MODEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_U01HL114494_7529"}, {"internal_id": 50095046, "Award ID": "U01HL112707", "Award Amount": 8533116.0, "Award Type": null, "Base Obligation Date": "2012-04-30", "CFDA Number": "93.838", "Description": "SARCOIDOSIS AND A1AT GENOMICS & INFORMATICS CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U01HL112707_7529"}, {"internal_id": 50095035, "Award ID": "U01HL111146", "Award Amount": 3235427.0, "Award Type": null, "Base Obligation Date": "2011-12-30", "CFDA Number": "93.838", "Description": "NANOPARTICLE DRUG DELIVERY  IN POST-PNEUMONECTOMY COMPENSATORY LUNG GROWTH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_U01HL111146_7529"}, {"internal_id": 50095033, "Award ID": "U01HL111018", "Award Amount": 3320207.0, "Award Type": null, "Base Obligation Date": "2011-12-30", "CFDA Number": "93.838", "Description": "AN INTEGRATED APPROACH TO AIRWAY EPITHELIAL REPAIR AND REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_U01HL111018_7529"}, {"internal_id": 50095032, "Award ID": "U01HL111016", "Award Amount": 3241736.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-12-30", "CFDA Number": "93.838", "Description": "MATRIX AND BIOREACTORS FOR HUMAN LUNG REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_U01HL111016_7529"}, {"internal_id": 50095030, "Award ID": "U01HL110964", "Award Amount": 3273591.0, "Award Type": null, "Base Obligation Date": "2011-12-30", "CFDA Number": "93.838", "Description": "AIRWAY PROGENITOR CELL PROFILERATION AND DIFFERENTIATION DURING LUNG REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_U01HL110964_7529"}, {"internal_id": 50095027, "Award ID": "U01HL108713", "Award Amount": 5062852.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-30", "CFDA Number": "93.838", "Description": "ALLOGENEIC HUMAN MESENCHYMAL STEM CELLS FOR THE TREATMENT OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_U01HL108713_7529"}, {"internal_id": 50095021, "Award ID": "U01HL108634", "Award Amount": 5305947.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-25", "CFDA Number": "93.838", "Description": "MAPGEN KNOWLEDGE BASE (MAPGENKB) AND COORDINATION CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_U01HL108634_7529"}, {"internal_id": 50095019, "Award ID": "U01HL108028", "Award Amount": 2813491.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-06-22", "CFDA Number": "93.838", "Description": "HALF-PINT: HEART AND LUNG FAILURE - PEDIATRIC INSULIN TITRATION TRIAL - DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_U01HL108028_7529"}, {"internal_id": 50095018, "Award ID": "U01HL107681", "Award Amount": 7623683.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-06-22", "CFDA Number": "93.838", "Description": "HALF-PINT: HEART AND LUNG FAILURE - PEDIATRIC INSULIN TITRATION TRIAL - CCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_U01HL107681_7529"}, {"internal_id": 50095010, "Award ID": "U01HL107393", "Award Amount": 8721630.0, "Award Type": null, "Base Obligation Date": "2011-07-01", "CFDA Number": "93.838", "Description": "IPSC DERIVED EC AS SURROGATES USING PULMONARY HYPERTENSION AS A PROTOTYPE DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_U01HL107393_7529"}, {"internal_id": 50094977, "Award ID": "U01HL101794", "Award Amount": 10226404.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2010-04-30", "CFDA Number": "93.838", "Description": "DATA COORDINATING CENTER FOR THE PREMATURITY AND RESPIRATORY OUTCOMES PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_U01HL101794_7529"}, {"internal_id": 50094948, "Award ID": "U01HL098960", "Award Amount": 3647312.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2009-09-21", "CFDA Number": "93.838", "Description": "LUNG MICROBIOME AND PULMONARY INFLAMMATION/IMMUNITY IN HIV INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_U01HL098960_7529"}, {"internal_id": 50094898, "Award ID": "U01HL089897", "Award Amount": 53344199.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2008-07-22", "CFDA Number": "93.837", "Description": "GENETIC EPIDEMIOLOGY OF COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_U01HL089897_7529"}, {"internal_id": 50094897, "Award ID": "U01HL089856", "Award Amount": 21390342.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2008-07-22", "CFDA Number": "93.837", "Description": "GENETIC EPIDEMIOLOGY OF COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_U01HL089856_7529"}, {"internal_id": 50033092, "Award ID": "T35HL113229", "Award Amount": 766922.95, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-04-02", "CFDA Number": "93.837", "Description": "RUTH L. KIRSCHSTEIN NATIONAL RESEARCH SERVICE AWARD SHORT-TERM INSTITUTIONAL RESE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_T35HL113229_7529"}, {"internal_id": 50033073, "Award ID": "T35HL007744", "Award Amount": 1868363.9, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-01", "CFDA Number": "93.837", "Description": "SHORT-TERM TRAINING: STUDENTS IN HEALTH PROFESSIONAL SCHOOLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_T35HL007744_7529"}, {"internal_id": 50033072, "Award ID": "T35HL007690", "Award Amount": 2360463.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-25", "CFDA Number": "93.837", "Description": "SHORT TERM BIOMEDICAL RESEARCH TRAINING PROGRAM FOR MEDICAL STUDENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_T35HL007690_7529"}, {"internal_id": 50033071, "Award ID": "T35HL007649", "Award Amount": 3651912.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-05", "CFDA Number": "93.837", "Description": "SHORT-TERM RESEARCH TRAINING: STUDENTS IN HEALTH PROFESSIONAL SCHOOLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_T35HL007649_7529"}, {"internal_id": 50033068, "Award ID": "T35HL007489", "Award Amount": 1387638.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-25", "CFDA Number": "93.837", "Description": "SHORT TERM TRAINING: HEALTH PROFESSIONAL SCHOOLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_T35HL007489_7529"}, {"internal_id": 80731187, "Award ID": "T32HL144909", "Award Amount": 1308942.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-17", "CFDA Number": "93.837", "Description": "POSTDOCTORAL TRAINING PROGRAM IN PULMONARY AND CRITICAL CARE TRANSLATIONAL RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_T32HL144909_7529"}, {"internal_id": 80726494, "Award ID": "T32HL144470", "Award Amount": 1448971.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-17", "CFDA Number": "93.837", "Description": "PULMONARY FOCUSED FOUNDATIONS IN INNOVATION AND SCHOLARSHIP (PUFFINS)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "SC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "04a78f04-ee86-46df-5fbf-c71e46ed8479-C", "generated_internal_id": "ASST_NON_T32HL144470_7529"}, {"internal_id": 76737856, "Award ID": "T32HL144461", "Award Amount": 1625741.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-04", "CFDA Number": "93.837", "Description": "IOWA LUNG IMAGING TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_T32HL144461_7529"}, {"internal_id": 76737980, "Award ID": "T32HL144442", "Award Amount": 537618.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-21", "CFDA Number": "93.837", "Description": "TRAINING PROGRAM IN POPULATION SCIENCE OF RESPIRATORY DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_T32HL144442_7529"}, {"internal_id": 50032436, "Award ID": "T32HL134640", "Award Amount": 1030909.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-14", "CFDA Number": "93.837", "Description": "UAB PREDOCTORAL TRAINING PROGRAM IN LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_T32HL134640_7529"}, {"internal_id": 50032435, "Award ID": "T32HL134637", "Award Amount": 1341307.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-24", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY PULMONARY RESEARCH TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_T32HL134637_7529"}, {"internal_id": 50032432, "Award ID": "T32HL134632", "Award Amount": 2133125.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-24", "CFDA Number": "93.837", "Description": "TRAINING IN THE NEXT GENERATION IN RESPIRATORY SCIENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_T32HL134632_7529"}, {"internal_id": 50032431, "Award ID": "T32HL134629", "Award Amount": 2706211.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-05", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY APPROACH TRAINING IN RESPIRATORY RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_T32HL134629_7529"}, {"internal_id": 50032430, "Award ID": "T32HL134625", "Award Amount": 3546764.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-23", "CFDA Number": "93.837", "Description": "BROWN RESPIRATORY RESEARCH TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "378fe7f9-e157-cd75-80cc-97cbe1a426db-C", "generated_internal_id": "ASST_NON_T32HL134625_7529"}, {"internal_id": 50032428, "Award ID": "T32HL134621", "Award Amount": 2155178.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-14", "CFDA Number": "93.837", "Description": "BREATHING RESEARCH AND THERAPEUTICS (BREATHE)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_T32HL134621_7529"}, {"internal_id": 50032424, "Award ID": "T32HL134598", "Award Amount": 1096364.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-26", "CFDA Number": "93.837", "Description": "DARTMOUTH CYSTIC FIBROSIS TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7eb6683a-d796-f7f5-68c0-ca8f32275b30-C", "generated_internal_id": "ASST_NON_T32HL134598_7529"}, {"internal_id": 50032419, "Award ID": "T32HL129970", "Award Amount": 2654899.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-12", "CFDA Number": "93.837", "Description": "STANFORD TRAINING PROGRAM IN LUNG BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_T32HL129970_7529"}, {"internal_id": 50032414, "Award ID": "T32HL129949", "Award Amount": 2103760.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-12", "CFDA Number": "93.837", "Description": "PITTSBURGH TRAINING GRANT IN PEDIATRIC PULMONARY MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_T32HL129949_7529"}, {"internal_id": 50032410, "Award ID": "T32HL125245", "Award Amount": 437852.34, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-06", "CFDA Number": "93.837", "Description": "PEDIATRIC RESPIRATORY RESEARCH TRAINING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_T32HL125245_7529"}, {"internal_id": 50032407, "Award ID": "T32HL125239", "Award Amount": 2800309.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-01-26", "CFDA Number": "93.837", "Description": "TRAINING FOR CLINICIAN SCIENTISTS IN PEDIATRIC CRITICAL CARDIOPULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_T32HL125239_7529"}, {"internal_id": 50032404, "Award ID": "T32HL125195", "Award Amount": 2905296.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-02-10", "CFDA Number": "93.837", "Description": "PALLIATIVE CARE RESEARCH TRAINING GRANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_T32HL125195_7529"}, {"internal_id": 50032397, "Award ID": "T32HL116275", "Award Amount": 6450627.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-28", "CFDA Number": "93.837", "Description": "RESEARCH TRAINING IN PULMONARY IMMUNOLOGY AND ALLERGY AT MGH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_T32HL116275_7529"}, {"internal_id": 50032395, "Award ID": "T32HL116271", "Award Amount": 4166296.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-29", "CFDA Number": "93.837", "Description": "EMORY ACUTE LUNG INJURY TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_T32HL116271_7529"}, {"internal_id": 50032388, "Award ID": "T32HL110849", "Award Amount": 3834343.39, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-03-21", "CFDA Number": "93.837", "Description": "TRANSLATIONAL PULMONARY VASCULAR BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_T32HL110849_7529"}, {"internal_id": 50032384, "Award ID": "T32HL105355", "Award Amount": 3907321.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-02-28", "CFDA Number": "93.837", "Description": "INTERDISCIPLINARY TRAINING IN LUNG PHYSIOLOGY AND BIOMEDICAL ENGINEERING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_T32HL105355_7529"}, {"internal_id": 50032382, "Award ID": "T32HL105346", "Award Amount": 3925978.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-09-20", "CFDA Number": "93.837", "Description": "TRAINING PROGRAM IN LUNG BIOLOGY AND TRANSLATIONAL MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_T32HL105346_7529"}, {"internal_id": 50032378, "Award ID": "T32HL105323", "Award Amount": 3743324.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-05-16", "CFDA Number": "93.837", "Description": "COLUMBIA UNIVERSITY TRAINING PROGRAM IN LUNG SCIENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_T32HL105323_7529"}, {"internal_id": 50032377, "Award ID": "T32HL105321", "Award Amount": 3521726.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-09-20", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY PULMONARY AND CRITICAL CARE RESEARCH TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_T32HL105321_7529"}, {"internal_id": 50032372, "Award ID": "T32HL098062", "Award Amount": 1989481.0, "Award Type": null, "Base Obligation Date": "2010-09-20", "CFDA Number": "93.838", "Description": "TRAINING IN RESPIRATORY BIOLOGY: INNOVATE  INTEGRATE  AND TRANSLATE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_T32HL098062_7529"}, {"internal_id": 50032367, "Award ID": "T32HL098040", "Award Amount": 4564301.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-09-24", "CFDA Number": "93.837", "Description": "TRAINING PROGRAM IN LUNG BIOLOGY AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_T32HL098040_7529"}, {"internal_id": 50032362, "Award ID": "T32HL094296", "Award Amount": 5043953.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-01", "CFDA Number": "93.837", "Description": "INTERDISCIPLINARY TRAINING PROGRAM IN LUNG RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_T32HL094296_7529"}, {"internal_id": 50032357, "Award ID": "T32HL094284", "Award Amount": 2705193.75, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-09-24", "CFDA Number": "93.837", "Description": "PULMONARY GENETIC MEDICINE TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_T32HL094284_7529"}, {"internal_id": 50032349, "Award ID": "T32HL091816", "Award Amount": 3119709.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-04-27", "CFDA Number": "93.837", "Description": "IU TRAINING PROG. IN MOLECULAR PHYSIOLOGY AND CLINICAL MECHANISMS OF LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_T32HL091816_7529"}, {"internal_id": 50032342, "Award ID": "T32HL087738", "Award Amount": 5348817.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-30", "CFDA Number": "93.837", "Description": "CLINICAL AND TRANSLATIONAL RESEARCH TRAINING PROGRAM IN PULMONARY MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_T32HL087738_7529"}, {"internal_id": 50032329, "Award ID": "T32HL083808", "Award Amount": 4509749.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-04-01", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY RESEARCH TRAINING IN PULMONARY MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_T32HL083808_7529"}, {"internal_id": 50032326, "Award ID": "T32HL082610", "Award Amount": 4371098.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-29", "CFDA Number": "93.837", "Description": "TRANSLATIONAL RESEARCH TRAINING IN SLEEP MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_T32HL082610_7529"}, {"internal_id": 50032325, "Award ID": "T32HL082547", "Award Amount": 2312273.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-05-01", "CFDA Number": "93.838", "Description": "PULMONARY AND CRITICAL CARE POST-DOCTORAL RESEARCH TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_T32HL082547_7529"}, {"internal_id": 50032316, "Award ID": "T32HL076139", "Award Amount": 6710677.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-01", "CFDA Number": "93.837", "Description": "TRAINING PROGRAM IN LUNG BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_T32HL076139_7529"}, {"internal_id": 50032311, "Award ID": "T32HL076125", "Award Amount": 1858700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-01", "CFDA Number": "93.838", "Description": "TRAINING IN CELL SIGNALING AND LUNG PATHOBIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_T32HL076125_7529"}, {"internal_id": 50032308, "Award ID": "T32HL076122", "Award Amount": 5259034.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-08", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY TRAINING IN LUNG BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_T32HL076122_7529"}, {"internal_id": 50032307, "Award ID": "T32HL076118", "Award Amount": 1187135.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-09", "CFDA Number": "93.838", "Description": "TRAINING PROGRAM IN ACADEMIC PULMONARY MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_T32HL076118_7529"}, {"internal_id": 50032304, "Award ID": "T32HL072752", "Award Amount": 5302291.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-29", "CFDA Number": "93.837", "Description": "PULMONARY AND CRITICAL CARE MEDICINE TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_T32HL072752_7529"}, {"internal_id": 50032302, "Award ID": "T32HL072748", "Award Amount": 3596579.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-07", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY TRAINING PROGRAM IN PEDIATRIC PULMONARY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_T32HL072748_7529"}, {"internal_id": 50032284, "Award ID": "T32HL066988", "Award Amount": 5290783.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-29", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY TRAINING IN PULMONARY RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_T32HL066988_7529"}, {"internal_id": 50032270, "Award ID": "T32HL007946", "Award Amount": 1626905.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-30", "CFDA Number": "93.838", "Description": "MOLECULAR MECHANISMS OF LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_T32HL007946_7529"}, {"internal_id": 50032261, "Award ID": "T32HL007913", "Award Amount": 1967771.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-06", "CFDA Number": "93.233", "Description": "SLEEP MEDICINE NEUROBIOLOGY AND EPIDEMIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_T32HL007913_7529"}, {"internal_id": 50032257, "Award ID": "T32HL007901", "Award Amount": 12029308.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-16", "CFDA Number": "93.837", "Description": "TRAINING IN SLEEP, CIRCADIAN AND RESPIRATORY NEUROBIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_T32HL007901_7529"}, {"internal_id": 50032244, "Award ID": "T32HL007829", "Award Amount": 10418240.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-16", "CFDA Number": "93.837", "Description": "TRAINING PROGRAM IN LUNG BIOLOGY AND PATHOBIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_T32HL007829_7529"}, {"internal_id": 50032240, "Award ID": "T32HL007820", "Award Amount": 3915580.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-25", "CFDA Number": "93.837", "Description": "EXPERIMENTAL THERAPEUTICS IN CRITICAL ILLNESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_T32HL007820_7529"}, {"internal_id": 50032235, "Award ID": "T32HL007778", "Award Amount": 9484217.2, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-30", "CFDA Number": "93.837", "Description": "TRAINING IN RESPIRATORY BIOLOGY AND PATHOBIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_T32HL007778_7529"}, {"internal_id": 50032231, "Award ID": "T32HL007752", "Award Amount": 3859054.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-29", "CFDA Number": "93.837", "Description": "PULMONARY AND CARDIOVASCULAR DEVELOPMENT TRAINING GRANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_T32HL007752_7529"}, {"internal_id": 50032229, "Award ID": "T32HL007749", "Award Amount": 12865435.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-30", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_T32HL007749_7529"}, {"internal_id": 50032227, "Award ID": "T32HL007747", "Award Amount": 3170261.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-20", "CFDA Number": "93.837", "Description": "RESEARCH TRAINING IN LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_T32HL007747_7529"}, {"internal_id": 50032225, "Award ID": "T32HL007741", "Award Amount": 9223667.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-30", "CFDA Number": "93.837", "Description": "TRAINING IN LUNG SCIENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_T32HL007741_7529"}, {"internal_id": 50032212, "Award ID": "T32HL007670", "Award Amount": 2870824.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-05", "CFDA Number": "93.310", "Description": "ACADEMIC TRAINING PROGRAM IN PEDIATRIC PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_T32HL007670_7529"}, {"internal_id": 50032209, "Award ID": "T32HL007638", "Award Amount": 10613885.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-01", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY LUNG RESEARCH CAREER DEVELOPMENT PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_T32HL007638_7529"}, {"internal_id": 50032208, "Award ID": "T32HL007633", "Award Amount": 8783248.68, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-02", "CFDA Number": "93.837", "Description": "INTEGRATED TRAINING IN RESPIRATORY RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_T32HL007633_7529"}, {"internal_id": 50032203, "Award ID": "T32HL007605", "Award Amount": 10607793.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-01", "CFDA Number": "93.837", "Description": "RESEARCH TRAINING IN RESPIRATORY BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_T32HL007605_7529"}, {"internal_id": 50032200, "Award ID": "T32HL007586", "Award Amount": 5650419.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-01", "CFDA Number": "93.837", "Description": "TRAINING IN PULMONARY IMMUNOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_T32HL007586_7529"}, {"internal_id": 50032193, "Award ID": "T32HL007563", "Award Amount": 7180687.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-11", "CFDA Number": "93.837", "Description": "MOLECULAR PHYSIOLOGY OF THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_T32HL007563_7529"}, {"internal_id": 50032190, "Award ID": "T32HL007538", "Award Amount": 4765209.74, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-01", "CFDA Number": "93.837", "Description": "INTERDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_T32HL007538_7529"}, {"internal_id": 50032189, "Award ID": "T32HL007534", "Award Amount": 16325411.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-20", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_T32HL007534_7529"}, {"internal_id": 50032187, "Award ID": "T32HL007517", "Award Amount": 4764274.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-25", "CFDA Number": "93.837", "Description": "LUNG IMMUNOPATHOLOGY TRAINING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_T32HL007517_7529"}, {"internal_id": 50032180, "Award ID": "T32HL007427", "Award Amount": 8486621.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-19", "CFDA Number": "93.837", "Description": "CLINICAL EPIDEMIOLOGY OF LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_T32HL007427_7529"}, {"internal_id": 50032168, "Award ID": "T32HL007317", "Award Amount": 9028931.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-29", "CFDA Number": "93.837", "Description": "PRINCIPLES IN PULMONARY RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_T32HL007317_7529"}, {"internal_id": 50032166, "Award ID": "T32HL007287", "Award Amount": 10704075.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-27", "CFDA Number": "93.837", "Description": "RESPIRATORY RESEARCH TRAINING GRANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_T32HL007287_7529"}, {"internal_id": 50032151, "Award ID": "T32HL007185", "Award Amount": 13853464.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-01", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_T32HL007185_7529"}, {"internal_id": 50032148, "Award ID": "T32HL007171", "Award Amount": 5543093.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-20", "CFDA Number": "93.837", "Description": "RESPIRATION AND CIRCULATION DURING HYPOXIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_T32HL007171_7529"}, {"internal_id": 50032141, "Award ID": "T32HL007118", "Award Amount": 9295254.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-02", "CFDA Number": "93.837", "Description": "TRAINING IN INTERDISCIPLINARY PULMONARY SCIENCES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_T32HL007118_7529"}, {"internal_id": 50032139, "Award ID": "T32HL007106", "Award Amount": 5323579.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-13", "CFDA Number": "93.837", "Description": "PULMONARY, CRITICAL CARE, AND MOLECULAR TRAINING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_T32HL007106_7529"}, {"internal_id": 50032137, "Award ID": "T32HL007093", "Award Amount": 8945896.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-05", "CFDA Number": "93.837", "Description": "RESEARCH TRAINING IN HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_T32HL007093_7529"}, {"internal_id": 50032134, "Award ID": "T32HL007085", "Award Amount": 13399065.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-25", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY RESEARCH TRAINING RESPIRATORY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_T32HL007085_7529"}, {"internal_id": 50032129, "Award ID": "T32HL007035", "Award Amount": 14708787.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-29", "CFDA Number": "93.837", "Description": "BIOLOGY OF THE LUNG: A MULTIDISCIPLINARY PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_T32HL007035_7529"}, {"internal_id": 50032125, "Award ID": "T32HL007013", "Award Amount": 6774911.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-07", "CFDA Number": "93.837", "Description": "TRAINING IN COMPARATIVE LUNG BIOLOGY AND MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_T32HL007013_7529"}, {"internal_id": 86319112, "Award ID": "SC1HL150742", "Award Amount": 1427232.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-20", "CFDA Number": "93.859", "Description": "MECHANISMS OF AIRWAY EPITHELIAL INJURY AND RESPONSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1ebd38d0-dcb9-749e-ab67-d7eff9806174-C", "generated_internal_id": "ASST_NON_SC1HL150742_7529"}, {"internal_id": 110464165, "Award ID": "R61HL156248", "Award Amount": 708424.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-17", "CFDA Number": "93.838", "Description": "TREATMENT OF FENTANYL OVERDOSE-INDUCED RESPIRATORY FAILURE BY LOW-DOSE DEXMEDETOMIDINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47ed9961-3300-5ed7-bb62-e5359d99eaf9-C", "generated_internal_id": "ASST_NON_R61HL156248_7529"}, {"internal_id": 110464537, "Award ID": "R61HL156240", "Award Amount": 736818.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-17", "CFDA Number": "93.279", "Description": "INTRANASAL LEPTIN AS A NOVEL TREATMENT OF OPIOID-INDUCED RESPIRATORY DEPRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R61HL156240_7529"}, {"internal_id": 109278378, "Award ID": "R61HL154136", "Award Amount": 1136609.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-20", "CFDA Number": "93.837", "Description": "SUDAXINE AS AN ANALGESIA SPARING RESPIRATORY STIMULANT FOR USE IN CRITICAL CARE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R61HL154136_7529"}, {"internal_id": 109190047, "Award ID": "R61HL154105", "Award Amount": 788746.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-15", "CFDA Number": "93.837", "Description": "COMMERCIAL TRANSLATION OF BIOMARKER-BASED PLATFORM FOR PERSONALIZED FORECASTING OF RAPID LUNG FUNCTION DECLINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R61HL154105_7529"}, {"internal_id": 111328706, "Award ID": "R61HL154095", "Award Amount": 648267.83, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-03", "CFDA Number": "93.837", "Description": "REAL-TIME STATE OF VIGILANCE MONITOR FOR THE NEONATAL INTENSIVE CARE UNIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R61HL154095_7529"}, {"internal_id": 110233485, "Award ID": "R61HL153011", "Award Amount": 452945.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-07", "CFDA Number": "93.837", "Description": "A PHASE 1B STUDY OF INHALED CO FOR THE TREATMENT OF SEPSIS-INDUCED ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R61HL153011_7529"}, {"internal_id": 110233927, "Award ID": "R61HL151951", "Award Amount": 414068.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-11", "CFDA Number": "93.837", "Description": "MAXIMIZING EFFICACY OF GOAL-DIRECTED SEDATION TO REDUCE NEUROLOGICAL DYSFUNCTION IN MECHANICALLY VENTILATED INFANTS AND CHILDREN STUDY (MINI-MENDS)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R61HL151951_7529"}, {"internal_id": 110862799, "Award ID": "R61HL147908", "Award Amount": 413856.55, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-24", "CFDA Number": "93.837", "Description": "EVALUATION OF THE ASTHMA MANAGEMENT PROGRAM TO PROMOTE ACTIVITY FOR STUDENTS IN SCHOOLS (ASTHMA-PASS)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R61HL147908_7529"}, {"internal_id": 85590221, "Award ID": "R61HL147906", "Award Amount": 416906.74, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-13", "CFDA Number": "93.837", "Description": "EXTENDING CPAP THERAPY IN STABLE PRETERM INFANTS TO INCREASE LUNG GROWTH AND FUNCTION: A RANDOMIZED CONTROLLED TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R61HL147906_7529"}, {"internal_id": 85590825, "Award ID": "R61HL147833", "Award Amount": 658357.85, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-12", "CFDA Number": "93.837", "Description": "SAFETY OF SILDENAFIL IN PREMATURE INFANTS WITH SEVERE BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R61HL147833_7529"}, {"internal_id": 85590333, "Award ID": "R61HL146365", "Award Amount": 836647.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-11", "CFDA Number": "93.837", "Description": "POINT-OF-CARE C-REACTIVE PROTEIN-BASED TUBERCULOSIS SCREENING IN PEOPLE LIVING WITH HIV: A RANDOMIZED TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R61HL146365_7529"}, {"internal_id": 68566141, "Award ID": "R61HL143317", "Award Amount": 1630721.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-17", "CFDA Number": "93.837", "Description": "COMPREHENSIVE HEALTH INFORMATICS ENGAGEMENT FRAMEWORK FOR PULMONARY REHAB", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R61HL143317_7529"}, {"internal_id": 68565403, "Award ID": "R61HL142933", "Award Amount": 731906.37, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-17", "CFDA Number": "93.837", "Description": "INCREASING ADHERENCE TO PULMONARY REHABILITATION AFTER COPD-RELATED HOSPITALIZATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R61HL142933_7529"}, {"internal_id": 68565571, "Award ID": "R61HL142539", "Award Amount": 333063.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-18", "CFDA Number": "93.838", "Description": "REHAB-PH TRIAL: REPURPOSING A HISTAMINE ANTAGONIST TO BENEFIT PATIENTS WITH PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R61HL142539_7529"}, {"internal_id": 66199581, "Award ID": "R61HL138650", "Award Amount": 215661.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-18", "CFDA Number": "93.838", "Description": "RANDOMIZED TRIAL OF ENDOTRACHEAL TUBES TO PREVENT VENTILATOR-ASSOCIATED PNEUMONIA - PREVENT 2 STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R61HL138650_7529"}, {"internal_id": 49827339, "Award ID": "R61HL137081", "Award Amount": 557849.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-24", "CFDA Number": "93.838", "Description": "THE B CELL REPERTOIRE AS A WINDOW INTO THE NATURE AND IMPACT OF THE LUNG VIROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R61HL137081_7529"}, {"internal_id": 49827338, "Award ID": "R61HL137079", "Award Amount": 431928.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-24", "CFDA Number": "93.838", "Description": "THE VIROME AND ADVERSE OUTCOMES IN LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R61HL137079_7529"}, {"internal_id": 49827337, "Award ID": "R61HL137077", "Award Amount": 491336.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-30", "CFDA Number": "93.838", "Description": "IMPACT OF VIROME ON MICROBIAL COMMUNITIES IN THE RESPIRATORY TRACT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R61HL137077_7529"}, {"internal_id": 49827336, "Award ID": "R61HL137063", "Award Amount": 605207.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-24", "CFDA Number": "93.838", "Description": "THE LUNG DNA VIROME IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R61HL137063_7529"}, {"internal_id": 110464860, "Award ID": "R56HL153460", "Award Amount": 275900.42, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-16", "CFDA Number": "93.837", "Description": "COPD CACHEXIA: DECIPHERING THE IMPACT OF ANTIOXIDANTS, IRON AND MITOCHONDRIAL FUNCTION USING  'OMICS APPROACHES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R56HL153460_7529"}, {"internal_id": 110862722, "Award ID": "R56HL153065", "Award Amount": 378750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-24", "CFDA Number": "93.838", "Description": "NOVEL COLLAGEN V-REACTIVE NATURAL TH17 CELLS IN HYPOXIC PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a5b5888e-f4b5-655c-bd88-d970f969d7c9-C", "generated_internal_id": "ASST_NON_R56HL153065_7529"}, {"internal_id": 110862481, "Award ID": "R56HL152167", "Award Amount": 674589.06, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-23", "CFDA Number": "93.837", "Description": "ROLE OF POLDIP2 IN ENDOTHELIAL BARRIER FUNCTION AND INFLAMMATION IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R56HL152167_7529"}, {"internal_id": 110464306, "Award ID": "R56HL151700", "Award Amount": 554211.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-16", "CFDA Number": "93.838", "Description": "HEDGEHOG AND PLATELET-DERIVED GROWTH FACTOR PATHWAY CROSSTALK IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_R56HL151700_7529"}, {"internal_id": 110464120, "Award ID": "R56HL151637", "Award Amount": 793065.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-16", "CFDA Number": "93.838", "Description": "IMPROVING THE HEALTH OF EMS PROFESSIONALS THROUGH SLEEP HEALTH EDUCATION AND SLEEP DISORDER SCREENING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R56HL151637_7529"}, {"internal_id": 110463792, "Award ID": "R56HL151602", "Award Amount": 586400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-16", "CFDA Number": "93.837", "Description": "DIASTOLIC DYSFUNCTION IN HIV INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce6cc294-968c-0136-a2e3-f34319ce4753-C", "generated_internal_id": "ASST_NON_R56HL151602_7529"}, {"internal_id": 110463859, "Award ID": "R56HL150658", "Award Amount": 382560.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-16", "CFDA Number": "93.838", "Description": "NEUTROPHIL HYPEREXOCYTOSIS AND HYPOCHLOROUS ACID EXPOSURE IN EARLY CYSTIC FIBROSIS LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R56HL150658_7529"}, {"internal_id": 110464591, "Award ID": "R56HL149733", "Award Amount": 342500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-16", "CFDA Number": "93.837", "Description": "CELLULAR SENESCENCE AS A NEW MECHANISM OF BRONCHOPULMONARY DYSPLASIA (BPD)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5019c65a-150d-0d35-67c3-d81832a20ef7-C", "generated_internal_id": "ASST_NON_R56HL149733_7529"}, {"internal_id": 110862496, "Award ID": "R56HL149129", "Award Amount": 857679.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-23", "CFDA Number": "93.837", "Description": "INVESTIGATION OF SEX VARIATION IN PD-1/PSTAT3/IL-17A SIGNALING IN SARCOIDOSIS PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R56HL149129_7529"}, {"internal_id": 85589463, "Award ID": "R56HL148774", "Award Amount": 429344.96, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-19", "CFDA Number": "93.837", "Description": "REGULATION OF LIPID METABOLISM IN PULMONARY TYPE 2 CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "753b4a63-1dfe-a327-a837-d9cf4908b025-C", "generated_internal_id": "ASST_NON_R56HL148774_7529"}, {"internal_id": 85588339, "Award ID": "R56HL148604", "Award Amount": 203560.73, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-17", "CFDA Number": "93.837", "Description": "MACROPHAGE IMMUNOMETABOLISM ALTERATION BY  INTENSE BETA AGONIST THERAPY.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R56HL148604_7529"}, {"internal_id": 85588673, "Award ID": "R56HL147863", "Award Amount": 425376.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-17", "CFDA Number": "93.837", "Description": "TGFB AND PULMONARY ALDEHYDES IN NEWBORN LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R56HL147863_7529"}, {"internal_id": 110464291, "Award ID": "R56HL147073", "Award Amount": 465181.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-16", "CFDA Number": "93.838", "Description": "MECHANISM FOR HYPERTONIC SALINE EFFECT ON MUCOCILIARY TRANSPORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R56HL147073_7529"}, {"internal_id": 69723526, "Award ID": "R56HL143366", "Award Amount": 579119.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-20", "CFDA Number": "93.838", "Description": "PULMONARY SPECIALIST-HEALTH COACH CONSULT (PUSHCON) MODEL TO IMPROVE ACCESS TO SPECIALIST CONSULTATION AND RECEIPT OF RECOMMENDED EVIDENCE-BASED CARE FOR VULNERABLE PATIENTS WITH COPD AND ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R56HL143366_7529"}, {"internal_id": 68565434, "Award ID": "R56HL143076", "Award Amount": 281275.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-07", "CFDA Number": "93.838", "Description": "BIOENGINEERED MULTI-CELL TYPE ORGANOIDS FOR AIRWAYS DISEASE MODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "623a4232-bd5e-fb60-cf01-48cd08a5a593-C", "generated_internal_id": "ASST_NON_R56HL143076_7529"}, {"internal_id": 110862074, "Award ID": "R56HL142890", "Award Amount": 404167.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-24", "CFDA Number": "93.838", "Description": "MECHANISMS OF RHINOVIRUS-INDUCED AIRWAY HYPERRESPONSIVENESS: AN AIRWAY SMOOTH MUSCLE PERSPECTIVE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9df96abd-2d31-e426-d699-23d012e1079e-C", "generated_internal_id": "ASST_NON_R56HL142890_7529"}, {"internal_id": 68568221, "Award ID": "R56HL142857", "Award Amount": 499834.87, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-07", "CFDA Number": "93.837", "Description": "BACTERIAL REGULATORY EVOLUTION DURING ADAPTATION TO CHRONIC INFECTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7c481d7-071a-ead9-3bda-e4e7d1e903a7-C", "generated_internal_id": "ASST_NON_R56HL142857_7529"}, {"internal_id": 68565396, "Award ID": "R56HL142767", "Award Amount": 583386.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-06", "CFDA Number": "93.837", "Description": "DISSECTING THE MOLECULAR MECHANISMS OF LUNG INJURY DURING MECHANICAL VENTILATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R56HL142767_7529"}, {"internal_id": 68565722, "Award ID": "R56HL142701", "Award Amount": 469988.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-06", "CFDA Number": "93.838", "Description": "DEFINING GROUP 2 INNATE LYMPHOID CELL LUNG NICHES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R56HL142701_7529"}, {"internal_id": 85590626, "Award ID": "R56HL141744", "Award Amount": 756559.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-14", "CFDA Number": "93.837", "Description": "NUTRITIONAL MODULATION TO MINIMIZE RESISTANCE EXERCISE INDUCED METABOLIC DEREGULATIONS AND IMPROVE TRAINING RESPONSIVENESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "44913900-e35a-479d-fd2b-81775f5f37a7-C", "generated_internal_id": "ASST_NON_R56HL141744_7529"}, {"internal_id": 68565608, "Award ID": "R56HL141567", "Award Amount": 726737.15, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-05", "CFDA Number": "93.837", "Description": "VITAMIN D TO IMPROVE OUTCOMES BY LEVERAGING EARLY TREATMENT: LONG-TERM BRAIN OUTCOMES IN VITAMIN D DEFICIENT PATIENTS (VIOLET-BUD)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R56HL141567_7529"}, {"internal_id": 68566555, "Award ID": "R56HL141499", "Award Amount": 397425.83, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-14", "CFDA Number": "93.837", "Description": "RHOA IN T CELL-MEDIATED AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R56HL141499_7529"}, {"internal_id": 69723971, "Award ID": "R56HL141394", "Award Amount": 769025.83, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-19", "CFDA Number": "93.837", "Description": "REACT AN ADAPTIVE MOBILE HEALTH INTERVENTION FOR ADOLESCENT ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "77c2126f-1eeb-1497-ee97-f5b830ca5e7d-C", "generated_internal_id": "ASST_NON_R56HL141394_7529"}, {"internal_id": 68567138, "Award ID": "R56HL141251", "Award Amount": 397638.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-15", "CFDA Number": "93.837", "Description": "CHOLINERGIC MECHANISMS INVOLVED IN TRANSDUCTION OF AIRWAY DEFENSIVE REFLEXES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R56HL141251_7529"}, {"internal_id": 68567645, "Award ID": "R56HL141237", "Award Amount": 440807.88, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-10", "CFDA Number": "93.837", "Description": "TSLP RESPONSES IN THE HUMAN INFANT AIRWAY EPITHELIUM AND RECURRENT WHEEZING AFTER RV AND RSV INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_R56HL141237_7529"}, {"internal_id": 85590685, "Award ID": "R56HL141206", "Award Amount": 599673.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-17", "CFDA Number": "93.837", "Description": "ENDOTHELIUM-DERIVED EXTRACELLULAR VESICLES, MICRORNAS AND PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R56HL141206_7529"}, {"internal_id": 68565704, "Award ID": "R56HL141098", "Award Amount": 670887.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-18", "CFDA Number": "93.838", "Description": "CLINICAL EFFECTS OF EVOLVED VARIATION IN INFECTING BACTERIAL POPULATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R56HL141098_7529"}, {"internal_id": 68565835, "Award ID": "R56HL139983", "Award Amount": 409905.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-14", "CFDA Number": "93.837", "Description": "THE ATX/LPA AXIS REGULATES MUCOSAL IMMUNITY AND ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R56HL139983_7529"}, {"internal_id": 68565282, "Award ID": "R56HL139767", "Award Amount": 369388.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-14", "CFDA Number": "93.837", "Description": "FLOW STRUCTURE INTERACTION MODEL FOR COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R56HL139767_7529"}, {"internal_id": 85590766, "Award ID": "R56HL139564", "Award Amount": 413645.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-14", "CFDA Number": "93.837", "Description": "NITRIC OXIDE INDUCED SOLUBLE GUANYLATE CYCLASE DYSFUNCTION OR ACTIVATION: IMPLICATIONS AS DISEASE BIOMARKERS OR IN THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R56HL139564_7529"}, {"internal_id": 85589326, "Award ID": "R56HL139559", "Award Amount": 401567.12, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-17", "CFDA Number": "93.837", "Description": "THE NLRP3 INFLAMMASOME IN REGULATING INJURY WITH LUNG TRANSPLANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R56HL139559_7529"}, {"internal_id": 49826917, "Award ID": "R56HL138496", "Award Amount": 402706.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-02", "CFDA Number": "93.838", "Description": "A NOVEL TRPV4-ENOS SIGNALING PATHWAY IN PULMONARY ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R56HL138496_7529"}, {"internal_id": 68567521, "Award ID": "R56HL138435", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-08", "CFDA Number": "93.838", "Description": "MITOCHONDRIAL QUALITY CONTROL IN CIGARETTE SMOKE INDUCED COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R56HL138435_7529"}, {"internal_id": 49826903, "Award ID": "R56HL137709", "Award Amount": 342761.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-01", "CFDA Number": "93.838", "Description": "EPIGENETIC REGULATION OF CHEMOKINES IN LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R56HL137709_7529"}, {"internal_id": 69726142, "Award ID": "R56HL136909", "Award Amount": 531587.74, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-21", "CFDA Number": "93.837", "Description": "REGULATION OF AIRWAY MUCUS HYDRATION/CLEARANCE BY RELEASED NUCLEOTIDES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R56HL136909_7529"}, {"internal_id": 68565550, "Award ID": "R56HL136733", "Award Amount": 427617.74, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-10", "CFDA Number": "93.837", "Description": "RESCUED CFTR FUNCTION IN PRECLINICAL MODELS OF AIRWAY EPITHELIAL INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R56HL136733_7529"}, {"internal_id": 49826901, "Award ID": "R56HL136715", "Award Amount": 549370.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-22", "CFDA Number": "93.838", "Description": "MOLECULAR MECHANISMS OF NEONATAL PULMONARY HEMORRHAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R56HL136715_7529"}, {"internal_id": 49826898, "Award ID": "R56HL136494", "Award Amount": 287355.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-26", "CFDA Number": "93.838", "Description": "MATRICELLULAR SIGNALING IN ENGINEERED TRACHEAL TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R56HL136494_7529"}, {"internal_id": 69725890, "Award ID": "R56HL136476", "Award Amount": 422530.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-19", "CFDA Number": "93.837", "Description": "MANIPULATING TISSUE STRAIN IN SURGICAL REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R56HL136476_7529"}, {"internal_id": 49826895, "Award ID": "R56HL136293", "Award Amount": 488606.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-01", "CFDA Number": "93.838", "Description": "THERAPEUTIC APPLICATION OF GENETIC ASSOCIATION RESULTS: CF LUNG DISEASE MODIFIERS AS A MODEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R56HL136293_7529"}, {"internal_id": 49826889, "Award ID": "R56HL135124", "Award Amount": 459654.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-23", "CFDA Number": "93.837", "Description": "DIFFERENTIAL ROLE OF TISSUE-RESIDENT AND MONOCYTE-DERIVED ALVEOLAR MACROPHAGES IN THE DEVELOPMENT OF PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R56HL135124_7529"}, {"internal_id": 49826887, "Award ID": "R56HL134736", "Award Amount": 614649.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-28", "CFDA Number": "93.838", "Description": "MECHANISMS OF RIGHT VENTRICLE ADAPTATION TO PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R56HL134736_7529"}, {"internal_id": 49826886, "Award ID": "R56HL134356", "Award Amount": 569917.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.838", "Description": "WHOLE BLOOD MICRORNAS AS RISK AND SURVIVAL BIOMARKERS FOR ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_R56HL134356_7529"}, {"internal_id": 49826878, "Award ID": "R56HL133336", "Award Amount": 100188.0, "Award Type": null, "Base Obligation Date": "2016-09-15", "CFDA Number": "93.838", "Description": "INNATE IMMUNITY IN PNEUMONIC SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07ed9f27-c528-e9d5-e332-90c8b04f48b8-C", "generated_internal_id": "ASST_NON_R56HL133336_7529"}, {"internal_id": 49826877, "Award ID": "R56HL133205", "Award Amount": 574016.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-02", "CFDA Number": "93.838", "Description": "CELL MECHANICAL ENDOTYPES IN THE ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R56HL133205_7529"}, {"internal_id": 49826855, "Award ID": "R56HL131787", "Award Amount": 444928.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-05", "CFDA Number": "93.838", "Description": "FIBROSOME REGULATION BY ALDOSTERONE IN PULMONARY VASCULAR DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R56HL131787_7529"}, {"internal_id": 49826852, "Award ID": "R56HL131745", "Award Amount": 338830.0, "Award Type": null, "Base Obligation Date": "2016-09-16", "CFDA Number": "93.838", "Description": "HYPERCAPNIA AND SUPPRESSION OF ANTI-VIRAL HOST DEFENSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R56HL131745_7529"}, {"internal_id": 49826845, "Award ID": "R56HL131466", "Award Amount": 371782.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-30", "CFDA Number": "93.838", "Description": "NEUTROPHIL EXTRACELLULAR TRAPS IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_R56HL131466_7529"}, {"internal_id": 49826843, "Award ID": "R56HL131054", "Award Amount": 438400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.838", "Description": "PAI-1 AND AGING-RELATED SUSCEPTIBILITY TO LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R56HL131054_7529"}, {"internal_id": 49826842, "Award ID": "R56HL131010", "Award Amount": 646533.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-14", "CFDA Number": "93.233", "Description": "NEUROCHEMICAL ASSESSMENT OF SLEEP APNEA USING ACCELERATED MR SPECTROSCOPIC IMAGING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R56HL131010_7529"}, {"internal_id": 49826836, "Award ID": "R56HL130422", "Award Amount": 418750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-22", "CFDA Number": "93.838", "Description": "ROLE OF ION CHANNELS IN THE PATHOGENESIS OF AIRWAY DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_R56HL130422_7529"}, {"internal_id": 49826833, "Award ID": "R56HL130130", "Award Amount": 415040.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.838", "Description": "THERAPEUTIC SURFACTANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R56HL130130_7529"}, {"internal_id": 49826822, "Award ID": "R56HL128746", "Award Amount": 386750.0, "Award Type": null, "Base Obligation Date": "2015-09-04", "CFDA Number": "93.838", "Description": "REGULATION OF THE LUNG ANTIVIRAL INFLAMMATORY RESPONSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47ed9961-3300-5ed7-bb62-e5359d99eaf9-C", "generated_internal_id": "ASST_NON_R56HL128746_7529"}, {"internal_id": 49826810, "Award ID": "R56HL128285", "Award Amount": 365053.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-13", "CFDA Number": "93.838", "Description": "TARGETED CELL THERAPY FOR ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R56HL128285_7529"}, {"internal_id": 49826801, "Award ID": "R56HL127245", "Award Amount": 611380.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-09", "CFDA Number": "93.838", "Description": "WNT/BETA-CATENIN SIGNALING AND INNATE IMMUNITY IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R56HL127245_7529"}, {"internal_id": 49826798, "Award ID": "R56HL127202", "Award Amount": 351554.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-13", "CFDA Number": "93.838", "Description": "NOVEL PATHWAYS IN TGF BETA SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R56HL127202_7529"}, {"internal_id": 49826794, "Award ID": "R56HL127020", "Award Amount": 721176.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-16", "CFDA Number": "93.838", "Description": "EFFECT OF OSA & CHRONIC INTERMITTENT HYPOXIA ON CEREBRAL METABOLIC O2 CONSUMPTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R56HL127020_7529"}, {"internal_id": 49826788, "Award ID": "R56HL126761", "Award Amount": 272237.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-01", "CFDA Number": "93.838", "Description": "LINKING SPATIAL ACCESS AND HEALTH OUTCOMES FOR PEDIATRIC ASTHMA IN THE MEDICAID SYSTEM: INFERENCES AND INTERVENTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7c481d7-071a-ead9-3bda-e4e7d1e903a7-C", "generated_internal_id": "ASST_NON_R56HL126761_7529"}, {"internal_id": 49826787, "Award ID": "R56HL126754", "Award Amount": 387500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.838", "Description": "OMICS OF PULMONARY EXACERBATIONS IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R56HL126754_7529"}, {"internal_id": 49826776, "Award ID": "R56HL126525", "Award Amount": 754992.0, "Award Type": null, "Base Obligation Date": "2014-09-03", "CFDA Number": "93.838", "Description": "IMMUNE DYSFUNCTION AND PULMONARY HYPERTENSION IN PRIMATE MODEL OF HIV INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_R56HL126525_7529"}, {"internal_id": 49826770, "Award ID": "R56HL125653", "Award Amount": 383741.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-31", "CFDA Number": "93.838", "Description": "ROLE OF INTERFERONS IN STAPHYLOCOCCUS AUREUS UPPER RESPIRATORY TRACT INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R56HL125653_7529"}, {"internal_id": 49826759, "Award ID": "R56HL125043", "Award Amount": 683047.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-11", "CFDA Number": "93.838", "Description": "ENDOTHELIAL MECHANISMS OF IMPAIRED LUNG GAS EXCHANGE BY HIV", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R56HL125043_7529"}, {"internal_id": 49826722, "Award ID": "R56HL122585", "Award Amount": 405000.0, "Award Type": null, "Base Obligation Date": "2015-09-01", "CFDA Number": "93.838", "Description": "EARLY EVENTS REGULATING POST-VIRAL IMMUNOPATHOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7eb6683a-d796-f7f5-68c0-ca8f32275b30-C", "generated_internal_id": "ASST_NON_R56HL122585_7529"}, {"internal_id": 49826702, "Award ID": "R56HL119321", "Award Amount": 396250.0, "Award Type": null, "Base Obligation Date": "2015-09-01", "CFDA Number": "93.838", "Description": "EFFECTOR CELL LINEAGE COMMITMENT IN ALLERGIC INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R56HL119321_7529"}, {"internal_id": 49826691, "Award ID": "R56HL117032", "Award Amount": 360515.0, "Award Type": null, "Base Obligation Date": "2015-09-01", "CFDA Number": "93.838", "Description": "MECHANISMS OF PRMT REGULATION OF PULMONARY ENDOTHELIAL CELL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_R56HL117032_7529"}, {"internal_id": 85590142, "Award ID": "R56HL113071", "Award Amount": 400099.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-17", "CFDA Number": "93.837", "Description": "GROUP VSPLA2 IN INNATE IMMUNITY AND PULMONARY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R56HL113071_7529"}, {"internal_id": 68566461, "Award ID": "R56HL107778", "Award Amount": 375321.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-13", "CFDA Number": "93.837", "Description": "IMMUNOPHILINS REGULATE SOC ENTRY CHANNELS IN PULMONARY ENDOTHELIAL CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_R56HL107778_7529"}, {"internal_id": 49826683, "Award ID": "R56HL107493", "Award Amount": 393619.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-22", "CFDA Number": "93.838", "Description": "CHIBBY AND ITS ASSOCIATED PROTEINS IN CILIATED CELL DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3313e5e7-fa36-d54b-e36d-0e1e09cc0c30-C", "generated_internal_id": "ASST_NON_R56HL107493_7529"}, {"internal_id": 49826682, "Award ID": "R56HL106041", "Award Amount": 393750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-16", "CFDA Number": "93.838", "Description": "VASCULAR ENDOTHELIAL ACTIVATION IN SLEEP APNEA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R56HL106041_7529"}, {"internal_id": 49826681, "Award ID": "R56HL105947", "Award Amount": 399750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-22", "CFDA Number": "93.838", "Description": "REGULATION OF TYPE II CELLS IN THE REPAIR OFALVEOLAR EPITHELIAL INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R56HL105947_7529"}, {"internal_id": 49826680, "Award ID": "R56HL105932", "Award Amount": 339457.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISMS OF HYPEROXIC LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ceec5ef7-d6a5-28f0-e23f-ec61155b7078-C", "generated_internal_id": "ASST_NON_R56HL105932_7529"}, {"internal_id": 49826678, "Award ID": "R56HL097566", "Award Amount": 528672.0, "Award Type": null, "Base Obligation Date": "2015-09-11", "CFDA Number": "93.838", "Description": "CHRONIC PROGRESSIVE HYPOXIA-INDUCED PULMONARY HYPERTENSION IN NEWBORNS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R56HL097566_7529"}, {"internal_id": 49826664, "Award ID": "R56HL088144", "Award Amount": 421630.0, "Award Type": null, "Base Obligation Date": "2015-09-01", "CFDA Number": "93.838", "Description": "CORTACTIN IN REGULATION OF PULMONARY VASCULAR PERMEABILITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R56HL088144_7529"}, {"internal_id": 68567107, "Award ID": "R56HL068702", "Award Amount": 426318.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-18", "CFDA Number": "93.837", "Description": "ROLE OF VEGF IN PERINATAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R56HL068702_7529"}, {"internal_id": 110025114, "Award ID": "R44HL154950", "Award Amount": 1902509.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-24", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A LOW DOSE CLINICAL LUNG SCREENING PROTOTYPE FOR EARLY DETECTION OF COPD AND LUNG CANCER USING A NOVEL X-RAY SOURCE TO ENABLE TALBOT-LAU INTERFEROMETRY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fcdbf93a-eebd-1c91-256d-8168e6a07cf9-C", "generated_internal_id": "ASST_NON_R44HL154950_7529"}, {"internal_id": 108463218, "Award ID": "R44HL154932", "Award Amount": 1919359.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-07", "CFDA Number": "93.837", "Description": "PORTABLE NONINVASIVE POSITIVE AIRWAY DEVICE FOR COPD PATIENT THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "efb98765-fc43-2914-81a5-4e958cb22964-C", "generated_internal_id": "ASST_NON_R44HL154932_7529"}, {"internal_id": 108463702, "Award ID": "R44HL152780", "Award Amount": 2049781.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-10", "CFDA Number": "93.837", "Description": "TREATING SEVERE ASTHMA IN THE SMALL AIRWAYS WITH A HIGHLY EFFICIENT AND PENETRATING INHALED DRY POWDER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ee807eb-bbea-335a-591b-d62a85fc121a-R", "generated_internal_id": "ASST_NON_R44HL152780_7529"}, {"internal_id": 98487235, "Award ID": "R44HL151144", "Award Amount": 1181971.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-29", "CFDA Number": "93.837", "Description": "PHASE 2 CLINICAL TRIAL EVALUATING A NOVEL THERAPY IN PATIENTS WHO ARE POST-LUNG TRANSPLANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5baa1096-c0f4-4d3d-2e40-184add318286-R", "generated_internal_id": "ASST_NON_R44HL151144_7529"}, {"internal_id": 95181714, "Award ID": "R44HL151067", "Award Amount": 1515600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-10", "CFDA Number": "93.838", "Description": "INHALED IRK INHIBITORS AS A NOVEL THERAPEUTIC FOR IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "949917e8-9218-4937-1910-5e2c1c8744e9-R", "generated_internal_id": "ASST_NON_R44HL151067_7529"}, {"internal_id": 96202261, "Award ID": "R44HL151032", "Award Amount": 2964550.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-03", "CFDA Number": "93.837", "Description": "NOVEL EXPANDABLE INFUSION CATHETER FOR THE TREATMENT OF ACUTE PULMONARY EMBOLISM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "12f45630-b77f-f644-5b5c-0134f4c0d290-R", "generated_internal_id": "ASST_NON_R44HL151032_7529"}, {"internal_id": 110024881, "Award ID": "R44HL150926", "Award Amount": 1722021.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-27", "CFDA Number": "93.837", "Description": "IMPROVED SYSTEMS FOR RESPIRATORY SUPPORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e46b3c39-8052-f072-21a4-6491e3e07cc4-R", "generated_internal_id": "ASST_NON_R44HL150926_7529"}, {"internal_id": 96557700, "Award ID": "R44HL149550", "Award Amount": 2166021.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-10", "CFDA Number": "93.837", "Description": "ENDOBRONCHIAL SUPERVALVE FOR THE TREATMENT OF EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7c98a346-2c57-7389-3243-34bd9eec146f-C", "generated_internal_id": "ASST_NON_R44HL149550_7529"}, {"internal_id": 82470114, "Award ID": "R44HL147724", "Award Amount": 1551949.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-30", "CFDA Number": "93.837", "Description": "TREATMENT OF LUNG FIBROSIS : IND PHARMACOLOGY AND TOXICOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "50173bc2-601b-b879-3982-b2df8ac7b2c0-R", "generated_internal_id": "ASST_NON_R44HL147724_7529"}, {"internal_id": 67833189, "Award ID": "R44HL142391", "Award Amount": 1720137.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-10", "CFDA Number": "93.837", "Description": "ANTIMICROBIAL AND BIOCOMPATIBLE ENDOTRACHEAL TUBES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7383efa7-b932-beb7-5317-68832bcf8ba1-R", "generated_internal_id": "ASST_NON_R44HL142391_7529"}, {"internal_id": 67579501, "Award ID": "R44HL140894", "Award Amount": 1717656.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-27", "CFDA Number": "93.837", "Description": "COMMERCIALIZATION OF A CT-BASED TECHNIQUE FOR BOS ASSESSMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4cdf4321-8fe8-7205-c994-e830181c4b9d-C", "generated_internal_id": "ASST_NON_R44HL140894_7529"}, {"internal_id": 49823617, "Award ID": "R44HL140735", "Award Amount": 1724117.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-18", "CFDA Number": "93.838", "Description": "DEVELOPMENT OF MODIFIED HUMAN THIOREDOXIN AS AN INHALED BIOLOGIC THERAPEUTIC FOR CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "02592754-c55f-3500-602c-95ebe9da034b-R", "generated_internal_id": "ASST_NON_R44HL140735_7529"}, {"internal_id": 83116221, "Award ID": "R44HL140709", "Award Amount": 1567058.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-05", "CFDA Number": "93.837", "Description": "REOPENING THE CENTRAL AIRWAY WITH NEEDLE-SIZE TENTACLE MANIPULATORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a4044fbb-310b-be55-c6e8-4141a4aad19c-R", "generated_internal_id": "ASST_NON_R44HL140709_7529"}, {"internal_id": 62420294, "Award ID": "R44HL140690", "Award Amount": 2773268.11, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-17", "CFDA Number": "93.837", "Description": "SAFETY, TOLERABILITY AND EFFICACY OF A NOVEL SUSTAINED RELEASE ANALOG OF VASOACTIVE INTESTINAL PEPTIDE, PB1046, IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a98b77a6-7f33-4125-2719-3cb03b798633-R", "generated_internal_id": "ASST_NON_R44HL140690_7529"}, {"internal_id": 67833167, "Award ID": "R44HL140680", "Award Amount": 2655879.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-15", "CFDA Number": "93.837", "Description": "OPTIMIZATION OF LGM2605 FOR USE AS A DEVICE IN LUNG TRANSPLANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b3a8f6bf-8524-f564-8f79-73b2ea7c91b0-C", "generated_internal_id": "ASST_NON_R44HL140680_7529"}, {"internal_id": 49823613, "Award ID": "R44HL139218", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-14", "CFDA Number": "93.837", "Description": "A GENE THERAPY FOR CYSTIC FIBROSIS USING GP64-PSEUDOTYPED LENTIVIRUS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47949a12-4426-123d-1113-b9b247b77e73-R", "generated_internal_id": "ASST_NON_R44HL139218_7529"}, {"internal_id": 49823610, "Award ID": "R44HL138185", "Award Amount": 2204828.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-10", "CFDA Number": "93.837", "Description": "WHOLE-ORGAN BIOREACTOR WITH INTEGRATED NONDESTRUCTIVE 3D MOLECULAR IMAGING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "52f8de5f-b38f-482b-e9c5-f5a947a0c09e-R", "generated_internal_id": "ASST_NON_R44HL138185_7529"}, {"internal_id": 49823608, "Award ID": "R44HL137502", "Award Amount": 1724981.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-01", "CFDA Number": "93.837", "Description": "INSPIRATION POINT-A DIGITAL PULMONARY REHABILITATION TOOL FOR USE WITH SELF-MANAGEMENT INTERVENTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c23afa28-7665-add4-c583-4b5e8a518463-C", "generated_internal_id": "ASST_NON_R44HL137502_7529"}, {"internal_id": 79434145, "Award ID": "R44HL134456", "Award Amount": 1215526.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-30", "CFDA Number": "93.837", "Description": "ANTIMICROBIAL TRACHEOSTOMY TUBE TO PREVENT BIOFILM AND REDUCE INFECTIONRISKS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "224ab16f-b9ea-3537-be8e-ea1ef491587f-C", "generated_internal_id": "ASST_NON_R44HL134456_7529"}, {"internal_id": 49823592, "Award ID": "R44HL134429", "Award Amount": 4466584.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.837", "Description": "IRIDIUM-ELECTRODE INHALED NITRIC OXIDE GENERATOR FOR TREATMENT OF HYPOXIC RESPIRATORY FAILURE IN NEONATES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0ccfd7ef-6584-3cd5-52c9-c272d8779a5b-C", "generated_internal_id": "ASST_NON_R44HL134429_7529"}, {"internal_id": 49823590, "Award ID": "R44HL134012", "Award Amount": 1591096.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-28", "CFDA Number": "93.837", "Description": "CELLULAR MODEL FOR PERSONALIZED CFTR-DIRECTED THERAPEUTICS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27e04eb3-6954-7a00-83ba-9d0601117131-R", "generated_internal_id": "ASST_NON_R44HL134012_7529"}, {"internal_id": 49823589, "Award ID": "R44HL132816", "Award Amount": 1659118.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-15", "CFDA Number": "93.837", "Description": "PORTABLE LOW-COST PULMONARY FORCED OSCILLATION TECHNIQUE INSTRUMENT USING A NOVEL SENSOR DESIGN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "efb98765-fc43-2914-81a5-4e958cb22964-C", "generated_internal_id": "ASST_NON_R44HL132816_7529"}, {"internal_id": 49823587, "Award ID": "R44HL132721", "Award Amount": 1730420.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-24", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF AN ORAL ACIDIC MAMMALIAN CHITINASE INHIBITOR TO TREAT ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d008274-fd6e-24a5-0807-8d50581284f7-R", "generated_internal_id": "ASST_NON_R44HL132721_7529"}, {"internal_id": 49823586, "Award ID": "R44HL132688", "Award Amount": 1674659.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-06", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A PEDIATRIC TRANSCATHETER PULMONARY VALVE SYSTEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3d12083d-3578-d0b7-030b-2741c48beea7-R", "generated_internal_id": "ASST_NON_R44HL132688_7529"}, {"internal_id": 49823576, "Award ID": "R44HL130189", "Award Amount": 1599984.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-21", "CFDA Number": "93.837", "Description": "HUMAN NASAL EPITHELIAL ORGANOIDS AS A NON-INVASIVE, PERSONALIZED MODEL FOR PREDICTING EFFECTIVENESS OF CFTR MODULATORS IN CYSTIC FIBROSIS PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9a556d-a643-018e-bb4c-d289fad639b9-R", "generated_internal_id": "ASST_NON_R44HL130189_7529"}, {"internal_id": 49823573, "Award ID": "R44HL129593", "Award Amount": 1725025.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-22", "CFDA Number": "93.838", "Description": "PRECLINICAL DEVELOPMENT OF INHALABLE GLUTAREDOXIN-1 FOR THE TREATMENT OF IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7563718c-2b38-08e1-4785-8c76f7e05d9b-C", "generated_internal_id": "ASST_NON_R44HL129593_7529"}, {"internal_id": 49823567, "Award ID": "R44HL127886", "Award Amount": 1706740.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-25", "CFDA Number": "93.838", "Description": "ARF6 INHIBITORS FOR TREATMENT OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fd356f95-7127-3722-0bb1-7542d07ea4d4-C", "generated_internal_id": "ASST_NON_R44HL127886_7529"}, {"internal_id": 49823565, "Award ID": "R44HL127873", "Award Amount": 1673916.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-24", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A FULLY HUMANIZED ANTIBODY FOR TREATING LUNG EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ae10754b-7455-947b-3ec0-9c9547fecfea-R", "generated_internal_id": "ASST_NON_R44HL127873_7529"}, {"internal_id": 68566500, "Award ID": "R44HL127834", "Award Amount": 1963074.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-13", "CFDA Number": "93.837", "Description": "AEROSOL DELIVERY OF SURFACTANT FOR ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f96e88e9-8d54-da05-0fcb-25d8f378f582-C", "generated_internal_id": "ASST_NON_R44HL127834_7529"}, {"internal_id": 49823562, "Award ID": "R44HL127826", "Award Amount": 1296377.0, "Award Type": null, "Base Obligation Date": "2015-05-07", "CFDA Number": "93.838", "Description": "MOBILE TECHNOLOGY AND ONLINE TOOLS TO IMPROVE ASTHMA CONTROL IN ADOLESCENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7417bff0-6082-2dc5-8a33-f03830a2466b-C", "generated_internal_id": "ASST_NON_R44HL127826_7529"}, {"internal_id": 49823559, "Award ID": "R44HL127734", "Award Amount": 4489760.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-06", "CFDA Number": "93.838", "Description": "RESORBABLE INFERIOR VENA CAVA FILTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f91cc9c2-ce2a-0d81-e1a1-a8e7c5f76847-R", "generated_internal_id": "ASST_NON_R44HL127734_7529"}, {"internal_id": 49823556, "Award ID": "R44HL127677", "Award Amount": 2980030.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-30", "CFDA Number": "93.838", "Description": "EXPANDING THE MARKET AND SUCCESS RATES FOR MYELOABLATIVE CANCER TREATMENTS USING PUL-042, AN INNATE IMMUNE STIMULANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "32d02d2f-d57e-8f4a-f7cd-d590acb622df-R", "generated_internal_id": "ASST_NON_R44HL127677_7529"}, {"internal_id": 49823551, "Award ID": "R44HL126441", "Award Amount": 1494521.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-15", "CFDA Number": "93.838", "Description": "AN ACOUSTOFLUIDIC DEVICE FOR POINT-OF-CARE SPUTUM PROCESSING AND ANALYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e45da44b-0f84-8321-f927-43b838c49c18-R", "generated_internal_id": "ASST_NON_R44HL126441_7529"}, {"internal_id": 49823550, "Award ID": "R44HL126375", "Award Amount": 1493613.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-19", "CFDA Number": "93.838", "Description": "RATIONAL ANTIBODY THERAPY FOR IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c498f73a-a834-d1c3-c9c2-78016ac15228-C", "generated_internal_id": "ASST_NON_R44HL126375_7529"}, {"internal_id": 49823539, "Award ID": "R44HL124872", "Award Amount": 1311323.95, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-25", "CFDA Number": "93.837", "Description": "MIXED-REALITY SIMULATION TRAINING FOR PEDIATRIC AIRWAY MANAGEMENT PROCEDURES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "84192b68-fc3d-a500-17a5-a7c37498756d-C", "generated_internal_id": "ASST_NON_R44HL124872_7529"}, {"internal_id": 85590084, "Award ID": "R44HL124724", "Award Amount": 1255072.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-05", "CFDA Number": "93.837", "Description": "ARTICULATING VIDEO STYLET FOR IMPROVED INTUBATION SUCCESS RATES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8c80c1b-e502-04e0-2179-367f6354a822-R", "generated_internal_id": "ASST_NON_R44HL124724_7529"}, {"internal_id": 49823536, "Award ID": "R44HL124699", "Award Amount": 1129896.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-25", "CFDA Number": "93.837", "Description": "PATIENT BREATH SIMULATOR FOR CAPNOMETER PERFORMANCE VERIFICATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1c80de5f-73df-4ad5-969e-8502b8d86875-R", "generated_internal_id": "ASST_NON_R44HL124699_7529"}, {"internal_id": 49823530, "Award ID": "R44HL123299", "Award Amount": 2978229.91, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-14", "CFDA Number": "93.837", "Description": "A PHASE III TRIAL TO VALIDATE HP 129XE MRI AS A FUNCTIONAL PULMONARY BIOMARKER IN PEDIATRIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c59beeb5-f694-066f-3998-db2c60515c91-R", "generated_internal_id": "ASST_NON_R44HL123299_7529"}, {"internal_id": 49823528, "Award ID": "R44HL123164", "Award Amount": 1439876.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-26", "CFDA Number": "93.838", "Description": "MOBILE MULTIFUNCTIONAL TOOL FOR MONITORING AND MANAGEMENT OF RESPIRATORY DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bf148559-7295-a25d-8a52-8b897965220e-R", "generated_internal_id": "ASST_NON_R44HL123164_7529"}, {"internal_id": 49823503, "Award ID": "R44HL117482", "Award Amount": 1164803.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-02-11", "CFDA Number": "93.838", "Description": "WEB SYSTEM FOR ENGAGING FAMILIES & DOCTORS IN CONTINUOUS ASTHMA QUALITY IMPROVEME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d8b25e87-d8a6-6205-f7b3-ce2aea408b3c-C", "generated_internal_id": "ASST_NON_R44HL117482_7529"}, {"internal_id": 49823498, "Award ID": "R44HL117337", "Award Amount": 999951.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-14", "CFDA Number": "93.838", "Description": "ASSESSMENT OF LUNG FUNCTION IN NEONATES AND INFANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aa693355-1038-fc86-4bc2-621b6a497625-C", "generated_internal_id": "ASST_NON_R44HL117337_7529"}, {"internal_id": 49823493, "Award ID": "R44HL114299", "Award Amount": 1335453.0, "Award Type": null, "Base Obligation Date": "2014-07-22", "CFDA Number": "93.838", "Description": "NOVEL MOLECULAR THERAPEUTICS FOR CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "85cd2fef-d249-bfd9-6f66-48a391363ada-R", "generated_internal_id": "ASST_NON_R44HL114299_7529"}, {"internal_id": 49823489, "Award ID": "R44HL114225", "Award Amount": 3196272.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-16", "CFDA Number": "93.838", "Description": "MITOCHONDRIAL DNA REPAIR AGENTS FOR ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "459b206b-faec-7883-e214-18bd6c369374-R", "generated_internal_id": "ASST_NON_R44HL114225_7529"}, {"internal_id": 49823487, "Award ID": "R44HL114162", "Award Amount": 1446539.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-23", "CFDA Number": "93.838", "Description": "HOME-BASED HEALTH MANAGEMENT OF COPD PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e46b3c39-8052-f072-21a4-6491e3e07cc4-R", "generated_internal_id": "ASST_NON_R44HL114162_7529"}, {"internal_id": 49823483, "Award ID": "R44HL112460", "Award Amount": 1499470.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-31", "CFDA Number": "93.837", "Description": "LONG TERM PULSE OXIMETER MONITORING FOR NEONATES WITH CHRONIC DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "112743f7-c64f-c3a9-273e-84752a545e3a-C", "generated_internal_id": "ASST_NON_R44HL112460_7529"}, {"internal_id": 49823482, "Award ID": "R44HL112397", "Award Amount": 1848415.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-16", "CFDA Number": "93.838", "Description": "SINGLE-SESSION BRONCHIAL THERMOPLASTY FOR SEVERE ASTHMATICS GUIDED BY HXE MRI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aa693355-1038-fc86-4bc2-621b6a497625-C", "generated_internal_id": "ASST_NON_R44HL112397_7529"}, {"internal_id": 49823463, "Award ID": "R44HL107000", "Award Amount": 5105805.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-12-13", "CFDA Number": "93.838", "Description": "DEVELOPMENT & UTILIZATION OF A NOVEL AEROSOL-GENERATING TECHNOLOGY TO DELIVER LUC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3649b9fb-63bc-2714-cffa-2f880592d3ad-C", "generated_internal_id": "ASST_NON_R44HL107000_7529"}, {"internal_id": 49823451, "Award ID": "R44HL104902", "Award Amount": 1406116.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-24", "CFDA Number": "93.838", "Description": "NOVEL ROCK INHIBITORS FOR COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c65e520d-3ed6-9583-8c72-0d8d1c2bc117-R", "generated_internal_id": "ASST_NON_R44HL104902_7529"}, {"internal_id": 49823440, "Award ID": "R44HL102946", "Award Amount": 5271635.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-25", "CFDA Number": "93.838", "Description": "AN INHALED  PDGF RECEPTOR INHIBITOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5238ec64-1513-0f65-4cee-bcd7bbede094-C", "generated_internal_id": "ASST_NON_R44HL102946_7529"}, {"internal_id": 49823336, "Award ID": "R44HL082397", "Award Amount": 4191648.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-14", "CFDA Number": "93.838", "Description": "TISSUE FACTOR ANTAGONISTS FOR ALI/ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d406ffd6-08ed-de5f-ca7b-b30fca8fa61f-R", "generated_internal_id": "ASST_NON_R44HL082397_7529"}, {"internal_id": 49823305, "Award ID": "R44HL073591", "Award Amount": 5070000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-05-09", "CFDA Number": "93.838", "Description": "CLINICAL DEVELOPMENT A THERAPEUTIC AGENT FOR COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d220242d-5ffc-985b-c94a-e1a50d8a7f9f-R", "generated_internal_id": "ASST_NON_R44HL073591_7529"}, {"internal_id": 109278334, "Award ID": "R43HL154975", "Award Amount": 252131.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-21", "CFDA Number": "93.837", "Description": "EVALUATION OF A NOVEL THERAPEUTIC APPROACH TO TREAT ALCOHOLIC LUNG SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "SC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8840a614-f1d5-6ff4-98d4-8d1e02a11a58-C", "generated_internal_id": "ASST_NON_R43HL154975_7529"}, {"internal_id": 107114391, "Award ID": "R43HL154960", "Award Amount": 251797.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-27", "CFDA Number": "93.837", "Description": "NOVEL DEVICE USED TO OPTIMIZE AEROSOL DRUG DELIVERY FOR PULMONARY HYPERTENSION TREATMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23e70892-c9da-7ee2-5cb3-68847ce7fa4c-R", "generated_internal_id": "ASST_NON_R43HL154960_7529"}, {"internal_id": 110025221, "Award ID": "R43HL154941", "Award Amount": 299749.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-24", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A NOVEL DIAGNOSTIC TEST FOR PULMONARY EMBOLISM BASED ON ARTIFICIAL INTELLIGENCE AND SPECTRAL ANALYSIS OF BLOOD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8cbe5644-06ec-a73a-a866-e48b8efd4341-R", "generated_internal_id": "ASST_NON_R43HL154941_7529"}, {"internal_id": 109278342, "Award ID": "R43HL154868", "Award Amount": 223276.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-21", "CFDA Number": "93.837", "Description": "NOVEL CLASS THERAPY FOR IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9353bca6-5b21-5bac-66a2-868ae0923ed0-R", "generated_internal_id": "ASST_NON_R43HL154868_7529"}, {"internal_id": 110024543, "Award ID": "R43HL154866", "Award Amount": 258631.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-24", "CFDA Number": "93.837", "Description": "ENDOSCOPIC MULTIFUNCTIONAL OPTICAL COHERENCE TOMOGRAPHY FOR AIRWAY TISSUE INJURY MANAGEMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f2421335-7cbc-e2ae-5e3c-a18e15cee45e-C", "generated_internal_id": "ASST_NON_R43HL154866_7529"}, {"internal_id": 111328707, "Award ID": "R43HL154833", "Award Amount": 299854.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-24", "CFDA Number": "93.837", "Description": "A CLINICAL SURVEILLANCE SOFTWARE PLATFORM FOR EARLY IDENTIFICATION OF SEVERE ASYNCHRONY IN MECHANICALLY VENTILATED PATIENTS IN THE INTENSIVE CARE UNIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "88bb3156-077c-f54f-b9b2-5eefe720a23b-C", "generated_internal_id": "ASST_NON_R43HL154833_7529"}, {"internal_id": 96202810, "Award ID": "R43HL152912", "Award Amount": 197130.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-31", "CFDA Number": "93.837", "Description": "SONOHEAL: SMART RESONATING CLOSED-LOOP AIRWAY CLEARANCE DEVICE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c4c57c0-1e6b-6031-5e25-00f20425b141-R", "generated_internal_id": "ASST_NON_R43HL152912_7529"}, {"internal_id": 97852363, "Award ID": "R43HL152825", "Award Amount": 291369.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-20", "CFDA Number": "93.837", "Description": "AUTOMATED ACUTE PULMONARY EMBOLISM DETECTION AND STAGING FROM CT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e46b3c39-8052-f072-21a4-6491e3e07cc4-R", "generated_internal_id": "ASST_NON_R43HL152825_7529"}, {"internal_id": 107114439, "Award ID": "R43HL151461", "Award Amount": 224948.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-24", "CFDA Number": "93.837", "Description": "ENABLING INDEPENDENT LIVING BY EXPANDING ACCESS TO HOME-BASED PULMONARY REHABILITATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e46b3c39-8052-f072-21a4-6491e3e07cc4-R", "generated_internal_id": "ASST_NON_R43HL151461_7529"}, {"internal_id": 97852828, "Award ID": "R43HL150991", "Award Amount": 224101.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-22", "CFDA Number": "93.837", "Description": "BIOMIMETIC LUNG SEALANT TO RAPIDLY HEAL PULMONARY AIR LEAKS, DECREASE RECOVERY TIME, AND REDUCE ASSOCIATED COSTS TO THE HEALTHCARE SYSTEM,", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "da4d6f01-8a1f-8dab-2a70-559544a12791-R", "generated_internal_id": "ASST_NON_R43HL150991_7529"}, {"internal_id": 96994092, "Award ID": "R43HL150986", "Award Amount": 299983.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-30", "CFDA Number": "93.837", "Description": "NOVEL AGENTS FOR IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c174ec1c-cf24-4fb2-2c75-369d31203808-C", "generated_internal_id": "ASST_NON_R43HL150986_7529"}, {"internal_id": 97471705, "Award ID": "R43HL150944", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-18", "CFDA Number": "93.837", "Description": "TARGETING NEUTROPHIL EXTRACELLULAR TRAPS FOR ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dca78d2c-3068-a24e-b607-49913bcdf85f-C", "generated_internal_id": "ASST_NON_R43HL150944_7529"}, {"internal_id": 97852887, "Award ID": "R43HL150897", "Award Amount": 224924.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-28", "CFDA Number": "93.837", "Description": "NOVEL ANTI-FIBROTIC THERAPY FOR IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b25cc9f5-285d-dad3-98fa-7c12442b4c68-R", "generated_internal_id": "ASST_NON_R43HL150897_7529"}, {"internal_id": 95181257, "Award ID": "R43HL150884", "Award Amount": 298273.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-17", "CFDA Number": "93.837", "Description": "DYNAMIC BREATH GAS SENSOR (DBGS?) FOR DETECTION OF PULMONARY EDEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a938aad6-88e8-b041-b524-f60efdc1886c-R", "generated_internal_id": "ASST_NON_R43HL150884_7529"}, {"internal_id": 85590576, "Award ID": "R43HL149580", "Award Amount": 390968.49, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-13", "CFDA Number": "93.837", "Description": "A DISEASE-MODIFYING PROTEIN THERAPEUTIC FOR THE TREATMENT OF COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "148a3d2c-3f9a-a06a-aef6-42b7db19199b-R", "generated_internal_id": "ASST_NON_R43HL149580_7529"}, {"internal_id": 85589807, "Award ID": "R43HL149554", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-14", "CFDA Number": "93.837", "Description": "OPTIMIZATION OF RECOMBINANT PROBIOTICS FOR ORAL DELIVERY OF ACE2/ANG-(1-7", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a2bdedb8-ee7d-5406-dcce-dc6bf1bca9f2-R", "generated_internal_id": "ASST_NON_R43HL149554_7529"}, {"internal_id": 98143389, "Award ID": "R43HL147788", "Award Amount": 218741.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-18", "CFDA Number": "93.837", "Description": "FEASIBILITY TESTING OF A MICROPHONE SYSTEM TO FACILITATE PATIENT COMMUNICATION DURING NONINVASIVE VENTILATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "014d61c6-febc-27ab-e0b7-e243cbbcd241-C", "generated_internal_id": "ASST_NON_R43HL147788_7529"}, {"internal_id": 97852880, "Award ID": "R43HL147747", "Award Amount": 222942.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-20", "CFDA Number": "93.837", "Description": "COMPUTER-AIDED DECISION SUPPORT SYSTEM FOR CATHETER-BASED PULMONARY VALVE REPLACEMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0a6f32c4-aa98-e7b4-22a9-7dbf4f664425-C", "generated_internal_id": "ASST_NON_R43HL147747_7529"}, {"internal_id": 80729300, "Award ID": "R43HL147700", "Award Amount": 286530.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-29", "CFDA Number": "93.837", "Description": "LIVE BIOTHERAPEUTICS FOR THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIA LUNG INFECTION ASSOCIATED WITH CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8f6e6289-20d0-0acf-b111-2dadcd00bf5a-R", "generated_internal_id": "ASST_NON_R43HL147700_7529"}, {"internal_id": 86318445, "Award ID": "R43HL147680", "Award Amount": 295473.94, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-25", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF SMALL MOLECULES MAP3K2/3 INHIBITOR FOR TREATMENT OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0db8b6f5-ef4f-3748-04c5-6c07e4dd9abb-R", "generated_internal_id": "ASST_NON_R43HL147680_7529"}, {"internal_id": 86317270, "Award ID": "R43HL147650", "Award Amount": 134132.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-23", "CFDA Number": "93.837", "Description": "FIBER-OPTIC SENSOR SYSTEM FOR SLEEP DISORDER MONITORING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5057d6d1-5641-e1f1-d6ce-1f34d3e39e01-C", "generated_internal_id": "ASST_NON_R43HL147650_7529"}, {"internal_id": 83104099, "Award ID": "R43HL146732", "Award Amount": 223000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-14", "CFDA Number": "93.837", "Description": "MOBILE RESPIRATORY AID DEVICE TO HELP COPD PATIENTS BREATH EASY AGAIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf865992-190f-63f0-d0de-841f7b38f8c9-R", "generated_internal_id": "ASST_NON_R43HL146732_7529"}, {"internal_id": 86316389, "Award ID": "R43HL146182", "Award Amount": 224536.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-25", "CFDA Number": "93.838", "Description": "MICRORNA-BASED DIAGNOSTIC BIOMARKER FOR PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b9b3a65-e1ee-397f-4c6b-dbe790e5cfe2-R", "generated_internal_id": "ASST_NON_R43HL146182_7529"}, {"internal_id": 80401076, "Award ID": "R43HL146045", "Award Amount": 224999.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-18", "CFDA Number": "93.837", "Description": "A MICROSCALE PLATFORM FOR AUGMENTATION OF CELL TRANSDUCTION (MPACT) TO ENHANCE EX VIVO GENE TRANSFER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9e2f4487-76d7-2910-a3d3-1618c590b613-C", "generated_internal_id": "ASST_NON_R43HL146045_7529"}, {"internal_id": 80401282, "Award ID": "R43HL146012", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-18", "CFDA Number": "93.838", "Description": "RT ASSISTANT - HANDHELD PATIENT SAFETY TOOL FOR MECHANICAL VENTILATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "09c270fb-97c3-21f1-de36-9505d9da8012-C", "generated_internal_id": "ASST_NON_R43HL146012_7529"}, {"internal_id": 68565992, "Award ID": "R43HL144341", "Award Amount": 279441.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-12", "CFDA Number": "93.838", "Description": "FIBROTIC LUNG EXTRACELLULAR MATRIX CELL CULTURE SUBSTRATE TO IMPROVE PREDICTIVE IN VITRO MODELS OF PULMONARY FIBROSIS FOR ACCELERATING DRUG DEVELOPMENT TOWARDS MORE EFFECTIVE TREATMENT OPTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "da4d6f01-8a1f-8dab-2a70-559544a12791-R", "generated_internal_id": "ASST_NON_R43HL144341_7529"}, {"internal_id": 67313523, "Award ID": "R43HL144290", "Award Amount": 224865.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-09", "CFDA Number": "93.837", "Description": "PEPTIDE THERAPIES FOR TREATING CF LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "97c08b72-d285-4b81-1580-52ae696d9800-R", "generated_internal_id": "ASST_NON_R43HL144290_7529"}, {"internal_id": 78991659, "Award ID": "R43HL144266", "Award Amount": 224115.46, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-19", "CFDA Number": "93.837", "Description": "MINIMALLY INVASIVE CARDIO-PULMONARY PLEXUS BLOCK FOR THE TREATMENT OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7c98a346-2c57-7389-3243-34bd9eec146f-C", "generated_internal_id": "ASST_NON_R43HL144266_7529"}, {"internal_id": 80726555, "Award ID": "R43HL144220", "Award Amount": 274222.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-10", "CFDA Number": "93.837", "Description": "TOOLS FOR IMPROVED TRANSLATION OF NOVEL INHALABLE THERAPEUTICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf28962-7a83-4250-415f-6369fe88631d-R", "generated_internal_id": "ASST_NON_R43HL144220_7529"}, {"internal_id": 68168209, "Award ID": "R43HL142407", "Award Amount": 224200.31, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-03", "CFDA Number": "93.837", "Description": "DRUG DISCOVERY FOR IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9353bca6-5b21-5bac-66a2-868ae0923ed0-R", "generated_internal_id": "ASST_NON_R43HL142407_7529"}, {"internal_id": 64141780, "Award ID": "R43HL142395", "Award Amount": 226781.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-15", "CFDA Number": "93.838", "Description": "MUCOADHESIVE DRUG CONJUGATES FOR CONTROLLED-RELEASE INHALATION DELIVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "02592754-c55f-3500-602c-95ebe9da034b-R", "generated_internal_id": "ASST_NON_R43HL142395_7529"}, {"internal_id": 62551278, "Award ID": "R43HL142367", "Award Amount": 224844.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-01", "CFDA Number": "93.838", "Description": "TREATING SEVERE ASTHMA IN THE SMALL AIRWAYS: A NOVEL INHALED DRY POWDER FORMULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ee807eb-bbea-335a-591b-d62a85fc121a-R", "generated_internal_id": "ASST_NON_R43HL142367_7529"}, {"internal_id": 66995449, "Award ID": "R43HL142353", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-25", "CFDA Number": "93.837", "Description": "AEROSOLIZED VITAMIN A IMPACT ON LUNG MATURATION AND HYPEROXIC NEONATAL LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a307b396-4471-2d8a-e7a2-454f65a7e748-R", "generated_internal_id": "ASST_NON_R43HL142353_7529"}, {"internal_id": 66994895, "Award ID": "R43HL142326", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-25", "CFDA Number": "93.838", "Description": "POINT-OF-CARE ASSAY USING BLOOD GLUCOSE METER FOR EARLY WARNING OF CHRONIC LUNG REJECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "685ef633-4402-fe7c-0d37-529dd03a22a8-C", "generated_internal_id": "ASST_NON_R43HL142326_7529"}, {"internal_id": 68565594, "Award ID": "R43HL142315", "Award Amount": 399429.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-17", "CFDA Number": "93.837", "Description": "DISCOVERING GIRK CHANNEL DIRECT ACTIVATOR AS A NOVEL CHRONIC INSOMNIA THERAPEUTIC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "65935cb6-ac04-1978-fa08-490d8f77e730-C", "generated_internal_id": "ASST_NON_R43HL142315_7529"}, {"internal_id": 65280089, "Award ID": "R43HL142308", "Award Amount": 299617.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-27", "CFDA Number": "93.838", "Description": "A POINT-OF-CARE ASSAY TO MONITOR TOBRAMYCIN IN CYSTIC FIBROSIS PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a3fc6920-5302-b700-0120-a5ba924f98ef-R", "generated_internal_id": "ASST_NON_R43HL142308_7529"}, {"internal_id": 62420330, "Award ID": "R43HL140890", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-12", "CFDA Number": "93.838", "Description": "OFF-THE-SHELF PATCH FOR REPAIRING TRACHEAL STENOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2b635e-4959-bbdc-4754-ec63f4c2f4f1-C", "generated_internal_id": "ASST_NON_R43HL140890_7529"}, {"internal_id": 49819995, "Award ID": "R43HL140829", "Award Amount": 201665.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-22", "CFDA Number": "93.838", "Description": "CALPAIN THERAPEUTICS TO INHIBIT MYOFIBROBLAST GENERATION IN FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "eda9e7ba-aeca-d135-1337-c496a247d8b0-R", "generated_internal_id": "ASST_NON_R43HL140829_7529"}, {"internal_id": 68566722, "Award ID": "R43HL140712", "Award Amount": 300000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-15", "CFDA Number": "93.837", "Description": "SOFT LXR AGONISTS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "58cbfdac-6c26-acfe-4a3f-0fa682c09a7d-R", "generated_internal_id": "ASST_NON_R43HL140712_7529"}, {"internal_id": 49819979, "Award ID": "R43HL137583", "Award Amount": 221923.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-17", "CFDA Number": "93.838", "Description": "A MODIFIED AAV GENE THERAPY FOR CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47949a12-4426-123d-1113-b9b247b77e73-R", "generated_internal_id": "ASST_NON_R43HL137583_7529"}, {"internal_id": 49819965, "Award ID": "R43HL136220", "Award Amount": 224628.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-09", "CFDA Number": "93.838", "Description": "A NON-INVASIVE ASSAY FOR OBSTRUCTIVE SLEEP APNEA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d5ae9063-d8de-a4e9-57bf-03dc865720fb-C", "generated_internal_id": "ASST_NON_R43HL136220_7529"}, {"internal_id": 49819964, "Award ID": "R43HL136050", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-21", "CFDA Number": "93.838", "Description": "LUNG RESEARCH BIOREACTOR WITH AEROSOLIZED AGENT DELIVERY TO AIRWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fcef82d9-6114-e7d8-6967-9d343dbc72f9-R", "generated_internal_id": "ASST_NON_R43HL136050_7529"}, {"internal_id": 49819959, "Award ID": "R43HL135956", "Award Amount": 222599.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-14", "CFDA Number": "93.838", "Description": "VALIDATION OF SPX-101 AS A CANDIDATE FOR THE TREATMENT OF CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a9f3ebe5-b817-fbc9-83f3-e3727a2d80d9-R", "generated_internal_id": "ASST_NON_R43HL135956_7529"}, {"internal_id": 49819958, "Award ID": "R43HL135951", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-14", "CFDA Number": "93.838", "Description": "ENAC INHIBITING PEPTIDE FOR CYSTIC FIBROSIS DELIVERED BY DRY POWDER INHALER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a9f3ebe5-b817-fbc9-83f3-e3727a2d80d9-R", "generated_internal_id": "ASST_NON_R43HL135951_7529"}, {"internal_id": 49819957, "Award ID": "R43HL135918", "Award Amount": 149187.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-26", "CFDA Number": "93.838", "Description": "VAGUS NERVE STIMULATION TREATMENT FOR ASTHMATIC BRONCHOCONSTRICTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "95ab7fdc-ce80-83de-277d-6aa03525e6a9-R", "generated_internal_id": "ASST_NON_R43HL135918_7529"}, {"internal_id": 49819955, "Award ID": "R43HL135910", "Award Amount": 482321.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-16", "CFDA Number": "93.838", "Description": "A PHOSPHOPEPTIDE MULTIPLEX PRM MASS SPECTROSCOPIC BIOMARKER ASSAY FOR PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5238ec64-1513-0f65-4cee-bcd7bbede094-C", "generated_internal_id": "ASST_NON_R43HL135910_7529"}, {"internal_id": 49819954, "Award ID": "R43HL135909", "Award Amount": 149470.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-14", "CFDA Number": "93.838", "Description": "RULE BASED SEMANTICS AND BIG DATA BASED METHODS FOR EARLY IDENTIFICATION OF PATIENTS AT RISK OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "da6d8249-2e95-f9c0-d9b3-d212a59a0013-C", "generated_internal_id": "ASST_NON_R43HL135909_7529"}, {"internal_id": 49819947, "Award ID": "R43HL134456", "Award Amount": 274497.0, "Award Type": null, "Base Obligation Date": "2016-07-22", "CFDA Number": "93.838", "Description": "ANTIMICROBIAL ENDOTRACHEAL TUBE TO COMBAT BIOFILM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "224ab16f-b9ea-3537-be8e-ea1ef491587f-C", "generated_internal_id": "ASST_NON_R43HL134456_7529"}, {"internal_id": 49819945, "Award ID": "R43HL134450", "Award Amount": 224341.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-03", "CFDA Number": "93.838", "Description": "PULMONARY ASSIST DEVICE FOR DESTINATION THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "473fa551-f1e0-d677-fe7b-2b72436338b4-R", "generated_internal_id": "ASST_NON_R43HL134450_7529"}, {"internal_id": 49819943, "Award ID": "R43HL134420", "Award Amount": 225452.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-17", "CFDA Number": "93.838", "Description": "TESSA  SLEEP QUALITY MONITORING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "20de0b23-ee8c-208d-882f-8f0c31d935c2-R", "generated_internal_id": "ASST_NON_R43HL134420_7529"}, {"internal_id": 49819935, "Award ID": "R43HL132828", "Award Amount": 208197.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.838", "Description": "SINGLE ADSORBER RPSA FOR IMPROVED O2 DELIVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c5fee3d0-847d-d988-2783-0c38cb77b754-R", "generated_internal_id": "ASST_NON_R43HL132828_7529"}, {"internal_id": 49819919, "Award ID": "R43HL132650", "Award Amount": 224966.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-26", "CFDA Number": "93.838", "Description": "PROMOTING ADHERENCE VIA OBJECTIVE TECHNOLOGY TO ASSESS CYSTIC FIBROSIS TREATMENT (PROTRACT)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2fe81d5e-6a61-78cb-de3e-e368142c49c3-C", "generated_internal_id": "ASST_NON_R43HL132650_7529"}, {"internal_id": 49819873, "Award ID": "R43HL127873", "Award Amount": 279779.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-27", "CFDA Number": "93.838", "Description": "DEVELOPMENT OF A FULLY HUMANIZED ANTIBODY FOR TREATING LUNG EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ae10754b-7455-947b-3ec0-9c9547fecfea-R", "generated_internal_id": "ASST_NON_R43HL127873_7529"}, {"internal_id": 97852889, "Award ID": "R42HL152888", "Award Amount": 2300001.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-27", "CFDA Number": "93.837", "Description": "ENAMPTORTM: A HUMANIZED MAB TO REDUCE THE SEVERITY OF RADIATION PNEUMONITIS AND FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "926ac255-0110-485e-c144-abc0109c2439-R", "generated_internal_id": "ASST_NON_R42HL152888_7529"}, {"internal_id": 110025084, "Award ID": "R42HL151045", "Award Amount": 2628172.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-24", "CFDA Number": "93.837", "Description": "INHALED FASUDIL AND DETA NONOATE CAR-TARGETED LIPOSOMES FOR PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75022a51-e8e5-2ced-5f7a-8b61ba6796dc-C", "generated_internal_id": "ASST_NON_R42HL151045_7529"}, {"internal_id": 107115325, "Award ID": "R42HL147728", "Award Amount": 1384779.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-28", "CFDA Number": "93.837", "Description": "FEELIX @ HOME: TESTING AND OPTIMIZATION OF A SMART STETHOSCOPE FOR HOME USE TO MONITOR CHANGES IN LUNG STATUS OF INDIVIDUALS WITH CHRONIC CONDITIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1d101517-978c-97b1-ae2e-8eaa261c7e12-R", "generated_internal_id": "ASST_NON_R42HL147728_7529"}, {"internal_id": 81071331, "Award ID": "R42HL145930", "Award Amount": 1725000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-25", "CFDA Number": "93.837", "Description": "NOVEL THERAPEUTIC ANTIBODY TARGETING OF EXTRACELLULAR NAMPT IN VENTILATOR-INDUCED LUNG INJURY (VILI)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "926ac255-0110-485e-c144-abc0109c2439-R", "generated_internal_id": "ASST_NON_R42HL145930_7529"}, {"internal_id": 66199585, "Award ID": "R42HL140701", "Award Amount": 1716843.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-18", "CFDA Number": "93.837", "Description": "PAR2 PEPDUCINS AS A NOVEL TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d25ca263-5608-063d-81ae-12f1067c8e71-R", "generated_internal_id": "ASST_NON_R42HL140701_7529"}, {"internal_id": 61611272, "Award ID": "R42HL140670", "Award Amount": 1724070.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-02", "CFDA Number": "93.837", "Description": "OXIDATION-RESISTANT ANTI-PROTEASE THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c23fec3f-7a97-0961-f8bb-ad453a0ede77-R", "generated_internal_id": "ASST_NON_R42HL140670_7529"}, {"internal_id": 49815130, "Award ID": "R42HL132742", "Award Amount": 2303971.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "HLS- CYCLIC CAR PEPTIDE: A TARGETED THERAPY FOR PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75022a51-e8e5-2ced-5f7a-8b61ba6796dc-C", "generated_internal_id": "ASST_NON_R42HL132742_7529"}, {"internal_id": 49815129, "Award ID": "R42HL132735", "Award Amount": 1755000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-15", "CFDA Number": "93.838", "Description": "JAMBOXX: INTERACTIVE RESPIRATORY THERAPY THROUGH MUSIC AND GAMING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ff858761-ab6a-a905-bed3-96624b5e3bbd-R", "generated_internal_id": "ASST_NON_R42HL132735_7529"}, {"internal_id": 49815123, "Award ID": "R42HL127802", "Award Amount": 1629717.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-18", "CFDA Number": "93.838", "Description": "PEPTIDE BASED THERAPY FOR LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fff9616f-15b7-4a0f-9744-ff7e21f00faa-R", "generated_internal_id": "ASST_NON_R42HL127802_7529"}, {"internal_id": 49815122, "Award ID": "R42HL126456", "Award Amount": 1971462.4, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-14", "CFDA Number": "93.837", "Description": "ALBUMIN NANOPARTICLES INCORPORATING PICEATANNOL (PANPS) FOR ALI/ARDS THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "85d9f182-b53d-3d7f-b0fe-2ef479498d72-C", "generated_internal_id": "ASST_NON_R42HL126456_7529"}, {"internal_id": 100873858, "Award ID": "R41HL154852", "Award Amount": 306500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-17", "CFDA Number": "93.837", "Description": "SOFT LXR AGONISTS FOR IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "58cbfdac-6c26-acfe-4a3f-0fa682c09a7d-R", "generated_internal_id": "ASST_NON_R41HL154852_7529"}, {"internal_id": 100874168, "Award ID": "R41HL152942", "Award Amount": 214912.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-13", "CFDA Number": "93.838", "Description": "DEVELOPMENT OF SURFACTANT PROTEIN A-DERIVED PEPTIDOMIMETICS FOR THE TREATMENT OF ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "feb0f333-e455-9692-93b2-d61076a4ebfa-R", "generated_internal_id": "ASST_NON_R41HL152942_7529"}, {"internal_id": 108463545, "Award ID": "R41HL152921", "Award Amount": 465219.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-10", "CFDA Number": "93.838", "Description": "CHEMICAL-BASED NITRIC OXIDE GAS-GENERATING DRUG DEVICE FOR THE TREATMENT OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b2119856-c85f-e83d-f067-144c06906b38-R", "generated_internal_id": "ASST_NON_R41HL152921_7529"}, {"internal_id": 111328708, "Award ID": "R41HL152915", "Award Amount": 252131.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "ADVANCING SMALL MOLECULE READ THROUGH COMPOUNDS TO PREVENT AND/OR TREAT HERITABLE PULMONARY ARTERY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a307b396-4471-2d8a-e7a2-454f65a7e748-R", "generated_internal_id": "ASST_NON_R41HL152915_7529"}, {"internal_id": 100875558, "Award ID": "R41HL152769", "Award Amount": 350000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-19", "CFDA Number": "93.837", "Description": "CLINICAL FEASIBILITY OF A NON-INVASIVE, LOW-COST WEARABLE FOR MEASURING AIR TRAPPING IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e2314f9e-f69a-e009-ca0d-d5211435437b-R", "generated_internal_id": "ASST_NON_R41HL152769_7529"}, {"internal_id": 83116013, "Award ID": "R41HL149523", "Award Amount": 300000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-05", "CFDA Number": "93.837", "Description": "A NEW SMALL-MOLECULE KINASE INHIBITOR FOR AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "05b53aaa-5283-003d-1bc4-6419f84405da-R", "generated_internal_id": "ASST_NON_R41HL149523_7529"}, {"internal_id": 81072063, "Award ID": "R41HL147771", "Award Amount": 369906.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-22", "CFDA Number": "93.837", "Description": "PULMONARY VALVED CONDUIT XENOGRAFT WITH REGENERATION POTENTIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "SC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9625e1d7-e85f-f45b-eda3-ab92ad603ee6-C", "generated_internal_id": "ASST_NON_R41HL147771_7529"}, {"internal_id": 83116191, "Award ID": "R41HL147769", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-08", "CFDA Number": "93.837", "Description": "THE CRIT-ICU BIOMARKER PANEL FOR STRATIFICATION OF MORTALITY RISK IN ARDS PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "926ac255-0110-485e-c144-abc0109c2439-R", "generated_internal_id": "ASST_NON_R41HL147769_7529"}, {"internal_id": 85590372, "Award ID": "R41HL147673", "Award Amount": 149978.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-16", "CFDA Number": "93.837", "Description": "A UNIVERSAL MECHANOBIOLOGY TOOL FOR DRUG DISCOVERY IN LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c377ff2-f0a6-47c5-9c39-1b55790e97cd-R", "generated_internal_id": "ASST_NON_R41HL147673_7529"}, {"internal_id": 80731526, "Award ID": "R41HL147658", "Award Amount": 224756.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-28", "CFDA Number": "93.837", "Description": "A NOVEL ASTHMA DRUG CANDIDATE TARGETING THE GABAERGIC SYSTEM IN LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "13638cdf-3ca7-9e33-4e96-ad8b7abf6b47-R", "generated_internal_id": "ASST_NON_R41HL147658_7529"}, {"internal_id": 86316600, "Award ID": "R41HL146027", "Award Amount": 259205.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-25", "CFDA Number": "93.837", "Description": "AN UNOBTRUSIVE MONITORING DEVICE USED FOR TRACKING ASTHMA SYMPTOMS AND LUNG FUNCTION VARIABILITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c1ea2f9f-4b4e-3ced-0b52-4c6bac0b5435-R", "generated_internal_id": "ASST_NON_R41HL146027_7529"}, {"internal_id": 86319203, "Award ID": "R41HL145871", "Award Amount": 224593.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-23", "CFDA Number": "93.837", "Description": "GENE THERAPY TO PROTECT THE LUNG FROM OXIDANT STRESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c23fec3f-7a97-0961-f8bb-ad453a0ede77-R", "generated_internal_id": "ASST_NON_R41HL145871_7529"}, {"internal_id": 97471453, "Award ID": "R41HL145848", "Award Amount": 299866.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-18", "CFDA Number": "93.838", "Description": "EVALUATION OF A PEPTIDE THAT INHIBITS  THE ACTIVATION OF NOX2 AND THE GENERATION OF REACTIVE OXYGEN SPECIES IN PROTECTION AGAINST ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fcded12a-2119-cb5e-0639-4374c78c9d8a-R", "generated_internal_id": "ASST_NON_R41HL145848_7529"}, {"internal_id": 85590325, "Award ID": "R41HL145842", "Award Amount": 148864.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-17", "CFDA Number": "93.837", "Description": "THE DIAGNOSTIC UTILITY OF THE IN-VITRO \"PROVOKED\" D DIMER TEST IN PATIENTS WITH SUSPECTED PULMONARY EMBOLISM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "142c4fa1-5aa9-169c-9ccb-26faea2fe93b-R", "generated_internal_id": "ASST_NON_R41HL145842_7529"}, {"internal_id": 86319175, "Award ID": "R41HL145840", "Award Amount": 274631.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-23", "CFDA Number": "93.837", "Description": "REPURPOSING A PINWORM DRUG TO TREAT PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "22527a49-cc62-d5c6-faba-496e7a59164a-R", "generated_internal_id": "ASST_NON_R41HL145840_7529"}, {"internal_id": 65579185, "Award ID": "R41HL145669", "Award Amount": 224812.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-13", "CFDA Number": "93.837", "Description": "IMAGING BIOMARKERS OF SEVERE RESPIRATORY INFECTIONS IN PREMATURE INFANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0a6f32c4-aa98-e7b4-22a9-7dbf4f664425-C", "generated_internal_id": "ASST_NON_R41HL145669_7529"}, {"internal_id": 67579995, "Award ID": "R41HL142384", "Award Amount": 299599.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-26", "CFDA Number": "93.838", "Description": "GRAFT-PROTECTIVE PROPERTIES OF LGM2605 IN LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b3a8f6bf-8524-f564-8f79-73b2ea7c91b0-C", "generated_internal_id": "ASST_NON_R41HL142384_7529"}, {"internal_id": 66199363, "Award ID": "R41HL142357", "Award Amount": 299974.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-04", "CFDA Number": "93.837", "Description": "CHRONIC INTRAPULMONARY DELIVERY OF A NOVEL SMALL MOLECULE WNT/BETA-CATENIN INHIBITOR FOR IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "576d8519-7031-119f-1e29-1a7bf03c43ce-C", "generated_internal_id": "ASST_NON_R41HL142357_7529"}, {"internal_id": 62420581, "Award ID": "R41HL140741", "Award Amount": 224984.0, "Award Type": null, "Base Obligation Date": "2018-02-17", "CFDA Number": "93.838", "Description": "NOVEL TARGETING OF THE S1P RECEPTOR, S1P1, AND NOX4 AS THERAPEUTIC APPROACHES IN ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0deb9665-860f-f37b-9a4a-16a1d3350371-R", "generated_internal_id": "ASST_NON_R41HL140741_7529"}, {"internal_id": 49814537, "Award ID": "R41HL140709", "Award Amount": 224598.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-15", "CFDA Number": "93.837", "Description": "REOPENING THE CENTRAL AIRWAY WITH NEEDLE-SIZE TENTACLE MANIPULATORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a4044fbb-310b-be55-c6e8-4141a4aad19c-R", "generated_internal_id": "ASST_NON_R41HL140709_7529"}, {"internal_id": 69726097, "Award ID": "R41HL140673", "Award Amount": 223729.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-21", "CFDA Number": "93.837", "Description": "ENHANCEMENT OF THE BENEFICIAL EFFECTS OF MESENCHYMAL STEM CELL (MSC) TREATMENT BY THE CAVEOLIN-1 SCAFFOLDING DOMAIN PEPTIDE (CSD)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c17356e9-4403-5ea2-3416-4a94e295582f-C", "generated_internal_id": "ASST_NON_R41HL140673_7529"}, {"internal_id": 69724017, "Award ID": "R41HL140640", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-20", "CFDA Number": "93.837", "Description": "DEVICE FOR MULTI-FREQUENCY OSCILLATORY VENTILATION IN ADULT PATIENTS WITH THE ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1d7c63e4-4de5-bda8-ce86-1d28874c71d4-R", "generated_internal_id": "ASST_NON_R41HL140640_7529"}, {"internal_id": 62421099, "Award ID": "R41HL135945", "Award Amount": 281155.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-05", "CFDA Number": "93.837", "Description": "HUMANIZED EMAP II MAB AS A NOVEL THERAPY FOR VIRAL-ASSOCIATED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ae10754b-7455-947b-3ec0-9c9547fecfea-R", "generated_internal_id": "ASST_NON_R41HL135945_7529"}, {"internal_id": 49814522, "Award ID": "R41HL131250", "Award Amount": 224634.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-15", "CFDA Number": "93.838", "Description": "DEVICE FOR TREATMENT OF CONGENITAL DIAPHRAGMATIC HERNIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1f7bf3ea-4f64-429e-c020-d08525f11c6d-R", "generated_internal_id": "ASST_NON_R41HL131250_7529"}, {"internal_id": 49814516, "Award ID": "R41HL129728", "Award Amount": 199096.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-05", "CFDA Number": "93.837", "Description": "DEVELOPING A DIAGNOSTIC BLOOD TEST FOR SARCOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d823f9d0-509c-44e5-fe6a-5028c3fb7a55-R", "generated_internal_id": "ASST_NON_R41HL129728_7529"}, {"internal_id": 49814511, "Award ID": "R41HL128991", "Award Amount": 224770.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-21", "CFDA Number": "93.838", "Description": "RAPID MONITORING AND ASSESSMENT OF TUBERCUOLOSIS TREATMENT AT THE POINT OF CARE USING BREATH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "11bdcff9-7de7-1c69-8c97-780c3e736ccd-R", "generated_internal_id": "ASST_NON_R41HL128991_7529"}, {"internal_id": 49814507, "Award ID": "R41HL127868", "Award Amount": 206886.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-19", "CFDA Number": "93.838", "Description": "ASTHMAGRAM: OBJECTIVE ASSESSMENT OF ASTHMA SYMPTOMS IN CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bce43657-fbae-ab37-6226-aa854234c281-R", "generated_internal_id": "ASST_NON_R41HL127868_7529"}, {"internal_id": 49814504, "Award ID": "R41HL126456", "Award Amount": 678123.81, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-28", "CFDA Number": "93.837", "Description": "HLS13-13 ALBUMIN NANOPARTICLE BASED TECHNOLOGY TO TREAT ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "85d9f182-b53d-3d7f-b0fe-2ef479498d72-C", "generated_internal_id": "ASST_NON_R41HL126456_7529"}, {"internal_id": 95484479, "Award ID": "R38HL150212", "Award Amount": 1349040.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-27", "CFDA Number": "93.837", "Description": "MGH NEXT GENERATION PHYSICIAN-SCIENTIST THROUGH STIMULATING ACCESS TO RESEARCH IN RESIDENCY PROGRAM (MGH-NEXT GEN STARR)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R38HL150212_7529"}, {"internal_id": 95181488, "Award ID": "R38HL150207", "Award Amount": 1233115.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-07", "CFDA Number": "93.837", "Description": "PITTSBURGH INNOVATION IN COLLABORATIVE TRAINING OF RESIDENTS ALLIANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R38HL150207_7529"}, {"internal_id": 95180686, "Award ID": "R38HL150086", "Award Amount": 1393368.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-07", "CFDA Number": "93.837", "Description": "MAYO CLINIC STARR PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R38HL150086_7529"}, {"internal_id": 66995519, "Award ID": "R38HL143619", "Award Amount": 1342915.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-26", "CFDA Number": "93.837", "Description": "VANDERBILT STIMULATING ACCESS TO RESEARCH IN RESIDENCY (V-STARR)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R38HL143619_7529"}, {"internal_id": 94713853, "Award ID": "R38HL143615", "Award Amount": 1354396.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-04", "CFDA Number": "93.837", "Description": "R38 STANFORD INTEGRATED CARDIOVASCULAR/PULMONARY RESIDENCY RESEARCH TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R38HL143615_7529"}, {"internal_id": 95181319, "Award ID": "R38HL143614", "Award Amount": 1066137.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-13", "CFDA Number": "93.837", "Description": "THE UNIVERSITY OF CALIFORNIA - LOS ANGELES (UCLA) RESIDENT SCIENTIST TRAINING PROGRAM (RSTP)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R38HL143614_7529"}, {"internal_id": 66994897, "Award ID": "R38HL143613", "Award Amount": 1406553.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-26", "CFDA Number": "93.837", "Description": "THE PENN-STARR PROGRAM FOR RESEARCH IN RESIDENCY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R38HL143613_7529"}, {"internal_id": 66995583, "Award ID": "R38HL143612", "Award Amount": 1702650.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-26", "CFDA Number": "93.837", "Description": "DUKE RESIDENT PHYSICIAN-SCIENTIST PROGRAM- NHLBI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R38HL143612_7529"}, {"internal_id": 66994954, "Award ID": "R38HL143605", "Award Amount": 1348100.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-26", "CFDA Number": "93.837", "Description": "UTAH STIMULATING ACCESS TO RESEARCH IN RESIDENCY TRANSITION SCHOLAR (STARRTS)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R38HL143605_7529"}, {"internal_id": 66994837, "Award ID": "R38HL143585", "Award Amount": 1515333.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-26", "CFDA Number": "93.837", "Description": "CHILDREN'S NATIONAL STIMULATING ACCESS TO RESEARCH IN RESIDENCY (CNSTARR) PROGRAM (NHLBI)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_R38HL143585_7529"}, {"internal_id": 95181294, "Award ID": "R38HL143584", "Award Amount": 1336102.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-05", "CFDA Number": "93.837", "Description": "PRIMER: PROMOTING RESEARCH IN MEDICAL RESIDENCY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R38HL143584_7529"}, {"internal_id": 66995499, "Award ID": "R38HL143581", "Award Amount": 1422135.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-26", "CFDA Number": "93.837", "Description": "ENHANCING RESIDENT INVESTIGATION AND CAREER ADVANCEMENT IN CARDIOVASCULAR AND PULMONARY SCIENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R38HL143581_7529"}, {"internal_id": 66995089, "Award ID": "R38HL143561", "Award Amount": 1096072.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-26", "CFDA Number": "93.837", "Description": "STIMULATING ACCESS TO RESEARCH IN RESIDENCY (STARR)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R38HL143561_7529"}, {"internal_id": 95181549, "Award ID": "R38HL143511", "Award Amount": 1372436.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-14", "CFDA Number": "93.837", "Description": "COLORADO STARR PROGRAM IN MEDICINE AND PEDIATRICS (CSPMP)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R38HL143511_7529"}, {"internal_id": 49813019, "Award ID": "R37HL079142", "Award Amount": 3233180.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-12-14", "CFDA Number": "93.838", "Description": "TH17 CYTOKINES AND LUNG IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_R37HL079142_7529"}, {"internal_id": 49813010, "Award ID": "R37HL071303", "Award Amount": 4054440.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-03-19", "CFDA Number": "93.838", "Description": "PROGENITOR CELLS IN LUNG DEVELOPMENT AND REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R37HL071303_7529"}, {"internal_id": 49813007, "Award ID": "R37HL068546", "Award Amount": 3197835.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-07-20", "CFDA Number": "93.838", "Description": "GLUCOCORTICOSTEROID ACTION IN INFLAMMATORY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R37HL068546_7529"}, {"internal_id": 49813003, "Award ID": "R37HL066289", "Award Amount": 13674474.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-03", "CFDA Number": "93.838", "Description": "THE GENETIC EPIDEMIOLOGY OF ASTHMA IN COSTA RICA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R37HL066289_7529"}, {"internal_id": 49812990, "Award ID": "R37HL060917", "Award Amount": 3516152.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-07-15", "CFDA Number": "93.838", "Description": "NITRIC OXIDE IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R37HL060917_7529"}, {"internal_id": 49812988, "Award ID": "R37HL060024", "Award Amount": 3510754.46, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-06-20", "CFDA Number": "93.837", "Description": "STORE-OPERATED CALCIUM ENTRY: LUNG ENDOTHELIAL PERMEABILITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_R37HL060024_7529"}, {"internal_id": 49812968, "Award ID": "R37HL051856", "Award Amount": 3185167.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-03-21", "CFDA Number": "93.838", "Description": "RESOLUTION OF CLINICAL LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R37HL051856_7529"}, {"internal_id": 49812961, "Award ID": "R37HL048129", "Award Amount": 3976776.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-01-25", "CFDA Number": "93.838", "Description": "ROLE AND REGULATION OF SODIUM, POTASIUM ATPASE IN LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R37HL048129_7529"}, {"internal_id": 95942829, "Award ID": "R35HL150876", "Award Amount": 3540000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-08", "CFDA Number": "93.837", "Description": "CELL-CELL INTERACTIONS GOVERNING LUNG EPITHELIAL PROGENITOR CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R35HL150876_7529"}, {"internal_id": 95180728, "Award ID": "R35HL150829", "Award Amount": 3390152.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-14", "CFDA Number": "93.837", "Description": "MOLECULAR REGULATION OF PROGRESSIVE PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R35HL150829_7529"}, {"internal_id": 95484408, "Award ID": "R35HL150803", "Award Amount": 3100411.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-27", "CFDA Number": "93.837", "Description": "CELLULAR AND MOLECULAR PROGRAMMING OF LUNG RESIDENT T CELL MEMORY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R35HL150803_7529"}, {"internal_id": 97852669, "Award ID": "R35HL150783", "Award Amount": 2547970.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-28", "CFDA Number": "93.837", "Description": "APPLYING INNOVATIVE LUNG MAPPING STRATEGIES TO UNDERSTAND ALVEOLAR CAPILLARY BARRIER PERMEABILITY IN ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R35HL150783_7529"}, {"internal_id": 95181619, "Award ID": "R35HL150767", "Award Amount": 3872008.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-14", "CFDA Number": "93.837", "Description": "PROGRAM TO PROMOTE LUNG REGENERATION AND BLOCK FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R35HL150767_7529"}, {"internal_id": 95181114, "Award ID": "R35HL150766", "Award Amount": 4015090.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-14", "CFDA Number": "93.837", "Description": "NOVEL VASCULAR SMOOTH MUSCLE CELL PROGENITORS IN DEVELOPMENT AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R35HL150766_7529"}, {"internal_id": 95181661, "Award ID": "R35HL150682", "Award Amount": 2739684.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-14", "CFDA Number": "93.837", "Description": "VIRAL AND ALLERGEN-DRIVEN IMMUNITY IN CHRONIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R35HL150682_7529"}, {"internal_id": 78990864, "Award ID": "R35HL145242", "Award Amount": 4718000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-08", "CFDA Number": "93.837", "Description": "DEFINING AND CONTROLLING AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R35HL145242_7529"}, {"internal_id": 79639176, "Award ID": "R35HL145235", "Award Amount": 4929795.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-15", "CFDA Number": "93.837", "Description": "AIRWAY EPITHELIAL CELL GENE REGULATION: NEW MECHANISMS AND THERAPEUTIC STRATEGIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R35HL145235_7529"}, {"internal_id": 79433908, "Award ID": "R35HL145000", "Award Amount": 3477719.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-21", "CFDA Number": "93.837", "Description": "ENGINEERING BIOPHYSICAL MICROTECHNOLOGIES FOR HEMATOLOGIC APPLICATIONS IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R35HL145000_7529"}, {"internal_id": 79433590, "Award ID": "R35HL144979", "Award Amount": 4649512.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-25", "CFDA Number": "93.837", "Description": "NOVEL FUNCTIONS OF LUNG MACROPHAGES AND FIBROBLASTS IN PULMONARY INFLAMMATION AND FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R35HL144979_7529"}, {"internal_id": 78991747, "Award ID": "R35HL144805", "Award Amount": 4413554.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-04", "CFDA Number": "93.837", "Description": "INDUCIBLE EPITHELIAL RESISTANCE: A PROGRAM INVESTIGATING MECHANISMS TO PROTECT AGAINST ACUTE AND CHRONIC COMPLICATIONS OF PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_R35HL144805_7529"}, {"internal_id": 77190789, "Award ID": "R35HL144804", "Award Amount": 4618195.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-20", "CFDA Number": "93.837", "Description": "ORGANIZATIONAL STRATEGIES FOR IMPROVING EVIDENCE-UPTAKE IN INTENSIVE CARE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R35HL144804_7529"}, {"internal_id": 77189565, "Award ID": "R35HL144481", "Award Amount": 4322650.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-17", "CFDA Number": "93.837", "Description": "IMMUNOBIOLOGY OF LUNG INJURY AND FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R35HL144481_7529"}, {"internal_id": 62420629, "Award ID": "R35HL140039", "Award Amount": 5467205.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-16", "CFDA Number": "93.837", "Description": "LUNG MACROPHAGE PROGRAMMING IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": 556324.0, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R35HL140039_7529"}, {"internal_id": 49811633, "Award ID": "R35HL140026", "Award Amount": 5818164.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-16", "CFDA Number": "93.837", "Description": "PRECISION MEDICINE IN THE ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R35HL140026_7529"}, {"internal_id": 64141414, "Award ID": "R35HL140019", "Award Amount": 4902054.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-09", "CFDA Number": "93.837", "Description": "GENOMICS OF PULMONARY VASCULAR DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R35HL140019_7529"}, {"internal_id": 49811625, "Award ID": "R35HL139930", "Award Amount": 5488152.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-16", "CFDA Number": "93.837", "Description": "CD4_T-CELL_IMMUNITY_IN_THE_LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_R35HL139930_7529"}, {"internal_id": 61612061, "Award ID": "R35HL139860", "Award Amount": 5417696.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-26", "CFDA Number": "93.837", "Description": "SYSTEMATIC INVESTIGATION OF PROTEIN UBIQUITINATION IN ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R35HL139860_7529"}, {"internal_id": 61611151, "Award ID": "R35HL139726", "Award Amount": 3545725.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-01", "CFDA Number": "93.837", "Description": "SOD3 REGULATION OF REDOX SENSITIVE SIGNALING IN PULMONARY VASCULAR DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R35HL139726_7529"}, {"internal_id": 49811620, "Award ID": "R35HL135834", "Award Amount": 6691831.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-27", "CFDA Number": "93.837", "Description": "MECHANISMS CONTROLLING EXPANSION AND LINEAGE SPECIFICATION OF AIRWAY PROGENITORS IN DEVELOPMENT AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": 946449.0, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R35HL135834_7529"}, {"internal_id": 49811617, "Award ID": "R35HL135830", "Award Amount": 5197500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.837", "Description": "PROGRAM ON CELLULAR METABOLISM AND LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R35HL135830_7529"}, {"internal_id": 49811616, "Award ID": "R35HL135828", "Award Amount": 6492935.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-20", "CFDA Number": "93.837", "Description": "S-GLUTATHIONYLATION CHEMISTRY IN FIBROTIC LUNG REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R35HL135828_7529"}, {"internal_id": 49811609, "Award ID": "R35HL135816", "Award Amount": 6083067.41, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-12", "CFDA Number": "93.837", "Description": "TRANSLATIONAL PROGRAM IN CFTR-RELATED AIRWAY DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": 825916.0, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R35HL135816_7529"}, {"internal_id": 49811608, "Award ID": "R35HL135807", "Award Amount": 5607243.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-12", "CFDA Number": "93.837", "Description": "ION CHANNELS AND MEMBRANE RECEPTORS IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R35HL135807_7529"}, {"internal_id": 49811607, "Award ID": "R35HL135805", "Award Amount": 6386198.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-31", "CFDA Number": "93.837", "Description": "SIGNALING MECHANISMS AND FUNCTIONS RELATED TO PATHO-PHYSIOLOGY OF VASCULAR, LUNG AND BLOOD SYSTEMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R35HL135805_7529"}, {"internal_id": 49811606, "Award ID": "R35HL135800", "Award Amount": 5891700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-11", "CFDA Number": "93.837", "Description": "INNATE IMMUNE CLEARANCE OF HOST-ADAPTED PULMONARY PATHOGENS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R35HL135800_7529"}, {"internal_id": 49811604, "Award ID": "R35HL135795", "Award Amount": 5720314.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-12", "CFDA Number": "93.837", "Description": "THERAPEUTIC IMPLICATIONS OF MOLECULAR DEFECTS IN BONE MARROW FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R35HL135795_7529"}, {"internal_id": 49811602, "Award ID": "R35HL135790", "Award Amount": 5540012.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-11", "CFDA Number": "93.837", "Description": "MECHANOBIOLOGY OF CARDIOPULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4a536007-27e4-2194-a125-f4b8c55294db-C", "generated_internal_id": "ASST_NON_R35HL135790_7529"}, {"internal_id": 49811599, "Award ID": "R35HL135779", "Award Amount": 5588585.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-11", "CFDA Number": "93.837", "Description": "NEURAL CONTROL OF BREATHING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R35HL135779_7529"}, {"internal_id": 49811592, "Award ID": "R35HL135756", "Award Amount": 6346182.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-11", "CFDA Number": "93.837", "Description": "PNEUMONIA BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": 445576.79, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R35HL135756_7529"}, {"internal_id": 49811587, "Award ID": "R35HL135747", "Award Amount": 6803369.72, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-15", "CFDA Number": "93.837", "Description": "BEYOND THE BARRIER: ALVEOLAR EPITHELIAL CELL BIOLOGY IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R35HL135747_7529"}, {"internal_id": 49811582, "Award ID": "R35HL135710", "Award Amount": 6797526.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-18", "CFDA Number": "93.837", "Description": "A NOVEL EXOSOMAL INFLAMMATORY PATHWAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R35HL135710_7529"}, {"internal_id": 110024776, "Award ID": "R34HL153474", "Award Amount": 705953.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-27", "CFDA Number": "93.837", "Description": "PROCALCITONIN TO REDUCE ANTIBIOTIC USE IN PEDIATRIC PNEUMONIA (P-RAPP)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_R34HL153474_7529"}, {"internal_id": 94713906, "Award ID": "R34HL150404", "Award Amount": 714192.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-21", "CFDA Number": "93.837", "Description": "THE FEASIBILITY OF IMPLEMENTING LIGHT SEDATION AFTER INITIATION OF MECHANICAL VENTILATION IN THE EMERGENCY DEPARTMENT: THE ED-SED PILOT TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R34HL150404_7529"}, {"internal_id": 107115376, "Award ID": "R34HL145442", "Award Amount": 657282.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-27", "CFDA Number": "93.837", "Description": "FEASIBILITY OF MHEALTH TECHNOLOGY FOR IMPROVING SELF-MANAGEMENT AND ADHERENCE AMONG ASTHMATIC ADOLESCENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ceec5ef7-d6a5-28f0-e23f-ec61155b7078-C", "generated_internal_id": "ASST_NON_R34HL145442_7529"}, {"internal_id": 79433567, "Award ID": "R34HL145387", "Award Amount": 713852.81, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-04", "CFDA Number": "93.837", "Description": "OPTIMIZING A SELF-DIRECTED MOBILE COPYING SKILLS TRAINING INTERVENTION FOR IMPROVING CARDIORESPIRATORY FAILTURE SURVIVORS' PSYCHOLOGICAL DISTRESS: A PILOT RANDOMIZED CLINICAL TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R34HL145387_7529"}, {"internal_id": 81395378, "Award ID": "R34HL143747", "Award Amount": 736937.68, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-07", "CFDA Number": "93.837", "Description": "COMPREHENSIVE HOME-BASED SELF-MANAGEMENT SUPPORT FOR COPD PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R34HL143747_7529"}, {"internal_id": 67314629, "Award ID": "R34HL142995", "Award Amount": 705388.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-04", "CFDA Number": "93.837", "Description": "PHARMACOKINETICS OF ORAL L-CITRULLINE IN INFANTS AT HIGH RISK OF DEVELOPING PULMONARY HYPERTENSION ASSOCIATED WITH BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R34HL142995_7529"}, {"internal_id": 49810580, "Award ID": "R34HL138235", "Award Amount": 712443.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-23", "CFDA Number": "93.837", "Description": "RESVERATROL AND SIROLIMUS IN LAM TRIAL (RESULT)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R34HL138235_7529"}, {"internal_id": 67313695, "Award ID": "R34HL138186", "Award Amount": 725537.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-10", "CFDA Number": "93.837", "Description": "A PILOT RANDOMIZED CONTROLLED TRIAL OF DE NOVO BELATACEPT-BASED IMMUNOSUPPRESSION IN LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R34HL138186_7529"}, {"internal_id": 67833722, "Award ID": "R34HL137851", "Award Amount": 724075.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-10", "CFDA Number": "93.837", "Description": "ED-INITIATED SCHOOL-BASED ASTHMA MEDICATION SUPERVISION (ED-SAMS)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R34HL137851_7529"}, {"internal_id": 65280097, "Award ID": "R34HL136991", "Award Amount": 735428.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-31", "CFDA Number": "93.837", "Description": "AZITHROMYCIN AND THE AIRWAY MICROBIOME IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R34HL136991_7529"}, {"internal_id": 49810578, "Award ID": "R34HL136989", "Award Amount": 718833.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-20", "CFDA Number": "93.837", "Description": "A MOBILE HEALTH INTERVENTION IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R34HL136989_7529"}, {"internal_id": 49810575, "Award ID": "R34HL136755", "Award Amount": 720628.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-11", "CFDA Number": "93.838", "Description": "PILOT OF LIFESTYLE IN ASTHMA INTERVENTION (PLAN)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R34HL136755_7529"}, {"internal_id": 49810574, "Award ID": "R34HL135361", "Award Amount": 590531.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-11", "CFDA Number": "93.837", "Description": "TRIAL OF ROFLUMILAST IN ASTHMA MANAGEMENT (TRIM)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R34HL135361_7529"}, {"internal_id": 49810566, "Award ID": "R34HL132369", "Award Amount": 627249.24, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "PILOT STUDY OF ZINC ACETATE FOR CHRONIC COUGH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R34HL132369_7529"}, {"internal_id": 49810560, "Award ID": "R34HL127166", "Award Amount": 600095.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-16", "CFDA Number": "93.838", "Description": "A PILOT STUDY OF THE EFFECT OF THE CFTR POTENTIATOR IVACAFTOR IN COPD (P-TOPIC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R34HL127166_7529"}, {"internal_id": 49810557, "Award ID": "R34HL125859", "Award Amount": 342161.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-14", "CFDA Number": "93.838", "Description": "ENTRAINMENT-BASED MECHANICAL VENTILATION TO IMPROVE PATIENT-VENTILATOR SYNCHRONY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "959819d4-fcbb-189c-44a9-a2fc0644251a-C", "generated_internal_id": "ASST_NON_R34HL125859_7529"}, {"internal_id": 49810553, "Award ID": "R34HL124038", "Award Amount": 717213.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-20", "CFDA Number": "93.838", "Description": "ECHOCARDIOGRAM TO DIAGNOSE PULMONARY HYPERTENSION IN PREMATURE INFANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R34HL124038_7529"}, {"internal_id": 49810550, "Award ID": "R34HL123438", "Award Amount": 593849.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-13", "CFDA Number": "93.838", "Description": "INTRAOPERATIVE PROTECTIVE VENTILATION AND POSTOPERATIVE PULMONARY COMPLICATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R34HL123438_7529"}, {"internal_id": 49810549, "Award ID": "R34HL122558", "Award Amount": 642614.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-15", "CFDA Number": "93.837", "Description": "COMPARING AND COMBINING BORTEZOMIB AND MYCOPHENOLATE IN SSC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R34HL122558_7529"}, {"internal_id": 110233500, "Award ID": "R33HL154135", "Award Amount": 831753.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-10", "CFDA Number": "93.837", "Description": "PRECLINICAL DEVELOPMENT OF A NOVEL DISEASE MODIFYING THERAPY FOR PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4eb784d6-c736-c581-1a21-e4de67f4e732-R", "generated_internal_id": "ASST_NON_R33HL154135_7529"}, {"internal_id": 108463379, "Award ID": "R33HL154125", "Award Amount": 1176000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-10", "CFDA Number": "93.837", "Description": "OPTIMIZATION OF PET PROBE FOR IMAGING LUNG FIBROGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R33HL154125_7529"}, {"internal_id": 109190071, "Award ID": "R33HL154117", "Award Amount": 913348.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-18", "CFDA Number": "93.837", "Description": "AN INFLAMMATION-INDUCED FIBROSIS-ON-CHIP SYSTEM FOR THE TESTING OF ANTI-FIBROSIS DRUGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f94a8263-c1eb-718b-03c5-bb8a878692fd-C", "generated_internal_id": "ASST_NON_R33HL154117_7529"}, {"internal_id": 109189991, "Award ID": "R33HL154103", "Award Amount": 881243.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-15", "CFDA Number": "93.837", "Description": "OPTIMIZATION OF A RABBIT RETAINED HEMOTHORAX MODEL FOR EVIDENCE-BASED PHARMACOLOGIC INTERVENTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6605b60b-2165-8c36-e954-428aa458f579-C", "generated_internal_id": "ASST_NON_R33HL154103_7529"}, {"internal_id": 110862163, "Award ID": "R33HL147906", "Award Amount": 2261243.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-23", "CFDA Number": "93.837", "Description": "EXTENDING CPAP THERAPY IN STABLE PRETERM INFANTS TO INCREASE LUNG GROWTH AND FUNCTION: A RANDOMIZED CONTROLLED TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R33HL147906_7529"}, {"internal_id": 110233047, "Award ID": "R33HL143317", "Award Amount": 2433696.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-07", "CFDA Number": "93.865", "Description": "COMPREHENSIVE HEALTH INFORMATICS ENGAGEMENT FRAMEWORK FOR PULMONARY REHAB", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R33HL143317_7529"}, {"internal_id": 109190068, "Award ID": "R33HL142933", "Award Amount": 2155706.63, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-18", "CFDA Number": "93.837", "Description": "INCREASING ADHERENCE TO PULMONARY REHABILITATION AFTER COPD-RELATED HOSPITALIZATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R33HL142933_7529"}, {"internal_id": 86317246, "Award ID": "R33HL142539", "Award Amount": 3043933.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-21", "CFDA Number": "93.837", "Description": "REHAB-PH TRIAL: REPURPOSING A HISTAMINE ANTAGONIST TO BENEFIT PATIENTS WITH PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R33HL142539_7529"}, {"internal_id": 81728343, "Award ID": "R33HL138650", "Award Amount": 3435386.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-21", "CFDA Number": "93.837", "Description": "RANDOMIZED TRIAL OF ENDOTRACHEAL TUBES TO PREVENT VENTILATOR-ASSOCIATED PNEUMONIA - PREVENT 2 STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R33HL138650_7529"}, {"internal_id": 80728740, "Award ID": "R33HL137081", "Award Amount": 2420703.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-10", "CFDA Number": "93.837", "Description": "THE B CELL REPERTOIRE AS A WINDOW INTO THE NATURE AND IMPACT OF THE LUNG VIROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R33HL137081_7529"}, {"internal_id": 80728851, "Award ID": "R33HL137079", "Award Amount": 2189703.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-10", "CFDA Number": "93.837", "Description": "THE VIROME AND ADVERSE OUTCOMES IN LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R33HL137079_7529"}, {"internal_id": 81071307, "Award ID": "R33HL137077", "Award Amount": 2235156.43, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-24", "CFDA Number": "93.837", "Description": "IMPACT OF VIROME ON MICROBIAL COMMUNITIES IN THE RESPIRATORY TRACT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R33HL137077_7529"}, {"internal_id": 80729084, "Award ID": "R33HL137063", "Award Amount": 2250470.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-06", "CFDA Number": "93.837", "Description": "THE LUNG DNA VIROME IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R33HL137063_7529"}, {"internal_id": 49809989, "Award ID": "R33HL120794", "Award Amount": 1679998.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-22", "CFDA Number": "93.838", "Description": "FUNCTIONAL GENOMIC APPROACHES TO DISSECT COPD GWAS LOCI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R33HL120794_7529"}, {"internal_id": 49809984, "Award ID": "R33HL120770", "Award Amount": 1556348.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-28", "CFDA Number": "93.838", "Description": "FUNCTIONAL GENETICS IN IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R33HL120770_7529"}, {"internal_id": 49809983, "Award ID": "R33HL120760", "Award Amount": 1358253.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-22", "CFDA Number": "93.838", "Description": "LIPIDOMIC SCREENING FOR FUNCTIONAL SURFACTANT GENE MUTATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R33HL120760_7529"}, {"internal_id": 49809980, "Award ID": "R33HL120751", "Award Amount": 1493961.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-18", "CFDA Number": "93.838", "Description": "HIGH ALTITUDE ADAPTATION: A MODEL FOR CHRONIC HYPOXIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R33HL120751_7529"}, {"internal_id": 76738055, "Award ID": "R25HL146166", "Award Amount": 2406747.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-03", "CFDA Number": "93.837", "Description": "PRIDE ACADEMY: IMPACT OF ANCESTRY AND GENDER TO OMICS OF LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R25HL146166_7529"}, {"internal_id": 49807062, "Award ID": "R25HL128639", "Award Amount": 610817.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-05", "CFDA Number": "93.837", "Description": "ADVANCED SKILLS DEVELOPMENT IN GLYCO-HEMATOLOGY AND GLYCO-ONCOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R25HL128639_7529"}, {"internal_id": 49807058, "Award ID": "R25HL126140", "Award Amount": 3588684.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-12", "CFDA Number": "93.837", "Description": "ARIZONA PRIDE-25: ADVANCED HEALTH DISPARITIES TRAINING PROGRAM IN HEART, LUNG, BLOOD, AND SLEEP CONDITIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R25HL126140_7529"}, {"internal_id": 49807038, "Award ID": "R25HL108857", "Award Amount": 1450820.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-06-06", "CFDA Number": "93.837", "Description": "SHORT-TERM RESEARCH TRAINING PROGRAM FOR MINORITY STUDENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R25HL108857_7529"}, {"internal_id": 49807031, "Award ID": "R25HL108823", "Award Amount": 593148.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-06-03", "CFDA Number": "93.837", "Description": "COLORADO SUMMER RESEARCH TRAINING FOR UNDERGRADUATE DIVERSITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R25HL108823_7529"}, {"internal_id": 49807021, "Award ID": "R25HL103286", "Award Amount": 1585794.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-06-18", "CFDA Number": "93.837", "Description": "SHORT-TERM INTERNSHIP PROGRAM FOR UNDERGRADUATES AND HEALTH PROFESSIONAL STUDENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R25HL103286_7529"}, {"internal_id": 49806997, "Award ID": "R25HL088992", "Award Amount": 1645108.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-05-31", "CFDA Number": "93.837", "Description": "SHORT-TERM TRAINING PROGRAM TO INCREASE DIVERSITY IN HEALTH-RELATED RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "378fe7f9-e157-cd75-80cc-97cbe1a426db-C", "generated_internal_id": "ASST_NON_R25HL088992_7529"}, {"internal_id": 49806989, "Award ID": "R25HL084762", "Award Amount": 1786518.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-11-20", "CFDA Number": "93.837", "Description": "SHORT-TERM TRAINING PROGRAM TO INCREASE DIVERSITY IN HEALTH-RELATED RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R25HL084762_7529"}, {"internal_id": 49805796, "Award ID": "R24HL123828", "Award Amount": 2691712.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-15", "CFDA Number": "93.837", "Description": "A NATIONAL RESOURCE FOR LUNG DISEASE-SPECIFIC IPS CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R24HL123828_7529"}, {"internal_id": 49805794, "Award ID": "R24HL123482", "Award Amount": 3835226.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-28", "CFDA Number": "93.837", "Description": "NATIONAL FERRET RESOURCE AND RESEARCH CENTER ON LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R24HL123482_7529"}, {"internal_id": 49805788, "Award ID": "R24HL111895", "Award Amount": 5391763.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-12", "CFDA Number": "93.838", "Description": "IMPROVING LONG-TERM OUTCOMES CLINICAL RESEARCH FOR ACUTE RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R24HL111895_7529"}, {"internal_id": 110025242, "Award ID": "R21HL154156", "Award Amount": 419247.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-24", "CFDA Number": "93.837", "Description": "NOVEL ULTRASONIC METHODS FOR THE ASSESSMENT OF PULMONARY EDEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4b0ff0c-e3a2-f597-7ab0-1c78e1010874-C", "generated_internal_id": "ASST_NON_R21HL154156_7529"}, {"internal_id": 107114563, "Award ID": "R21HL154032", "Award Amount": 418864.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-22", "CFDA Number": "93.837", "Description": "HYPERPOLARIZED DIETHYL ETHER FOR SUB-SECOND PULMONARY MRI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "57f1d8a4-43a0-9952-a047-67afb28d0b55-C", "generated_internal_id": "ASST_NON_R21HL154032_7529"}, {"internal_id": 85589525, "Award ID": "R21HL151261", "Award Amount": 343640.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-18", "CFDA Number": "93.838", "Description": "IDENTIFYING MEASURES OF PULMONARY MORBIDITY FOR CLINICAL TRIALS IN CHILDREN WITH DOWN SYNDROME AND ASPIRATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R21HL151261_7529"}, {"internal_id": 85588405, "Award ID": "R21HL151256", "Award Amount": 526319.15, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-13", "CFDA Number": "93.310", "Description": "BRONCHUS-ASSOCIATED LYMPHOID TISSUE & LUNG INFECTION IN DOWN SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R21HL151256_7529"}, {"internal_id": 109190107, "Award ID": "R21HL150431", "Award Amount": 234750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "MULTI-OMICS ANALYSIS OF CHILDHOOD ASTHMA IN HISPANICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R21HL150431_7529"}, {"internal_id": 94714483, "Award ID": "R21HL149773", "Award Amount": 243750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-24", "CFDA Number": "93.837", "Description": "WILL CANNABIS LEGALIZATION HAVE UNINTENDED CONSEQUENCES FOR CHILDREN'S RESPIRATORY HEALTH? AN ECOLOGICAL ANALYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "130495ab-f026-f140-5971-3aea377a73d4-C", "generated_internal_id": "ASST_NON_R21HL149773_7529"}, {"internal_id": 82054492, "Award ID": "R21HL148488", "Award Amount": 243000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-04", "CFDA Number": "93.837", "Description": "SIGLEC 9 FOR THE DIAGNOSIS OF ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R21HL148488_7529"}, {"internal_id": 81728821, "Award ID": "R21HL148089", "Award Amount": 212775.94, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-25", "CFDA Number": "93.837", "Description": "DIAGNOSTIC CLASSIFIERS FOR SARCOIDOSIS USING A NOVEL T7 PHAGE DISPLAY TECHNOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "57f1d8a4-43a0-9952-a047-67afb28d0b55-C", "generated_internal_id": "ASST_NON_R21HL148089_7529"}, {"internal_id": 108463633, "Award ID": "R21HL148088", "Award Amount": 248405.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-06", "CFDA Number": "93.837", "Description": "EVALUATION OF ALTERNATIVE COMPLEMENT ACTIVITY WITHIN AN ARDS COHORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R21HL148088_7529"}, {"internal_id": 80724845, "Award ID": "R21HL146250", "Award Amount": 398384.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-15", "CFDA Number": "93.837", "Description": "EXTRACELLULAR MATRIX-DERIVED NANOPARTICLES FOR REPAIRING LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R21HL146250_7529"}, {"internal_id": 80401740, "Award ID": "R21HL145506", "Award Amount": 223024.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-19", "CFDA Number": "93.837", "Description": "MEASURING LUNG STRESS TO IDENTIFY OCCULT VENTILATION-INDUCED LUNG INJURY IN ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R21HL145506_7529"}, {"internal_id": 79433482, "Award ID": "R21HL145422", "Award Amount": 135535.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-29", "CFDA Number": "93.838", "Description": "ROLE OF IGF IN PULMONARY ARTERIAL HYPERTENSION SEVERITY AND SURVIVAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R21HL145422_7529"}, {"internal_id": 77190972, "Award ID": "R21HL145420", "Award Amount": 286861.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-18", "CFDA Number": "93.837", "Description": "NETWORK MEDICINE, RISK STRATIFICATION, AND PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R21HL145420_7529"}, {"internal_id": 78991645, "Award ID": "R21HL145415", "Award Amount": 241234.84, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-04", "CFDA Number": "93.837", "Description": "MULTIFACTORIAL SPATIOTEMPORAL ANALYSES TO EVALUATE ENVIRONMENTAL TRIGGERS AND PATIENT-LEVEL CLINICAL CHARACTERISTICS OF SEVERE ASTHMA EXACERBATIONS IN CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R21HL145415_7529"}, {"internal_id": 86318320, "Award ID": "R21HL145246", "Award Amount": 342628.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-20", "CFDA Number": "93.837", "Description": "BIOMARKERS OF INTERSTITIAL LUNG ABNORMALITIES PREDICT POOR OUTCOMES IN ARDS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R21HL145246_7529"}, {"internal_id": 69723904, "Award ID": "R21HL145216", "Award Amount": 245626.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-20", "CFDA Number": "93.837", "Description": "PROGNOSTIC ROLE OF PLASMA XANTHINE OXIDOREDUCTASE IN ARDS PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R21HL145216_7529"}, {"internal_id": 85590225, "Award ID": "R21HL144673", "Award Amount": 604197.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-13", "CFDA Number": "93.077", "Description": "USING PET TO MEASURE PULMONARY OXIDATIVE STRESS IN E-CIGARETTE USERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R21HL144673_7529"}, {"internal_id": 76738601, "Award ID": "R21HL144253", "Award Amount": 453750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-31", "CFDA Number": "93.837", "Description": "MULTI-FUNCTIONAL TARGETED BIO-CONJUGATE PLATFORM TO DISMANTLE NEUTROPHIL EXTRACELLULAR TRAPS (NETS)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6bb5676d-1119-4abb-3c6a-1bdba277e0cd-C", "generated_internal_id": "ASST_NON_R21HL144253_7529"}, {"internal_id": 67580040, "Award ID": "R21HL143091", "Award Amount": 230736.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-26", "CFDA Number": "93.837", "Description": "DETERMINATION OF IMMUNOGENIC MICROBIOTA IN THE LUNG: LEVERAGING THE LUNG HIV MICROBIOME PROJECT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R21HL143091_7529"}, {"internal_id": 81072296, "Award ID": "R21HL142507", "Award Amount": 599649.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-21", "CFDA Number": "93.837", "Description": "ELECTRONIC CIGARETTE CARDIOTOXICITY VARIES BY FLAVORINGS: WHAT CAN WE LEARN FROM MICE?", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_R21HL142507_7529"}, {"internal_id": 65579458, "Award ID": "R21HL140995", "Award Amount": 428500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-18", "CFDA Number": "93.837", "Description": "PORTABLE CO2 SERVOREGULATION SYSTEM FOR MEMBRANE LUNGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R21HL140995_7529"}, {"internal_id": 67833769, "Award ID": "R21HL140465", "Award Amount": 226482.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-16", "CFDA Number": "93.837", "Description": "AUTOMATED DIAGNOSIS AND PROGRESSION RATE OF IPF USING HRCT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R21HL140465_7529"}, {"internal_id": 49801188, "Award ID": "R21HL140436", "Award Amount": 244463.39, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-09", "CFDA Number": "93.837", "Description": "COUPLING MRI-DERIVED VENTILATION WITH COMPUTATIONAL MODELS TO ASSESS INHALED AEROSOL TREATMENT FEASIBILITY IN SEVERE ASTHMATIC ADULTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4787a47d-4e7a-9c8a-99e6-91ba7f4c9b8b-C", "generated_internal_id": "ASST_NON_R21HL140436_7529"}, {"internal_id": 49801186, "Award ID": "R21HL140422", "Award Amount": 263674.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-09", "CFDA Number": "93.837", "Description": "CT-BASED PREDICTORS OF ILA PROGRESSION IN COPDGENE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R21HL140422_7529"}, {"internal_id": 49801183, "Award ID": "R21HL140376", "Award Amount": 234742.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-09", "CFDA Number": "93.837", "Description": "OMICS DATA INTEGRATION TO IDENTIFY DISEASE PATHWAYS IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R21HL140376_7529"}, {"internal_id": 67834091, "Award ID": "R21HL140287", "Award Amount": 258741.42, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-10", "CFDA Number": "93.310", "Description": "STEP DOWN OF ASTHMA BIOLOGICS IN REAL-WORLD PRACTICE SETTINGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2439d942-d439-953a-5588-98392dd15217-C", "generated_internal_id": "ASST_NON_R21HL140287_7529"}, {"internal_id": 49801172, "Award ID": "R21HL139156", "Award Amount": 411601.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-14", "CFDA Number": "93.838", "Description": "RAPID BREATH ANALYSIS FOR ACUTE RESPIRATORY DISTRESS SYNDROME DIAGNOSTICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R21HL139156_7529"}, {"internal_id": 49801156, "Award ID": "R21HL135368", "Award Amount": 234000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.233", "Description": "DISCOVERY AND CHARACTERIZATION OF CANDIDATE THERAPEUTICS FOR DRUG-INDUCED PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R21HL135368_7529"}, {"internal_id": 49801154, "Award ID": "R21HL135306", "Award Amount": 234000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-25", "CFDA Number": "93.838", "Description": "A NOVEL DONOR RISK SCORING SYSTEM FOR BETTER ORGAN UTILIZATION IN LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R21HL135306_7529"}, {"internal_id": 49801145, "Award ID": "R21HL133742", "Award Amount": 237000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-01", "CFDA Number": "93.838", "Description": "ANTIBIOTIC TIMING, SPECTRUM, AND CUMULATIVE DOSE DURING PREGNANCY AND INFANCY ON RISK OF ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R21HL133742_7529"}, {"internal_id": 49801142, "Award ID": "R21HL133539", "Award Amount": 248485.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-01", "CFDA Number": "93.838", "Description": "INTEGRATIVE ANALYSIS OF MULTI-OMICS DATA TO TARGET FIBROBLAST ACTIVATION IN IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R21HL133539_7529"}, {"internal_id": 49801130, "Award ID": "R21HL132256", "Award Amount": 443320.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-08", "CFDA Number": "93.838", "Description": "MATRIX REMODELING IN MICROFLUIDIC CO-CULTURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R21HL132256_7529"}, {"internal_id": 49801121, "Award ID": "R21HL130956", "Award Amount": 444028.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-29", "CFDA Number": "93.838", "Description": "PRODUCING NITRIC OXIDE BY PULSED ELECTRICAL DISCHARGE IN AIR FOR INHALATION THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R21HL130956_7529"}, {"internal_id": 49801120, "Award ID": "R21HL130901", "Award Amount": 416994.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-20", "CFDA Number": "93.838", "Description": "IMAGING NANOPHYSICAL PROPERTIES OF ACTIVELY TRANSPORTING BRONCHIAL MUCUS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R21HL130901_7529"}, {"internal_id": 49801118, "Award ID": "R21HL130839", "Award Amount": 435875.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-09", "CFDA Number": "93.838", "Description": "MAGNETIC RESONANCE FINGERPRINTING ASSESSMENTS OF LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R21HL130839_7529"}, {"internal_id": 49801107, "Award ID": "R21HL129852", "Award Amount": 422606.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-10", "CFDA Number": "93.838", "Description": "INVESTIGATING THE ROLE OF HIV X4 VARIANTS IN PULMONARY VASCULAR REMODELING AND PULMONARY HYPERTENSION IN HUMANIZED MICE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30f9aa19-2773-fb77-2e44-59c99374edf2-C", "generated_internal_id": "ASST_NON_R21HL129852_7529"}, {"internal_id": 49801105, "Award ID": "R21HL129468", "Award Amount": 442700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-11", "CFDA Number": "93.838", "Description": "ADVANCED IMAGE-BASED APPROACH TO ASSESS HOW FIBRILLAR COLLAGEN MODULATES AIRWAY REACTIVITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4787a47d-4e7a-9c8a-99e6-91ba7f4c9b8b-C", "generated_internal_id": "ASST_NON_R21HL129468_7529"}, {"internal_id": 49801101, "Award ID": "R21HL129144", "Award Amount": 405929.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-23", "CFDA Number": "93.838", "Description": "OXYGEN MICROBUBBLE PERITONEAL VENTILATION TREATMENT FOR ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b80a61bf-aab0-2f35-db05-67fd682ea201-C", "generated_internal_id": "ASST_NON_R21HL129144_7529"}, {"internal_id": 49801100, "Award ID": "R21HL129115", "Award Amount": 355273.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-01", "CFDA Number": "93.838", "Description": "NANOPARTICLE REMODELING OF PULMONARY JUNCTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2c3d8c8a-27ef-b1e9-7164-bbfa490faa27-C", "generated_internal_id": "ASST_NON_R21HL129115_7529"}, {"internal_id": 49801099, "Award ID": "R21HL129112", "Award Amount": 274209.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-07", "CFDA Number": "93.838", "Description": "XE129 MRI OF THE LUNG: A NEW TECHNOLOGY TO ASSESS TREATMENT FOR COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R21HL129112_7529"}, {"internal_id": 49801095, "Award ID": "R21HL129047", "Award Amount": 394163.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-31", "CFDA Number": "93.838", "Description": "PULMONARY HYPERTENSION ASSOCIATED WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R21HL129047_7529"}, {"internal_id": 49801092, "Award ID": "R21HL129023", "Award Amount": 430850.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-01", "CFDA Number": "93.838", "Description": "COMPREHENSIVE ANALYSIS OF GENE-ENVIRONMENT INTERACTION IN SARCOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4397aef3-70da-b831-0f7a-71049f3e955b-C", "generated_internal_id": "ASST_NON_R21HL129023_7529"}, {"internal_id": 49801090, "Award ID": "R21HL129020", "Award Amount": 230846.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-02", "CFDA Number": "93.838", "Description": "STATISTICAL METHODS FOR RECURRENT EVENT DATA IN RSV IMMUNOPROPHYLAXIS STUDIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R21HL129020_7529"}, {"internal_id": 49801087, "Award ID": "R21HL128875", "Award Amount": 243973.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-08", "CFDA Number": "93.838", "Description": "PREDICTING APPROPRIATE ADMISSION OF BRONCHIOLITIS PATIENTS IN THE EMERGENCY ROOM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R21HL128875_7529"}, {"internal_id": 49801080, "Award ID": "R21HL128141", "Award Amount": 409541.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.837", "Description": "TRACHEOBRONCHIAL MUCOCILIARY DYSFUNCTION IN HIV PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8521f543-2302-80cf-d989-c2ff7cf07ef3-C", "generated_internal_id": "ASST_NON_R21HL128141_7529"}, {"internal_id": 49801077, "Award ID": "R21HL127900", "Award Amount": 441619.0, "Award Type": null, "Base Obligation Date": "2014-09-19", "CFDA Number": "93.838", "Description": "REAL-TIME TRACKING OF SINGLE CELLS IN LIVE ANIMALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R21HL127900_7529"}, {"internal_id": 49801059, "Award ID": "R21HL126190", "Award Amount": 399319.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-07", "CFDA Number": "93.838", "Description": "SECOND HARMONIC GENERATION ANALYSIS OF THE ECM IN IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R21HL126190_7529"}, {"internal_id": 49801052, "Award ID": "R21HL126040", "Award Amount": 451175.0, "Award Type": null, "Base Obligation Date": "2015-07-10", "CFDA Number": "93.838", "Description": "PULMONARY ARTERIAL ENDOTHELIAL STIFFNESS AND SHEAR-STRESS INDUCED SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6bb5676d-1119-4abb-3c6a-1bdba277e0cd-C", "generated_internal_id": "ASST_NON_R21HL126040_7529"}, {"internal_id": 49801051, "Award ID": "R21HL126032", "Award Amount": 461667.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-10", "CFDA Number": "93.838", "Description": "GENOME-WIDE GENE-BY-SMOKING INTERACTION ANALYSIS OF PULMONARY FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_R21HL126032_7529"}, {"internal_id": 49801045, "Award ID": "R21HL125999", "Award Amount": 487938.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-31", "CFDA Number": "93.838", "Description": "REGIONAL MEASUREMENT OF ALVEOLAR PARTIAL PRESSURE OF OXYGEN WITH HPXE MRI.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R21HL125999_7529"}, {"internal_id": 49801035, "Award ID": "R21HL125021", "Award Amount": 404453.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-31", "CFDA Number": "93.838", "Description": "HIV AND MORPHINE INCREASE SUSCEPTIBILITY TO LUNG OPPORTUNISTIC INFECTIONS BY MODULATING TLR2/IL17A MEDIATED LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_R21HL125021_7529"}, {"internal_id": 49801029, "Award ID": "R21HL124462", "Award Amount": 461361.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-03", "CFDA Number": "93.838", "Description": "DYNAMIC MRI IMAGE ANALYSIS FOR STUDYING THORACIC INSUFFICIENCY SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R21HL124462_7529"}, {"internal_id": 49801026, "Award ID": "R21HL124440", "Award Amount": 484951.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-23", "CFDA Number": "93.838", "Description": "PORTABLE LOW FIELD MAGNETIC RESONANCE DEVICE FOR ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R21HL124440_7529"}, {"internal_id": 49801019, "Award ID": "R21HL123666", "Award Amount": 225833.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-02", "CFDA Number": "93.233", "Description": "CPAP ADHERENCE AND POSTOPERATIVE DELIRIUM IN PATIENTS WITH OSA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R21HL123666_7529"}, {"internal_id": 49801015, "Award ID": "R21HL123522", "Award Amount": 492476.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-19", "CFDA Number": "93.838", "Description": "MONITORING CONTRACTILE FORCES DURING AIRWAY CONSTRICTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R21HL123522_7529"}, {"internal_id": 49801013, "Award ID": "R21HL123477", "Award Amount": 214580.0, "Award Type": null, "Base Obligation Date": "2015-08-07", "CFDA Number": "93.838", "Description": "PREDICTION OF IPF PROGRESSION USING IMAGING PATTERNS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R21HL123477_7529"}, {"internal_id": 49801010, "Award ID": "R21HL123044", "Award Amount": 444357.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-20", "CFDA Number": "93.838", "Description": "CENTRAL ROLE OF ENDOTHELIAL STEM CELLS IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R21HL123044_7529"}, {"internal_id": 49800978, "Award ID": "R21HL121521", "Award Amount": 237000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-28", "CFDA Number": "93.233", "Description": "PREDICTIVE ADHERENCE MODELING (PAM) STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R21HL121521_7529"}, {"internal_id": 49784442, "Award ID": "R18HL116285", "Award Amount": 3560259.56, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-30", "CFDA Number": "93.837", "Description": "A PATIENT ADVOCATE TO IMPROVE REAL-WORLD ASTHMA MANAGEMENT FOR INNER CITY ADULTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R18HL116285_7529"}, {"internal_id": 49784440, "Award ID": "R18HL116244", "Award Amount": 3598240.51, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-06-17", "CFDA Number": "93.837", "Description": "SCHOOL-BASED ASTHMA CARE FOR TEENS (SB-ACT)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R18HL116244_7529"}, {"internal_id": 49784437, "Award ID": "R18HL110858", "Award Amount": 3155975.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-07", "CFDA Number": "93.838", "Description": "THE COST EFFECTIVENESS OF SCHOOL-BASED SUPERVISED ASTHMA THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R18HL110858_7529"}, {"internal_id": 49784436, "Award ID": "R18HL108810", "Award Amount": 2044836.0, "Award Type": null, "Base Obligation Date": "2011-08-02", "CFDA Number": "93.838", "Description": "IMPLEMENTATION AND OUTCOMES OF NONINVASIVE VENTILATION IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e1acd199-78e8-9c81-52eb-45206f3dab16-C", "generated_internal_id": "ASST_NON_R18HL108810_7529"}, {"internal_id": 49784434, "Award ID": "R18HL107223", "Award Amount": 3371519.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-06-27", "CFDA Number": "93.838", "Description": "REDUCING ASTHMA MORBIDITY IN HIGH RISK MINORITY PRESCHOOL CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R18HL107223_7529"}, {"internal_id": 100875196, "Award ID": "R15HL152257", "Award Amount": 450000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-12", "CFDA Number": "93.837", "Description": "RAGE TARGETING ATTENUATES SMOKE-INDUCED INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a97b483-a237-d46a-d79b-15d987dc5a4f-C", "generated_internal_id": "ASST_NON_R15HL152257_7529"}, {"internal_id": 103897560, "Award ID": "R15HL148870", "Award Amount": 447700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-20", "CFDA Number": "93.837", "Description": "CHOLINERGIC MODULATION OF XII MOTONEURONS AND XII PREMOTONEURONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e6cfdff7-fbfd-be64-8c66-ee35900d0308-C", "generated_internal_id": "ASST_NON_R15HL148870_7529"}, {"internal_id": 96203652, "Award ID": "R15HL148850", "Award Amount": 432330.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-22", "CFDA Number": "93.837", "Description": "LIMITATIONS TO NORMAL CARDIOPULMONARY FUNCTION IN ADULT SURVIVORS OF PRETERM BIRTH.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7b52fa5f-5875-14d7-6b49-dba3db4692f2-C", "generated_internal_id": "ASST_NON_R15HL148850_7529"}, {"internal_id": 78599858, "Award ID": "R15HL143545", "Award Amount": 423000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-27", "CFDA Number": "93.838", "Description": "GLUTATHIONE DEPLETION IN LUNG PARENCHYMA AND ITS EFFECTS ON MTB INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6351ef2d-360a-b619-c4ca-055c9e8e8064-C", "generated_internal_id": "ASST_NON_R15HL143545_7529"}, {"internal_id": 68167525, "Award ID": "R15HL143480", "Award Amount": 430998.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-30", "CFDA Number": "93.837", "Description": "IMPACT OF IN UTERO SMOKE EXPOSURE ON NK CELLS AND ALLERGIC LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "84053321-0a5c-9d0f-aed8-d82c189c0cca-C", "generated_internal_id": "ASST_NON_R15HL143480_7529"}, {"internal_id": 68170289, "Award ID": "R15HL138718", "Award Amount": 454962.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-23", "CFDA Number": "93.837", "Description": "RECEPTOR-GUIDED TARGETED THERAPY FOR ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "089552f8-befb-f70f-7326-f1773de8f5a3-C", "generated_internal_id": "ASST_NON_R15HL138718_7529"}, {"internal_id": 68167668, "Award ID": "R15HL138606", "Award Amount": 492000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-23", "CFDA Number": "93.837", "Description": "TARGETING OF APOPTOTIC AND AUTOPHAGY PATHWAYS FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "beba57bd-0498-4640-8fa0-4edf99811d85-C", "generated_internal_id": "ASST_NON_R15HL138606_7529"}, {"internal_id": 49783396, "Award ID": "R15HL138603", "Award Amount": 887160.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-01", "CFDA Number": "93.837", "Description": "THE ROLE OF ROS ON BETA-2-ADRENERGIC RECEPTOR FUNCTION IN HUMAN AIRWAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "089552f8-befb-f70f-7326-f1773de8f5a3-C", "generated_internal_id": "ASST_NON_R15HL138603_7529"}, {"internal_id": 66486745, "Award ID": "R15HL137135", "Award Amount": 204427.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-21", "CFDA Number": "93.837", "Description": "THE ROLE OF FK506 BINDING PROTEIN 51 IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "074f0dde-7f49-37bd-797e-f249dd2fae98-C", "generated_internal_id": "ASST_NON_R15HL137135_7529"}, {"internal_id": 49783386, "Award ID": "R15HL135696", "Award Amount": 432260.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-01", "CFDA Number": "93.837", "Description": "PREVENTION OF AIRWAY SENSITIZATION TO AIRBORNE HOUSE DUST MITE ALLERGEN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "84053321-0a5c-9d0f-aed8-d82c189c0cca-C", "generated_internal_id": "ASST_NON_R15HL135696_7529"}, {"internal_id": 49783382, "Award ID": "R15HL133918", "Award Amount": 455999.96, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-22", "CFDA Number": "93.837", "Description": "NOVEL SYNERGISM BETWEEN LTD4 AND PGE2 SIGNALING IN MC-MEDICATED INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "94c6018c-29a3-ac88-2dc1-5026597fb0a3-C", "generated_internal_id": "ASST_NON_R15HL133918_7529"}, {"internal_id": 49783372, "Award ID": "R15HL130955", "Award Amount": 416798.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-13", "CFDA Number": "93.837", "Description": "EXAMINATION OF HABITUAL SLEEP TRAJECTORIES ACROSS THE FIRST TWO YEARS OF COLLEGE: RELATION TO WEIGHT GAIN RISK BEHAVIORS AND OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "48daf3ab-82a8-30af-8bdd-7bc3f35e54ec-C", "generated_internal_id": "ASST_NON_R15HL130955_7529"}, {"internal_id": 49783368, "Award ID": "R15HL129209", "Award Amount": 1202563.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-30", "CFDA Number": "93.837", "Description": "SPECT IMAGING AND COMPUTATIONAL MODELING FOR ASSESSMENT OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "93823bac-b8d2-7860-f871-2884c7daa75f-C", "generated_internal_id": "ASST_NON_R15HL129209_7529"}, {"internal_id": 49783357, "Award ID": "R15HL126122", "Award Amount": 449942.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-25", "CFDA Number": "93.838", "Description": "IDENTIFYING BACTERIAL BIOMARKERS ASSOCIATED WITH DISEASE PROGRESSION IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a1b3f72b-bb6f-8fd7-5ecd-fb4c67001bdd-C", "generated_internal_id": "ASST_NON_R15HL126122_7529"}, {"internal_id": 49783356, "Award ID": "R15HL126119", "Award Amount": 443025.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-17", "CFDA Number": "93.838", "Description": "VITAMIN C, SEPSIS AND COAGULOPATHY: AN ANCILLARY STUDY OF THE CITRIS-ALI TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R15HL126119_7529"}, {"internal_id": 49783354, "Award ID": "R15HL126105", "Award Amount": 141139.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-24", "CFDA Number": "93.837", "Description": "CHARACTERIZING A RAPHE CHEMOSENSORY AMPLIFIER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "80dea171-5e28-7ab0-907e-93f184ba21cf-C", "generated_internal_id": "ASST_NON_R15HL126105_7529"}, {"internal_id": 49783345, "Award ID": "R15HL122919", "Award Amount": 463056.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-29", "CFDA Number": "93.838", "Description": "SLEEP DEPRIVATION AND NEURAL CARDIOVASCULAR CONTROL IN POSTMENOPAUSAL WOMEN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "79479b13-472d-876c-1e70-acfd49a73825-C", "generated_internal_id": "ASST_NON_R15HL122919_7529"}, {"internal_id": 49783311, "Award ID": "R15HL109843", "Award Amount": 1346240.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-07-22", "CFDA Number": "93.838", "Description": "COMPLEMENT ACTIVATION IN PREGNANCY AND HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8d049101-e68a-ff74-0eca-05c43475ca77-C", "generated_internal_id": "ASST_NON_R15HL109843_7529"}, {"internal_id": 103895586, "Award ID": "R13HL154586", "Award Amount": 29805.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-21", "CFDA Number": "93.837", "Description": "2021 INTERNATIONAL WORKSHOP ON PULMONARY IMAGING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R13HL154586_7529"}, {"internal_id": 97471774, "Award ID": "R13HL152479", "Award Amount": 29629.43, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-11", "CFDA Number": "93.837", "Description": "ARDS IN THE 21ST CENTURY: NEW INSIGHTS INTO CLINICAL AND MECHANISTIC HETEROGENEITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R13HL152479_7529"}, {"internal_id": 107115447, "Award ID": "R13HL152474", "Award Amount": 13200.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-02", "CFDA Number": "93.837", "Description": "ASTHMA: MAKING NEW DISCOVERIES INTO BETTER THERAPIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "26eb2b26-f47e-582b-f630-555df416109f-C", "generated_internal_id": "ASST_NON_R13HL152474_7529"}, {"internal_id": 96201366, "Award ID": "R13HL152470", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-02", "CFDA Number": "93.837", "Description": "FASEB'S \"THE LUNG EPITHELIUM CONFERENCE: IN HEALTH AND DISEASE\"", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aec82df6-57e1-0dc8-4366-42d51f4039ff-C", "generated_internal_id": "ASST_NON_R13HL152470_7529"}, {"internal_id": 82469293, "Award ID": "R13HL149443", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-25", "CFDA Number": "93.838", "Description": "NEW FRONTIERS IN ORGAN FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R13HL149443_7529"}, {"internal_id": 83103594, "Award ID": "R13HL149440", "Award Amount": 20000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-15", "CFDA Number": "93.310", "Description": "THE SAFETY OF ASTHMA MEDICATIONS DURING PREGNANCY AND LACTATION: EVIDENCE GAPS AND HOW TO FILL THEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R13HL149440_7529"}, {"internal_id": 82036312, "Award ID": "R13HL149436", "Award Amount": 29970.66, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-04", "CFDA Number": "93.837", "Description": "STEM CELLS, CELL THERAPIES AND BIOENGINEERING IN LUNG BIOLOGY AND DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R13HL149436_7529"}, {"internal_id": 81728622, "Award ID": "R13HL149435", "Award Amount": 6625.85, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-20", "CFDA Number": "93.837", "Description": "2019 AMERICAN SOCIETY FOR MATRIX BIOLOGY WORKSHOP ON FIBROBLASTS: THE ARBITERS OF MATRIX REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R13HL149435_7529"}, {"internal_id": 78598131, "Award ID": "R13HL147557", "Award Amount": 14605.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-22", "CFDA Number": "93.838", "Description": "2019 ASPEN LUNG CONFERENCE: EXPLORING NEW THERAPEUTIC PATHWAYS IN PULMONARY HYPERTENSION: METABOLISM, PROLIFERATION, AND PERSONALIZED MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R13HL147557_7529"}, {"internal_id": 79433417, "Award ID": "R13HL147537", "Award Amount": 3106.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-13", "CFDA Number": "93.837", "Description": "SUPPORT FOR CONFERENCES AND SCIENTIFIC MEETINGS R13", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R13HL147537_7529"}, {"internal_id": 78991336, "Award ID": "R13HL147505", "Award Amount": 7073.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-06", "CFDA Number": "93.838", "Description": "BIOMARKERS FOR SEVERITY, THERAPY, AND DISPARITY IN SARCOIDOSIS: DISCOVERY TO DELIVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R13HL147505_7529"}, {"internal_id": 66995286, "Award ID": "R13HL144010", "Award Amount": 29496.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-21", "CFDA Number": "93.838", "Description": "2018 INTERNATIONAL MOLECULAR AND FUNCTIONAL PULMONARY IMAGING WORKSHOP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R13HL144010_7529"}, {"internal_id": 67314388, "Award ID": "R13HL144006", "Award Amount": 40000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-09", "CFDA Number": "93.838", "Description": "THE 2018 INTERNATIONAL RARE LUNG DISEASES CLINICAL RESEARCH CONFERENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R13HL144006_7529"}, {"internal_id": 62550811, "Award ID": "R13HL142300", "Award Amount": 5000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-20", "CFDA Number": "93.838", "Description": "2018 MEETING OF THE AMERICAN ASSOCIATION OF SARCOIDOSIS AND OTHER GRANULOMATOUS DISORDERS (AASOG)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R13HL142300_7529"}, {"internal_id": 64141324, "Award ID": "R13HL142299", "Award Amount": 19800.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-06", "CFDA Number": "93.838", "Description": "THERAPEUTIC TARGETING OF HYPOXIA-SENSITIVE PATHWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "26eb2b26-f47e-582b-f630-555df416109f-C", "generated_internal_id": "ASST_NON_R13HL142299_7529"}, {"internal_id": 64141521, "Award ID": "R13HL142277", "Award Amount": 30000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-09", "CFDA Number": "93.838", "Description": "FASEB SRC ON THE LUNG EPITHELIUM IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aec82df6-57e1-0dc8-4366-42d51f4039ff-C", "generated_internal_id": "ASST_NON_R13HL142277_7529"}, {"internal_id": 49779970, "Award ID": "R13HL140841", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-11", "CFDA Number": "93.838", "Description": "20TH BIENNIAL INTERNATIONAL CONFERENCE ON LUNG AND AIRWAY FIBROSIS (ICLAF)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R13HL140841_7529"}, {"internal_id": 49779966, "Award ID": "R13HL139002", "Award Amount": 26615.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-22", "CFDA Number": "93.838", "Description": "STEM CELL, CELL THERAPIES AND BIOENGINEERING IN LUNG BIOLOGY AND LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R13HL139002_7529"}, {"internal_id": 49779959, "Award ID": "R13HL137361", "Award Amount": 14954.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-06", "CFDA Number": "93.838", "Description": "FROM BENCH TO CLINIC: HOW BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH IN CONJUNCTION WITH FOCUSED OUTREACH CONTINUES TO BE TRANSFORMATIVE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47ed9961-3300-5ed7-bb62-e5359d99eaf9-C", "generated_internal_id": "ASST_NON_R13HL137361_7529"}, {"internal_id": 49779957, "Award ID": "R13HL137354", "Award Amount": 8000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-25", "CFDA Number": "93.838", "Description": "2017 GROVER CONFERENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R13HL137354_7529"}, {"internal_id": 49779954, "Award ID": "R13HL137316", "Award Amount": 5000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-01", "CFDA Number": "93.838", "Description": "CLINICAL & TRANSLATIONAL RESEARCH IN PNEUMONIA: DEFINING A RESEARCH AGENDA FOR TODAY AND TOMORROW", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c9476c3-c39d-74de-31b6-2c9a10197e11-C", "generated_internal_id": "ASST_NON_R13HL137316_7529"}, {"internal_id": 49779950, "Award ID": "R13HL137283", "Award Amount": 30000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-03", "CFDA Number": "93.838", "Description": "ASPEN LUNG CONFERENCE: ENVIRONMENT AND GLOBAL LUNG HEALTH, SUSCEPTIBILITY, AND INTERVENTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R13HL137283_7529"}, {"internal_id": 49779937, "Award ID": "R13HL134326", "Award Amount": 15000.0, "Award Type": null, "Base Obligation Date": "2016-07-15", "CFDA Number": "93.838", "Description": "THE 2016 INTERNATIONAL RARE LUNG DISEASES CLINICAL RESEARCH CONFERENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R13HL134326_7529"}, {"internal_id": 49779930, "Award ID": "R13HL134193", "Award Amount": 25000.0, "Award Type": null, "Base Obligation Date": "2016-07-20", "CFDA Number": "93.838", "Description": "LUNG IMMUNE RESPONSES AND INFLAMMATION IN HEALTH AND DISEASE CONFERENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R13HL134193_7529"}, {"internal_id": 49779690, "Award ID": "R13HL093774", "Award Amount": 232000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-04-02", "CFDA Number": "93.838", "Description": "2008 LAM FOUNDATION INTERNATIONAL RESEARCH CONFERENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R13HL093774_7529"}, {"internal_id": 108463438, "Award ID": "R03HL154287", "Award Amount": 172487.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-05", "CFDA Number": "93.837", "Description": "LAMININ BINDING INTEGRINS IN LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R03HL154287_7529"}, {"internal_id": 108463386, "Award ID": "R03HL154276", "Award Amount": 167500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-12", "CFDA Number": "93.837", "Description": "SPUTUM-BASED PROFILING TO PREDICT CYSTIC FIBROSIS EXACERBATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R03HL154276_7529"}, {"internal_id": 103897218, "Award ID": "R03HL154275", "Award Amount": 167500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-21", "CFDA Number": "93.837", "Description": "REGULATION OF NEUTROPHILIC AIRWAY INFLAMMATION BY MIR-223-3P", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R03HL154275_7529"}, {"internal_id": 107115428, "Award ID": "R03HL154242", "Award Amount": 136160.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-27", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF PATHWAYS AND TARGETS IN POST-INFLUENZA INVASIVE PULMONARY ASPERGILLOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R03HL154242_7529"}, {"internal_id": 100874842, "Award ID": "R03HL154231", "Award Amount": 156500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-17", "CFDA Number": "93.837", "Description": "DOMAIN-SPECIFIC ROLE OF IL-17RA IN CONTROLLING KLEBSIELLA PNEUMONIAE LUNG INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R03HL154231_7529"}, {"internal_id": 85590623, "Award ID": "R03HL148486", "Award Amount": 157000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-10", "CFDA Number": "93.838", "Description": "ISOPRENOID BIOLOGY IN ASTHMA: PROOF-OF-PRINCIPLE AND METHOD DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R03HL148486_7529"}, {"internal_id": 82469083, "Award ID": "R03HL148484", "Award Amount": 133860.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-25", "CFDA Number": "93.837", "Description": "MOLECULAR AND GENETIC CHARACTERISTICS OF PROGRESSIVE RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R03HL148484_7529"}, {"internal_id": 83797956, "Award ID": "R03HL148467", "Award Amount": 148500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-21", "CFDA Number": "93.838", "Description": "OLIGOTHERAPEUTICS TO ENHANCE CFTR CORRECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R03HL148467_7529"}, {"internal_id": 68568205, "Award ID": "R03HL145255", "Award Amount": 154746.91, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-10", "CFDA Number": "93.837", "Description": "DEFINING THE ROLE OF REGULATORY T CELL-DERIVED MMP12 IN ACUTE LUNG INJURY RESOLUTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R03HL145255_7529"}, {"internal_id": 68567960, "Award ID": "R03HL144890", "Award Amount": 161000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-11", "CFDA Number": "93.837", "Description": "UNDERSTANDING FACTORS UNDERLYING LOW UTILIZATION OF PRONE POSITIONING FOR ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R03HL144890_7529"}, {"internal_id": 69723602, "Award ID": "R03HL144888", "Award Amount": 150347.34, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-22", "CFDA Number": "93.837", "Description": "DERANGEMENT OF ALVEOLAR MACROPHAGE IMMUNUOMETABOLISM BY PROLONGED BETA AGONIST THERAPY: IMPLICATIONS FOR HOST DEFENSE AND TISSUE HEALTH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R03HL144888_7529"}, {"internal_id": 68566782, "Award ID": "R03HL144883", "Award Amount": 162000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-11", "CFDA Number": "93.837", "Description": "BRINGING RESPIRATORY EDUCATION FOR IMPROVED ADHERENCE AND TECHNIQUE HOME THROUGH E-INTERVENTIONS FOR SELF-MANAGEMENT (BREATHES) PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R03HL144883_7529"}, {"internal_id": 69725045, "Award ID": "R03HL144534", "Award Amount": 176854.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-21", "CFDA Number": "93.837", "Description": "CROSSTALK BETWEEN T CELLS AND AIRWAY SMOOTH MUSCLE IN OBESITY-RELATED ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_R03HL144534_7529"}, {"internal_id": 68566858, "Award ID": "R03HL144427", "Award Amount": 159000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-10", "CFDA Number": "93.837", "Description": "THE ROLE OF B-CELLS IN LUNG INJURY AND REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R03HL144427_7529"}, {"internal_id": 65281429, "Award ID": "R03HL141618", "Award Amount": 154400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-23", "CFDA Number": "93.837", "Description": "SEX- BASED DIFFERENCES IN AIRWAY STRUCTURAL PROPERTIES AND IMMUNE RESPONSE IN HDM CHALLENGED ANIMALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R03HL141618_7529"}, {"internal_id": 66199362, "Award ID": "R03HL141572", "Award Amount": 136849.47, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-05", "CFDA Number": "93.837", "Description": "SEX-SPECIFIC DIFFERENCES IN NEONATAL HYPEROXIC LUNG INJURY: ROLE OF THE NF-KAPPA B PATHWAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R03HL141572_7529"}, {"internal_id": 66800384, "Award ID": "R03HL141523", "Award Amount": 148050.96, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-08", "CFDA Number": "93.837", "Description": "MASS CYTOMETRY TO DEFINE THE ROLE OF CELL-SPECIFIC INTERLEUKIN-17A IN ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R03HL141523_7529"}, {"internal_id": 49774700, "Award ID": "R03HL140272", "Award Amount": 164467.85, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-10", "CFDA Number": "93.837", "Description": "COMPARATIVE EFFECTIVENESS OF DIURETICS AND INHALED CORTICOSTEROIDS FOR BRONCHOPULMONARY DYSPLASIA IN PRETERM INFANTS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_R03HL140272_7529"}, {"internal_id": 49774696, "Award ID": "R03HL139946", "Award Amount": 158991.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-15", "CFDA Number": "93.838", "Description": "BETA-ARRESTIN REGULATION OF VEGFR3 SIGNALING IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R03HL139946_7529"}, {"internal_id": 49774692, "Award ID": "R03HL138309", "Award Amount": 152294.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-07", "CFDA Number": "93.838", "Description": "CAUSES AND EFFECTS OF HOSPITAL-LEVEL CHANGES IN ICU BED SUPPLY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R03HL138309_7529"}, {"internal_id": 49774691, "Award ID": "R03HL138068", "Award Amount": 163113.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-22", "CFDA Number": "93.233", "Description": "PILOT STUDY OF BETA ADRENERGIC BLOCKADE TO PREVENT METABOLIC CONSEQUENCES OF SLEEP APNEA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R03HL138068_7529"}, {"internal_id": 49774689, "Award ID": "R03HL136795", "Award Amount": 153000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-22", "CFDA Number": "93.838", "Description": "TNS1 IN CELL-MATRIX INTERACTIONS AND PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R03HL136795_7529"}, {"internal_id": 49774688, "Award ID": "R03HL136794", "Award Amount": 150500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-21", "CFDA Number": "93.838", "Description": "THE ROLE OF ARGINASE 2 IN CHRONIC HYPOXIA-INDUCED PULMONARY HYPERTENSION.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_R03HL136794_7529"}, {"internal_id": 49774679, "Award ID": "R03HL135227", "Award Amount": 161000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-16", "CFDA Number": "93.838", "Description": "ADVANCED DIAGNOSTICS FOR DONOR LUNG ASSESSMENT AND EX VIVO LUNG PERFUSION CANDIDATE SELECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R03HL135227_7529"}, {"internal_id": 49774676, "Award ID": "R03HL135213", "Award Amount": 154097.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-16", "CFDA Number": "93.838", "Description": "FEASIBILITY AND ACCEPTABILITY OF AN INTERNET-BASED COGNITIVE-BEHAVIORAL TREATMENT FOR INSOMNIA IN ADULTS WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R03HL135213_7529"}, {"internal_id": 49774674, "Award ID": "R03HL133713", "Award Amount": 156000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-26", "CFDA Number": "93.838", "Description": "ANCESTRY-ENVIRONMENTAL EXPOSURE INTERACTIONS AND ASTHMA RISK IN ADMIXED POPULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R03HL133713_7529"}, {"internal_id": 49774669, "Award ID": "R03HL133423", "Award Amount": 159086.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-23", "CFDA Number": "93.838", "Description": "THE ROLE OF THE WNT5A/ROR2 IN THE PATHOGENESIS OF PULMONARY ARTERIAL HYPERTENSION.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R03HL133423_7529"}, {"internal_id": 49774668, "Award ID": "R03HL133420", "Award Amount": 156000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.838", "Description": "MOLECULAR BASIS OF DORSAL-VENTRAL PATTERNING OF THE CONDUCTING AIRWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R03HL133420_7529"}, {"internal_id": 108463501, "Award ID": "R01HL156803", "Award Amount": 2289659.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-05", "CFDA Number": "93.837", "Description": "EXOSOMAL GASDERMIN D MEDIATED LUNG TO BRAIN CROSSWALK IN PRETERM BRAIN INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_R01HL156803_7529"}, {"internal_id": 109189947, "Award ID": "R01HL155986", "Award Amount": 2988169.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "THE CIRCADIAN RHYTHM AS A LENTIVIRAL VECTOR RESTRICTION FACTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL155986_7529"}, {"internal_id": 110464973, "Award ID": "R01HL155691", "Award Amount": 3038439.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-16", "CFDA Number": "93.838", "Description": "CHARACTERIZING INNATE IMMUNE DYSREGULATION IN TONSILS OF INDIVIDUALS WITH DOWN SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL155691_7529"}, {"internal_id": 109278362, "Award ID": "R01HL154860", "Award Amount": 4360321.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-19", "CFDA Number": "93.837", "Description": "STUDY OF HIV INFECTION IN THE ETIOLOGY OF LUNG DISEASE (SHIELD) AIR: AIR POLLUTION IMPACT ON RESPIRATORY HEALTH IN HIV", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL154860_7529"}, {"internal_id": 110025818, "Award ID": "R01HL154754", "Award Amount": 1967780.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-26", "CFDA Number": "93.837", "Description": "ENDOTHELIUM-DRIVEN SIGNALING NETWORK IN THE DEVELOPMENT OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R01HL154754_7529"}, {"internal_id": 100875152, "Award ID": "R01HL154747", "Award Amount": 2495709.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-06", "CFDA Number": "93.837", "Description": "FGF18 REGULATION OF POSTNATAL LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL154747_7529"}, {"internal_id": 110234122, "Award ID": "R01HL154686", "Award Amount": 435525.45, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-09", "CFDA Number": "93.837", "Description": "TARGETING LINEAR UBIQUITINATION TO ATTENUATE INFLAMMATION AND PROMOTE REPAIR AFTER IAV INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL154686_7529"}, {"internal_id": 110025133, "Award ID": "R01HL154429", "Award Amount": 2444571.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-28", "CFDA Number": "93.837", "Description": "PREDICTING THE NEED FOR SURGERY IN PEDIATRIC SUBGLOTTIC STENOSIS USING AIRWAY ELASTOGRAPHY DERIVED FROM ENDOSCOPIC OCT AND INTRALUMINAL PRESSURE MEASUREMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL154429_7529"}, {"internal_id": 100875539, "Award ID": "R01HL154343", "Award Amount": 2541682.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-03", "CFDA Number": "93.837", "Description": "STRATEGIES FOR ANGIOTENSIN RECEPTOR BLOCKER MEDIATED TISSUE REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL154343_7529"}, {"internal_id": 109189840, "Award ID": "R01HL153641", "Award Amount": 2251760.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-16", "CFDA Number": "93.837", "Description": "OXIDATIVE STRESS AND REGIONAL AIRWAY REMODELING AND FIBROSIS IN OBESE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL153641_7529"}, {"internal_id": 110464935, "Award ID": "R01HL153611", "Award Amount": 2506528.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-15", "CFDA Number": "93.837", "Description": "WHO ARE THE ULTRA-POSITIVE, CULTURE-NEGATIVE? UNDERSTANDING THE TRAJECTORIES OF INDIVIDUALS IN UGANDA WITH TRACE M. TUBERCULOSIS NUCLEIC ACID IN SPUTUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL153611_7529"}, {"internal_id": 98144496, "Award ID": "R01HL153604", "Award Amount": 2818029.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-18", "CFDA Number": "93.837", "Description": "SYSTEMS BIOLOGY OF A MICRORNA NETWORK IN NEUTROPHILIC ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL153604_7529"}, {"internal_id": 97853196, "Award ID": "R01HL153539", "Award Amount": 1596206.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-26", "CFDA Number": "93.837", "Description": "SOLITARY CHEMOSENSORY / TUFT CELLS IN LUNG REGENERATION AND INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL153539_7529"}, {"internal_id": 110233361, "Award ID": "R01HL153519", "Award Amount": 2844134.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-04", "CFDA Number": "93.310", "Description": "ASCEND (ARDS IN CHILDREN AND ECMO INITIATION STRATEGIES IMPACT ON NEURO-DEVELOPMENT)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL153519_7529"}, {"internal_id": 98485997, "Award ID": "R01HL153511", "Award Amount": 2496278.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-27", "CFDA Number": "93.837", "Description": "TRANSCRIPTIONAL AND EPIGENETIC BASIS OF LUNG EPITHELIAL CELL FATE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_R01HL153511_7529"}, {"internal_id": 98143364, "Award ID": "R01HL153510", "Award Amount": 1623750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-15", "CFDA Number": "93.837", "Description": "NANOMEDICINE FOR ARDS:  A NEW PARADIGM TO TARGET DRUGS TO MULTIPLE CELL TYPES WITHIN ALVEOLAR CAPILLARIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL153510_7529"}, {"internal_id": 97852509, "Award ID": "R01HL153502", "Award Amount": 1729328.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-28", "CFDA Number": "93.837", "Description": "NEDD9-SMAD3, FIBRINOLYSIS, AND CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL153502_7529"}, {"internal_id": 97852166, "Award ID": "R01HL153407", "Award Amount": 2373030.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-25", "CFDA Number": "93.837", "Description": "TARGETING UNDERLYING PATHOPHYSIOLOGICAL MECHANISMS TO DEVELOP NOVEL THERAPIES FOR CHRONIC OBSTRUCTIVE LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL153407_7529"}, {"internal_id": 100874906, "Award ID": "R01HL153400", "Award Amount": 1899084.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-14", "CFDA Number": "93.837", "Description": "ROLE OF FBXO24 MEDIATED UBIQUITINATION OF FOXP1 PROTEIN IN THE PATHOGENESIS AND TREATMENT OF COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL153400_7529"}, {"internal_id": 98487008, "Award ID": "R01HL153375", "Award Amount": 2008015.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-26", "CFDA Number": "93.837", "Description": "MOLECULAR CONTROL OF A NOVEL TRANSITIONAL CELL STATE IN ALVEOLAR REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL153375_7529"}, {"internal_id": 98486359, "Award ID": "R01HL153369", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-19", "CFDA Number": "93.837", "Description": "MYELOID LINEAGES AND TYPE 2 CYTOKINES IN LUNG HOMEOSTASIS AND REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL153369_7529"}, {"internal_id": 110024347, "Award ID": "R01HL153312", "Award Amount": 2201895.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-26", "CFDA Number": "93.837", "Description": "LUNG TRANSPLANT INJURY DRIVES CHRONIC LUNG ALLOGRAFT DYSFUNCTION VIA RECRUITMENT OFMONOCYTE-DERIVED ALVEOLAR MACROPHAGES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL153312_7529"}, {"internal_id": 100875098, "Award ID": "R01HL153246", "Award Amount": 2264051.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-13", "CFDA Number": "93.837", "Description": "MECHANISMS OF EPITHELIAL REPAIR AND REMODELING IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL153246_7529"}, {"internal_id": 97852580, "Award ID": "R01HL153195", "Award Amount": 1495000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-25", "CFDA Number": "93.837", "Description": "IGF-II REGULATES LUNG FIBROSIS IN SCLERODERMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "SC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "04a78f04-ee86-46df-5fbf-c71e46ed8479-C", "generated_internal_id": "ASST_NON_R01HL153195_7529"}, {"internal_id": 97852788, "Award ID": "R01HL153175", "Award Amount": 3023846.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-25", "CFDA Number": "93.837", "Description": "FORECASTING LUNG TRANSPLANT BENEFIT: A DYNAMIC RISK MODELING APPROACH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL153175_7529"}, {"internal_id": 108463567, "Award ID": "R01HL153140", "Award Amount": 1525000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-07", "CFDA Number": "93.837", "Description": "HYPERBARIC OXYGEN THERAPY MITIGATES RESPIRATORYNEUROMUSCULAR PATHOLOGY AFTER SPINAL CORD INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL153140_7529"}, {"internal_id": 98143200, "Award ID": "R01HL153119", "Award Amount": 2893977.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-10", "CFDA Number": "93.837", "Description": "AIM2ACT: A MOBILE HEALTH TOOL TO FACILITATE ASTHMA SELF-MANAGEMENT DURING EARLY ADOLESCENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL153119_7529"}, {"internal_id": 110024138, "Award ID": "R01HL153113", "Award Amount": 2188676.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-26", "CFDA Number": "93.837", "Description": "ROLE OF HEME AND PGP MATRIKINES IN LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL153113_7529"}, {"internal_id": 107115279, "Award ID": "R01HL153096", "Award Amount": 2069378.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-27", "CFDA Number": "93.837", "Description": "HYBRID HYDROGEL BIOMATERIALS COMPRISING CLICKABLE DECELLULARIZED EXTRACELLULAR MATRIX FOR ENGINEERING DYNAMIC 3D MODELS OF FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL153096_7529"}, {"internal_id": 98487334, "Award ID": "R01HL153058", "Award Amount": 2828306.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-30", "CFDA Number": "93.837", "Description": "MUCIN SIALYLATION DRIVES EPITHELIAL CELL SENESCENCE AND SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL153058_7529"}, {"internal_id": 108463504, "Award ID": "R01HL153052", "Award Amount": 3544217.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-05", "CFDA Number": "93.837", "Description": "TELEMEDICINE ENHANCED ASTHMA MANAGEMENT - UNITING PROVIDERS FOR TEENS (TEAM-UP FOR TEENS)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL153052_7529"}, {"internal_id": 110862021, "Award ID": "R01HL153047", "Award Amount": 1574509.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-21", "CFDA Number": "93.837", "Description": "ROLE OF INTRAVASCULAR ERO1@ IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL153047_7529"}, {"internal_id": 103897524, "Award ID": "R01HL153045", "Award Amount": 3075079.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-21", "CFDA Number": "93.837", "Description": "UTERINE SIGNALING NETWORKS IN THE PATHOGENESIS OF PULMONARY LYMPHANGIOLEIOMYOMATOSIS (LAM)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL153045_7529"}, {"internal_id": 100873907, "Award ID": "R01HL153026", "Award Amount": 1894342.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-10", "CFDA Number": "93.837", "Description": "TARGETING CEBPA TO RESTORE EPITHELIAL-MESENCHYMAL HOMEOSTASIS IN LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL153026_7529"}, {"internal_id": 96202868, "Award ID": "R01HL152804", "Award Amount": 2388372.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-29", "CFDA Number": "93.837", "Description": "EXPLORATORY RESEARCH ON HIV CONTRIBUTION TO HEART AND LUNG COMORBIDITIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_R01HL152804_7529"}, {"internal_id": 96203892, "Award ID": "R01HL152756", "Award Amount": 2418863.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-31", "CFDA Number": "93.837", "Description": "ROLE OF CHEMOKINES IN INNATE AND ADAPTIVE IMMUNITY IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL152756_7529"}, {"internal_id": 96202281, "Award ID": "R01HL152735", "Award Amount": 3088398.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-03", "CFDA Number": "93.837", "Description": "MULTI-OMIC NETWORKS ASSOCIATED WITH COPD PROGRESSION IN TOPMED COHORTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL152735_7529"}, {"internal_id": 97015038, "Award ID": "R01HL152724", "Award Amount": 1555000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-29", "CFDA Number": "93.837", "Description": "THE PULMONARY HYPERTENSION- MULTI-DIMENSIONAL OMICS TO CHARACTERIZE RIGHT HEART ADAPTATION (PH-MOCHA) STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL152724_7529"}, {"internal_id": 110233521, "Award ID": "R01HL152696", "Award Amount": 1760396.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-09", "CFDA Number": "93.837", "Description": "TARGETING THE HOST IMMUNE RESPONSE DURING SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL152696_7529"}, {"internal_id": 96202707, "Award ID": "R01HL152677", "Award Amount": 2430612.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-03", "CFDA Number": "93.837", "Description": "MACROPHAGE DRIVEN, PROFIBROTIC ADRENERGIC NERVE REMODELING IN SSC-ILD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL152677_7529"}, {"internal_id": 97852422, "Award ID": "R01HL152288", "Award Amount": 1533500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-26", "CFDA Number": "93.837", "Description": "HYPERPOLARIZED XENON MRI IN TREATMENT OF SEVERE ASTHMA BY MEPOLIZUMAB: TOWARD EARLIER DETECTION OF INDIVIDUAL PATIENT RESPONSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f261384c-3ac1-b344-de46-81708f87aa6a-C", "generated_internal_id": "ASST_NON_R01HL152288_7529"}, {"internal_id": 97469830, "Award ID": "R01HL152246", "Award Amount": 3153441.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-15", "CFDA Number": "93.837", "Description": "METABOLIC LANDSCAPE OF THE AGING LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL152246_7529"}, {"internal_id": 98142951, "Award ID": "R01HL152245", "Award Amount": 2145995.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-10", "CFDA Number": "93.837", "Description": "NON-CLASSICAL CYTOKINE SECRETION IN CHRONIC AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL152245_7529"}, {"internal_id": 97853243, "Award ID": "R01HL152244", "Award Amount": 3572321.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-26", "CFDA Number": "93.837", "Description": "PHARMACOGENOMICS OF ADRENAL SUPPRESSION WITH INHALED CORTICOSTEROIDS (PHASIC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL152244_7529"}, {"internal_id": 97468849, "Award ID": "R01HL152210", "Award Amount": 2172415.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-15", "CFDA Number": "93.837", "Description": "THE ROLE OF MITOCHONDRIAL METABOLISM IN NEUTROPHILIC LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL152210_7529"}, {"internal_id": 97852603, "Award ID": "R01HL152190", "Award Amount": 2028048.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-29", "CFDA Number": "93.837", "Description": "TESTING THE HYPOTHESIS THAT MICROBIAL ENERGETIC HIJACKING OF THE CF IMMUNE RESPONSE SELECTS FOR SPECIFIC PATHOGENS DURING LUNG FUNCTION DECLINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "74bac010-0a24-8f82-8021-0fa16ab4bc6d-C", "generated_internal_id": "ASST_NON_R01HL152190_7529"}, {"internal_id": 96201722, "Award ID": "R01HL152160", "Award Amount": 2156184.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-31", "CFDA Number": "93.837", "Description": "NOVEL NEURAL MECHANISMS UNDERLYING LUNG-HEART PATHOLOGICAL CROSSTALK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce6cc294-968c-0136-a2e3-f34319ce4753-C", "generated_internal_id": "ASST_NON_R01HL152160_7529"}, {"internal_id": 97853251, "Award ID": "R01HL152094", "Award Amount": 2349250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-26", "CFDA Number": "93.837", "Description": "A ROLE FOR EYA3 IN VASCULAR REMODELING AND PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL152094_7529"}, {"internal_id": 108463048, "Award ID": "R01HL152083", "Award Amount": 2477928.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-06", "CFDA Number": "93.837", "Description": "MOLECULAR CHARACTERIZATION OF PULMONARY EDEMA: A WINDOW TO AN INJURED LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL152083_7529"}, {"internal_id": 97852730, "Award ID": "R01HL152075", "Award Amount": 3262228.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-25", "CFDA Number": "93.837", "Description": "IN VIVO ENDOBRONCHIAL OCT FOR IPF DIAGNOSIS AND THERAPY RESPONSE ASSESSMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL152075_7529"}, {"internal_id": 97852440, "Award ID": "R01HL151782", "Award Amount": 2026347.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-20", "CFDA Number": "93.837", "Description": "TARGETING ABL KINASES TO REGULATE EPITHELIAL CELL PLASTICITY AND REGENERATION FOLLOWING INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL151782_7529"}, {"internal_id": 97852837, "Award ID": "R01HL151769", "Award Amount": 2268998.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-20", "CFDA Number": "93.837", "Description": "E-CIGARETTE VAPING DURING PREGNANCY AND LACTATION, GERM CELL EPIGENETIC MEMORY, AND TRANSGENERATIONAL ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5c561522-ef19-011a-85ba-0ef6e9e9c878-C", "generated_internal_id": "ASST_NON_R01HL151769_7529"}, {"internal_id": 96202521, "Award ID": "R01HL151680", "Award Amount": 1620000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-18", "CFDA Number": "93.837", "Description": "METABOLIC REGULATION OF MYOFIBROBLAST DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL151680_7529"}, {"internal_id": 97015631, "Award ID": "R01HL151607", "Award Amount": 2315421.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-01", "CFDA Number": "93.837", "Description": "EVALUATING ROUTINE OPIOID USE DURING ACUTE RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL151607_7529"}, {"internal_id": 97470551, "Award ID": "R01HL151552", "Award Amount": 1189461.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-08", "CFDA Number": "93.837", "Description": "TELOMERE DYSFUNCTION AS A CAUSE OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL151552_7529"}, {"internal_id": 97853222, "Award ID": "R01HL151513", "Award Amount": 1739420.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-20", "CFDA Number": "93.837", "Description": "DEUBIQUITINATING AND INHIBITING HSP90 BY USP40 MITIGATES LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL151513_7529"}, {"internal_id": 96203395, "Award ID": "R01HL151498", "Award Amount": 1747088.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-25", "CFDA Number": "93.837", "Description": "IMMUNOTHERAPY FOR ACUTE LUNG INJURY SECONDARY TO INFLUENZA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f94a8263-c1eb-718b-03c5-bb8a878692fd-C", "generated_internal_id": "ASST_NON_R01HL151498_7529"}, {"internal_id": 98486410, "Award ID": "R01HL151493", "Award Amount": 2924495.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-26", "CFDA Number": "93.837", "Description": "STUDY THE LINK OF AUTOPHAGY DYSFUNCTION TO ALLERGIC AND NEUTROPHILIC ASTHMA ONSET", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL151493_7529"}, {"internal_id": 97470682, "Award ID": "R01HL151467", "Award Amount": 1951407.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-13", "CFDA Number": "93.837", "Description": "MTOR SIGNALING IN LUNG HOMEOSTASIS, AGING AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL151467_7529"}, {"internal_id": 97014648, "Award ID": "R01HL151447", "Award Amount": 2071020.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-29", "CFDA Number": "93.837", "Description": "HEMOLYSIS AND FREE HEME SIGNALING IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R01HL151447_7529"}, {"internal_id": 96201595, "Award ID": "R01HL151421", "Award Amount": 2100283.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-03", "CFDA Number": "93.837", "Description": "STRUCTURAL DETERMINANTS OF DISEASE PROGRESSION IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL151421_7529"}, {"internal_id": 96556533, "Award ID": "R01HL151419", "Award Amount": 2089324.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-15", "CFDA Number": "93.837", "Description": "BIOPHYSICAL MECHANISMS OF HYPEROXIA-INDUCED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R01HL151419_7529"}, {"internal_id": 98487351, "Award ID": "R01HL151352", "Award Amount": 1201855.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-22", "CFDA Number": "93.837", "Description": "PRENATAL PULMONARY CELL GENE EDITING TO CURE MONOGENIC LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL151352_7529"}, {"internal_id": 86317984, "Award ID": "R01HL151306", "Award Amount": 2424422.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-20", "CFDA Number": "93.837", "Description": "ROLE OF PTP4A1 IN SYSTEMIC SCLEROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL151306_7529"}, {"internal_id": 98143874, "Award ID": "R01HL151153", "Award Amount": 2370837.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-15", "CFDA Number": "93.837", "Description": "PREDICTING THE ONSET OF CHRONIC REJECTION IN LUNG TRANSPLANT RECIPIENTS USING HYPERPOLARIZED 129XE IMAGING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL151153_7529"}, {"internal_id": 95181004, "Award ID": "R01HL151151", "Award Amount": 2499700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-07", "CFDA Number": "93.837", "Description": "PERITONEAL OXYGEN DELIVERY FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7d586cfa-95f6-0e31-3589-fbd59b788eda-C", "generated_internal_id": "ASST_NON_R01HL151151_7529"}, {"internal_id": 96204722, "Award ID": "R01HL151107", "Award Amount": 2447416.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-03", "CFDA Number": "93.837", "Description": "ROLE OF E-CADHERIN IN MODULATING AIRWAY EPITHELIAL FUNCTION AND PARENCHYMAL REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL151107_7529"}, {"internal_id": 95943193, "Award ID": "R01HL151079", "Award Amount": 3256875.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-04", "CFDA Number": "93.837", "Description": "REAL-TIME WIDEBAND CARDIAC MRI FOR PATIENTS WITH A CARDIAC IMPLANTABLE ELECTRONIC DEVICE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": 680708.0, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL151079_7529"}, {"internal_id": 92603028, "Award ID": "R01HL151016", "Award Amount": 2134268.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-11-27", "CFDA Number": "93.837", "Description": "THROMBOXANE RECEPTOR SIGNALING IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL151016_7529"}, {"internal_id": 95484295, "Award ID": "R01HL150638", "Award Amount": 2575340.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-03", "CFDA Number": "93.837", "Description": "GATA-6 IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL150638_7529"}, {"internal_id": 93912149, "Award ID": "R01HL150587", "Award Amount": 2219000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-27", "CFDA Number": "93.837", "Description": "REGULATION OF ALVEOLAR EPITHELIAL REGENERATION BY T CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL150587_7529"}, {"internal_id": 97852087, "Award ID": "R01HL150560", "Award Amount": 2352332.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-20", "CFDA Number": "93.837", "Description": "TRNA-DERIVED NON-CODING RNAS IN ASM FUNCTION AND IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL150560_7529"}, {"internal_id": 95181657, "Award ID": "R01HL150541", "Award Amount": 1549450.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-11", "CFDA Number": "93.837", "Description": "HOST MICROBIOTA AND AIRWAY MUCUS: A NOVEL PARADIGM FOR LUNG DEFENSE AND IMMUNE HOMEOSTASIS DURING EARLY POST-NATAL DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL150541_7529"}, {"internal_id": 95181200, "Award ID": "R01HL150520", "Award Amount": 1860451.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-11", "CFDA Number": "93.837", "Description": "FUNCTION AND APPLICATION OF LUNG SURFACTANT PROTEINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_R01HL150520_7529"}, {"internal_id": 110024671, "Award ID": "R01HL150370", "Award Amount": 1485349.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-26", "CFDA Number": "93.837", "Description": "INNATE IMMUNE DEFECT AND NEUTROPHILIC INFLAMMATION IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6a863c9b-365c-816d-1f3a-a0096107ff16-C", "generated_internal_id": "ASST_NON_R01HL150370_7529"}, {"internal_id": 94714370, "Award ID": "R01HL150147", "Award Amount": 3070275.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-20", "CFDA Number": "93.837", "Description": "VIRTUAL GROWING CHILD 5-DIMENSIONAL FUNCTIONAL MODELS FOR TREATING RESPIRATORY ANOMALIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL150147_7529"}, {"internal_id": 98144160, "Award ID": "R01HL150070", "Award Amount": 2792649.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-12", "CFDA Number": "93.837", "Description": "ROLE OF IGF AXIS IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL150070_7529"}, {"internal_id": 100874324, "Award ID": "R01HL150049", "Award Amount": 1622769.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-15", "CFDA Number": "93.837", "Description": "NITRIC OXIDE INDUCED SOLUBLE GUANYLATE CYCLASE DYSFUNCTION OR ACTIVATION: IMPLICATIONS AS A DISEASE INDICATOR OR IN THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL150049_7529"}, {"internal_id": 95942887, "Award ID": "R01HL150023", "Award Amount": 2758900.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-09", "CFDA Number": "93.837", "Description": "PREDICTION OF COPD PROGRESSION BY PRM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL150023_7529"}, {"internal_id": 108463167, "Award ID": "R01HL149993", "Award Amount": 2093895.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-10", "CFDA Number": "93.837", "Description": "FIBROBLAST BIOLOGY AND PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL149993_7529"}, {"internal_id": 110232965, "Award ID": "R01HL149944", "Award Amount": 1113750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-10", "CFDA Number": "93.837", "Description": "INFLUENZA REGULATION OF EPITHELIAL PNEUMOCOCCAL HOST DEFENSE.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL149944_7529"}, {"internal_id": 93243002, "Award ID": "R01HL149910", "Award Amount": 2935246.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-18", "CFDA Number": "93.837", "Description": "ENDOTYPES IN CHILDREN WITH SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME: IMPACT ON RESPONSE TO TREATMENT (ENSNARE)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL149910_7529"}, {"internal_id": 95484248, "Award ID": "R01HL149883", "Award Amount": 2008117.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-28", "CFDA Number": "93.837", "Description": "MECHANISMS OF REGULATORY T CELL-MEDIATED RECOVERY FROM SEVERE INFLUENZA A VIRUS INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL149883_7529"}, {"internal_id": 95943131, "Award ID": "R01HL149877", "Award Amount": 2805222.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-12", "CFDA Number": "93.837", "Description": "PROGNOSTIC MARKERS OF EMPHYSEMA PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL149877_7529"}, {"internal_id": 108463136, "Award ID": "R01HL149861", "Award Amount": 3171340.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-06", "CFDA Number": "93.837", "Description": "CLINICAL IMPLICATIONS, GENOMICS, AND TRANSCRIPTIONS OF MUCUS PLUGGING IN SMOKERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL149861_7529"}, {"internal_id": 111328703, "Award ID": "R01HL149853", "Award Amount": 1971938.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-12", "CFDA Number": "93.837", "Description": "FUNCTIONAL CHARACTERIZATION OF ABCA3 GENOMIC VARIANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL149853_7529"}, {"internal_id": 97852165, "Award ID": "R01HL149836", "Award Amount": 2957870.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-29", "CFDA Number": "93.837", "Description": "GENES AND TRANSCRIPTS THAT INTERACT WITH MUC5B IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL149836_7529"}, {"internal_id": 92603874, "Award ID": "R01HL149825", "Award Amount": 2140650.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-11-27", "CFDA Number": "93.837", "Description": "TYPE II ALVEOLAR REDOX CONTROL IN FIBROGENESIS AND RESOLUTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL149825_7529"}, {"internal_id": 107115101, "Award ID": "R01HL149744", "Award Amount": 2799829.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-27", "CFDA Number": "93.837", "Description": "B CELL-ADAPTIVE IMMUNE PROFILE IN EMPHYSEMA-PREDOMINANT COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL149744_7529"}, {"internal_id": 97852802, "Award ID": "R01HL149741", "Award Amount": 3031587.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-25", "CFDA Number": "93.837", "Description": "ROLES FOR INTERSTITIAL AND AIRSPACE MACROPHAGES IN RESOLUTION OF PULMONARY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL149741_7529"}, {"internal_id": 95181426, "Award ID": "R01HL149719", "Award Amount": 1583924.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-12", "CFDA Number": "93.837", "Description": "ROLE OF TACC2 IN SMOKING-INDUCED COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL149719_7529"}, {"internal_id": 95484415, "Award ID": "R01HL149693", "Award Amount": 2353675.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-21", "CFDA Number": "93.837", "Description": "OBESITY AND CHILDHOOD ASTHMA: THE ROLE OF ADIPOSE TISSUE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL149693_7529"}, {"internal_id": 110233258, "Award ID": "R01HL149676", "Award Amount": 2622100.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-04", "CFDA Number": "93.837", "Description": "IMMUNE CHECKPOINTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (IC-ARDS)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c187478-165a-1db6-d6e6-2be34431a2b3-C", "generated_internal_id": "ASST_NON_R01HL149676_7529"}, {"internal_id": 97853185, "Award ID": "R01HL149631", "Award Amount": 1693078.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-22", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISMS REGULATED BY FOXM1 IN CHRONIC LUNG REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL149631_7529"}, {"internal_id": 82469401, "Award ID": "R01HL149450", "Award Amount": 3917776.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-25", "CFDA Number": "93.837", "Description": "FOAM CELLS AS DRUG TARGETS IN TUBERCULOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": 753853.0, "Infrastructure Obligations": null, "recipient_id": "0c9d7554-cb59-0dff-6547-d9102319b537-C", "generated_internal_id": "ASST_NON_R01HL149450_7529"}, {"internal_id": 83797224, "Award ID": "R01HL149422", "Award Amount": 1682734.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-28", "CFDA Number": "93.837", "Description": "THE IMPACT OF FLUID RESUSCITATION ON GLYCOCALYX DEGRADATION IN SEPTIC SHOCK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL149422_7529"}, {"internal_id": 81395277, "Award ID": "R01HL149385", "Award Amount": 1901963.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-15", "CFDA Number": "93.837", "Description": "REGULATION OF AIRWAY EPITHELIAL CELL-MEDIATED INFLAMMATION BY CRAC CHANNELS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL149385_7529"}, {"internal_id": 98143182, "Award ID": "R01HL149366", "Award Amount": 1608930.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-09", "CFDA Number": "93.837", "Description": "PERINATAL DYSBIOSIS, LUNG DEVELOPMENT AND ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL149366_7529"}, {"internal_id": 86317679, "Award ID": "R01HL149352", "Award Amount": 2265642.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-21", "CFDA Number": "93.837", "Description": "NUTRITIONAL OMICS OF PULMONARY FUNCTION DECLINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8303ed9b-9fb4-3e90-ca81-50bbcf400948-C", "generated_internal_id": "ASST_NON_R01HL149352_7529"}, {"internal_id": 83103245, "Award ID": "R01HL149300", "Award Amount": 2396868.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-10", "CFDA Number": "93.837", "Description": "NANOPARTICLE TARGETING OF NEUTROPHIL SUBPOPULATIONS IN INFLAMMATORY LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL149300_7529"}, {"internal_id": 96202703, "Award ID": "R01HL148825", "Award Amount": 2298764.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-03", "CFDA Number": "93.837", "Description": "A MULTIMODAL DELIVERY AND TREATMENT APPROACH FOR ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL148825_7529"}, {"internal_id": 81728615, "Award ID": "R01HL148821", "Award Amount": 2521754.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-24", "CFDA Number": "93.837", "Description": "IDENTIFICATION AND PRECLINICAL EVALUATION OF NOVEL THERAPEUTIC APPROACHES TO DYSKERATOSIS CONGENITA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL148821_7529"}, {"internal_id": 96556570, "Award ID": "R01HL148810", "Award Amount": 2271278.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-17", "CFDA Number": "93.837", "Description": "NOVEL MECHANISMS OF ENDOTHELIAL INJURY IN THE PATHOGENESIS OF ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_R01HL148810_7529"}, {"internal_id": 97015284, "Award ID": "R01HL148781", "Award Amount": 3181697.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-22", "CFDA Number": "93.837", "Description": "THERAPEUTIC USE OF HIGH MOLECULAR WEIGHT HYALURONIC ACID IN ACUTE LUNG INJURY FOLLOWING SEVERE BACTERIAL PNEUMONIA OR SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL148781_7529"}, {"internal_id": 96560440, "Award ID": "R01HL148758", "Award Amount": 2064474.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-06", "CFDA Number": "93.837", "Description": "REGULATION OF THE HOST IMMUNE RESPONSE TO INFLUENZA BY THE CHECKPOINT RECEPTOR TIM3", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL148758_7529"}, {"internal_id": 81729368, "Award ID": "R01HL148727", "Award Amount": 1638745.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-20", "CFDA Number": "93.837", "Description": "ROLE OF ENDOTHELIAL ANOCTAMIN-1 IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d04e50b2-a099-d508-c9da-d97e2528c9d7-C", "generated_internal_id": "ASST_NON_R01HL148727_7529"}, {"internal_id": 96989295, "Award ID": "R01HL148718", "Award Amount": 2622064.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-23", "CFDA Number": "93.837", "Description": "LUNG LEUKOCYTES PROMOTE ALVEOLAR EPITHELIAL REGENERATION AFTER SEVERE INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL148718_7529"}, {"internal_id": 97469317, "Award ID": "R01HL148715", "Award Amount": 1911936.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-08", "CFDA Number": "93.837", "Description": "REDUCING AIRWAY SMOOTH MUSCLE TONE USING INHALED STATINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R01HL148715_7529"}, {"internal_id": 81071866, "Award ID": "R01HL148712", "Award Amount": 1947775.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-29", "CFDA Number": "93.837", "Description": "ENDOTHELIAL REPROGRAMMING IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL148712_7529"}, {"internal_id": 98143340, "Award ID": "R01HL148695", "Award Amount": 2357716.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-09", "CFDA Number": "93.837", "Description": "MITIGATING ACUTE LUNG INJURY BY CELL-SPECIFIC TARGETING OF MTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL148695_7529"}, {"internal_id": 96202945, "Award ID": "R01HL148667", "Award Amount": 2641786.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-31", "CFDA Number": "93.837", "Description": "INTEGRATIVE CHARACTERIZATION ON THE FUNCTION OF COPD GWAS GENE, HHIP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL148667_7529"}, {"internal_id": 97469281, "Award ID": "R01HL148604", "Award Amount": 1716902.27, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-07", "CFDA Number": "93.837", "Description": "MACROPHAGE IMMUNOMETABOLISM ALTERATION BY INTENSE BETA AGONIST THERAPY.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL148604_7529"}, {"internal_id": 107114958, "Award ID": "R01HL148437", "Award Amount": 2512296.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-27", "CFDA Number": "93.837", "Description": "DEVELOPMENT AND VALIDATION OF A PROGNOSTIC TRANSCRIPTOMIC SIGNATURE FOR CHRONIC HYPERSENSITIVITY PNEUMONITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL148437_7529"}, {"internal_id": 98485841, "Award ID": "R01HL148351", "Award Amount": 2409600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-26", "CFDA Number": "93.837", "Description": "MECHANISMS GOVERNING THE PHYSIOLOGIC REGULATION OF CELL FATE: HYPOXIA-INDUCED DIFFERENTIATION OF NEUROENDOCRINE CELLS FROM STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL148351_7529"}, {"internal_id": 107114568, "Award ID": "R01HL148347", "Award Amount": 1800124.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-28", "CFDA Number": "93.837", "Description": "MICROBIOTA CONTROL LUNG TH17 CELL RESPONSE AND PLASTICITY LEADING TO AUTOIMMUNE LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL148347_7529"}, {"internal_id": 96203184, "Award ID": "R01HL148337", "Award Amount": 1515000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-25", "CFDA Number": "93.837", "Description": "THE CYTOKINE SUPPRESSOR CIS IN GIANT CELL PNEUMONITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a5b5888e-f4b5-655c-bd88-d970f969d7c9-C", "generated_internal_id": "ASST_NON_R01HL148337_7529"}, {"internal_id": 81071330, "Award ID": "R01HL148335", "Award Amount": 2265402.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-24", "CFDA Number": "93.837", "Description": "TEMPORAL REGULATION OF PULMONARY INFLAMMATION BY MYD88 ALTERNATIVE PRE-MRNA SPLICING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL148335_7529"}, {"internal_id": 82054119, "Award ID": "R01HL148280", "Award Amount": 1850230.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-12", "CFDA Number": "93.837", "Description": "THIOL ISOMERASES AND ERO1? IN SICKLE CELL VASO-OCCLUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL148280_7529"}, {"internal_id": 83116000, "Award ID": "R01HL148274", "Award Amount": 2897148.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-07", "CFDA Number": "93.837", "Description": "FIELD STUDY TO UNDERSTAND PROGRESSION OF CHRONIC AIRWAY INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL148274_7529"}, {"internal_id": 96559050, "Award ID": "R01HL148247", "Award Amount": 7066101.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-15", "CFDA Number": "93.837", "Description": "BEDSIDE EXCLUSION OF PULMONARY EMBOLISM IN CHILDREN WITHOUT RADIATION (BEEPER)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "57f1d8a4-43a0-9952-a047-67afb28d0b55-C", "generated_internal_id": "ASST_NON_R01HL148247_7529"}, {"internal_id": 82054114, "Award ID": "R01HL148223", "Award Amount": 2099724.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-12", "CFDA Number": "93.837", "Description": "REGULATORY MECHANISMS OF CELL COMPETITION IN LUNG REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL148223_7529"}, {"internal_id": 85590462, "Award ID": "R01HL148215", "Award Amount": 2359720.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-12", "CFDA Number": "93.837", "Description": "MATRIKINES AND COPD-PH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL148215_7529"}, {"internal_id": 83795653, "Award ID": "R01HL148185", "Award Amount": 1946303.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-23", "CFDA Number": "93.837", "Description": "A MECHANISTIC CLINICAL TRIAL OF JAK INHIBITION TO PREVENT VENTILATOR-INDUCED DIAPHRAGM DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL148185_7529"}, {"internal_id": 82469304, "Award ID": "R01HL148184", "Award Amount": 1678619.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-25", "CFDA Number": "93.837", "Description": "PATHOGENESIS OF PF BACTERIOPHAGES IN PSEUDOMONAS CYSTIC FIBROSIS LUNG INFECTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL148184_7529"}, {"internal_id": 96202108, "Award ID": "R01HL148171", "Award Amount": 1548632.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-25", "CFDA Number": "93.837", "Description": "THE ROLE OF CFTR DURING MACROPHAGE-MEDIATED KILLING OF BACTERIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL148171_7529"}, {"internal_id": 100873908, "Award ID": "R01HL148156", "Award Amount": 1757844.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-10", "CFDA Number": "93.837", "Description": "ROLE OF THE LYSOSOME IN THE PATHOGENESIS AND THERAPY OF LAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL148156_7529"}, {"internal_id": 83116015, "Award ID": "R01HL148152", "Award Amount": 2236000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-14", "CFDA Number": "93.837", "Description": "PHYSICS OF BRONCHIAL EPITHELIAL UNJAMMING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_R01HL148152_7529"}, {"internal_id": 98486057, "Award ID": "R01HL148069", "Award Amount": 1540000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-01", "CFDA Number": "93.837", "Description": "LUNG ENDOTHELIAL A? IN INFECTIOUS PROTEINOPATHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_R01HL148069_7529"}, {"internal_id": 81394967, "Award ID": "R01HL148057", "Award Amount": 2196818.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-05", "CFDA Number": "93.837", "Description": "MECHANISMS OF AIRWAY EPITHELIAL BARRIER DYSFUNCTION BY RESPIRATORY SYNCYTIAL VIRUS AND ENVIRONMENTAL STIMULI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL148057_7529"}, {"internal_id": 96201573, "Award ID": "R01HL148033", "Award Amount": 1700942.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-25", "CFDA Number": "93.837", "Description": "TARGETING CHITIN IN FIBROTIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL148033_7529"}, {"internal_id": 82469798, "Award ID": "R01HL148030", "Award Amount": 2375836.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-18", "CFDA Number": "93.837", "Description": "REGULATION OF INTERMITTENT HYPOXIA-INDUCED RESPIRATORY MOTOR PLASTICITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL148030_7529"}, {"internal_id": 96204335, "Award ID": "R01HL147942", "Award Amount": 1599000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-03", "CFDA Number": "93.837", "Description": "SPHINGOLIPIDS AS NOVEL THERAPEUTIC TARGETS IN RADIATION LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL147942_7529"}, {"internal_id": 97468984, "Award ID": "R01HL147920", "Award Amount": 913875.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-15", "CFDA Number": "93.837", "Description": "ROLE OF TGF?/BMP ANTAGONISM IN REGENERATION OF THE ALVEOLAR EPITHELIUM AFTER LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL147920_7529"}, {"internal_id": 81071903, "Award ID": "R01HL147860", "Award Amount": 2679276.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-22", "CFDA Number": "93.837", "Description": "REDUCING FIBROBLAST PERSISTENCE IN PULMONARY FIBROSIS AS A MECHANISM OF RESOLUTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL147860_7529"}, {"internal_id": 81072370, "Award ID": "R01HL147856", "Award Amount": 1560729.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-21", "CFDA Number": "93.837", "Description": "MECHANISMS UNDERLYING METAL NANOPARTICLE-INDUCED LUNG INJURY AND FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c9476c3-c39d-74de-31b6-2c9a10197e11-C", "generated_internal_id": "ASST_NON_R01HL147856_7529"}, {"internal_id": 82054803, "Award ID": "R01HL147715", "Award Amount": 1855782.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-15", "CFDA Number": "93.837", "Description": "MECHANISMS OF DEFECTIVE MITOPHAGY AND CELLULAR SENESCENCE IN HIV ASSOCIATED COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8521f543-2302-80cf-d989-c2ff7cf07ef3-C", "generated_internal_id": "ASST_NON_R01HL147715_7529"}, {"internal_id": 83116142, "Award ID": "R01HL147603", "Award Amount": 2803674.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-14", "CFDA Number": "93.837", "Description": "THE IMPACT OF INSOMNIA ON PAIN, PHYSICAL FUNCTION, AND INFLAMMATION IN HIV", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL147603_7529"}, {"internal_id": 97852349, "Award ID": "R01HL147590", "Award Amount": 2725940.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-21", "CFDA Number": "93.837", "Description": "MECHANOBIOLOGICAL MECHANISMS OF PULMONARY HYPERTENSION SECONDARY TO LEFT HEART FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b710df3-c98e-f245-bbed-8bbbc32a803b-C", "generated_internal_id": "ASST_NON_R01HL147590_7529"}, {"internal_id": 92602817, "Award ID": "R01HL147586", "Award Amount": 1899576.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-11-27", "CFDA Number": "93.837", "Description": "ROLE OF MIR125 IN PULMONARY HYPERTENSION SECONDARY TO INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R01HL147586_7529"}, {"internal_id": 79433228, "Award ID": "R01HL147575", "Award Amount": 3164274.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-25", "CFDA Number": "93.837", "Description": "ROLE OF SPLEEN EDUCATED MONOCYTES IN MEDIATING ISCHEMIA-REPERFUSION INJURY FOLLOWING LUNG TRANSPLANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL147575_7529"}, {"internal_id": 79433753, "Award ID": "R01HL147554", "Award Amount": 2860961.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-03", "CFDA Number": "93.837", "Description": "DIVERSITY SUPPLEMENT FOR ASHLEY  ROSS OPTIMIZING RESPIRATORY PLASTICITY WITH CHRONIC CERVICAL SCI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL147554_7529"}, {"internal_id": 83795835, "Award ID": "R01HL147525", "Award Amount": 2031298.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-27", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF A DAMAGING SUBSET OF NEUTROPHILS THAT ARISES IN SEPTIC PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f21f887-ca03-f1f2-6e30-1c1498f78b9e-C", "generated_internal_id": "ASST_NON_R01HL147525_7529"}, {"internal_id": 96557989, "Award ID": "R01HL147472", "Award Amount": 2518959.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-15", "CFDA Number": "93.837", "Description": "REGULATION OF NEONATAL INFLAMMATION BY MYELOID-DERIVED SUPPRESSOR CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ad990d53-dba6-60b8-30bf-48cdeeb15c1c-C", "generated_internal_id": "ASST_NON_R01HL147472_7529"}, {"internal_id": 98486930, "Award ID": "R01HL147351", "Award Amount": 1710098.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-19", "CFDA Number": "93.837", "Description": "INVESTIGATING OF THE MECHANISMS OF ACTION OF CFTR CORRECTORS IN RESCUING  DELTA F508-CFTR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL147351_7529"}, {"internal_id": 79433907, "Award ID": "R01HL147290", "Award Amount": 3166390.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-25", "CFDA Number": "93.837", "Description": "PATHOGENESIS OF LUNG INJURY MEDIATED BY LUNG-RESTRICTED ANTIBODIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL147290_7529"}, {"internal_id": 94237029, "Award ID": "R01HL147261", "Award Amount": 2934859.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-09", "CFDA Number": "93.837", "Description": "SLEEP-DISORDERED BREATHING IN INFANTS WITH MYELOMENINGOCELE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL147261_7529"}, {"internal_id": 80401615, "Award ID": "R01HL147148", "Award Amount": 3542756.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-22", "CFDA Number": "93.837", "Description": "GENETIC AND FUNCTIONAL DISSECTION OF A CLUSTER OF COPD GWAS SIGNALS ON CHROMOSOME 4Q", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL147148_7529"}, {"internal_id": 96204577, "Award ID": "R01HL147088", "Award Amount": 1560000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-18", "CFDA Number": "93.837", "Description": "EARLY LIFE EXPOSURES AND CHRONIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL147088_7529"}, {"internal_id": 79433267, "Award ID": "R01HL147070", "Award Amount": 1854137.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-29", "CFDA Number": "93.837", "Description": "ROLE OF HYPERCAPNIA ON THE LUNG AIRWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL147070_7529"}, {"internal_id": 78990837, "Award ID": "R01HL147059", "Award Amount": 2100000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-15", "CFDA Number": "93.837", "Description": "TARGETING THE ADAM10-SEPHRIN-B2 PATHWAY IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL147059_7529"}, {"internal_id": 79639528, "Award ID": "R01HL146914", "Award Amount": 2492760.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-11", "CFDA Number": "93.837", "Description": "CAV-1.TRPV4 REGULATION OF ENDOTHELIAL FUNCTION IN SMALL PULMONARY ARTERIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL146914_7529"}, {"internal_id": 79433397, "Award ID": "R01HL146859", "Award Amount": 1990787.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-03", "CFDA Number": "93.837", "Description": "GENETIC AND DEVELOPMENTAL MECHANISMS OF CONGENITAL DIAPHRAGMATIC HERNIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL146859_7529"}, {"internal_id": 97015243, "Award ID": "R01HL146856", "Award Amount": 1575000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-30", "CFDA Number": "93.837", "Description": "OPTIMIZING DONOR MANAGEMENT IN LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL146856_7529"}, {"internal_id": 95484469, "Award ID": "R01HL146829", "Award Amount": 1536226.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-21", "CFDA Number": "93.837", "Description": "MODULATION OF INFLAMMATION IN AGING LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL146829_7529"}, {"internal_id": 95484223, "Award ID": "R01HL146821", "Award Amount": 2224640.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-21", "CFDA Number": "93.837", "Description": "TREK-1 POTASSIUM CHANNELS PROTECT FROM HYPEROXIA-INDUCED ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R01HL146821_7529"}, {"internal_id": 79433506, "Award ID": "R01HL146802", "Award Amount": 1962500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-21", "CFDA Number": "93.837", "Description": "DEFINING AND TARGETING MECHANISMS OF SMOKE-MEDIATED FIBROSIS PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R01HL146802_7529"}, {"internal_id": 79639178, "Award ID": "R01HL146764", "Award Amount": 1577083.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-16", "CFDA Number": "93.837", "Description": "ROLE OF GAP JUNCTION IN HYPOXIA-INDUCED PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL146764_7529"}, {"internal_id": 95181609, "Award ID": "R01HL146753", "Award Amount": 2125255.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-11", "CFDA Number": "93.837", "Description": "THE GUT-LUNG AXIS: IMMUNOMETABOLISM LINKING THE GUT MICROBIOME AND LUNG IMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL146753_7529"}, {"internal_id": 79434147, "Award ID": "R01HL146736", "Award Amount": 3318582.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-21", "CFDA Number": "93.837", "Description": "NANOPARTICLES BASED MRNA DELIVERY FOR TREATMENT OF CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a560dc75-2cd0-baf4-415b-f60d20ba8491-C", "generated_internal_id": "ASST_NON_R01HL146736_7529"}, {"internal_id": 95943430, "Award ID": "R01HL146705", "Award Amount": 1812961.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-04", "CFDA Number": "93.837", "Description": "KISSPEPTINS IN THE AIRWAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "ND", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "abd98500-a812-0a76-1610-357bcd3f88de-C", "generated_internal_id": "ASST_NON_R01HL146705_7529"}, {"internal_id": 79434132, "Award ID": "R01HL146689", "Award Amount": 3078825.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-28", "CFDA Number": "93.837", "Description": "MRI PHENOTYPING OF EARLY BPD AND PREDICTION OF OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL146689_7529"}, {"internal_id": 79433338, "Award ID": "R01HL146645", "Award Amount": 2115433.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-21", "CFDA Number": "93.837", "Description": "DIACYLGLYCEROL KINASE IN AIRWAY SMOOTH MUSCLE FUNCTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL146645_7529"}, {"internal_id": 97853233, "Award ID": "R01HL146644", "Award Amount": 3158432.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-26", "CFDA Number": "93.837", "Description": "THE VIRTUAL MENTORED IMPLEMENTATION TO REDUCE REVISITS (REDUCING RESPIRATORY EMERGENT VISITS USING IMPLEMENTATION SCIENCE INTERVENTIONS TAILORED TO SETTING) STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL146644_7529"}, {"internal_id": 80727406, "Award ID": "R01HL146615", "Award Amount": 1518119.37, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-09", "CFDA Number": "93.837", "Description": "IMPLEMENTATION OF INTERPROFESSIONAL TRAINING TO IMPROVE UPTAKE OF NONINVASIVE VENTILATION IN PATIENTS HOSPITALIZED WITH SEVERE COPD EXACERBATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3b77461b-d74c-9784-e800-bb061239d65f-C", "generated_internal_id": "ASST_NON_R01HL146615_7529"}, {"internal_id": 79434210, "Award ID": "R01HL146601", "Award Amount": 2270407.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-21", "CFDA Number": "93.837", "Description": "CELLULAR AND MOLECULAR FEATURES OF GENE MUTATIONS IN PRIMARY CILIARY DYSKINESIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL146601_7529"}, {"internal_id": 79639388, "Award ID": "R01HL146588", "Award Amount": 3442695.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-11", "CFDA Number": "93.837", "Description": "CLINICAL, GENETIC, AND PROTEOMIC RISK FACTORS FOR PULMONARY HYPERTENSION IN HEART FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL146588_7529"}, {"internal_id": 81728931, "Award ID": "R01HL146557", "Award Amount": 2012500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-02", "CFDA Number": "93.837", "Description": "MECHANISMS OF SUBMUCOSAL GLAND CELL MEDIATED AIRWAY REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL146557_7529"}, {"internal_id": 81728297, "Award ID": "R01HL146542", "Award Amount": 2928856.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-28", "CFDA Number": "93.837", "Description": "SANDIA: SUPPLEMENTING L-CITRULLINE TO OVERWEIGHT LATE ASTHMA ONSET PHENOTYPES TO INCREASE AIRWAY L-ARGININE/ADMA RATIO AND IMPROVE ASTHMA CONTROL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL146542_7529"}, {"internal_id": 79434192, "Award ID": "R01HL146541", "Award Amount": 2607375.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-25", "CFDA Number": "93.837", "Description": "PATHOGENIC MECHANISMS OF PULMONARY LYMPHANGIOLEIOMYOMATOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R01HL146541_7529"}, {"internal_id": 79433290, "Award ID": "R01HL146501", "Award Amount": 2320894.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-25", "CFDA Number": "93.837", "Description": "S100A4 REGULATION OF IPF MESENCHYMAL PROGENITOR CELL FIBROGENICITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL146501_7529"}, {"internal_id": 94714429, "Award ID": "R01HL146500", "Award Amount": 3397630.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-28", "CFDA Number": "93.837", "Description": "NEXT GENERATION FUNCTIONAL GENOMICS OF HEMATOLOGY TRAITS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": 400263.0, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL146500_7529"}, {"internal_id": 96203575, "Award ID": "R01HL146498", "Award Amount": 1681510.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-19", "CFDA Number": "93.837", "Description": "TARGETING CHI3L1 AND ITS RECEPTORS IN HERMANSKY-PUDLAK SYNDROME-ASSOCIATED LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "378fe7f9-e157-cd75-80cc-97cbe1a426db-C", "generated_internal_id": "ASST_NON_R01HL146498_7529"}, {"internal_id": 80401620, "Award ID": "R01HL146461", "Award Amount": 1574367.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-22", "CFDA Number": "93.837", "Description": "EPITHELIAL STEM CELL HIPPO SIGNALING IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL146461_7529"}, {"internal_id": 95484661, "Award ID": "R01HL146445", "Award Amount": 1666149.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-21", "CFDA Number": "93.837", "Description": "IMMUNE MEDIATORS OF IL-22 SIGNALING ALTER ALLERGIC AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL146445_7529"}, {"internal_id": 80401184, "Award ID": "R01HL146443", "Award Amount": 1858302.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-28", "CFDA Number": "93.837", "Description": "DOXORUBICIN-INDUCED RESPIRATORY DYSFUNCTION AND THE PROTECTIVE EFFECTS OF EXERCISE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL146443_7529"}, {"internal_id": 79433880, "Award ID": "R01HL146402", "Award Amount": 1721250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-22", "CFDA Number": "93.837", "Description": "ELUCIDATING TENSIN1-ASSOCIATED SIGNALS THAT PROMOTE FIBRONECTIN MATRIX ASSEMBLY AND LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL146402_7529"}, {"internal_id": 79434199, "Award ID": "R01HL146401", "Award Amount": 1912500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-25", "CFDA Number": "93.837", "Description": "MOLECULAR INTERROGATION OF THE HOST-PATHOGEN INTERFACE IN IDIOPATHIC SUBGLOTTIC STENSOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL146401_7529"}, {"internal_id": 97469156, "Award ID": "R01HL146395", "Award Amount": 1583511.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-08", "CFDA Number": "93.837", "Description": "LEVERAGING MULTIOMICS AND ADVANCED MOUSE MODELS TO DELINEATE MECHANISMS UNDERLYING SEX?SPECIFIC DIFFERENCES IN RECOVERY AND REPAIR AFTER NEONATAL HYPEROXIA EXPOSURE IN THE DEVELOPING LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL146395_7529"}, {"internal_id": 97469512, "Award ID": "R01HL146386", "Award Amount": 1808960.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-19", "CFDA Number": "93.837", "Description": "ECONOMIC MODELING TO UNDERSTAND THE RELATIONSHIP BETWEEN CLINICIANS AND OUTCOMES OF MECHANICALLY VENTILATED PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL146386_7529"}, {"internal_id": 77189008, "Award ID": "R01HL146266", "Award Amount": 1932006.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-17", "CFDA Number": "93.837", "Description": "THE ROLE OF SEX IN THE LIFE CYCLE AND TRANSMISSION OF PNEUMOCYSTIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R01HL146266_7529"}, {"internal_id": 77190279, "Award ID": "R01HL146228", "Award Amount": 1654316.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-23", "CFDA Number": "93.837", "Description": "PROSPECTIVE LONGITUDINAL ASSESSMENT OF CULTURE-INDEPENDENT MOLECULAR AIRWAY MARKERS OF NONTUBERCULOUS MYCOBACTERIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL146228_7529"}, {"internal_id": 77189312, "Award ID": "R01HL146206", "Award Amount": 2430895.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-31", "CFDA Number": "93.837", "Description": "STUDIES ON THE EFFECTS OF COLCHICINE ON NEUTROPHIL BIOLOGY IN ACUTE MYOCARDIAL INFARCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": 836425.0, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_R01HL146206_7529"}, {"internal_id": 79434265, "Award ID": "R01HL146141", "Award Amount": 2243609.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-01", "CFDA Number": "93.837", "Description": "DECIPHERING THE MECHANISMS UNDERLYING NEUROENDOCRINE CELL HYPERPLASIA OF INFANCY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL146141_7529"}, {"internal_id": 78598148, "Award ID": "R01HL146128", "Award Amount": 3975257.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-26", "CFDA Number": "93.837", "Description": "MSC EXOSOME TREATMENT FOR BPD: IMPACT ON IMMUNITY AND LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL146128_7529"}, {"internal_id": 76737935, "Award ID": "R01HL146114", "Award Amount": 3088394.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-31", "CFDA Number": "93.837", "Description": "ENHANCING RESPIRATORY MOTOR FUNCTION AFTER SPINAL CORD INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL146114_7529"}, {"internal_id": 77190829, "Award ID": "R01HL146054", "Award Amount": 1989754.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-29", "CFDA Number": "93.837", "Description": "ROLE OF ANO1 CHANNELS AND ITS REGULATION BY PIP2 IN EC-COUPLING IN PULMONARY ARTERY MYOCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NV", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "73a4ecd1-65ed-80de-ae3d-fa537fa2df50-C", "generated_internal_id": "ASST_NON_R01HL146054_7529"}, {"internal_id": 95943310, "Award ID": "R01HL145709", "Award Amount": 1612363.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-13", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF POLYASPIRIN PARTICLES FOR THERAPEUTIC INTERVENTION IN ALI/ARDS VIA THE PASSIVE RESTRAINT OF NEUTROPHIL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL145709_7529"}, {"internal_id": 78598219, "Award ID": "R01HL145679", "Award Amount": 3079467.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-26", "CFDA Number": "93.837", "Description": "PHYSIOLOGICAL PHENOTYPING OF RESPIRATORY OUTCOMES IN INFANTS BORN PREMATURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL145679_7529"}, {"internal_id": 78991154, "Award ID": "R01HL145660", "Award Amount": 3254994.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-08", "CFDA Number": "93.837", "Description": "DETECTING PLEIOTROPIC EFFECTS THROUGH INTEGRATION OF OMICS DATA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL145660_7529"}, {"internal_id": 76738292, "Award ID": "R01HL145478", "Award Amount": 2756135.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-24", "CFDA Number": "93.837", "Description": "DONOR NONCLASSICAL MONOCYTES INITIATE LUNG INJURY FOLLOWING TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL145478_7529"}, {"internal_id": 76908565, "Award ID": "R01HL145477", "Award Amount": 3581635.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-10", "CFDA Number": "93.837", "Description": "ROLE OF CYTOSOLIC DNA-MULTIPROTEIN INTERACTOME IN ALLERGIC AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b5d65b01-d8ce-624c-a95e-e23d872445a2-C", "generated_internal_id": "ASST_NON_R01HL145477_7529"}, {"internal_id": 76908741, "Award ID": "R01HL145411", "Award Amount": 3357574.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-10", "CFDA Number": "93.837", "Description": "PREDICTING TUBERCULOSIS OUTCOMES USING GENOTYPIC AND BIOMARKER SIGNATURES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cdccf6e8-ef8a-cae2-df55-71592c218cfb-C", "generated_internal_id": "ASST_NON_R01HL145411_7529"}, {"internal_id": 81071807, "Award ID": "R01HL145408", "Award Amount": 2202282.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-22", "CFDA Number": "93.837", "Description": "ALVEOLAR EPITHELIAL CELL DYSFUNCTION IN PULMONARY FIBROSIS: LEVERAGING SFTPC MUTATIONS FOR DISCOVERY OF MOLECULAR AND CELLULAR TARGETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL145408_7529"}, {"internal_id": 76738035, "Award ID": "R01HL145396", "Award Amount": 2343044.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-19", "CFDA Number": "93.837", "Description": "TRAFFICKING AND FUNCTION OF MACROPHAGE SUBPOPULATIONS WITHIN THE LUNG MICROENVIRONMENT DURING PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL145396_7529"}, {"internal_id": 82470285, "Award ID": "R01HL145392", "Award Amount": 1916593.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-24", "CFDA Number": "93.837", "Description": "COOPERATIVE TARGETING OF PHARMACOMECHANICAL COUPLING AND THE ACTIN CYTOSKELETON TO REGULATE ASM CONTRACTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL145392_7529"}, {"internal_id": 76738323, "Award ID": "R01HL145372", "Award Amount": 3567825.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-24", "CFDA Number": "93.837", "Description": "COMBINING GENOME, FUNCTION, AND PHENOTYPE TO DEFINE THE CELL TYPE SPECIFIC GENE REGULATORY ARCHITECTURE OF IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "60587a9e-09a0-2376-e8f1-3e5b652e7843-C", "generated_internal_id": "ASST_NON_R01HL145372_7529"}, {"internal_id": 96201441, "Award ID": "R01HL145302", "Award Amount": 1230477.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-27", "CFDA Number": "93.310", "Description": "IMPACT OF PRENATAL VITAMIN A DEFICIENCY ON CELL FATE ALTERATIONS IN ADULT AIRWAY HYPERRESPONSIVENESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R01HL145302_7529"}, {"internal_id": 83115654, "Award ID": "R01HL145154", "Award Amount": 1899858.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-15", "CFDA Number": "93.837", "Description": "ROLES AND THERAPEUTIC POTENTIAL OF CD150HIGH NICHE-ASSOCIATED REGULATORY T CELLS IN BONE MARROW INJURY AND ENGRAFTMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL145154_7529"}, {"internal_id": 76738444, "Award ID": "R01HL145152", "Award Amount": 1675000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-20", "CFDA Number": "93.837", "Description": "THE ROLE OF MAP3K2/3 IN MODULATING NEUTROPHIL ROS RELEASE AND ITS TRANSLATIONAL POTENTIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL145152_7529"}, {"internal_id": 76908844, "Award ID": "R01HL145147", "Award Amount": 1903149.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-15", "CFDA Number": "93.837", "Description": "MECHANICAL CONTROL OF CELL PROLIFERATION AND BRANCHING MORPHOGENESIS IN THE EMBRYONIC LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b31a6584-f8ff-0848-3b7a-04422c7b4762-C", "generated_internal_id": "ASST_NON_R01HL145147_7529"}, {"internal_id": 76909229, "Award ID": "R01HL145037", "Award Amount": 2955315.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-15", "CFDA Number": "93.837", "Description": "INTERVENTIONAL TARGETING OF THE IRE1ALPHA-TGFBETA SIGNALING LOOP IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL145037_7529"}, {"internal_id": 82054579, "Award ID": "R01HL145025", "Award Amount": 4013193.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-15", "CFDA Number": "93.837", "Description": "METHODS AND SOFTWARE FOR LARGE-SCALE GENE-ENVIRONMENT INTERACTION STUDIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_R01HL145025_7529"}, {"internal_id": 78991155, "Award ID": "R01HL144932", "Award Amount": 2010076.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-06", "CFDA Number": "93.837", "Description": "WNT5A SIGNALING IN STAGE SPECIFIC ALVEOLAR EPITHELIAL CELL DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL144932_7529"}, {"internal_id": 83795657, "Award ID": "R01HL144859", "Award Amount": 3922650.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-29", "CFDA Number": "93.837", "Description": "LINGUAL MUSCLE CONTROL OF UPPER AIRWAY PATENCY IN OBSTRUCTIVE SLEEP APNEA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL144859_7529"}, {"internal_id": 111328699, "Award ID": "R01HL144852", "Award Amount": 1915528.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-11-29", "CFDA Number": "93.837", "Description": "NOVEL NUTRICEUTICALS RELAX AIRWAY SMOOTH MUSCLE AND DECREASE INFLAMMATION IN ALLERGIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL144852_7529"}, {"internal_id": 78990537, "Award ID": "R01HL144849", "Award Amount": 1602313.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-06", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF IMMUNE CELL-CELL COMMUNICATION NETWORKS AND INFLAMMATORY PULMONARY MICROENVIRONMENTS ASSOCIATED WITH THE PROGRESSION OF COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL144849_7529"}, {"internal_id": 76738103, "Award ID": "R01HL144801", "Award Amount": 3323754.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-31", "CFDA Number": "93.837", "Description": "UNRAVELING THE DYNAMIC MECHANISMS UNDERLYING OPIOID RESPIRATORY DEPRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL144801_7529"}, {"internal_id": 81728524, "Award ID": "R01HL144790", "Award Amount": 2649536.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-29", "CFDA Number": "93.837", "Description": "INDUCTION OF CELLS AND PATHWAYS THAT PROMOTE RESPIRATORY TOLERANCE IN ALLERGIC ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL144790_7529"}, {"internal_id": 78990673, "Award ID": "R01HL144785", "Award Amount": 1610318.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-06", "CFDA Number": "93.837", "Description": "MECHANISMS OF EARLY TRACHEAL SPECIFICATION AND MORPHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL144785_7529"}, {"internal_id": 81395931, "Award ID": "R01HL144775", "Award Amount": 2692421.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-07", "CFDA Number": "93.837", "Description": "MECHANISMS OF SEX DIFFERENCES IN NEONATAL PULMONARY OXYGEN TOXICITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL144775_7529"}, {"internal_id": 79433981, "Award ID": "R01HL144774", "Award Amount": 2184669.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-03", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISMS UNDERLYING TRACHEA FORMATION AND THE PATHOLOGY OF TRACHEOMALACIA AND COMPLETE TRACHEAL RINGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL144774_7529"}, {"internal_id": 83796254, "Award ID": "R01HL144727", "Award Amount": 2498534.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-23", "CFDA Number": "93.837", "Description": "MECHANISMS OF RIGHT VENTRICLE ADAPTATION TO PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL144727_7529"}, {"internal_id": 97015172, "Award ID": "R01HL144718", "Award Amount": 9104860.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-24", "CFDA Number": "93.837", "Description": "UNDERSTANDING THE ORIGINS OF EARLY COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL144718_7529"}, {"internal_id": 78598565, "Award ID": "R01HL144660", "Award Amount": 2597975.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-11", "CFDA Number": "93.837", "Description": "HUMAN-SCALE MICROFLUIDIC ARTIFICIAL LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL144660_7529"}, {"internal_id": 78599560, "Award ID": "R01HL144656", "Award Amount": 2355504.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-23", "CFDA Number": "93.837", "Description": "MACROPHAGE SIGNALING PATHWAYS IN ACUTE LUNG INJURY AND RESOLUTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL144656_7529"}, {"internal_id": 83796211, "Award ID": "R01HL144652", "Award Amount": 2464833.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-22", "CFDA Number": "93.837", "Description": "SCHOOL-BASED ASTHMA THERAPY (SBAT) TO REDUCE DISPARITIES IN CHILDHOOD ASTHMA: PRAGMATIC PROCESS AND PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8f7c7d27-684d-9b39-0e46-80a8c294c54a-C", "generated_internal_id": "ASST_NON_R01HL144652_7529"}, {"internal_id": 81395544, "Award ID": "R01HL144624", "Award Amount": 1787179.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-07", "CFDA Number": "93.837", "Description": "STUDY OF TREATMENT'S ECHOCARDIOGRAPHIC MECHANISMS (CLOVERS-STEM)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2ec62179-269e-eca7-af13-c17efa73189f-C", "generated_internal_id": "ASST_NON_R01HL144624_7529"}, {"internal_id": 78991658, "Award ID": "R01HL144599", "Award Amount": 2140947.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-13", "CFDA Number": "93.837", "Description": "THE ROLE OF THE LUNG MICROBIOME IN OXYGEN-INDUCED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL144599_7529"}, {"internal_id": 77189122, "Award ID": "R01HL144590", "Award Amount": 1937349.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-24", "CFDA Number": "93.837", "Description": "RECAPITULATION OF SEX- DISPARITY IN PAH ON A MICROFLUIDIC DEVICE AND ELUCIDATION OF  THE DIFFERENCES AND SIMILARITIES  IN THE DEVELOPMENT, PROGRESSION AND THERAPY OF PAH IN MALE VERSUS FEMALE PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0e99018-560d-146b-09d5-7627bb8c86dc-C", "generated_internal_id": "ASST_NON_R01HL144590_7529"}, {"internal_id": 79639502, "Award ID": "R01HL144566", "Award Amount": 1812764.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-16", "CFDA Number": "93.837", "Description": "PRECISION MEDICINE APPROACH TO VITAMIN D3 ADMINISTRATION IN CRITICAL ILLNESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL144566_7529"}, {"internal_id": 77190853, "Award ID": "R01HL144539", "Award Amount": 1720794.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-22", "CFDA Number": "93.837", "Description": "CORRECTING PATHOGENIC TGF BETA ACTIVITY IN THE AIRWAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL144539_7529"}, {"internal_id": 78990119, "Award ID": "R01HL144519", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-06", "CFDA Number": "93.838", "Description": "LIVER KINASE B1 SIGNALING IN PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL144519_7529"}, {"internal_id": 95484534, "Award ID": "R01HL144497", "Award Amount": 1609167.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-21", "CFDA Number": "93.837", "Description": "THE ROLE OF TRAF4 E3 LIGASE IN IL-25-MEDIATED ALLERGIC ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL144497_7529"}, {"internal_id": 76909185, "Award ID": "R01HL144478", "Award Amount": 1560000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-14", "CFDA Number": "93.837", "Description": "HOW HIV-RELATED PROTEINS INCREASE THE SUSCEPTIBILITY TO LUNG INJURY DESPITE ANTI-RETROVIRAL THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL144478_7529"}, {"internal_id": 67580401, "Award ID": "R01HL144406", "Award Amount": 3139046.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-31", "CFDA Number": "93.837", "Description": "OPTIONS FOR DELIVERY OF SHORT-COURSE TUBERCULOSIS PREVENTIVE THERAPY: THE 3HP OPTIONS TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b710df3-c98e-f245-bbed-8bbbc32a803b-C", "generated_internal_id": "ASST_NON_R01HL144406_7529"}, {"internal_id": 69718140, "Award ID": "R01HL144396", "Award Amount": 1911286.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-20", "CFDA Number": "93.837", "Description": "IMMUNOSUPPRESSIVE INJURIOUS EFFECTS OF E-CIGARETTES ON HUMAN LUNG PARENCHYMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL144396_7529"}, {"internal_id": 68168181, "Award ID": "R01HL144089", "Award Amount": 2984104.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-23", "CFDA Number": "93.837", "Description": "A CLINICAL INDICATIONS PREDICTION (CLIP) SCALE FOR HUMAN MESENCHYMAL STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL144089_7529"}, {"internal_id": 68170702, "Award ID": "R01HL144086", "Award Amount": 1789015.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-21", "CFDA Number": "93.837", "Description": "HOX5 GENE REGULATION OF LUNG FIBROBROBLASTS AND DISTAL LUNG EXTRACELLULAR MATRIX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL144086_7529"}, {"internal_id": 79434565, "Award ID": "R01HL144008", "Award Amount": 2361972.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-25", "CFDA Number": "93.837", "Description": "PRENATAL CONTROL OF OFFSPRING AIRWAY RESPONSIVENESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL144008_7529"}, {"internal_id": 85589249, "Award ID": "R01HL143998", "Award Amount": 3213101.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-12", "CFDA Number": "93.837", "Description": "ENHANCING THE I AM GOLD STUDY WITH SINGLE-CELL DEEP PHENOTYPING AND MACHINE LEARNING META-ANALYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL143998_7529"}, {"internal_id": 66994886, "Award ID": "R01HL143896", "Award Amount": 2514554.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-28", "CFDA Number": "93.837", "Description": "ANGIOPOIETIN/TIE SIGNALING REGULATION OF VASCULAR LEAKAGE IN LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL143896_7529"}, {"internal_id": 68169602, "Award ID": "R01HL143520", "Award Amount": 1600000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-25", "CFDA Number": "93.837", "Description": "ROLE OF CUL4A IN GOVERNING TH2-TYPE TOLERANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_R01HL143520_7529"}, {"internal_id": 68567619, "Award ID": "R01HL143452", "Award Amount": 3213579.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-12", "CFDA Number": "93.837", "Description": "EFFECTS OF EXERCISE ON INFLAMMATION-INDUCED LUNG AND MUSCLE INJURY IN CRITICAL ILLNESS (NEXIS-FLAME)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL143452_7529"}, {"internal_id": 83795702, "Award ID": "R01HL143366", "Award Amount": 3142301.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-29", "CFDA Number": "93.837", "Description": "PULMONARY SPECIALIST-HEALTH COACH CONSULT (PUSHCON) MODEL TO IMPROVE ACCESS TO SPECIALIST CONSULTATION AND RECEIPT OF RECOMMENDED EVIDENCE-BASED CARE FOR VULNERABLE PATIENTS WITH COPD AND ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL143366_7529"}, {"internal_id": 81072213, "Award ID": "R01HL143364", "Award Amount": 3945995.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-20", "CFDA Number": "93.837", "Description": "CLINIC NAVIGATION AND HOME VISITS TO IMPROVE GUIDELINE-BASED CARE AND OUTCOMES IN LOW INCOME MINORITY ADULTS WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL143364_7529"}, {"internal_id": 68171814, "Award ID": "R01HL143256", "Award Amount": 2108819.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-24", "CFDA Number": "93.837", "Description": "IMPACT OF EARLY-IN-LIFE DISRUPTION OF LUNG DEVELOPMENT ON ADULT LUNG PROGENITOR FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL143256_7529"}, {"internal_id": 80728548, "Award ID": "R01HL143076", "Award Amount": 1269549.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-09", "CFDA Number": "93.837", "Description": "BIOENGINEERED MULTI-CELL TYPE ORGANOIDS FOR AIRWAYS DISEASE MODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "623a4232-bd5e-fb60-cf01-48cd08a5a593-C", "generated_internal_id": "ASST_NON_R01HL143076_7529"}, {"internal_id": 68170864, "Award ID": "R01HL143059", "Award Amount": 2077994.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-24", "CFDA Number": "93.837", "Description": "POSTNATAL ALVEOLAR FORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL143059_7529"}, {"internal_id": 66994795, "Award ID": "R01HL143017", "Award Amount": 2227500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-29", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISM OF LUNG BARRIER DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL143017_7529"}, {"internal_id": 76737915, "Award ID": "R01HL143011", "Award Amount": 3720779.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-26", "CFDA Number": "93.837", "Description": "VALIDATING QUANTITATIVE MAGNETIC RESONANCE IMAGING BIOMARKERS OF IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL143011_7529"}, {"internal_id": 67314933, "Award ID": "R01HL143000", "Award Amount": 3376665.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-11", "CFDA Number": "93.837", "Description": "PRESERVATION AND RESCUE OF THE LUNG DONOR ALLOGRAFT FOR TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL143000_7529"}, {"internal_id": 80724905, "Award ID": "R01HL142997", "Award Amount": 1848315.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-14", "CFDA Number": "93.837", "Description": "EPIGENETIC MODULATION IN SEPTIC IMMUNOSUPPRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL142997_7529"}, {"internal_id": 77189511, "Award ID": "R01HL142992", "Award Amount": 3722238.16, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-22", "CFDA Number": "93.837", "Description": "EFFECTS OF RARE VARIANTS AND ANCESTRY ON BETA AGONIST RESPONSE IN ASTHMA AND COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2439d942-d439-953a-5588-98392dd15217-C", "generated_internal_id": "ASST_NON_R01HL142992_7529"}, {"internal_id": 66995511, "Award ID": "R01HL142985", "Award Amount": 2828893.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-29", "CFDA Number": "93.837", "Description": "LOSS OF CELLULAR IDENTITY AFTER INFLUENZA VIRUS INFECTION AND EFFECTS ON PULMONARY FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL142985_7529"}, {"internal_id": 96202036, "Award ID": "R01HL142887", "Award Amount": 1525000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-05", "CFDA Number": "93.837", "Description": "ROLE OF ADAM17 IN MDSC-MEDIATED DEVELOPMENT OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL142887_7529"}, {"internal_id": 66995291, "Award ID": "R01HL142876", "Award Amount": 2059200.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-29", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISMS OF ALVEOLAR DEVELOPMENT AND REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL142876_7529"}, {"internal_id": 68171100, "Award ID": "R01HL142866", "Award Amount": 1650859.91, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-31", "CFDA Number": "93.837", "Description": "CATALYTIC NANOTHERAPIES TO TREAT LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL142866_7529"}, {"internal_id": 81728113, "Award ID": "R01HL142853", "Award Amount": 1901186.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-25", "CFDA Number": "93.837", "Description": "MYOCARDIN IN THE PATHOGENESIS OF PLEURAL REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6605b60b-2165-8c36-e954-428aa458f579-C", "generated_internal_id": "ASST_NON_R01HL142853_7529"}, {"internal_id": 67579133, "Award ID": "R01HL142777", "Award Amount": 2358330.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-20", "CFDA Number": "93.837", "Description": "DCAF7/HDAC4/TFEB AXIS IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL142777_7529"}, {"internal_id": 82469067, "Award ID": "R01HL142776", "Award Amount": 1877383.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-25", "CFDA Number": "93.837", "Description": "ROLE OF CXCR2-MEDIATED CELL TRAFFICKING IN PULMONARY VASCULAR REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL142776_7529"}, {"internal_id": 67314567, "Award ID": "R01HL142775", "Award Amount": 3391182.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-13", "CFDA Number": "93.866", "Description": "THE DALLAS ASTHMA BRAIN AND COGNITION STUDY (DALLAS ABC STUDY)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f196066d-bb5d-187e-c134-9680d15f484f-C", "generated_internal_id": "ASST_NON_R01HL142775_7529"}, {"internal_id": 83797221, "Award ID": "R01HL142769", "Award Amount": 1980754.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-25", "CFDA Number": "93.837", "Description": "CC16: A LINK BETWEEN AIRWAY INFECTION AND OBSTRUCTIVE LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R01HL142769_7529"}, {"internal_id": 83796962, "Award ID": "R01HL142758", "Award Amount": 1982586.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-23", "CFDA Number": "93.837", "Description": "LNCRNA REGULATES LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL142758_7529"}, {"internal_id": 81071864, "Award ID": "R01HL142749", "Award Amount": 3351151.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-28", "CFDA Number": "93.837", "Description": "DEPRESSION IN OLDER ASTHMATICS: UNDERSTANDING INFLAMMATORY AND BEHAVIORAL PATHWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL142749_7529"}, {"internal_id": 79433518, "Award ID": "R01HL142727", "Award Amount": 2271744.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-28", "CFDA Number": "93.837", "Description": "LUNG EPITHELIAL CELL SPECIFICATION IN HUMAN PLURIPOTENT STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL142727_7529"}, {"internal_id": 80727311, "Award ID": "R01HL142720", "Award Amount": 2659504.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-06", "CFDA Number": "93.837", "Description": "GENOMIC AND CIRCULATING PREDICTORS OF PAH RESPONSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL142720_7529"}, {"internal_id": 68168605, "Award ID": "R01HL142708", "Award Amount": 2088242.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-28", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF NEONATAL INNATE LUNG DEFENSES IS DEPENDENT ON GASTROINTESTINAL COMMENSAL BACTERIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL142708_7529"}, {"internal_id": 68566990, "Award ID": "R01HL142702", "Award Amount": 2576833.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-10", "CFDA Number": "93.837", "Description": "PRESERVING EPITHELIAL BARRIER INTEGRITY IN VENTILATOR-INDUCED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL142702_7529"}, {"internal_id": 79638640, "Award ID": "R01HL142701", "Award Amount": 2451025.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-15", "CFDA Number": "93.837", "Description": "DEFINING GROUP 2 INNATE LYMPHOID CELL LUNG NICHES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL142701_7529"}, {"internal_id": 67313606, "Award ID": "R01HL142691", "Award Amount": 3592758.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-12", "CFDA Number": "93.837", "Description": "TELEMEDICINE ENHANCED ASTHMA MANAGEMENT - UNITING PROVIDERS (TEAM-UP)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL142691_7529"}, {"internal_id": 68168969, "Award ID": "R01HL142674", "Award Amount": 1144106.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-23", "CFDA Number": "93.837", "Description": "VASCULAR DISEASE PATHOGENESIS: THE INTERFACE OF SMOOTH MUSCLE AND IMMUNE CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL142674_7529"}, {"internal_id": 67833706, "Award ID": "R01HL142638", "Award Amount": 2783639.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-15", "CFDA Number": "93.837", "Description": "ROLE OF SKELETAL MUSCLE IN PULMONARY VASCULAR REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL142638_7529"}, {"internal_id": 79639309, "Award ID": "R01HL142636", "Award Amount": 1998750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-10", "CFDA Number": "93.837", "Description": "FIBROBLAST MEDIATED MECHANISMS OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL142636_7529"}, {"internal_id": 78991699, "Award ID": "R01HL142626", "Award Amount": 2041694.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-13", "CFDA Number": "93.837", "Description": "CONTROLLING BACTERMIC PNEUMOCOCCAL PNEUMONIA WITH SYNTHETIC DOMINANT-NEGATIVE COMPETENCE PEPTIDES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2c3d8c8a-27ef-b1e9-7164-bbfa490faa27-C", "generated_internal_id": "ASST_NON_R01HL142626_7529"}, {"internal_id": 67579534, "Award ID": "R01HL142625", "Award Amount": 2164587.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-21", "CFDA Number": "93.837", "Description": "LUNG BIOMECHANICS AND DISEASE PROGRESSION IN SPIROMICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL142625_7529"}, {"internal_id": 66800477, "Award ID": "R01HL142596", "Award Amount": 2047500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-15", "CFDA Number": "93.837", "Description": "EPIGENETIC GENE REPRESSION IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL142596_7529"}, {"internal_id": 80400887, "Award ID": "R01HL142587", "Award Amount": 1565000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-19", "CFDA Number": "93.837", "Description": "POLYMICROBIAL INTERACTIONS IN THE RESPIRATORY TRACT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7eb6683a-d796-f7f5-68c0-ca8f32275b30-C", "generated_internal_id": "ASST_NON_R01HL142587_7529"}, {"internal_id": 81728799, "Award ID": "R01HL142578", "Award Amount": 1533508.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-24", "CFDA Number": "93.837", "Description": "THE ROLE OF YAP1 IN ANGIOGENESIS DURING ORGAN REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL142578_7529"}, {"internal_id": 96203023, "Award ID": "R01HL142568", "Award Amount": 2878578.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-25", "CFDA Number": "93.837", "Description": "FIBROBLAST HETEROGENEITY IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL142568_7529"}, {"internal_id": 68170824, "Award ID": "R01HL142559", "Award Amount": 2238700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-27", "CFDA Number": "93.837", "Description": "LIVE IMAGING OF INTACT AIRWAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL142559_7529"}, {"internal_id": 68172032, "Award ID": "R01HL142552", "Award Amount": 2282825.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-22", "CFDA Number": "93.837", "Description": "MAINTENANCE OF THE ALVEOLAR NICHE IN EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL142552_7529"}, {"internal_id": 68172040, "Award ID": "R01HL142549", "Award Amount": 2185489.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-21", "CFDA Number": "93.837", "Description": "IDENTIFYING NICHE FACTORS REGULATING DISTINCT PROPERTIES OF AT2 STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL142549_7529"}, {"internal_id": 81072277, "Award ID": "R01HL142543", "Award Amount": 1945150.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-27", "CFDA Number": "93.837", "Description": "NUCLEAR RECEPTOR REV-ERB ALPHA ROLE IN THE PATHOPHYSIOLOGY OF ALLERGIC ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1a1108fb-0099-a708-6def-aa6d101c8ba8-C", "generated_internal_id": "ASST_NON_R01HL142543_7529"}, {"internal_id": 67579336, "Award ID": "R01HL142503", "Award Amount": 3259133.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-25", "CFDA Number": "93.837", "Description": "USING COMPUTATIONAL APPROACHES TO OPTIMIZE ASTHMA CARE MANAGEMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL142503_7529"}, {"internal_id": 66199628, "Award ID": "R01HL142269", "Award Amount": 3939193.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-18", "CFDA Number": "93.837", "Description": "NOVEL MECHANISMS OF HEPATOPULMONARY SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL142269_7529"}, {"internal_id": 77190403, "Award ID": "R01HL142265", "Award Amount": 588009.14, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-31", "CFDA Number": "93.837", "Description": "LOXL-2 DEPENDENT BLOCKADE OF TGF BETA1 SIGNALING AND LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL142265_7529"}, {"internal_id": 67833520, "Award ID": "R01HL142258", "Award Amount": 3075522.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-15", "CFDA Number": "93.837", "Description": "IMPROVING LUNG TRANSPLANT OUTCOMES THROUGH THE USE OF IMAGING IN A DBD RAT MODEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL142258_7529"}, {"internal_id": 68168353, "Award ID": "R01HL142215", "Award Amount": 1959395.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-22", "CFDA Number": "93.837", "Description": "GENETIC BASIS OF NORMAL AND PATHOLOGICAL ALVEOLOGENESIS IN LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL142215_7529"}, {"internal_id": 67314930, "Award ID": "R01HL142212", "Award Amount": 1815323.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-16", "CFDA Number": "93.837", "Description": "PKG SIGNALING AND SEPSIS INDUCED ALI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8521f543-2302-80cf-d989-c2ff7cf07ef3-C", "generated_internal_id": "ASST_NON_R01HL142212_7529"}, {"internal_id": 80401654, "Award ID": "R01HL142210", "Award Amount": 1749996.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-29", "CFDA Number": "93.837", "Description": "PREDICTIVE MOLECULAR MARKERS OF LUNG FUNCTION DECLINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL142210_7529"}, {"internal_id": 62420567, "Award ID": "R01HL142111", "Award Amount": 2260800.88, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-12", "CFDA Number": "93.837", "Description": "UBIQUITIN REGULATION OF K CHANNELS IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": 659761.64, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL142111_7529"}, {"internal_id": 65579279, "Award ID": "R01HL142110", "Award Amount": 2320279.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-13", "CFDA Number": "93.837", "Description": "IN VIVO LUNG PERFUSION FOR THE SURGICAL TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL142110_7529"}, {"internal_id": 78991288, "Award ID": "R01HL142093", "Award Amount": 2841005.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-15", "CFDA Number": "93.837", "Description": "THERAPEUTIC MODULATION OF ZINC FOR LUNG INJURY AND MECHANOBIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL142093_7529"}, {"internal_id": 62421266, "Award ID": "R01HL142084", "Award Amount": 2371558.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-07", "CFDA Number": "93.837", "Description": "HOST CONTROL MECHANISMS AGAINST K. PNEUMONIAE INFECTION IN THE LUNGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL142084_7529"}, {"internal_id": 62420275, "Award ID": "R01HL142081", "Award Amount": 1800007.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-05", "CFDA Number": "93.837", "Description": "KETONE BODY SUPPLEMENTATION IN OBESE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL142081_7529"}, {"internal_id": 81072382, "Award ID": "R01HL142061", "Award Amount": 2039996.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-04", "CFDA Number": "93.837", "Description": "NICOTINE, AIRWAY SMOOTH MUSCLE AND ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL142061_7529"}, {"internal_id": 79433946, "Award ID": "R01HL142049", "Award Amount": 2566263.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-26", "CFDA Number": "93.837", "Description": "NOVEL INTEGRATIVE APPROACHES FOR DISEASE PHENOTYPING, UTILIZING RADIOMICS IN SARCOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL142049_7529"}, {"internal_id": 66995325, "Award ID": "R01HL142042", "Award Amount": 3473764.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-20", "CFDA Number": "93.837", "Description": "CT-BASED MODELING OF BONE MICRO-ARCHITECTURE AND FRACTURE-RISK IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL142042_7529"}, {"internal_id": 65281074, "Award ID": "R01HL142028", "Award Amount": 789727.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-26", "CFDA Number": "93.837", "Description": "INTEGRATION OF OMICS DATA TO IMPROVE INTERPRETATION OF GENETIC RISK VARIANTS IN LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL142028_7529"}, {"internal_id": 76738422, "Award ID": "R01HL141999", "Award Amount": 2872357.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-23", "CFDA Number": "93.837", "Description": "A NOVEL PATHWAY OF TH17/TH2 INDUCTION: THE ROLE OF CAMP SIGNALING IN DC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL141999_7529"}, {"internal_id": 65280674, "Award ID": "R01HL141992", "Award Amount": 853821.37, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-27", "CFDA Number": "93.837", "Description": "INTEGRATIVE ANALYSES TO UNCOVER BIOLOGICAL MECHANISMS MEDIATING GENE ASSOCIATIONS WITH ASTHMA DRUG RESPONSE AMONG MINORITY CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL141992_7529"}, {"internal_id": 66487204, "Award ID": "R01HL141856", "Award Amount": 2515247.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-25", "CFDA Number": "93.837", "Description": "MECHANISMS CONTROLLING EARLY HUMAN LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c10cf51-1fb6-c52e-c48f-8fcef0f37eff-C", "generated_internal_id": "ASST_NON_R01HL141856_7529"}, {"internal_id": 76473250, "Award ID": "R01HL141852", "Award Amount": 3367121.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-14", "CFDA Number": "93.837", "Description": "EPITHELIAL PROTECTIVE EFFECTS OF THYROID HORMONE SIGNALING IN FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL141852_7529"}, {"internal_id": 77190266, "Award ID": "R01HL141849", "Award Amount": 2374213.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-18", "CFDA Number": "93.837", "Description": "INVESTIGATING THE CDC42 PATHWAY AS A NOVEL PATHWAY FOR PEDIATRIC NON-ATOPIC OBESITY-RELATED ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_R01HL141849_7529"}, {"internal_id": 76909139, "Award ID": "R01HL141845", "Award Amount": 3041438.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-12", "CFDA Number": "93.837", "Description": "POLY-OMIC STUDY OF ASTHMA EXACERBATIONS IN DIVERSE POPULATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4397aef3-70da-b831-0f7a-71049f3e955b-C", "generated_internal_id": "ASST_NON_R01HL141845_7529"}, {"internal_id": 66198970, "Award ID": "R01HL141826", "Award Amount": 3383971.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-07", "CFDA Number": "93.837", "Description": "MECHANISTIC INSIGHTS INTO ASTHMA PATHOGENESIS THROUGH THE INTEGRATION OF ASTHMA GENES, RISK EXPOSURES, AND METABOLOMICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL141826_7529"}, {"internal_id": 65894282, "Award ID": "R01HL141813", "Award Amount": 2828794.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-30", "CFDA Number": "93.837", "Description": "AN INTEGRATIVE RADIOGENOMIC APPROACH TO DESIGN GENETICALLY-INFORMED IMAGE BIOMARKER FOR CHARACTERIZING COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6bb5676d-1119-4abb-3c6a-1bdba277e0cd-C", "generated_internal_id": "ASST_NON_R01HL141813_7529"}, {"internal_id": 67315145, "Award ID": "R01HL141810", "Award Amount": 1935000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-16", "CFDA Number": "93.837", "Description": "MANAGING THE FOLDING LANDSCAPE IN ALPHA1 LIVER-LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL141810_7529"}, {"internal_id": 78991309, "Award ID": "R01HL141608", "Award Amount": 3731963.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-05", "CFDA Number": "93.837", "Description": "IMPLEMENTATION OF BEHAVIORAL ECONOMIC APPROACHES TO IMPROVE EVIDENCE UPTAKE FOR MECHANICALLY VENTILATED PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL141608_7529"}, {"internal_id": 65578777, "Award ID": "R01HL141493", "Award Amount": 1553362.22, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-06", "CFDA Number": "93.837", "Description": "SUPPRESSION OF BASOPHIL ACTIVATION BY IGE GLYCOVARIANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL141493_7529"}, {"internal_id": 64141509, "Award ID": "R01HL141490", "Award Amount": 1637343.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-09", "CFDA Number": "93.837", "Description": "IMMUNOTHERAPY INDUCED TRM ARREST AND REVERSE LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL141490_7529"}, {"internal_id": 61611665, "Award ID": "R01HL141473", "Award Amount": 1525855.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-01", "CFDA Number": "93.837", "Description": "REGULATION OF PHOSPHODIESTERASES AND CAMP SIGNALING DURING THE HOST-PATHOGEN INTERACTION IN THE PULMONARY ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_R01HL141473_7529"}, {"internal_id": 67832562, "Award ID": "R01HL141459", "Award Amount": 2001584.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-15", "CFDA Number": "93.837", "Description": "THE TRANSCRIPTION FACTOR MIZ1-MEDIATED MECHANISMS OF LUNG AGING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL141459_7529"}, {"internal_id": 77190391, "Award ID": "R01HL141387", "Award Amount": 1842000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-25", "CFDA Number": "93.837", "Description": "NOVEL INVOLVEMENT OF NAMPT AND TLR4 IN PAH VASCULAR REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R01HL141387_7529"}, {"internal_id": 77190642, "Award ID": "R01HL141380", "Award Amount": 2104959.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-18", "CFDA Number": "93.837", "Description": "NON-CANONICAL WNT SIGNALING IN EMPHYSEMA AND LUNG REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL141380_7529"}, {"internal_id": 76909232, "Award ID": "R01HL141364", "Award Amount": 1560065.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-11", "CFDA Number": "93.837", "Description": "UNFOLDED PROTEIN RESPONSE IN INFLUENZA VIRUS INFECTION AND INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL141364_7529"}, {"internal_id": 66994963, "Award ID": "R01HL141356", "Award Amount": 2171124.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-23", "CFDA Number": "93.837", "Description": "MITOCHONDRIALLY TARGETED THERAPIES FOR SEPSIS INDUCED DIAPHRAGM DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R01HL141356_7529"}, {"internal_id": 61612853, "Award ID": "R01HL141352", "Award Amount": 2595815.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-26", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISMS OF PULMONARY DISEASE IN BIRT-HOGG-DUBE SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R01HL141352_7529"}, {"internal_id": 77190739, "Award ID": "R01HL141286", "Award Amount": 2286948.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-18", "CFDA Number": "93.837", "Description": "R01- MAPPING ENVIRONMENTAL CONTRIBUTIONS TO RAPID LUNG DISEASE PROGRESSION IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL141286_7529"}, {"internal_id": 64141629, "Award ID": "R01HL141269", "Award Amount": 1912580.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-05", "CFDA Number": "93.837", "Description": "THE FUNCTION OF MRGPRC11+ VAGAL SENSORY NEURONS IN THE AIRWAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7c481d7-071a-ead9-3bda-e4e7d1e903a7-C", "generated_internal_id": "ASST_NON_R01HL141269_7529"}, {"internal_id": 66198998, "Award ID": "R01HL141268", "Award Amount": 3720462.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-15", "CFDA Number": "93.837", "Description": "EFFECTS OF DHEA IN PULMONARY HYPERTENSION (DIPH)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f21f887-ca03-f1f2-6e30-1c1498f78b9e-C", "generated_internal_id": "ASST_NON_R01HL141268_7529"}, {"internal_id": 81395713, "Award ID": "R01HL141264", "Award Amount": 1973404.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-07", "CFDA Number": "93.837", "Description": "ROLE OF FABP5 IN COPD EXACERBATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL141264_7529"}, {"internal_id": 78991722, "Award ID": "R01HL141255", "Award Amount": 1998750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-15", "CFDA Number": "93.837", "Description": "ENCAPSULATION OF MESENCHYMAL STROMAL CELLS IN ENGINEERED MICROGELS FOR RESOLUTION OF LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL141255_7529"}, {"internal_id": 83795697, "Award ID": "R01HL141251", "Award Amount": 1612256.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-22", "CFDA Number": "93.837", "Description": "CHOLINERGIC MECHANISMS INVOLVED IN TRANSDUCTION OF AIRWAY DEFENSIVE REFLEXES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL141251_7529"}, {"internal_id": 66199565, "Award ID": "R01HL141249", "Award Amount": 1963940.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-12", "CFDA Number": "93.837", "Description": "NEONATAL INFLAMMATION IMPAIRS CONTROL OF BREATHING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e9ad8bff-1815-2dce-c711-ea8977aee9fe-C", "generated_internal_id": "ASST_NON_R01HL141249_7529"}, {"internal_id": 79434328, "Award ID": "R01HL141237", "Award Amount": 2820417.12, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-21", "CFDA Number": "93.837", "Description": "IFN RESPONSES AND SARS-COV-2 RECEPTOR ACE2 EXPRESSION IN THE AIRWAY EPITHELIUM OF YOUNG CHILDREN WITH DOWN SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_R01HL141237_7529"}, {"internal_id": 76475497, "Award ID": "R01HL141236", "Award Amount": 1614288.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-17", "CFDA Number": "93.837", "Description": "NATURAL KILLER CELL FUNCTIONS IN LYMPHANGIOLEIOMYOMATOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R01HL141236_7529"}, {"internal_id": 68169402, "Award ID": "R01HL141229", "Award Amount": 2645805.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-15", "CFDA Number": "93.837", "Description": "CHYMOTRYPSIN-LIKE ELASTASE 1 IN LUNG DEVELOPMENT AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL141229_7529"}, {"internal_id": 78991302, "Award ID": "R01HL141217", "Award Amount": 2532936.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-18", "CFDA Number": "93.837", "Description": "THE PIVOTAL ROLE OF MACROPHAGES IN REGULATING PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL141217_7529"}, {"internal_id": 49759429, "Award ID": "R01HL141195", "Award Amount": 2328541.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-13", "CFDA Number": "93.837", "Description": "X-LINKED INHIBITOR OF APOPTOSIS IN FIBROBLAST PHENOTYPES AND LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL141195_7529"}, {"internal_id": 62551054, "Award ID": "R01HL141174", "Award Amount": 2097292.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-24", "CFDA Number": "93.837", "Description": "TRANSCRIPTIONAL REGULATION OF ENDOTHELIAL CELLS AFTER ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL141174_7529"}, {"internal_id": 76738393, "Award ID": "R01HL141146", "Award Amount": 1606541.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-27", "CFDA Number": "93.837", "Description": "SELENOCYANATE AS A NOVEL TREATMENT OF CYSTIC FIBROSIS LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL141146_7529"}, {"internal_id": 64141661, "Award ID": "R01HL141078", "Award Amount": 2385909.97, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-05", "CFDA Number": "93.837", "Description": "CONTROL OF MACROPHAGE ACTIVATION IN LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL141078_7529"}, {"internal_id": 69723960, "Award ID": "R01HL140971", "Award Amount": 2748934.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-20", "CFDA Number": "93.837", "Description": "SPINGOLIPIDS IN HIV-ASSOCIATED CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL140971_7529"}, {"internal_id": 67580311, "Award ID": "R01HL140963", "Award Amount": 3670650.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-31", "CFDA Number": "93.837", "Description": "SYSTEMS BIOLOGY OF DIFFUSION IMPAIRMENT IN HIV", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL140963_7529"}, {"internal_id": 49759422, "Award ID": "R01HL140898", "Award Amount": 4329342.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-21", "CFDA Number": "93.837", "Description": "INNATE IMMUNE ACTIVATION AND ENDOTHELIAL CELL DYSFUNCTION IN ACUTE KAWASAKI DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": 727650.0, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL140898_7529"}, {"internal_id": 67579899, "Award ID": "R01HL140839", "Award Amount": 2832547.35, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-25", "CFDA Number": "93.837", "Description": "WOOD SMOKE AND CHRONIC MUCOUS HYPERSECRETION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL140839_7529"}, {"internal_id": 61610952, "Award ID": "R01HL140623", "Award Amount": 2387697.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-29", "CFDA Number": "93.837", "Description": "MECHANISM OF PATHOGENIC MACROPHAGE ACTIVATION IN EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL140623_7529"}, {"internal_id": 61611576, "Award ID": "R01HL140595", "Award Amount": 2458836.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-22", "CFDA Number": "93.837", "Description": "FIBROBLAST RESISTANCE TO APOPTOSIS IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL140595_7529"}, {"internal_id": 61611874, "Award ID": "R01HL140572", "Award Amount": 1948959.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-28", "CFDA Number": "93.837", "Description": "EARLY LIFE HYPEROXIC EXPOSURE, LUNG INNATE IMMUNE RESPONSES, BRONCHOPULMONARY DYSPLASIA AND ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL140572_7529"}, {"internal_id": 49759409, "Award ID": "R01HL140496", "Award Amount": 1877780.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-12", "CFDA Number": "93.837", "Description": "ILC2-MEDIATED PROTECTION FROM ACUTE LUNG INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "84c69770-7b20-b9e0-d502-4ceb449256bf-C", "generated_internal_id": "ASST_NON_R01HL140496_7529"}, {"internal_id": 64141657, "Award ID": "R01HL140486", "Award Amount": 3399032.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-05", "CFDA Number": "93.837", "Description": "HOME BASED REHABILITATION FOR COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL140486_7529"}, {"internal_id": 67314653, "Award ID": "R01HL140470", "Award Amount": 2000887.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-16", "CFDA Number": "93.837", "Description": "COMPLEMENT DRIVEN INNATE AND ADAPTIVE AUTOREACTIVITY IN LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL140470_7529"}, {"internal_id": 66199390, "Award ID": "R01HL140409", "Award Amount": 1983961.97, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-15", "CFDA Number": "93.837", "Description": "TARGETING SMOOTH MUSCLE PROGENITOR CELLS FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_R01HL140409_7529"}, {"internal_id": 67833719, "Award ID": "R01HL140398", "Award Amount": 2365679.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-17", "CFDA Number": "93.837", "Description": "MECHANISM AND FUNCTION OF LET-7, A NOVEL MODULATOR OF TH17-DEPENDENT EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL140398_7529"}, {"internal_id": 68566701, "Award ID": "R01HL140362", "Award Amount": 3648158.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-08", "CFDA Number": "93.837", "Description": "A NOVEL DATA SCIENCE AND NETWORK ANALYSIS APPROACH TO QUANTIFYING FACILITATORS AND BARRIERS OF LOW TIDAL VOLUME VENTILATION IN AN INTERNATIONAL CONSORTIUM OF MEDICAL CENTERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5260402a-a27e-e33b-309d-fe9324c3f0e2-C", "generated_internal_id": "ASST_NON_R01HL140362_7529"}, {"internal_id": 66995279, "Award ID": "R01HL140357", "Award Amount": 2797880.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-26", "CFDA Number": "93.837", "Description": "EPIGENETIC REGULATION OF IMMUNE PATHWAYS IN SARCOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL140357_7529"}, {"internal_id": 67834151, "Award ID": "R01HL140231", "Award Amount": 2724193.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-13", "CFDA Number": "93.837", "Description": "THE ROAD TO DESTINATION THERAPY: OPTIMIZING LONG-TERM MECHANICAL CARDIOPULMONARY SUPPORT FOR PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL140231_7529"}, {"internal_id": 65280948, "Award ID": "R01HL140182", "Award Amount": 2654095.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-01", "CFDA Number": "93.837", "Description": "NOSOCOMIAL PNEUMONIAS IMPAIR COGNITIVE FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_R01HL140182_7529"}, {"internal_id": 62420609, "Award ID": "R01HL140064", "Award Amount": 1950000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-13", "CFDA Number": "93.837", "Description": "BIASED MUSCARINIC ACETYLCHOLINE RECEPTOR SIGNALING IN OBSTRUCTIVE LUNG DISEASE PATHOLOGY AND THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL140064_7529"}, {"internal_id": 67313388, "Award ID": "R01HL139897", "Award Amount": 3160631.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-05", "CFDA Number": "93.837", "Description": "LUNG FIBROSIS MEDIATED BY TELOMERE DYSFUNCTION IN ALVEOLAR TYPE II CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL139897_7529"}, {"internal_id": 76738569, "Award ID": "R01HL139881", "Award Amount": 2460333.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-27", "CFDA Number": "93.837", "Description": "ENDOTHELIAL TOLL-LIKE RECEPTOR 3 IN THE PATHOGENESIS AND THERAPY OF PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL139881_7529"}, {"internal_id": 67579011, "Award ID": "R01HL139876", "Award Amount": 3783695.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-01", "CFDA Number": "93.837", "Description": "RARE MUTATIONS IN CYSTIC FIBROSIS: OVERCOMING BARRIERS TO PERSONALIZED MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL139876_7529"}, {"internal_id": 64141516, "Award ID": "R01HL139828", "Award Amount": 2467420.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-14", "CFDA Number": "93.837", "Description": "CHARACTERIZATION OF MECHANISMS REGULATING MULTICILIATED CELL SPECIFICATION USING PATIENT-SPECIFIC INDUCED PLURIPOTENT STEM CELLS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL139828_7529"}, {"internal_id": 68172019, "Award ID": "R01HL139799", "Award Amount": 2071410.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-24", "CFDA Number": "93.837", "Description": "IPSC-DERIVED AIRWAY BASAL CELLS TO MODEL HUMAN AIRWAY DEVELOPMENT AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL139799_7529"}, {"internal_id": 62420967, "Award ID": "R01HL139798", "Award Amount": 2494967.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-15", "CFDA Number": "93.837", "Description": "THE ROLE OF PLACENTAL MATERNAL VASCULAR UNDERPERFUSION IN NEONATAL PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL139798_7529"}, {"internal_id": 66995460, "Award ID": "R01HL139797", "Award Amount": 2239334.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-29", "CFDA Number": "93.837", "Description": "MECHANISMS OF TREG AND IL-35 IN REGULATING LV FAILURE-INDUCED LUNG REMODELING AND RIGHT HEART HYPERTROPHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "38806202-b2e1-fa5b-5787-e80ab7888442-C", "generated_internal_id": "ASST_NON_R01HL139797_7529"}, {"internal_id": 65280986, "Award ID": "R01HL139717", "Award Amount": 2697689.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-23", "CFDA Number": "93.837", "Description": "EVALUATION OF A NOVEL BREATH SENSOR FOR RAPID, LOW-COST DIAGNOSIS OF TUBERCULOSIS IN CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL139717_7529"}, {"internal_id": 67314805, "Award ID": "R01HL139708", "Award Amount": 1496172.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-08", "CFDA Number": "93.837", "Description": "AMPAKINES AND RESPIRATORY NEUROPLASTICITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL139708_7529"}, {"internal_id": 81072161, "Award ID": "R01HL139690", "Award Amount": 1927244.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-28", "CFDA Number": "93.837", "Description": "AN EARLY IMAGING MARKER OF EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL139690_7529"}, {"internal_id": 49759377, "Award ID": "R01HL139686", "Award Amount": 1675000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-08", "CFDA Number": "93.837", "Description": "CALCIUM SIGNALING AND ION CHANNELS IN AIRWAY DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_R01HL139686_7529"}, {"internal_id": 61610300, "Award ID": "R01HL139673", "Award Amount": 2839560.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-24", "CFDA Number": "93.837", "Description": "HIGH EFFICIENCY DELIVERY OF SURFACTANT AEROSOLS TO INFANTS WITHOUT INTUBATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R01HL139673_7529"}, {"internal_id": 49759374, "Award ID": "R01HL139664", "Award Amount": 3316384.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-07", "CFDA Number": "93.837", "Description": "ENDOTHELIAL-PERICYTE INTERACTIONS IN THE PATHOGENESIS OF PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL139664_7529"}, {"internal_id": 64141341, "Award ID": "R01HL139643", "Award Amount": 1186335.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-07", "CFDA Number": "93.838", "Description": "CHIBBY AND ITS ASSOCIATED PROTEINS IN CILIATED CELL DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3313e5e7-fa36-d54b-e36d-0e1e09cc0c30-C", "generated_internal_id": "ASST_NON_R01HL139643_7529"}, {"internal_id": 66995038, "Award ID": "R01HL139641", "Award Amount": 2062500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-28", "CFDA Number": "93.837", "Description": "NEW GENETIC MODELS FOR C5A RECEPTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL139641_7529"}, {"internal_id": 77190750, "Award ID": "R01HL139638", "Award Amount": 1229504.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-22", "CFDA Number": "93.837", "Description": "ROLE OF ENDOTHELIAL TWIST1 IN VASCULAR REMODELING IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL139638_7529"}, {"internal_id": 49759371, "Award ID": "R01HL139634", "Award Amount": 4283400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-09", "CFDA Number": "93.837", "Description": "ASTHMA EXACERBATIONS AND MICRORNA PREDICTION: TREATMENT RESPONSE IN AN UNDERSERVED ETHNICITY (AEM-TRUE)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL139634_7529"}, {"internal_id": 76908842, "Award ID": "R01HL139617", "Award Amount": 2113860.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-15", "CFDA Number": "93.837", "Description": "AMPK IN THE DEVELOPMENT AND RESOLUTION OF LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL139617_7529"}, {"internal_id": 49759370, "Award ID": "R01HL139613", "Award Amount": 2384966.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-22", "CFDA Number": "93.837", "Description": "SYSTEMS BIOLOGY, ENDOTHELIAL REGULATION OF FIBROSIS, AND PULMONARY VASCULAR DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL139613_7529"}, {"internal_id": 68171383, "Award ID": "R01HL139594", "Award Amount": 1981250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-21", "CFDA Number": "93.837", "Description": "MECHANISTIC ROLES OF ADRENOMEDULLIN AND ITS SIGNALING RECEPTORS IN EXPERIMENTAL BRONCHOPULMONARY DYSPLASIA AND PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL139594_7529"}, {"internal_id": 68169084, "Award ID": "R01HL139584", "Award Amount": 2154114.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-21", "CFDA Number": "93.837", "Description": "TARGETING MATRIX STIFFNESS IN LUNG FIBROSIS ASSOCIATED WITH AGING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL139584_7529"}, {"internal_id": 67313561, "Award ID": "R01HL139552", "Award Amount": 3263777.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-18", "CFDA Number": "93.838", "Description": "MOLECULAR AND GENETIC BASIS OF DEEP VENOUS THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": 779063.0, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL139552_7529"}, {"internal_id": 66995392, "Award ID": "R01HL139547", "Award Amount": 1565000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-22", "CFDA Number": "93.837", "Description": "MACROPHAGE PYROPTOSIS MECHANISM OF POST-TRAUMA ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL139547_7529"}, {"internal_id": 49759365, "Award ID": "R01HL139496", "Award Amount": 2076586.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-13", "CFDA Number": "93.837", "Description": "MICRORNA-10A IN AIRWAY SMOOTH MUSCLE AND ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_R01HL139496_7529"}, {"internal_id": 49759357, "Award ID": "R01HL139369", "Award Amount": 2381569.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-13", "CFDA Number": "93.837", "Description": "E-CIG FLAVORS AND THEIR EFFECTS ON RESPIRATORY INNATE IMMUNE RESPONSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL139369_7529"}, {"internal_id": 69718214, "Award ID": "R01HL139365", "Award Amount": 1833933.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-20", "CFDA Number": "93.837", "Description": "TRP-MEDIATED AIRWAY INFLAMMATION BY E-CIGARETTE VAPING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1a1108fb-0099-a708-6def-aa6d101c8ba8-C", "generated_internal_id": "ASST_NON_R01HL139365_7529"}, {"internal_id": 68565185, "Award ID": "R01HL139335", "Award Amount": 2444289.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-13", "CFDA Number": "93.077", "Description": "INTEGRATED RISK ASSESSMENT AND MOLECULAR CHARACTERIZATION OF PULMONARY RESPONSE TO E-CIGARETTE EXPOSURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "74457bb7-b18d-9762-896e-e575e7a4ed82-C", "generated_internal_id": "ASST_NON_R01HL139335_7529"}, {"internal_id": 49759353, "Award ID": "R01HL139278", "Award Amount": 2898366.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-17", "CFDA Number": "93.837", "Description": "TARGETING MACROPHAGES IN AGING SIV-INFECTED RHESUS MACAQUES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R01HL139278_7529"}, {"internal_id": 49759352, "Award ID": "R01HL139239", "Award Amount": 1952545.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-13", "CFDA Number": "93.837", "Description": "AIR QUALITY, CHILD, AND ADULT HEALTH IN HOMES WHERE E-CIGARETTES ARE SMOKED", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_R01HL139239_7529"}, {"internal_id": 49759350, "Award ID": "R01HL139066", "Award Amount": 2355778.09, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-05", "CFDA Number": "93.837", "Description": "ASSESSMENT OF LUNG INJURY WITH INTEGRATED IMAGING TECHNIQUES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL139066_7529"}, {"internal_id": 49759336, "Award ID": "R01HL138728", "Award Amount": 3681429.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-11", "CFDA Number": "93.837", "Description": "A COMPREHENSIVE SNAPSHOT OF TUBERCULOSIS TRANSMISSION IN AN URBAN UGANDAN COMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL138728_7529"}, {"internal_id": 49759334, "Award ID": "R01HL138708", "Award Amount": 2129600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-03", "CFDA Number": "93.837", "Description": "DUOX1 AND MITOCHONDRIA IN OBESE  ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL138708_7529"}, {"internal_id": 76738313, "Award ID": "R01HL138673", "Award Amount": 2320072.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-26", "CFDA Number": "93.837", "Description": "MECHANISMS OF ANTIBODY-MEDIATED LUNG INJURY AFTER BLOOD TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL138673_7529"}, {"internal_id": 49759332, "Award ID": "R01HL138656", "Award Amount": 2894693.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-28", "CFDA Number": "93.838", "Description": "ENGINEERING IPSC-RBCS FOR TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": 298115.98, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL138656_7529"}, {"internal_id": 49759330, "Award ID": "R01HL138639", "Award Amount": 1877936.02, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-17", "CFDA Number": "93.837", "Description": "HIV-ASSOCIATED GUT MICROBIOME AFFECTS LUNG IMMUNITY AND PNEUMOCOCCAL IMMUNE RESPONSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL138639_7529"}, {"internal_id": 49759329, "Award ID": "R01HL138633", "Award Amount": 3223883.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-18", "CFDA Number": "93.837", "Description": "TRANSLATING AN EFFICACIOUS ILLNESS MANAGEMENT INTERVENTION FOR AFRICAN AMERICAN YOUTH WITH POORLY CONTROLLED ASTHMA TO REAL WORLD SETTINGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "57f1d8a4-43a0-9952-a047-67afb28d0b55-C", "generated_internal_id": "ASST_NON_R01HL138633_7529"}, {"internal_id": 49759328, "Award ID": "R01HL138630", "Award Amount": 2291472.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-17", "CFDA Number": "93.837", "Description": "DYSBIOSIS IMPACT ON LUNG DISEASE IN HIV (DIMPL) STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL138630_7529"}, {"internal_id": 61612023, "Award ID": "R01HL138628", "Award Amount": 3566122.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-25", "CFDA Number": "93.837", "Description": "PRECISION MEDICINE IN SARCOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL138628_7529"}, {"internal_id": 49759320, "Award ID": "R01HL138540", "Award Amount": 2453119.02, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-04", "CFDA Number": "93.837", "Description": "ENGINEERED TRACHEAL REPLACEMENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL138540_7529"}, {"internal_id": 49759318, "Award ID": "R01HL138538", "Award Amount": 2209735.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-29", "CFDA Number": "93.837", "Description": "NOVEL PEPTIDE/SIRNA NANOPARTICLES FOR TREATMENT OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL138538_7529"}, {"internal_id": 49759315, "Award ID": "R01HL138510", "Award Amount": 2314836.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-09", "CFDA Number": "93.837", "Description": "3'UTR SHORTENING IN PULMONARY VASCULAR DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_R01HL138510_7529"}, {"internal_id": 49759314, "Award ID": "R01HL138508", "Award Amount": 1170000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-12", "CFDA Number": "93.837", "Description": "REGULATION OF LUNG TRM MAINTENANCE AND THE DECLINE OF PULMONARY CELLULAR IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL138508_7529"}, {"internal_id": 67579287, "Award ID": "R01HL138497", "Award Amount": 1819636.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-23", "CFDA Number": "93.837", "Description": "DAMP SIGNALING MEDIATES HIMF-INDUCED PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL138497_7529"}, {"internal_id": 49759310, "Award ID": "R01HL138481", "Award Amount": 1843109.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-29", "CFDA Number": "93.837", "Description": "TARGETING PROSTAGLANDIN BIOSYNTHESIS AND ACTION IN LYMPHANGIOLEIOMYOMATOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R01HL138481_7529"}, {"internal_id": 49759308, "Award ID": "R01HL138473", "Award Amount": 2936394.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-12", "CFDA Number": "93.837", "Description": "ENDOTHELIAL INJURY, BMPR2 DYSFUNCTION AND MACROPHAGE ACTIVATION CAUSE ENDMT AND PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL138473_7529"}, {"internal_id": 65281428, "Award ID": "R01HL138468", "Award Amount": 2363349.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-25", "CFDA Number": "93.837", "Description": "A NOVEL MOLECULAR DETERMINANT OF THE CARDIAC BETA1-ADRENERGIC RECEPTOR RESPONSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL138468_7529"}, {"internal_id": 77499836, "Award ID": "R01HL138465", "Award Amount": 440999.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-04", "CFDA Number": "93.837", "Description": "TARGETING A NOVEL AGGF1 SIGNALING PATHWAY FOR THERAPY OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL138465_7529"}, {"internal_id": 49759304, "Award ID": "R01HL138437", "Award Amount": 2441867.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-09", "CFDA Number": "93.837", "Description": "MOLECULAR DRIVERS OF VASCULAR STIFFNESS AND METABOLIC DYSFUNCTION IN HIV-INDUCED PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL138437_7529"}, {"internal_id": 49759302, "Award ID": "R01HL138424", "Award Amount": 1184684.22, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "AIRWAY EPITHELIAL REPROGRAMMING IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL138424_7529"}, {"internal_id": 62420648, "Award ID": "R01HL138417", "Award Amount": 2281242.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-16", "CFDA Number": "93.837", "Description": "BM ALTERATIONS IN EXACERBATION OF PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL138417_7529"}, {"internal_id": 66996837, "Award ID": "R01HL138410", "Award Amount": 2015505.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-29", "CFDA Number": "93.837", "Description": "ENAC-? MEDIATES LUNG FLUID CLEARANCE AND CAPILLARY BARRIER FUNCTION IN PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_R01HL138410_7529"}, {"internal_id": 49759300, "Award ID": "R01HL138402", "Award Amount": 2451788.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-09", "CFDA Number": "93.837", "Description": "UNDERSTANDING CPAP EFFECTS IN THE DEVELOPING AIRWAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL138402_7529"}, {"internal_id": 49759299, "Award ID": "R01HL138396", "Award Amount": 1446898.66, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-03", "CFDA Number": "93.837", "Description": "TLR4-MEDIATED EPIGENETIC AND SENESCENCE MECHANISMS IN EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL138396_7529"}, {"internal_id": 49759296, "Award ID": "R01HL138251", "Award Amount": 1648104.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-04", "CFDA Number": "93.837", "Description": "VIRUS-INSPIRED NANOPARTICLES FOR MUCUS PENETRATING GENE DELIVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "395e4a2c-bac8-c9f0-4271-75643a4de192-C", "generated_internal_id": "ASST_NON_R01HL138251_7529"}, {"internal_id": 65613999, "Award ID": "R01HL138181", "Award Amount": 1606103.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-17", "CFDA Number": "93.837", "Description": "EPIGENETIC AND FETAL ORIGINS OF HYPOXIA-INDUCED PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL138181_7529"}, {"internal_id": 66995259, "Award ID": "R01HL138013", "Award Amount": 946882.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-26", "CFDA Number": "93.838", "Description": "INHIBITION OF STEM CELL FACTOR IN ALLERGIC ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL138013_7529"}, {"internal_id": 67579943, "Award ID": "R01HL137995", "Award Amount": 3357327.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-03", "CFDA Number": "93.310", "Description": "BIOMARKER OF LUNG DISEASE IN AFRICAN AMERICANS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL137995_7529"}, {"internal_id": 49759275, "Award ID": "R01HL137927", "Award Amount": 3466471.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "IDENTIFYING FUNCTIONAL VARIANTS IN COPD GWAS LOCI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL137927_7529"}, {"internal_id": 49759271, "Award ID": "R01HL137915", "Award Amount": 2050946.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "RECONSIDERING THE IL-1 AXIS IN SEPSIS-ASSOCIATED ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL137915_7529"}, {"internal_id": 49759268, "Award ID": "R01HL137842", "Award Amount": 734085.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-30", "CFDA Number": "93.837", "Description": "AIRWAY EPITHELIAL CELL FARNESOID X RECEPTOR IN COPD PATHOPHYSIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL137842_7529"}, {"internal_id": 49759265, "Award ID": "R01HL137816", "Award Amount": 1543361.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-16", "CFDA Number": "93.837", "Description": "STRATEGIES TO ENHANCE PNEUMONIA CARE VIA INTERMEDIATE INTENSIVE CARE (STEP IN)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL137816_7529"}, {"internal_id": 65579530, "Award ID": "R01HL137813", "Award Amount": 1632043.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-12", "CFDA Number": "93.837", "Description": "DEVELOPMENT AND FUNCTION OF INFLAMMATORY INNATE LYMPHOID CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18e10ac5-0c9e-d0fa-8dbc-a56771e0703d-C", "generated_internal_id": "ASST_NON_R01HL137813_7529"}, {"internal_id": 49759262, "Award ID": "R01HL137807", "Award Amount": 1477556.68, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-17", "CFDA Number": "93.837", "Description": "MECHANISMS OF INFLAMMATORY ACTIVATION OF VAGAL C-FIBERS IN THE RESPIRATORY TRACT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL137807_7529"}, {"internal_id": 49759253, "Award ID": "R01HL137738", "Award Amount": 1496522.51, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-19", "CFDA Number": "93.837", "Description": "MECHANISM OF MITOCHONDRIAL DYSFUNCTION IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL137738_7529"}, {"internal_id": 66199848, "Award ID": "R01HL137709", "Award Amount": 1621252.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-07", "CFDA Number": "93.837", "Description": "EPIGENETIC REGULATION OF CHEMOKINES IN LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL137709_7529"}, {"internal_id": 49759250, "Award ID": "R01HL137703", "Award Amount": 1981250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-31", "CFDA Number": "93.837", "Description": "COMBINATION OF PPI AND PIRFENIDONE TO ENHANCE ANTIFIBROTIC EFFICACY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c0534dd6-007b-cfc7-2a77-9b3602a48251-C", "generated_internal_id": "ASST_NON_R01HL137703_7529"}, {"internal_id": 68172025, "Award ID": "R01HL137680", "Award Amount": 2585035.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-27", "CFDA Number": "93.837", "Description": "CHILD ASTHMA EXACERBATION: ROLE OF CAREGIVER RISK BELIEFS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL137680_7529"}, {"internal_id": 66994705, "Award ID": "R01HL137389", "Award Amount": 3031542.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-29", "CFDA Number": "93.837", "Description": "AN INTEGRATED APPROACH TO PREDICT AND IMPROVE THE OUTCOMES OF LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL137389_7529"}, {"internal_id": 49759235, "Award ID": "R01HL137366", "Award Amount": 2668732.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-22", "CFDA Number": "93.837", "Description": "MECHANOTRANSDUCTION AND YAP/TAZ SIGNALING IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL137366_7529"}, {"internal_id": 49759229, "Award ID": "R01HL137268", "Award Amount": 2129422.29, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-11", "CFDA Number": "93.837", "Description": "S-GLUTATHIONYLATION CHEMISTRY, GLYCOLYSIS AND OBESE ALLERGIC ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL137268_7529"}, {"internal_id": 49759224, "Award ID": "R01HL137234", "Award Amount": 3240595.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-01", "CFDA Number": "93.837", "Description": "OBSTRUCTIVE SLEEP APNEA AND SUBCLINICAL LUNG INJURY IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL137234_7529"}, {"internal_id": 49759221, "Award ID": "R01HL137228", "Award Amount": 2164680.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-09", "CFDA Number": "93.837", "Description": "DECODING THE ENIGMA OF CARDIAC AMPLIFICATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R01HL137228_7529"}, {"internal_id": 49759220, "Award ID": "R01HL137224", "Award Amount": 3356142.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-08", "CFDA Number": "93.837", "Description": "REGULATION OF THE MACROPHAGE INFLAMMATORY PHENOTYPE IN ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL137224_7529"}, {"internal_id": 49759213, "Award ID": "R01HL137203", "Award Amount": 1946096.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-22", "CFDA Number": "93.837", "Description": "EPIGENOMIC DYSFUNCTION AT 16Q24.1 VASCULAR DEFECTS AND PERINATAL CONSEQUENCES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL137203_7529"}, {"internal_id": 49759210, "Award ID": "R01HL137192", "Award Amount": 3522867.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-07", "CFDA Number": "93.837", "Description": "ENVIRONMENTAL RISK FACTORS FOR PEDIATRIC SLEEP DISORDERED BREATHING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL137192_7529"}, {"internal_id": 49759209, "Award ID": "R01HL137169", "Award Amount": 2078700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-06", "CFDA Number": "93.837", "Description": "MECHANISMS OF ENDOTHELIAL REGENERATION AND RESOLUTION OF LUNG VASCULAR INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL137169_7529"}, {"internal_id": 49759204, "Award ID": "R01HL137094", "Award Amount": 2966818.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-16", "CFDA Number": "93.837", "Description": "ROLE OF KCNQ2 CHANNELS IN CONTROL OF BREATHING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7d4a874-2ab3-85f8-4c06-002c8728886d-C", "generated_internal_id": "ASST_NON_R01HL137094_7529"}, {"internal_id": 49759202, "Award ID": "R01HL137090", "Award Amount": 2537338.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-10", "CFDA Number": "93.837", "Description": "ROLE OF ALTERATIONS IN THE ATII CELL LIPIDOME IN INFLUENZA PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL137090_7529"}, {"internal_id": 49759201, "Award ID": "R01HL137076", "Award Amount": 1885895.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-08", "CFDA Number": "93.837", "Description": "DYNACTIN 4 REGULATION OF LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL137076_7529"}, {"internal_id": 49759200, "Award ID": "R01HL137052", "Award Amount": 2276508.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-18", "CFDA Number": "93.837", "Description": "ELECTRONIC CIGARETTE VAPOR INHALATION ADVERSELY AFFECTS LUNG CELLULAR AND PHYSIOLOGIC FUNCTION AND ALTERS SYSTEMIC INFLAMMATORY PATHWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL137052_7529"}, {"internal_id": 66486846, "Award ID": "R01HL137033", "Award Amount": 1549991.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-25", "CFDA Number": "93.837", "Description": "OXIDIZED GLUTATHIONE REGULATION OF EPITHELIAL SODIUM CHANNELS IN NEWBORN LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R01HL137033_7529"}, {"internal_id": 49759198, "Award ID": "R01HL137030", "Award Amount": 2153470.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-08", "CFDA Number": "93.837", "Description": "FUNCTIONAL DIVERSITY OF COMPARTMENTALIZED CALCIUM SIGNALING IN AIRWAY SMOOTH MUSCLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL137030_7529"}, {"internal_id": 49759195, "Award ID": "R01HL137006", "Award Amount": 2496139.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-16", "CFDA Number": "93.837", "Description": "TARGETING ANGIOPOIETIN-2 IN ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL137006_7529"}, {"internal_id": 65579033, "Award ID": "R01HL136965", "Award Amount": 2726854.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-09", "CFDA Number": "93.837", "Description": "MRI METHODS FOR HIGH RESOLUTION IMAGING OF THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL136965_7529"}, {"internal_id": 64141607, "Award ID": "R01HL136963", "Award Amount": 2440443.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-07", "CFDA Number": "93.837", "Description": "REGULATION OF PDE3 IN THE PATHOBIOLOGY OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_R01HL136963_7529"}, {"internal_id": 49759191, "Award ID": "R01HL136961", "Award Amount": 3197752.91, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-20", "CFDA Number": "93.837", "Description": "MULTISCALE BIOCHEMICAL/BIOPHYSICAL INTEGRATION OF PULMONARY MUCUS TRANSPORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL136961_7529"}, {"internal_id": 49759188, "Award ID": "R01HL136946", "Award Amount": 2052647.72, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-10", "CFDA Number": "93.837", "Description": "ROLE OF NRF2 IN ALVEOLAR EPITHELIAL CELL REGENERATION DURING LUNG REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL136946_7529"}, {"internal_id": 65894559, "Award ID": "R01HL136945", "Award Amount": 3537905.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-25", "CFDA Number": "93.837", "Description": "IMPROVING MEDICATION ADHERENCE WITH TELEHEALTHCARE MEDICATION THERAPY MANAGEMENT TO CHANGE HEALTH OUTCOMES IN ADOLESCENTS AND YOUNG ADULTS WITH ASTHMA (MATCH) ADMINISTRATIVE SUPPLEMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "562cc929-4eb1-a7b4-36b7-1525777883f2-C", "generated_internal_id": "ASST_NON_R01HL136945_7529"}, {"internal_id": 49759185, "Award ID": "R01HL136919", "Award Amount": 2090822.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-18", "CFDA Number": "93.837", "Description": "BACTERIAL MUCIN DEGRADATION IN CYSTIC FIBROSIS AIRWAY DISEASE.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL136919_7529"}, {"internal_id": 68567748, "Award ID": "R01HL136917", "Award Amount": 3624067.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-04", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL REDOX PERTURBATIONS IN OBESE ALLERGIC ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL136917_7529"}, {"internal_id": 49759182, "Award ID": "R01HL136833", "Award Amount": 1570000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-12", "CFDA Number": "93.837", "Description": "PROTEASOME DEGRADATION OF P53 DRIVES HPS LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL136833_7529"}, {"internal_id": 49759180, "Award ID": "R01HL136813", "Award Amount": 5290597.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-10", "CFDA Number": "93.837", "Description": "AIRWAY ALKALINIZATION AND REPURPOSING TROMETHAMINE AS A THERAPEUTIC APPROACH IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL136813_7529"}, {"internal_id": 49759175, "Award ID": "R01HL136753", "Award Amount": 3620591.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-01", "CFDA Number": "93.837", "Description": "TRANSLATING AN EVIDENCE-BASED URBAN ASTHMA PROGRAM FOR RURAL ADOLESCENTS:  TESTING EFFECTIVENESS & COST-EFFECTIVENESS AND UNDERSTANDING FACTORS ASSOCIATED WITH IMPLEMENTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL136753_7529"}, {"internal_id": 49759173, "Award ID": "R01HL136748", "Award Amount": 2487603.46, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-06", "CFDA Number": "93.837", "Description": "ROLE OF BONE MARROW CELLS IN PATHOGENESIS AND THERAPY OF HERITABLE PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL136748_7529"}, {"internal_id": 62550815, "Award ID": "R01HL136734", "Award Amount": 1580819.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-20", "CFDA Number": "93.837", "Description": "MECHANISMS OF PULMONARY SURFACTANT FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL136734_7529"}, {"internal_id": 64141819, "Award ID": "R01HL136725", "Award Amount": 1649584.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-07", "CFDA Number": "93.837", "Description": "ORIGINS AND FUNCTIONAL ROLES OF MIWI2-POSITIVE MULTICILIATED CELLS DURING INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL136725_7529"}, {"internal_id": 49759169, "Award ID": "R01HL136722", "Award Amount": 2110282.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-11", "CFDA Number": "93.837", "Description": "ROLE OF EMC3/TMEM111 IN ALVEOLAR EPITHELIAL CELL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL136722_7529"}, {"internal_id": 49759168, "Award ID": "R01HL136721", "Award Amount": 1560000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-06", "CFDA Number": "93.837", "Description": "GENOME EDITED IPS CELL-DERIVED MACROPHAGES AS A NOVEL LUNG CELL THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL136721_7529"}, {"internal_id": 49759167, "Award ID": "R01HL136719", "Award Amount": 2959077.44, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-20", "CFDA Number": "93.837", "Description": "BENEFITS OF ICU ADMISSION FOR PATIENTS WITH ACUTE RESPIRATORY FAILURE OR SEPSIS: A MIXED-METHODS STUDY ACROSS 26 HOSPITALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL136719_7529"}, {"internal_id": 49759165, "Award ID": "R01HL136707", "Award Amount": 2592257.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-20", "CFDA Number": "93.837", "Description": "NEUTROPHIL EXTRACELLULAR TRAPS IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_R01HL136707_7529"}, {"internal_id": 49759164, "Award ID": "R01HL136706", "Award Amount": 1618112.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-30", "CFDA Number": "93.837", "Description": "MECHANISMS OF DIFFERENTIAL SUSCEPTIBILITY OF HUMAN SP-B GENETIC VARIANTS TO PNEUMONIA AND LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e5b43944-be6e-5bdd-7962-fa368b8b5699-C", "generated_internal_id": "ASST_NON_R01HL136706_7529"}, {"internal_id": 49759160, "Award ID": "R01HL136682", "Award Amount": 10736204.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-29", "CFDA Number": "93.837", "Description": "THE CAPTURE STUDY:  VALIDATING A UNIQUE COPD SCREENING TOOL IN PRIMARY CARE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL136682_7529"}, {"internal_id": 65579005, "Award ID": "R01HL136681", "Award Amount": 4047238.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-10", "CFDA Number": "93.837", "Description": "A PROSPECTIVE STUDY OF T CELL IMMUNE-PHENOTYPE AND DISEASE OUTCOME IN PULMONARY SARCOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL136681_7529"}, {"internal_id": 49759157, "Award ID": "R01HL136664", "Award Amount": 3586634.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-10", "CFDA Number": "93.837", "Description": "TARGETING TH17 CELL METABOLISM IN STEROID RESISTANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL136664_7529"}, {"internal_id": 49759152, "Award ID": "R01HL136647", "Award Amount": 1335283.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-03", "CFDA Number": "93.837", "Description": "DYNAMICS OF AIRWAY MICROBIOTA AT PULMONARY EXACERBATION IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL136647_7529"}, {"internal_id": 49759151, "Award ID": "R01HL136643", "Award Amount": 3232720.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-04", "CFDA Number": "93.837", "Description": "RESPIRATORY EFFECTS OF OBESITY IN CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_R01HL136643_7529"}, {"internal_id": 49759145, "Award ID": "R01HL136617", "Award Amount": 1636719.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-24", "CFDA Number": "93.837", "Description": "NEW INHALATION THERAPY FOR COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL136617_7529"}, {"internal_id": 66995412, "Award ID": "R01HL136597", "Award Amount": 1520000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-27", "CFDA Number": "93.837", "Description": "AMP KINASE REGULATION IN PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL136597_7529"}, {"internal_id": 65894410, "Award ID": "R01HL136499", "Award Amount": 1495558.81, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-28", "CFDA Number": "93.837", "Description": "THE MICROBIOTA OF THE PEDIATRIC CF AIRWAY: WHAT ROLE DOES IT PLAY?", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_R01HL136499_7529"}, {"internal_id": 66487071, "Award ID": "R01HL136494", "Award Amount": 1302051.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-21", "CFDA Number": "93.838", "Description": "MATRICELLULAR SIGNALING IN ENGINEERED TRACHEAL TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL136494_7529"}, {"internal_id": 61611478, "Award ID": "R01HL136449", "Award Amount": 2158585.72, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-01", "CFDA Number": "93.837", "Description": "LUNG MSC REGULATE ANGIOGENESIS AND REPAIR DURING FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL136449_7529"}, {"internal_id": 49759116, "Award ID": "R01HL136414", "Award Amount": 3384038.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-12", "CFDA Number": "93.837", "Description": "RIBOSOMAL PERTURBATION AS A MECHANISM TO PREVENT MISFOLDING OF CFTR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL136414_7529"}, {"internal_id": 49759107, "Award ID": "R01HL136377", "Award Amount": 1864145.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-23", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE OF CELL-MEDIATED COLLAGEN TURNOVER IN REGULATING TISSUE FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL136377_7529"}, {"internal_id": 79434112, "Award ID": "R01HL136370", "Award Amount": 2946183.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-26", "CFDA Number": "93.837", "Description": "PATHOGENESIS OF AIRWAY STEM CELL ABNORMALITIES IN OBLITERATIVE BRONCHIOLITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL136370_7529"}, {"internal_id": 49759099, "Award ID": "R01HL136325", "Award Amount": 1790000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-08", "CFDA Number": "93.837", "Description": "SURFACTANT PROTEIN-A REGIONS AS TLR4-IMMUNOMODULATORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "35c9af52-79d6-b585-258b-ae9342223de1-C", "generated_internal_id": "ASST_NON_R01HL136325_7529"}, {"internal_id": 61610536, "Award ID": "R01HL136294", "Award Amount": 1817437.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-19", "CFDA Number": "93.837", "Description": "MOLECULAR REGULATION OF ANTI-INFLAMMATORY CYTOKINE RECEPTOR IN SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL136294_7529"}, {"internal_id": 49759094, "Award ID": "R01HL136253", "Award Amount": 2014842.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-08", "CFDA Number": "93.837", "Description": "OPTIMIZING SMOKING CESSATION TREATMENTS IN SMOKERS LIVING WITH HIV/AIDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL136253_7529"}, {"internal_id": 49759090, "Award ID": "R01HL136211", "Award Amount": 2639375.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.837", "Description": "BIOLOGY OF INNATE IL-22 DURING LUNG FUNGAL INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_R01HL136211_7529"}, {"internal_id": 49759089, "Award ID": "R01HL136209", "Award Amount": 2192184.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-26", "CFDA Number": "93.837", "Description": "OPTIMIZING EP RECEPTOR SUBTYPE TARGETING FOR ASTHMA THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL136209_7529"}, {"internal_id": 49759083, "Award ID": "R01HL136143", "Award Amount": 3297811.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-30", "CFDA Number": "93.837", "Description": "MECHANISMS OF HOST PROTECTION AGAINST PATHOGEN-SECRETED PROTEASES IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL136143_7529"}, {"internal_id": 49759082, "Award ID": "R01HL136141", "Award Amount": 2893573.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-05", "CFDA Number": "93.837", "Description": "MICROFLUIDIC TISSUE ENGINEERING OF SMALL AIRWAY INJURIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7c481d7-071a-ead9-3bda-e4e7d1e903a7-C", "generated_internal_id": "ASST_NON_R01HL136141_7529"}, {"internal_id": 49759080, "Award ID": "R01HL136137", "Award Amount": 4103260.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-05", "CFDA Number": "93.837", "Description": "T CELL EPITOPES IN SARCOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL136137_7529"}, {"internal_id": 49759068, "Award ID": "R01HL135872", "Award Amount": 2775986.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-09", "CFDA Number": "93.837", "Description": "ACTIVATION, PHENOTYPE AND FUNCTION OF CD4 T CELLS IN SCHISTOSOMA-PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL135872_7529"}, {"internal_id": 49759063, "Award ID": "R01HL135849", "Award Amount": 2185214.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-30", "CFDA Number": "93.837", "Description": "TARGETING CELL-FREE HEMOGLOBIN IN SEPSIS TO REDUCE LUNG MICROVASCULAR PERMEABILITY: MECHANISTIC AND TRANSLATIONAL STUDIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL135849_7529"}, {"internal_id": 49759061, "Award ID": "R01HL135846", "Award Amount": 2226863.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-15", "CFDA Number": "93.837", "Description": "CLOCK GENE CONTROL OF VIRAL INFECTION AND ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL135846_7529"}, {"internal_id": 49759058, "Award ID": "R01HL135670", "Award Amount": 1653849.41, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-16", "CFDA Number": "93.837", "Description": "ERP29: PROMOTING ION CHANNEL BIOGENESIS FROM THE ER LUMEN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL135670_7529"}, {"internal_id": 49759054, "Award ID": "R01HL135642", "Award Amount": 2909345.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-26", "CFDA Number": "93.837", "Description": "THE EFFECT OF INHALED NICOTINE ON PULMONARY SURFACES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL135642_7529"}, {"internal_id": 49759050, "Award ID": "R01HL135613", "Award Amount": 2682571.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-06", "CFDA Number": "93.837", "Description": "INFLAMMATORY AND DYSREGULATED REPAIR RESPONSES TO INHALED NICOTINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL135613_7529"}, {"internal_id": 49759049, "Award ID": "R01HL135610", "Award Amount": 1806669.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.837", "Description": "AEROSOLIZED NICOTINE MODULATION OF HOST INFLAMMATION AND MICROBIOTA DYSBIOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R01HL135610_7529"}, {"internal_id": 49759037, "Award ID": "R01HL135496", "Award Amount": 2712597.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "SPATIAL IDENTIFICATION OF LUNG ABNORMALITIES IN CF VIA A PROBABILISTIC LIBRARY OF MRI MEASURES OF LUNG WATER DENSITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL135496_7529"}, {"internal_id": 49759032, "Award ID": "R01HL135482", "Award Amount": 2873588.22, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-07", "CFDA Number": "93.837", "Description": "AMBULATORY ASSIST LUNG FOR CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL135482_7529"}, {"internal_id": 49759020, "Award ID": "R01HL135239", "Award Amount": 1590000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-05", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL QUALITY CONTROL AND ALVEOLAR DAMAGE RESOLUTION AFTER ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL135239_7529"}, {"internal_id": 49759019, "Award ID": "R01HL135235", "Award Amount": 2715534.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-05", "CFDA Number": "93.837", "Description": "IL-1 RECEPTOR BLOCKADE AS A NOVEL TREATMENT FOR EXACERBATION OF ALLERGIC AIRWAY RESPONSES IN HUMANS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL135235_7529"}, {"internal_id": 49759011, "Award ID": "R01HL135163", "Award Amount": 2656564.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-28", "CFDA Number": "93.837", "Description": "EPITHELIAL PROGENITOR CELLS FOR LUNG REPAIR AND REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL135163_7529"}, {"internal_id": 49759008, "Award ID": "R01HL135156", "Award Amount": 4064163.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-27", "CFDA Number": "93.307", "Description": "TRANSCRIPTOMIC AND PHARMACOGENETIC ASTHMA ENDOTYPES IN MINORITY CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL135156_7529"}, {"internal_id": 49759007, "Award ID": "R01HL135152", "Award Amount": 1496000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-21", "CFDA Number": "93.837", "Description": "THE ROLE OF LNCRNAS IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36e3dd88-13d6-cef1-8b61-a96bca2cc984-C", "generated_internal_id": "ASST_NON_R01HL135152_7529"}, {"internal_id": 49759005, "Award ID": "R01HL135144", "Award Amount": 2228587.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-21", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL DETERMINANTS OF COGNITIVE OUTCOMES IN ARDS AND SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL135144_7529"}, {"internal_id": 49759003, "Award ID": "R01HL135142", "Award Amount": 3096514.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-23", "CFDA Number": "93.837", "Description": "GENETIC AND GENOMIC CHARACTERIZATION OF THE OCCURRENCE AND PROGRESSION OF INTERSTITIAL LUNG ABNORMALITIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL135142_7529"}, {"internal_id": 49759001, "Award ID": "R01HL135122", "Award Amount": 1950859.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-07", "CFDA Number": "93.837", "Description": "PULMONARY EPITHELIAL DYNAMICS AND INNATE HOST DEFENSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R01HL135122_7529"}, {"internal_id": 49758998, "Award ID": "R01HL135114", "Award Amount": 2869704.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-08", "CFDA Number": "93.837", "Description": "CLINICAL AND MECHANISTIC ROLE OF HDGF IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL135114_7529"}, {"internal_id": 49758997, "Award ID": "R01HL135112", "Award Amount": 1979632.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-09", "CFDA Number": "93.837", "Description": "HYPEROXIC MODULATION OF THIOREDOXIN SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "35c9af52-79d6-b585-258b-ae9342223de1-C", "generated_internal_id": "ASST_NON_R01HL135112_7529"}, {"internal_id": 49758986, "Award ID": "R01HL135065", "Award Amount": 1451684.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-27", "CFDA Number": "93.837", "Description": "HETEROGENEOUS LUNG SURFACTANT MORPHOLOGIES: EFFECT ON ALVEOLAR DYNAMICS, AND ROLE IN PROMOTING ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2e3fd571-0484-5e6b-3e26-4381689012c6-C", "generated_internal_id": "ASST_NON_R01HL135065_7529"}, {"internal_id": 67314852, "Award ID": "R01HL135062", "Award Amount": 1914415.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-09", "CFDA Number": "93.837", "Description": "MECHANISMS OF TELOMERE-MEDIATED LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL135062_7529"}, {"internal_id": 49758978, "Award ID": "R01HL135022", "Award Amount": 1977135.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-07", "CFDA Number": "93.837", "Description": "INSULIN RECEPTOR SUBSTRATE SIGNALING IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL135022_7529"}, {"internal_id": 49758970, "Award ID": "R01HL135001", "Award Amount": 2276942.17, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-10", "CFDA Number": "93.837", "Description": "FUNCTIONAL ROLES OF HUMAN PULMONARY DC'S IN THE LUNG DRAINING LYMPH NODES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7eb6683a-d796-f7f5-68c0-ca8f32275b30-C", "generated_internal_id": "ASST_NON_R01HL135001_7529"}, {"internal_id": 49758958, "Award ID": "R01HL134934", "Award Amount": 2277968.74, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-24", "CFDA Number": "93.837", "Description": "PFKFB3 IN VASCULAR REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_R01HL134934_7529"}, {"internal_id": 49758954, "Award ID": "R01HL134905", "Award Amount": 5540633.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-15", "CFDA Number": "93.837", "Description": "ANASTROZOLE IN PULMONARY ARTERIAL HYPERTENSION (AIPH2) - CCC (LEAD)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL134905_7529"}, {"internal_id": 49758953, "Award ID": "R01HL134904", "Award Amount": 990022.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-15", "CFDA Number": "93.837", "Description": "ANASTROZOLE IN PULMONARY ARTERIAL HYPERTENSION (AIPH2) - DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL134904_7529"}, {"internal_id": 49758948, "Award ID": "R01HL134893", "Award Amount": 2861915.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-16", "CFDA Number": "93.837", "Description": "THE ASSOCIATION OF METABOLIC DISEASE AND PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL134893_7529"}, {"internal_id": 49758944, "Award ID": "R01HL134870", "Award Amount": 1842121.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-08", "CFDA Number": "93.837", "Description": "ROLE OF TYPE III INTERFERONS IN STAPHYLOCOCCUS AUREUS RESPIRATORY TRACT INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c9d7554-cb59-0dff-6547-d9102319b537-C", "generated_internal_id": "ASST_NON_R01HL134870_7529"}, {"internal_id": 49758940, "Award ID": "R01HL134851", "Award Amount": 3394455.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-26", "CFDA Number": "93.837", "Description": "FRAILTY AND PATIENT CENTERED OUTCOMES IN CANDIDATES FOR LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL134851_7529"}, {"internal_id": 49758937, "Award ID": "R01HL134846", "Award Amount": 3709184.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-24", "CFDA Number": "93.837", "Description": "PURINERGIC MODULATION OF THE AUTOIMMUNE VASCULAR PHENOTYPE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": 390000.0, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL134846_7529"}, {"internal_id": 49758930, "Award ID": "R01HL134828", "Award Amount": 2444264.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-02", "CFDA Number": "93.837", "Description": "NOVEL PARACRINE MECHANISMS FOR CELL-BASED THERAPY OF INJURED LUNGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f2defd6b-38d0-6c66-8586-39b99ba99117-C", "generated_internal_id": "ASST_NON_R01HL134828_7529"}, {"internal_id": 49758928, "Award ID": "R01HL134822", "Award Amount": 3126183.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-25", "CFDA Number": "93.837", "Description": "DETERMINANTS OF ALTERED BRAIN STRUCTURE AND FUNCTION IN SMOKERS WITH COPD-RELATED LUNG PATHOPHYSIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL134822_7529"}, {"internal_id": 49758922, "Award ID": "R01HL134802", "Award Amount": 3734182.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-01", "CFDA Number": "93.837", "Description": "ESTROGEN SIGNALING AND ENERGY METABOLISM IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL134802_7529"}, {"internal_id": 49758921, "Award ID": "R01HL134801", "Award Amount": 3003863.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-22", "CFDA Number": "93.837", "Description": "WT1 REGULATION OF PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL134801_7529"}, {"internal_id": 49758920, "Award ID": "R01HL134800", "Award Amount": 2938776.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-22", "CFDA Number": "93.837", "Description": "WNT-BETA-CATENIN CROSS INTERACTIONS IN ALVEOLAR MACROPHAGES AND EPITHELIAL CELLS IN PERSISTENCE OF SSC-ILD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL134800_7529"}, {"internal_id": 49758914, "Award ID": "R01HL134776", "Award Amount": 3956023.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-10", "CFDA Number": "93.837", "Description": "THE WNT7A/ROR2 AXIS IN THE PATHOGENESIS OF PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL134776_7529"}, {"internal_id": 49758910, "Award ID": "R01HL134723", "Award Amount": 1770000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-19", "CFDA Number": "93.837", "Description": "ATYPICAL INTEGRIN ALPHAV BETA8", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL134723_7529"}, {"internal_id": 49758902, "Award ID": "R01HL134673", "Award Amount": 2756565.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-01", "CFDA Number": "93.837", "Description": "PHORA: A CLINICAL DECISION SUPPORT TOOL FOR PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL134673_7529"}, {"internal_id": 49758900, "Award ID": "R01HL134666", "Award Amount": 3254727.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "IDENTIFYING AND PREVENTING VENTILATOR INDUCED DIAPHRAGM WEAKNESS IN CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c10cf51-1fb6-c52e-c48f-8fcef0f37eff-C", "generated_internal_id": "ASST_NON_R01HL134666_7529"}, {"internal_id": 49758887, "Award ID": "R01HL134375", "Award Amount": 2876004.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-12", "CFDA Number": "93.837", "Description": "MACROPHAGE MODULATION OF LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL134375_7529"}, {"internal_id": 49758886, "Award ID": "R01HL134373", "Award Amount": 2776328.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.837", "Description": "STRUCTURAL PLASTICITY IN COMPENSATORY LUNG GROWTH AND REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_R01HL134373_7529"}, {"internal_id": 49758884, "Award ID": "R01HL134369", "Award Amount": 1549941.3, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-24", "CFDA Number": "93.837", "Description": "TLR2 AND RHINOVIRUS-INDUCED ASTHMA EXACERBATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL134369_7529"}, {"internal_id": 49758870, "Award ID": "R01HL134183", "Award Amount": 5096781.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-04", "CFDA Number": "93.837", "Description": "STRUCTURAL MECHANISM OF INTEGRIN-MEDIATED TGF-B ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL134183_7529"}, {"internal_id": 49758862, "Award ID": "R01HL134015", "Award Amount": 3151287.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-12", "CFDA Number": "93.837", "Description": "APPROACHES TO GENETIC HETEROGENEITY OF OBSTRUCTIVE SLEEP APNEA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL134015_7529"}, {"internal_id": 49758860, "Award ID": "R01HL133951", "Award Amount": 4307292.45, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-27", "CFDA Number": "93.837", "Description": "NOVEL MECHANISMS OF OBLITERATIVE PULMONARY VASCULAR REMODELING AND SEVERE PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_R01HL133951_7529"}, {"internal_id": 49758857, "Award ID": "R01HL133920", "Award Amount": 3870942.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-15", "CFDA Number": "93.837", "Description": "OBESE ALLERGIC ASTHMA AND THE IMPACT OF WEIGHT LOSS ON AIRWAY EPITHELIAL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL133920_7529"}, {"internal_id": 49758856, "Award ID": "R01HL133900", "Award Amount": 1523178.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-08", "CFDA Number": "93.837", "Description": "MICRORNA SHUTTLING DURING ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_R01HL133900_7529"}, {"internal_id": 49758854, "Award ID": "R01HL133889", "Award Amount": 2333895.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-24", "CFDA Number": "93.837", "Description": "ITK-LUNG: A SOFTWARE FRAMEWORK FOR LUNG IMAGE PROCESSING AND ANALYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL133889_7529"}, {"internal_id": 49758841, "Award ID": "R01HL133801", "Award Amount": 2107926.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "NOVEL ROLE OF RIPK3-DEPENDENT NECROPTOSIS PATHWAY IN LUNG AND KIDNEY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL133801_7529"}, {"internal_id": 49758838, "Award ID": "R01HL133789", "Award Amount": 4175785.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-07", "CFDA Number": "93.837", "Description": "PROMOTING ASTHMA GUIDELINES AND MANAGEMENT THROUGH TECHNOLOGY-BASED INTERVENTION AND CARE COORDINATION (PRAGMATIC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R01HL133789_7529"}, {"internal_id": 49758835, "Award ID": "R01HL133751", "Award Amount": 2006636.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-10", "CFDA Number": "93.310", "Description": "ROLE OF PERICYTES IN SCLERODERMA SKIN AND LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL133751_7529"}, {"internal_id": 49758832, "Award ID": "R01HL133721", "Award Amount": 2243499.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-09", "CFDA Number": "93.837", "Description": "TRPV4-PI3K AXIS MEDIATES PULMONARY AND CARDIAC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL133721_7529"}, {"internal_id": 49758822, "Award ID": "R01HL133664", "Award Amount": 3695005.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-18", "CFDA Number": "93.837", "Description": "PHENOTYPING ASTHMA FOR BRONCHIAL THERMOPLASTY: AIRWAY SMOOTH MUSCLE STRUCTURE AND FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL133664_7529"}, {"internal_id": 49758810, "Award ID": "R01HL133554", "Award Amount": 2226886.46, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-29", "CFDA Number": "93.837", "Description": "INTERACTIONS OF SERCA2A AND BMPRII IN VASCULAR DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL133554_7529"}, {"internal_id": 49758808, "Award ID": "R01HL133506", "Award Amount": 3104204.56, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-25", "CFDA Number": "93.837", "Description": "MULTI-COMPONENT TECHNOLOGY INTERVENTION FOR AFRICAN AMERICAN EMERGING ADULTS WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "57f1d8a4-43a0-9952-a047-67afb28d0b55-C", "generated_internal_id": "ASST_NON_R01HL133506_7529"}, {"internal_id": 49758800, "Award ID": "R01HL133433", "Award Amount": 3223906.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-27", "CFDA Number": "93.837", "Description": "CEBPD-MEDIATED MECHANISMS OF GLUCOCORTICOID INSENSITIVITY IN SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL133433_7529"}, {"internal_id": 49758799, "Award ID": "R01HL133413", "Award Amount": 2047475.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-30", "CFDA Number": "93.837", "Description": "TARGETING DIVERGENT ROLES OF CASPASE 3 TO PROMOTE ENDOTHELIAL BARRIER INTEGRITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL133413_7529"}, {"internal_id": 49758796, "Award ID": "R01HL133404", "Award Amount": 1525403.54, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-18", "CFDA Number": "93.837", "Description": "MOLECULAR CLOCK REV-ERB? IN COPD AND ITS EXACERBATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL133404_7529"}, {"internal_id": 49758791, "Award ID": "R01HL133336", "Award Amount": 1892312.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-07", "CFDA Number": "93.837", "Description": "INNATE IMMUNITY IN PNEUMONIC SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL133336_7529"}, {"internal_id": 49758786, "Award ID": "R01HL133320", "Award Amount": 2151214.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-15", "CFDA Number": "93.837", "Description": "TARGETING MATRIX STIFFNESS IN LUNG AND LIVER FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL133320_7529"}, {"internal_id": 49758783, "Award ID": "R01HL133293", "Award Amount": 2276331.13, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-29", "CFDA Number": "93.837", "Description": "PANNEXIN-1 SIGNALING IN LUNG ISCHEMIA-REPERFUSION INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL133293_7529"}, {"internal_id": 49758777, "Award ID": "R01HL133240", "Award Amount": 2728453.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-14", "CFDA Number": "93.837", "Description": "ANTI-INFLAMMATORY THERAPY TO AUGMENT CFTR RESCUE IN CF PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1a1108fb-0099-a708-6def-aa6d101c8ba8-C", "generated_internal_id": "ASST_NON_R01HL133240_7529"}, {"internal_id": 49758769, "Award ID": "R01HL133190", "Award Amount": 2968203.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-15", "CFDA Number": "93.837", "Description": "ABERRANT IMMUNE ACTIVATION IN THE TUBERCULOSIS GRANULOMA: A PIVOTAL ROLE IN NECROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL133190_7529"}, {"internal_id": 49758768, "Award ID": "R01HL133184", "Award Amount": 2139630.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-14", "CFDA Number": "93.837", "Description": "ROLE OF F-BOX PROTEINS IN LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL133184_7529"}, {"internal_id": 49758761, "Award ID": "R01HL133163", "Award Amount": 1903070.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-10", "CFDA Number": "93.837", "Description": "PRESSURE IN LUNG DEVELOPMENT AND CONGENITAL DIAPHRAGMATIC HERNIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "88f4772d-e0bd-42e6-ed20-c3144d3bace8-C", "generated_internal_id": "ASST_NON_R01HL133163_7529"}, {"internal_id": 49758760, "Award ID": "R01HL133162", "Award Amount": 2857589.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-01", "CFDA Number": "93.837", "Description": "RABBIT MODEL FOR CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL133162_7529"}, {"internal_id": 49758759, "Award ID": "R01HL133153", "Award Amount": 2692844.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-23", "CFDA Number": "93.837", "Description": "TARGETING CELL-SPECIFIC FUNCTIONS OF THE RHO KINASE PATHWAY IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL133153_7529"}, {"internal_id": 49758757, "Award ID": "R01HL133137", "Award Amount": 2864138.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-20", "CFDA Number": "93.837", "Description": "CLINICAL IMPLICATIONS OF BRONCHIECTASIS IN SMOKERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL133137_7529"}, {"internal_id": 49758756, "Award ID": "R01HL133135", "Award Amount": 5460333.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-13", "CFDA Number": "93.837", "Description": "COPD SUSCEPTIBILITY, HETEROGENEITY, AND PROGRESSION:  PROTEOMICS AND GENETICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL133135_7529"}, {"internal_id": 49758750, "Award ID": "R01HL133089", "Award Amount": 3069351.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-24", "CFDA Number": "93.837", "Description": "A HYBRID VIRAL/NONVIRAL VECTOR FOR CFTR DELIVERY TO CF PIG AIRWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL133089_7529"}, {"internal_id": 49758749, "Award ID": "R01HL133085", "Award Amount": 1918361.83, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-01", "CFDA Number": "93.837", "Description": "HMGBG1 AND GENDER DIFFERENCE IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R01HL133085_7529"}, {"internal_id": 49758745, "Award ID": "R01HL133067", "Award Amount": 1565324.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-19", "CFDA Number": "93.837", "Description": "CONTROL OF FIBROSING LUNG DISEASE BY P53-MIR-34A-TARGETED THERAPEUTICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6605b60b-2165-8c36-e954-428aa458f579-C", "generated_internal_id": "ASST_NON_R01HL133067_7529"}, {"internal_id": 49758744, "Award ID": "R01HL133066", "Award Amount": 1513942.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-21", "CFDA Number": "93.837", "Description": "CIRCULATING MICROPARTICLE EFFECTS ON PHENOTYPICALLY DISTINCT PULMONARY ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_R01HL133066_7529"}, {"internal_id": 49758743, "Award ID": "R01HL133059", "Award Amount": 1626375.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-30", "CFDA Number": "93.837", "Description": "GROUP V PHOSPHOLIPASE A2 MEDIATES ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL133059_7529"}, {"internal_id": 49758742, "Award ID": "R01HL133053", "Award Amount": 1280773.77, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-06", "CFDA Number": "93.837", "Description": "THE ROLE OF PPARY IN THE PATHOGENESIS AND THERAPY OF SICKLE CELL DISEASE-PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL133053_7529"}, {"internal_id": 49758739, "Award ID": "R01HL133046", "Award Amount": 2494396.9, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-26", "CFDA Number": "93.837", "Description": "A MIXED METHODS STUDY TO ANALYZE THE USE OF PULMONARY REHABILITATION FOLLOWING HOSPITALIZATION FOR COPD, AND TO IDENTIFY EFFECTIVE STRATEGIES FOR INCREASING RATES OF PARTICIPATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3b77461b-d74c-9784-e800-bb061239d65f-C", "generated_internal_id": "ASST_NON_R01HL133046_7529"}, {"internal_id": 49758738, "Award ID": "R01HL133043", "Award Amount": 2307289.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-25", "CFDA Number": "93.837", "Description": "SMART STETHOSCOPE FOR MONITORING AND DIAGNOSIS OF LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL133043_7529"}, {"internal_id": 49758734, "Award ID": "R01HL133024", "Award Amount": 1066092.52, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-31", "CFDA Number": "93.837", "Description": "MECHANISMS REGULATING ALLOIMMUNIZATION AND TOLERANCE WITH PATHOGEN REDUCTION AND TRANSFUSION OF ALLOGENEIC PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aac0d53c-fc30-bb05-192d-4bb66ca0eae1-C", "generated_internal_id": "ASST_NON_R01HL133024_7529"}, {"internal_id": 49758730, "Award ID": "R01HL133016", "Award Amount": 1674943.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-26", "CFDA Number": "93.838", "Description": "SMOOTH MUSCLE PROGENITORS IN VASCULAR REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL133016_7529"}, {"internal_id": 49758726, "Award ID": "R01HL133006", "Award Amount": 1735567.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-01", "CFDA Number": "93.837", "Description": "IVACAFTOR FOR ACQUIRED CFTR DYSFUNCTION IN CHRONIC RHINOSINUSITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL133006_7529"}, {"internal_id": 49758724, "Award ID": "R01HL132999", "Award Amount": 4608536.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-27", "CFDA Number": "93.837", "Description": "MOLECULAR PATHWAYS CONTROLLING ALVEOLAR EPITHELIAL REMODELING IN DEVELOPMENT AND REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL132999_7529"}, {"internal_id": 49758723, "Award ID": "R01HL132996", "Award Amount": 1958792.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-20", "CFDA Number": "93.837", "Description": "MECHANISM OF RESPIRATORY SYSTEM-ESOPHAGEAL SEPARATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL132996_7529"}, {"internal_id": 49758722, "Award ID": "R01HL132991", "Award Amount": 1773361.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-01", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF PNEC INNERVATION AND NEUROPLASTICITY AFTER EARLY LIFE INSULT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL132991_7529"}, {"internal_id": 49758714, "Award ID": "R01HL132950", "Award Amount": 2012845.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-23", "CFDA Number": "93.837", "Description": "CHECKPOINT FUNCTION OF PTPALPHA IN PATHOLOGICAL FIBROGENESIS IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL132950_7529"}, {"internal_id": 49758712, "Award ID": "R01HL132941", "Award Amount": 2262532.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-26", "CFDA Number": "93.837", "Description": "ROLE OF HEPATIC IKBB-MEDIATED SUSTAINED NFKB ACTIVATION IN NEONATAL LUNG INJURY AND ABNORMAL DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL132941_7529"}, {"internal_id": 61615010, "Award ID": "R01HL132919", "Award Amount": 1427956.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-19", "CFDA Number": "93.837", "Description": "BREAKING A NOVEL FEEDBACK LOOP TO INHIBIT FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "44913900-e35a-479d-fd2b-81775f5f37a7-C", "generated_internal_id": "ASST_NON_R01HL132919_7529"}, {"internal_id": 49758709, "Award ID": "R01HL132918", "Award Amount": 3202979.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-29", "CFDA Number": "93.837", "Description": "ANAPLEROTIC REPROGRAMMING OF ENDOTHELIAL CELLS IN PULMONARY HYPERTENSION.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R01HL132918_7529"}, {"internal_id": 49758702, "Award ID": "R01HL132887", "Award Amount": 3540989.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-01", "CFDA Number": "93.837", "Description": "NUTRITION AND EXERCISE IN CRITICAL ILLNESS (THE NEXIS TRIAL): A RANDOMIZED TRIAL OF COMBINED CYCLE ERGOMETRY AND AMINO ACIDS IN THE ICU", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL132887_7529"}, {"internal_id": 49758701, "Award ID": "R01HL132883", "Award Amount": 1515000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-10", "CFDA Number": "93.837", "Description": "VASCULAR SMOOTH MUSCLE SIGNALING IN INTERMITTENT HYPOXIA-INDUCED PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a5b5888e-f4b5-655c-bd88-d970f969d7c9-C", "generated_internal_id": "ASST_NON_R01HL132883_7529"}, {"internal_id": 49758696, "Award ID": "R01HL132870", "Award Amount": 1204493.85, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-19", "CFDA Number": "93.837", "Description": "P311 IN PULMONARY REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL132870_7529"}, {"internal_id": 49758694, "Award ID": "R01HL132862", "Award Amount": 827783.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-19", "CFDA Number": "93.838", "Description": "HECT-DOMAIN E3 LIGASE AND ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL132862_7529"}, {"internal_id": 49758691, "Award ID": "R01HL132849", "Award Amount": 1482000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-29", "CFDA Number": "93.837", "Description": "TARGETING FOXM1 IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL132849_7529"}, {"internal_id": 49758679, "Award ID": "R01HL132585", "Award Amount": 3260995.72, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-08", "CFDA Number": "93.310", "Description": "MECHANOSENSORS THAT DETECT AND TREAT LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL132585_7529"}, {"internal_id": 49758676, "Award ID": "R01HL132574", "Award Amount": 2515158.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-31", "CFDA Number": "93.837", "Description": "REGULATION OF VASCULAR SMOOTH MUSCLE CELL PHENOTYPE BY A NOVEL ISOFORM OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": 547406.0, "Infrastructure Obligations": null, "recipient_id": "f00078f8-f585-79c7-3349-6773e6685d91-C", "generated_internal_id": "ASST_NON_R01HL132574_7529"}, {"internal_id": 49758675, "Award ID": "R01HL132573", "Award Amount": 1941024.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-20", "CFDA Number": "93.837", "Description": "PROTEOGLYCAN-CHEMOKINE INTERACTIONS IN LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL132573_7529"}, {"internal_id": 49758667, "Award ID": "R01HL132550", "Award Amount": 2882323.25, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "ANTI-INFLAMMATORY LIPID MEDIATORS IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL132550_7529"}, {"internal_id": 49758665, "Award ID": "R01HL132523", "Award Amount": 11568181.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-25", "CFDA Number": "93.837", "Description": "EARLY ORIGINS OF CHRONIC AIRFLOW LIMITATION: OUTCOMES INTO THE 4TH DECADE OF LIFE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R01HL132523_7529"}, {"internal_id": 49758650, "Award ID": "R01HL132358", "Award Amount": 2312543.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-05", "CFDA Number": "93.837", "Description": "THE CONTRIBUTION OF CONTRAST MEDIA EXPOSURE TO ACUTE KIDNEY INJURY IN PATIENTS EVALUATED FOR PULMONARY EMBOLISM IN THE EMERGENCY CARE SETTING: A PROSPECTIVE, RANDOMIZED TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL132358_7529"}, {"internal_id": 49758649, "Award ID": "R01HL132355", "Award Amount": 2523370.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-25", "CFDA Number": "93.837", "Description": "MECHANISMS OF CONGENITAL HYPOVENTILATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL132355_7529"}, {"internal_id": 49758645, "Award ID": "R01HL132349", "Award Amount": 2287376.05, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-11", "CFDA Number": "93.837", "Description": "DEVELOPMENTAL PATHWAYS REGULATING ADULT LUNG QUIESCENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL132349_7529"}, {"internal_id": 49758643, "Award ID": "R01HL132344", "Award Amount": 3361325.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-18", "CFDA Number": "93.837", "Description": "UNRAVELING ANCESTRY AND ENVIRONMENTAL EXPOSURE INTERACTIONS IN CHILDHOOD ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL132344_7529"}, {"internal_id": 49758642, "Award ID": "R01HL132338", "Award Amount": 3792791.91, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-27", "CFDA Number": "93.837", "Description": "MATERNAL TRAUMATIC STRESS, OXIDATIVE STRESS, ANTIOXIDANT EXPOSURES, AND CHILD ASTHMA AND LUNG FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL132338_7529"}, {"internal_id": 49758640, "Award ID": "R01HL132321", "Award Amount": 3183776.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-25", "CFDA Number": "93.837", "Description": "EFFECT OF PRENATAL COMPOUNDS ON ADULT LUNG FUNCTION VIA NEONATAL DNA METHYLATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f97d8891-aed5-b95f-0a7b-0cbb8a1230b1-C", "generated_internal_id": "ASST_NON_R01HL132321_7529"}, {"internal_id": 49758635, "Award ID": "R01HL132287", "Award Amount": 2393323.47, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-31", "CFDA Number": "93.837", "Description": "DISCOVERY OF NEW ANTI-INFLAMMATORY AGENTS TO TREAT COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "959a5b47-d407-9807-55f0-ee776cca4bce-C", "generated_internal_id": "ASST_NON_R01HL132287_7529"}, {"internal_id": 49758633, "Award ID": "R01HL132266", "Award Amount": 1532106.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-06", "CFDA Number": "93.838", "Description": "MECHANISMS OF THROMBOSPONDIN-1 AS A PULMONARY VASCULAR MEDIATOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL132266_7529"}, {"internal_id": 49758631, "Award ID": "R01HL132255", "Award Amount": 1695000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-13", "CFDA Number": "93.837", "Description": "SENSORY BIOLOGY OF RESPIRATORY CONTROL NEURONS IN THE VAGUS NERVE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_R01HL132255_7529"}, {"internal_id": 49758626, "Award ID": "R01HL132232", "Award Amount": 2880201.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-16", "CFDA Number": "93.837", "Description": "EFFECT OF RANDOMIZATION TO NEUROMUSCULAR BLOCKADE ON PHYSICAL FUNCTIONAL IMPAIRMENT AND RECOVERY IN ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL132232_7529"}, {"internal_id": 49758624, "Award ID": "R01HL132225", "Award Amount": 1702178.52, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-31", "CFDA Number": "93.837", "Description": "SMALL MOLECULE NOTCH INHIBITORS FOR THE TREATMENT OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL132225_7529"}, {"internal_id": 49758621, "Award ID": "R01HL132198", "Award Amount": 2171736.27, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-26", "CFDA Number": "93.837", "Description": "METABOLIC DYSFUNCTION REGULATES MITOPHAGY-DEPENDENT NECROPTOSIS IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL132198_7529"}, {"internal_id": 49758617, "Award ID": "R01HL132177", "Award Amount": 3915827.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-09", "CFDA Number": "93.837", "Description": "HYPERPOLARIZED XENON-129 MRI: A NEW MULTI-DIMENSIONAL BIOMARKER TO DETERMINE PULMONARY PHYSIOLOGIC RESPONSES TO COPD THERAPEUTICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL132177_7529"}, {"internal_id": 49758614, "Award ID": "R01HL132156", "Award Amount": 2002388.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-17", "CFDA Number": "93.838", "Description": "HL-LUNG STEM CELLS AND THEIR NICHES.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL132156_7529"}, {"internal_id": 49758611, "Award ID": "R01HL132153", "Award Amount": 2539337.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-12", "CFDA Number": "93.837", "Description": "FUNCTIONAL IMPACT OF COL18A1/ENDOSTATIN VARIANTS IN PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL132153_7529"}, {"internal_id": 49758610, "Award ID": "R01HL132150", "Award Amount": 1184805.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-20", "CFDA Number": "93.233", "Description": "BIOMARKERS OF INSUFFICIENT SLEEP AND SLEEPINESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7d586cfa-95f6-0e31-3589-fbd59b788eda-C", "generated_internal_id": "ASST_NON_R01HL132150_7529"}, {"internal_id": 49758607, "Award ID": "R01HL132115", "Award Amount": 1980800.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-11", "CFDA Number": "93.837", "Description": "REGULATION OF DISTAL LUNG EPITHELIAL REGENERATION BY MICRORNA-HIPPO PATHWAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL132115_7529"}, {"internal_id": 49758600, "Award ID": "R01HL132058", "Award Amount": 2531633.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-31", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF A NOVEL MODULATOR OF PULMONARY ARTERY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL132058_7529"}, {"internal_id": 49758590, "Award ID": "R01HL131960", "Award Amount": 2101922.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-19", "CFDA Number": "93.837", "Description": "IN VIVO IMAGING OF DESTRUCTIVE PROCESSES IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL131960_7529"}, {"internal_id": 49758583, "Award ID": "R01HL131910", "Award Amount": 2283698.61, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-11", "CFDA Number": "93.837", "Description": "MOLECULAR IMAGING OF ANGIOGENIC ACTIVITY IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL131910_7529"}, {"internal_id": 49758582, "Award ID": "R01HL131908", "Award Amount": 1970597.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.838", "Description": "PET IMAGING CCR2 IN LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL131908_7529"}, {"internal_id": 49758581, "Award ID": "R01HL131907", "Award Amount": 2273651.45, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-08", "CFDA Number": "93.837", "Description": "PET IMAGING OF PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL131907_7529"}, {"internal_id": 49758580, "Award ID": "R01HL131906", "Award Amount": 2089729.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-26", "CFDA Number": "93.837", "Description": "IMAGING ACTIVATED MACROPHAGES IN THE LUNGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL131906_7529"}, {"internal_id": 49758570, "Award ID": "R01HL131829", "Award Amount": 2159545.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.837", "Description": "MOLECULAR IMAGING FOR PULMONARY INFECTIONS AND INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL131829_7529"}, {"internal_id": 49758567, "Award ID": "R01HL131812", "Award Amount": 1638900.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-27", "CFDA Number": "93.838", "Description": "LUNG INJURY REPAIR BY REGULATORY T CELL LGP2", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL131812_7529"}, {"internal_id": 49758565, "Award ID": "R01HL131789", "Award Amount": 1735694.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-27", "CFDA Number": "93.837", "Description": "SIGNALING MECHANISMS BY WHICH MITOCHONDRIA REGULATES FIBROSIS IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL131789_7529"}, {"internal_id": 49758563, "Award ID": "R01HL131784", "Award Amount": 1576682.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-22", "CFDA Number": "93.837", "Description": "METABOLIC CONTROL OF DNA REPAIR IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL131784_7529"}, {"internal_id": 49758555, "Award ID": "R01HL131745", "Award Amount": 1237420.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-20", "CFDA Number": "93.837", "Description": "HYPERCAPNIA AND SUPPRESSION OF ANTI-VIRAL HOST DEFENSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL131745_7529"}, {"internal_id": 49758549, "Award ID": "R01HL131730", "Award Amount": 3229974.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-31", "CFDA Number": "93.837", "Description": "MOBILE CRITICAL CARE RECOVERY PROGRAM (M-CCRP) FOR ACUTE RESPIRATORY FAILURE (ARF) SURVIVORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL131730_7529"}, {"internal_id": 49758546, "Award ID": "R01HL131716", "Award Amount": 3025705.48, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-14", "CFDA Number": "93.837", "Description": "MODELING THE ROLE OF THE NTS IN THE NEUROGENESIS OF AIRWAY DEFENSIVE BEHAVIORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL131716_7529"}, {"internal_id": 49758544, "Award ID": "R01HL131697", "Award Amount": 1925000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-23", "CFDA Number": "93.837", "Description": "THE CFTR INTERACTOME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL131697_7529"}, {"internal_id": 49758536, "Award ID": "R01HL131665", "Award Amount": 1541323.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-17", "CFDA Number": "93.837", "Description": "REGULATION OF PROTEOLYSIS BY DEUBIQUITING ENZYME IN LUNG INFLAMMATORY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL131665_7529"}, {"internal_id": 49758535, "Award ID": "R01HL131661", "Award Amount": 1903388.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-20", "CFDA Number": "93.837", "Description": "INTERSTITIAL RESIDENT FIBROBLASTS DIRECT ALVEOLAR EPITHELIAL DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL131661_7529"}, {"internal_id": 49758528, "Award ID": "R01HL131634", "Award Amount": 1978165.4, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-18", "CFDA Number": "93.837", "Description": "ROLE OF GPR116 IN ALVEOLAR HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL131634_7529"}, {"internal_id": 49758526, "Award ID": "R01HL131626", "Award Amount": 2552713.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-10", "CFDA Number": "93.837", "Description": "LYMPHANGIOGENESIS IN PULMONARY LYMPHANGIOLEIOMYOMATOSIS (LAM)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL131626_7529"}, {"internal_id": 49758520, "Award ID": "R01HL131608", "Award Amount": 1890300.4, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-22", "CFDA Number": "93.837", "Description": "MECHANISMS OF REPAIR OF THE ALVEOLAR EPITHELIUM AFTER LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL131608_7529"}, {"internal_id": 49758517, "Award ID": "R01HL131587", "Award Amount": 1957302.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-20", "CFDA Number": "93.837", "Description": "IMPROVING ASTHMA CONTROL USING INTERNET-BASED COGNITIVE-BEHAVIORAL TREATMENT FOR INSOMNIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL131587_7529"}, {"internal_id": 49758513, "Award ID": "R01HL131565", "Award Amount": 2046208.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-09", "CFDA Number": "93.837", "Description": "GENOMIC AND TRANSCRIPTOMIC ANALYSIS OF EMPHYSEMA AND SUBCLINICAL ILD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL131565_7529"}, {"internal_id": 49758512, "Award ID": "R01HL131560", "Award Amount": 1946852.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-25", "CFDA Number": "93.837", "Description": "THE REGULATION OF RHOA ACTIVATION IN AIRWAY SMOOTH MUSCLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL131560_7529"}, {"internal_id": 49758505, "Award ID": "R01HL131526", "Award Amount": 1743990.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-15", "CFDA Number": "93.837", "Description": "ASK1 AND VENTILATOR-INDUCED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R01HL131526_7529"}, {"internal_id": 49758504, "Award ID": "R01HL131525", "Award Amount": 1859427.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-09", "CFDA Number": "93.837", "Description": "INSULIN MODULATES PARASYMPATHETIC NERVE CONTROL OF LUNGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL131525_7529"}, {"internal_id": 49758494, "Award ID": "R01HL131449", "Award Amount": 3085794.37, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-23", "CFDA Number": "93.837", "Description": "IMMUNOPATHOGENESIS OF HIV-ASSOCIATED PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_R01HL131449_7529"}, {"internal_id": 49758491, "Award ID": "R01HL131422", "Award Amount": 1616242.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-16", "CFDA Number": "93.838", "Description": "THE TRINUCLEOTIDE REPEAT CONTAINING 6A-MEDIATED MIRNA ACTIVITIES IN THE CILIOGENESIS OF AIRWAY EPITHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL131422_7529"}, {"internal_id": 49758490, "Award ID": "R01HL131418", "Award Amount": 4214289.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-18", "CFDA Number": "93.837", "Description": "SYMPTOM PERCEPTION, BEHAVIOR, AND OUTCOMES IN OLDER ASTHMATICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL131418_7529"}, {"internal_id": 49758479, "Award ID": "R01HL131143", "Award Amount": 3017760.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-21", "CFDA Number": "93.838", "Description": "DEVELOPMENT OF A GENE THERAPY APPROACH TO TREAT ACUTE LUNG INJURY USING A PRECLINICAL, LARGE ANIMAL MODEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL131143_7529"}, {"internal_id": 49758475, "Award ID": "R01HL131049", "Award Amount": 2307843.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-12", "CFDA Number": "93.837", "Description": "SLEEP, AGING, AND HIV INFECTION COHORT STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL131049_7529"}, {"internal_id": 49758469, "Award ID": "R01HL131012", "Award Amount": 4475529.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-11", "CFDA Number": "93.837", "Description": "UTE MRI TO MONITOR CF LUNG DISEASE AND RESPONSE TO CFTR MODULATION IN YOUNG CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL131012_7529"}, {"internal_id": 49758463, "Award ID": "R01HL130974", "Award Amount": 6164621.04, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-17", "CFDA Number": "93.837", "Description": "CLINICAL GENETICS AND SCREENING FOR PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL130974_7529"}, {"internal_id": 49758461, "Award ID": "R01HL130938", "Award Amount": 3955801.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-25", "CFDA Number": "93.837", "Description": "MECHANISMS OF LUNG MACROPHAGE PROGRAMMING BY MUC5B DURING HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL130938_7529"}, {"internal_id": 49758456, "Award ID": "R01HL130883", "Award Amount": 3587299.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-24", "CFDA Number": "93.837", "Description": "FUNCTIONAL CT ASSESSMENT OF PULMONARY ARTERIAL DYSFUNCTION IN SMOKING ASSOCIATED EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL130883_7529"}, {"internal_id": 49758455, "Award ID": "R01HL130881", "Award Amount": 3232884.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-17", "CFDA Number": "93.837", "Description": "EFFICACY OF SELF-MANAGEMENT OF SEDATIVE THERAPY BY VENTILATED ICU PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL130881_7529"}, {"internal_id": 49758453, "Award ID": "R01HL130876", "Award Amount": 3685731.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-14", "CFDA Number": "93.837", "Description": "AZITHROMYCIN TO PREVENT RECURRENT WHEEZING FOLLOWING SEVERE RSV BRONCHIOLITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL130876_7529"}, {"internal_id": 49758451, "Award ID": "R01HL130870", "Award Amount": 1898786.94, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-08", "CFDA Number": "93.837", "Description": "ER-MITOCHONDRIAL CONTROL OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL130870_7529"}, {"internal_id": 49758446, "Award ID": "R01HL130847", "Award Amount": 2315555.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-14", "CFDA Number": "93.837", "Description": "NON-ALLERGIC LATE-ONSET ASTHMA OF OBESITY: PATHOPHYSIOLOGY AND THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL130847_7529"}, {"internal_id": 49758442, "Award ID": "R01HL130826", "Award Amount": 2443916.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-20", "CFDA Number": "93.837", "Description": "ENDOTHELIAL CELL-DERIVED MMP14 IN LUNG ALVEOLAR REGENERATION AND FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL130826_7529"}, {"internal_id": 49758438, "Award ID": "R01HL130796", "Award Amount": 3071220.22, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-26", "CFDA Number": "93.837", "Description": "ARCHITECTURAL STRUCTURE AND REGULATION OF TOLLIP IN IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL130796_7529"}, {"internal_id": 49758427, "Award ID": "R01HL130702", "Award Amount": 2586418.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-04", "CFDA Number": "93.310", "Description": "PREDICTORS OF DE NOVO DEVELOPMENT OF OBSTRUCTIVE SLEEP APNEA IN PREGNANCY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c42360e-cd0f-f49d-f961-6ea333c13ac6-C", "generated_internal_id": "ASST_NON_R01HL130702_7529"}, {"internal_id": 49758422, "Award ID": "R01HL130669", "Award Amount": 1662094.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-10", "CFDA Number": "93.837", "Description": "AGING AND INNATE IMMUNE MECHANISMS IN PULMONARY INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL130669_7529"}, {"internal_id": 49758414, "Award ID": "R01HL130559", "Award Amount": 3701146.34, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-29", "CFDA Number": "93.837", "Description": "STEPPED-CARE MANAGEMENT OF INSOMNIA CO-OCCURRING WITH SLEEP APNEA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL130559_7529"}, {"internal_id": 49758406, "Award ID": "R01HL130512", "Award Amount": 3524668.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-16", "CFDA Number": "93.837", "Description": "SYSTEMS GENOMICS OF THE ASTHMA-COPD OVERLAP SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL130512_7529"}, {"internal_id": 49758405, "Award ID": "R01HL130506", "Award Amount": 5000838.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-27", "CFDA Number": "93.837", "Description": "CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN NON-SMOKERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL130506_7529"}, {"internal_id": 49758393, "Award ID": "R01HL130468", "Award Amount": 4198176.44, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "A COMPUTATIONAL BIOMECHANICAL AIRWAY MODEL FOR OBESE CHILDREN AT RISK FOR OSAS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R01HL130468_7529"}, {"internal_id": 49758386, "Award ID": "R01HL130431", "Award Amount": 1536657.05, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-26", "CFDA Number": "93.837", "Description": "DIFFERENTIAL MECHANO-SIGNALING IN VASCULAR ENDOTHELIUM BY VARYING DEGREES OF MECHANICAL STRETCH - RESUBMISSION 01", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL130431_7529"}, {"internal_id": 49758380, "Award ID": "R01HL130402", "Award Amount": 3231082.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-22", "CFDA Number": "93.837", "Description": "DELIVERY OF PAI-1-TARGETED INTRAPLEURAL FIBRINOLYTIC THERAPY FOR EMPYEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6605b60b-2165-8c36-e954-428aa458f579-C", "generated_internal_id": "ASST_NON_R01HL130402_7529"}, {"internal_id": 49758372, "Award ID": "R01HL130353", "Award Amount": 2159133.51, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-14", "CFDA Number": "93.837", "Description": "SEQUENTIAL RELEASE OF IL-1ALPHA AND IL-1BETA LEADS TO A TWO-HIT MODEL OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL130353_7529"}, {"internal_id": 49758369, "Award ID": "R01HL130336", "Award Amount": 2187751.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-14", "CFDA Number": "93.837", "Description": "TARGETING CHOLINE PHOSPHOLIPID METABOLISM IN LYMPHANGIOLEIOMYOMATOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL130336_7529"}, {"internal_id": 49758367, "Award ID": "R01HL130324", "Award Amount": 2179982.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-31", "CFDA Number": "93.837", "Description": "INNATE IMMUNE MECHANISMS OF PRIMARY GRAFT DYSFUNCTION AFTER LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL130324_7529"}, {"internal_id": 49758363, "Award ID": "R01HL130307", "Award Amount": 1975400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-26", "CFDA Number": "93.837", "Description": "EXTRAPULMONARY MICROVASCULAR DYSFUNCTION IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL130307_7529"}, {"internal_id": 49758362, "Award ID": "R01HL130304", "Award Amount": 3030884.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-24", "CFDA Number": "93.837", "Description": "PLK1 REGULATION OF AIRWAY SMOOTH MUSCLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "84c69770-7b20-b9e0-d502-4ceb449256bf-C", "generated_internal_id": "ASST_NON_R01HL130304_7529"}, {"internal_id": 49758356, "Award ID": "R01HL130287", "Award Amount": 1677663.49, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-20", "CFDA Number": "93.837", "Description": "REGULATION OF AIRWAY SMOOTH MUSCLE PHENOTYPE BY RETINOIC ACID", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL130287_7529"}, {"internal_id": 49758355, "Award ID": "R01HL130283", "Award Amount": 1675000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-15", "CFDA Number": "93.837", "Description": "ROLE OF NLRX1 IN CIGARETTE SMOKE-INDUCED PULMONARY INFLAMMATION AND REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL130283_7529"}, {"internal_id": 49758354, "Award ID": "R01HL130275", "Award Amount": 2175247.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-17", "CFDA Number": "93.837", "Description": "LYMPHATICS AND LUNG ALLOGRAFT REJECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL130275_7529"}, {"internal_id": 49758352, "Award ID": "R01HL130268", "Award Amount": 1946808.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-06", "CFDA Number": "93.837", "Description": "DUAL ROLE OF HMGB1 IN PATHOGENIC PLATELET BIOLOGY IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL130268_7529"}, {"internal_id": 49758350, "Award ID": "R01HL130261", "Award Amount": 3542141.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-09", "CFDA Number": "93.837", "Description": "HIPPO SIGNALING IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R01HL130261_7529"}, {"internal_id": 49758348, "Award ID": "R01HL130249", "Award Amount": 4717387.87, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-15", "CFDA Number": "93.837", "Description": "MAPPING THE DEVELOPMENTAL, GENETIC, AND FUNCTIONAL ORGANIZATION OF NORADRENERGIC RESPIRATORY NEURAL CIRCUITS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL130249_7529"}, {"internal_id": 49758345, "Award ID": "R01HL130234", "Award Amount": 2084443.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-16", "CFDA Number": "93.310", "Description": "MECHANISMS THAT DIRECT AIRWAY REMODELING IN OBESE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL130234_7529"}, {"internal_id": 49758342, "Award ID": "R01HL130230", "Award Amount": 1287000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-03", "CFDA Number": "93.837", "Description": "HDAC6 REGULATES CIGARETTE SMOKE-INDUCED ENDOTHELIAL BARRIER DYSFUNCTION AND LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d04e50b2-a099-d508-c9da-d97e2528c9d7-C", "generated_internal_id": "ASST_NON_R01HL130230_7529"}, {"internal_id": 49758339, "Award ID": "R01HL130209", "Award Amount": 2854668.94, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-05", "CFDA Number": "93.837", "Description": "MECHANISMS OF METABOLIC DYSREGULATION IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL130209_7529"}, {"internal_id": 49758337, "Award ID": "R01HL130192", "Award Amount": 3221843.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-12", "CFDA Number": "93.837", "Description": "SINGLE-SAMPLE TUBERCULOSIS EVALUATION TO FACILITATE LINKAGE TO CARE: THE SIMPLE TB TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL130192_7529"}, {"internal_id": 49758331, "Award ID": "R01HL130150", "Award Amount": 2869204.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-25", "CFDA Number": "93.837", "Description": "PREDICTORS OF RESILIENCE AND POSITIVE OUTCOMES FOR PATIENTS WITH ACUTE RESPIRATORY FAILURE AND THEIR FAMILY MEMBERS: AN OBSERVATIONAL STUDY TO GUIDE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL130150_7529"}, {"internal_id": 49758326, "Award ID": "R01HL130133", "Award Amount": 1844271.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-20", "CFDA Number": "93.837", "Description": "FIBRINOLYTIC PROTEASES, MESO-MESENCHYMAL TRANSITION AND PLEURAL REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6605b60b-2165-8c36-e954-428aa458f579-C", "generated_internal_id": "ASST_NON_R01HL130133_7529"}, {"internal_id": 49758325, "Award ID": "R01HL130129", "Award Amount": 4093233.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-16", "CFDA Number": "93.837", "Description": "ROLE OF AT1 CELLS IN PERINATAL LUNG MATURATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_R01HL130129_7529"}, {"internal_id": 49758315, "Award ID": "R01HL130084", "Award Amount": 1476591.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-10", "CFDA Number": "93.837", "Description": "THE ROLE OF ACUTE KIDNEY IN THE PATHOGENESIS OF SEPSIS FROM PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL130084_7529"}, {"internal_id": 49758311, "Award ID": "R01HL130061", "Award Amount": 1474257.23, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-09", "CFDA Number": "93.837", "Description": "AMELIORATION OF MITOCHONDRIAL DYSFUNCTION BY THIOREDOXIN IN HYPEROXIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30f9aa19-2773-fb77-2e44-59c99374edf2-C", "generated_internal_id": "ASST_NON_R01HL130061_7529"}, {"internal_id": 49758308, "Award ID": "R01HL130053", "Award Amount": 2632356.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-25", "CFDA Number": "93.837", "Description": "ADENOSINE A2 RECEPTORS AND IMAGING OF INFLAMMATION IN LUNG REPERFUSION INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL130053_7529"}, {"internal_id": 49758297, "Award ID": "R01HL129990", "Award Amount": 2366354.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-11", "CFDA Number": "93.837", "Description": "IMAGING HYPOXIC PULMONARY VASOCONSTRICTION IN THE AGING LUNG WITH PROTON MRI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL129990_7529"}, {"internal_id": 49758295, "Award ID": "R01HL129937", "Award Amount": 1306806.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.838", "Description": "SPHINGOLIPIDS AND INFLAMMATORY BIOMARKERS OF COPD PROGRESSION IN HEALTHY SMOKERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL129937_7529"}, {"internal_id": 49758292, "Award ID": "R01HL129920", "Award Amount": 1308281.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-17", "CFDA Number": "93.838", "Description": "CLINICAL AND MOLECULAR PROFILES OF SMOKERS WITH SUBCLINICAL INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL129920_7529"}, {"internal_id": 49758290, "Award ID": "R01HL129887", "Award Amount": 1708132.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-30", "CFDA Number": "93.838", "Description": "ANTI-TB STERILIZING IMMUNITY IN IMMUNE AND HIV+ INDIVIDUALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL129887_7529"}, {"internal_id": 49758289, "Award ID": "R01HL129881", "Award Amount": 2131020.87, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.837", "Description": "HIV-INDUCED DEFECTS IN PULMONARY MACROPHAGES EXACERBATE MYCOBACTERIUM TUBERCULOSIS CO-INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b5d65b01-d8ce-624c-a95e-e23d872445a2-C", "generated_internal_id": "ASST_NON_R01HL129881_7529"}, {"internal_id": 49758287, "Award ID": "R01HL129875", "Award Amount": 1689690.34, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.837", "Description": "IMPACT OF OPIATE ABUSE ON HIV-MEDIATED PULMONARY VASCULAR REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1a1108fb-0099-a708-6def-aa6d101c8ba8-C", "generated_internal_id": "ASST_NON_R01HL129875_7529"}, {"internal_id": 49758282, "Award ID": "R01HL129805", "Award Amount": 3015158.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-17", "CFDA Number": "93.837", "Description": "PREDICTION AND ASSESSMENT OF COPD LUNG VOLUME REDUCTION OUTCOMES WITH POLARIZED MRI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL129805_7529"}, {"internal_id": 49758279, "Award ID": "R01HL129795", "Award Amount": 3794981.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-31", "CFDA Number": "93.837", "Description": "CONTROLLING THE CORE AIRWAY MUCIN SECRETION MACHINERY TO PREVENT PATHOPHYSIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_R01HL129795_7529"}, {"internal_id": 49758278, "Award ID": "R01HL129794", "Award Amount": 2242238.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-18", "CFDA Number": "93.837", "Description": "MECHANISTIC ROLES OF CYTOCHROME P4501A ENZYMES IN HYPEROXIC LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL129794_7529"}, {"internal_id": 49758272, "Award ID": "R01HL129735", "Award Amount": 3186403.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-01", "CFDA Number": "93.837", "Description": "PRENATAL ORIGINS OF ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL129735_7529"}, {"internal_id": 49758260, "Award ID": "R01HL129239", "Award Amount": 1353271.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-22", "CFDA Number": "93.838", "Description": "A SOFTWARE FRAMEWORK FOR EXPLORING 1,000 GENOMES OF AFRICAN DESCENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL129239_7529"}, {"internal_id": 49758259, "Award ID": "R01HL129223", "Award Amount": 1942242.55, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-27", "CFDA Number": "93.837", "Description": "HL-P73 IS A NOVEL MASTER REGULATOR OF THE AIRWAY EPITHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3313e5e7-fa36-d54b-e36d-0e1e09cc0c30-C", "generated_internal_id": "ASST_NON_R01HL129223_7529"}, {"internal_id": 49758258, "Award ID": "R01HL129198", "Award Amount": 3152067.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-25", "CFDA Number": "93.837", "Description": "OBESITY AND ASTHMA: UNVEILING METABOLIC AND BEHAVIORAL PATHWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL129198_7529"}, {"internal_id": 49758251, "Award ID": "R01HL129150", "Award Amount": 1893076.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-01", "CFDA Number": "93.837", "Description": "THE BIOLOGY OF THE ABCA3 LIPID TRANSPORTER IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL129150_7529"}, {"internal_id": 49758243, "Award ID": "R01HL129060", "Award Amount": 3934286.28, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-10", "CFDA Number": "93.837", "Description": "CPAP DRIVES LUNG GROWTH AND PULMONARY FUNCTION IN MODERATELY PRETERM PRIMATES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL129060_7529"}, {"internal_id": 49758242, "Award ID": "R01HL129051", "Award Amount": 2287400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-10", "CFDA Number": "93.837", "Description": "ROLE OF MIR193 IN OXIDIZED LIPID INDUCED PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R01HL129051_7529"}, {"internal_id": 49758234, "Award ID": "R01HL128903", "Award Amount": 1585000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-26", "CFDA Number": "93.838", "Description": "EPITHELIAL CHITINASE AND LUNG HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL128903_7529"}, {"internal_id": 49758223, "Award ID": "R01HL128785", "Award Amount": 2548122.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-26", "CFDA Number": "93.837", "Description": "COMPUTER-AIDED DIAGNOSIS OF PULMONARY EMBOLISM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18ebe923-151d-7095-dfea-7767365ba71d-C", "generated_internal_id": "ASST_NON_R01HL128785_7529"}, {"internal_id": 49758220, "Award ID": "R01HL128778", "Award Amount": 1678980.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-05", "CFDA Number": "93.837", "Description": "INNATE IMMUNITY OF GRANULOMATOUS INFLAMMATION: THE ROLE OF VEGF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL128778_7529"}, {"internal_id": 49758216, "Award ID": "R01HL128734", "Award Amount": 2103449.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-29", "CFDA Number": "93.837", "Description": "TARGETING NOVEL BMPR2 MODIFIERS IN PULMONARY HYPERTENSION WITH REPURPOSED DRUGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL128734_7529"}, {"internal_id": 49758205, "Award ID": "R01HL128658", "Award Amount": 2617275.36, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-10", "CFDA Number": "93.837", "Description": "CLINICAL METHODS FOR DETERMINING THE SITE AND SEVERITY OF PHARYNGEAL COLLAPSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL128658_7529"}, {"internal_id": 49758201, "Award ID": "R01HL128620", "Award Amount": 3506506.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-29", "CFDA Number": "93.837", "Description": "LONGITUDINAL STUDY OF DETERMINANTS OF MEDICATION ADHERENCE IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL128620_7529"}, {"internal_id": 49758186, "Award ID": "R01HL128538", "Award Amount": 3550930.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-13", "CFDA Number": "93.837", "Description": "INFLUENCE OF SLEEP REGULARITY ON CIRCADIAN RHYTHMS, LEARNING, PERFORMANCE, AND MOOD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL128538_7529"}, {"internal_id": 49758179, "Award ID": "R01HL128502", "Award Amount": 1812450.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-01", "CFDA Number": "93.837", "Description": "MYELOID-DERIVED REGULATORY CELLS IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL128502_7529"}, {"internal_id": 49758176, "Award ID": "R01HL128492", "Award Amount": 3771904.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-11", "CFDA Number": "93.837", "Description": "PREVENTION OF LUNG TRANSPLANT INJURY WITH ADENOSINE 2A RECEPTOR AGONIST", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": 436658.0, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL128492_7529"}, {"internal_id": 49758174, "Award ID": "R01HL128484", "Award Amount": 2308311.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-10", "CFDA Number": "93.838", "Description": "EPITHELIAL STEM/PROGENITOR CELLS IN REPAIR OF THE INJURED LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL128484_7529"}, {"internal_id": 49758173, "Award ID": "R01HL128475", "Award Amount": 1134000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-03", "CFDA Number": "93.837", "Description": "GENE-ENVIRONMENT INTERACTIONS IN CYSTIC FIBROSIS LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL128475_7529"}, {"internal_id": 49758168, "Award ID": "R01HL128454", "Award Amount": 1982040.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-20", "CFDA Number": "93.837", "Description": "NEUROPHYSIOLOGY AND PLASTICITY OF CARDIORESPIRATORY CIRCUITS TO HYPOXIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f261384c-3ac1-b344-de46-81708f87aa6a-C", "generated_internal_id": "ASST_NON_R01HL128454_7529"}, {"internal_id": 49758163, "Award ID": "R01HL128439", "Award Amount": 3097069.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-04", "CFDA Number": "93.837", "Description": "GENETIC CONTROL OF AIRWAY EPITHELIUM GENE EXPRESSION IN CHILDHOOD ASTHMATICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL128439_7529"}, {"internal_id": 49758159, "Award ID": "R01HL128398", "Award Amount": 2199492.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-23", "CFDA Number": "93.838", "Description": "TARGETING NOVEL BIOTHERAPEUTICS TO ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL128398_7529"}, {"internal_id": 49758152, "Award ID": "R01HL128374", "Award Amount": 1844916.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-07", "CFDA Number": "93.837", "Description": "INFLAMMATORY ANGIOGENESIS IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "43049b95-a970-fc61-495d-0de7d1349319-C", "generated_internal_id": "ASST_NON_R01HL128374_7529"}, {"internal_id": 49758150, "Award ID": "R01HL128370", "Award Amount": 5419288.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "REGULATION OF MOTILE CILIA ASSEMBLY IN LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL128370_7529"}, {"internal_id": 49758147, "Award ID": "R01HL128361", "Award Amount": 1486726.43, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "DYSREGULATED AIRWAY EPITHELIAL SIGNALING AS A DRIVER OF AIRWAY REMODELING IN ASTHMATIC CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL128361_7529"}, {"internal_id": 49758146, "Award ID": "R01HL128359", "Award Amount": 1598750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-03", "CFDA Number": "93.837", "Description": "ENDOTHELIAL CELL DEUBIQUITINASE A20 SIGNALS REPAIR OF LUNG VASCULAR INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL128359_7529"}, {"internal_id": 49758133, "Award ID": "R01HL128289", "Award Amount": 1925000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-18", "CFDA Number": "93.837", "Description": "AUTOIMMUNITY AND EMPHYSEMA AND RISK OF OSTEOPOROSIS IN SMOKERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL128289_7529"}, {"internal_id": 49758128, "Award ID": "R01HL128260", "Award Amount": 3693271.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-14", "CFDA Number": "93.837", "Description": "ASTHMA SYMPTOM PERCEPTION FEEDBACK INTERVENTION FOR ETHNIC MINORITY ADOLESCENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R01HL128260_7529"}, {"internal_id": 49758126, "Award ID": "R01HL128241", "Award Amount": 2218542.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "PROSTAGLANDIN D2: A KEY MEDIATOR OF ASPIRIN-EXACERBATED RESPIRATORY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL128241_7529"}, {"internal_id": 49758119, "Award ID": "R01HL128226", "Award Amount": 2892132.77, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-17", "CFDA Number": "93.837", "Description": "EFFECT OF LONG-TERM SLEEP RESTRICTION ON ENERGY BALANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL128226_7529"}, {"internal_id": 49758116, "Award ID": "R01HL128194", "Award Amount": 1545000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-31", "CFDA Number": "93.837", "Description": "VIMENTIN-MEDIATED REGULATION OF THE INFLAMMASOME IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL128194_7529"}, {"internal_id": 49758112, "Award ID": "R01HL128172", "Award Amount": 2219805.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.837", "Description": "EPIGENENOMIC AND TRANSCRIPTOMIC NETWORKS IN NORMAL AND DEFECTIVE LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL128172_7529"}, {"internal_id": 49758108, "Award ID": "R01HL128156", "Award Amount": 6311955.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-26", "CFDA Number": "93.837", "Description": "INFLAMMATION, AGING, MICROBES, AND OBSTRUCTIVE LUNG DISEASE (I AM OLD) STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL128156_7529"}, {"internal_id": 49758089, "Award ID": "R01HL127969", "Award Amount": 2828892.7, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "IMAGING-BASED CHARACTERIZATION OF THE COPDGENE COHORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL127969_7529"}, {"internal_id": 49758084, "Award ID": "R01HL127805", "Award Amount": 1217092.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-19", "CFDA Number": "93.838", "Description": "HSCT-INDUCED ALTERATIONS IN DCS TO PROMOTE IL-17 AND LUNG PATHOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL127805_7529"}, {"internal_id": 49758065, "Award ID": "R01HL127651", "Award Amount": 1520751.73, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-16", "CFDA Number": "93.837", "Description": "THE ROLE OF MICRORNA-CALIBRATED AUTOPHAGY IN INNATE IMMUNITY AND INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL127651_7529"}, {"internal_id": 49758059, "Award ID": "R01HL127602", "Award Amount": 1585000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-13", "CFDA Number": "93.837", "Description": "BETA ADRENERGIC RECEPTOR RESENSITIZATION IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL127602_7529"}, {"internal_id": 49758053, "Award ID": "R01HL127461", "Award Amount": 2080504.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-16", "CFDA Number": "93.837", "Description": "EPIGENETIC REGULATION OF ALTERED T-CELL IMMUNITY IN SARCOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL127461_7529"}, {"internal_id": 49758052, "Award ID": "R01HL127455", "Award Amount": 1593115.23, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-10", "CFDA Number": "93.837", "Description": "PATHOGENESIS-DRIVEN THERAPEUTIC DEVELOPMENT FOR PULMONARY ALVEOLAR MICROLITHIASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R01HL127455_7529"}, {"internal_id": 49758051, "Award ID": "R01HL127449", "Award Amount": 1683893.21, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-31", "CFDA Number": "93.837", "Description": "ENDOCYTIC REGULATION OF INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68c287e4-398a-6c6b-c0db-5ce9430c6ce3-C", "generated_internal_id": "ASST_NON_R01HL127449_7529"}, {"internal_id": 49758047, "Award ID": "R01HL127426", "Award Amount": 1640391.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-01", "CFDA Number": "93.837", "Description": "MOLECULAR AND BIOLOGICAL FUNCTION OF LONG NON-CODING RNA TRANSCRIPTS DIVERGENT TO LUNG DEVELOPMENTAL GENES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL127426_7529"}, {"internal_id": 49758045, "Award ID": "R01HL127413", "Award Amount": 1601352.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-11", "CFDA Number": "93.838", "Description": "BIODEGRADABLE MUCUS PENETRATING DNA NANOPARTICLE FOR GENE THERAPY OF CF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL127413_7529"}, {"internal_id": 49758044, "Award ID": "R01HL127403", "Award Amount": 1550000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-01", "CFDA Number": "93.838", "Description": "ENDOTHELIN RECEPTORS MODULATE CARDIORESPIRATORY FUNCTION DURING HYPOXIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL127403_7529"}, {"internal_id": 49758043, "Award ID": "R01HL127402", "Award Amount": 2217947.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-15", "CFDA Number": "93.838", "Description": "MECHANISMS, CONSEQUENCES, AND REVERSAL OF ABNORMALITIES IN LUNG LYMPHATICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL127402_7529"}, {"internal_id": 49758042, "Award ID": "R01HL127393", "Award Amount": 1694969.66, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-09", "CFDA Number": "93.837", "Description": "AMPHIREGULIN-DRIVEN COPD-RELEVANT REMODELING OF HUMAN AIRWAY EPITHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL127393_7529"}, {"internal_id": 49758040, "Award ID": "R01HL127384", "Award Amount": 2194344.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-03", "CFDA Number": "93.837", "Description": "DETERMINANTS OF TUBERCULOSIS SEVERITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_R01HL127384_7529"}, {"internal_id": 49758038, "Award ID": "R01HL127349", "Award Amount": 4448132.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.310", "Description": "GENOMIC ANALYSIS OF TISSUE AND CELLULAR HETEROGENEITY IN IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL127349_7529"}, {"internal_id": 49758037, "Award ID": "R01HL127342", "Award Amount": 4544621.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-04", "CFDA Number": "93.837", "Description": "ROLE OF SPHINGOLIPID PATHWAYS IN THE PATHOBIOLOGY OF PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL127342_7529"}, {"internal_id": 49758034, "Award ID": "R01HL127338", "Award Amount": 1465672.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-01", "CFDA Number": "93.837", "Description": "THE ROLE OF ZFP36 IN CONTROL OF IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL127338_7529"}, {"internal_id": 49758033, "Award ID": "R01HL127332", "Award Amount": 3169674.05, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-25", "CFDA Number": "93.837", "Description": "MICRORNAS IN CIRCULATION: ONTOLOGIES OF ASTHMA SEVERITY AND TREATMENT (MICROCOAST)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL127332_7529"}, {"internal_id": 49758031, "Award ID": "R01HL127283", "Award Amount": 1560019.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-11", "CFDA Number": "93.837", "Description": "TARGETING THE ALPHA V INTEGRIN MECHANOTRANSDUCTION AXIS IN IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL127283_7529"}, {"internal_id": 49758027, "Award ID": "R01HL127237", "Award Amount": 1823303.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-01", "CFDA Number": "93.837", "Description": "DEVELOPMENTAL NICOTINE EXPOSURE & TRANSGENERATIONALLY ALTERED LUNG PHENOTYPE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5c561522-ef19-011a-85ba-0ef6e9e9c878-C", "generated_internal_id": "ASST_NON_R01HL127237_7529"}, {"internal_id": 49758022, "Award ID": "R01HL127203", "Award Amount": 3943370.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-10", "CFDA Number": "93.837", "Description": "CDKN2B AS A NOVEL EPIGENETICALLY REGULATED GENE IN IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL127203_7529"}, {"internal_id": 49758021, "Award ID": "R01HL127200", "Award Amount": 4239763.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-31", "CFDA Number": "93.837", "Description": "HL-FAM13A REGULATES THE BETA-CATENIN/WNT PATHWAY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL127200_7529"}, {"internal_id": 49758020, "Award ID": "R01HL127192", "Award Amount": 1523604.63, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-28", "CFDA Number": "93.837", "Description": "MICRORNA-25 ATTENUATES ALLERGIC INFLAMMATION BY ALTERING AIRWAY SMOOTH MUSCLE PHENOTYPE AND FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NV", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "73a4ecd1-65ed-80de-ae3d-fa537fa2df50-C", "generated_internal_id": "ASST_NON_R01HL127192_7529"}, {"internal_id": 49758013, "Award ID": "R01HL127144", "Award Amount": 1524876.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-13", "CFDA Number": "93.838", "Description": "OPTIMIZING FUNCTIONAL RECELLULARIZATION OF ACELLULAR HUMAN LUNG SCAFFOLDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL127144_7529"}, {"internal_id": 49757991, "Award ID": "R01HL127002", "Award Amount": 2949728.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-22", "CFDA Number": "93.837", "Description": "MECHANISMS OF ADULT LUNG ALVEOLOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL127002_7529"}, {"internal_id": 49757990, "Award ID": "R01HL127001", "Award Amount": 1538125.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-16", "CFDA Number": "93.837", "Description": "LACTATE PROMOTES SCARRING AFTER IRRADIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R01HL127001_7529"}, {"internal_id": 49757989, "Award ID": "R01HL126990", "Award Amount": 1919600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-10", "CFDA Number": "93.838", "Description": "TWIST1 SUBPHENOTYPES AND PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL126990_7529"}, {"internal_id": 49757968, "Award ID": "R01HL126897", "Award Amount": 1399406.51, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-10", "CFDA Number": "93.837", "Description": "THE MECHANISMS OF PROFIBROTIC SENSITIZATION BY IL33", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL126897_7529"}, {"internal_id": 49757966, "Award ID": "R01HL126895", "Award Amount": 1787372.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-20", "CFDA Number": "93.837", "Description": "AIRWAY TH2TH17 CELLS IN REFRACTORY ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL126895_7529"}, {"internal_id": 64141581, "Award ID": "R01HL126887", "Award Amount": 2397667.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-15", "CFDA Number": "93.837", "Description": "INFLUENCE OF THE LUNG MICROBIOME ON MACROPHAGE RESPONSES TO LUNG DAMAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "378fe7f9-e157-cd75-80cc-97cbe1a426db-C", "generated_internal_id": "ASST_NON_R01HL126887_7529"}, {"internal_id": 49757964, "Award ID": "R01HL126877", "Award Amount": 562289.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-01", "CFDA Number": "93.838", "Description": "ROLE OF CLAUDIN 18 IN REGULATION OF LUNG STEM/PROGENITOR CELL HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL126877_7529"}, {"internal_id": 49757959, "Award ID": "R01HL126852", "Award Amount": 2001189.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-01", "CFDA Number": "93.837", "Description": "ROLE OF ALTERNATIVELY ACTIVATED MACROPHAGES IN ALLERGIC ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL126852_7529"}, {"internal_id": 49757955, "Award ID": "R01HL126838", "Award Amount": 3128904.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-15", "CFDA Number": "93.837", "Description": "DEFINING THE ROLE OF EARLY PULMONARY VASCULAR DISEASE IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL126838_7529"}, {"internal_id": 49757946, "Award ID": "R01HL126788", "Award Amount": 2026366.53, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-14", "CFDA Number": "93.837", "Description": "ROLE OF RAGE AND NECROPTOSIS IN TRANSFUSION MEDIATED LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL126788_7529"}, {"internal_id": 49757942, "Award ID": "R01HL126771", "Award Amount": 5059623.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-06", "CFDA Number": "93.837", "Description": "USING MRI TO VISUALIZE REGIONAL THERAPY RESPONSE IN IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL126771_7529"}, {"internal_id": 49757935, "Award ID": "R01HL126736", "Award Amount": 1930379.13, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-12", "CFDA Number": "93.837", "Description": "INNATE EFFECTS OF BERYLLIUM ON PULMONARYDENDRITIC CELL FUNCTION IN CHRONIC BERYLLIUM DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL126736_7529"}, {"internal_id": 49757933, "Award ID": "R01HL126732", "Award Amount": 1807495.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-10", "CFDA Number": "93.837", "Description": "HL-ROLE OF C-MYC IN MYOFIBROBLAST DIFFERENTIATION IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL126732_7529"}, {"internal_id": 49757929, "Award ID": "R01HL126711", "Award Amount": 1945008.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-31", "CFDA Number": "93.837", "Description": "COMBINED VIRAL AND BACTERIAL INFECTION AND ZINC HOMEOSTASIS IN DISTAL LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL126711_7529"}, {"internal_id": 49757926, "Award ID": "R01HL126703", "Award Amount": 1550000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-08", "CFDA Number": "93.838", "Description": "TRANSCRIPTIONAL CONTROL OF LUNG MACROPHAGE DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL126703_7529"}, {"internal_id": 49757923, "Award ID": "R01HL126694", "Award Amount": 965538.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-06", "CFDA Number": "93.838", "Description": "NOVEL APPROACHES TO PROFILING HOSPITALS ON CRITICAL ILLNESS MORTALITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL126694_7529"}, {"internal_id": 49757922, "Award ID": "R01HL126671", "Award Amount": 2034697.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-06", "CFDA Number": "93.838", "Description": "HEMOGLOBIN IN ARDS: A NOVEL MEDIATOR OF AVEOLAR EPITHELIAL CELL DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL126671_7529"}, {"internal_id": 49757920, "Award ID": "R01HL126667", "Award Amount": 4348414.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-10", "CFDA Number": "93.837", "Description": "ASTHMA ASCERTAINMENT AND CHARACTERIZATION THROUGH ELECTRONIC HEALTH RECORDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL126667_7529"}, {"internal_id": 49757918, "Award ID": "R01HL126647", "Award Amount": 1950000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-06", "CFDA Number": "93.838", "Description": "REGULATION OF PULMONARY ANTI-VIRAL IMMUNITY IN NORMAL AND OBESE HOSTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL126647_7529"}, {"internal_id": 49757912, "Award ID": "R01HL126603", "Award Amount": 1640993.8, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-11", "CFDA Number": "93.837", "Description": "CONTRIBUTION OF NEUTROPHILS TO EARLY AIRWAY DISEASE IN CYSTIC FIBROSIS CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL126603_7529"}, {"internal_id": 49757911, "Award ID": "R01HL126600", "Award Amount": 1576350.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-16", "CFDA Number": "93.837", "Description": "EPIGENETIC REGULATION OF IMMUNITY IN ALPHA-1 ANTI-TRYPSIN DEFICIENCY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL126600_7529"}, {"internal_id": 49757910, "Award ID": "R01HL126596", "Award Amount": 1498306.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-11", "CFDA Number": "93.837", "Description": "GENETICS OF SMOKE-ALTERED LTA4H IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL126596_7529"}, {"internal_id": 49757900, "Award ID": "R01HL126549", "Award Amount": 3227559.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-12", "CFDA Number": "93.837", "Description": "PREDICTORS, CONSEQUENCES AND MECHANISMS OF ACCELERATED LUNG AGING IN HIV", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL126549_7529"}, {"internal_id": 49757895, "Award ID": "R01HL126536", "Award Amount": 2797473.22, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-12", "CFDA Number": "93.837", "Description": "HIV AND EMPHYSEMA _ ROLE OF PULMONARY VASCULAR DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL126536_7529"}, {"internal_id": 49757891, "Award ID": "R01HL126523", "Award Amount": 5447067.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-15", "CFDA Number": "93.837", "Description": "UNRAVELING RESPIRATORY RHYTHM GENERATION IN THE MEDULLARY NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL126523_7529"}, {"internal_id": 49757888, "Award ID": "R01HL126514", "Award Amount": 3010342.29, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-28", "CFDA Number": "93.837", "Description": "AQUAPORIN 1 AND PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL126514_7529"}, {"internal_id": 49757886, "Award ID": "R01HL126508", "Award Amount": 3960610.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-03", "CFDA Number": "93.837", "Description": "SELF-MANAGEMENT BEHAVIORS AMONG COPD PATIENTS WITH MULTI-MORBIDITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL126508_7529"}, {"internal_id": 49757885, "Award ID": "R01HL126492", "Award Amount": 1093465.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-12", "CFDA Number": "93.838", "Description": "USING REAL WORLD DECISIONS TO DEVELOP A MODIFIED CENTRAL IRB MODEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL126492_7529"}, {"internal_id": 49757883, "Award ID": "R01HL126451", "Award Amount": 1913960.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-18", "CFDA Number": "93.838", "Description": "ROLE OF MITOCHONDRIA IN AIRWAY SMOOTH MUSCLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL126451_7529"}, {"internal_id": 49757880, "Award ID": "R01HL126176", "Award Amount": 2787064.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-10", "CFDA Number": "93.837", "Description": "THE GOLD STUDY:  GOAL OF OPEN LUNG VENTILATION IN DONORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL126176_7529"}, {"internal_id": 49757872, "Award ID": "R01HL126125", "Award Amount": 3290464.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-01", "CFDA Number": "93.837", "Description": "THE BREATHEWELL PROGRAM TO IMPROVE ASTHMA OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL126125_7529"}, {"internal_id": 49757868, "Award ID": "R01HL126094", "Award Amount": 2097643.97, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-10", "CFDA Number": "93.837", "Description": "HOST-PNEUMOCOCCAL INTERACTION IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL126094_7529"}, {"internal_id": 49757865, "Award ID": "R01HL126066", "Award Amount": 4271258.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-25", "CFDA Number": "93.837", "Description": "NECROSIS IN PULMONARY TB GRANULOMAS: DYNAMICS, MECHANISMS, THERAPIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL126066_7529"}, {"internal_id": 49757858, "Award ID": "R01HL125926", "Award Amount": 3551304.46, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-12", "CFDA Number": "93.837", "Description": "GALECTIN-3: A MEDIATOR OF VASCULAR REMODELING IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_R01HL125926_7529"}, {"internal_id": 49757855, "Award ID": "R01HL125897", "Award Amount": 2080984.66, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-22", "CFDA Number": "93.837", "Description": "NOVEL ROLE OF EGFR IN VIRUS-INDUCED ASTHMA EXACERBATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL125897_7529"}, {"internal_id": 49757853, "Award ID": "R01HL125892", "Award Amount": 2219400.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-07", "CFDA Number": "93.837", "Description": "TARGETED CORRECTION OF THE HUMAN CFTR GENE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL125892_7529"}, {"internal_id": 49757845, "Award ID": "R01HL125850", "Award Amount": 1689206.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-26", "CFDA Number": "93.837", "Description": "NEUROIMMUNE MOLECULES IN SCLERODERMA LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL125850_7529"}, {"internal_id": 49757842, "Award ID": "R01HL125821", "Award Amount": 1769792.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-21", "CFDA Number": "93.837", "Description": "SIGNALING PATHWAYS IN LUNG STEM CELL DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL125821_7529"}, {"internal_id": 49757841, "Award ID": "R01HL125816", "Award Amount": 3250115.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-31", "CFDA Number": "93.837", "Description": "MICROBIAL TRIGGERS AND MOLECULAR MECHANISMS OF TH17 MEDIATED AIRWAY INFLAMMATION-RESUBMISSION-1", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_R01HL125816_7529"}, {"internal_id": 49757829, "Award ID": "R01HL125734", "Award Amount": 3480764.72, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-01", "CFDA Number": "93.837", "Description": "MICRORNAS AND EARLY LIFE EXPOSURES IN THE DEVELOPMENTAL ORIGIN OF ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL125734_7529"}, {"internal_id": 49757828, "Award ID": "R01HL125715", "Award Amount": 1733710.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "TGFB AND NITRIC OXIDE SIGNALING IN PEDIATRIC PULMONARY VASCULAR DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL125715_7529"}, {"internal_id": 49757814, "Award ID": "R01HL125602", "Award Amount": 1900477.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-03", "CFDA Number": "93.837", "Description": "SURFACTANT PROTEIN-A REGULATION OF EOSINOPHIL APOPTOSIS IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL125602_7529"}, {"internal_id": 49757812, "Award ID": "R01HL125583", "Award Amount": 3523125.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-27", "CFDA Number": "93.837", "Description": "INTEGRATIVE GENOMICS OF CLINICAL SUBTYPES IN COPDGENE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL125583_7529"}, {"internal_id": 49757808, "Award ID": "R01HL125555", "Award Amount": 2149308.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-01", "CFDA Number": "93.838", "Description": "SECRETED SOCS PROTEINS AS VECTORS OF LUNG MACROPHAGE TO EPITHELIAL CELL CROSSTALK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL125555_7529"}, {"internal_id": 49757805, "Award ID": "R01HL125520", "Award Amount": 1363854.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-27", "CFDA Number": "93.837", "Description": "EXPLANATORY MODELS OF CF SURVIVAL, INFECTION AND INTERMEDIATE CLINICAL OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R01HL125520_7529"}, {"internal_id": 49757801, "Award ID": "R01HL125462", "Award Amount": 2277498.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-24", "CFDA Number": "93.838", "Description": "TARGETED NANOMEDICINE FOR ALI AND I/R", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL125462_7529"}, {"internal_id": 49757797, "Award ID": "R01HL125435", "Award Amount": 1533415.74, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-23", "CFDA Number": "93.837", "Description": "EPIGENETIC REGULATION IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL125435_7529"}, {"internal_id": 49757796, "Award ID": "R01HL125432", "Award Amount": 3100296.31, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-01", "CFDA Number": "93.837", "Description": "CATHELICIDIN AND VITAMIN D: IMPACT ON POPULATIONS AT-RISK AND WITH COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL125432_7529"}, {"internal_id": 49757778, "Award ID": "R01HL125280", "Award Amount": 3065960.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-03", "CFDA Number": "93.837", "Description": "THE ROLE OF MUCUS AND PULMONARY SURFACE INTERACTIONS IN LUNG DEFENSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL125280_7529"}, {"internal_id": 49757773, "Award ID": "R01HL125236", "Award Amount": 1874700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-08", "CFDA Number": "93.838", "Description": "ROLE OF FIBROTIC EXTRACELLULAR MATRIX IN GENERATING THE IPF FIBROBLAST", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL125236_7529"}, {"internal_id": 49757772, "Award ID": "R01HL125234", "Award Amount": 1539850.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-27", "CFDA Number": "93.837", "Description": "MEASUREMENT OF SURFACE LUNG TISSUE USING ULTRASOUND", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL125234_7529"}, {"internal_id": 49757770, "Award ID": "R01HL125227", "Award Amount": 1843539.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-26", "CFDA Number": "93.838", "Description": "INTEGRIN-MATRIX REGULATION OF IPF FIBROBLAST PHENOTYPE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL125227_7529"}, {"internal_id": 49757768, "Award ID": "R01HL125186", "Award Amount": 1868457.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-15", "CFDA Number": "93.837", "Description": "IMMUNE EVASION IN EMBRYONIC STEM CELL-BASED TISSUE REPAIR AND TRANSPLANTATION.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68c287e4-398a-6c6b-c0db-5ce9430c6ce3-C", "generated_internal_id": "ASST_NON_R01HL125186_7529"}, {"internal_id": 49757766, "Award ID": "R01HL125169", "Award Amount": 1662612.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-14", "CFDA Number": "93.837", "Description": "MUCUS MICROSTRUCTURE AND OSMOTIC PRESSURE: BIOMARKERS FOR CB IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL125169_7529"}, {"internal_id": 49757765, "Award ID": "R01HL125128", "Award Amount": 1921033.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-13", "CFDA Number": "93.837", "Description": "SPLUNC1 IN SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL125128_7529"}, {"internal_id": 49757761, "Award ID": "R01HL125076", "Award Amount": 4978762.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-09", "CFDA Number": "93.837", "Description": "PHAGOSOMAL ION CHANNELS AS THERAPEUTIC TARGETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL125076_7529"}, {"internal_id": 49757760, "Award ID": "R01HL125060", "Award Amount": 1693377.33, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-29", "CFDA Number": "93.837", "Description": "EXERCISE MRI EVALUATION OF HIV-PAH LONGITUDINAL DETERMINANTS(EXHALTED)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL125060_7529"}, {"internal_id": 49757758, "Award ID": "R01HL125054", "Award Amount": 3278523.95, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-08", "CFDA Number": "93.837", "Description": "ROLE OF MACROPHAGES IN LUNG DISEASE PATHOGENESIS OF PEDIATRIC AIDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_R01HL125054_7529"}, {"internal_id": 49757756, "Award ID": "R01HL125050", "Award Amount": 1729007.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-17", "CFDA Number": "93.837", "Description": "MODULATION OF SP1/SP3 BY HIV-1 TAT CONTRIBUTES TO OXIDATIVE STRESS IN HIV-PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL125050_7529"}, {"internal_id": 49757755, "Award ID": "R01HL125049", "Award Amount": 3198643.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-15", "CFDA Number": "93.838", "Description": "LONGITUDINAL EVALUATION OF HIV-ASSOCIATED LUNG DISEASE PHENOTYPES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL125049_7529"}, {"internal_id": 49757754, "Award ID": "R01HL125042", "Award Amount": 2811084.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-06", "CFDA Number": "93.838", "Description": "HIV-INDUCED REDOX STRESS AND THE ALVEOLAR MACROPHAGE AS A RESISTANT RESERVOIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL125042_7529"}, {"internal_id": 49757747, "Award ID": "R01HL125000", "Award Amount": 2961783.4, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-12", "CFDA Number": "93.837", "Description": "HIV-ASSOCIATED CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f2d34976-4cec-07f8-d072-fb7f1eb21cbe-C", "generated_internal_id": "ASST_NON_R01HL125000_7529"}, {"internal_id": 49757746, "Award ID": "R01HL124986", "Award Amount": 2967384.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-02-06", "CFDA Number": "93.837", "Description": "A NEW APPROACH FOR THE ASSESSMENT OF PULMONARY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL124986_7529"}, {"internal_id": 49757739, "Award ID": "R01HL124747", "Award Amount": 1155000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-24", "CFDA Number": "93.838", "Description": "CAVEOLIN-1-MEDIATED SENESCENCE, CHRONIC INFLAMMATION AND AGE-RELATED LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL124747_7529"}, {"internal_id": 49757735, "Award ID": "R01HL124477", "Award Amount": 2018924.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-18", "CFDA Number": "93.837", "Description": "SEX DIFFERENCES IN MACROPHAGE DIFFERENTIATION IN ALLERGIC LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL124477_7529"}, {"internal_id": 49757730, "Award ID": "R01HL124392", "Award Amount": 4016195.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-08", "CFDA Number": "93.837", "Description": "DEFINING EPITHELIAL CELL POLARITY CUES THAT DIRECT CELL FATE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL124392_7529"}, {"internal_id": 49757729, "Award ID": "R01HL124325", "Award Amount": 1901030.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-25", "CFDA Number": "93.837", "Description": "MICROPARTICULATE CASPASE-1 MEDIATED LUNG INJURY.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL124325_7529"}, {"internal_id": 49757726, "Award ID": "R01HL124285", "Award Amount": 2170425.03, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-31", "CFDA Number": "93.837", "Description": "MASSIVELY PARALLEL IDENTIFICATION OF FUNCTIONAL 3' UTR VARIANTS IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL124285_7529"}, {"internal_id": 49757723, "Award ID": "R01HL124280", "Award Amount": 1630809.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-01", "CFDA Number": "93.838", "Description": "BIOMECHANICAL DETERMINANTS OF LUNG CELL FATE IN PLURIPOTENT STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL124280_7529"}, {"internal_id": 49757718, "Award ID": "R01HL124233", "Award Amount": 6405460.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-16", "CFDA Number": "93.837", "Description": "USING INTEGRATIVE GENOMICS TO IDENTIFY AND CHARACTERIZE EMPHYSEMA-ASSOCIATED EQTL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL124233_7529"}, {"internal_id": 49757710, "Award ID": "R01HL124165", "Award Amount": 3109664.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-01", "CFDA Number": "93.838", "Description": "AIRWAY SENSORY NERVES IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL124165_7529"}, {"internal_id": 49757700, "Award ID": "R01HL124103", "Award Amount": 2649291.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-31", "CFDA Number": "93.838", "Description": "THE MICROBIOME, VIROME AND HOST RESPONSES PRECEDING VENTILATOR-ASSOCIATED PNEUMON", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL124103_7529"}, {"internal_id": 49757698, "Award ID": "R01HL124099", "Award Amount": 2114236.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-26", "CFDA Number": "93.837", "Description": "ACTIN-MYOSIN CONTRACTILITY PROMOTES THE DEVELOPMENT OF CHRONIC BRONCHITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL124099_7529"}, {"internal_id": 49757694, "Award ID": "R01HL124076", "Award Amount": 1438192.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-18", "CFDA Number": "93.838", "Description": "THE ROLE OF BIOMECHANICAL SIGNALING IN LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL124076_7529"}, {"internal_id": 49757691, "Award ID": "R01HL124053", "Award Amount": 2762093.47, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-24", "CFDA Number": "93.837", "Description": "A PROSPECTIVE TRIAL OF ORAL AZITHROMYCIN WHEN ADDED TO INHALED TOBRAMYCIN IN CF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL124053_7529"}, {"internal_id": 49757690, "Award ID": "R01HL124052", "Award Amount": 2350042.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-26", "CFDA Number": "93.838", "Description": "PERSONALIZED MECHANICAL VENTILATION FOR THE INJURED LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL124052_7529"}, {"internal_id": 49757689, "Award ID": "R01HL124021", "Award Amount": 3436164.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-18", "CFDA Number": "93.837", "Description": "DEFINING THE COMPLEX BIOLOGY OF THE MIR-130/301 FAMILY IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL124021_7529"}, {"internal_id": 49757683, "Award ID": "R01HL123978", "Award Amount": 3588116.14, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-15", "CFDA Number": "93.837", "Description": "ENHANCING THE EFFICACY OF A SMOKING QUIT LINE IN THE MILITARY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL123978_7529"}, {"internal_id": 49757680, "Award ID": "R01HL123965", "Award Amount": 1229368.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-23", "CFDA Number": "93.837", "Description": "THE ROLE OF NPR-C IN MODULATION OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f21f887-ca03-f1f2-6e30-1c1498f78b9e-C", "generated_internal_id": "ASST_NON_R01HL123965_7529"}, {"internal_id": 49757679, "Award ID": "R01HL123957", "Award Amount": 1963868.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-08", "CFDA Number": "93.837", "Description": "NOVEL SIGNALINGS AND MOLECULAR TARGETS OF ENDOTHELIAL REGENERATION IN AGING LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_R01HL123957_7529"}, {"internal_id": 49757673, "Award ID": "R01HL123915", "Award Amount": 6997109.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-28", "CFDA Number": "93.837", "Description": "INTEGRATIVE METABOLOMICS OF ASTHMA SEVERITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL123915_7529"}, {"internal_id": 49757670, "Award ID": "R01HL123899", "Award Amount": 2023083.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-21", "CFDA Number": "93.837", "Description": "INNATE DNA SENSING IN RAPIDLY PROGRESSING IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL123899_7529"}, {"internal_id": 49757668, "Award ID": "R01HL123851", "Award Amount": 1675000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-18", "CFDA Number": "93.837", "Description": "CFTR AND TOLL-LIKE RECEPTOR SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL123851_7529"}, {"internal_id": 49757667, "Award ID": "R01HL123804", "Award Amount": 1598750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-10", "CFDA Number": "93.837", "Description": "ROLE OF MICRORNA-17-92 AND PDLIM5 SIGNALING IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL123804_7529"}, {"internal_id": 49757666, "Award ID": "R01HL123797", "Award Amount": 3255007.28, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-13", "CFDA Number": "93.837", "Description": "THE ASTHMA ACTION AT ERIE TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL123797_7529"}, {"internal_id": 49757663, "Award ID": "R01HL123771", "Award Amount": 1499876.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-27", "CFDA Number": "93.837", "Description": "VIRAL-BACTERIAL CO-INFECTIONS IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL123771_7529"}, {"internal_id": 49757662, "Award ID": "R01HL123766", "Award Amount": 1939865.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-20", "CFDA Number": "93.837", "Description": "AGING OF MESENCHYMAL STEM CELLS MISSING LINK IN IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL123766_7529"}, {"internal_id": 49757650, "Award ID": "R01HL123609", "Award Amount": 3923487.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-01", "CFDA Number": "93.837", "Description": "TREATING CAREGIVER DEPRESSION TO IMPROVE CHILDHOOD ASTHMA: IMPACT AND MEDIATORS -", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_R01HL123609_7529"}, {"internal_id": 49757646, "Award ID": "R01HL123557", "Award Amount": 2060339.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-25", "CFDA Number": "93.837", "Description": "ANATOMIC OPTICAL COHERENCE TOMOGRAPHY FOR QUANTITATIVE BRONCHOSCOPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL123557_7529"}, {"internal_id": 49757645, "Award ID": "R01HL123546", "Award Amount": 3366798.15, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-20", "CFDA Number": "93.837", "Description": "THE FUNCTIONAL CONSEQUENCES OF THE 17Q12 ASTHMA SUSCEPTIBILITY LOCUS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL123546_7529"}, {"internal_id": 49757644, "Award ID": "R01HL123544", "Award Amount": 2118620.84, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-10", "CFDA Number": "93.837", "Description": "DEFECTIVE FGFR2 SIGNALING IN THE SMALL AIRWAY BASAL PROGENITOR CELLS IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL123544_7529"}, {"internal_id": 49757642, "Award ID": "R01HL123540", "Award Amount": 1494368.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-17", "CFDA Number": "93.838", "Description": "CXCR4 SIGNALING IN LUNG EPITHELIAL REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R01HL123540_7529"}, {"internal_id": 49757641, "Award ID": "R01HL123535", "Award Amount": 1884469.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-08", "CFDA Number": "93.837", "Description": "CHARACTERIZATION OF AN INHIBITORY PROTEIN COMPLEX FOR CYSTIC FIBROSIS THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7bb49047-7166-d4e3-8873-4218d87cf06c-C", "generated_internal_id": "ASST_NON_R01HL123535_7529"}, {"internal_id": 49757639, "Award ID": "R01HL123515", "Award Amount": 2455777.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-10", "CFDA Number": "93.838", "Description": "NOVEL IL-1 FAMILY MEMBERS IN LUNG INNATE IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL123515_7529"}, {"internal_id": 49757638, "Award ID": "R01HL123494", "Award Amount": 1917840.45, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-22", "CFDA Number": "93.837", "Description": "ESTROGEN RECEPTOR SIGNALING IN AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "ND", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "abd98500-a812-0a76-1610-357bcd3f88de-C", "generated_internal_id": "ASST_NON_R01HL123494_7529"}, {"internal_id": 49757637, "Award ID": "R01HL123490", "Award Amount": 1540826.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-05", "CFDA Number": "93.838", "Description": "TRANSCRIPTIONAL REGULATION OF GOBLET CELL METAPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL123490_7529"}, {"internal_id": 49757632, "Award ID": "R01HL123385", "Award Amount": 1810389.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-06", "CFDA Number": "93.838", "Description": "IMPROVED PREDICTION OF RESPONSE TO ASTHMA MEDICATION USING SMALL MOLECULES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL123385_7529"}, {"internal_id": 49757628, "Award ID": "R01HL123364", "Award Amount": 1546669.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-28", "CFDA Number": "93.838", "Description": "LEUKOTRIENE C4 AND STIM/ORAI CHANNELS IN AIRWAY SMOOTH MUSCLE REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47ed9961-3300-5ed7-bb62-e5359d99eaf9-C", "generated_internal_id": "ASST_NON_R01HL123364_7529"}, {"internal_id": 49757616, "Award ID": "R01HL123284", "Award Amount": 2871808.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-24", "CFDA Number": "93.866", "Description": "ASTHMATIC INFLAMMATION AND NEUROCIRCUITRY ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL123284_7529"}, {"internal_id": 49757603, "Award ID": "R01HL122995", "Award Amount": 4609396.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-31", "CFDA Number": "93.837", "Description": "ASTHMA SUSCEPTIBILITY DUE TO ENVIRONMENTAL PROGRAMING OF INNATE IMMUNITY IN UTERO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL122995_7529"}, {"internal_id": 49757602, "Award ID": "R01HL122993", "Award Amount": 2534059.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-20", "CFDA Number": "93.838", "Description": "FUNCTION OF THE INCRNA TRANSCRIPTOME IN LUNG DEVELOPMENT AND REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL122993_7529"}, {"internal_id": 49757596, "Award ID": "R01HL122921", "Award Amount": 2305458.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-31", "CFDA Number": "93.838", "Description": "CNS PATHWAYS INTEGRATING RESPIRATORY AND METABOLIC CONTROL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL122921_7529"}, {"internal_id": 49757595, "Award ID": "R01HL122918", "Award Amount": 2289919.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-30", "CFDA Number": "93.837", "Description": "NOVEL MOLECULAR MECHANISMS REGULATING POSTNATAL PULMONARY ANGIOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL122918_7529"}, {"internal_id": 49757593, "Award ID": "R01HL122895", "Award Amount": 1706232.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-06", "CFDA Number": "93.838", "Description": "PDGFR-BETA+ STROMAL CELLS AS CRITICAL REGULATORS OF IMMUNE RESPONSE TO TISSUE INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL122895_7529"}, {"internal_id": 49757592, "Award ID": "R01HL122887", "Award Amount": 4057530.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-20", "CFDA Number": "93.838", "Description": "INTEGRATIVE OMICS AS A DISCOVERY TOOL FOR PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL122887_7529"}, {"internal_id": 49757589, "Award ID": "R01HL122865", "Award Amount": 1913898.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-05", "CFDA Number": "93.837", "Description": "NOVEL SIGNALING IN CHRONIC HYPOXIC RESPONSES IN PULMONARY ARTERIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "84c69770-7b20-b9e0-d502-4ceb449256bf-C", "generated_internal_id": "ASST_NON_R01HL122865_7529"}, {"internal_id": 49757571, "Award ID": "R01HL122764", "Award Amount": 1649375.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-24", "CFDA Number": "93.838", "Description": "THE BIOLOGY OF PULMONARY ALVEOLAR FORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL122764_7529"}, {"internal_id": 49757570, "Award ID": "R01HL122760", "Award Amount": 1496244.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-10", "CFDA Number": "93.837", "Description": "IL-22: A THERAPEUTIC CYTOKINE FOR THE AMELIORATION OF PULMONARY INFLUENZA INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_R01HL122760_7529"}, {"internal_id": 49757564, "Award ID": "R01HL122730", "Award Amount": 1758568.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-14", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL DYNAMICS IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL122730_7529"}, {"internal_id": 49757563, "Award ID": "R01HL122712", "Award Amount": 3109310.61, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-21", "CFDA Number": "93.837", "Description": "MENDELIAN DISEASE - ASTHMA COMORBIDITY TO FIND SUBGROUP-SPECIFIC ASTHMA GENES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL122712_7529"}, {"internal_id": 49757562, "Award ID": "R01HL122711", "Award Amount": 1955257.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-04", "CFDA Number": "93.837", "Description": "SYSTEMS-LEVEL TRANSCRIPTOMIC ANALYSES TO IDENTIFY MOUSE MODELS OF ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL122711_7529"}, {"internal_id": 49757551, "Award ID": "R01HL122624", "Award Amount": 3486703.04, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-18", "CFDA Number": "93.837", "Description": "TRIAL OF VITAMIN D SUPPLEMENTATION TO PREVENT TB INFECTION IN SCHOOLCHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_R01HL122624_7529"}, {"internal_id": 49757549, "Award ID": "R01HL122596", "Award Amount": 3847888.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-23", "CFDA Number": "93.837", "Description": "IRON-SULFUR DEFICIENCY AS A CRITICAL PATHOGENIC CAUSE OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL122596_7529"}, {"internal_id": 49757547, "Award ID": "R01HL122582", "Award Amount": 1525000.0, "Award Type": null, "Base Obligation Date": "2015-05-06", "CFDA Number": "93.838", "Description": "ROLE OF MYB FOR AIRWAY EPITHELIAL CELL DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL122582_7529"}, {"internal_id": 49757541, "Award ID": "R01HL122559", "Award Amount": 1939500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-03", "CFDA Number": "93.837", "Description": "IMPRINTING OF LUNG-RESIDENT T CELL MEMORY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL122559_7529"}, {"internal_id": 49757540, "Award ID": "R01HL122554", "Award Amount": 4825007.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-18", "CFDA Number": "93.837", "Description": "ROLE OF GENDER IN TH17-MEDIATED INFLAMMATION IN SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL122554_7529"}, {"internal_id": 49757537, "Award ID": "R01HL122533", "Award Amount": 1934173.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-07", "CFDA Number": "93.838", "Description": "TRANSLATIONAL STUDIES OF AUTOIMMUNE-MEDIATED LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL122533_7529"}, {"internal_id": 49757536, "Award ID": "R01HL122531", "Award Amount": 3945289.8, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-16", "CFDA Number": "93.837", "Description": "SPECIALIZED PRO-RESOLVING MEDIATORS IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL122531_7529"}, {"internal_id": 49757529, "Award ID": "R01HL122477", "Award Amount": 12674523.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-16", "CFDA Number": "93.837", "Description": "LUNG FUNCTION DECLINE AND DISEASE RISK FROM YOUNG ADULTHOOD TO MIDDLE AGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL122477_7529"}, {"internal_id": 49757526, "Award ID": "R01HL122464", "Award Amount": 2127800.28, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-19", "CFDA Number": "93.837", "Description": "SKELETAL MUSCLE, SUBCUTANEOUS FAT, AND CLINICAL OUTCOMES IN SMOKERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL122464_7529"}, {"internal_id": 49757523, "Award ID": "R01HL122442", "Award Amount": 1609773.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-01", "CFDA Number": "93.838", "Description": "IPSC MODELING OF THE ROLE OF NKX2-1 IN HUMAN LUNG DEVELOPMENT AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL122442_7529"}, {"internal_id": 49757522, "Award ID": "R01HL122438", "Award Amount": 3958457.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-05", "CFDA Number": "93.838", "Description": "PARAMETRIC RESPONSE MAPPING IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL122438_7529"}, {"internal_id": 49757521, "Award ID": "R01HL122426", "Award Amount": 3735942.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-08", "CFDA Number": "93.837", "Description": "IMMUNOPATHOGENESIS IN FUNGAL ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_R01HL122426_7529"}, {"internal_id": 49757520, "Award ID": "R01HL122424", "Award Amount": 1881631.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-24", "CFDA Number": "93.838", "Description": "EPITHELIAL BARRIER DYSFUNCTION AND MUCOSAL INFLAMMATION IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL122424_7529"}, {"internal_id": 49757518, "Award ID": "R01HL122417", "Award Amount": 2703318.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-24", "CFDA Number": "93.838", "Description": "LIPID DEPOSITION IN THE RIGHT VENTRICLE IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL122417_7529"}, {"internal_id": 49757516, "Award ID": "R01HL122406", "Award Amount": 1778240.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "RESPIRATORY DEFICIENCIES IN CONGENITAL DIAPHRAGMATIC HERNIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL122406_7529"}, {"internal_id": 49757509, "Award ID": "R01HL122383", "Award Amount": 3466250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-23", "CFDA Number": "93.837", "Description": "ENDOPLASMIC RETICULUM STRESS SIGNALING IN ALLERGEN-INDUCED AIRWAY REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL122383_7529"}, {"internal_id": 49757507, "Award ID": "R01HL122372", "Award Amount": 1968543.13, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-21", "CFDA Number": "93.837", "Description": "REGIONAL HYPOXIA IMPACTS THE HETEROGENEITY OF INFLAMMATORY LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "67b657d0-7435-9fe5-63cc-b4a9cbf99f25-C", "generated_internal_id": "ASST_NON_R01HL122372_7529"}, {"internal_id": 49757506, "Award ID": "R01HL122358", "Award Amount": 3753509.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-17", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISMS OF CENTRAL C02 CHEMORECEPTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL122358_7529"}, {"internal_id": 49757503, "Award ID": "R01HL122340", "Award Amount": 1600000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-15", "CFDA Number": "93.838", "Description": "TARGETING AIRWAY SMOOTH MUSCLE CHLORIDE FLUXES FOR BRONCHORELAXATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL122340_7529"}, {"internal_id": 49757498, "Award ID": "R01HL122321", "Award Amount": 1585000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-18", "CFDA Number": "93.837", "Description": "NOVEL FUNCTION OF MUC18: AMPLIFICATION OF INFLAMMATION IN ALLERGIC LUNGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL122321_7529"}, {"internal_id": 49757495, "Award ID": "R01HL122307", "Award Amount": 1806800.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-10", "CFDA Number": "93.837", "Description": "LUNG EPITHELIAL-IMMUNE INTERACTIONS IN RESPIRATORY VIRUS INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL122307_7529"}, {"internal_id": 49757493, "Award ID": "R01HL122300", "Award Amount": 2181704.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-28", "CFDA Number": "93.837", "Description": "MECHANISMS OF IL-17A-MEDIATED ENHANCEMENT OF ASTHMA SEVERITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL122300_7529"}, {"internal_id": 49757490, "Award ID": "R01HL122267", "Award Amount": 3290515.81, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-13", "CFDA Number": "93.837", "Description": "CF GENE THERAPY WITH ADENO-ASSOCIATED VIRAL VECTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL122267_7529"}, {"internal_id": 49757485, "Award ID": "R01HL122228", "Award Amount": 2831327.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-21", "CFDA Number": "93.837", "Description": "CONTROL OF AIRWAY NOCICEPTOR FUNCTION BY VOLTAGE-GATED SODIUM CHANNEL SUBTYPES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL122228_7529"}, {"internal_id": 49757481, "Award ID": "R01HL122215", "Award Amount": 2605114.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-14", "CFDA Number": "93.837", "Description": "ANTI-ANGIOGENIC PREECLAMPTIC MILIEU IMPAIRS INFANT LUNG AND VASCULAR DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL122215_7529"}, {"internal_id": 49757472, "Award ID": "R01HL122154", "Award Amount": 1508702.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-23", "CFDA Number": "93.838", "Description": "IMPROVING TOPICAL DRUG DELIVERY FOR TREATMENT OF CHRONIC RHINOSINUSITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL122154_7529"}, {"internal_id": 49757468, "Award ID": "R01HL122130", "Award Amount": 1554150.0, "Award Type": null, "Base Obligation Date": "2013-12-18", "CFDA Number": "93.838", "Description": "STARD7, A NOVEL INHIBITOR OF ALLERGIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL122130_7529"}, {"internal_id": 49757464, "Award ID": "R01HL122068", "Award Amount": 2142108.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-22", "CFDA Number": "93.838", "Description": "TARGETING BETA-ARRESTINS IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL122068_7529"}, {"internal_id": 49757463, "Award ID": "R01HL122062", "Award Amount": 1970185.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-16", "CFDA Number": "93.838", "Description": "METABOLIC REGULATION OF PULMONARY VASCULAR REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL122062_7529"}, {"internal_id": 49757458, "Award ID": "R01HL121791", "Award Amount": 1886526.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-01-09", "CFDA Number": "93.838", "Description": "IL-33 AND EXCESS MUCUS PRODUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL121791_7529"}, {"internal_id": 49757457, "Award ID": "R01HL121788", "Award Amount": 3668306.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-18", "CFDA Number": "93.837", "Description": "MICRO COHERENCE IMAGING TECHNOLOGY FOR ASSESSING OBSTRUCTIVE LUNG DISEASE IN VIVO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL121788_7529"}, {"internal_id": 49757455, "Award ID": "R01HL121774", "Award Amount": 3103026.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-27", "CFDA Number": "93.837", "Description": "FUNCTIONAL ANALYSIS OF THE PULMONARY MICROBIOME DURING COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL121774_7529"}, {"internal_id": 49757452, "Award ID": "R01HL121708", "Award Amount": 4162383.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-11", "CFDA Number": "93.838", "Description": "DEPRESSION AND HEART FAILURE DISEASE PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL121708_7529"}, {"internal_id": 49757441, "Award ID": "R01HL121513", "Award Amount": 1514166.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-15", "CFDA Number": "93.837", "Description": "BICARBONATE REGULATION OF THE PULMONARY ENDOTHELIAL BARRIER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_R01HL121513_7529"}, {"internal_id": 49757439, "Award ID": "R01HL121500", "Award Amount": 4434451.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-30", "CFDA Number": "93.837", "Description": "ROLE OF TITIN IN THE PATHOPHYSIOLOGY OF DIAPHRAGM WEAKNESS DURING MECHANICAL VENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R01HL121500_7529"}, {"internal_id": 49757423, "Award ID": "R01HL121270", "Award Amount": 5550343.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-18", "CFDA Number": "93.838", "Description": "NOVEL QUANTITATIVE EMPHYSEMA SUBTYPES IN MESA AND SPIROMICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": 806343.0, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL121270_7529"}, {"internal_id": 49757421, "Award ID": "R01HL121266", "Award Amount": 1998618.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-30", "CFDA Number": "93.838", "Description": "MOLECULAR AND BIOCHEMICAL BASIS OF LYMPHANGIOLEIOMYOMATOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL121266_7529"}, {"internal_id": 49757419, "Award ID": "R01HL121262", "Award Amount": 1495000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-19", "CFDA Number": "93.837", "Description": "MECHANISM OF ACTION OF ANTI-FIBROTIC PEPTIDE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "SC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "04a78f04-ee86-46df-5fbf-c71e46ed8479-C", "generated_internal_id": "ASST_NON_R01HL121262_7529"}, {"internal_id": 49757414, "Award ID": "R01HL121228", "Award Amount": 6175684.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-20", "CFDA Number": "93.837", "Description": "REGIONAL TIDAL LUNG STRAIN AND NEUTROPHILIC INFLAMMATION IN EARLY LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL121228_7529"}, {"internal_id": 49757412, "Award ID": "R01HL121218", "Award Amount": 2806455.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-01-13", "CFDA Number": "93.838", "Description": "POSITRON EMISSION TOMOGRAPHIC IMAGING OF LUNG TRANSPLANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL121218_7529"}, {"internal_id": 49757407, "Award ID": "R01HL121139", "Award Amount": 1522417.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-09", "CFDA Number": "93.837", "Description": "PROCESSING AND PRESENTATION OF MINOR HISTOCOMPATIBILITY ANTIGENS THAT CAUSE GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL121139_7529"}, {"internal_id": 49757406, "Award ID": "R01HL121134", "Award Amount": 2564196.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-19", "CFDA Number": "93.838", "Description": "DRUG DELIVERY BY CARRIER ERYTHROCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL121134_7529"}, {"internal_id": 49757405, "Award ID": "R01HL121105", "Award Amount": 1901563.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-08", "CFDA Number": "93.838", "Description": "THE ROLE OF TREM-1 IN NEUTROPHIL TRANSEPITHELIAL MIGRATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL121105_7529"}, {"internal_id": 49757402, "Award ID": "R01HL121067", "Award Amount": 4349215.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-14", "CFDA Number": "93.837", "Description": "PEDIATRIC RESPIRATORY ILLNESS INPATIENT MEASUREMENT SYSTEM STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d192652e-3551-3991-1674-6885c846fff2-C", "generated_internal_id": "ASST_NON_R01HL121067_7529"}, {"internal_id": 49757394, "Award ID": "R01HL120980", "Award Amount": 1926410.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-28", "CFDA Number": "93.838", "Description": "ORGANIZATIONAL DETERMINANTS OF ICU TELEMEDICINE EFFECTIVENESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL120980_7529"}, {"internal_id": 49757388, "Award ID": "R01HL120952", "Award Amount": 1987759.34, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-16", "CFDA Number": "93.837", "Description": "ALLERGIC PULMONARY INFLAMMATION THROUGH THE DECTIN-2 PATHWAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL120952_7529"}, {"internal_id": 49757386, "Award ID": "R01HL120947", "Award Amount": 1676988.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-23", "CFDA Number": "93.838", "Description": "SYNDECAN-1 REGULATIONS OF INFLUENZA INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL120947_7529"}, {"internal_id": 49757381, "Award ID": "R01HL120908", "Award Amount": 1564897.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-15", "CFDA Number": "93.838", "Description": "NOVEL THERAPIES FOR CIGARETTE SMOKE INDUCED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL120908_7529"}, {"internal_id": 49757375, "Award ID": "R01HL120872", "Award Amount": 1981354.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-01", "CFDA Number": "93.838", "Description": "GENETIC INVESTIGATION OF PULMONARY LYMPHATIC DEVELOPMENT AND FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL120872_7529"}, {"internal_id": 49757360, "Award ID": "R01HL120521", "Award Amount": 1527703.0, "Award Type": null, "Base Obligation Date": "2013-12-20", "CFDA Number": "93.838", "Description": "CELL-SPECIFIC GENE DELIVERY METHODS FOR EXPRESSION AND SILENCING IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL120521_7529"}, {"internal_id": 49757357, "Award ID": "R01HL120398", "Award Amount": 3383685.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-09-04", "CFDA Number": "93.838", "Description": "TRANSLATIONAL EVALUATION OF AGING, INFLAMMATION, AND HIV IN LUNG DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL120398_7529"}, {"internal_id": 49757352, "Award ID": "R01HL120153", "Award Amount": 1136098.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.838", "Description": "TREM2 AND AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL120153_7529"}, {"internal_id": 49757351, "Award ID": "R01HL120142", "Award Amount": 1613924.96, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-11", "CFDA Number": "93.837", "Description": "MECHANICAL REGULATION OF MESENCHYME AND MAMMALIAN LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c1ec395-7a2e-ac81-70e3-371cfa83f023-C", "generated_internal_id": "ASST_NON_R01HL120142_7529"}, {"internal_id": 49757347, "Award ID": "R01HL120046", "Award Amount": 6059572.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-15", "CFDA Number": "93.837", "Description": "BIOENGINEERING A CHIMERIC HUMAN LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL120046_7529"}, {"internal_id": 49757340, "Award ID": "R01HL119960", "Award Amount": 3403341.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.837", "Description": "RITUXIMAB THERAPY IN PATIENTS WITH IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL119960_7529"}, {"internal_id": 49757339, "Award ID": "R01HL119946", "Award Amount": 2052172.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-30", "CFDA Number": "93.838", "Description": "CARTILAGE AND SMOOTH MUSCLE IN AIRWAY TONE AND MICROENVIRONMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL119946_7529"}, {"internal_id": 49757336, "Award ID": "R01HL119872", "Award Amount": 2338912.0, "Award Type": null, "Base Obligation Date": "2013-07-30", "CFDA Number": "93.838", "Description": "IDENTIFICATION OF VASCULAR-DERIVED SIGNALS FOR ALVEOLAR LUNG REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL119872_7529"}, {"internal_id": 49757331, "Award ID": "R01HL119845", "Award Amount": 1705730.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-31", "CFDA Number": "93.838", "Description": "MEASUREMENT OF QUALITY OF LIFE AND PERCEIVED DISEASE IMPACT ON QUALITY OF LIFE IN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d1c9f7b9-4ab2-6d29-420c-b4ac5736938a-C", "generated_internal_id": "ASST_NON_R01HL119845_7529"}, {"internal_id": 49757323, "Award ID": "R01HL119813", "Award Amount": 1932808.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-24", "CFDA Number": "93.838", "Description": "STRUCTURAL REGULATION OF CLCA1 ACTIVITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL119813_7529"}, {"internal_id": 49757322, "Award ID": "R01HL119802", "Award Amount": 1995740.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-19", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL REACTIVE OXYGEN SPECIES INDUCE AIRWAY SENSORY NERVE ACTIVITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ceec5ef7-d6a5-28f0-e23f-ec61155b7078-C", "generated_internal_id": "ASST_NON_R01HL119802_7529"}, {"internal_id": 49757319, "Award ID": "R01HL119792", "Award Amount": 1593833.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-14", "CFDA Number": "93.838", "Description": "MYOFIBROBLAST DIFFERENTIATION AND FIBROSIS ARE MEDIATED BY TRPV4 MECHANOSENSING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL119792_7529"}, {"internal_id": 49757318, "Award ID": "R01HL119770", "Award Amount": 1391362.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-01", "CFDA Number": "93.838", "Description": "ADAPTIVE IMMUNITY AGAINST PNEUMOCYSTIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL119770_7529"}, {"internal_id": 49757313, "Award ID": "R01HL119683", "Award Amount": 2115180.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-28", "CFDA Number": "93.838", "Description": "LETHAL H5N1 VIRUS INFECTION AND RESPIRATORY DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f2d34976-4cec-07f8-d072-fb7f1eb21cbe-C", "generated_internal_id": "ASST_NON_R01HL119683_7529"}, {"internal_id": 49757312, "Award ID": "R01HL119682", "Award Amount": 1493418.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-24", "CFDA Number": "93.838", "Description": "POST VIRAL BACTERIAL PNEUMONIA: ROLE OF MICRORNA AND AUTOPHAGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL119682_7529"}, {"internal_id": 49757307, "Award ID": "R01HL119543", "Award Amount": 1808091.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-29", "CFDA Number": "93.837", "Description": "NOTCH3 SIGNALING IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL119543_7529"}, {"internal_id": 49757305, "Award ID": "R01HL119538", "Award Amount": 1573347.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-25", "CFDA Number": "93.838", "Description": "CLEC5A REGULATION OF MACROPHAGE FUNCTION IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R01HL119538_7529"}, {"internal_id": 49757304, "Award ID": "R01HL119533", "Award Amount": 2454512.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-25", "CFDA Number": "93.838", "Description": "MIRNA REGULATION OF VASCULAR PERMEABILITY AND INFLAMMATION IN THE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL119533_7529"}, {"internal_id": 49757299, "Award ID": "R01HL119503", "Award Amount": 3647542.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-22", "CFDA Number": "93.837", "Description": "MECHANISMS OF PULMONARY FIBROSIS IN HERMANSKY-PUDLAK SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL119503_7529"}, {"internal_id": 49757298, "Award ID": "R01HL119501", "Award Amount": 1715388.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-25", "CFDA Number": "93.838", "Description": "IRF4-MEDIATED REGULATION OF LUNG DENDRITIC CELLS DURING VIRAL INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36c41119-2158-d09a-55ce-00590b81ab14-C", "generated_internal_id": "ASST_NON_R01HL119501_7529"}, {"internal_id": 49757294, "Award ID": "R01HL119476", "Award Amount": 4493188.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-18", "CFDA Number": "93.837", "Description": "MECHANISMS OF TELOMERE-INDUCED EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL119476_7529"}, {"internal_id": 49757289, "Award ID": "R01HL119441", "Award Amount": 1465011.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-17", "CFDA Number": "93.838", "Description": "DEFICIENT SLEEP LUNG FUNCTION, AND FUNCTIONAL OUTCOMES IN ADOLESCENTS WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL119441_7529"}, {"internal_id": 49757287, "Award ID": "R01HL119436", "Award Amount": 1985860.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-09-09", "CFDA Number": "93.838", "Description": "BIOSYNTHESIS AND TRAFFICKING OF SURFACTANT PROTEIN C IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL119436_7529"}, {"internal_id": 49757280, "Award ID": "R01HL119344", "Award Amount": 3325305.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-23", "CFDA Number": "93.838", "Description": "USE OF ADVANCED IMAGING TECHNIQUES TO IMPROVE DIAGNOSTIC METHODS FOR ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL119344_7529"}, {"internal_id": 49757278, "Award ID": "R01HL119326", "Award Amount": 2109473.13, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-07", "CFDA Number": "93.837", "Description": "RAGE MEDIATES LPA INDUCED PULMONARY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_R01HL119326_7529"}, {"internal_id": 49757271, "Award ID": "R01HL119280", "Award Amount": 2002878.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-28", "CFDA Number": "93.837", "Description": "TARGETING THIOREDOXIN REDUCTASE-1 TO PREVENT BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL119280_7529"}, {"internal_id": 49757270, "Award ID": "R01HL119263", "Award Amount": 3646933.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-11", "CFDA Number": "93.837", "Description": "PROTON MRI TO MEASURE LUNG VENTILATION AND PERFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL119263_7529"}, {"internal_id": 49757268, "Award ID": "R01HL119248", "Award Amount": 2859670.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-20", "CFDA Number": "93.838", "Description": "DEVELOPMENT AND VALIDATION OF A VIRTUAL AIRWAY SKILL TRAINER (VAST)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d3be7d3a-ba4a-8f04-76e3-df70beba3000-C", "generated_internal_id": "ASST_NON_R01HL119248_7529"}, {"internal_id": 49757261, "Award ID": "R01HL119218", "Award Amount": 3243999.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-27", "CFDA Number": "93.838", "Description": "EX VIVO PERFUSION IN A LUNG BOX FOR REHABILITATION OF DONOR LUNGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL119218_7529"}, {"internal_id": 49757260, "Award ID": "R01HL119215", "Award Amount": 4152102.2, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-31", "CFDA Number": "93.837", "Description": "A HOX-WNT-SOX SIGNALING AXIS REGULATES LUNG DEVELOPMENT, PATTERNING AND BRANCHING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL119215_7529"}, {"internal_id": 49757259, "Award ID": "R01HL119201", "Award Amount": 2488734.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-03", "CFDA Number": "93.837", "Description": "IMAGING BLOOD FLOW, VENTILATION, AND DENSITY INTERACTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL119201_7529"}, {"internal_id": 49757257, "Award ID": "R01HL119190", "Award Amount": 2084480.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-22", "CFDA Number": "93.837", "Description": "DIRECTED CULTURING OF PNEUMOCYSTIS USING METATRANSCRIPTOMICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R01HL119190_7529"}, {"internal_id": 49757247, "Award ID": "R01HL119068", "Award Amount": 1527016.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-02", "CFDA Number": "93.838", "Description": "ROLE OF VITAMIN D PROHORMONE 25-OHD IN THE IMMUNE RESPONSE TO TUBERCULOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R01HL119068_7529"}, {"internal_id": 49757234, "Award ID": "R01HL118857", "Award Amount": 3950582.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-22", "CFDA Number": "93.838", "Description": "HIV-RELATED ACCELERATED AGING OF THE AIRWAY EPITHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL118857_7529"}, {"internal_id": 49757228, "Award ID": "R01HL118758", "Award Amount": 2863159.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-14", "CFDA Number": "93.838", "Description": "FUNCTIONAL GENOMICS OF IL-33 EXPRESSION AND ASTHMA RISK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL118758_7529"}, {"internal_id": 49757219, "Award ID": "R01HL118624", "Award Amount": 2687491.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-06-13", "CFDA Number": "93.233", "Description": "SLEEP DISORDERED BREATHING IN NORMAL ELDERLY AND RISK FOR ALZHEIMERS DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_R01HL118624_7529"}, {"internal_id": 49757218, "Award ID": "R01HL118612", "Award Amount": 2287515.0, "Award Type": null, "Base Obligation Date": "2014-01-13", "CFDA Number": "93.838", "Description": "SECONDHAND SMOKE AND ASTHMA: MECHANISTIC OUTCOMES OF DNA METHYLATION IN T CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL118612_7529"}, {"internal_id": 49757212, "Award ID": "R01HL118561", "Award Amount": 1958579.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-10", "CFDA Number": "93.838", "Description": "DEVELOPMENT OF NEW DRUGS FOR ASTHMA BY TARGETING GABA(A) RECEPTORS IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce5b9c13-e48f-352f-0463-48ec7b709bd7-C", "generated_internal_id": "ASST_NON_R01HL118561_7529"}, {"internal_id": 49757208, "Award ID": "R01HL118542", "Award Amount": 2747554.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-05", "CFDA Number": "93.838", "Description": "INTEGRATIVE OMICS TO DISCOVER MOLECULAR DETERMINANTS OF COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL118542_7529"}, {"internal_id": 49757207, "Award ID": "R01HL118541", "Award Amount": 3849183.28, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-11", "CFDA Number": "93.837", "Description": "INTEGRATIVE-OMICS NETWORK MODEL OF THE DISORDERED COPD SMALL AIRWAY EPITHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL118541_7529"}, {"internal_id": 49757203, "Award ID": "R01HL118507", "Award Amount": 1399324.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-14", "CFDA Number": "93.838", "Description": "PENTRAXIN REGULATION OF MACROPHAGE DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "44913900-e35a-479d-fd2b-81775f5f37a7-C", "generated_internal_id": "ASST_NON_R01HL118507_7529"}, {"internal_id": 49757198, "Award ID": "R01HL118455", "Award Amount": 5788762.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-06", "CFDA Number": "93.837", "Description": "THE INTEGRATIVE GENOMICS OF ACUTE ASTHMA CONTROL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL118455_7529"}, {"internal_id": 49757194, "Award ID": "R01HL118419", "Award Amount": 2046701.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-06-17", "CFDA Number": "93.838", "Description": "QUANTITATIVE OPTICAL IMAGING OF CILIA-DRIVEN FLUID FLOW", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL118419_7529"}, {"internal_id": 49757192, "Award ID": "R01HL118408", "Award Amount": 3878109.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-22", "CFDA Number": "93.837", "Description": "OXIDATIVE BURST IN INFLUENZA AND MRSA CO-INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b5d65b01-d8ce-624c-a95e-e23d872445a2-C", "generated_internal_id": "ASST_NON_R01HL118408_7529"}, {"internal_id": 49757191, "Award ID": "R01HL118401", "Award Amount": 3010287.47, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-25", "CFDA Number": "93.837", "Description": "AIRWAY DELIVERY OF FIBRINOLYTIC THERAPY FOR ISALI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6605b60b-2165-8c36-e954-428aa458f579-C", "generated_internal_id": "ASST_NON_R01HL118401_7529"}, {"internal_id": 49757186, "Award ID": "R01HL118372", "Award Amount": 7897445.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-05", "CFDA Number": "93.837", "Description": "FIRST-IN-HUMAN USE OF AN ARTIFICIAL LUNG FOR AMBULATORY RESPIRATORY SUPPORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL118372_7529"}, {"internal_id": 49757182, "Award ID": "R01HL118346", "Award Amount": 3175695.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-05", "CFDA Number": "93.838", "Description": "LONGITUDINAL ANALYSIS OF TRANSCRIPTOMIC ENDOPHENOTYPES IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL118346_7529"}, {"internal_id": 49757181, "Award ID": "R01HL118342", "Award Amount": 4459632.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-28", "CFDA Number": "93.837", "Description": "MACROPHAGE BASED GENE THERAPY FOR HEREDITARY PULMONARY ALVEOLAR PROTEINOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL118342_7529"}, {"internal_id": 49757179, "Award ID": "R01HL118334", "Award Amount": 2007663.48, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-31", "CFDA Number": "93.837", "Description": "CASPASE-1, THE MICROVASCULAR ENDOTHELIUM, AND INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_R01HL118334_7529"}, {"internal_id": 49757169, "Award ID": "R01HL118268", "Award Amount": 1140910.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-20", "CFDA Number": "93.838", "Description": "ROLE OF ZIP8 IN FIRST HAND CIGARETTE SMOKE EXPOSURE-MEDIATED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce6cc294-968c-0136-a2e3-f34319ce4753-C", "generated_internal_id": "ASST_NON_R01HL118268_7529"}, {"internal_id": 49757155, "Award ID": "R01HL118185", "Award Amount": 4098071.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-01-11", "CFDA Number": "93.837", "Description": "DEFINING THE MECHANISM OF CLARA CELL DEDIFFERENTIATION INTO BASAL STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL118185_7529"}, {"internal_id": 49757151, "Award ID": "R01HL118171", "Award Amount": 1956556.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-15", "CFDA Number": "93.837", "Description": "DJ-1 PATHWAY IMPAIRMENT IN ALVEOLAR TYPE II CELLS IN EMPHYSEMA.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL118171_7529"}, {"internal_id": 49757144, "Award ID": "R01HL118068", "Award Amount": 2423386.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-20", "CFDA Number": "93.838", "Description": "ENDOTHELIAL REGENERATION FOLLOWING LUNG VASCULAR INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL118068_7529"}, {"internal_id": 49757138, "Award ID": "R01HL118017", "Award Amount": 2030918.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-14", "CFDA Number": "93.838", "Description": "AUTOTAXIN LYSOPHOPHATIDIC ACID PATHWAY IN BRONCHIOLITIS OBLITERANS POST-LUNG TRAN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL118017_7529"}, {"internal_id": 49757136, "Award ID": "R01HL118000", "Award Amount": 1859381.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-01-21", "CFDA Number": "93.838", "Description": "MINING A MICRORNA REGULATED GENE NETWORK TO RESCUE CFTR-DELTAF508 FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL118000_7529"}, {"internal_id": 49757135, "Award ID": "R01HL117995", "Award Amount": 3103830.61, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-14", "CFDA Number": "93.837", "Description": "EXAMINING SLEEP & SOCIAL RHYTHMS AS MECHANISMS FOR WEIGHT GAIN AFTER JOB LOSS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R01HL117995_7529"}, {"internal_id": 49757128, "Award ID": "R01HL117976", "Award Amount": 1994000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-17", "CFDA Number": "93.838", "Description": "EPITHELIAL MECHANISMS OF INDUCIBLE RESISTANCE TO AML-ASSOCIATED PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_R01HL117976_7529"}, {"internal_id": 49757110, "Award ID": "R01HL117843", "Award Amount": 2921004.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-15", "CFDA Number": "93.838", "Description": "MINING OPEN CHROMATIN TO DEFINE MOLECULAR MECHANISMS OF CF MODIFIER GENES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL117843_7529"}, {"internal_id": 49757109, "Award ID": "R01HL117836", "Award Amount": 4438888.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-14", "CFDA Number": "93.837", "Description": "FUNCTIONAL STUDIES OF NOVEL GENES MUTATED IN PRIMARY CILIARY DYSKINESIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL117836_7529"}, {"internal_id": 49757106, "Award ID": "R01HL117823", "Award Amount": 3498756.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-01-13", "CFDA Number": "93.837", "Description": "TYPE 2 INNATE LYMPHOID CELLS AND ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2439d942-d439-953a-5588-98392dd15217-C", "generated_internal_id": "ASST_NON_R01HL117823_7529"}, {"internal_id": 49757087, "Award ID": "R01HL117637", "Award Amount": 3520509.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-02-13", "CFDA Number": "93.838", "Description": "PARACORPOREAL AMBULATORY ASSIST LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL117637_7529"}, {"internal_id": 49757077, "Award ID": "R01HL117328", "Award Amount": 2050125.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-09-21", "CFDA Number": "93.838", "Description": "GEOBIOLOGICAL APPROACHES TO UNDERSTANDING PULMONARY INFECTIONS IN SITU", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "74bac010-0a24-8f82-8021-0fa16ab4bc6d-C", "generated_internal_id": "ASST_NON_R01HL117328_7529"}, {"internal_id": 49757065, "Award ID": "R01HL117191", "Award Amount": 5167373.77, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-24", "CFDA Number": "93.837", "Description": "EPIGENETIC VARIATION AND CHILDHOOD ASTHMA IN PUERTO RICANS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL117191_7529"}, {"internal_id": 49757064, "Award ID": "R01HL117181", "Award Amount": 1532526.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-13", "CFDA Number": "93.838", "Description": "TH1 AND TH17 MEDIATORS IN EXPERIMENTAL EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL117181_7529"}, {"internal_id": 49757062, "Award ID": "R01HL117164", "Award Amount": 3444805.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-05", "CFDA Number": "93.837", "Description": "DEVELOPMENT AND FUNCTION IN MUCOCILIARY EPITHELIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "395e4a2c-bac8-c9f0-4271-75643a4de192-C", "generated_internal_id": "ASST_NON_R01HL117164_7529"}, {"internal_id": 49757055, "Award ID": "R01HL117074", "Award Amount": 3770127.02, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.837", "Description": "MICROBIAL INDUCTION OF SARCOIDOSIS CD4+ T CELL DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL117074_7529"}, {"internal_id": 49757049, "Award ID": "R01HL117004", "Award Amount": 9325318.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-30", "CFDA Number": "93.837", "Description": "PHARMACOGENOMICS OF BRONCHODILATOR RESPONSE IN MINORITY CHILDREN WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL117004_7529"}, {"internal_id": 49757044, "Award ID": "R01HL116931", "Award Amount": 2196715.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-14", "CFDA Number": "93.838", "Description": "AIRWAY INSPECTOR: A CHEST IMAGING BIOMARKER SOFTWARE PLATFORM FOR COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL116931_7529"}, {"internal_id": 49757034, "Award ID": "R01HL116876", "Award Amount": 1418402.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-21", "CFDA Number": "93.838", "Description": "MIR-101 CONTROL OF PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36e3dd88-13d6-cef1-8b61-a96bca2cc984-C", "generated_internal_id": "ASST_NON_R01HL116876_7529"}, {"internal_id": 49757033, "Award ID": "R01HL116863", "Award Amount": 1418910.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-15", "CFDA Number": "93.838", "Description": "INVESTIGATION INTO COLD-INDUCED PULMONARY VASCULAR INFLAMMATION AND DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7bb49047-7166-d4e3-8873-4218d87cf06c-C", "generated_internal_id": "ASST_NON_R01HL116863_7529"}, {"internal_id": 49757031, "Award ID": "R01HL116849", "Award Amount": 1424808.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-24", "CFDA Number": "93.838", "Description": "DYSREGULATION OF RGS2 PROTEIN AND AIRWAY HYPERRESPONSIVENESS IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aa1efd22-2d00-6e2e-3ada-bfb839ed9539-C", "generated_internal_id": "ASST_NON_R01HL116849_7529"}, {"internal_id": 49757029, "Award ID": "R01HL116845", "Award Amount": 1204477.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-24", "CFDA Number": "93.838", "Description": "NORADRENERGIC A7 NEURONS AND UPPER AIRWAY MOTOR CONTROL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c2cda529-14e3-4e1b-da1d-defaec6798c7-C", "generated_internal_id": "ASST_NON_R01HL116845_7529"}, {"internal_id": 49757027, "Award ID": "R01HL116826", "Award Amount": 1948956.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-07", "CFDA Number": "93.838", "Description": "TARGETING MEMBRANE REPAIR IN DEFORMATION-INDUCED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d97dff14-1826-f436-5817-b2496b9c59da-C", "generated_internal_id": "ASST_NON_R01HL116826_7529"}, {"internal_id": 49757026, "Award ID": "R01HL116756", "Award Amount": 2164311.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-15", "CFDA Number": "93.838", "Description": "DEFINING THE ROLE OF HIPPO SIGNALING IN AIRWAY INJURY REPAIR AND REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL116756_7529"}, {"internal_id": 49757024, "Award ID": "R01HL116742", "Award Amount": 4095908.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-15", "CFDA Number": "93.838", "Description": "FAMILY-SPECIFIC GENETIC VARIANTS CONTRIBUTING TO ASTHMA SUSCEPTIBILITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL116742_7529"}, {"internal_id": 49757011, "Award ID": "R01HL116597", "Award Amount": 3912857.49, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-21", "CFDA Number": "93.837", "Description": "ROLE OF LUNG MSC IN EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL116597_7529"}, {"internal_id": 49757005, "Award ID": "R01HL116573", "Award Amount": 1715132.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-28", "CFDA Number": "93.838", "Description": "VASCULAR SMOOTH MUSCLE CELL PHENOTYPIC SWITCHING IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL116573_7529"}, {"internal_id": 49757000, "Award ID": "R01HL116530", "Award Amount": 1065000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-30", "CFDA Number": "93.838", "Description": "NOVEL IMAGING TO IDENTIFY LUNG MITOCHONDRIAL INJURY AND PREDICT RECOVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL116530_7529"}, {"internal_id": 49756995, "Award ID": "R01HL116514", "Award Amount": 2167475.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-20", "CFDA Number": "93.838", "Description": "MMP28 REGULATION OF MACROPHAGE RECRUITMENT AND POLARIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL116514_7529"}, {"internal_id": 49756989, "Award ID": "R01HL116473", "Award Amount": 5028437.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-31", "CFDA Number": "93.837", "Description": "THE CLINICAL IMPACT OF PULMONARY VASCULAR REMODELING IN SMOKERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL116473_7529"}, {"internal_id": 49756988, "Award ID": "R01HL116472", "Award Amount": 1860603.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-17", "CFDA Number": "93.838", "Description": "REGULATION OF INNATE IMMUNITY BY F-BOX PROTEINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL116472_7529"}, {"internal_id": 49756980, "Award ID": "R01HL116434", "Award Amount": 4167884.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-24", "CFDA Number": "93.837", "Description": "ULTRASOUND-INDUCED PULMONARY HEMORRHAGE DURING DIAGNOSTIC EXAMINATION OF THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL116434_7529"}, {"internal_id": 49756956, "Award ID": "R01HL116235", "Award Amount": 2577291.0, "Award Type": null, "Base Obligation Date": "2012-09-24", "CFDA Number": "93.838", "Description": "MICROBIOME ACQUISTION AND THE PROGRESSION OF INFLAMMATION AND AIRWAY DISEASE IN I", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL116235_7529"}, {"internal_id": 49756955, "Award ID": "R01HL116232", "Award Amount": 1601338.13, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-09-24", "CFDA Number": "93.837", "Description": "THE LUNG CLEARANCE INDEX AS A MARKER OF EARLY LUNG DISEASE IN PRESCHOOL CHILDREN", "Place of Performance Country Code": "CAN", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7a5435ac-5cf9-7672-7047-b6fc396ccab1-C", "generated_internal_id": "ASST_NON_R01HL116232_7529"}, {"internal_id": 49756954, "Award ID": "R01HL116228", "Award Amount": 2083571.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-09-24", "CFDA Number": "93.838", "Description": "MUCUS AND HYPOXIA IN HETEROGENEOUS AND PROGRESSIVE CF LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL116228_7529"}, {"internal_id": 49756953, "Award ID": "R01HL116226", "Award Amount": 2144920.0, "Award Type": null, "Base Obligation Date": "2012-09-24", "CFDA Number": "93.838", "Description": "MR PREDICTORS OF INFECTION, INFLAMMATION, AND STRUCTURAL LUNG DAMAGE IN CF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL116226_7529"}, {"internal_id": 49756950, "Award ID": "R01HL116213", "Award Amount": 2013299.0, "Award Type": null, "Base Obligation Date": "2012-09-24", "CFDA Number": "93.838", "Description": "FUNCTIONAL ANATOMIC IMAGING OF CF PATIENTS WITH EARLY LUNG DISEASE USING MICROOCT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL116213_7529"}, {"internal_id": 49756949, "Award ID": "R01HL116211", "Award Amount": 2170374.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-09-24", "CFDA Number": "93.838", "Description": "VIRAL PATHOGENESIS OF EARLY CYSTIC FIBROSIS LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL116211_7529"}, {"internal_id": 49756947, "Award ID": "R01HL116191", "Award Amount": 1546701.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-05", "CFDA Number": "93.838", "Description": "ROLE OF THE PDGF SIGNALING PATHWAY IN PULMONARY ARTERY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL116191_7529"}, {"internal_id": 49756946, "Award ID": "R01HL116163", "Award Amount": 2276198.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-02", "CFDA Number": "93.838", "Description": "THE FETAL LUNG MESOTHELIAL DIFFERENTIATION PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL116163_7529"}, {"internal_id": 49756945, "Award ID": "R01HL116136", "Award Amount": 1592010.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-08", "CFDA Number": "93.838", "Description": "LUNG RESIDENT NICHES FOR MEMORY CD4 T CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL116136_7529"}, {"internal_id": 49756935, "Award ID": "R01HL115813", "Award Amount": 1455661.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-21", "CFDA Number": "93.838", "Description": "CHITINASE1 AS A BIOMARKER AND THERAPEUTIC TARGET IN SCLERODERMA LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "378fe7f9-e157-cd75-80cc-97cbe1a426db-C", "generated_internal_id": "ASST_NON_R01HL115813_7529"}, {"internal_id": 49756934, "Award ID": "R01HL115778", "Award Amount": 1600868.0, "Award Type": null, "Base Obligation Date": "2013-01-11", "CFDA Number": "93.838", "Description": "PLASMA GELSOLIN AND HOST DEFENSE AFTER LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_R01HL115778_7529"}, {"internal_id": 49756932, "Award ID": "R01HL115619", "Award Amount": 1506955.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-24", "CFDA Number": "93.838", "Description": "ROLE OF TGFBETA SUPERFAMILY IN BRONCOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL115619_7529"}, {"internal_id": 49756931, "Award ID": "R01HL115618", "Award Amount": 1627605.0, "Award Type": null, "Base Obligation Date": "2013-07-21", "CFDA Number": "93.838", "Description": "PERIOSTIN REGULATION OF LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL115618_7529"}, {"internal_id": 49756920, "Award ID": "R01HL115334", "Award Amount": 3301207.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-04", "CFDA Number": "93.837", "Description": "INDUCTION OF CYTOTOXIC T CELLS BY PULMONARY DENDRITIC CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7eb6683a-d796-f7f5-68c0-ca8f32275b30-C", "generated_internal_id": "ASST_NON_R01HL115334_7529"}, {"internal_id": 49756907, "Award ID": "R01HL115207", "Award Amount": 1547316.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-01", "CFDA Number": "93.838", "Description": "THE LINEAGE AND FUNCTION OF NEUROENDOCRINE CELLS IN LUNG HOMEOSTASIS AND INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL115207_7529"}, {"internal_id": 49756892, "Award ID": "R01HL115133", "Award Amount": 1488460.0, "Award Type": null, "Base Obligation Date": "2012-08-05", "CFDA Number": "93.838", "Description": "MODELING THE ROLE OF DNA VARIANTS IN THE PATHOGENESIS OF LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL115133_7529"}, {"internal_id": 49756890, "Award ID": "R01HL115124", "Award Amount": 1576592.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.838", "Description": "ECSOD DERIVED PEROXIDE IN PULMONARY ADAPTATION TO HYPOXIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f00078f8-f585-79c7-3349-6773e6685d91-C", "generated_internal_id": "ASST_NON_R01HL115124_7529"}, {"internal_id": 49756888, "Award ID": "R01HL115118", "Award Amount": 2376836.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-17", "CFDA Number": "93.838", "Description": "NUCLEOTIDE RECEPTOR MODULATION OF AIRWAY EICOSANOIDS DURING ASTHMA EXACERBATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL115118_7529"}, {"internal_id": 49756882, "Award ID": "R01HL115061", "Award Amount": 3177440.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-20", "CFDA Number": "93.837", "Description": "RIGHT HEART-PULMONARY VASCULAR INTERACTIONS IN BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL115061_7529"}, {"internal_id": 49756877, "Award ID": "R01HL115008", "Award Amount": 3145979.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-14", "CFDA Number": "93.838", "Description": "PULMONARY VASCULAR-RIGHT VENTRICULAR AXIS RESEARCH PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL115008_7529"}, {"internal_id": 49756875, "Award ID": "R01HL115001", "Award Amount": 3932534.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-30", "CFDA Number": "93.838", "Description": "GENE THERAPY IN CANINE MYOTUBULAR MYOPATHY FOR CLINICAL TRANSLATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL115001_7529"}, {"internal_id": 49756871, "Award ID": "R01HL114977", "Award Amount": 1767328.0, "Award Type": null, "Base Obligation Date": "2012-08-20", "CFDA Number": "93.838", "Description": "EMAP II: PULMONARY VASCULAR MEDIATOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL114977_7529"}, {"internal_id": 49756870, "Award ID": "R01HL114959", "Award Amount": 3125745.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-01", "CFDA Number": "93.837", "Description": "EPITHELIAL ABNORMALITIES IN IPF: ROLE OF ER STRESS AND GRP78/BIP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL114959_7529"}, {"internal_id": 49756863, "Award ID": "R01HL114933", "Award Amount": 1467221.45, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-12", "CFDA Number": "93.837", "Description": "HYPOXIC FACTORS IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL114933_7529"}, {"internal_id": 49756859, "Award ID": "R01HL114910", "Award Amount": 6219209.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-14", "CFDA Number": "93.837", "Description": "MECHANISMS OF RIGHT VENTRICULAR DYSFUNCTION IN PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL114910_7529"}, {"internal_id": 49756858, "Award ID": "R01HL114907", "Award Amount": 1545878.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-13", "CFDA Number": "93.838", "Description": "CONTRIBUTION OF TOLL-LIKE RECEPTORS IN THE PULMONARY RESPONSE TO NANOPARTICLES AN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL114907_7529"}, {"internal_id": 49756855, "Award ID": "R01HL114898", "Award Amount": 2133472.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-08", "CFDA Number": "93.838", "Description": "OSR TRANSCRIPTION FACTORS REGULATE EMBRYONIC LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL114898_7529"}, {"internal_id": 49756853, "Award ID": "R01HL114887", "Award Amount": 3368478.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-13", "CFDA Number": "93.838", "Description": "FIBROBLASTS AND MONONUCLEAR FIBROGENIC CELLS DRIVE RIGHT VENTRICULAR PULMONARY AR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL114887_7529"}, {"internal_id": 49756852, "Award ID": "R01HL114858", "Award Amount": 3178455.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-23", "CFDA Number": "93.837", "Description": "AUTOPHAGY REGULATION OF RSV-INDUCED PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL114858_7529"}, {"internal_id": 49756850, "Award ID": "R01HL114839", "Award Amount": 2053367.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-15", "CFDA Number": "93.838", "Description": "MECHANOBIOLOGY OF VASCULAR REMODELING IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL114839_7529"}, {"internal_id": 49756841, "Award ID": "R01HL114800", "Award Amount": 3298502.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-06-13", "CFDA Number": "93.837", "Description": "RESOLUTION OF DIFFUSE INFLAMMATORY LUNG INJURY IN NEONATAL MICE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL114800_7529"}, {"internal_id": 49756840, "Award ID": "R01HL114795", "Award Amount": 3406693.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-20", "CFDA Number": "93.838", "Description": "RV/PA RECOUPLING BY BONE MARROW DERIVED MESENCHYMAL STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL114795_7529"}, {"internal_id": 49756834, "Award ID": "R01HL114769", "Award Amount": 1638855.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-15", "CFDA Number": "93.838", "Description": "MECHANISM AND FUNCTION OF BETA-2 ADRENERGIC RECEPTOR DEGRADATION IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_R01HL114769_7529"}, {"internal_id": 49756832, "Award ID": "R01HL114763", "Award Amount": 1554320.0, "Award Type": null, "Base Obligation Date": "2013-12-20", "CFDA Number": "93.838", "Description": "REGULATION OF INFLAMMATION AND ACUTE LUNG INJURY BY THE TRANSCRIPTION FACTOR MIZ1", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL114763_7529"}, {"internal_id": 49756830, "Award ID": "R01HL114754", "Award Amount": 1549721.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-23", "CFDA Number": "93.838", "Description": "DUSP1 AS A THERAPEUTIC TARGET IN FIBROPROLIFERATIVE ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL114754_7529"}, {"internal_id": 49756829, "Award ID": "R01HL114753", "Award Amount": 2541258.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-13", "CFDA Number": "93.838", "Description": "FUNCTIONAL AND BIOLOGICAL PHENOTYPING OF PEDIATRIC PH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL114753_7529"}, {"internal_id": 49756823, "Award ID": "R01HL114677", "Award Amount": 1507760.37, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-25", "CFDA Number": "93.837", "Description": "TARGETABLE AND INHALABLE NANOPARTICLE BASED COMBINATION THERAPY FOR PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0e99018-560d-146b-09d5-7627bb8c86dc-C", "generated_internal_id": "ASST_NON_R01HL114677_7529"}, {"internal_id": 49756819, "Award ID": "R01HL114662", "Award Amount": 1478510.0, "Award Type": null, "Base Obligation Date": "2013-05-31", "CFDA Number": "93.838", "Description": "PATHOLOGICAL ALTERATION OF FOXO3A IN IPF PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL114662_7529"}, {"internal_id": 49756817, "Award ID": "R01HL114626", "Award Amount": 3099753.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-23", "CFDA Number": "93.838", "Description": "OBESITY, INFLAMMATION, AND LUNG INJURY AFTER LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL114626_7529"}, {"internal_id": 49756813, "Award ID": "R01HL114587", "Award Amount": 3159342.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-30", "CFDA Number": "93.838", "Description": "GENETIC RISK FOR GRANULOMATOUS INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL114587_7529"}, {"internal_id": 49756802, "Award ID": "R01HL114529", "Award Amount": 1914101.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-23", "CFDA Number": "93.233", "Description": "MULTIDISCIPLINARY TREATMENT FOR OBSTRUCTIVE SLEEP APNEA AND INSOMNIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL114529_7529"}, {"internal_id": 49756798, "Award ID": "R01HL114484", "Award Amount": 1557418.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-26", "CFDA Number": "93.838", "Description": "COAGULATION AND FIBRINOLYSIS IN PEDIATRIC INSULIN TITRATION TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R01HL114484_7529"}, {"internal_id": 49756793, "Award ID": "R01HL114439", "Award Amount": 1249659.0, "Award Type": null, "Base Obligation Date": "2012-09-12", "CFDA Number": "93.077", "Description": "PGP, A POSSIBLE BIOMARKER FOR COPD EXACERBATIONS AND OR PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL114439_7529"}, {"internal_id": 49756786, "Award ID": "R01HL114396", "Award Amount": 2751674.0, "Award Type": null, "Base Obligation Date": "2012-05-04", "CFDA Number": "93.838", "Description": "PRENATAL STRESS AND EPIGENETIC PROGRAMMING OF THE HPA AXIS AND AUTONOMIC BALANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL114396_7529"}, {"internal_id": 49756784, "Award ID": "R01HL114388", "Award Amount": 3032461.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-05-23", "CFDA Number": "93.838", "Description": "RHO-MEDIATED SIGNALING IN LUNG ENDOTHELIAL CELLS INDUCED BY NEUTROPHIL ADHESION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL114388_7529"}, {"internal_id": 49756782, "Award ID": "R01HL114381", "Award Amount": 2621229.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-30", "CFDA Number": "93.838", "Description": "MACROPHAGE ENDOCYTOSIS IN RESOLVING LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL114381_7529"}, {"internal_id": 49756771, "Award ID": "R01HL114097", "Award Amount": 5584641.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-09-21", "CFDA Number": "93.837", "Description": "RISKY FAMILY ENVIRONMENTS AND CHILDHOOD ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "57f1d8a4-43a0-9952-a047-67afb28d0b55-C", "generated_internal_id": "ASST_NON_R01HL114097_7529"}, {"internal_id": 49756769, "Award ID": "R01HL114094", "Award Amount": 3312743.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-09-21", "CFDA Number": "93.838", "Description": "EPIGENETIC PROFILING OF HUMAN ALVEOLAR EPITHELIAL CELLS IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL114094_7529"}, {"internal_id": 49756768, "Award ID": "R01HL114093", "Award Amount": 8533700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-09-21", "CFDA Number": "93.837", "Description": "EPIGENOMICS OF T CELLS AND INNATE IMMUNE CELLS IN HUMAN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1ab7ef77-dc1b-636f-13b5-a16c421f1438-C", "generated_internal_id": "ASST_NON_R01HL114093_7529"}, {"internal_id": 49756762, "Award ID": "R01HL114055", "Award Amount": 2437394.0, "Award Type": null, "Base Obligation Date": "2012-05-21", "CFDA Number": "93.838", "Description": "DESIGN AND TESTING OF TOOLS TO IDENTIFY INDIVIDUALS AT HIGH RISK FOR COPD 73", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL114055_7529"}, {"internal_id": 49756757, "Award ID": "R01HL113988", "Award Amount": 3759697.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-05-11", "CFDA Number": "93.838", "Description": "ESTROGEN SIGNALING IN PORTOPULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL113988_7529"}, {"internal_id": 49756756, "Award ID": "R01HL113956", "Award Amount": 3549841.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-02", "CFDA Number": "93.837", "Description": "UNDERSTANDING SEVERE ASTHMA USING AN EXPERIMENTAL MODEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL113956_7529"}, {"internal_id": 49756751, "Award ID": "R01HL113870", "Award Amount": 2063359.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-04-18", "CFDA Number": "93.838", "Description": "FGF SIGNALING IN LUNG MATURATION AND RESPONSE TO INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL113870_7529"}, {"internal_id": 49756746, "Award ID": "R01HL113655", "Award Amount": 1911432.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-04-15", "CFDA Number": "93.838", "Description": "REGULATION OF ALVEOLAR EPITHELIAL HOMEOSTASIS IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R01HL113655_7529"}, {"internal_id": 49756743, "Award ID": "R01HL113614", "Award Amount": 3535477.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-04-16", "CFDA Number": "93.837", "Description": "MTDNA REPAIR: AN ISOLATED PHARMACOLOGIC TARGET IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_R01HL113614_7529"}, {"internal_id": 49756739, "Award ID": "R01HL113577", "Award Amount": 3328532.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-02-12", "CFDA Number": "93.837", "Description": "IMPROVED VENTILATION OF THE EDEMATOUS LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07d37a8-0918-a0a2-e051-4a7df7f14f47-C", "generated_internal_id": "ASST_NON_R01HL113577_7529"}, {"internal_id": 49756734, "Award ID": "R01HL113548", "Award Amount": 3088035.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-03", "CFDA Number": "93.837", "Description": "METHOD DEVELOPMENT FOR SURVIVAL DYNAMIC REGRESSION IN CHRONIC DISEASE RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL113548_7529"}, {"internal_id": 49756731, "Award ID": "R01HL113508", "Award Amount": 1893548.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-18", "CFDA Number": "93.838", "Description": "ROLE AND REGULATION OF MKP-1 IN SARCOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "57f1d8a4-43a0-9952-a047-67afb28d0b55-C", "generated_internal_id": "ASST_NON_R01HL113508_7529"}, {"internal_id": 49756726, "Award ID": "R01HL113494", "Award Amount": 2287606.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-28", "CFDA Number": "93.838", "Description": "TREATMENT OF SKELETAL MUSCLE DYSFUNCTION IN ICU PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R01HL113494_7529"}, {"internal_id": 49756724, "Award ID": "R01HL113436", "Award Amount": 1488460.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-26", "CFDA Number": "93.838", "Description": "GRANULOPOIESIS REGULATION IN LUNG GRAFT ISCHEMIA-REPERFUSION INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL113436_7529"}, {"internal_id": 49756723, "Award ID": "R01HL113395", "Award Amount": 2007453.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-02-27", "CFDA Number": "93.838", "Description": "DISSECTING THE GENETIC ARCHITECTURE OF AIRWAY HYPERRESPONSIVENESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL113395_7529"}, {"internal_id": 49756722, "Award ID": "R01HL113392", "Award Amount": 3299113.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-04-06", "CFDA Number": "93.838", "Description": "THERANOSTIC APPROACH TO ASTHMA USING ANTI-ANGIOGENIC NANOMEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL113392_7529"}, {"internal_id": 49756717, "Award ID": "R01HL113350", "Award Amount": 1386228.0, "Award Type": null, "Base Obligation Date": "2013-08-01", "CFDA Number": "93.838", "Description": "ROLE OF THE NA K ATPASE BETA 1 SUBUNIT IN ALVEOLAR EPITHELIAL INTEGRITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL113350_7529"}, {"internal_id": 49756716, "Award ID": "R01HL113338", "Award Amount": 4413642.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-09-24", "CFDA Number": "93.838", "Description": "LEVERAGING FAMILY DATA TO IDENTIFY GENETIC VARIANTS FOR SLEEP APNEA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL113338_7529"}, {"internal_id": 49756715, "Award ID": "R01HL113326", "Award Amount": 8740592.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-03-30", "CFDA Number": "93.837", "Description": "COMPREHENSIVE GENOME INTERROGATION OF AFRICAN AMERICAN SARCOIDOSIS FAMILIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36c41119-2158-d09a-55ce-00590b81ab14-C", "generated_internal_id": "ASST_NON_R01HL113326_7529"}, {"internal_id": 49756714, "Award ID": "R01HL113325", "Award Amount": 1558689.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-19", "CFDA Number": "93.838", "Description": "TSG-6: NOVEL REGULATOR OF VIRAL-INDUCED HYALURONAN SYNTHESIS IN INFLAMED AIRWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL113325_7529"}, {"internal_id": 49756709, "Award ID": "R01HL113294", "Award Amount": 1967938.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-03", "CFDA Number": "93.838", "Description": "ECM COSTIMULATION OF IMMUNOREGULATORY PATHWAYS IN AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL113294_7529"}, {"internal_id": 49756705, "Award ID": "R01HL113264", "Award Amount": 5999295.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-03-30", "CFDA Number": "93.838", "Description": "IDENTIFYING GENETIC DETERMINANTS OF SEVERE, EARLY-ONSET COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL113264_7529"}, {"internal_id": 49756704, "Award ID": "R01HL113252", "Award Amount": 2936124.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-23", "CFDA Number": "93.838", "Description": "LUNG TRANSPLANT MICROBIOME AND CHRONIC ALLOGRAFT DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL113252_7529"}, {"internal_id": 49756699, "Award ID": "R01HL113208", "Award Amount": 1747993.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-04-11", "CFDA Number": "93.838", "Description": "CYTOSKELETAL REGULATION OF AIRWAY SMOOTH MUSCLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "84c69770-7b20-b9e0-d502-4ceb449256bf-C", "generated_internal_id": "ASST_NON_R01HL113208_7529"}, {"internal_id": 49756695, "Award ID": "R01HL113178", "Award Amount": 3081323.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-20", "CFDA Number": "93.837", "Description": "MTOR COORDINATES CELL METABOLISM, GROWTH AND SURVIVAL IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R01HL113178_7529"}, {"internal_id": 49756687, "Award ID": "R01HL113071", "Award Amount": 1938824.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-15", "CFDA Number": "93.838", "Description": "GROUP V SPLA2 IN ALTERNATIVE ACTIVATION OF MACROPHAGES AND PULMONARY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL113071_7529"}, {"internal_id": 49756678, "Award ID": "R01HL113023", "Award Amount": 2140883.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-03-30", "CFDA Number": "93.838", "Description": "ACUTE AIRWAY EFFECTS OF TLR7 AND TLR8 STIMULATION IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL113023_7529"}, {"internal_id": 49756677, "Award ID": "R01HL113022", "Award Amount": 4094329.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-05-02", "CFDA Number": "93.837", "Description": "HUMAN MESENCHYMAL STEM CELL MICROVESICLES FOR THE TREATMENT OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL113022_7529"}, {"internal_id": 49756673, "Award ID": "R01HL113005", "Award Amount": 2045417.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-20", "CFDA Number": "93.838", "Description": "ROLE OF MICRORNAS 424 AND 503 IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL113005_7529"}, {"internal_id": 49756671, "Award ID": "R01HL113003", "Award Amount": 1070550.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-03-29", "CFDA Number": "93.838", "Description": "THE ROLE OF DRP-1 AND MITOCHONDRIAL FISSION IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "CAN", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "31c52a9e-da0c-ec79-7a06-e3638da811f8-C", "generated_internal_id": "ASST_NON_R01HL113003_7529"}, {"internal_id": 49756668, "Award ID": "R01HL112996", "Award Amount": 1471893.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-17", "CFDA Number": "93.838", "Description": "INTERDEPENDENCE AMONG NEUROMODULATORS OF VENTILATORY CONTROL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL112996_7529"}, {"internal_id": 49756665, "Award ID": "R01HL112987", "Award Amount": 3389705.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-07", "CFDA Number": "93.837", "Description": "AUTOLOGOUS LUNG MULTIPOTENT STROMAL CELL THERAPY FOR EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL112987_7529"}, {"internal_id": 49756664, "Award ID": "R01HL112986", "Award Amount": 4616767.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-20", "CFDA Number": "93.838", "Description": "MULTI-CENTER STRUCTURAL & FUNCTIONAL QUANTITATIVE CT PULMONARY PHENOTYPING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL112986_7529"}, {"internal_id": 49756657, "Award ID": "R01HL112919", "Award Amount": 1586385.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-15", "CFDA Number": "93.838", "Description": "RESPIRATORY VIRUS INDUCED SENSORY NEUROPLASTICITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL112919_7529"}, {"internal_id": 49756653, "Award ID": "R01HL112897", "Award Amount": 2210797.0, "Award Type": null, "Base Obligation Date": "2013-06-14", "CFDA Number": "93.838", "Description": "CYTOKINE-INDUCED EPIGENETIC CHANGES DURING CHRONIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL112897_7529"}, {"internal_id": 49756649, "Award ID": "R01HL112880", "Award Amount": 1952085.0, "Award Type": null, "Base Obligation Date": "2013-05-25", "CFDA Number": "93.838", "Description": "RESISTIN-LIKE MOLECULES IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL112880_7529"}, {"internal_id": 49756647, "Award ID": "R01HL112863", "Award Amount": 1859401.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-04-13", "CFDA Number": "93.838", "Description": "TH2 INFLAMMATION PROMOTES AIRWAY SURFACE LIQUID DEHYDRATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL112863_7529"}, {"internal_id": 49756624, "Award ID": "R01HL112671", "Award Amount": 1654761.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-15", "CFDA Number": "93.838", "Description": "INTERACTIONS OF PDCS WITH ASPERGILUS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_R01HL112671_7529"}, {"internal_id": 49756615, "Award ID": "R01HL112638", "Award Amount": 2235268.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-06-13", "CFDA Number": "93.838", "Description": "MECHANISMS OF BETA-CATENIN SIGNALING IN ALVEOLAR EPITHELIAL CELL DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL112638_7529"}, {"internal_id": 49756605, "Award ID": "R01HL112516", "Award Amount": 2876718.0, "Award Type": null, "Base Obligation Date": "2011-12-30", "CFDA Number": "93.838", "Description": "FUNCTIONAL ROLES OF NRF2 AND NQO1 GENETIC VARIANTS IN HYPEROXIC LUNG INJURY-ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL112516_7529"}, {"internal_id": 49756598, "Award ID": "R01HL112286", "Award Amount": 1688628.0, "Award Type": null, "Base Obligation Date": "2013-01-22", "CFDA Number": "93.838", "Description": "NRF2 AND RADIATION-INDUCED PULMONARY FIBROSIS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL112286_7529"}, {"internal_id": 49756591, "Award ID": "R01HL112088", "Award Amount": 3635581.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-03-06", "CFDA Number": "93.838", "Description": "FUNCTIONAL IMPACT OF IL33 POLYMORPHISMS ON ASTHMA & OTHER TH2-MEDIATED DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL112088_7529"}, {"internal_id": 49756577, "Award ID": "R01HL111759", "Award Amount": 3379531.0, "Award Type": null, "Base Obligation Date": "2012-08-24", "CFDA Number": "93.838", "Description": "USING NETWORKS TO ASSIGN GENE FUNCTION IN LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_R01HL111759_7529"}, {"internal_id": 49756567, "Award ID": "R01HL111674", "Award Amount": 1948361.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-06-08", "CFDA Number": "93.838", "Description": "ADAM17-NRG-1 SIGNALING IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL111674_7529"}, {"internal_id": 49756560, "Award ID": "R01HL111624", "Award Amount": 1512941.0, "Award Type": null, "Base Obligation Date": "2013-08-01", "CFDA Number": "93.838", "Description": "5 -HYDROXYTRYPTOPHAN REGULATION OF ENDOTHELIAL CELL SIGNALS FOR LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL111624_7529"}, {"internal_id": 49756558, "Award ID": "R01HL111614", "Award Amount": 1686008.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-28", "CFDA Number": "93.838", "Description": "MECHANISTIC ROLE OF CD36 IN THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL111614_7529"}, {"internal_id": 49756556, "Award ID": "R01HL111598", "Award Amount": 2844408.0, "Award Type": null, "Base Obligation Date": "2011-12-31", "CFDA Number": "93.838", "Description": "INTERMITTENT HYPOXIA-INDUCED INFLAMMATION MODULATES RESPIRATORY PLASTICITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL111598_7529"}, {"internal_id": 49756555, "Award ID": "R01HL111589", "Award Amount": 2244212.0, "Award Type": null, "Base Obligation Date": "2011-12-09", "CFDA Number": "93.838", "Description": "DEVELOPMENT OF A VACCINE FOR VIRAL EXACERBATION OF ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL111589_7529"}, {"internal_id": 49756553, "Award ID": "R01HL111574", "Award Amount": 2106642.0, "Award Type": null, "Base Obligation Date": "2011-12-20", "CFDA Number": "93.838", "Description": "DEFINING THE GENETIC PROGRAM OF PRIMORDIAL LUNG PROGENITORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL111574_7529"}, {"internal_id": 49756551, "Award ID": "R01HL111552", "Award Amount": 1498252.0, "Award Type": null, "Base Obligation Date": "2012-06-08", "CFDA Number": "93.838", "Description": "NOVEL PROTEIN KINASE C TARGETED THERAPY FOR ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL111552_7529"}, {"internal_id": 49756550, "Award ID": "R01HL111541", "Award Amount": 3336160.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-02-15", "CFDA Number": "93.837", "Description": "AIRWAY INFLAMMATORY PATHWAYS REGULATING GLUCOCORTICOID RECEPTOR PHOSPHORYLATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8f234e5-d929-51e5-4a22-37acb8e45afa-C", "generated_internal_id": "ASST_NON_R01HL111541_7529"}, {"internal_id": 49756549, "Award ID": "R01HL111527", "Award Amount": 3855593.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-12-30", "CFDA Number": "93.837", "Description": "NON-CODING RNA STRUCTURE CHANGE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL111527_7529"}, {"internal_id": 49756548, "Award ID": "R01HL111523", "Award Amount": 2555027.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-07", "CFDA Number": "93.838", "Description": "EXPRESSION SIGNATURES OF TB-SPECIFIC MEMORY RESPONSES WITHIN THE HUMAN LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL111523_7529"}, {"internal_id": 49756544, "Award ID": "R01HL111497", "Award Amount": 1386646.0, "Award Type": null, "Base Obligation Date": "2012-08-03", "CFDA Number": "93.838", "Description": "MECHANISM OF OXYGEN SENSING BY CHEMORECEPTOR CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3097aef-8c28-5560-7442-592c3de59e18-C", "generated_internal_id": "ASST_NON_R01HL111497_7529"}, {"internal_id": 49756541, "Award ID": "R01HL111469", "Award Amount": 1650036.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-24", "CFDA Number": "93.838", "Description": "MIF-THYROXINE INTERACTIONS IN THE PATHOGENESIS OF PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f9f0ca2a-aa8d-05a3-861f-1f3e215d88e8-C", "generated_internal_id": "ASST_NON_R01HL111469_7529"}, {"internal_id": 49756536, "Award ID": "R01HL111449", "Award Amount": 3656412.91, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-08", "CFDA Number": "93.837", "Description": "THE BIOLOGY OF LIF DURING PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL111449_7529"}, {"internal_id": 49756522, "Award ID": "R01HL111294", "Award Amount": 2875536.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-13", "CFDA Number": "93.838", "Description": "HUMAN LUNG REGIONAL VENTILATION DEFECT SEVERITY MEASURED BY FLUORINE-19 GAS MRI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL111294_7529"}, {"internal_id": 49756513, "Award ID": "R01HL111259", "Award Amount": 3487212.0, "Award Type": null, "Base Obligation Date": "2011-12-30", "CFDA Number": "93.838", "Description": "CAVEOLAR DEFECTS UNDERLIE THE GENETIC ORIGINS OF PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL111259_7529"}, {"internal_id": 49756507, "Award ID": "R01HL111190", "Award Amount": 3878636.22, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-22", "CFDA Number": "93.837", "Description": "FGF9 REGULATION OF LUNG DEVELOPMENT AND PATHOGENESIS OF PLEUROPULMONARY BLASTOMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL111190_7529"}, {"internal_id": 49756496, "Award ID": "R01HL111111", "Award Amount": 3684204.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-14", "CFDA Number": "93.838", "Description": "ALTERING SEDATION PARADIGMS TO IMPROVE BRAIN INJURY AND SURVIVAL IN SEVERE SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL111111_7529"}, {"internal_id": 49756495, "Award ID": "R01HL111108", "Award Amount": 2965198.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-31", "CFDA Number": "93.838", "Description": "EARLY LIFE DNA METHYLATION AND CHILDHOOD ALLERGIC DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL111108_7529"}, {"internal_id": 49756490, "Award ID": "R01HL111084", "Award Amount": 3389287.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-18", "CFDA Number": "93.837", "Description": "VASCULAR SMOOTH MUSCLE FUNCTION IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a5b5888e-f4b5-655c-bd88-d970f969d7c9-C", "generated_internal_id": "ASST_NON_R01HL111084_7529"}, {"internal_id": 49756482, "Award ID": "R01HL111024", "Award Amount": 6361943.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-06-17", "CFDA Number": "93.837", "Description": "INTERSTITIAL LUNG ABNORMALITIES: DEFINING THE PHENOTYPE, CAUSES, AND CONSEQUENCES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL111024_7529"}, {"internal_id": 49756478, "Award ID": "R01HL110969", "Award Amount": 1898663.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-12-02", "CFDA Number": "93.838", "Description": "CIGARETTE SMOKE EXPOSURE AND ACUTE LUNG INJURY AFTER SEVERE BLUNT TRAUMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL110969_7529"}, {"internal_id": 49756475, "Award ID": "R01HL110951", "Award Amount": 3562215.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-11-25", "CFDA Number": "93.837", "Description": "REORGANIZATION OF THE ACTIN CYTOSKELETON IN AIRWAY SMOOTH MUSCLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "84c69770-7b20-b9e0-d502-4ceb449256bf-C", "generated_internal_id": "ASST_NON_R01HL110951_7529"}, {"internal_id": 49756471, "Award ID": "R01HL110906", "Award Amount": 1421938.0, "Award Type": null, "Base Obligation Date": "2011-08-22", "CFDA Number": "93.838", "Description": "AIRWAY MUCUS/MUCIN COMPOSITION AND PROTEOME IN COPD: A SPIROMICS ANCILLARY STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL110906_7529"}, {"internal_id": 49756467, "Award ID": "R01HL110811", "Award Amount": 5892062.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-10", "CFDA Number": "93.838", "Description": "PREDICTING IMMUNE RESPONSES THAT CORRELATE WITH PROTECTION AGAINST TUBERCULOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL110811_7529"}, {"internal_id": 49756444, "Award ID": "R01HL110344", "Award Amount": 1557399.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-01", "CFDA Number": "93.838", "Description": "MESENCHYMAL STEM CELL SECRETOME IN LUNG FIBROSIS: MITOCHONDRIA AND RNA SHUTTLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL110344_7529"}, {"internal_id": 49756436, "Award ID": "R01HL110068", "Award Amount": 2916976.0, "Award Type": null, "Base Obligation Date": "2012-05-24", "CFDA Number": "93.233", "Description": "SLEEP-DISORDERED BREATHING AND RISK FOR CVD AND STROKE IN THE JACKSON HEART STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "38806202-b2e1-fa5b-5787-e80ab7888442-C", "generated_internal_id": "ASST_NON_R01HL110068_7529"}, {"internal_id": 49756434, "Award ID": "R01HL109977", "Award Amount": 3404056.0, "Award Type": null, "Base Obligation Date": "2011-07-06", "CFDA Number": "93.838", "Description": "PREGNANCY FOLATE STATUS & EARLY CHILDHOOD RESPIRATORY & ATOPIC DISEASE OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL109977_7529"}, {"internal_id": 49756430, "Award ID": "R01HL109823", "Award Amount": 3474204.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-06-30", "CFDA Number": "93.838", "Description": "IMPROVING DECISION MAKING FOR PATIENTS WITH PROLONGED MECHANICAL VENTILATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL109823_7529"}, {"internal_id": 49756421, "Award ID": "R01HL109629", "Award Amount": 2062367.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-24", "CFDA Number": "93.838", "Description": "TARGETING ACTIN DYNAMICS TO INHIBIT AIRWAY HYPPERRESPONSIVENESS AND INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL109629_7529"}, {"internal_id": 49756420, "Award ID": "R01HL109618", "Award Amount": 2362432.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-06-08", "CFDA Number": "93.838", "Description": "SIMULTANEOUS XE129 MRI OF REGIONAL LUNG VENTILATION AND GAS UPTAKE IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL109618_7529"}, {"internal_id": 49756409, "Award ID": "R01HL109557", "Award Amount": 5804407.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-04-13", "CFDA Number": "93.837", "Description": "ROLE OF KLF15 IN AIRWAY SMOOTH MUSCLE AND THE RESPONSE TO GLUCOCORTICOIDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL109557_7529"}, {"internal_id": 49756406, "Award ID": "R01HL109517", "Award Amount": 3091242.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-04-18", "CFDA Number": "93.838", "Description": "MACROPHAGE APOPTOSIS IN RESOLUTION OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL109517_7529"}, {"internal_id": 49756398, "Award ID": "R01HL109481", "Award Amount": 1624357.0, "Award Type": null, "Base Obligation Date": "2012-09-25", "CFDA Number": "93.838", "Description": "THE ROLE OF EPIGENETICS AND MIRNAS IN IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WV", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "38457ff7-68b1-7220-5dec-347ecba3483d-C", "generated_internal_id": "ASST_NON_R01HL109481_7529"}, {"internal_id": 49756397, "Award ID": "R01HL109478", "Award Amount": 4203068.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-06-10", "CFDA Number": "93.837", "Description": "REDOX REGULATION OF VASCULAR CGMP SIGNALING IN NEONATAL LUNGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_R01HL109478_7529"}, {"internal_id": 49756378, "Award ID": "R01HL109293", "Award Amount": 3246325.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-06-30", "CFDA Number": "93.838", "Description": "WHEEZING IN BLACK PRETERM INFANTS: IMPACT OF VITAMIN D SUPPLEMENTATION STRATEGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL109293_7529"}, {"internal_id": 49756377, "Award ID": "R01HL109288", "Award Amount": 1905230.0, "Award Type": null, "Base Obligation Date": "2011-07-26", "CFDA Number": "93.838", "Description": "ROLE OF IL-17 IN THE INDUCTION OF EPITHELIAL TO MESENCHYMAL TRANSITION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL109288_7529"}, {"internal_id": 49756369, "Award ID": "R01HL109233", "Award Amount": 3717136.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-08-03", "CFDA Number": "93.837", "Description": "NOVEL IMMUNOLOGIC EFFECTS OF SEMAPHORIN 7A IN IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL109233_7529"}, {"internal_id": 49756355, "Award ID": "R01HL109102", "Award Amount": 4474952.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-07-29", "CFDA Number": "93.837", "Description": "ROLE OF MIRNAS IN TH2-DRIVEN INFLAMMATION IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL109102_7529"}, {"internal_id": 49756344, "Award ID": "R01HL108962", "Award Amount": 2172982.0, "Award Type": null, "Base Obligation Date": "2011-06-10", "CFDA Number": "93.838", "Description": "GENE-BY-GENE INTERACTIONS AND LUNG FLUID BALANCE IN PATIENTS WITH HEART FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL108962_7529"}, {"internal_id": 49756342, "Award ID": "R01HL108949", "Award Amount": 1823045.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-10", "CFDA Number": "93.838", "Description": "MECHANISMS OF IMPAIRED NEUTROPHIL RESPONSES IN POSTINFLUENZA BACTERIAL PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL108949_7529"}, {"internal_id": 49756337, "Award ID": "R01HL108929", "Award Amount": 1852834.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-07-15", "CFDA Number": "93.838", "Description": "IMAGING AIRWAY LIQUID ABSORPTION IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL108929_7529"}, {"internal_id": 49756331, "Award ID": "R01HL108904", "Award Amount": 3456263.65, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-05-15", "CFDA Number": "93.837", "Description": "FUNCTION OF EPITHELIAL-MESENCHYMAL TRANSITION DURING PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL108904_7529"}, {"internal_id": 49756322, "Award ID": "R01HL108723", "Award Amount": 1981323.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-09-10", "CFDA Number": "93.838", "Description": "MULTI-LEVEL UNDERSTANDING OF SOCIAL CONTRIBUTORS TO SES DISPARITIES IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b0be845a-babe-8a5d-2f4b-002e5eff7fcd-C", "generated_internal_id": "ASST_NON_R01HL108723_7529"}, {"internal_id": 49756307, "Award ID": "R01HL108609", "Award Amount": 4606563.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-04-20", "CFDA Number": "93.837", "Description": "CELLULAR/MOLECULAR MECHANISMS OF RESPIRATORY NEURONAL CHEMOSENSITIVITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL108609_7529"}, {"internal_id": 49756291, "Award ID": "R01HL108232", "Award Amount": 1547215.0, "Award Type": null, "Base Obligation Date": "2011-11-25", "CFDA Number": "93.838", "Description": "SIGNALING MECHANISMS FOR HYPOXIC PULMONARY VASOCONSTRICTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "84c69770-7b20-b9e0-d502-4ceb449256bf-C", "generated_internal_id": "ASST_NON_R01HL108232_7529"}, {"internal_id": 49756268, "Award ID": "R01HL107920", "Award Amount": 2821911.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-07-14", "CFDA Number": "93.837", "Description": "MICROTUBULE-ASSOCIATED RAC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL107920_7529"}, {"internal_id": 49756260, "Award ID": "R01HL107883", "Award Amount": 2731218.0, "Award Type": null, "Base Obligation Date": "2011-06-24", "CFDA Number": "93.838", "Description": "THE EMPHYSEMATOUS MICROENVIRONMENT PROMOTES LUNG TUMORIGENESIS AND PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL107883_7529"}, {"internal_id": 49756255, "Award ID": "R01HL107778", "Award Amount": 1472006.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-18", "CFDA Number": "93.838", "Description": "IMMUNOPHILINS REGULATE SOC ENTRY CHANNELS IN PULMONARY ENDOTHELIAL CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_R01HL107778_7529"}, {"internal_id": 49756236, "Award ID": "R01HL107590", "Award Amount": 1552725.0, "Award Type": null, "Base Obligation Date": "2013-01-02", "CFDA Number": "93.838", "Description": "MODULATION OF ASTHMA BY GSNO-BASED THERAPIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL107590_7529"}, {"internal_id": 49756234, "Award ID": "R01HL107585", "Award Amount": 1433761.0, "Award Type": null, "Base Obligation Date": "2012-01-15", "CFDA Number": "93.838", "Description": "AMPK ACTIVATION AND ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL107585_7529"}, {"internal_id": 49756232, "Award ID": "R01HL107572", "Award Amount": 6170377.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-03-14", "CFDA Number": "93.837", "Description": "TISSUE-ENGINEERED PULMONIC VALVE GROWN FROM HUMAN CELLS FOR PEDIATRIC PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL107572_7529"}, {"internal_id": 49756231, "Award ID": "R01HL107561", "Award Amount": 3070916.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-04-06", "CFDA Number": "93.838", "Description": "MECHANICS OF MONOLAYER MIGRATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_R01HL107561_7529"}, {"internal_id": 49756206, "Award ID": "R01HL107386", "Award Amount": 4236383.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-03-10", "CFDA Number": "93.837", "Description": "MECHANISMS OF ACUTE LUNG INJURY FROM BLOOD TRANSFUSIONS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL107386_7529"}, {"internal_id": 49756203, "Award ID": "R01HL107380", "Award Amount": 4946283.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-12-09", "CFDA Number": "93.837", "Description": "INFLUENZA A INHIBITS TH17 HOST DEFENSE AGAINST BACTERIAL PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL107380_7529"}, {"internal_id": 49756195, "Award ID": "R01HL107333", "Award Amount": 4172929.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-05-30", "CFDA Number": "93.837", "Description": "EFFECTIVE DELIVERY OF PHARMACEUTICAL AEROSOLS DURING NON-INVASIVE VENTILATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R01HL107333_7529"}, {"internal_id": 49756115, "Award ID": "R01HL105971", "Award Amount": 1650778.0, "Award Type": null, "Base Obligation Date": "2011-06-27", "CFDA Number": "93.838", "Description": "REGULATION OF AIRWAY PROGENITOR CELL FATE IN DEVELOPMENT AND REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL105971_7529"}, {"internal_id": 49756113, "Award ID": "R01HL105947", "Award Amount": 3813804.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-04-20", "CFDA Number": "93.837", "Description": "REGULATION OF TYPE II CELLS IN THE REPAIR OF ALVEOLAR EPITHELIAL INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL105947_7529"}, {"internal_id": 49756111, "Award ID": "R01HL105932", "Award Amount": 2920681.52, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-01-14", "CFDA Number": "93.837", "Description": "INFLAMMASOMES IN HYPEROXIC ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ceec5ef7-d6a5-28f0-e23f-ec61155b7078-C", "generated_internal_id": "ASST_NON_R01HL105932_7529"}, {"internal_id": 49756105, "Award ID": "R01HL105903", "Award Amount": 2316924.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-06-09", "CFDA Number": "93.838", "Description": "A MULTIFACETED INTERVENTION TO REDUCE VENTILATOR-ASSOCIATED PNEUMONIA IN THE ICU", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL105903_7529"}, {"internal_id": 49756099, "Award ID": "R01HL105821", "Award Amount": 1948478.0, "Award Type": null, "Base Obligation Date": "2011-12-30", "CFDA Number": "93.838", "Description": "TARGETED INTEGRATION OF A DNA TRANSPOSON-BASED NONVIRAL VECTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL105821_7529"}, {"internal_id": 49756084, "Award ID": "R01HL105702", "Award Amount": 2775151.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.838", "Description": "GASTRIN-RELEASING PEPTIDE AND BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL105702_7529"}, {"internal_id": 49756078, "Award ID": "R01HL105643", "Award Amount": 3716360.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-01-21", "CFDA Number": "93.837", "Description": "EARLY DETECTION OF CHANGES IN PULMONARY GAS EXCHANGE BY HYPERPOLARIZED  XE MRI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL105643_7529"}, {"internal_id": 49756076, "Award ID": "R01HL105635", "Award Amount": 2344159.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-12-30", "CFDA Number": "93.838", "Description": "COUNTER-IRRITATION BY MENTHOL: MOLECULAR TARGETS AND ROLE IN AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL105635_7529"}, {"internal_id": 49756067, "Award ID": "R01HL105586", "Award Amount": 1462941.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-08-09", "CFDA Number": "93.838", "Description": "OPTIMIZATION OF HYPERPOLARIZED XENON-129 DIFFUSION MRI FOR COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL105586_7529"}, {"internal_id": 49756066, "Award ID": "R01HL105573", "Award Amount": 1886786.0, "Award Type": null, "Base Obligation Date": "2011-11-25", "CFDA Number": "93.838", "Description": "L-ARGININE AS A THERAPY IN SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R01HL105573_7529"}, {"internal_id": 49756059, "Award ID": "R01HL105511", "Award Amount": 3325149.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-12-29", "CFDA Number": "93.837", "Description": "MECHANISMS OF INACTIVITY-INDUCED RESPIRATORY PLASTICITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL105511_7529"}, {"internal_id": 49756055, "Award ID": "R01HL105490", "Award Amount": 1926629.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-07-18", "CFDA Number": "93.838", "Description": "ADIPONECTIN INHIBITS ACTIVATION AND INJURY OF LUNG ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL105490_7529"}, {"internal_id": 49756052, "Award ID": "R01HL105479", "Award Amount": 2180086.0, "Award Type": null, "Base Obligation Date": "2011-07-22", "CFDA Number": "93.838", "Description": "REGULATION OF FIBROTIC REMODELING BY THE ALVEOLAR EPITHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL105479_7529"}, {"internal_id": 49756050, "Award ID": "R01HL105470", "Award Amount": 2074221.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-12-09", "CFDA Number": "93.838", "Description": "IMPROVING INHALED DRUG DELIVERY WITH SELF-DISPERSING LIQUIDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c8e3c1b2-847b-fd38-8430-6da62d956103-C", "generated_internal_id": "ASST_NON_R01HL105470_7529"}, {"internal_id": 49756049, "Award ID": "R01HL105460", "Award Amount": 2427049.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-06-30", "CFDA Number": "93.837", "Description": "VITC TO DECREASE EFFECTS OF SMOKING IN PREGNANCY ON INFANT LUNG FUNCTION-DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL105460_7529"}, {"internal_id": 49756044, "Award ID": "R01HL105447", "Award Amount": 9764732.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-17", "CFDA Number": "93.837", "Description": "VITC TO DECREASE EFFECTS OF SMOKING IN PREGNANCY ON INFANT LUNG FUNCTION-CCC-LEAD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL105447_7529"}, {"internal_id": 49756041, "Award ID": "R01HL105427", "Award Amount": 4151736.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-12-15", "CFDA Number": "93.837", "Description": "ROLE OF IL-17 IN PROTECTIVE VACCINE-INDUCED IMMUNE RESPONSES AGAINST TUBERCULOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL105427_7529"}, {"internal_id": 49756022, "Award ID": "R01HL105278", "Award Amount": 3968953.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-03-16", "CFDA Number": "93.837", "Description": "SPATIAL REGULATION OF DEVELOPMENTAL GENE EXPRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f6bc70f7-8c40-69d8-4bff-bddaa8c52b59-C", "generated_internal_id": "ASST_NON_R01HL105278_7529"}, {"internal_id": 49756005, "Award ID": "R01HL104608", "Award Amount": 23070386.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-09-25", "CFDA Number": "93.837", "Description": "NEW APPROACHES FOR EMPOWERING STUDIES OF ASTHMA IN POPULATIONS OF AFRICAN DESCENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL104608_7529"}, {"internal_id": 49755969, "Award ID": "R01HL104092", "Award Amount": 3923052.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-07-15", "CFDA Number": "93.837", "Description": "ROLE OF P120 CATENIN IN SEPSIS-INDUCED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL104092_7529"}, {"internal_id": 49755923, "Award ID": "R01HL103764", "Award Amount": 3058249.0, "Award Type": null, "Base Obligation Date": "2010-08-30", "CFDA Number": "93.838", "Description": "DIAGNOSIS OF SUBGLOTTIC STENOSIS AND EDEMA IN NEONATES USING OCT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b710df3-c98e-f245-bbed-8bbbc32a803b-C", "generated_internal_id": "ASST_NON_R01HL103764_7529"}, {"internal_id": 49755905, "Award ID": "R01HL103676", "Award Amount": 6364195.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-04-15", "CFDA Number": "93.837", "Description": "SUBCLINICAL INTERSTITIAL LUNG DISEASE IN MESA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL103676_7529"}, {"internal_id": 49755841, "Award ID": "R01HL102371", "Award Amount": 3274512.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-06-14", "CFDA Number": "93.837", "Description": "A NOVEL PROTEOLYTIC SYSTEM OF PULMONARY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL102371_7529"}, {"internal_id": 49755835, "Award ID": "R01HL102321", "Award Amount": 5756964.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-03-18", "CFDA Number": "93.837", "Description": "A METHOD FOR MEASURING AND MODELING THE PHYSIOLOGIC TRAITS CAUSING SLEEP APNEA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL102321_7529"}, {"internal_id": 49755819, "Award ID": "R01HL102167", "Award Amount": 2524351.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-12-20", "CFDA Number": "93.838", "Description": "PPAR GAMMA AND NOX4 IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL102167_7529"}, {"internal_id": 49755805, "Award ID": "R01HL102076", "Award Amount": 2121457.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-05-20", "CFDA Number": "93.838", "Description": "CROSS TALK BETWEEN CAV-1 AND FLOT1 IN LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL102076_7529"}, {"internal_id": 49755800, "Award ID": "R01HL102033", "Award Amount": 4268415.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-04-30", "CFDA Number": "93.837", "Description": "ANGIOTENSIN-CONVERTING ENZYME2 IN VASCULAR ENDOTHELIAL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL102033_7529"}, {"internal_id": 49755798, "Award ID": "R01HL102020", "Award Amount": 2291408.0, "Award Type": null, "Base Obligation Date": "2011-05-16", "CFDA Number": "93.838", "Description": "ROLE OF BMPR2 EXPRESSION IN HPAH; IMPLICATIONS FOR NOVEL THERAPEUTIC APPROACHES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL102020_7529"}, {"internal_id": 49755797, "Award ID": "R01HL102016", "Award Amount": 4633556.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-04-15", "CFDA Number": "93.838", "Description": "PEROXIREDOXIN 6 AS AN ANTI-OXIDANT ENZYME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL102016_7529"}, {"internal_id": 49755739, "Award ID": "R01HL098554", "Award Amount": 837794.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-03", "CFDA Number": "93.837", "Description": "PULMONARY COMPLICATIONS IN A BIRTH COHORT AFTER A RANDOMIZED TRIAL OF ANTENATAL CORTICOSTEROIDS: THE ALPS FOLLOW-UP STUDY - CLINICAL COORDINATING CEN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL098554_7529"}, {"internal_id": 49755725, "Award ID": "R01HL098437", "Award Amount": 1894506.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-04-04", "CFDA Number": "93.838", "Description": "SELF ORGANIZED CRITICALITY AS A NEW PARADIGM OF SLEEP REGULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL098437_7529"}, {"internal_id": 49755720, "Award ID": "R01HL098416", "Award Amount": 3278700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-03-05", "CFDA Number": "93.837", "Description": "TARGETED REPLACEMENT OF DEFECTIVE LYSOSOMAL ENZYMES IN THE LUNG AND BRAIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e04c3b49-28c8-efb6-f8ea-b4c853900d6f-C", "generated_internal_id": "ASST_NON_R01HL098416_7529"}, {"internal_id": 49755715, "Award ID": "R01HL098354", "Award Amount": 9427856.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-03", "CFDA Number": "93.837", "Description": "PULMONARY COMPLICATIONS IN A BIRTH COHORT AFTER A RANDOMIZED TRIAL OF ANTENATAL CORTICOSTEROIDS: THE ALPS FOLLOW-UP STUDY - DATA COORDINATING CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ee8636d0-3f78-fbb3-4346-eb49aabbb2b3-C", "generated_internal_id": "ASST_NON_R01HL098354_7529"}, {"internal_id": 49755689, "Award ID": "R01HL098216", "Award Amount": 2109315.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-08-09", "CFDA Number": "93.838", "Description": "TARGETING THE ESTROGEN PATHWAY FOR THE PREVENTION AND TREATMENT OF LAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R01HL098216_7529"}, {"internal_id": 49755685, "Award ID": "R01HL098199", "Award Amount": 2139149.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-03-24", "CFDA Number": "93.838", "Description": "GERMLINE AND SOMATIC GENETIC CHANGES IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "AFG", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL098199_7529"}, {"internal_id": 49755682, "Award ID": "R01HL098174", "Award Amount": 3590467.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-01-12", "CFDA Number": "93.837", "Description": "SEPTIC LUNG INJURY AND SURFACTANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL098174_7529"}, {"internal_id": 49755635, "Award ID": "R01HL097376", "Award Amount": 3855680.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-09-01", "CFDA Number": "93.837", "Description": "MECHANISMS OF LUNG PHOSPHOLIPID HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL097376_7529"}, {"internal_id": 49755622, "Award ID": "R01HL097163", "Award Amount": 16414910.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-09-01", "CFDA Number": "93.838", "Description": "GWAS IN FIBROSING INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL097163_7529"}, {"internal_id": 49755580, "Award ID": "R01HL096845", "Award Amount": 2244849.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-05-14", "CFDA Number": "93.838", "Description": "ROLE OF ANTI-COL (V) IMMUNITY IN PRIMARY GRAFT DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL096845_7529"}, {"internal_id": 49755544, "Award ID": "R01HL096651", "Award Amount": 3131118.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-07-29", "CFDA Number": "93.838", "Description": "THE ROLE OF LONG TERM ACUTE CARE HOSPITALS IN PROLONGED MECHANICAL VENTILATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL096651_7529"}, {"internal_id": 49755536, "Award ID": "R01HL096613", "Award Amount": 1933647.87, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-04-22", "CFDA Number": "93.837", "Description": "CT ASSESSMENT OF LUNG FISSURES: ANATOMY AND CORRELATED FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL096613_7529"}, {"internal_id": 49755508, "Award ID": "R01HL096453", "Award Amount": 4198997.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-07-20", "CFDA Number": "93.838", "Description": "EFFECTS OF HIV ANTIRETROVIRAL THERAPY ON PULMOMARY FUNCTION IN A RANDOMIZED TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL096453_7529"}, {"internal_id": 49755505, "Award ID": "R01HL096376", "Award Amount": 3621420.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-01-13", "CFDA Number": "93.837", "Description": "CARDIOLIPIN INDUCED LUNG INJURY AND FIC1", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL096376_7529"}, {"internal_id": 49755489, "Award ID": "R01HL095993", "Award Amount": 6415251.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-07-20", "CFDA Number": "93.837", "Description": "DERIVATION OF TRANSPLANTABLE LUNG EPITHELIAL PROGENITORS FROM IPS CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL095993_7529"}, {"internal_id": 49755465, "Award ID": "R01HL095797", "Award Amount": 6661237.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-06-17", "CFDA Number": "93.837", "Description": "INTERVENTIONS AGAINST THE MOLECULAR ETIOLOGY OF BMPR2-INDUCED PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL095797_7529"}, {"internal_id": 49755442, "Award ID": "R01HL095686", "Award Amount": 4681107.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-03-24", "CFDA Number": "93.837", "Description": "A CRITICAL ROLE FOR THE MICROVASCULATURE IN AIRWAY TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ac01697b-b884-dbec-12f8-2f029a7cc4bb-C", "generated_internal_id": "ASST_NON_R01HL095686_7529"}, {"internal_id": 49755422, "Award ID": "R01HL095580", "Award Amount": 4651244.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-03-13", "CFDA Number": "93.838", "Description": "TRANSCRIPTIONAL PROGRAMMING OF ASTHMA RELATED PATHOLOGY IN RESPIRATORY EPITHELIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL095580_7529"}, {"internal_id": 49755410, "Award ID": "R01HL095524", "Award Amount": 6157338.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-03-19", "CFDA Number": "93.837", "Description": "EPIGENOMIC MODULATION OF CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL095524_7529"}, {"internal_id": 49755383, "Award ID": "R01HL095349", "Award Amount": 3641542.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-04-17", "CFDA Number": "93.838", "Description": "MECHANISM OF LUNG DEVELOPMENT AND INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL095349_7529"}, {"internal_id": 49755321, "Award ID": "R01HL094639", "Award Amount": 2146749.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-08-24", "CFDA Number": "93.838", "Description": "EFFECT OF PRONE POSITION ON VENTILATOR-INDUCED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL094639_7529"}, {"internal_id": 49755318, "Award ID": "R01HL094622", "Award Amount": 5902590.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-07-22", "CFDA Number": "93.837", "Description": "ROLE OF RESIDENT MESENCHYMAL STEM CELLS IN LUNG ALLOGRAFT REJECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL094622_7529"}, {"internal_id": 49755312, "Award ID": "R01HL094601", "Award Amount": 5566634.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-08-31", "CFDA Number": "93.837", "Description": "THE ROLE OF ISCHEMIA REPERFUSION INJURY IN LUNG ALLOGRAFT REJECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL094601_7529"}, {"internal_id": 49755306, "Award ID": "R01HL094585", "Award Amount": 2937021.4, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-12", "CFDA Number": "93.837", "Description": "TISSUE-SPECIFIC REGULATION OF A GENE ESSENTIAL FOR NORMAL AIRWAY EPITHELIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL094585_7529"}, {"internal_id": 49755129, "Award ID": "R01HL093096", "Award Amount": 6196010.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-03-04", "CFDA Number": "93.837", "Description": "PULMONARY FIBROSIS AND TELOMERASE DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL093096_7529"}, {"internal_id": 49755124, "Award ID": "R01HL093081", "Award Amount": 15071997.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-28", "CFDA Number": "93.837", "Description": "PULMONARY VASCULAR CHANGES IN EARLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL093081_7529"}, {"internal_id": 49755103, "Award ID": "R01HL092994", "Award Amount": 3116728.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-03-02", "CFDA Number": "93.838", "Description": "S-NITROSOTHIOLS, NF-KAPPAB AND INFLAMMATION IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL092994_7529"}, {"internal_id": 49755093, "Award ID": "R01HL092961", "Award Amount": 6203341.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-08-04", "CFDA Number": "93.837", "Description": "MECHANOBIOLOGY OF LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL092961_7529"}, {"internal_id": 49755063, "Award ID": "R01HL092774", "Award Amount": 3566066.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-18", "CFDA Number": "93.838", "Description": "VIRULENCE REGULATION BY THE MYCOBACTERIUM TUBERCULOSIS PROTEASOME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_R01HL092774_7529"}, {"internal_id": 49755050, "Award ID": "R01HL092514", "Award Amount": 3032671.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-08-04", "CFDA Number": "93.837", "Description": "ALLOANTIBODIES TO MHC INDUCES AUTOIMMUNITY AND OBLITERATIVE AIRWAY DISEASE (OAD)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d286cc0-2f1a-05c3-91cb-c92d5b0ff18a-C", "generated_internal_id": "ASST_NON_R01HL092514_7529"}, {"internal_id": 49754976, "Award ID": "R01HL092020", "Award Amount": 5249448.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-07-28", "CFDA Number": "93.837", "Description": "ENHANCING NEUTROPHIL FUNCTION IN NEUTROPENIA-RELATED PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL092020_7529"}, {"internal_id": 49754966, "Award ID": "R01HL091968", "Award Amount": 5412638.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-08", "CFDA Number": "93.837", "Description": "EFFECT OF NEONATAL HYPEROXIA ON ALVEOLAR DEVELOPMENT AND INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL091968_7529"}, {"internal_id": 49754965, "Award ID": "R01HL091958", "Award Amount": 3879227.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-26", "CFDA Number": "93.838", "Description": "NEUTROPHIL ACCUMULATION IN BACTERIAL PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07ed9f27-c528-e9d5-e332-90c8b04f48b8-C", "generated_internal_id": "ASST_NON_R01HL091958_7529"}, {"internal_id": 49754941, "Award ID": "R01HL091889", "Award Amount": 3175991.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-02", "CFDA Number": "93.838", "Description": "REGULATION OF ASTHMATIC INFLAMMATION BY NON-MUSCLE MLCK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R01HL091889_7529"}, {"internal_id": 49754929, "Award ID": "R01HL091835", "Award Amount": 7325802.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-19", "CFDA Number": "93.837", "Description": "A MULTIFACETED PROMPTING INTERVENTION FOR URBAN CHILDREN WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL091835_7529"}, {"internal_id": 49754903, "Award ID": "R01HL091528", "Award Amount": 9148398.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-13", "CFDA Number": "93.837", "Description": "RANDOMIZED CONTROLLED TRIAL: VDAART CONTINUATION STUDY - DCC - LEAD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL091528_7529"}, {"internal_id": 49754864, "Award ID": "R01HL091075", "Award Amount": 2113043.47, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-15", "CFDA Number": "93.837", "Description": "RANDOMIZED CONTROLLED TRIAL: VDAART CONTINUATION STUDY - CCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL091075_7529"}, {"internal_id": 49754748, "Award ID": "R01HL090586", "Award Amount": 3939023.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-06-22", "CFDA Number": "93.837", "Description": "DUAL DIRECT INHIBITORS OF THROMBIN AND FACTOR XA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R01HL090586_7529"}, {"internal_id": 49754725, "Award ID": "R01HL090152", "Award Amount": 5406317.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-17", "CFDA Number": "93.837", "Description": "ENDOTHELIAL PROGENITOR CELL TREATMENT OF LUNG VASCULAR INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL090152_7529"}, {"internal_id": 49754704, "Award ID": "R01HL089897", "Award Amount": 34641637.0, "Award Type": null, "Base Obligation Date": "2007-09-28", "CFDA Number": "93.838", "Description": "(1 OF 2) GENETIC EPIDEMIOLOGY OF COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL089897_7529"}, {"internal_id": 49754696, "Award ID": "R01HL089856", "Award Amount": 18256698.0, "Award Type": null, "Base Obligation Date": "2007-09-28", "CFDA Number": "93.838", "Description": "(2 OF 2) GENETIC EPIDEMIOLOGY OF COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL089856_7529"}, {"internal_id": 49754579, "Award ID": "R01HL089224", "Award Amount": 7116666.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-04", "CFDA Number": "93.837", "Description": "CARBOHYDRATE-MEDIATED PLATELET CLEARANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": 495000.0, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL089224_7529"}, {"internal_id": 49754578, "Award ID": "R01HL089221", "Award Amount": 5939720.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-11", "CFDA Number": "93.837", "Description": "DETERMINANTS OF AAV LUNG TROPISM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL089221_7529"}, {"internal_id": 49754576, "Award ID": "R01HL089215", "Award Amount": 3989412.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-03-13", "CFDA Number": "93.838", "Description": "SECRETORY PHOSPHOLIPASE A2S IN AIRWAY PATHOPHYSIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL089215_7529"}, {"internal_id": 49754567, "Award ID": "R01HL089043", "Award Amount": 4200048.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-23", "CFDA Number": "93.838", "Description": "COMPLIANT THORACIC ARTIFICIAL LUNGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c8e3c1b2-847b-fd38-8430-6da62d956103-C", "generated_internal_id": "ASST_NON_R01HL089043_7529"}, {"internal_id": 49754464, "Award ID": "R01HL088256", "Award Amount": 6842503.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-03", "CFDA Number": "93.837", "Description": "ROLE OF RAB27 IN GRANULOCYTE FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": 434000.0, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL088256_7529"}, {"internal_id": 49754433, "Award ID": "R01HL088029", "Award Amount": 5902102.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-03-20", "CFDA Number": "93.837", "Description": "NEUROTROPHINS IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL088029_7529"}, {"internal_id": 49754403, "Award ID": "R01HL087825", "Award Amount": 6436497.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-10", "CFDA Number": "93.837", "Description": "REGULATION OF AIRWAY MORPHOGENESIS AND DIFFERENTIATION BY WNT SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL087825_7529"}, {"internal_id": 49754401, "Award ID": "R01HL087823", "Award Amount": 4631899.7, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-10", "CFDA Number": "93.837", "Description": "MECHANISMS OF  PROSTACYCLIN-MEDIATED LUNG ENDOTHELIAL BARRIER PROTECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL087823_7529"}, {"internal_id": 49754396, "Award ID": "R01HL087778", "Award Amount": 3699257.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-02", "CFDA Number": "93.837", "Description": "DENDRITIC CELLS IN ATOPIC AND VIRUS-INDUCED AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_R01HL087778_7529"}, {"internal_id": 49754345, "Award ID": "R01HL087118", "Award Amount": 7245647.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-03-27", "CFDA Number": "93.837", "Description": "THE BMP-PPARGAMMA AXIS AND PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL087118_7529"}, {"internal_id": 49754344, "Award ID": "R01HL087115", "Award Amount": 6374485.61, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-15", "CFDA Number": "93.837", "Description": "CLINICAL RISK FACTORS FOR PRIMARY GRAFT DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL087115_7529"}, {"internal_id": 49754311, "Award ID": "R01HL086939", "Award Amount": 3283478.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-20", "CFDA Number": "93.838", "Description": "VASCULAR COLLAGEN ACCUMULATION & MECHANICAL MECHANISMS IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL086939_7529"}, {"internal_id": 49754310, "Award ID": "R01HL086936", "Award Amount": 3284256.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-02-19", "CFDA Number": "93.838", "Description": "SMOKE INDUCED AIRWAY INJURY IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL086936_7529"}, {"internal_id": 49754295, "Award ID": "R01HL086884", "Award Amount": 3673723.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-17", "CFDA Number": "93.838", "Description": "DUFFY ANTIGEN: MODIFIER OF SYSTEMIC AND LUNG CHEMOKINE RESPONSES IN INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL086884_7529"}, {"internal_id": 49754270, "Award ID": "R01HL086783", "Award Amount": 4188309.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-09", "CFDA Number": "93.838", "Description": "EXTRACELLULAR ATP: POTENTIAL REGULATOR OF HYPOXIA-INDUCED VASA VASORUM NEOVASCULA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL086783_7529"}, {"internal_id": 49754252, "Award ID": "R01HL086680", "Award Amount": 4703166.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-11-30", "CFDA Number": "93.838", "Description": "EXTRACELLULAR SUPEROXIDE INDUCES EGR-1 IN THE HYPOXIC PULMONARY ARTERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL086680_7529"}, {"internal_id": 49754242, "Award ID": "R01HL086621", "Award Amount": 2842666.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-11", "CFDA Number": "93.838", "Description": "NO-MODIFIED BIOMOLECULES AND PULMONARY SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "83d0dcf4-2a9e-ab83-7a4e-b740e9121600-C", "generated_internal_id": "ASST_NON_R01HL086621_7529"}, {"internal_id": 49754241, "Award ID": "R01HL086601", "Award Amount": 5969987.0, "Award Type": null, "Base Obligation Date": "2007-03-17", "CFDA Number": "93.838", "Description": "GENETICS AND GENE EXPRESSION PROFILING IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL086601_7529"}, {"internal_id": 49754205, "Award ID": "R01HL086324", "Award Amount": 3734587.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-04-15", "CFDA Number": "93.838", "Description": "FGF-10 EXPRESSION IN A FETAL MOUSE LUNG MODEL OF BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL086324_7529"}, {"internal_id": 49754147, "Award ID": "R01HL085646", "Award Amount": 4676492.54, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-01", "CFDA Number": "93.837", "Description": "DUAL OXIDASE IN AIRWAY EPITHELIAL REPAIR AND REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL085646_7529"}, {"internal_id": 49754142, "Award ID": "R01HL085613", "Award Amount": 3609756.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-20", "CFDA Number": "93.838", "Description": "MECHANISMS OF CIGARETTE SMOKE-INDUCED CHROMATIN REMODELING IN LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL085613_7529"}, {"internal_id": 49754123, "Award ID": "R01HL085534", "Award Amount": 4061453.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-03", "CFDA Number": "93.838", "Description": "THE INJURIOUS EFFECTS OF HYPERCAPNIA ON THE ALVEOLAR EPITHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL085534_7529"}, {"internal_id": 49754108, "Award ID": "R01HL085453", "Award Amount": 6127469.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-26", "CFDA Number": "93.837", "Description": "ROLE OF ANTI-GM-CSF ANTIBODIES IN MYELOID CELL FUNCTION & INNATE IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL085453_7529"}, {"internal_id": 49754082, "Award ID": "R01HL085324", "Award Amount": 3513536.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-05-04", "CFDA Number": "93.838", "Description": "THE ROLE OF FAK-RELATED-NON-KINASE (FRNK) IN LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL085324_7529"}, {"internal_id": 49754062, "Award ID": "R01HL085197", "Award Amount": 6699606.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-05-09", "CFDA Number": "93.838", "Description": "SEX-SPECIFIC GENETIC ARCHITECTURE OF ASTHMA-ASSOCIATED QUANTITATIVE TRAITS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL085197_7529"}, {"internal_id": 49753934, "Award ID": "R01HL084153", "Award Amount": 5034497.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2006-12-07", "CFDA Number": "93.837", "Description": "FOCAL ADHESION KINASE REGULATION OF LUNG VASCULAR PERMEABILITY AND EDEMAGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL084153_7529"}, {"internal_id": 49753933, "Award ID": "R01HL084151", "Award Amount": 4163399.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-27", "CFDA Number": "93.837", "Description": "FOX TRANSCRIPTION FACTORS IN DEVELOPMENT OF PULMONARY CAPILLARIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL084151_7529"}, {"internal_id": 49753755, "Award ID": "R01HL082818", "Award Amount": 3314822.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-13", "CFDA Number": "93.838", "Description": "REGULATION OF FIBROBLAST PHENOTYPE IN LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL082818_7529"}, {"internal_id": 49753692, "Award ID": "R01HL081823", "Award Amount": 3402793.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-12", "CFDA Number": "93.837", "Description": "NEURAL PLASTICITY DURING ACCLIMATIZATION TO HYPOXIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL081823_7529"}, {"internal_id": 49753686, "Award ID": "R01HL081784", "Award Amount": 4195442.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-15", "CFDA Number": "93.837", "Description": "TNF-ALPHA CONTROL OF A SURFACTANT ENZYME IN LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL081784_7529"}, {"internal_id": 49753595, "Award ID": "R01HL081149", "Award Amount": 4475442.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-02-28", "CFDA Number": "93.837", "Description": "IMPACT OF DIABETES AND HYPERLIPIDEMIA ON HOST DEFENSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_R01HL081149_7529"}, {"internal_id": 49753518, "Award ID": "R01HL080414", "Award Amount": 5743746.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-05-25", "CFDA Number": "93.837", "Description": "HISTOBLOOD GROUP ANTIGENS, VIRUSES & ASTHMA EXCERBATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL080414_7529"}, {"internal_id": 49753513, "Award ID": "R01HL080396", "Award Amount": 6603391.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-07-31", "CFDA Number": "93.837", "Description": "ROLE OF MUCIN IN LUNG HOMEOSTASIS AND PATHOPHYSIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL080396_7529"}, {"internal_id": 49753457, "Award ID": "R01HL079954", "Award Amount": 5075951.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-08", "CFDA Number": "93.838", "Description": "SCHOOL-BASED ASTHMA THERAPY: STAGE 2 EFFECTIVENESS STUDY REVISED", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL079954_7529"}, {"internal_id": 49753450, "Award ID": "R01HL079669", "Award Amount": 3246992.23, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-12", "CFDA Number": "93.837", "Description": "CELL PRIMING, RECEPTOR CROSS-TALK, AND ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL079669_7529"}, {"internal_id": 49753347, "Award ID": "R01HL078871", "Award Amount": 3684650.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-24", "CFDA Number": "93.837", "Description": "THE ANTI-PROTEASE AND VITRONECTIN-BINDING FUNCTIONS OF PAI-1 IN LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL078871_7529"}, {"internal_id": 49753304, "Award ID": "R01HL077783", "Award Amount": 2410433.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-07", "CFDA Number": "93.838", "Description": "A NEW PATHWAY FOR NEUTROPHIL-INDUCED AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL077783_7529"}, {"internal_id": 49753284, "Award ID": "R01HL077612", "Award Amount": 10996569.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-09", "CFDA Number": "93.837", "Description": "ENDOTHELIAL DYSFUNCTION, BIOMARKERS AND LUNG FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL077612_7529"}, {"internal_id": 49753254, "Award ID": "R01HL077328", "Award Amount": 6761106.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-24", "CFDA Number": "93.837", "Description": "CERAMIDE-INDUCED LUNG DESTRUCTION IN EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R01HL077328_7529"}, {"internal_id": 49753249, "Award ID": "R01HL077291", "Award Amount": 1931860.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-02-27", "CFDA Number": "93.838", "Description": "REGULATION OF PULMONARY FIBROSIS BY CXCR3", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL077291_7529"}, {"internal_id": 49753231, "Award ID": "R01HL077177", "Award Amount": 2262160.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-02-28", "CFDA Number": "93.839", "Description": "NOVEL MECHANISMS OF C-KIT REGULATION IN MAST CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL077177_7529"}, {"internal_id": 49753190, "Award ID": "R01HL076278", "Award Amount": 3411724.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2006-12-07", "CFDA Number": "93.837", "Description": "MACROPHAGE INFLAMMASOME REGULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL076278_7529"}, {"internal_id": 49753189, "Award ID": "R01HL076259", "Award Amount": 5726986.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-26", "CFDA Number": "93.837", "Description": "CONTROL OF LUNG PERMEABILITY BY OXIDIZED PHOSPHOLIPIDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL076259_7529"}, {"internal_id": 49753151, "Award ID": "R01HL075557", "Award Amount": 3689212.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2006-11-30", "CFDA Number": "93.838", "Description": "MACROPHAGE GENE EXPRESSION IN ACUTE LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL075557_7529"}, {"internal_id": 49753090, "Award ID": "R01HL074186", "Award Amount": 8328381.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-13", "CFDA Number": "93.837", "Description": "PULMONARY HYPERTENSION IN GENETICALLY MODIFIED MICE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL074186_7529"}, {"internal_id": 49753087, "Award ID": "R01HL074175", "Award Amount": 3611290.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-07-24", "CFDA Number": "93.837", "Description": "PSEUDOMONAS-HOST INTERACTIONS IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7eb6683a-d796-f7f5-68c0-ca8f32275b30-C", "generated_internal_id": "ASST_NON_R01HL074175_7529"}, {"internal_id": 49753077, "Award ID": "R01HL074011", "Award Amount": 4636727.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-01", "CFDA Number": "93.838", "Description": "RETROTRAPEZOID NUCLEUS AND CENTRAL CHEMORECEPTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL074011_7529"}, {"internal_id": 49753066, "Award ID": "R01HL073859", "Award Amount": 3087704.15, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-06-17", "CFDA Number": "93.837", "Description": "CHRONIC HYPOXIA AND PH HOMEOSTASIS IN PULMONARY MYOCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL073859_7529"}, {"internal_id": 49752995, "Award ID": "R01HL072844", "Award Amount": 2029185.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-13", "CFDA Number": "93.838", "Description": "MECHANISM OF APOPTOSIS IN LUNG VASCULAR SMOOTH MUSCLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "82335220-b01b-63c5-95b9-6dcae60104e4-C", "generated_internal_id": "ASST_NON_R01HL072844_7529"}, {"internal_id": 49752954, "Award ID": "R01HL071798", "Award Amount": 6116017.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2006-12-25", "CFDA Number": "93.837", "Description": "PATHOGENESIS OF PCD LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL071798_7529"}, {"internal_id": 49752898, "Award ID": "R01HL070952", "Award Amount": 4130361.8, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-30", "CFDA Number": "93.837", "Description": "ADENOSINE SIGNALING AND LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_R01HL070952_7529"}, {"internal_id": 49752813, "Award ID": "R01HL069409", "Award Amount": 2607703.0, "Award Type": null, "Base Obligation Date": "2006-12-21", "CFDA Number": "93.838", "Description": "UNIQUE ASPECTS OF RESPIRATORY IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL069409_7529"}, {"internal_id": 49752802, "Award ID": "R01HL069064", "Award Amount": 1428967.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-02-11", "CFDA Number": "93.838", "Description": "RESPIRATORY PLASTICITY AND SPINAL CORD INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL069064_7529"}, {"internal_id": 49752801, "Award ID": "R01HL069057", "Award Amount": 3101304.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-11", "CFDA Number": "93.838", "Description": "MECHANISMS OF FEVER-ENHANCED ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL069057_7529"}, {"internal_id": 49752797, "Award ID": "R01HL069031", "Award Amount": 4513839.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-12", "CFDA Number": "93.837", "Description": "COLLECTIN-MEDIATED DEFENSE AGAINST INFLUENZA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "54768301-b245-c1c5-66ec-e0c90b049cc4-C", "generated_internal_id": "ASST_NON_R01HL069031_7529"}, {"internal_id": 49752769, "Award ID": "R01HL068702", "Award Amount": 5143474.22, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-17", "CFDA Number": "93.837", "Description": "ROLE OF VEGF IN PERINATAL PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL068702_7529"}, {"internal_id": 49752742, "Award ID": "R01HL068111", "Award Amount": 8846175.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-05-05", "CFDA Number": "93.837", "Description": "REGULATION OF MUCOUS CELL METAPLASIA IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL068111_7529"}, {"internal_id": 49752586, "Award ID": "R01HL065228", "Award Amount": 3991816.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-06", "CFDA Number": "93.838", "Description": "EOSINOPHIL ACTIVITIES IN MURINE MODELS OF LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2439d942-d439-953a-5588-98392dd15217-C", "generated_internal_id": "ASST_NON_R01HL065228_7529"}, {"internal_id": 49752445, "Award ID": "R01HL062410", "Award Amount": 3673997.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-10", "CFDA Number": "93.838", "Description": "PATHOGENIC T CELLS IN CHRONIC BERYLLIUM DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL062410_7529"}, {"internal_id": 49752424, "Award ID": "R01HL062150", "Award Amount": 5836757.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-11", "CFDA Number": "93.837", "Description": "PNEUMOCYSTIS CARINII: MACROPHAGE AND EPITHELIAL ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL062150_7529"}, {"internal_id": 49752420, "Award ID": "R01HL062052", "Award Amount": 3027046.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-29", "CFDA Number": "93.838", "Description": "CD8 T-CELLS AND HOST DEFENSE AGAINST P. CARINII", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_R01HL062052_7529"}, {"internal_id": 49752393, "Award ID": "R01HL061284", "Award Amount": 4949290.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-28", "CFDA Number": "93.838", "Description": "PERINATAL PULMONARY HYPERTENSION: DEVELOPMENTAL MEDIATORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL061284_7529"}, {"internal_id": 49752386, "Award ID": "R01HL061007", "Award Amount": 5607726.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-19", "CFDA Number": "93.837", "Description": "NEUROGENIC INFLAMMATORY RESPONSE TO RSV", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_R01HL061007_7529"}, {"internal_id": 49752379, "Award ID": "R01HL060917", "Award Amount": 3718530.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-05-24", "CFDA Number": "93.837", "Description": "NITRIC OXIDE PRODUCTION AND REACTIONS IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL060917_7529"}, {"internal_id": 49752353, "Award ID": "R01HL060539", "Award Amount": 4331250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-13", "CFDA Number": "93.838", "Description": "MECHANISMS OF MACROPHAGE ACTIVATION IN LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL060539_7529"}, {"internal_id": 49752350, "Award ID": "R01HL060234", "Award Amount": 3652515.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-07", "CFDA Number": "93.838", "Description": "HEME OXYGENASE 1\\CARBON MONOXIDE IN LUNG VASCULAR INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL060234_7529"}, {"internal_id": 49752348, "Award ID": "R01HL060190", "Award Amount": 4080188.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2006-12-04", "CFDA Number": "93.837", "Description": "PERINATAL REGULATION OF ENDOTHELIAL NOS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8521f543-2302-80cf-d989-c2ff7cf07ef3-C", "generated_internal_id": "ASST_NON_R01HL060190_7529"}, {"internal_id": 49752335, "Award ID": "R01HL059842", "Award Amount": 5125000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-28", "CFDA Number": "93.837", "Description": "SYNERGY OF HOST DEFENSE MECHANISMS IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL059842_7529"}, {"internal_id": 49752287, "Award ID": "R01HL058506", "Award Amount": 6280003.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-10", "CFDA Number": "93.837", "Description": "G PROTEIN-COUPLED RECEPTOR REGULATION IN AIRWAY MYOCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL058506_7529"}, {"internal_id": 49752280, "Award ID": "R01HL058234", "Award Amount": 3344310.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-07-20", "CFDA Number": "93.838", "Description": "DNA LESIONS AND GENE EXPRESSION IN HYPOXIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_R01HL058234_7529"}, {"internal_id": 49752265, "Award ID": "R01HL057556", "Award Amount": 5138817.12, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-20", "CFDA Number": "93.837", "Description": "CALCIUM REGULATION IN LUNG MICROVASCULAR ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL057556_7529"}, {"internal_id": 49752232, "Award ID": "R01HL056643", "Award Amount": 4021402.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-07", "CFDA Number": "93.838", "Description": "IMMUNE MECHANISMS OF REJECTION IN HUMAN LUNG ALLOGRAFTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d286cc0-2f1a-05c3-91cb-c92d5b0ff18a-C", "generated_internal_id": "ASST_NON_R01HL056643_7529"}, {"internal_id": 49752227, "Award ID": "R01HL056470", "Award Amount": 7276676.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-07-15", "CFDA Number": "93.837", "Description": "NEONATAL MODULATION OF AIRWAY CONTRACTILITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL056470_7529"}, {"internal_id": 49752192, "Award ID": "R01HL055454", "Award Amount": 3940382.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-15", "CFDA Number": "93.838", "Description": "CELLULAR RESPONSES TO HYPOXIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL055454_7529"}, {"internal_id": 49752185, "Award ID": "R01HL055330", "Award Amount": 4503909.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-04-30", "CFDA Number": "93.837", "Description": "ROLE OF HEME OXYGENASE IN HYPEROXIC LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL055330_7529"}, {"internal_id": 49752161, "Award ID": "R01HL054352", "Award Amount": 4164448.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-01", "CFDA Number": "93.838", "Description": "ALPHA-V INTEGINS AND ADENOVIRUS CELL ENTRY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL054352_7529"}, {"internal_id": 49752141, "Award ID": "R01HL053325", "Award Amount": 3622754.63, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-06-10", "CFDA Number": "93.837", "Description": "ASSEMBLY OF LUNG ELASTIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL053325_7529"}, {"internal_id": 49752128, "Award ID": "R01HL052285", "Award Amount": 3408578.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-03-24", "CFDA Number": "93.838", "Description": "MYOFIBROBLASTS IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL052285_7529"}, {"internal_id": 49752127, "Award ID": "R01HL052246", "Award Amount": 7578142.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2006-12-14", "CFDA Number": "93.838", "Description": "STRUCTURE AND FUNCTION OF PROTEIN C", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL052246_7529"}, {"internal_id": 49752114, "Award ID": "R01HL051177", "Award Amount": 5405253.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-20", "CFDA Number": "93.837", "Description": "LIPID AND PROTEIN EFFECTS ON MONOLAYER STABILITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL051177_7529"}, {"internal_id": 49752096, "Award ID": "R01HL050022", "Award Amount": 6576388.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-15", "CFDA Number": "93.837", "Description": "MECHANISMS IN THE REGULATION OF SP-A GENE EXPRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_R01HL050022_7529"}, {"internal_id": 49752079, "Award ID": "R01HL049192", "Award Amount": 3958129.02, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-03-13", "CFDA Number": "93.837", "Description": "OXIDATIVE STRESS AND VASCULAR SMOTH MUSCLE CELL GROWTH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL049192_7529"}, {"internal_id": 49752064, "Award ID": "R01HL048522", "Award Amount": 4086121.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-23", "CFDA Number": "93.838", "Description": "MODULATION OF AIRWAY REACTIVITY BY CHRONIC MECHANICAL STRAIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL048522_7529"}, {"internal_id": 49752052, "Award ID": "R01HL047125", "Award Amount": 2783272.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-03-21", "CFDA Number": "93.838", "Description": "REGULATION OF MUC1 MUCIN DURING AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R01HL047125_7529"}, {"internal_id": 49752034, "Award ID": "R01HL045638", "Award Amount": 7542735.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-21", "CFDA Number": "93.837", "Description": "THROMBIN-INDUCED PULMONARY VASCULAR PERMEABILITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL045638_7529"}, {"internal_id": 49751948, "Award ID": "R01HL036024", "Award Amount": 5473972.63, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-04-30", "CFDA Number": "93.837", "Description": "MICROPUNCTURE STUDIES OF LUNG WATER AND SOLUTE EXCHANGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL036024_7529"}, {"internal_id": 49751941, "Award ID": "R01HL035440", "Award Amount": 3382466.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-02-24", "CFDA Number": "93.837", "Description": "RESPIRATORY AND METABOLIC ADAPTATION TO HYPOXIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL035440_7529"}, {"internal_id": 49751910, "Award ID": "R01HL031237", "Award Amount": 3722200.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-06", "CFDA Number": "93.838", "Description": "MONOKINE GENE EXPRESSION/REGULATION IN LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL031237_7529"}, {"internal_id": 49751909, "Award ID": "R01HL031197", "Award Amount": 2190481.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-08-18", "CFDA Number": "93.310", "Description": "MECHANISMS OF ENAC INHIBITION BY REPLICATING INFLUENZA VIRUS: ROLE OF M2 PROTEIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL031197_7529"}, {"internal_id": 49751896, "Award ID": "R01HL029289", "Award Amount": 5300283.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-30", "CFDA Number": "93.837", "Description": "SMOOTH MUSCLE MECHANISMS IN DYNAMIC AIRWAY PROPERTIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL029289_7529"}, {"internal_id": 49751885, "Award ID": "R01HL028066", "Award Amount": 3096068.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-12-25", "CFDA Number": "93.838", "Description": "CSF AND THE CENTRAL CHEMICAL CONTROL OF BREATHING.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7eb6683a-d796-f7f5-68c0-ca8f32275b30-C", "generated_internal_id": "ASST_NON_R01HL028066_7529"}, {"internal_id": 49723251, "Award ID": "R01CA164782", "Award Amount": 3156906.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-08-04", "CFDA Number": "93.838", "Description": "EPIGENETIC CHANGES LINK COPD AND LUNG CANCER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f2d34976-4cec-07f8-d072-fb7f1eb21cbe-C", "generated_internal_id": "ASST_NON_R01CA164782_7529"}, {"internal_id": 95943158, "Award ID": "R00HL143207", "Award Amount": 837249.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-14", "CFDA Number": "93.837", "Description": "PHRENIC AFFERENTS AND NEUROMUSCULAR PLASTICITY FOLLOWING SPINAL CORD INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "93823bac-b8d2-7860-f871-2884c7daa75f-C", "generated_internal_id": "ASST_NON_R00HL143207_7529"}, {"internal_id": 111229128, "Award ID": "R00HL141685", "Award Amount": 742715.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-08", "CFDA Number": "93.837", "Description": "LINCENC1 REGULATES THE LIPOPOLYSACCHARIDE-INDUCED INFLAMMATORY RESPONSE IN MACROPHAGES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_R00HL141685_7529"}, {"internal_id": 111229126, "Award ID": "R00HL141684", "Award Amount": 750953.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-26", "CFDA Number": "93.837", "Description": "DEFINING THE MOLECULAR DETERMINANTS OF MESENCHYMAL LINEAGE ALLOCATION IN LUNG DEVELOPMENT AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R00HL141684_7529"}, {"internal_id": 111229123, "Award ID": "R00HL141678", "Award Amount": 771254.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-11-29", "CFDA Number": "93.837", "Description": "IMPROVING THE MEASUREMENT AND ANALYSIS OF LONG-TERM, PATIENT-CENTERED OUTCOMES FOLLOWING ACUTE RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R00HL141678_7529"}, {"internal_id": 111229132, "Award ID": "R00HL141658", "Award Amount": 749547.73, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "MACROPHAGE METABOLISM AFTER TARGET CELL INGESTION REGULATES ANTI-INFLAMMATORY REPROGRAMMING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_R00HL141658_7529"}, {"internal_id": 83797096, "Award ID": "R00HL138278", "Award Amount": 774731.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-23", "CFDA Number": "93.837", "Description": "ROLE OF SMOOTH MUSCLE PROGENITOR CELLS IN OBLITERATIVE VASCULAR REMODELING AND PH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R00HL138278_7529"}, {"internal_id": 95942947, "Award ID": "R00HL138255", "Award Amount": 820092.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-09", "CFDA Number": "93.837", "Description": "EARLY DETECTION OF REGIONAL BOS IN BMT PATIENTS USING UTE AND 129XE MRI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R00HL138255_7529"}, {"internal_id": 111229122, "Award ID": "R00HL135403", "Award Amount": 746918.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-11-28", "CFDA Number": "93.837", "Description": "GENETIC VARIATION IMPACTING THE AIRWAY SMOOTH MUSCLE IN CHILDREN WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R00HL135403_7529"}, {"internal_id": 111229125, "Award ID": "R00HL135258", "Award Amount": 747000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-13", "CFDA Number": "93.837", "Description": "UNCOVERING COMPENSATORY MECHANISMS IN  FAMILY MEMBERS WITH DISEASE CAUSING MUTATIONS OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R00HL135258_7529"}, {"internal_id": 67313863, "Award ID": "R00HL131866", "Award Amount": 731102.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-15", "CFDA Number": "93.838", "Description": "METABOLIC DRIVERS AND SENSORS OF CELL PROLIFERATION IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R00HL131866_7529"}, {"internal_id": 49705501, "Award ID": "R00HL131817", "Award Amount": 722058.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-05", "CFDA Number": "93.837", "Description": "HETEROGENEITY AND BIAS OF LINEAGE NEGATIVE PROGENITORS IN LUNG EPITHELIAL REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R00HL131817_7529"}, {"internal_id": 67833354, "Award ID": "R00HL131682", "Award Amount": 839841.48, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-15", "CFDA Number": "93.837", "Description": "ENHANCING CORTICOSTEROID SENSITIVITY IN NEONATAL AND PEDIATRIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_R00HL131682_7529"}, {"internal_id": 49705488, "Award ID": "R00HL128944", "Award Amount": 746998.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.837", "Description": "THE IMPORTANCE OF INHOMOGENEITY IN THE PATHOGENESIS OF LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R00HL128944_7529"}, {"internal_id": 83115796, "Award ID": "R00HL127267", "Award Amount": 746998.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-09", "CFDA Number": "93.837", "Description": "REVERSE ENGINEERING THE ALVEOLUS: FROM CELLULAR TO MICROENVIRONMENT SPECIFICATION DURING DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R00HL127267_7529"}, {"internal_id": 49705485, "Award ID": "R00HL127181", "Award Amount": 734328.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.837", "Description": "TO DEFINE THE ROLE OF SOX9 AND SOX9+ CELLS IN ALVEOLAR HOMEOSTASIS AND REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R00HL127181_7529"}, {"internal_id": 49705482, "Award ID": "R00HL125899", "Award Amount": 744383.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-29", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL IRON METABOLISM IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R00HL125899_7529"}, {"internal_id": 68171996, "Award ID": "R00HL125756", "Award Amount": 739991.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-24", "CFDA Number": "93.837", "Description": "NITRIC OXIDE COUPLING AND BH4 AVAILABILITY ROLES IN MUSCLE DYSFUNCTION WITH COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f879ffdd-a594-a5e7-2f71-72b5613abc69-C", "generated_internal_id": "ASST_NON_R00HL125756_7529"}, {"internal_id": 61614633, "Award ID": "R00HL125728", "Award Amount": 727381.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-01", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF ZR-89 BASED IMMUNOPET AGENTS FOR IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3313e5e7-fa36-d54b-e36d-0e1e09cc0c30-C", "generated_internal_id": "ASST_NON_R00HL125728_7529"}, {"internal_id": 49705460, "Award ID": "R00HL122513", "Award Amount": 747552.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-17", "CFDA Number": "93.837", "Description": "EXTRACELLULAR DETERMINANTS OF AIRWAY SMOOTH MUSCLE FORCE: A NEW PARADIGM FOR SUST", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4787a47d-4e7a-9c8a-99e6-91ba7f4c9b8b-C", "generated_internal_id": "ASST_NON_R00HL122513_7529"}, {"internal_id": 49705453, "Award ID": "R00HL122365", "Award Amount": 739758.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.838", "Description": "THE ROLE OF RIP2 KINASE IN THE PATHOGENESIS OF ALLERGIC ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "94a5f913-3d90-0392-f8a2-22465ba63352-C", "generated_internal_id": "ASST_NON_R00HL122365_7529"}, {"internal_id": 49705443, "Award ID": "R00HL121087", "Award Amount": 747000.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-26", "CFDA Number": "93.837", "Description": "NETWORK MEDICINE APPROACHES TO CACHEXIA IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R00HL121087_7529"}, {"internal_id": 49705440, "Award ID": "R00HL121073", "Award Amount": 733586.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-11", "CFDA Number": "93.838", "Description": "A NOVEL ROLE FOR THE ADAPTER MOLECULE NHERF1 IN REGULATING ASTHMA AND ALLERGIC RE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "55f37363-0a0a-cf69-f770-ef6464f3ff05-C", "generated_internal_id": "ASST_NON_R00HL121073_7529"}, {"internal_id": 49705436, "Award ID": "R00HL119606", "Award Amount": 724240.0, "Award Type": null, "Base Obligation Date": "2015-02-13", "CFDA Number": "93.838", "Description": "ENHANCED RESPIRATORY PLASTICITY IN MODELS OF RESPIRATORY MOTOR NEURON DEATH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f261384c-3ac1-b344-de46-81708f87aa6a-C", "generated_internal_id": "ASST_NON_R00HL119606_7529"}, {"internal_id": 49705432, "Award ID": "R00HL119560", "Award Amount": 739899.17, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.837", "Description": "NEURAL PATHOGENESIS OF AIRWAY SMOOTH MUSCLE DEFECTS IN AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R00HL119560_7529"}, {"internal_id": 49705403, "Award ID": "R00HL114651", "Award Amount": 740935.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-15", "CFDA Number": "93.837", "Description": "CAUSAL INFERENCE OF DISEASE-RELEVANT REGULATORY NETWORKS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R00HL114651_7529"}, {"internal_id": 49705400, "Award ID": "R00HL113105", "Award Amount": 743181.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-07", "CFDA Number": "93.838", "Description": "MECHANISMS OF TELEOMERE-MEDIATED EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R00HL113105_7529"}, {"internal_id": 49705389, "Award ID": "R00HL111348", "Award Amount": 747000.0, "Award Type": null, "Base Obligation Date": "2014-05-12", "CFDA Number": "93.838", "Description": "MIRNAS REGULATE LUNG EPITHELIAL PROGENITOR CELLS IN DEVELOPMENT AND INJURY REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R00HL111348_7529"}, {"internal_id": 49705384, "Award ID": "R00HL111217", "Award Amount": 727518.45, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-10", "CFDA Number": "93.837", "Description": "TIME-RESOLVED 129XE VENTILATION-PERFUSION MRI IN  MODELS OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R00HL111217_7529"}, {"internal_id": 49705383, "Award ID": "R00HL111215", "Award Amount": 708245.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-26", "CFDA Number": "93.838", "Description": "REGULATION OF AIRWAY PROTECTIVE BEHAVIORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c9476c3-c39d-74de-31b6-2c9a10197e11-C", "generated_internal_id": "ASST_NON_R00HL111215_7529"}, {"internal_id": 49705381, "Award ID": "R00HL111151", "Award Amount": 715958.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-06-27", "CFDA Number": "93.838", "Description": "THE ROLE OF SP-A IN MP-INDUCED EXACERBATIONS DURING ALLERGIC AIRWAY DISEASE.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_R00HL111151_7529"}, {"internal_id": 49705377, "Award ID": "R00HL109162", "Award Amount": 741004.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-07", "CFDA Number": "93.838", "Description": "AN INTEGRATIVE GENOMICS APPROACH TO GENE BY ENVIRONMENT INTERACTIONS IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c0103b26-3b3f-708e-e041-01c60221a8b9-C", "generated_internal_id": "ASST_NON_R00HL109162_7529"}, {"internal_id": 49577888, "Award ID": "P20HL113443", "Award Amount": 5296156.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2012-04-05", "CFDA Number": "93.077", "Description": "COPD METABOLOME, SMOKING OXIDANTS AND ABERRANT CILIATED CELL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_P20HL113443_7529"}, {"internal_id": 107115540, "Award ID": "P01HL152961", "Award Amount": 8692961.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-27", "CFDA Number": "93.866", "Description": "COMPLEMENT MEDIATED REMODELING IN PULMONARY VASCULAR DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_P01HL152961_7529"}, {"internal_id": 110862401, "Award ID": "P01HL152960", "Award Amount": 9306847.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-27", "CFDA Number": "93.837", "Description": "MOLECULAR THERAPIES FOR CYSTIC FIBROSIS LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_P01HL152960_7529"}, {"internal_id": 108463295, "Award ID": "P01HL146369", "Award Amount": 7187290.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-10", "CFDA Number": "93.837", "Description": "METABOLIC REPROGRAMMING AND PULMONARY VASCULAR DISEASE IN CONGENITAL HEART DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8521f543-2302-80cf-d989-c2ff7cf07ef3-C", "generated_internal_id": "ASST_NON_P01HL146369_7529"}, {"internal_id": 49359428, "Award ID": "P01HL136275", "Award Amount": 18516625.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-22", "CFDA Number": "93.837", "Description": "IMMUNE CELL INTERACTIONS IN ATHEROSCLEROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": 523914.0, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_P01HL136275_7529"}, {"internal_id": 61614071, "Award ID": "P01HL134610", "Award Amount": 11560866.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-02", "CFDA Number": "93.837", "Description": "GENETICS, EPIGENETICS, AND POST-TRANSLATIONAL MODIFICATIONS AND THE DEVELOPMENT OF VENTILATOR-INDUCED LUNG INJURY (VILI)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8521f543-2302-80cf-d989-c2ff7cf07ef3-C", "generated_internal_id": "ASST_NON_P01HL134610_7529"}, {"internal_id": 49359422, "Award ID": "P01HL132825", "Award Amount": 12584301.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-29", "CFDA Number": "93.837", "Description": "SYSTEMS BIOLOGY OF AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_P01HL132825_7529"}, {"internal_id": 49359421, "Award ID": "P01HL132821", "Award Amount": 8970289.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-25", "CFDA Number": "93.837", "Description": "DEFINING MOLECULAR PHENOTYPES OF EXACERBATION PRONE ASTHMATICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_P01HL132821_7529"}, {"internal_id": 49359415, "Award ID": "P01HL131471", "Award Amount": 11339094.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-28", "CFDA Number": "93.837", "Description": "NEW APPROACHES TO GENE THERAPY FOR ALPHA-1 ANTITRYPSIN DEFICIENCY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_P01HL131471_7529"}, {"internal_id": 49359412, "Award ID": "P01HL128192", "Award Amount": 12234491.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.837", "Description": "PERSONALIZED SMALL MOLECULE THERAPY FOR SEVERE ASTHMA AND CYSTIC FIBROSIS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": 140306.0, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_P01HL128192_7529"}, {"internal_id": 49359411, "Award ID": "P01HL128191", "Award Amount": 13408111.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-26", "CFDA Number": "93.837", "Description": "CARBOHYDRATE-BASED THERAPY FOR LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": 768543.0, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_P01HL128191_7529"}, {"internal_id": 49359410, "Award ID": "P01HL126609", "Award Amount": 13596341.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-31", "CFDA Number": "93.837", "Description": "CYTOSKELETAL REGULATION OF LUNG ENDOTHELIAL PATHOBIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_P01HL126609_7529"}, {"internal_id": 49359406, "Award ID": "P01HL120839", "Award Amount": 12228519.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-28", "CFDA Number": "93.838", "Description": "PHYSICS OF COLLECTIVE CELLULAR MIGRATION IN LUNG HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_P01HL120839_7529"}, {"internal_id": 49359405, "Award ID": "P01HL119165", "Award Amount": 13574852.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-03", "CFDA Number": "93.837", "Description": "NOVEL TARGETED THERAPIES FOR PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "477a63d4-719d-b906-aac9-e6f4de4b2342-R", "generated_internal_id": "ASST_NON_P01HL119165_7529"}, {"internal_id": 49359402, "Award ID": "P01HL114501", "Award Amount": 19825172.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-09-06", "CFDA Number": "93.837", "Description": "DISTINCT AND OVERLAPPING PATHWAYS OF FIBROSIS AND EMPHYSEMA IN CIGARETTE SMOKERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_P01HL114501_7529"}, {"internal_id": 49359401, "Award ID": "P01HL114471", "Award Amount": 23901912.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-15", "CFDA Number": "93.837", "Description": "NOVEL MOLECULAR MECHANISMS PROMOTE GPCR-INDUCED BRONCHODILATION IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f360f59f-4329-903a-affb-d7870b1503be-C", "generated_internal_id": "ASST_NON_P01HL114471_7529"}, {"internal_id": 49359400, "Award ID": "P01HL114470", "Award Amount": 17822549.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-09-16", "CFDA Number": "93.837", "Description": "THERAPEUTIC TARGETING OF THE MYOFIBROBLAST IN FIBROTIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_P01HL114470_7529"}, {"internal_id": 49359399, "Award ID": "P01HL114457", "Award Amount": 9956739.8, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-23", "CFDA Number": "93.837", "Description": "HYPOXIC ADENOSINE RESPONSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_P01HL114457_7529"}, {"internal_id": 49359398, "Award ID": "P01HL114453", "Award Amount": 21344111.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-01-09", "CFDA Number": "93.837", "Description": "CARDIOLIPIN AS A NOVEL MEDIATOR OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_P01HL114453_7529"}, {"internal_id": 49359394, "Award ID": "P01HL110873", "Award Amount": 10687014.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-05-08", "CFDA Number": "93.838", "Description": "PULMONARY SURFACE LIQUID HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_P01HL110873_7529"}, {"internal_id": 49359391, "Award ID": "P01HL108808", "Award Amount": 23866710.96, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-06-15", "CFDA Number": "93.837", "Description": "NOVEL THERAPIES FOR MUCO-OBSTRUCTIVE LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_P01HL108808_7529"}, {"internal_id": 49359389, "Award ID": "P01HL108801", "Award Amount": 13705696.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-08-15", "CFDA Number": "93.838", "Description": "CARBON MONOXIDE: NOVEL OPPORTUNITIES FOR THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_P01HL108801_7529"}, {"internal_id": 49359388, "Award ID": "P01HL108800", "Award Amount": 21953192.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-20", "CFDA Number": "93.837", "Description": "HORMONAL, METABOLIC AND SIGNALING INTERACTIONS IN PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_P01HL108800_7529"}, {"internal_id": 49359387, "Award ID": "P01HL108797", "Award Amount": 19651051.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-08-17", "CFDA Number": "93.837", "Description": "ELAFIN THERAPY FOR LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_P01HL108797_7529"}, {"internal_id": 49359385, "Award ID": "P01HL108794", "Award Amount": 12606201.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-09", "CFDA Number": "93.838", "Description": "TARGETING EPITHELIAL CELLS TO TREAT PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_P01HL108794_7529"}, {"internal_id": 49359384, "Award ID": "P01HL108793", "Award Amount": 21269635.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-19", "CFDA Number": "93.837", "Description": "HOST FACTORS IN REGULATION OF INFLAMMATORY AND FIBROPROLIFERATIVE LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_P01HL108793_7529"}, {"internal_id": 49359382, "Award ID": "P01HL107202", "Award Amount": 23326031.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-08", "CFDA Number": "93.837", "Description": "INNATE AND ADAPTIVE IMMUNE RESPONSES IN TH2-HIGH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_P01HL107202_7529"}, {"internal_id": 49359379, "Award ID": "P01HL107151", "Award Amount": 15436148.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-06-23", "CFDA Number": "93.838", "Description": "GLYCOBIOLOGY OF INFLAMMATORY LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_P01HL107151_7529"}, {"internal_id": 49359375, "Award ID": "P01HL105339", "Award Amount": 12213978.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-08-17", "CFDA Number": "93.838", "Description": "FUNCTIONAL GENETICS OF COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_P01HL105339_7529"}, {"internal_id": 49359373, "Award ID": "P01HL103455", "Award Amount": 26064694.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-05-27", "CFDA Number": "93.837", "Description": "VASCULAR SUBPHENOTYPES OF LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_P01HL103455_7529"}, {"internal_id": 49359372, "Award ID": "P01HL103453", "Award Amount": 26624923.91, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-08-02", "CFDA Number": "93.837", "Description": "ASTHMA INFLAMMATION RESEARCH (AIR)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_P01HL103453_7529"}, {"internal_id": 49359371, "Award ID": "P01HL101902", "Award Amount": 11204180.0, "Award Type": null, "Base Obligation Date": "2011-07-07", "CFDA Number": "93.838", "Description": "ENDOTHELIAL BARRIER PROTECTION AND REPAIR IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_P01HL101902_7529"}, {"internal_id": 49359370, "Award ID": "P01HL101871", "Award Amount": 8674351.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-04-07", "CFDA Number": "93.838", "Description": "CELLULAR S-NITROSOTHIOL SIGNALING IN RESPIRATORY BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_P01HL101871_7529"}, {"internal_id": 49359365, "Award ID": "P01HL098050", "Award Amount": 10943499.0, "Award Type": null, "Base Obligation Date": "2011-05-18", "CFDA Number": "93.838", "Description": "ROLE OF SPHINGOLIPIDS IN THE PATHOBIOLOGY OF LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_P01HL098050_7529"}, {"internal_id": 49359352, "Award ID": "P01HL092870", "Award Amount": 21616027.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-01-19", "CFDA Number": "93.837", "Description": "MECHANISMS OF FAMILIAL PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_P01HL092870_7529"}, {"internal_id": 49359350, "Award ID": "P01HL091842", "Award Amount": 34243478.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-10", "CFDA Number": "93.837", "Description": "PPG -AIRWAY PHYSIOLOGY AND PATHOPHYSIOLOGY IN A PORCINE CF MODEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_P01HL091842_7529"}, {"internal_id": 49359346, "Award ID": "P01HL090554", "Award Amount": 20680176.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-22", "CFDA Number": "93.838", "Description": "INTEGRATIVE CONSEQUENCES OF HYPOXIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_P01HL090554_7529"}, {"internal_id": 49359340, "Award ID": "P01HL088594", "Award Amount": 21027263.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-01-18", "CFDA Number": "93.838", "Description": "ROLE OF EOSINOPHILS IN AIRWAY INFLAMMATION AND REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_P01HL088594_7529"}, {"internal_id": 49359317, "Award ID": "P01HL081064", "Award Amount": 14030420.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-30", "CFDA Number": "93.837", "Description": "PATHOBIOLOGY OF ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_P01HL081064_7529"}, {"internal_id": 49359304, "Award ID": "P01HL077806", "Award Amount": 21803532.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-07", "CFDA Number": "93.837", "Description": "MECHANISMS OF PMN-MEDIATED LUNG INFLAMMATION AND INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_P01HL077806_7529"}, {"internal_id": 49359297, "Award ID": "P01HL076100", "Award Amount": 11519404.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-09", "CFDA Number": "93.838", "Description": "HOST DEFENSE AGAINST HIV-RELATED PULMONARY INFECTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6a863c9b-365c-816d-1f3a-a0096107ff16-C", "generated_internal_id": "ASST_NON_P01HL076100_7529"}, {"internal_id": 49359288, "Award ID": "P01HL071643", "Award Amount": 22387193.33, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-05-31", "CFDA Number": "93.837", "Description": "PATHOPHYSIOLOGY OF ALVEOLAR EPITHELIAL LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_P01HL071643_7529"}, {"internal_id": 49359287, "Award ID": "P01HL070831", "Award Amount": 22361167.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-04-15", "CFDA Number": "93.838", "Description": "RHINOVIRUS INFECTIONS AND CHILDHOOD ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_P01HL070831_7529"}, {"internal_id": 49359276, "Award ID": "P01HL066299", "Award Amount": 24490288.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-09", "CFDA Number": "93.837", "Description": "LUNG ENDOTHELIAL CELL PHENOTYPES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_P01HL066299_7529"}, {"internal_id": 49359267, "Award ID": "P01HL060678", "Award Amount": 26992669.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-03-14", "CFDA Number": "93.837", "Description": "SIGNALING OF ENDOTHELIAL PERMEABILITY AND LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_P01HL060678_7529"}, {"internal_id": 49359240, "Award ID": "P01HL051670", "Award Amount": 23986565.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-22", "CFDA Number": "93.837", "Description": "PPG-GENE THERAPY FOR CYSTIC FIBROSIS LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_P01HL051670_7529"}, {"internal_id": 49359214, "Award ID": "P01HL034303", "Award Amount": 11920732.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-21", "CFDA Number": "93.838", "Description": "ETHER LIPIDS, EICOSANOIDS, AND LUNG CELL PATHOPHYSIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_P01HL034303_7529"}, {"internal_id": 49359191, "Award ID": "P01HL014985", "Award Amount": 22227542.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-06", "CFDA Number": "93.837", "Description": "ADAPTATIONS TO HYPOXIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_P01HL014985_7529"}, {"internal_id": 96204434, "Award ID": "K99HL151965", "Award Amount": 209369.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-01", "CFDA Number": "93.837", "Description": "MODULATION OF RIBOSOME VELOCITY AS A MEANS TO RESCUE REFRACTORY CF-CAUSING VARIANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K99HL151965_7529"}, {"internal_id": 107114130, "Award ID": "K99HL151670", "Award Amount": 123850.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-30", "CFDA Number": "93.837", "Description": "ENGINEERED ALVEOLAR ORGANOIDS TO UNDERSTAND ECM SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K99HL151670_7529"}, {"internal_id": 94714199, "Award ID": "K99HL146986", "Award Amount": 92923.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-04", "CFDA Number": "93.837", "Description": "MECHANISMS OF IMMUNOMODULATION IN LUNG INJURY BY MESENCHYMAL STROMAL CELL EXOSOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_K99HL146986_7529"}, {"internal_id": 76738059, "Award ID": "K99HL145113", "Award Amount": 318421.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-04", "CFDA Number": "93.837", "Description": "REGULATION OF VASCULAR METABOLISM IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_K99HL145113_7529"}, {"internal_id": 83796269, "Award ID": "K99HL145097", "Award Amount": 220581.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-22", "CFDA Number": "93.837", "Description": "THERAPEUTIC RESCUE OF A DEFICIENT BMPR2 HYPOXIC RESPONSE IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K99HL145097_7529"}, {"internal_id": 83104103, "Award ID": "K99HL145094", "Award Amount": 215960.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-15", "CFDA Number": "93.837", "Description": "DEFINING THE ROLE OF RESPIRATORY GLAND PATTERNING IN RHINOSINUSITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K99HL145094_7529"}, {"internal_id": 76738415, "Award ID": "K99HL145004", "Award Amount": 208628.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-31", "CFDA Number": "93.837", "Description": "HOMEOSTATIC PLASTICITY OF THE RESPIRATORY RHYTHM GENERATING NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_K99HL145004_7529"}, {"internal_id": 83796884, "Award ID": "K99HL143441", "Award Amount": 155231.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-30", "CFDA Number": "93.837", "Description": "THE IMPACT OF DIETARY ZINC DEFICIENCY ON INNATE IMMUNITY TO LUNG INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K99HL143441_7529"}, {"internal_id": 67832596, "Award ID": "K99HL143207", "Award Amount": 158132.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-16", "CFDA Number": "93.838", "Description": "PHRENIC AFFERENTS AND NEUROMUSCULAR PLASTICITY FOLLOWING SPINAL CORD INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_K99HL143207_7529"}, {"internal_id": 65614058, "Award ID": "K99HL141685", "Award Amount": 157169.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-14", "CFDA Number": "93.838", "Description": "LINCENC1 REGULATES THE LIPOPOLYSACCHARIDE-INDUCED INFLAMMATORY RESPONSE IN MACROPHAGES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_K99HL141685_7529"}, {"internal_id": 66487431, "Award ID": "K99HL141684", "Award Amount": 276760.42, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-25", "CFDA Number": "93.837", "Description": "DEFINING THE MOLECULAR DETERMINANTS OF MESENCHYMAL LINEAGE ALLOCATION IN LUNG DEVELOPMENT AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K99HL141684_7529"}, {"internal_id": 65613996, "Award ID": "K99HL141678", "Award Amount": 188723.4, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-06", "CFDA Number": "93.837", "Description": "IMPROVING THE MEASUREMENT AND ANALYSIS OF LONG-TERM, PATIENT-CENTERED OUTCOMES FOLLOWING ACUTE RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K99HL141678_7529"}, {"internal_id": 66995611, "Award ID": "K99HL141658", "Award Amount": 309910.27, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-02", "CFDA Number": "93.837", "Description": "MACROPHAGE METABOLISM AFTER TARGET CELL INGESTION REGULATES ANTI-INFLAMMATORY REPROGRAMMING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_K99HL141658_7529"}, {"internal_id": 48920211, "Award ID": "K99HL139996", "Award Amount": 249367.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-29", "CFDA Number": "93.837", "Description": "TOLL-LIKE RECEPTORS AND RESPIRATORY MICROBIOTA INTERACTIONS IN IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K99HL139996_7529"}, {"internal_id": 48920210, "Award ID": "K99HL138278", "Award Amount": 237451.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-25", "CFDA Number": "93.838", "Description": "ROLE OF SMOOTH MUSCLE PROGENITOR CELLS IN OBLITERATIVE VASCULAR REMODELING AND PH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_K99HL138278_7529"}, {"internal_id": 48920207, "Award ID": "K99HL138255", "Award Amount": 148973.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-14", "CFDA Number": "93.838", "Description": "EARLY DETECTION OF REGIONAL BOS IN BMT PATIENTS USING UTE AND 129XE MRI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_K99HL138255_7529"}, {"internal_id": 48920193, "Award ID": "K99HL135403", "Award Amount": 343698.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-17", "CFDA Number": "93.838", "Description": "GENETIC VARIATION IMPACTING THE AIRWAY SMOOTH MUSCLE IN CHILDREN WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K99HL135403_7529"}, {"internal_id": 48920190, "Award ID": "K99HL135258", "Award Amount": 336072.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-26", "CFDA Number": "93.838", "Description": "UNCOVERING COMPENSATORY MECHANISMS IN  FAMILY MEMBERS WITH DISEASE CAUSING MUTATIONS OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K99HL135258_7529"}, {"internal_id": 48920188, "Award ID": "K99HL133606", "Award Amount": 264480.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-25", "CFDA Number": "93.838", "Description": "UNDERSTANDING THE MOLECULAR AND CELLULAR REGULATIONOF CILIA ASSEMBLY AND REGENERATION IN MULTICILIATED CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_K99HL133606_7529"}, {"internal_id": 48920175, "Award ID": "K99HL131866", "Award Amount": 271728.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-14", "CFDA Number": "93.838", "Description": "METABOLIC DRIVERS AND SENSORS OF CELL PROLIFERATION IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K99HL131866_7529"}, {"internal_id": 48920173, "Award ID": "K99HL131682", "Award Amount": 169941.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-10", "CFDA Number": "93.838", "Description": "ENHANCING CORTICOSTEROID SENSITIVITY IN NEONATAL AND PEDIATRIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_K99HL131682_7529"}, {"internal_id": 48920152, "Award ID": "K99HL128912", "Award Amount": 308880.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-23", "CFDA Number": "93.838", "Description": "MIR-34/449 MIRNAS IN AIRWAY MULTICILIATED CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2f14ac11-bc8d-d1e9-d103-1585414b0792-C", "generated_internal_id": "ASST_NON_K99HL128912_7529"}, {"internal_id": 48920146, "Award ID": "K99HL127275", "Award Amount": 267940.0, "Award Type": null, "Base Obligation Date": "2016-03-07", "CFDA Number": "93.838", "Description": "MOLECULAR MECHANISMS OF MUCOCILIARY FUNCTION AND AIRWAY CLEARANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2f14ac11-bc8d-d1e9-d103-1585414b0792-C", "generated_internal_id": "ASST_NON_K99HL127275_7529"}, {"internal_id": 48920144, "Award ID": "K99HL127267", "Award Amount": 260943.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-12", "CFDA Number": "93.838", "Description": "REVERSE ENGINEERING THE ALVEOLUS: FROM CELLULAR TO MICROENVIRONMENT SPECIFICATION DURING DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K99HL127267_7529"}, {"internal_id": 109278397, "Award ID": "K38HL154202", "Award Amount": 227038.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-20", "CFDA Number": "93.837", "Description": "THE ROLE OF PPARGAMMA IN TH2 CELLS AND OBESITY-ASSOCIATED ASTHMA.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K38HL154202_7529"}, {"internal_id": 100874910, "Award ID": "K25HL150336", "Award Amount": 756000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-18", "CFDA Number": "93.837", "Description": "INTEGRATIVE NETWORK-BASED ANALYSIS OF MULTI-OMICS DATA TO ELUCIDATE THE MOLECULAR CONNECTION BETWEEN ASTHMA AND COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K25HL150336_7529"}, {"internal_id": 110863005, "Award ID": "K25HL148837", "Award Amount": 526503.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-25", "CFDA Number": "93.837", "Description": "QUANTITATIVE MRI-PET IMAGING OF PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K25HL148837_7529"}, {"internal_id": 82470987, "Award ID": "K25HL145120", "Award Amount": 941257.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-25", "CFDA Number": "93.837", "Description": "ASSESSING AIRWAY SMOOTH MUSCLE TONE IN ASTHMA WITH ENDOBRONCHIAL OPTICAL COHERENCE TOMOGRAPHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K25HL145120_7529"}, {"internal_id": 82469253, "Award ID": "K25HL143278", "Award Amount": 935360.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-23", "CFDA Number": "93.837", "Description": "STATISTICAL STANDARDIZATION OF CT FOR THE ANALYSIS OF PARENCHYMAL INJURY PROGRESSION IN SMOKERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K25HL143278_7529"}, {"internal_id": 68167449, "Award ID": "K25HL140186", "Award Amount": 925747.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-24", "CFDA Number": "93.837", "Description": "CONTEXT MATTERS: NETWORK MODELING OF COPD REGULATORY VARIANTS ACROSS TISSUES AND EXPOSURES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_K25HL140186_7529"}, {"internal_id": 48918340, "Award ID": "K25HL136869", "Award Amount": 797740.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-01", "CFDA Number": "93.837", "Description": "TRPC4-MEDIATED CALCIUM SIGNALS ACCELERATE VASCULAR REMODELING IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_K25HL136869_7529"}, {"internal_id": 48918339, "Award ID": "K25HL136846", "Award Amount": 944995.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-01", "CFDA Number": "93.837", "Description": "INTEGRATIVE OMICS PIPELINE TO IDENTIFY NOVEL COPD GENES AND PATHWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K25HL136846_7529"}, {"internal_id": 48918336, "Award ID": "K25HL133611", "Award Amount": 827669.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "AN INTEGRATED INVESTIGATION OF THE INTERACTION BETWEEN PUFAS AND GENETIC VARIANTS IN TRAUMA AND CRITICAL CARE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "623a4232-bd5e-fb60-cf01-48cd08a5a593-C", "generated_internal_id": "ASST_NON_K25HL133611_7529"}, {"internal_id": 48918335, "Award ID": "K25HL133599", "Award Amount": 944975.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-22", "CFDA Number": "93.837", "Description": "USING INTEGRATIVE NETWORKS TO EXPLORE HETEROGENEOUS PHENOTYPES IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K25HL133599_7529"}, {"internal_id": 48918330, "Award ID": "K25HL130637", "Award Amount": 929613.14, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-15", "CFDA Number": "93.837", "Description": "MACHINE LEARNING DEVELOPMENT FOR SUBTYPING COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K25HL130637_7529"}, {"internal_id": 48918328, "Award ID": "K25HL125954", "Award Amount": 761704.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-28", "CFDA Number": "93.838", "Description": "PREVENTING RAPID DECLINE IN CF: STATISTICAL RESEARCH CAREER COMMITMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_K25HL125954_7529"}, {"internal_id": 48918324, "Award ID": "K25HL121295", "Award Amount": 784271.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-18", "CFDA Number": "93.838", "Description": "RICHER MODELS OF ASTHMA RISK: BRIDGING THE ENVIRONMENT-GENETICS DIVIDE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_K25HL121295_7529"}, {"internal_id": 98487018, "Award ID": "K24HL150453", "Award Amount": 436471.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-01", "CFDA Number": "93.837", "Description": "MACROPHAGE PATHOGEN INTERACTIONS IN REGIONAL CYSTIC FIBROSIS LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "67b657d0-7435-9fe5-63cc-b4a9cbf99f25-C", "generated_internal_id": "ASST_NON_K24HL150453_7529"}, {"internal_id": 92603763, "Award ID": "K24HL150312", "Award Amount": 445755.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-11-29", "CFDA Number": "93.837", "Description": "MIDCAREER INVESTIGATOR AWARD IN PATIENT-ORIENTED RESEARCH IN PEDIATRIC ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_K24HL150312_7529"}, {"internal_id": 83796955, "Award ID": "K24HL148314", "Award Amount": 570957.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-22", "CFDA Number": "93.837", "Description": "MENTORED PATIENT ORIENTED RESEARCH IN IMPROVING SURROGATE DECISION MAKING FOR PATIENTS WITH ADVANCED RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K24HL148314_7529"}, {"internal_id": 67580411, "Award ID": "K24HL143291", "Award Amount": 598185.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-29", "CFDA Number": "93.837", "Description": "PATIENT-ORIENTED RESEARCH AND MENTORING PROGRAM IN PREMATURITY-ASSOCIATED PULMONARY MORBIDITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_K24HL143291_7529"}, {"internal_id": 67314903, "Award ID": "K24HL143289", "Award Amount": 722083.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-04", "CFDA Number": "93.837", "Description": "IMPROVING THE EFFICIENCY OF RANDOMIZED TRIALS OF BEHAVIORAL INTERVENTIONS FOR ACUTE AND CHRONIC RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K24HL143289_7529"}, {"internal_id": 80735151, "Award ID": "K24HL143285", "Award Amount": 579329.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-13", "CFDA Number": "93.837", "Description": "PATIENT-ORIENTED RESEARCH IN ACUTE LUNG INJURY AND HOST DEFENSE IN THE ICU", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K24HL143285_7529"}, {"internal_id": 83115695, "Award ID": "K24HL143283", "Award Amount": 612520.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-14", "CFDA Number": "93.837", "Description": "MENTORSHIP OF EARLY-CAREER CLINICIANS IN BRONCHOPULMONARY DYSPLASIA DRUG THERAPIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_K24HL143283_7529"}, {"internal_id": 67313475, "Award ID": "K24HL143281", "Award Amount": 539873.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-18", "CFDA Number": "93.837", "Description": "MIDCAREER INVESTIGATOR AWARD IN PATIENT-ORIENTED RESEARCH IN PEDIATRIC RARE LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_K24HL143281_7529"}, {"internal_id": 65894386, "Award ID": "K24HL141669", "Award Amount": 554287.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-20", "CFDA Number": "93.837", "Description": "PATIENT-ORIENTED MICROBIOME AND ADVANCED CULTURE APPROACHES TO IDENTIFYING THE MICROBIAL DETERMINANTS OF CHRONIC PEDIATRIC DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K24HL141669_7529"}, {"internal_id": 81395587, "Award ID": "K24HL141526", "Award Amount": 592765.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-14", "CFDA Number": "93.837", "Description": "MENTORED PATIENT ORIENTED RESEARCH IN ARDS AND CRITICAL ILLNESS OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_K24HL141526_7529"}, {"internal_id": 48918031, "Award ID": "K24HL140108", "Award Amount": 438657.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-01", "CFDA Number": "93.837", "Description": "UAB MENTORING PROGRAM IN COPD PATIENT ORIENTED RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K24HL140108_7529"}, {"internal_id": 48918030, "Award ID": "K24HL138188", "Award Amount": 840654.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-23", "CFDA Number": "93.837", "Description": "DEFINING PATHWAYS IN COPD PATIENT ORIENTED RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K24HL138188_7529"}, {"internal_id": 65894882, "Award ID": "K24HL138150", "Award Amount": 602225.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-21", "CFDA Number": "93.837", "Description": "MECHANISTIC EFFECTS OF HEALTH COACHING TO REDUCE COPD HOSPITALIZATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_K24HL138150_7529"}, {"internal_id": 48918029, "Award ID": "K24HL137013", "Award Amount": 843452.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-27", "CFDA Number": "93.837", "Description": "MENTORING RESEARCH IN PRECISION MEDICINE FOR LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K24HL137013_7529"}, {"internal_id": 48918024, "Award ID": "K24HL133444", "Award Amount": 266169.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-25", "CFDA Number": "93.838", "Description": "PATIENT ORIENTED RESEARCH AND MENTORING IN CRITICAL CARE IMPLEMENTATION SCIENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K24HL133444_7529"}, {"internal_id": 48918023, "Award ID": "K24HL133390", "Award Amount": 137305.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-15", "CFDA Number": "93.838", "Description": "ARDS ENDOTYPES: EXPANDED ANALYSIS OF CLINICAL AND BIOLOGICAL PHENOTYPES AND EVOLUTION OVER TIME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K24HL133390_7529"}, {"internal_id": 48918019, "Award ID": "K24HL132008", "Award Amount": 574306.48, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-22", "CFDA Number": "93.837", "Description": "RESEARCH AND MENTORING IN COMPARATIVE EFFECTIVENESS AND IMPLEMENTATION SCIENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3b77461b-d74c-9784-e800-bb061239d65f-C", "generated_internal_id": "ASST_NON_K24HL132008_7529"}, {"internal_id": 48918018, "Award ID": "K24HL131937", "Award Amount": 314080.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-25", "CFDA Number": "93.838", "Description": "MENTORED PATIENT ORIENTED RESEARCH IN PULMONARY FIBROSIS AND LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K24HL131937_7529"}, {"internal_id": 48918016, "Award ID": "K24HL130451", "Award Amount": 507660.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-20", "CFDA Number": "93.837", "Description": "PEDIATRIC ASTHMA DISPARITIES: THE ROLE OF SLEEP AND IMMUNE BALANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f21f887-ca03-f1f2-6e30-1c1498f78b9e-C", "generated_internal_id": "ASST_NON_K24HL130451_7529"}, {"internal_id": 48918014, "Award ID": "K24HL127301", "Award Amount": 872853.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-15", "CFDA Number": "93.837", "Description": "MENTORING IN TRANSLATIONAL RESEARCH IN INTERSTITIAL LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K24HL127301_7529"}, {"internal_id": 48918013, "Award ID": "K24HL127131", "Award Amount": 597275.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-09", "CFDA Number": "93.837", "Description": "PATIENT ORIENTED RESEARCH AND MENTORING IN INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K24HL127131_7529"}, {"internal_id": 48918008, "Award ID": "K24HL123342", "Award Amount": 569450.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-12", "CFDA Number": "93.838", "Description": "MENTORING AND PATIENT-ORIENTED RESEARCH IN HIV OBSTRUCTIVE LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K24HL123342_7529"}, {"internal_id": 48918007, "Award ID": "K24HL115354", "Award Amount": 1187590.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-03", "CFDA Number": "93.837", "Description": "MENTORED PATIENT ORIENTED RESEARCH IN LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K24HL115354_7529"}, {"internal_id": 48918004, "Award ID": "K24HL111316", "Award Amount": 907421.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-04-25", "CFDA Number": "93.838", "Description": "FORGING A ROAD TO PERSONALIZED MEDICINE IN INTERSTITIAL LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K24HL111316_7529"}, {"internal_id": 48917995, "Award ID": "K24HL103844", "Award Amount": 1545990.72, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-04-15", "CFDA Number": "93.837", "Description": "AROMATASE INHIBITORS IN PULMONARY VASCULAR COMPLICATIONS OF LIVER DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K24HL103844_7529"}, {"internal_id": 48917994, "Award ID": "K24HL103836", "Award Amount": 1611509.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-07-09", "CFDA Number": "93.837", "Description": "MIDCAREER INVESTIGATOR AWARD IN PATIENT-ORIENTED RESEARCH IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K24HL103836_7529"}, {"internal_id": 48917992, "Award ID": "K24HL102246", "Award Amount": 1628229.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-08-12", "CFDA Number": "93.837", "Description": "STUDIES ON BACTERIAL POPULATIONS AND NEW THERAPEUTICS FOR CF LUNG INFECTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K24HL102246_7529"}, {"internal_id": 48917991, "Award ID": "K24HL102245", "Award Amount": 1351152.34, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-04-01", "CFDA Number": "93.837", "Description": "PATIENT-ORIENTED RESEARCH IN BERYLLIUM-INDUCED DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K24HL102245_7529"}, {"internal_id": 48917981, "Award ID": "K24HL089223", "Award Amount": 1282257.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-10", "CFDA Number": "93.838", "Description": "ENHANCING PATIENT-ORIENTED RESEARCH IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K24HL089223_7529"}, {"internal_id": 48917979, "Award ID": "K24HL087713", "Award Amount": 1417023.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-25", "CFDA Number": "93.838", "Description": "PATIENT-ORIENTED RESEARCH AND MENTORING IN PNEUMOCYSTIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K24HL087713_7529"}, {"internal_id": 110025047, "Award ID": "K23HL154863", "Award Amount": 794379.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-03", "CFDA Number": "93.837", "Description": "THE INFLUENCE OF AIR POLLUTION ON LUNG HEALTH AMONG PEOPLE LIVING WITH HIV.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K23HL154863_7529"}, {"internal_id": 109189843, "Award ID": "K23HL153781", "Award Amount": 706320.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "THE ROLE OF XANTHINE OXIDOREDUCTASE ACTIVITY AND ALTERED METABOLISM IN SCLERODERMA-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K23HL153781_7529"}, {"internal_id": 107115501, "Award ID": "K23HL153672", "Award Amount": 674007.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-31", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A COMMUNITY HEALTH WORKER-LED STRESS REDUCTION INTERVENTION FOR LOW-INCOME COPD PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "395e4a2c-bac8-c9f0-4271-75643a4de192-C", "generated_internal_id": "ASST_NON_K23HL153672_7529"}, {"internal_id": 107115304, "Award ID": "K23HL153584", "Award Amount": 550714.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-30", "CFDA Number": "93.837", "Description": "BAG-MASK VENTILATION TO PREVENT HYPOXEMIA DURING TRACHEAL INTUBATION IN THE EMERGENCY DEPARTMENT: A CLINICAL TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K23HL153584_7529"}, {"internal_id": 110024098, "Award ID": "K23HL153581", "Award Amount": 630394.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-27", "CFDA Number": "93.837", "Description": "HOST PROTEOMIC BIOSIGNATURES FOR A URINE-BASED DIAGNOSIS OF PULMONARY TUBERCULOSIS IN CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL153581_7529"}, {"internal_id": 100875182, "Award ID": "K23HL153482", "Award Amount": 725153.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-13", "CFDA Number": "93.837", "Description": "PROLONGED MECHANICAL VENTILATION: PATTERNS OF POST-ACUTE CARE AND PATIENT OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_K23HL153482_7529"}, {"internal_id": 96203259, "Award ID": "K23HL151897", "Award Amount": 762468.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-01", "CFDA Number": "93.837", "Description": "AIRWAY IMMUNE RESPONSE IN CRITICALLY ILL CHILDREN-PRECISION MEDICINE IN CHILDREN AT RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K23HL151897_7529"}, {"internal_id": 98143561, "Award ID": "K23HL151892", "Award Amount": 580608.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-15", "CFDA Number": "93.837", "Description": "RECLASSIFYING PULMONARY ARTERIAL HYPERTENSION INTO IMMUNE PHENOTYPES USING MACHINE LEARNING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K23HL151892_7529"}, {"internal_id": 98486849, "Award ID": "K23HL151759", "Award Amount": 680644.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-25", "CFDA Number": "93.837", "Description": "IMPACT OF TISSUE RESIDENT MEMORY T CELLS ON CHRONIC REJECTION AFTER LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K23HL151759_7529"}, {"internal_id": 98485916, "Award ID": "K23HL151751", "Award Amount": 699840.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-01", "CFDA Number": "93.837", "Description": "LEVERAGING SERUM METABOLOMICS TO UNDERSTAND CLINICAL PHENOTYPES IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K23HL151751_7529"}, {"internal_id": 95181341, "Award ID": "K23HL150341", "Award Amount": 736920.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-14", "CFDA Number": "93.837", "Description": "ASTHMA LINK: SCHOOL SUPERVISED THERAPY TO IMPROVE MEDICATION ADHERENCE IN CHILDREN WITH POORLY CONTROLLED ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_K23HL150341_7529"}, {"internal_id": 96204745, "Award ID": "K23HL150331", "Award Amount": 709392.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-27", "CFDA Number": "93.837", "Description": "VASCULAR LEAK AND OUTCOMES IN IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K23HL150331_7529"}, {"internal_id": 110234062, "Award ID": "K23HL150280", "Award Amount": 512568.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-11", "CFDA Number": "93.837", "Description": "ROLE OF VISCERAL ADIPOSE TISSUE IN FRAILTY AMONG PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K23HL150280_7529"}, {"internal_id": 110024295, "Award ID": "K23HL150244", "Award Amount": 537801.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-24", "CFDA Number": "93.837", "Description": "PROGNOSTIC BIOMARKERS FOR RESPIRATORY FAILURE POST HEMATOPOIETIC CELL TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_K23HL150244_7529"}, {"internal_id": 96204602, "Award ID": "K23HL150237", "Award Amount": 728264.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-30", "CFDA Number": "93.837", "Description": "IDENTIFYING PREDICTORS OF TREATMENT RESPONSE IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_K23HL150237_7529"}, {"internal_id": 96202725, "Award ID": "K23HL149991", "Award Amount": 650355.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-24", "CFDA Number": "93.837", "Description": "EARLY ADMINISTRATION OF STEROIDS IN THE AMBULANCE SETTING: AN OBSERVATIONAL DESIGN TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_K23HL149991_7529"}, {"internal_id": 108463255, "Award ID": "K23HL149829", "Award Amount": 673511.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-05", "CFDA Number": "93.837", "Description": "HOMEVENT4KIDS: HOME-BASED OPTIMIZATION OF MECHANICAL VENTILATION FOR CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_K23HL149829_7529"}, {"internal_id": 83116137, "Award ID": "K23HL148638", "Award Amount": 908626.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-14", "CFDA Number": "93.837", "Description": "THE EFFECT OF EARLY-LIFE NASAL COLONIZATION WITH LACTOBACILLUS ON THE DEVELOPMENT OF THE LOCAL IMMUNE RESPONSE AND THE LATER ONSET OF RECURRENT WHEEZE, CHILDHOOD ASTHMA, AND ALLERGIC RHINITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K23HL148638_7529"}, {"internal_id": 96201344, "Award ID": "K23HL148541", "Award Amount": 633662.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-27", "CFDA Number": "93.837", "Description": "PULMONARY HYPERTENSION-ASSOCIATED PEDIATRIC CARDIAC ARREST", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_K23HL148541_7529"}, {"internal_id": 98144474, "Award ID": "K23HL148502", "Award Amount": 784068.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-12", "CFDA Number": "93.837", "Description": "PATIENT ENTERED DATA FOR CLINICAL DECISION SUPPORT TO PERSONALIZE PEDIATRIC ASTHMA MANAGEMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_K23HL148502_7529"}, {"internal_id": 97852112, "Award ID": "K23HL148498", "Award Amount": 712780.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-29", "CFDA Number": "93.837", "Description": "MOLECULAR MARKERS OF IDIOPATHIC PULMONARY FIBROSIS PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_K23HL148498_7529"}, {"internal_id": 111328705, "Award ID": "K23HL148387", "Award Amount": 649710.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-07", "CFDA Number": "93.837", "Description": "EARLY MOBILIZATION: OPERATIONALIZING BIG DATA & IMPLEMENTATION SCIENCE TO LEAD EXPANSION TO ICUS (E-MOBILE-ICU)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_K23HL148387_7529"}, {"internal_id": 80401640, "Award ID": "K23HL146970", "Award Amount": 1017447.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-22", "CFDA Number": "93.837", "Description": "THE IMPACT OF ASPERGILLUS SPECIES IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K23HL146970_7529"}, {"internal_id": 82053810, "Award ID": "K23HL146946", "Award Amount": 984516.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-15", "CFDA Number": "93.837", "Description": "EFFECTIVENESS OF LOW-DOSE THEOPHYLLINE FOR THE MANAGEMENT OF BIOMASS-ASSOCIATED COPD IN PERU", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_K23HL146946_7529"}, {"internal_id": 96203944, "Award ID": "K23HL146942", "Award Amount": 647168.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-27", "CFDA Number": "93.837", "Description": "IMPROVING PULMONARY FIBROSIS CLASSIFICATION WITH GENOMICS INFORMED PHENOTYPIC CLUSTERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_K23HL146942_7529"}, {"internal_id": 94714049, "Award ID": "K23HL146936", "Award Amount": 786170.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-20", "CFDA Number": "93.837", "Description": "PATHOBIOLOGIC TRANSCRIPTIONAL SIGNATURES OF PULMONARY COMPLICATIONS IN PEDIATRIC HEMATOPOIETIC CELLULAR TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL146936_7529"}, {"internal_id": 83797183, "Award ID": "K23HL146894", "Award Amount": 1014778.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-21", "CFDA Number": "93.837", "Description": "THE INFLUENCE OF WARD CAPACITY STRAIN ON OUTCOMES AMONG SURVIVORS OF ACUTE RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K23HL146894_7529"}, {"internal_id": 79433602, "Award ID": "K23HL146889", "Award Amount": 885600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-30", "CFDA Number": "93.837", "Description": "MECHANISMS AND TREATMENT OF RIGHT VENTRICULAR SARCOMERE DYSFUNCTION IN SCLERODERMA-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K23HL146889_7529"}, {"internal_id": 94714523, "Award ID": "K23HL146791", "Award Amount": 669772.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-03", "CFDA Number": "93.837", "Description": "TREATMENT PHENOTYPES FOR ADOLESCENTS WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K23HL146791_7529"}, {"internal_id": 95181001, "Award ID": "K23HL146741", "Award Amount": 743040.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-23", "CFDA Number": "93.837", "Description": "PSYCHOLOGICAL SUPPORT BASED ON POSITIVE SUGGESTIONS IN ACUTE RESPIRATORY FAILURE PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_K23HL146741_7529"}, {"internal_id": 76476426, "Award ID": "K23HL145114", "Award Amount": 862908.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-14", "CFDA Number": "93.837", "Description": "NUDGING PROVIDER ADOPTION OF CLINICAL DECISION SUPPORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_K23HL145114_7529"}, {"internal_id": 76738019, "Award ID": "K23HL145011", "Award Amount": 846030.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-06", "CFDA Number": "93.837", "Description": "THE DETECTION, QUANTIFICATION, AND MANAGEMENT OF VENTILATOR DYSSYNCHRONY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K23HL145011_7529"}, {"internal_id": 83797546, "Award ID": "K23HL144918", "Award Amount": 818558.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-28", "CFDA Number": "93.837", "Description": "TRAJECTORIES OF LUNG FUNCTION IN EXTREMELY PREMATURE INFANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_K23HL144918_7529"}, {"internal_id": 83797831, "Award ID": "K23HL144916", "Award Amount": 950940.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-26", "CFDA Number": "93.837", "Description": "THE ROLE OF ALVEOLAR MONONUCLEAR PHAGOCYTES IN ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K23HL144916_7529"}, {"internal_id": 82469610, "Award ID": "K23HL144830", "Award Amount": 715356.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-18", "CFDA Number": "93.837", "Description": "IMPROVING PATIENT- AND FAMILY-CENTERED OUTCOMES AND VALUE OF CARE FOR PATIENTS WITH CHRONIC ILLNESS WHO DEVELOP ACUTE RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K23HL144830_7529"}, {"internal_id": 65280391, "Award ID": "K23HL144418", "Award Amount": 492118.25, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-26", "CFDA Number": "93.837", "Description": "GENOMIC ANALYSIS OF EPITHELIAL GROWTH AND REPAIR MECHANISMS IN ASPIRIN EXACERBATED RESPIRATORY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_K23HL144418_7529"}, {"internal_id": 67313540, "Award ID": "K23HL143181", "Award Amount": 808800.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-16", "CFDA Number": "93.837", "Description": "IDENTIFYING PALLIATIVE CARE NEEDS AMONG HOSPITALIZED PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K23HL143181_7529"}, {"internal_id": 95180659, "Award ID": "K23HL143167", "Award Amount": 688608.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-14", "CFDA Number": "93.837", "Description": "PHARMACOMETRIC APPROACHES TO PRECISION OPTIMIZATION OF IVACAFTOR RESPONSE IN CYSTIC FIBROSIS PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K23HL143167_7529"}, {"internal_id": 67579436, "Award ID": "K23HL143135", "Award Amount": 655310.63, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-20", "CFDA Number": "93.837", "Description": "T CELLS IN IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_K23HL143135_7529"}, {"internal_id": 97470460, "Award ID": "K23HL143128", "Award Amount": 801413.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-05", "CFDA Number": "93.837", "Description": "CHICAGO ASTHMA SCHOOL-DIRECTED CHILD-CENTERED ASSESSMENT AND DISSEMINATION OF EVIDENCE (CASCADE) PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_K23HL143128_7529"}, {"internal_id": 67314195, "Award ID": "K23HL143053", "Award Amount": 853591.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-05", "CFDA Number": "93.837", "Description": "OXYGEN SATURATION TARGETS DURING MECHANICAL VENTILATION OF CRITICALLY ILL ADULTS: A CLINICAL TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K23HL143053_7529"}, {"internal_id": 67314804, "Award ID": "K23HL143050", "Award Amount": 986434.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-16", "CFDA Number": "93.310", "Description": "RESPIRATORY VIRAL DETERMINANTS OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K23HL143050_7529"}, {"internal_id": 83103754, "Award ID": "K23HL143042", "Award Amount": 1010946.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-14", "CFDA Number": "93.837", "Description": "PATIENT-REPORTED OUTCOMES FOR ACUTE ASTHMA CARE AND TREATMENT (PROAACT)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K23HL143042_7529"}, {"internal_id": 76738421, "Award ID": "K23HL141704", "Award Amount": 817613.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-03", "CFDA Number": "93.837", "Description": "DEVELOPING A NOVEL DECISION AID FOR TRACHEOSTOMY TO SUPPORT SHARED DECISION-MAKING IN THE INTENSIVE CARE UNIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dfa7ce4a-d4d7-797d-919b-8a8b8fa1eda3-C", "generated_internal_id": "ASST_NON_K23HL141704_7529"}, {"internal_id": 79639054, "Award ID": "K23HL141651", "Award Amount": 982810.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-16", "CFDA Number": "93.837", "Description": "THE PULMONARY VASCULATURE AND PLATELETS IN EMPHYSEMA AND COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K23HL141651_7529"}, {"internal_id": 65614014, "Award ID": "K23HL141639", "Award Amount": 932689.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-06", "CFDA Number": "93.837", "Description": "USING NATURAL LANGUAGE PROCESSING AND MACHINE LEARNING TO IDENTIFY POTENTIALLY PREVENTABLE HOSPITAL ADMISSIONS AMONG OUTPATIENTS WITH CHRONIC LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K23HL141639_7529"}, {"internal_id": 66800829, "Award ID": "K23HL141584", "Award Amount": 970447.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-09", "CFDA Number": "93.837", "Description": "OBESITY IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K23HL141584_7529"}, {"internal_id": 78599331, "Award ID": "K23HL141539", "Award Amount": 856202.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-16", "CFDA Number": "93.837", "Description": "HOST RESPONSE, LUNG MICROBIOME, AND CLINICAL PHENOTYPE IN HYPERSENSITIVITY PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K23HL141539_7529"}, {"internal_id": 65614092, "Award ID": "K23HL140482", "Award Amount": 958910.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-18", "CFDA Number": "93.837", "Description": "NEUROCOGNITIVE IMPAIRMENT IN ACUTE RESPIRATORY FAILURE  AND SHOCK: UNDERSTANDING THE ROLE OF NEURONAL EXCITOTOXICITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K23HL140482_7529"}, {"internal_id": 48916930, "Award ID": "K23HL140199", "Award Amount": 858060.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-18", "CFDA Number": "93.837", "Description": "ROLE OF HIGH DENSITY LIPOPROTEINS IN INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_K23HL140199_7529"}, {"internal_id": 67833416, "Award ID": "K23HL140165", "Award Amount": 915472.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-07", "CFDA Number": "93.837", "Description": "PREVENTING AVOIDABLE DEATHS FROM PNEUMONIA BY IMPROVING USE OF INTENSIVE CARE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K23HL140165_7529"}, {"internal_id": 83103872, "Award ID": "K23HL139992", "Award Amount": 868494.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-15", "CFDA Number": "93.837", "Description": "USING TECHNOLOGY-ASSISTED STEPPED-CARE INTERVENTIONS TO IMPROVE ADHERENCE IN ADOLESCENTS WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_K23HL139992_7529"}, {"internal_id": 61614855, "Award ID": "K23HL139987", "Award Amount": 805588.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-19", "CFDA Number": "93.837", "Description": "MICROBIOME-BASED DIAGNOSIS OF PNEUMONIA IN THE ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K23HL139987_7529"}, {"internal_id": 67314696, "Award ID": "K23HL138461", "Award Amount": 718258.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-19", "CFDA Number": "93.837", "Description": "PROFILING THE LUNG TRANSCRIPTOME FOR PRECISION DIAGNOSIS OF RESPIRATORY INFECTIONS USING HOST/PATHOGEN METAGENOMIC SEQUENCING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL138461_7529"}, {"internal_id": 48916926, "Award ID": "K23HL138303", "Award Amount": 709128.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "UNCOVERING BIOLOGIC MECHANISMS OF SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL138303_7529"}, {"internal_id": 110232975, "Award ID": "K23HL138257", "Award Amount": 603039.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-10", "CFDA Number": "93.837", "Description": "QUANTITATION AND SPATIAL REGISTRATION OF AIRWAYS DYSFUNCTION WITH DYNAMIC 19F MRI IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_K23HL138257_7529"}, {"internal_id": 48916922, "Award ID": "K23HL138256", "Award Amount": 901800.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-04", "CFDA Number": "93.837", "Description": "NON-INVASIVE SURVEILLANCE OF THE LUNG ALLOGRAFT POST TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_K23HL138256_7529"}, {"internal_id": 65579301, "Award ID": "K23HL138229", "Award Amount": 721936.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-09", "CFDA Number": "93.837", "Description": "CIRCADIAN RHYTHM AS A NOVEL THERAPEUTIC TARGET IN THE INTENSIVE CARE UNIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_K23HL138229_7529"}, {"internal_id": 48916920, "Award ID": "K23HL138206", "Award Amount": 667993.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-16", "CFDA Number": "93.837", "Description": "A PILOT, FEASIBILITY RANDOMIZED CONTROLLED TRIAL OF A BEHAVIORAL ACTIVATION AND REHABILITATION INTERVENTION TO IMPROVE PSYCHOLOGICAL AND PHYSICAL IMPAIRMENTS IN ACUTE RESPIRATORY FAILURE SURVIVORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K23HL138206_7529"}, {"internal_id": 67580275, "Award ID": "K23HL138191", "Award Amount": 806870.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-20", "CFDA Number": "93.837", "Description": "IMPROVING ACCESS TO LUNG TRANSPLANT THROUGH BROADER GEOGRAPHIC SHARING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_K23HL138191_7529"}, {"internal_id": 48916919, "Award ID": "K23HL138190", "Award Amount": 913680.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-01", "CFDA Number": "93.837", "Description": "ELUCIDATING THE GENOMIC DETERMINANTS OF OUTCOMES IN IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K23HL138190_7529"}, {"internal_id": 48916917, "Award ID": "K23HL138165", "Award Amount": 776708.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "ADDRESSING PSYCHOLOGICAL RISK FACTORS UNDERLYING SMOKING PERSISTENCE IN COPD PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3686b736-a954-3213-3e70-ff260e0ab96a-C", "generated_internal_id": "ASST_NON_K23HL138165_7529"}, {"internal_id": 48916915, "Award ID": "K23HL138162", "Award Amount": 836750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "HOST GENETIC FACTORS MEDIATING THE SEVERITY OF RHINOVIRUS-TRIGGERED ASTHMA EXACERBATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_K23HL138162_7529"}, {"internal_id": 48916914, "Award ID": "K23HL138154", "Award Amount": 946620.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-07", "CFDA Number": "93.837", "Description": "PREDICTING SURVIVAL AND PLANNING FOR LUNG TRANSPLANTATION IN SEVERE CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K23HL138154_7529"}, {"internal_id": 48916913, "Award ID": "K23HL138131", "Award Amount": 576298.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-16", "CFDA Number": "93.837", "Description": "RHEUMATOID ARTHRITIS PATIENTS AT RISK FOR INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K23HL138131_7529"}, {"internal_id": 61610727, "Award ID": "K23HL136934", "Award Amount": 549603.56, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-02", "CFDA Number": "93.837", "Description": "THE ROLE OF AIRWAY MICROBIOTA IN NONTUBERCULOUS MYCOBACTERIAL INFECTION IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K23HL136934_7529"}, {"internal_id": 48916910, "Award ID": "K23HL136905", "Award Amount": 1067241.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-16", "CFDA Number": "93.837", "Description": "COMPUTED TOMOGRAPHIC  INSIGHTS INTO PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K23HL136905_7529"}, {"internal_id": 48916906, "Award ID": "K23HL136854", "Award Amount": 603077.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-31", "CFDA Number": "93.837", "Description": "EFFECTS OF ELECTRONIC CIGARETTE USE ON SMOKERS WITH MILD TO MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K23HL136854_7529"}, {"internal_id": 48916905, "Award ID": "K23HL136851", "Award Amount": 968835.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-01", "CFDA Number": "93.837", "Description": "GENETIC EPIDEMIOLOGY OF RESPIRATORY FUNCTION IN FORMER PRETERM CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K23HL136851_7529"}, {"internal_id": 48916904, "Award ID": "K23HL136844", "Award Amount": 397169.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-28", "CFDA Number": "93.838", "Description": "CIGARETTE SMOKE AND THE ACUTE RESPIRATORY DISTRESS SYNDROME: MECHANISMS AND THE ROLE OF ALVEOLAR MACROPHAGES IN PRIMING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL136844_7529"}, {"internal_id": 61611794, "Award ID": "K23HL136843", "Award Amount": 818994.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-31", "CFDA Number": "93.837", "Description": "MICROBIOME OF THE AIRWAY AND THE RISK FOR BRONCHOPULMONARY DYSPLASIA IN THE LUNGS OF EXTREME PRETERMS: THE MARBLE STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_K23HL136843_7529"}, {"internal_id": 77189043, "Award ID": "K23HL136842", "Award Amount": 907996.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-30", "CFDA Number": "93.837", "Description": "INCENTIVE-BASED MOBILE HEALTH ADHERENCE INTERVENTION FOR HIGH RISK CHILDREN WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_K23HL136842_7529"}, {"internal_id": 48916902, "Award ID": "K23HL136785", "Award Amount": 181240.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-01", "CFDA Number": "93.838", "Description": "GENOMIC PROFILING OF EARLY PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K23HL136785_7529"}, {"internal_id": 48916900, "Award ID": "K23HL136688", "Award Amount": 692759.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-18", "CFDA Number": "93.837", "Description": "CLINICAL AND PROTEOMIC CHARACTERIZATION OF NUCLEOSOMES IN PEDIATRIC ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_K23HL136688_7529"}, {"internal_id": 48916899, "Award ID": "K23HL136525", "Award Amount": 809276.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-23", "CFDA Number": "93.837", "Description": "HOME OXYGEN USE FOR INFANTS WITH BRONCHOPULMONARY DYSPLASIA: BALANCING INFANT, FAMILY, AND HEALTH SYSTEM OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_K23HL136525_7529"}, {"internal_id": 48916891, "Award ID": "K23HL135352", "Award Amount": 849302.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-14", "CFDA Number": "93.837", "Description": "NON-INVASIVE ASSESSMENT OF PULMONARY VASCULAR FUNCTION BY MRI IN CHILDREN WITH PULMONARY ARTERIAL HYPERTENSION CORRELATE WITH INVASIVE MEASUREMENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_K23HL135352_7529"}, {"internal_id": 48916890, "Award ID": "K23HL135349", "Award Amount": 884083.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-19", "CFDA Number": "93.837", "Description": "PRENATAL PM2.5 AND PROGRAMMING OF RESPIRATORY OUTCOMES: PLACENTAL BIOMARKERS AND EFFECT MODIFICATION BY STRESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_K23HL135349_7529"}, {"internal_id": 48916886, "Award ID": "K23HL135263", "Award Amount": 536315.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-13", "CFDA Number": "93.837", "Description": "THE ROLE OF CIRCULATING MICRO RNAS IN ARDS PATHOGENESIS AND OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "SC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "04a78f04-ee86-46df-5fbf-c71e46ed8479-C", "generated_internal_id": "ASST_NON_K23HL135263_7529"}, {"internal_id": 48916881, "Award ID": "K23HL133596", "Award Amount": 722424.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "A PATIENT-CENTERED ASTHMA MANAGEMENT COMMUNICATION INTERVENTION FOR RURAL LATINO CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "SC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "873ae72b-bace-b481-a973-8304b7346bc0-C", "generated_internal_id": "ASST_NON_K23HL133596_7529"}, {"internal_id": 48916880, "Award ID": "K23HL133495", "Award Amount": 994124.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-01", "CFDA Number": "93.837", "Description": "ACUTE RESPIRATORY DISTRESS SYNDROME AFTER ISOLATED TRAUMATIC BRAIN INJURY: PLATELET BIOLOGY, ENDOTHELIAL ACTIVATION, AND MECHANICAL VENTILATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL133495_7529"}, {"internal_id": 48916879, "Award ID": "K23HL133489", "Award Amount": 828109.65, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-21", "CFDA Number": "93.837", "Description": "BREATH STACKING DYSSYNCHRONY IN ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K23HL133489_7529"}, {"internal_id": 48916877, "Award ID": "K23HL133476", "Award Amount": 925587.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-23", "CFDA Number": "93.837", "Description": "CT CHARACTERISTICS OF EMPHYSEMA FOR EVALUATION OF PULMONARY NODULES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_K23HL133476_7529"}, {"internal_id": 48916869, "Award ID": "K23HL133438", "Award Amount": 921426.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-18", "CFDA Number": "93.837", "Description": "ASSIGNMENT OF \"DIASTOLIC DYSFUNCTION AND PAUCI-INFLAMMATORY ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE\"", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K23HL133438_7529"}, {"internal_id": 61614251, "Award ID": "K23HL133437", "Award Amount": 1021230.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-20", "CFDA Number": "93.837", "Description": "RISK FACTORS FOR WORSE LUNG FUNCTION IN LATINOS WITH CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL133437_7529"}, {"internal_id": 48916867, "Award ID": "K23HL132120", "Award Amount": 895673.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-23", "CFDA Number": "93.837", "Description": "LOW RISK IN VIVO DIAGNOSIS OF IPF WITH OPTICAL IMAGING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K23HL132120_7529"}, {"internal_id": 48916866, "Award ID": "K23HL132065", "Award Amount": 693097.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-29", "CFDA Number": "93.837", "Description": "OPTIMIZING OUTCOME PREDICTIONS AMONG PATIENTS WITH SMOKING-ASSOCIATED LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K23HL132065_7529"}, {"internal_id": 48916859, "Award ID": "K23HL131930", "Award Amount": 864023.12, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-13", "CFDA Number": "93.837", "Description": "NEBULIZED NITRITE AS A NOVEL ANTIMICROBIAL THERAPY IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K23HL131930_7529"}, {"internal_id": 48916858, "Award ID": "K23HL131440", "Award Amount": 668856.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-20", "CFDA Number": "93.837", "Description": "IMPROVING THE SAFETY AND EFFICACY OF OUT-OF-HOSPITAL PEDIATRIC AIRWAY MANAGEMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_K23HL131440_7529"}, {"internal_id": 48916856, "Award ID": "K23HL130648", "Award Amount": 669385.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-04", "CFDA Number": "93.837", "Description": "OPTIMIZING ED TO ICU TRIAGE DECISIONS FOR CRITICALLY ILL PATIENTS IN RESPIRATORY DISTRESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_K23HL130648_7529"}, {"internal_id": 48916855, "Award ID": "K23HL130641", "Award Amount": 857343.75, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-30", "CFDA Number": "93.837", "Description": "THE ROLE OF THE MICROBIOME IN THE ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K23HL130641_7529"}, {"internal_id": 48916854, "Award ID": "K23HL130627", "Award Amount": 653578.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "HYPERCOAGULABILITY AND CHRONIC LUNG DISEASE IN OLDER ADULTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K23HL130627_7529"}, {"internal_id": 48916851, "Award ID": "K23HL130524", "Award Amount": 595209.87, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-15", "CFDA Number": "93.837", "Description": "PROMOTING ACTIVITY AFTER COPD EXACERBATIONS (PACE)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_K23HL130524_7529"}, {"internal_id": 48916848, "Award ID": "K23HL129888", "Award Amount": 1031939.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-13", "CFDA Number": "93.837", "Description": "MECHANISMS & RISK FACTORS OF CHRONIC LUNG DISEASE IN HIV+ ADOLESCENTS IN NAIROBI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K23HL129888_7529"}, {"internal_id": 48916846, "Award ID": "K23HL128936", "Award Amount": 192594.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-27", "CFDA Number": "93.838", "Description": "PERSONALIZING COPD THERAPIES BY EXPLORING HETEROGENEITY OF TREATMENT EFFECTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K23HL128936_7529"}, {"internal_id": 48916836, "Award ID": "K23HL128793", "Award Amount": 941219.95, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-15", "CFDA Number": "93.837", "Description": "IMPROVING CLINICAL OUTCOMES AFTER ICU TRANSFER FOR ACUTE RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K23HL128793_7529"}, {"internal_id": 48916824, "Award ID": "K23HL127185", "Award Amount": 522803.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-19", "CFDA Number": "93.837", "Description": "USING BREATH METABOLITES TO DETERMINE SPECIFIC VIRUS INFECTION IN ASTHMATIC PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_K23HL127185_7529"}, {"internal_id": 48916822, "Award ID": "K23HL127132", "Award Amount": 940630.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-01", "CFDA Number": "93.837", "Description": "DEVELOPING A PREDICTIVE MODEL OF THE OUTCOMES OF ADENOTONSILLECTOMY FOR PEDIATRIC OBSTRUCTIVE SLEEP APNEA SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_K23HL127132_7529"}, {"internal_id": 48916816, "Award ID": "K23HL126912", "Award Amount": 796608.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-02-27", "CFDA Number": "93.838", "Description": "AUTOIMMUNITY AS A MECHANISM FOR ATHEROSCLEROSIS IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K23HL126912_7529"}, {"internal_id": 48916811, "Award ID": "K23HL125982", "Award Amount": 436541.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-24", "CFDA Number": "93.837", "Description": "AN EVALUATION OF SENSOR TECHNOLOGY TO MONITOR AND REPORT COMPLIANCE WITH AN EVIDENCE-BASED INTERVENTION TO PREVENT VENTILATOR-ASSOCIATED PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K23HL125982_7529"}, {"internal_id": 48916805, "Award ID": "K23HL125723", "Award Amount": 828772.04, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-15", "CFDA Number": "93.837", "Description": "THE ROLE OF ABO GLYCOSYLTRANSFERASES IN THE ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K23HL125723_7529"}, {"internal_id": 48916804, "Award ID": "K23HL125697", "Award Amount": 834404.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-26", "CFDA Number": "93.838", "Description": "INSULIN RESISTANCE IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_K23HL125697_7529"}, {"internal_id": 48916802, "Award ID": "K23HL125663", "Award Amount": 743767.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-12", "CFDA Number": "93.838", "Description": "METABOLIC DERANGEMENTS IN ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K23HL125663_7529"}, {"internal_id": 48916801, "Award ID": "K23HL125551", "Award Amount": 1025503.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-30", "CFDA Number": "93.837", "Description": "SOCIAL ADVERSITIES AND ASTHMA: A NEW PHENOTYPE?", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL125551_7529"}, {"internal_id": 48916796, "Award ID": "K23HL123778", "Award Amount": 847377.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-01", "CFDA Number": "93.837", "Description": "IDENTIFYING THE TH2 ENDOTYPE IN COPD: CLINICAL AND PATHOLOGIC IMPLICATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL123778_7529"}, {"internal_id": 48916792, "Award ID": "K23HL123594", "Award Amount": 1021115.29, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-13", "CFDA Number": "93.837", "Description": "THE ASSOCIATION OF ALLERGIC DISEASE WITH CLINICAL OUTCOMES IN COPD.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K23HL123594_7529"}, {"internal_id": 48916791, "Award ID": "K23HL123533", "Award Amount": 880862.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-30", "CFDA Number": "93.837", "Description": "UTILITY OF LUNG ULTRASOUND IN ASSESSING PULMONARY CONGESTION IN HEART FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K23HL123533_7529"}, {"internal_id": 48916784, "Award ID": "K23HL121406", "Award Amount": 624460.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-28", "CFDA Number": "93.838", "Description": "LONG PENTRAXIN-3 GENOMICS AND OUTCOMES AFTER LUNG TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K23HL121406_7529"}, {"internal_id": 48916779, "Award ID": "K23HL121090", "Award Amount": 542490.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-28", "CFDA Number": "93.838", "Description": "IMPAIRED ANGIOGENESIS IN PRETERM INFANTS AFTER MATERNAL COMPLICATIONS OF PREGNANCY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K23HL121090_7529"}, {"internal_id": 48916778, "Award ID": "K23HL120896", "Award Amount": 877219.68, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-06-06", "CFDA Number": "93.837", "Description": "INFLUENCE OF TLR1 POLYMORPHISMS ON T-REGULATORY CELLS IN ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K23HL120896_7529"}, {"internal_id": 48916776, "Award ID": "K23HL119623", "Award Amount": 931578.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-26", "CFDA Number": "93.838", "Description": "EARLY DETECTION OF SCLERODERMA-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K23HL119623_7529"}, {"internal_id": 48916771, "Award ID": "K23HL119558", "Award Amount": 758378.31, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-28", "CFDA Number": "93.837", "Description": "CLINICAL AND MOLECULAR CHARACTERISTICS OF RHEUMATOID ARTHRITIS-ASSOCIATED ILD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K23HL119558_7529"}, {"internal_id": 48916767, "Award ID": "K23HL118733", "Award Amount": 885894.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-21", "CFDA Number": "93.837", "Description": "GENETIC AND EPIGENETIC DETERMINANTS OF PEDIATRIC OBESITY-ASSOCIATED ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_K23HL118733_7529"}, {"internal_id": 48916762, "Award ID": "K23HL118151", "Award Amount": 657944.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-22", "CFDA Number": "93.838", "Description": "VIDEO VS. TTG RESPIRATORY INHALER TECHNIQUE ASSESSMENT AND INSTRUCTION (V-TRAIN)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_K23HL118151_7529"}, {"internal_id": 48916760, "Award ID": "K23HL118139", "Award Amount": 585214.0, "Award Type": null, "Base Obligation Date": "2013-08-05", "CFDA Number": "93.838", "Description": "A NOVEL IMPLEMENTATION AND SOCIAL NETWORK STRATEGY FOR ACUTE PULMONARY ILLNESSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_K23HL118139_7529"}, {"internal_id": 48916756, "Award ID": "K23HL116800", "Award Amount": 875938.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-02-08", "CFDA Number": "93.838", "Description": "CHEMOKINE-RELATED ACUTE LUNG INJURY PATHOGENESIS IN AFRICAN-AMERICAN PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL116800_7529"}, {"internal_id": 48916751, "Award ID": "K23HL116657", "Award Amount": 781542.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-21", "CFDA Number": "93.837", "Description": "TRANSLATIONAL RESEARCH ON THE ROLE OF IL-17 CYTOKINES IN SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL116657_7529"}, {"internal_id": 48916750, "Award ID": "K23HL116656", "Award Amount": 869549.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-30", "CFDA Number": "93.838", "Description": "LUNG TRANSPLANT DONOR: PREDICTION, EVALUATION, AND MECHANISM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K23HL116656_7529"}, {"internal_id": 48916738, "Award ID": "K23HL114883", "Award Amount": 615060.0, "Award Type": null, "Base Obligation Date": "2013-12-26", "CFDA Number": "93.838", "Description": "AIRWAY MICROBIOME IN CYSTIC FIBROSIS PULMONARY EXACERBATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K23HL114883_7529"}, {"internal_id": 48916734, "Award ID": "K23HL114640", "Award Amount": 542182.0, "Award Type": null, "Base Obligation Date": "2013-08-02", "CFDA Number": "93.838", "Description": "A NATIONAL REGISTRY TO SUPPORT SARCOIDOSIS INVESTIGATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_K23HL114640_7529"}, {"internal_id": 48916721, "Award ID": "K23HL111636", "Award Amount": 677974.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-20", "CFDA Number": "93.838", "Description": "WOOD SMOKE AND GENETIC SUSCEPTIBILITY TO ASTHMA IN AN HONDURAN POPULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL111636_7529"}, {"internal_id": 48916717, "Award ID": "K23HL111116", "Award Amount": 466052.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-02-28", "CFDA Number": "93.838", "Description": "FACILITATING ADOPTION OF COPD EVIDENCE-BASED CARE IN OUTPATIENT SETTINGS (FACES)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K23HL111116_7529"}, {"internal_id": 48916716, "Award ID": "K23HL111115", "Award Amount": 832305.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-20", "CFDA Number": "93.838", "Description": "THE EFFECTS OF LUNG TRANSPLANT ON DISABILITY AND HEALTH-RELATED QUALITY OF LIFE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K23HL111115_7529"}, {"internal_id": 48916715, "Award ID": "K23HL111113", "Award Amount": 721077.0, "Award Type": null, "Base Obligation Date": "2012-08-10", "CFDA Number": "93.838", "Description": "THE INFLAMMATORY ROLE OF THE PLATELET IN ASPIRIN-EXACERBATED RESPIRATORY DISEASE.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K23HL111113_7529"}, {"internal_id": 48916686, "Award ID": "K23HL105784", "Award Amount": 558160.0, "Award Type": null, "Base Obligation Date": "2013-01-30", "CFDA Number": "93.838", "Description": "THE SEROTONIN TRANSPORTER IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_K23HL105784_7529"}, {"internal_id": 48914857, "Award ID": "K22HL131694", "Award Amount": 713902.28, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-24", "CFDA Number": "93.837", "Description": "FUNCTIONAL ROLE OF MYELOID PROGENITOR CELLS IN OBESITY-ASSOCIATED AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dff5ea13-87ef-1d23-7ba0-fbf570ef2475-C", "generated_internal_id": "ASST_NON_K22HL131694_7529"}, {"internal_id": 67578987, "Award ID": "K12HL143961", "Award Amount": 1779350.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-31", "CFDA Number": "93.837", "Description": "UCSF CAREER DEVELOPMENT PROGRAM IN CARDIOPULMONARY, HEMATOLOGIC, AND IMMUNOLOGIC COMORBIDITIES OF HIV (CHIC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K12HL143961_7529"}, {"internal_id": 67580288, "Award ID": "K12HL143960", "Award Amount": 1558030.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-27", "CFDA Number": "93.837", "Description": "HAWAII INTERDISCIPLINARY MENTORED CAREER DEVELOPMENT IN HIV CO-MORBIDITIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "HI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7997b0e4-1373-a617-5e8b-0e0e80c459d7-C", "generated_internal_id": "ASST_NON_K12HL143960_7529"}, {"internal_id": 67833988, "Award ID": "K12HL143959", "Award Amount": 1535759.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-09", "CFDA Number": "93.837", "Description": "THIRD  COAST HIV-RELATED CARDIOVASCULAR AND SLEEP DISORDERS K12 CAREER DEVELOPMENT PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_K12HL143959_7529"}, {"internal_id": 67579713, "Award ID": "K12HL143958", "Award Amount": 1628704.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-31", "CFDA Number": "93.837", "Description": "UAB INSTITUTIONAL CAREER DEVELOPMENT PROGRAM IN HIV-RELATED HEART, LUNG, BLOOD AND RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K12HL143958_7529"}, {"internal_id": 67579597, "Award ID": "K12HL143957", "Award Amount": 1778353.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-31", "CFDA Number": "93.837", "Description": "JOHNS HOPKINS HIV AND HEART, LUNG, BLOOD & SLEEP DISORDERS TRAINING PROGRAM (H3TP)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K12HL143957_7529"}, {"internal_id": 67833233, "Award ID": "K12HL143956", "Award Amount": 1646815.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-09", "CFDA Number": "93.837", "Description": "VANDERBILT SCHOLARS IN HIV AND HEART, LUNG, BLOOD, AND SLEEP RESEARCH (V-SCHOLARS, K12)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K12HL143956_7529"}, {"internal_id": 67834192, "Award ID": "K12HL143886", "Award Amount": 1729859.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-14", "CFDA Number": "93.837", "Description": "PITTSBURGH HIV MENTORED TRAINING FOR INVESTIGATION OF CO-MORBIDITIES AND CURE (HIV METRICC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K12HL143886_7529"}, {"internal_id": 48914354, "Award ID": "K12HL120002", "Award Amount": 1090225.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.838", "Description": "OMICS OF INFLAMMATORY AIRWAY DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K12HL120002_7529"}, {"internal_id": 48914353, "Award ID": "K12HL120001", "Award Amount": 1328978.44, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.837", "Description": "STANFORD CAREER DEVELOPMENT PROGRAM IN OMICS OF LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K12HL120001_7529"}, {"internal_id": 48914352, "Award ID": "K12HL119998", "Award Amount": 1361913.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.838", "Description": "APPLICATION OF OMICS IN LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_K12HL119998_7529"}, {"internal_id": 48914351, "Award ID": "K12HL119997", "Award Amount": 1252007.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.838", "Description": "UCSF CAREER DEVELOPMENT PROGRAM IN OMICS OF LUNG DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K12HL119997_7529"}, {"internal_id": 48914349, "Award ID": "K12HL119994", "Award Amount": 1284077.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.838", "Description": "K12 CAREER DEVELOPMENT PROGRAM: OMICS OF PEDIATRIC LUNG DISEASES IN DC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_K12HL119994_7529"}, {"internal_id": 109189962, "Award ID": "K08HL153955", "Award Amount": 628128.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-15", "CFDA Number": "93.837", "Description": "GENETICS OF ASTHMA SUB-PHENOTYPES IMPACT GENE REGULATION IN CELL-SPECIFIC PATTERNS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_K08HL153955_7529"}, {"internal_id": 98485924, "Award ID": "K08HL151976", "Award Amount": 675459.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-01", "CFDA Number": "93.837", "Description": "UBIQUITINATION AND ENDOTHELIAL FIBROSIS IN EARLY PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL151976_7529"}, {"internal_id": 107115202, "Award ID": "K08HL151970", "Award Amount": 671760.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-31", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL DNA AND TLR9 IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_K08HL151970_7529"}, {"internal_id": 98487456, "Award ID": "K08HL151907", "Award Amount": 688824.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-29", "CFDA Number": "93.837", "Description": "THE GUT-LUNG AXIS INFLUENCES THE DEVELOPMENT OF BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K08HL151907_7529"}, {"internal_id": 100874737, "Award ID": "K08HL151760", "Award Amount": 648000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-10", "CFDA Number": "93.837", "Description": "ROLE OF ALVEOLAR EPITHELIAL CELL-DERIVED CELLULAR COMMUNICATION NETWORK FACTOR 2 (CCN2) IN ALVEOLOGENESIS AND BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1c8a728b-7acd-e759-0d91-9bb62a57eaec-C", "generated_internal_id": "ASST_NON_K08HL151760_7529"}, {"internal_id": 98487130, "Award ID": "K08HL150226", "Award Amount": 671760.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-22", "CFDA Number": "93.837", "Description": "UNDERSTANDING HOW ALVEOLAR EPITHELIAL CELL STRESS DRIVES ABERRANT REPAIR IN INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K08HL150226_7529"}, {"internal_id": 95180553, "Award ID": "K08HL150223", "Award Amount": 637740.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-05", "CFDA Number": "93.837", "Description": "THE ROLE OF DYNEIN MOTOR MUTATIONS IN MOTILE CILIA DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K08HL150223_7529"}, {"internal_id": 95180642, "Award ID": "K08HL150222", "Award Amount": 647596.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-11", "CFDA Number": "93.837", "Description": "ROLE OF VITAMIN D IN LUNG DEVELOPMENT AND BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K08HL150222_7529"}, {"internal_id": 83103664, "Award ID": "K08HL149051", "Award Amount": 846829.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-15", "CFDA Number": "93.837", "Description": "ALVEOLAR MACROPHAGE-DERIVED EXTRACELLULAR VESICLES INHIBIT INFLUENZA INFECTION IN EPITHELIAL CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K08HL149051_7529"}, {"internal_id": 82470751, "Award ID": "K08HL148529", "Award Amount": 673770.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-22", "CFDA Number": "93.837", "Description": "TARGETING GLUTAMINE METABOLISM DURING THE DEVELOPMENT AND RESOLUTION OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_K08HL148529_7529"}, {"internal_id": 98143944, "Award ID": "K08HL148514", "Award Amount": 659124.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-15", "CFDA Number": "93.837", "Description": "ACTIVATED NEUTROPHILIC EXOSOME AS BIOMARKER AND THERAPEUTIC TARGET IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K08HL148514_7529"}, {"internal_id": 83796707, "Award ID": "K08HL148510", "Award Amount": 739696.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-01", "CFDA Number": "93.837", "Description": "C3 MITIGATES EPITHELIAL INJURY IN PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K08HL148510_7529"}, {"internal_id": 100875148, "Award ID": "K08HL148403", "Award Amount": 661824.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-15", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL MECHANISMS UNDERLYING ALVEOLAR-CAPILLARY BARRIER REGULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K08HL148403_7529"}, {"internal_id": 85588505, "Award ID": "K08HL148178", "Award Amount": 682560.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-05", "CFDA Number": "93.837", "Description": "MULTI-OMICS ANALYSIS OF THE ASSOCIATION OF POLYUNSATURATED FATTY ACIDS WITH ASTHMA AND ALLERGY IN CHILDHOOD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL148178_7529"}, {"internal_id": 97471719, "Award ID": "K08HL146979", "Award Amount": 540000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-15", "CFDA Number": "93.837", "Description": "INHIBITION OF HISTONE DEACETYLASE 8 (HDAC8) AS A THERAPY FOR PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_K08HL146979_7529"}, {"internal_id": 95943013, "Award ID": "K08HL146972", "Award Amount": 678240.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-17", "CFDA Number": "93.837", "Description": "THE ROLE OF COPD GENETIC RISK FACTOR HHIP ON LYMPHOCYTIC INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL146972_7529"}, {"internal_id": 95484825, "Award ID": "K08HL146943", "Award Amount": 229743.52, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-20", "CFDA Number": "93.837", "Description": "SINGLE-CELL TRANSCRIPTOMIC ANALYSIS TO IDENTIFY DRIVERS OF PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_K08HL146943_7529"}, {"internal_id": 79433991, "Award ID": "K08HL146933", "Award Amount": 180142.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-28", "CFDA Number": "93.837", "Description": "COMPARING OVINE MODELS OF CONGENITAL HEART DISEASE TO DISTINGUISH PATHOBIOLOGICAL MECHANISMS UNDERLYING PULMONARY VASCULAR DISEASE: TOWARD PRECISION MEDICINE FOR CHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K08HL146933_7529"}, {"internal_id": 76738386, "Award ID": "K08HL145132", "Award Amount": 858600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-31", "CFDA Number": "93.837", "Description": "THE THERAPEUTIC ROLE FOR LOLX2 IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K08HL145132_7529"}, {"internal_id": 76738587, "Award ID": "K08HL145118", "Award Amount": 681280.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-31", "CFDA Number": "93.837", "Description": "CHARACTERIZATION OF EARLY RESPONSE TO CHRONIC LUNG INJURY USING CHEST CT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL145118_7529"}, {"internal_id": 82471104, "Award ID": "K08HL145098", "Award Amount": 690720.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-25", "CFDA Number": "93.837", "Description": "SPECIALIZED PRO-RESOLVING MEDIATOR REGULATION OF NK CELLS IN HUMAN RSV BRONCHIOLITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL145098_7529"}, {"internal_id": 83115740, "Award ID": "K08HL145015", "Award Amount": 853254.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-05", "CFDA Number": "93.837", "Description": "ROLE OF ENDO180 REGULATION IN TISSUE FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_K08HL145015_7529"}, {"internal_id": 82471086, "Award ID": "K08HL144825", "Award Amount": 818100.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-23", "CFDA Number": "93.837", "Description": "PERSONALIZED MODEL SYSTEMS TO PREDICT AND INVESTIGATE CFTR DRUG RESPONSE IN CF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_K08HL144825_7529"}, {"internal_id": 76908829, "Award ID": "K08HL144820", "Award Amount": 809502.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-07", "CFDA Number": "93.837", "Description": "DEGRADATION OF TOLL-LIKE RECEPTOR 8 BY RNF216 IN RESPONSE TO PLASMA MICRORNA?S ? A NOVEL MECHANISM REGULATING INFLAMMATION IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K08HL144820_7529"}, {"internal_id": 67313558, "Award ID": "K08HL144085", "Award Amount": 248219.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-13", "CFDA Number": "93.838", "Description": "ROLE OF MYELOID-DERIVED SUPPRESSOR CELLS IN PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_K08HL144085_7529"}, {"internal_id": 79639291, "Award ID": "K08HL143271", "Award Amount": 534651.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-08", "CFDA Number": "93.837", "Description": "MACROPHAGE AND MONOCYTE TBK1 FUNCTION IN HOST DEFENSE AGAINST INFLUENZA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_K08HL143271_7529"}, {"internal_id": 67313451, "Award ID": "K08HL143197", "Award Amount": 661059.35, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-13", "CFDA Number": "93.837", "Description": "YAP/TAZ-MEDIATED MECHANOTRANSDUCTION IN PULMONARY HYPERTENSION PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL143197_7529"}, {"internal_id": 67833911, "Award ID": "K08HL143183", "Award Amount": 869395.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-13", "CFDA Number": "93.837", "Description": "MECHANISTICALLY DISENTANGLING THE INFECTED, INFLAMED LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K08HL143183_7529"}, {"internal_id": 67579278, "Award ID": "K08HL143143", "Award Amount": 490637.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-24", "CFDA Number": "93.837", "Description": "IMMUNE CHECKPOINT INHIBITORS AS ANTIFIBROTIC THERAPY FOR IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K08HL143143_7529"}, {"internal_id": 83796616, "Award ID": "K08HL143138", "Award Amount": 653184.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-20", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL METABOLIC REGULATION OF LUNG EPITHELIUM: ALVEOLAR GENERATION AND REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_K08HL143138_7529"}, {"internal_id": 67832927, "Award ID": "K08HL143127", "Award Amount": 646779.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-06", "CFDA Number": "93.837", "Description": "PATHOPHYSIOLOGY OF INFLUENZA A VIRUS-INDUCED LUNG INJURY IN JUVENILES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_K08HL143127_7529"}, {"internal_id": 67579692, "Award ID": "K08HL143052", "Award Amount": 821190.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-18", "CFDA Number": "93.837", "Description": "GELSOLIN MODULATION OF AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K08HL143052_7529"}, {"internal_id": 83116006, "Award ID": "K08HL143051", "Award Amount": 697500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-14", "CFDA Number": "93.837", "Description": "WNT SIGNALING IN BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K08HL143051_7529"}, {"internal_id": 80400858, "Award ID": "K08HL141995", "Award Amount": 879120.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-29", "CFDA Number": "93.837", "Description": "ROLE OF THE NOVEL MICRORNA-125B IN PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_K08HL141995_7529"}, {"internal_id": 76476276, "Award ID": "K08HL141770", "Award Amount": 793260.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-17", "CFDA Number": "93.837", "Description": "MANNOSE BINDING LECTIN-DEPENDENT COMPLEMENT ACTIVATION IN EMPHYSEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_K08HL141770_7529"}, {"internal_id": 80400827, "Award ID": "K08HL141694", "Award Amount": 864000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-25", "CFDA Number": "93.837", "Description": "PURINERGIC MODULATION OF NKT CELLS AMELIORATES HYPEROXIC LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K08HL141694_7529"}, {"internal_id": 77190438, "Award ID": "K08HL141652", "Award Amount": 838080.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-01", "CFDA Number": "93.837", "Description": "MECHANISMS OF PULMONARY MICROBIOTA-INDUCED INFLAMMATION AND VASCULAR DYSFUNCTION IN NEONATAL LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K08HL141652_7529"}, {"internal_id": 65579534, "Award ID": "K08HL141648", "Award Amount": 798120.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-09", "CFDA Number": "93.837", "Description": "METABOLIC REPROGRAMMING OF RECRUITED ALVEOLAR MACROPHAGES BY ARGININE IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_K08HL141648_7529"}, {"internal_id": 65578782, "Award ID": "K08HL141623", "Award Amount": 863460.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-09", "CFDA Number": "93.837", "Description": "SELPLG AS A CANDIDATE GENE IN ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_K08HL141623_7529"}, {"internal_id": 65280407, "Award ID": "K08HL141601", "Award Amount": 853196.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-23", "CFDA Number": "93.837", "Description": "CLINICAL SIGNIFICANCE AND GENETIC DETERMINANTS OF NOVEL IMAGING MEASURES OF EMPHYSEMA DISTRIBUTION IN 9,743 SMOKERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL141601_7529"}, {"internal_id": 67832384, "Award ID": "K08HL141595", "Award Amount": 812700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-15", "CFDA Number": "93.837", "Description": "THE ROLE OF ADENINE NUCLEOTIDE TRANSLOCASE IN THE PROTECTION OF AIRWAY EPITHELIAL CELLS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K08HL141595_7529"}, {"internal_id": 100874693, "Award ID": "K08HL141590", "Award Amount": 682992.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-05", "CFDA Number": "93.837", "Description": "SYNDECAN-1 REGULATION OF LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_K08HL141590_7529"}, {"internal_id": 67580514, "Award ID": "K08HL140222", "Award Amount": 870860.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-25", "CFDA Number": "93.837", "Description": "ROLE OF LUNG WWOX DEFICIENCY IN VASCULAR LEAK DURING LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_K08HL140222_7529"}, {"internal_id": 48913676, "Award ID": "K08HL140198", "Award Amount": 885600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-12", "CFDA Number": "93.837", "Description": "EPIGENOMICS OF MONONUCLEAR PHAGOCYTES IN PREMATURITY ASSOCIATED LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_K08HL140198_7529"}, {"internal_id": 48913675, "Award ID": "K08HL140190", "Award Amount": 504792.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-21", "CFDA Number": "93.837", "Description": "OVERCOMING BARRIERS TO F508DEL CFTR CORRECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K08HL140190_7529"}, {"internal_id": 67313456, "Award ID": "K08HL140178", "Award Amount": 815400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-19", "CFDA Number": "93.837", "Description": "MECHANISTIC EVALUATION OF A NOVEL WNT-RESPONSIVE ADULT ALVEOLAR EPITHELIAL PROGENITOR POPULATION DURING REGENERATION AFTER DIFFUSE ALVEOLAR DAMAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_K08HL140178_7529"}, {"internal_id": 67832370, "Award ID": "K08HL140175", "Award Amount": 864000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-06", "CFDA Number": "93.837", "Description": "ROLE AND REGULATION OF VASCULAR PERMEABILITY IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K08HL140175_7529"}, {"internal_id": 48913674, "Award ID": "K08HL140173", "Award Amount": 866085.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-07", "CFDA Number": "93.837", "Description": "THE ROLE OF LUNG-RESIDENT MEMORY TH2 CELLS IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K08HL140173_7529"}, {"internal_id": 48913673, "Award ID": "K08HL140152", "Award Amount": 816920.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-13", "CFDA Number": "93.837", "Description": "MIR-17~92 HAPLOINSUFFICIENCY INFLUENCES ALVEOLAR AND VASCULAR ENDOTHELIAL DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_K08HL140152_7529"}, {"internal_id": 61615092, "Award ID": "K08HL140129", "Award Amount": 797040.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-19", "CFDA Number": "93.837", "Description": "WNT-MEDIATED EPITHELIAL-ENDOTHELIAL CROSSTALK IN THE GENERATION AND REGENERATION OF THE LUNG ALVEOLUS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_K08HL140129_7529"}, {"internal_id": 93243429, "Award ID": "K08HL140104", "Award Amount": 644084.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-11", "CFDA Number": "93.837", "Description": "THE ROLE OF IL-33 IN HYPEROXIA-INDUCED NEONATAL LUNG INJURY AND BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K08HL140104_7529"}, {"internal_id": 48913670, "Award ID": "K08HL140102", "Award Amount": 831060.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-09", "CFDA Number": "93.837", "Description": "GABAA RECEPTOR-MEDIATED MODULATION OF LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K08HL140102_7529"}, {"internal_id": 65579094, "Award ID": "K08HL140100", "Award Amount": 784782.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-10", "CFDA Number": "93.837", "Description": "MECHANISMS OF JUNCTOPHILIN-2 MISREGULATION THAT CONTRIBUTE TO RIGHT VENTRICULAR DYSFUNCTION IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_K08HL140100_7529"}, {"internal_id": 48913669, "Award ID": "K08HL140087", "Award Amount": 851600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-18", "CFDA Number": "93.837", "Description": "PROGRESSION OF INTERSTITIAL LUNG ABNORMALITIES: THE ROLE OF IMAGING AND TELOMERE LENGTH REGULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL140087_7529"}, {"internal_id": 48913668, "Award ID": "K08HL139994", "Award Amount": 793610.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-08", "CFDA Number": "93.837", "Description": "IMPROVED TOOLS FOR NONTUBERCULOUS MYCOBACTERIA LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K08HL139994_7529"}, {"internal_id": 48913667, "Award ID": "K08HL138460", "Award Amount": 788042.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-13", "CFDA Number": "93.837", "Description": "MECHANISMS OF REGENERATION IN TISSUE ENGINEERED TRACHEAL GRAFTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_K08HL138460_7529"}, {"internal_id": 48913665, "Award ID": "K08HL138289", "Award Amount": 731387.9, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-31", "CFDA Number": "93.837", "Description": "HOST-PATHOGEN INTERACTIONS THAT PROMOTE CARBAPENEM-RESISTANT?KLEBSIELLA PNEUMONIAE?PULMONARY INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K08HL138289_7529"}, {"internal_id": 48913664, "Award ID": "K08HL138285", "Award Amount": 828900.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-09", "CFDA Number": "93.837", "Description": "GLUT1-DEPENDENT GLYCOLYSIS REGULATES AGE-SUSCEPTIBLE LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_K08HL138285_7529"}, {"internal_id": 48913663, "Award ID": "K08HL138269", "Award Amount": 735164.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "NANONSCALE DRUG CARRIERS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K08HL138269_7529"}, {"internal_id": 76737877, "Award ID": "K08HL138153", "Award Amount": 799410.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-03", "CFDA Number": "93.837", "Description": "FUNCTIONAL CATEGORIZATION OF CILIARY MOTION IN PCD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K08HL138153_7529"}, {"internal_id": 48913660, "Award ID": "K08HL138088", "Award Amount": 228404.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-14", "CFDA Number": "93.838", "Description": "ROLE OF P73 IN COPD PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K08HL138088_7529"}, {"internal_id": 48913659, "Award ID": "K08HL136928", "Award Amount": 864000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-01", "CFDA Number": "93.837", "Description": "MULTI-OMIC SUBTYPING OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL136928_7529"}, {"internal_id": 48913658, "Award ID": "K08HL136927", "Award Amount": 639448.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-01", "CFDA Number": "93.837", "Description": "INITIAL ATTACHMENT OF BACTERIA TO MUCUS STRANDS IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_K08HL136927_7529"}, {"internal_id": 48913657, "Award ID": "K08HL136903", "Award Amount": 894132.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-03", "CFDA Number": "93.837", "Description": "REGULATION OF DENDRITIC CELL FUNCTION BY NEUTROPHIL-DERIVED REACTIVE OXYGEN SPECIES IN PULMONARY ASPERGILLOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL136903_7529"}, {"internal_id": 48913654, "Award ID": "K08HL136888", "Award Amount": 858438.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-01", "CFDA Number": "93.837", "Description": "MECHANISMS OF AIRSPACE INFLAMMATION CAUSED BY CELL-FREE HEMOGLOBIN DURING ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K08HL136888_7529"}, {"internal_id": 65579422, "Award ID": "K08HL136885", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-09", "CFDA Number": "93.838", "Description": "INTEGRATED STRESS RESPONSE-MEDIATED EPITHELIAL INJURY IN MECHANICAL VENTILATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K08HL136885_7529"}, {"internal_id": 66199742, "Award ID": "K08HL136857", "Award Amount": 969880.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-05", "CFDA Number": "93.837", "Description": "DISCOVERING AND DEVELOPING RECOMBINANT MOLECULAR SCAVENGING AGENTS FOR THE TREATMENT OF CARBON MONOXIDE INDUCED CARDIOVASCULAR DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": 160708.0, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K08HL136857_7529"}, {"internal_id": 65281290, "Award ID": "K08HL136786", "Award Amount": 797150.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-30", "CFDA Number": "93.837", "Description": "MODULATING MACROPHAGE-MEDIATED INFLAMMATION IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_K08HL136786_7529"}, {"internal_id": 64141709, "Award ID": "K08HL136698", "Award Amount": 506088.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-11", "CFDA Number": "93.837", "Description": "G-CSF AND STAT3 LINK INFLAMMATION TO ALVEOLAR EPITHELIAL REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K08HL136698_7529"}, {"internal_id": 48913647, "Award ID": "K08HL135443", "Award Amount": 860630.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-14", "CFDA Number": "93.837", "Description": "CHOLINERGIC HYPERINNERNATION IN EARLY LIFE REGULATES LONG-TERM AIRWAY REACTIVITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K08HL135443_7529"}, {"internal_id": 48913644, "Award ID": "K08HL135433", "Award Amount": 800820.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-25", "CFDA Number": "93.837", "Description": "MECHANISMS OF IMPAIRED MUCOCILIARY TRANSPORT IN CF AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_K08HL135433_7529"}, {"internal_id": 48913643, "Award ID": "K08HL135402", "Award Amount": 833773.63, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-29", "CFDA Number": "93.837", "Description": "MIF AND DNA REPAIR IN THE EMPHYSEMATOUS LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_K08HL135402_7529"}, {"internal_id": 48913641, "Award ID": "K08HL135399", "Award Amount": 840780.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-01", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL UCP2 IN AGE-RELATED LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K08HL135399_7529"}, {"internal_id": 48913638, "Award ID": "K08HL135324", "Award Amount": 779730.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-22", "CFDA Number": "93.837", "Description": "ADENOSINE SIGNALING IN BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_K08HL135324_7529"}, {"internal_id": 48913637, "Award ID": "K08HL135318", "Award Amount": 975153.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-30", "CFDA Number": "93.837", "Description": "PROTEIN REGULATION AND CYTOSKELETAL DYNAMICS OF PULMONARY ENDOTHELIAL BARRIER FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_K08HL135318_7529"}, {"internal_id": 82470904, "Award ID": "K08HL135279", "Award Amount": 809615.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-22", "CFDA Number": "93.837", "Description": "PHOSPHORYLATION CONTROL OF FIBROPROLIFERATIVE ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K08HL135279_7529"}, {"internal_id": 48913636, "Award ID": "K08HL135266", "Award Amount": 811620.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-16", "CFDA Number": "93.837", "Description": "AIRWAY EPITHELIAL REGULATION OF FIBROBLAST HYALURONAN AND VERSICAN PRODUCTION IN ASTHMATIC AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_K08HL135266_7529"}, {"internal_id": 48913634, "Award ID": "K08HL133603", "Award Amount": 868440.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "EPITHELIAL CELL ACTIVATION OF FIBROBLASTS IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K08HL133603_7529"}, {"internal_id": 48913630, "Award ID": "K08HL133484", "Award Amount": 651233.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-05", "CFDA Number": "93.837", "Description": "REGULATION OF ELASTIN ASSEMBLY DURING SACCULAR STAGE LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K08HL133484_7529"}, {"internal_id": 48913628, "Award ID": "K08HL133475", "Award Amount": 652540.68, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-21", "CFDA Number": "93.837", "Description": "THE CALPAIN/CAMKII/NHE SIGNALING PATHWAY IN PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K08HL133475_7529"}, {"internal_id": 48913627, "Award ID": "K08HL133474", "Award Amount": 975151.39, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "THE ROLE OF NFATC3 IN ALTERED HYPOXIC PULMONARY VASOCONSTRICTION DURING ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_K08HL133474_7529"}, {"internal_id": 48913626, "Award ID": "K08HL133459", "Award Amount": 821444.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-14", "CFDA Number": "93.837", "Description": "S-NITROSOGLUTATHIONE REDUCTASE AND AIRWAYS HYPERREACTIVITY IN MURINE BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_K08HL133459_7529"}, {"internal_id": 48913624, "Award ID": "K08HL133445", "Award Amount": 792017.53, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-22", "CFDA Number": "93.837", "Description": "ROLE OF IL-33 IN INFLUENZA AND STAPHYLOCOCCUS AUREUS CO-INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K08HL133445_7529"}, {"internal_id": 48913623, "Award ID": "K08HL133381", "Award Amount": 835883.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-07", "CFDA Number": "93.838", "Description": "GENDER-BASED PRECISION CARE FOR ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": 100384.0, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_K08HL133381_7529"}, {"internal_id": 48913622, "Award ID": "K08HL133380", "Award Amount": 809404.68, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-18", "CFDA Number": "93.837", "Description": "TRANSIENT RECEPTOR POTENTIAL VANILLOID 4 (TRPV4) MEDIATES THE HOST DEFENSE AND LUNG INJURY RESPONSE TO BACTERIAL PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_K08HL133380_7529"}, {"internal_id": 48913621, "Award ID": "K08HL133379", "Award Amount": 821193.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "AKT-MEDIATED PHOSPHORYLATION OF HSP70 REGULATES MITOCHONDRIAL LOCALIZATION OF SOD2 AND OXIDATIVE STRESS IN PULMONARY ARTERY ENDOTHELIAL CELLS DURING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_K08HL133379_7529"}, {"internal_id": 48913618, "Award ID": "K08HL132203", "Award Amount": 821340.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-30", "CFDA Number": "93.837", "Description": "ANTAGONISM OF THE CALCIUM -ACTIVATED CHLORIDE CHANNEL TMEM16A; BENEFICIAL THERAPEUTIC EFFECTS ON AIRWAY EPITHELIUM AND SMOOTH MUSCLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K08HL132203_7529"}, {"internal_id": 48913612, "Award ID": "K08HL132099", "Award Amount": 435222.31, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-14", "CFDA Number": "93.837", "Description": "DONOR SPECIFIC EXTRACELLULAR VESICLE CHARACTERIZATION FOR MONITORING LUNG TRANSPLANT REJECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K08HL132099_7529"}, {"internal_id": 48913611, "Award ID": "K08HL132079", "Award Amount": 815185.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-11", "CFDA Number": "93.837", "Description": "MATRIX-MYOSIN II INTERACTIONS DRIVE FIBROSIS IN IDIOPATHIC PULMONARY FIBROSIS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_K08HL132079_7529"}, {"internal_id": 48913609, "Award ID": "K08HL132055", "Award Amount": 827997.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-11", "CFDA Number": "93.837", "Description": "ROS-INDUCED ENDOTHELIAL DYSFUNCTION IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K08HL132055_7529"}, {"internal_id": 48913608, "Award ID": "K08HL132053", "Award Amount": 637632.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-15", "CFDA Number": "93.837", "Description": "ROLE OF CIRCADIAN CLOCK IN LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_K08HL132053_7529"}, {"internal_id": 48913607, "Award ID": "K08HL132014", "Award Amount": 660959.61, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-29", "CFDA Number": "93.837", "Description": "PLATELET-DERIVED SEROTONIN IN NEONATAL PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K08HL132014_7529"}, {"internal_id": 48913603, "Award ID": "K08HL131992", "Award Amount": 789655.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-14", "CFDA Number": "93.837", "Description": "AUTOPHAGY REGULATES AIRWAY EPITHELIAL CELL MUCIN SECRETION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce6cc294-968c-0136-a2e3-f34319ce4753-C", "generated_internal_id": "ASST_NON_K08HL131992_7529"}, {"internal_id": 48913600, "Award ID": "K08HL131867", "Award Amount": 637335.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-26", "CFDA Number": "93.837", "Description": "THE MECHANISMS UNDERLYING ABNORMAL MUCUS AND ITS CLEARANCE IN THE CYSTIC FIBROSIS RAT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K08HL131867_7529"}, {"internal_id": 48913599, "Award ID": "K08HL131261", "Award Amount": 595357.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-06", "CFDA Number": "93.837", "Description": "CELA1 MEDIATES STRETCH-REGULATED ELASTIN REMODELING DURING ALVEOLAR SEPTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_K08HL131261_7529"}, {"internal_id": 48913596, "Award ID": "K08HL130666", "Award Amount": 806643.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-28", "CFDA Number": "93.837", "Description": "THE ROLE OF THE LONG NON-CODING RNA FALCOR IN EARLY ENDODERM AND LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_K08HL130666_7529"}, {"internal_id": 48913592, "Award ID": "K08HL130595", "Award Amount": 769529.55, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-23", "CFDA Number": "93.837", "Description": "DNA-DAMAGE REPAIR IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K08HL130595_7529"}, {"internal_id": 48913588, "Award ID": "K08HL130586", "Award Amount": 695384.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-01", "CFDA Number": "93.837", "Description": "ALVEOLAR EPITHELIAL CARBOHYDRATE METABOLISM IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K08HL130586_7529"}, {"internal_id": 48913587, "Award ID": "K08HL130582", "Award Amount": 819486.33, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "THE ROLE OF ONCOSTATIN-M IN PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_K08HL130582_7529"}, {"internal_id": 48913585, "Award ID": "K08HL130557", "Award Amount": 545085.45, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-12", "CFDA Number": "93.837", "Description": "ROLE OF S-NITROSOTHIOLS IN AKT1 SIGNALING AND PNEUMONIA RESOLUTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_K08HL130557_7529"}, {"internal_id": 48913583, "Award ID": "K08HL130540", "Award Amount": 673877.37, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-09", "CFDA Number": "93.837", "Description": "ROLE OF MARESIN 1 IN THE RESOLUTION OF LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL130540_7529"}, {"internal_id": 48913580, "Award ID": "K08HL130430", "Award Amount": 665064.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "ICAM-1 TARGETED THROMBOMODULIN: AN EXPERIMENTAL THERAPEUTIC FOR THE ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K08HL130430_7529"}, {"internal_id": 48913578, "Award ID": "K08HL129081", "Award Amount": 672192.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-27", "CFDA Number": "93.837", "Description": "GENETIC AND MOLECULAR DISSECTION OF PULMONARY NEUROENDOCRINE (NE) CELL DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K08HL129081_7529"}, {"internal_id": 48913577, "Award ID": "K08HL129080", "Award Amount": 768260.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-26", "CFDA Number": "93.837", "Description": "NOVEL THERAPEUTIC TARGETS FOR BRONCHOPULMONARY DYSPLASIA-ASSOCIATED PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_K08HL129080_7529"}, {"internal_id": 48913576, "Award ID": "K08HL129075", "Award Amount": 684562.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-18", "CFDA Number": "93.837", "Description": "REGULATORY T CELLS PROMOTE ALVEOLAR EPITHELIAL REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_K08HL129075_7529"}, {"internal_id": 48913572, "Award ID": "K08HL128867", "Award Amount": 778406.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-30", "CFDA Number": "93.837", "Description": "REGULATORY T CELL UHRF1 AND DNA METHYLATION IN REPAIR OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K08HL128867_7529"}, {"internal_id": 48913570, "Award ID": "K08HL128842", "Award Amount": 837200.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-05", "CFDA Number": "93.837", "Description": "MECHANISTIC STUDIES OF HEDGEHOG SIGNALING IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_K08HL128842_7529"}, {"internal_id": 48913566, "Award ID": "K08HL128809", "Award Amount": 674911.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-25", "CFDA Number": "93.837", "Description": "A CRITICAL ROLE FOR FOLLISTATIN-LIKE PROTEIN-1 IN LUNG HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K08HL128809_7529"}, {"internal_id": 48913564, "Award ID": "K08HL128802", "Award Amount": 854314.21, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-08", "CFDA Number": "93.837", "Description": "REGULATION OF PULMONARY VASCULAR CELL REDOX STATE BY L-2-HYDROXYGLUTARATE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL128802_7529"}, {"internal_id": 48913555, "Award ID": "K08HL127103", "Award Amount": 816049.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-10", "CFDA Number": "93.837", "Description": "MECHANISMS OF SEX SPECIFIC DIFFERENCES IN NEONATAL HYPEROXIC LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_K08HL127103_7529"}, {"internal_id": 48913554, "Award ID": "K08HL127102", "Award Amount": 708124.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-01", "CFDA Number": "93.837", "Description": "BETA 1 INTEGRIN IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K08HL127102_7529"}, {"internal_id": 48913553, "Award ID": "K08HL127075", "Award Amount": 775436.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-22", "CFDA Number": "93.837", "Description": "ROLE OF INTEGRIN ALPHA 8 IN RESOLUTION OF LUNG INJURY AND REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K08HL127075_7529"}, {"internal_id": 48913552, "Award ID": "K08HL126135", "Award Amount": 765842.65, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-18", "CFDA Number": "93.837", "Description": "CELLULAR REGULATION OF THE IL-22 RECEPTOR AND ITS IMPORTANCE IN LUNG IMMUNITY.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K08HL126135_7529"}, {"internal_id": 48913551, "Award ID": "K08HL126071", "Award Amount": 787814.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-24", "CFDA Number": "93.838", "Description": "SMOKE INDUCED ALTERATIONS IN ION CHANNEL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K08HL126071_7529"}, {"internal_id": 48913549, "Award ID": "K08HL125940", "Award Amount": 616776.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-22", "CFDA Number": "93.837", "Description": "HIGH CARBON DIOXIDE IMPAIRS LUNG REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_K08HL125940_7529"}, {"internal_id": 48913548, "Award ID": "K08HL125910", "Award Amount": 777400.21, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-05", "CFDA Number": "93.837", "Description": "MECHANISM OF FIBROBLAST GROWTH FACTOR 2-MEDIATED ALVEOLAR EPITHELIAL REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_K08HL125910_7529"}, {"internal_id": 48913544, "Award ID": "K08HL125806", "Award Amount": 725482.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-24", "CFDA Number": "93.838", "Description": "IL-1BETA IN THE DEVELOPMENT OF HYPOXEMIA IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_K08HL125806_7529"}, {"internal_id": 48913541, "Award ID": "K08HL125666", "Award Amount": 587288.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-26", "CFDA Number": "93.838", "Description": "OBESITY AND ASTHMA SUBPHENOTYPES AND UNDERLYING GENETIC AND GENOMIC PATHWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K08HL125666_7529"}, {"internal_id": 48913539, "Award ID": "K08HL124298", "Award Amount": 782560.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-31", "CFDA Number": "93.838", "Description": "RE-ESTABLISHMENT OF DIRECTIONAL MUCOCILIARY TRANSPORT AFTER EPITHELIAL INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K08HL124298_7529"}, {"internal_id": 48913538, "Award ID": "K08HL124295", "Award Amount": 817400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-06", "CFDA Number": "93.837", "Description": "MECHANISMS OF HYDROCORTISONE REGULATION OF THE PERINATAL PULMONARY VASCULATURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_K08HL124295_7529"}, {"internal_id": 48913536, "Award ID": "K08HL124191", "Award Amount": 900144.9, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "THE NET EFFECT: HUMAN CF EPITHELIAL RESPONSES TO NETOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_K08HL124191_7529"}, {"internal_id": 48913534, "Award ID": "K08HL124049", "Award Amount": 821718.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-25", "CFDA Number": "93.837", "Description": "ROLE OF HUMAN CHYMASE IN SMOOTH MUSCLE CONTRACTION IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K08HL124049_7529"}, {"internal_id": 48913533, "Award ID": "K08HL123940", "Award Amount": 744063.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-31", "CFDA Number": "93.837", "Description": "THE ROLE OF PGP IN COPD-ASSOCIATED PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K08HL123940_7529"}, {"internal_id": 48913526, "Award ID": "K08HL122528", "Award Amount": 795978.2, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-30", "CFDA Number": "93.837", "Description": "HIF-1 MEDIATED VASCULAR INTEGRITY LIMITS ASPERGILLUS INVASION IN AIRWAY REJECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K08HL122528_7529"}, {"internal_id": 48913523, "Award ID": "K08HL122521", "Award Amount": 572723.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-05", "CFDA Number": "93.838", "Description": "THE ROLE OF PDGFRA+ FIBROBLASTS IN LUNG FIBROSIS AND ALVEOLAR HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_K08HL122521_7529"}, {"internal_id": 48913522, "Award ID": "K08HL122478", "Award Amount": 606005.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-08", "CFDA Number": "93.838", "Description": "UNDERSTANDING REGIONAL CRITICAL CARE DELIVERY IN ACUTE RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K08HL122478_7529"}, {"internal_id": 48913518, "Award ID": "K08HL121254", "Award Amount": 732300.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-01", "CFDA Number": "93.838", "Description": "RAPID TOLL-LIKE RECEPTOR 7-MEDIATED NITRIC OXIDE PRODUCTION IN THE AIRWAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_K08HL121254_7529"}, {"internal_id": 48913516, "Award ID": "K08HL121187", "Award Amount": 752634.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-18", "CFDA Number": "93.838", "Description": "THE ROLE OF APOPTOTIC CELL CLEARANCE IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_K08HL121187_7529"}, {"internal_id": 48913515, "Award ID": "K08HL121185", "Award Amount": 659002.63, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-14", "CFDA Number": "93.837", "Description": "ROLE OF RESIDENT MONOCYTES IN THE PATHOGENESIS OF PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_K08HL121185_7529"}, {"internal_id": 48913512, "Award ID": "K08HL121174", "Award Amount": 620479.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-22", "CFDA Number": "93.838", "Description": "METABOLIC REPROGRAMMING IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K08HL121174_7529"}, {"internal_id": 48913511, "Award ID": "K08HL121168", "Award Amount": 692761.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-31", "CFDA Number": "93.838", "Description": "EPITHELIAL IL-33 IN THE PATHOGENESIS OF CHRONIC AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K08HL121168_7529"}, {"internal_id": 48913510, "Award ID": "K08HL121146", "Award Amount": 773765.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-11", "CFDA Number": "93.838", "Description": "THE ROLES OF HEDGEHOG SIGNALING IN PULMONARY VASCULAR DEVELOPMENT AND REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K08HL121146_7529"}, {"internal_id": 48913500, "Award ID": "K08HL119359", "Award Amount": 714993.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-28", "CFDA Number": "93.837", "Description": "MATRIX METALLOPROTEINASE DRIVEN LUNG INFLAMMATION IN RSV DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K08HL119359_7529"}, {"internal_id": 48913495, "Award ID": "K08HL118128", "Award Amount": 399310.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-25", "CFDA Number": "93.838", "Description": "EFFECTS OF RARE VARIANTS AND ANCESTRY ON BETA AGONIST RESPONSE IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "623a4232-bd5e-fb60-cf01-48cd08a5a593-C", "generated_internal_id": "ASST_NON_K08HL118128_7529"}, {"internal_id": 48913494, "Award ID": "K08HL118118", "Award Amount": 792396.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-01-21", "CFDA Number": "93.838", "Description": "THE ROLE OF 2-PORE DOMAIN POTASSIUM CHANNELS IN ACUTE LUNG INJURY.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_K08HL118118_7529"}, {"internal_id": 48913486, "Award ID": "K08HL116771", "Award Amount": 740826.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-22", "CFDA Number": "93.838", "Description": "THE ROLE OF PHYSICIAN EXPERIENCE IN OUTCOMES OF PATIENTS WITH ACUTE RESPIRATORY F", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K08HL116771_7529"}, {"internal_id": 48913485, "Award ID": "K08HL116763", "Award Amount": 579960.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-19", "CFDA Number": "93.838", "Description": "ALTERED LYMPHATICS IN AN OVINE CARDIAC MODEL OF INCREASED PULMONARY BLOOD FLOW", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K08HL116763_7529"}, {"internal_id": 48913477, "Award ID": "K08HL116429", "Award Amount": 787536.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-18", "CFDA Number": "93.837", "Description": "CC CHEMOKINE-MEDIATED DIFFERENTIAL IMMUNOREGULATION BY HUMAN EOSINOPHILS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_K08HL116429_7529"}, {"internal_id": 48913474, "Award ID": "K08HL114882", "Award Amount": 434754.0, "Award Type": null, "Base Obligation Date": "2013-12-26", "CFDA Number": "93.838", "Description": "THE MODULATION OF EOTAXIN EXPRESSION BY STATINS: IMPLICATIONS FOR ASTHMA THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_K08HL114882_7529"}, {"internal_id": 48913470, "Award ID": "K08HL114645", "Award Amount": 740451.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-30", "CFDA Number": "93.838", "Description": "THE FUNCTION AND REGULATION OF IL-33 IN THE AIRWAY EPITHELIUM IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K08HL114645_7529"}, {"internal_id": 48913469, "Award ID": "K08HL114643", "Award Amount": 606440.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-05", "CFDA Number": "93.838", "Description": "NONCANONICAL RECEPTOR SIGNALING IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_K08HL114643_7529"}, {"internal_id": 48913467, "Award ID": "K08HL114641", "Award Amount": 657450.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-20", "CFDA Number": "93.838", "Description": "IQGAP1 IN VASCULAR BARRIER REGULATION DURING ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K08HL114641_7529"}, {"internal_id": 48913463, "Award ID": "K08HL112849", "Award Amount": 712017.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-15", "CFDA Number": "93.838", "Description": "MODULATION OF HOST IMMUNE DEFENSE BY PNEUMOCYSTIS BETA-GLUCANS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_K08HL112849_7529"}, {"internal_id": 48913456, "Award ID": "K08HL111208", "Award Amount": 708577.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-25", "CFDA Number": "93.838", "Description": "ROLE OF TH17 AND IL17A IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c10cf51-1fb6-c52e-c48f-8fcef0f37eff-C", "generated_internal_id": "ASST_NON_K08HL111208_7529"}, {"internal_id": 48913455, "Award ID": "K08HL111207", "Award Amount": 722876.0, "Award Type": null, "Base Obligation Date": "2013-02-01", "CFDA Number": "93.838", "Description": "ALDOSTERONE IMPAIRS ENDOTHELIN B-DEPENDENT SYNTHESIS OF NITRIC OXIDE TO PROMOTE P", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL111207_7529"}, {"internal_id": 48913433, "Award ID": "K08HL105884", "Award Amount": 700811.0, "Award Type": null, "Base Obligation Date": "2012-07-20", "CFDA Number": "93.838", "Description": "THE ROLE OF THE WNT/PLANAR CELL POLARITY PATHWAY IN PULMONARY ANGIOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K08HL105884_7529"}, {"internal_id": 48913429, "Award ID": "K08HL105677", "Award Amount": 633001.0, "Award Type": null, "Base Obligation Date": "2011-06-17", "CFDA Number": "93.838", "Description": "REGULATION OF ARGINASE IN MODELS OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_K08HL105677_7529"}, {"internal_id": 48913421, "Award ID": "K08HL105538", "Award Amount": 643655.0, "Award Type": null, "Base Obligation Date": "2010-12-30", "CFDA Number": "93.838", "Description": "PULMONARY ENDOTHELIAL GLYCOCALYX DEGRADATION CAUSES ARDS DURING SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K08HL105538_7529"}, {"internal_id": 48913420, "Award ID": "K08HL105537", "Award Amount": 492114.0, "Award Type": null, "Base Obligation Date": "2012-04-18", "CFDA Number": "93.838", "Description": "REGULATION OF LUNG FIBROSIS BY ALTERNATIVELY ACTIVATED MACROPHAGES AND ARGINASE-1", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_K08HL105537_7529"}, {"internal_id": 48913419, "Award ID": "K08HL105536", "Award Amount": 653287.0, "Award Type": null, "Base Obligation Date": "2011-06-30", "CFDA Number": "93.838", "Description": "SCHISTOSOMIASIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K08HL105536_7529"}, {"internal_id": 107114101, "Award ID": "K01HL153941", "Award Amount": 712800.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-27", "CFDA Number": "93.837", "Description": "INTEGRATIVE METABOLOMIC CHARACTERIZATION OF ADHD AND ASTHMA COMORBIDITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K01HL153941_7529"}, {"internal_id": 108463294, "Award ID": "K01HL153792", "Award Amount": 421374.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-05", "CFDA Number": "93.837", "Description": "IDENTIFYING GENETIC AND EPIGENETIC RISK FACTORS REGULATING GENE EXPRESSION FOR CHILDHOOD ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K01HL153792_7529"}, {"internal_id": 95943086, "Award ID": "K01HL150275", "Award Amount": 446359.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-13", "CFDA Number": "93.837", "Description": "EVALUATING PATIENT-REPORTED OUTCOMES FOR PULMONARY NONTUBERCULOUS MYCOBACTERIAL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_K01HL150275_7529"}, {"internal_id": 109189948, "Award ID": "K01HL149989", "Award Amount": 647670.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF EARLY METABOLOMIC AND IMMUNE ENDOTYPES OF ALLERGY AND ASTHMA: AN INTEGRATED MULTIOMICS APPROACH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "74ccc06e-57e8-7489-fbc7-f6229ad4aaf6-C", "generated_internal_id": "ASST_NON_K01HL149989_7529"}, {"internal_id": 95943392, "Award ID": "K01HL149851", "Award Amount": 647999.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-04", "CFDA Number": "93.837", "Description": "OPERATIONALIZING THE RAGE AXIS IN ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K01HL149851_7529"}, {"internal_id": 80400926, "Award ID": "K01HL146980", "Award Amount": 891000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-17", "CFDA Number": "93.837", "Description": "MULTI-OMIC ENDOTYPING OF ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K01HL146980_7529"}, {"internal_id": 93911729, "Award ID": "K01HL146977", "Award Amount": 698691.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-03", "CFDA Number": "93.837", "Description": "INTEGRATIVE LONGITUDINAL GENOMICS OF MATERNAL ASTHMA-PREECLAMPSIA OVERLAP AND RISK OF CHILDHOOD ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K01HL146977_7529"}, {"internal_id": 82471125, "Award ID": "K01HL145365", "Award Amount": 773544.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-22", "CFDA Number": "93.837", "Description": "THE PULMONARY LYMPHATICS IN INFLAMMATION AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_K01HL145365_7529"}, {"internal_id": 78989465, "Award ID": "K01HL145338", "Award Amount": 672907.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-14", "CFDA Number": "93.837", "Description": "CD8+ T CELL DYSFUNCTION PROMOTES SARCOIDOSIS PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_K01HL145338_7529"}, {"internal_id": 76908646, "Award ID": "K01HL141771", "Award Amount": 831600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-12", "CFDA Number": "93.837", "Description": "PREDICTING PULMONARY AND CARDIAC MORBIDITY IN PRETERM INFANTS WITH DEEP LEARNING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_K01HL141771_7529"}, {"internal_id": 65579020, "Award ID": "K01HL141637", "Award Amount": 853034.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-12", "CFDA Number": "93.837", "Description": "UNDERSTANDING RESPONSE SHIFT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) SURVIVORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K01HL141637_7529"}, {"internal_id": 76738482, "Award ID": "K01HL140804", "Award Amount": 955800.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-06", "CFDA Number": "93.837", "Description": "THE IMPACT OF THE HIV RESERVOIR ON PULMONARY MYELOID CELLS: VIROLOGY, PHENOTYPE, AND FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K01HL140804_7529"}, {"internal_id": 62550952, "Award ID": "K01HL140279", "Award Amount": 884520.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-28", "CFDA Number": "93.837", "Description": "COGNITIVE-MOTOR INTERFERENCE ASSESSMENT FOR IMPROVING NEUROLOGIC AND PHYSICAL DISABILITY OUTCOMES (CAMINANDO) IN SURVIVORS OF SEVERE ACUTE RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_K01HL140279_7529"}, {"internal_id": 77190329, "Award ID": "K01HL140261", "Award Amount": 745620.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-18", "CFDA Number": "93.837", "Description": "HEAT-SHOCK PROTEIN 90 MODULATES GOBLET CELL METAPLASIA IN HUMAN AIRWAY EPITHELIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_K01HL140261_7529"}, {"internal_id": 61611162, "Award ID": "K01HL140218", "Award Amount": 456664.24, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-24", "CFDA Number": "93.837", "Description": "INTEGRATIVE GENETICS AND GENOMICS OF OBESE-ASTHMA IN MINORITY CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K01HL140218_7529"}, {"internal_id": 65578985, "Award ID": "K01HL140216", "Award Amount": 691942.96, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-06", "CFDA Number": "93.837", "Description": "PHYSICAL ACTIVITY AND DOSE OF AIR POLLUTION IN PEDIATRIC URBAN ASTHMA: IMPACT OF MINUTE VENTILATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K01HL140216_7529"}, {"internal_id": 48910264, "Award ID": "K01HL140048", "Award Amount": 449662.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-22", "CFDA Number": "93.837", "Description": "A MULTI-FACETED INTERVENTION TO PROMOTE ADOPTION OF CLEAN FUEL TECHNOLOGIES FOR RESPIRATORY HEALTH IN PERU", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K01HL140048_7529"}, {"internal_id": 48910259, "Award ID": "K01HL138124", "Award Amount": 666430.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-31", "CFDA Number": "93.837", "Description": "ANTIMICROBIAL AGENTS AND ASTHMA MORBIDITY AMONG AFRICAN AMERICAN CHILDREN WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K01HL138124_7529"}, {"internal_id": 65579338, "Award ID": "K01HL138098", "Award Amount": 714630.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-06", "CFDA Number": "93.837", "Description": "NOVEL METHODS FOR ANALYSIS OF GENETIC AND EPIGENETIC STUDIES OF CHILDHOOD ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K01HL138098_7529"}, {"internal_id": 48910255, "Award ID": "K01HL136687", "Award Amount": 862002.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-28", "CFDA Number": "93.837", "Description": "DATA-DRIVEN IDENTIFICATION OF THE ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K01HL136687_7529"}, {"internal_id": 48910254, "Award ID": "K01HL135476", "Award Amount": 836460.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-18", "CFDA Number": "93.837", "Description": "ROLE OF IL-22/IL-22RA2 DURING PNEUMOCOCCAL PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K01HL135476_7529"}, {"internal_id": 65280188, "Award ID": "K01HL135474", "Award Amount": 853345.51, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-19", "CFDA Number": "93.837", "Description": "THE ROLE OF EXTRACELLULAR CAMP IN THE PATHOGENESIS OF PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_K01HL135474_7529"}, {"internal_id": 48910250, "Award ID": "K01HL135459", "Award Amount": 924027.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-28", "CFDA Number": "93.837", "Description": "DETERMINANTS OF IDIOPATHIC INFLAMMATORY MYOPATHY ASSOCIATED INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K01HL135459_7529"}, {"internal_id": 48910242, "Award ID": "K01HL133796", "Award Amount": 818068.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-12", "CFDA Number": "93.837", "Description": "REGULATION OF SMOOTH MUSCLE HYPERPLASTIC GROWTH IN PULMONARY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "34640ee3-dce1-9923-6e06-25f6c48e1690-C", "generated_internal_id": "ASST_NON_K01HL133796_7529"}, {"internal_id": 48910238, "Award ID": "K01HL133520", "Award Amount": 504399.51, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-15", "CFDA Number": "93.837", "Description": "SEX-SPECIFIC MECHANISMS OF OZONE-INDUCED ACUTE LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_K01HL133520_7529"}, {"internal_id": 48910230, "Award ID": "K01HL133370", "Award Amount": 736595.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-15", "CFDA Number": "93.837", "Description": "ACTION INTERVENTION: PHYSICAL ACTIVITY IN MINORITY WOMEN WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_K01HL133370_7529"}, {"internal_id": 48910228, "Award ID": "K01HL133333", "Award Amount": 307561.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-22", "CFDA Number": "93.838", "Description": "HORMONAL REGULATION OF AIRWAY DIAMETER BY BONE AND ITS IMPLICATION TO ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_K01HL133333_7529"}, {"internal_id": 48910219, "Award ID": "K01HL130704", "Award Amount": 835056.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-15", "CFDA Number": "93.837", "Description": "MECHANISMS AND CLINICAL RELEVANCE OF HYPERCAPNIA-INDUCED SKELETAL MUSCLE ATROPHY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "84c69770-7b20-b9e0-d502-4ceb449256bf-C", "generated_internal_id": "ASST_NON_K01HL130704_7529"}, {"internal_id": 48910216, "Award ID": "K01HL130629", "Award Amount": 818100.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-15", "CFDA Number": "93.837", "Description": "ROLE OF MICRORNA MOLECULES IN THERAPEUTIC RESPONSE TO LEUKOTRIENE MODIFYING AGENTS IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K01HL130629_7529"}, {"internal_id": 48910208, "Award ID": "K01HL129039", "Award Amount": 843792.53, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-09", "CFDA Number": "93.837", "Description": "NETWORK-BASED METHODS FOR UNDERSTANDING GENETIC DETERMINANTS AND EPISTASIS IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K01HL129039_7529"}, {"internal_id": 48910204, "Award ID": "K01HL127265", "Award Amount": 843818.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-08", "CFDA Number": "93.837", "Description": "WEIGHT LOSS-INDUCED MODIFICATION OF THE GENOMIC NETWORK UNDERLYING OBESE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K01HL127265_7529"}, {"internal_id": 48910197, "Award ID": "K01HL125514", "Award Amount": 887918.88, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-03", "CFDA Number": "93.837", "Description": "SPLUNC1 AND NEUTROPHILIC INFLAMMATION IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_K01HL125514_7529"}, {"internal_id": 48910192, "Award ID": "K01HL125474", "Award Amount": 829642.91, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-06", "CFDA Number": "93.837", "Description": "FUNCTIONAL ROLE OF HSA-MIR-504 IN AIRWAY INFLAMMATION AND REMODELING IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_K01HL125474_7529"}, {"internal_id": 48910181, "Award ID": "K01HL121041", "Award Amount": 688707.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-15", "CFDA Number": "93.838", "Description": "ETHANOL-INDUCED DYSFUNCTION OF LUNG ANTI-MICROBIAL ACTIVITY VIA VITAMIN D MODULAT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_K01HL121041_7529"}, {"internal_id": 48910180, "Award ID": "K01HL121028", "Award Amount": 761392.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-15", "CFDA Number": "93.838", "Description": "CONTROL OF PROLIFERATION-RELATED GENES AND MIRS BY NKX2-1 IN LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_K01HL121028_7529"}, {"internal_id": 48910176, "Award ID": "K01HL120912", "Award Amount": 233029.0, "Award Type": null, "Base Obligation Date": "2014-06-19", "CFDA Number": "93.838", "Description": "TNF-A INDUCED INCREASE IN ALVEOLAR EPITHELIAL CELL STIFFNESS INCREASE AND LUNG IN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f97d8891-aed5-b95f-0a7b-0cbb8a1230b1-C", "generated_internal_id": "ASST_NON_K01HL120912_7529"}, {"internal_id": 48910174, "Award ID": "K01HL118714", "Award Amount": 782880.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-24", "CFDA Number": "93.838", "Description": "COMPUTED TOMOGRAPHIC-BASED ASSESSMENT OF AIRWAY REMODELING IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K01HL118714_7529"}, {"internal_id": 48910173, "Award ID": "K01HL118712", "Award Amount": 591800.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-31", "CFDA Number": "93.838", "Description": "MECHANISMS OF INCREASED LUNG FIBROSIS IN MALES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_K01HL118712_7529"}, {"internal_id": 48910171, "Award ID": "K01HL118683", "Award Amount": 681915.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-09-26", "CFDA Number": "93.838", "Description": "DDAH AS A NOVEL TARGET IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_K01HL118683_7529"}, {"internal_id": 48910162, "Award ID": "K01HL115466", "Award Amount": 550800.0, "Award Type": null, "Base Obligation Date": "2012-07-18", "CFDA Number": "93.838", "Description": "THE ROLE OF COAGULATION CASCADE PROTEASES IN PLEURAL FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6605b60b-2165-8c36-e954-428aa458f579-C", "generated_internal_id": "ASST_NON_K01HL115466_7529"}, {"internal_id": 48910160, "Award ID": "K01HL115447", "Award Amount": 561985.0, "Award Type": null, "Base Obligation Date": "2012-07-23", "CFDA Number": "93.838", "Description": "MOLECULAR MECHANISMS UNDERLYING UPPER AIRWAY PATTERNING AND TRACHEOMALACIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_K01HL115447_7529"}, {"internal_id": 48910157, "Award ID": "K01HL114631", "Award Amount": 564767.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-12", "CFDA Number": "93.838", "Description": "COMPARING NONINVASIVE AND INVASIVE VENTILATION IN ACUTE RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e1acd199-78e8-9c81-52eb-45206f3dab16-C", "generated_internal_id": "ASST_NON_K01HL114631_7529"}, {"internal_id": 110024887, "Award ID": "F32HL154676", "Award Amount": 67586.46, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-31", "CFDA Number": "93.837", "Description": "PATIENT-CENTERED OUTCOMES OF RECOVERY AFTER HOSPITALIZATIONS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F32HL154676_7529"}, {"internal_id": 109278298, "Award ID": "F32HL154672", "Award Amount": 150654.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-21", "CFDA Number": "93.837", "Description": "MECHANISMS OF HIF-INDUCED MICROVASCULAR ENDOTHELIAL DYSFUNCTION IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL154672_7529"}, {"internal_id": 109190012, "Award ID": "F32HL154666", "Award Amount": 177206.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-17", "CFDA Number": "93.837", "Description": "THE ROLE OF MULTICILIATED CELL DYSFUNCTION IN PATHOGENESIS OF IPF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F32HL154666_7529"}, {"internal_id": 109190119, "Award ID": "F32HL154641", "Award Amount": 59371.48, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "CHI3L1 REGULATES NET FORMATION DURING BACTERIAL PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_F32HL154641_7529"}, {"internal_id": 100875065, "Award ID": "F32HL154638", "Award Amount": 201118.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-06", "CFDA Number": "93.837", "Description": "CELLULAR CROSSTALK IN THE MAINTENANCE OF LUNG EPITHELIAL HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "eb1c4bd6-22a0-1796-63d6-bdf7123782cd-C", "generated_internal_id": "ASST_NON_F32HL154638_7529"}, {"internal_id": 107115522, "Award ID": "F32HL154611", "Award Amount": 131307.16, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-01", "CFDA Number": "93.837", "Description": "CELLULAR AND MOLECULAR REGULATION OF AIRWAY MULTICILIATED CELL SPECIFICATION AND DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL154611_7529"}, {"internal_id": 109278242, "Award ID": "F32HL154558", "Award Amount": 204300.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-21", "CFDA Number": "93.837", "Description": "RHYTHMOGENIC STATES OF THE RESPIRATORY NETWORK REVEAL DIFFERENTIAL OPIOID SENSITIVITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_F32HL154558_7529"}, {"internal_id": 110024499, "Award ID": "F32HL154525", "Award Amount": 139544.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-27", "CFDA Number": "93.837", "Description": "TISSUE STIFFNESS PROMOTES PRO-FIBROTIC METABOLIC DYSREGULATION IN LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_F32HL154525_7529"}, {"internal_id": 108463348, "Award ID": "F32HL154516", "Award Amount": 98998.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-07", "CFDA Number": "93.837", "Description": "THE EFFECT OF PHTHALATES ON COPD MORBIDITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL154516_7529"}, {"internal_id": 96557280, "Award ID": "F32HL152664", "Award Amount": 126647.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-10", "CFDA Number": "93.837", "Description": "FUNCTIONS OF SPECIALIZED PULMONARY ENDOTHELIAL CELL TYPES IN REGENERATION OF THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F32HL152664_7529"}, {"internal_id": 107115383, "Award ID": "F32HL152534", "Award Amount": 64315.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-29", "CFDA Number": "93.837", "Description": "NOX1-MEDIATED TRANSCRIPTIONAL DE-REPRESSION AND ACTIVATION OF CXCL12 EXPRESSION IN HYPOXIC PULMONARY ENDOTHELIAL CELLS AND PAH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WV", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "38457ff7-68b1-7220-5dec-347ecba3483d-C", "generated_internal_id": "ASST_NON_F32HL152534_7529"}, {"internal_id": 96560112, "Award ID": "F32HL152504", "Award Amount": 78123.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-14", "CFDA Number": "93.837", "Description": "ENDOTHELIAL THROMBOSPONDIN-1 IN MATRIX PROTEOLYSIS DURING PSEUDOMONAL LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F32HL152504_7529"}, {"internal_id": 96559590, "Award ID": "F32HL152503", "Award Amount": 140144.45, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-16", "CFDA Number": "93.837", "Description": "THE ROLE OF THE EPITHELIAL-DERIVED CHEMOKINE, CXCL12, IN IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F32HL152503_7529"}, {"internal_id": 96559918, "Award ID": "F32HL152497", "Award Amount": 106846.04, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-16", "CFDA Number": "93.837", "Description": "IMMUNE MECHANISMS OF ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F32HL152497_7529"}, {"internal_id": 94237337, "Award ID": "F32HL151133", "Award Amount": 72734.61, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-13", "CFDA Number": "93.837", "Description": "THE ROLE OF POLDIP2 IN MACROPHAGES DURING SEPSIS-INDUCED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F32HL151133_7529"}, {"internal_id": 95943514, "Award ID": "F32HL151132", "Award Amount": 97871.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-04", "CFDA Number": "93.837", "Description": "PAD4 CONTRIBUTES TO THE PROFIBROTIC PHENOTYPE OF FIBROBLASTS FROM PATIENTS WITH IPF AND PROMOTES LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_F32HL151132_7529"}, {"internal_id": 94237861, "Award ID": "F32HL151128", "Award Amount": 247526.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-13", "CFDA Number": "93.837", "Description": "ENHANCING ADSORPTION OF LUNG SURFACTANTS AT THE AIR-WATER INTERFACE USING METHODS FROM COLLOID STABILITY THEORY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_F32HL151128_7529"}, {"internal_id": 95484357, "Award ID": "F32HL151127", "Award Amount": 107297.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-25", "CFDA Number": "93.837", "Description": "DETERMINANTS OF AGE-RELATED REGULATORY T CELL FUNCTION DURING INFLUENZA A VIRUS-INDUCED LUNG INJURY.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_F32HL151127_7529"}, {"internal_id": 95181105, "Award ID": "F32HL151117", "Award Amount": 189226.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-10", "CFDA Number": "93.837", "Description": "TRANSCRIPTOMIC SIGNATURES OF AIRWAY INFLAMMATION IN ACUTE RESPIRATORY DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL151117_7529"}, {"internal_id": 95484581, "Award ID": "F32HL151114", "Award Amount": 37495.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-25", "CFDA Number": "93.837", "Description": "MAPPING THE GENETIC AND CELLULAR REGULATORY LANDSCAPE OF LUNG EPITHELIAL REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F32HL151114_7529"}, {"internal_id": 109190143, "Award ID": "F32HL151076", "Award Amount": 99130.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-17", "CFDA Number": "93.837", "Description": "THE ROLE OF SMOOTH MUSCLE CELL FATTY ACID OXIDATION IN THE PATHOGENESIS OF PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL151076_7529"}, {"internal_id": 95943600, "Award ID": "F32HL151026", "Award Amount": 238366.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-04", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF NEUTROPHIL-AVID NANOCARRIERS AS AN ANTIBIOTIC DELIVERY SYSTEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_F32HL151026_7529"}, {"internal_id": 94236189, "Award ID": "F32HL150954", "Award Amount": 64926.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-08", "CFDA Number": "93.837", "Description": "SPUTUM MICROBIAL-IMMUNE RELATIONSHIPS TO CLINICAL PHENOTYPE IN ASTHMA AND COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F32HL150954_7529"}, {"internal_id": 83796239, "Award ID": "F32HL149337", "Award Amount": 150679.75, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-01", "CFDA Number": "93.837", "Description": "THE ROLE OF AMBULATORY CARE IN REDUCING THE BURDEN OF RESPIRATORY FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F32HL149337_7529"}, {"internal_id": 83103480, "Award ID": "F32HL149329", "Award Amount": 241768.27, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-02", "CFDA Number": "93.837", "Description": "INVESTIGATING THE RESILIENT SMOKER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL149329_7529"}, {"internal_id": 82054513, "Award ID": "F32HL149290", "Award Amount": 193222.33, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-03", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF A WNT/ BETA-CATENIN RESPONSIVE ADULT LUNG EPITHELIAL PROGENITOR CELL FOR TISSUE REPAIR IN CHRONIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F32HL149290_7529"}, {"internal_id": 98486716, "Award ID": "F32HL149262", "Award Amount": 65716.8, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-02", "CFDA Number": "93.837", "Description": "INDOOR AIR POLLUTION AND OUTCOMES IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL149262_7529"}, {"internal_id": 82469032, "Award ID": "F32HL149258", "Award Amount": 142403.21, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-29", "CFDA Number": "93.837", "Description": "MACROPHAGE PHENOTYPE AND COPD SEVERITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL149258_7529"}, {"internal_id": 83797019, "Award ID": "F32HL149236", "Award Amount": 153055.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-22", "CFDA Number": "93.837", "Description": "DETERMINING DISPARITIES IN TREATMENT OF PULMONARY ARTERIAL HYPERTENSION NATIONALLY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F32HL149236_7529"}, {"internal_id": 82469296, "Award ID": "F32HL149195", "Award Amount": 135243.05, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-31", "CFDA Number": "93.837", "Description": "UNDERSTANDING THE IMPACT OF SCHOOL ENVIRONMENT ON ASTHMA OUTCOMES TO INFORM IMPLEMENTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL149195_7529"}, {"internal_id": 82054643, "Award ID": "F32HL149184", "Award Amount": 130201.11, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-15", "CFDA Number": "93.837", "Description": "CHEMICAL BIOLOGY OF CFTR REGULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_F32HL149184_7529"}, {"internal_id": 83797861, "Award ID": "F32HL149182", "Award Amount": 126680.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-20", "CFDA Number": "93.837", "Description": "EPIGENETIC MECHANISMS OF IMMUNE REPROGRAMMING IN MURINE SEPSIS SURVIVORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F32HL149182_7529"}, {"internal_id": 81728718, "Award ID": "F32HL149178", "Award Amount": 78036.35, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-24", "CFDA Number": "93.837", "Description": "VITAMIN D DEFICIENCY AND NONTUBERCULOUS MYCOBACTERIA RISK IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL149178_7529"}, {"internal_id": 85589075, "Award ID": "F32HL149163", "Award Amount": 133336.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-13", "CFDA Number": "93.837", "Description": "ROLE OF NON-VISUAL OPSINS IN LIGHT-DEPENDENT APOPTOSIS OF PULMONARY ARTERIAL SMOOTH MUSCLE CELLS IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL149163_7529"}, {"internal_id": 80401356, "Award ID": "F32HL147461", "Award Amount": 122572.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-23", "CFDA Number": "93.837", "Description": "THE ROLE OF LOX-1 DURING PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F32HL147461_7529"}, {"internal_id": 80727598, "Award ID": "F32HL147437", "Award Amount": 148334.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-09", "CFDA Number": "93.837", "Description": "MMP-8 DEFICIENCY IMPROVES HOST RESPONSES TO  INFLUENZA VIRAL INFECTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_F32HL147437_7529"}, {"internal_id": 81729073, "Award ID": "F32HL147417", "Award Amount": 72144.36, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-27", "CFDA Number": "93.837", "Description": "THE ROLE OF NKX2-1 IN THE DISTAL LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_F32HL147417_7529"}, {"internal_id": 80736648, "Award ID": "F32HL147415", "Award Amount": 119090.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-16", "CFDA Number": "93.837", "Description": "IL-18 SIGNALING AND LUNG EPITHELIAL CELL BARRIER INTEGRITY IN SEVERE ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F32HL147415_7529"}, {"internal_id": 78990301, "Award ID": "F32HL147405", "Award Amount": 122745.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-09", "CFDA Number": "93.837", "Description": "INFLAMMATORY CYTOKINES PROMOTES PRO-FIBROTIC THY-1 NEGATIVE FIBROBLAST SUBPOPULATIONS IN LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_F32HL147405_7529"}, {"internal_id": 76909370, "Award ID": "F32HL146070", "Award Amount": 34696.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-10", "CFDA Number": "93.837", "Description": "LUNG-ON-A-CHIP PULMONARY FIBROSIS MODEL FOR DRUG DISCOVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c727a6e-aeb7-b7bb-b622-36f566d604a5-C", "generated_internal_id": "ASST_NON_F32HL146070_7529"}, {"internal_id": 77189556, "Award ID": "F32HL146064", "Award Amount": 214988.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-30", "CFDA Number": "93.837", "Description": "A GRIEVING HEART: DOES FEELING BURDENSOME TO OTHERS IMPACT INFLAMMATORY OUTCOMES DURING SPOUSAL BEREAVEMENT?", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7c6d4e6a-e5c4-b348-571b-42f4d585f5a8-C", "generated_internal_id": "ASST_NON_F32HL146064_7529"}, {"internal_id": 79434380, "Award ID": "F32HL146017", "Award Amount": 67914.29, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-22", "CFDA Number": "93.837", "Description": "GENETIC EPIDEMIOLOGY OF CIGARETTE SMOKERS WITHOUT EVIDENCE OF SMOKING RELATED LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F32HL146017_7529"}, {"internal_id": 76738532, "Award ID": "F32HL145990", "Award Amount": 134663.61, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-02", "CFDA Number": "93.837", "Description": "THE UNFOLDED PROTEIN RESPONSE AND TGF-BETA SIGNALING IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL145990_7529"}, {"internal_id": 77190394, "Award ID": "F32HL145988", "Award Amount": 93995.88, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-25", "CFDA Number": "93.837", "Description": "THE ROLE OF THE RNA-BINDING PROTEIN AUF1 IN IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_F32HL145988_7529"}, {"internal_id": 78598192, "Award ID": "F32HL145915", "Award Amount": 19049.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-22", "CFDA Number": "93.837", "Description": "SLEEP-DISORDERED BREATHING IN PEDIATRIC CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F32HL145915_7529"}, {"internal_id": 78598485, "Award ID": "F32HL145900", "Award Amount": 67240.8, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-22", "CFDA Number": "93.837", "Description": "STEREOLOGIC LOCALIZATION OF INTERSTITIAL MACROPHAGES IN THE LUNGS OF SMOKERS AND NONSMOKERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F32HL145900_7529"}, {"internal_id": 81728568, "Award ID": "F32HL145839", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-02", "CFDA Number": "93.838", "Description": "A MODIFIED APPROACH TO A SINGLE-BEAT ELASTANCE METHOD TO COMPUTE VENTRICULAR-VASCULAR COUPLING RATIO IN PULMONARY ARTERIAL HYPERTENSION: CLINICAL UTILITY AND OUTCOMES STUDIES.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F32HL145839_7529"}, {"internal_id": 67580717, "Award ID": "F32HL144145", "Award Amount": 68559.52, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-24", "CFDA Number": "93.837", "Description": "PREDICTORS OF RESPIRATORY INSUFFICIENCY IN AMYOTROPHIC LATERAL SCLEROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F32HL144145_7529"}, {"internal_id": 67580554, "Award ID": "F32HL144121", "Award Amount": 57381.28, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-30", "CFDA Number": "93.837", "Description": "CHANGES IN AIRWAY WALL MICROSTRUCTURES FOLLOWING BRONCHIAL THERMOPLASTY DETECTED BY OPTICAL COHERENCE TOMOGRAPHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL144121_7529"}, {"internal_id": 67314690, "Award ID": "F32HL144063", "Award Amount": 70039.87, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-12", "CFDA Number": "93.837", "Description": "THE M-PULSE STUDY: DETECTING PULMONARY EDEMA IN SEPSIS WITH LUNG ULTRASONOGRAPHY IN MALAWI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL144063_7529"}, {"internal_id": 67832354, "Award ID": "F32HL144040", "Award Amount": 162484.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-06", "CFDA Number": "93.837", "Description": "TRPC4-DEPENDENT CYTOSOLIC CALCIUM SIGNALS COORDINATE INTERENDOTHELIAL FORCES THAT ELICIT GAP FORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_F32HL144040_7529"}, {"internal_id": 67313415, "Award ID": "F32HL143949", "Award Amount": 102918.37, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-10", "CFDA Number": "93.837", "Description": "MODELING VON WILLEBRAND FACTOR BEHAVIOR IN THE PULMONARY CIRCULATION IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F32HL143949_7529"}, {"internal_id": 67832364, "Award ID": "F32HL143938", "Award Amount": 127231.63, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-15", "CFDA Number": "93.837", "Description": "PRECISION MESSAGE APPROACHES TO COMBATING LATE STAGE COPD DIAGNOSIS AMONG RURAL ADULTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_F32HL143938_7529"}, {"internal_id": 79433999, "Award ID": "F32HL143931", "Award Amount": 117750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-04", "CFDA Number": "93.837", "Description": "INTERFERON-MEDIATED IN VITRO AND IN VIVO REGULATION OF AIRWAY PROGENITOR CELLS IN REGENERATION OF FUNCTIONAL ALVEOLI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL143931_7529"}, {"internal_id": 67315030, "Award ID": "F32HL143920", "Award Amount": 71077.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-16", "CFDA Number": "93.838", "Description": "CLINICAL PRACTICE PATTERNS AND HEALTHCARE RESOURCE UTILIZATION IN ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS: USING REAL WORLD DATA TO BRIDGE THE EVIDENCE GAP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL143920_7529"}, {"internal_id": 67313677, "Award ID": "F32HL143909", "Award Amount": 133348.61, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-10", "CFDA Number": "93.837", "Description": "COST EFFECTIVENESS ANALYSIS OF AN LPG STOVE AND FUEL DISTRIBUTION INTERVENTION.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL143909_7529"}, {"internal_id": 67834154, "Award ID": "F32HL143867", "Award Amount": 141771.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-08", "CFDA Number": "93.837", "Description": "CLINICAL SIGNIFICANCE OF THE ANTIMICROBIAL PEPTIDE CATHELICIDIN IN ACUTE EXACERBATIONS OF COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_F32HL143867_7529"}, {"internal_id": 67833399, "Award ID": "F32HL143864", "Award Amount": 137577.94, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-15", "CFDA Number": "93.837", "Description": "MEDICATION PLAN CONCORDANCE BETWEEN PATIENTS AND PROVIDERS IN COPD PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL143864_7529"}, {"internal_id": 85589717, "Award ID": "F32HL143835", "Award Amount": 54138.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-12", "CFDA Number": "93.838", "Description": "URIC ACID AND ITS GENETIC REGULATORS AS BIOMARKERS OF PULMONARY ARTERIAL HYPERTENSION IN SCLERODERMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL143835_7529"}, {"internal_id": 68167585, "Award ID": "F32HL143833", "Award Amount": 135034.44, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-20", "CFDA Number": "93.837", "Description": "SEX DIFFERENCES IN PULMONARY EXACERBATIONS IN CYSTIC FIBROSIS PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL143833_7529"}, {"internal_id": 79639237, "Award ID": "F32HL143819", "Award Amount": 248423.06, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-11", "CFDA Number": "93.837", "Description": "CARDIOPULMONARY MANIFESTATIONS AND TRANSLATIONAL POTENTIAL OF A NOVEL RADIOGRAPHIC BIOMARKER OF PULMONARY VASCULAR MORPHOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_F32HL143819_7529"}, {"internal_id": 65894508, "Award ID": "F32HL142237", "Award Amount": 65158.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-03", "CFDA Number": "93.837", "Description": "ELUCIDATING RESIDENTIAL MESENCHYMAL STROMAL CELLS IN AN ADULT LUNG AND THEIR ROLE IN BRONCHIOLITIS OBLITERANS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F32HL142237_7529"}, {"internal_id": 66199698, "Award ID": "F32HL142226", "Award Amount": 113479.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-08", "CFDA Number": "93.837", "Description": "DEFINING THE STROMAL CONTRIBUTION TO THE AGING NICHE IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL142226_7529"}, {"internal_id": 65281455, "Award ID": "F32HL142211", "Award Amount": 99054.24, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-29", "CFDA Number": "93.837", "Description": "GOAL-DISCORDANT CARE IN ACUTE RESPIRATORY FAILURE: RISK FACTORS AND MECHANISMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F32HL142211_7529"}, {"internal_id": 65894687, "Award ID": "F32HL142207", "Award Amount": 57584.06, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-02", "CFDA Number": "93.837", "Description": "MECHANISMS OF TELOMERASE RNA INSUFFICIENCY IN FAMILIAL PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL142207_7529"}, {"internal_id": 65281097, "Award ID": "F32HL142172", "Award Amount": 101342.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-28", "CFDA Number": "93.837", "Description": "MECHANISMS OF PLATELET PROTECTION IN PATHOGEN-TRIGGERED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F32HL142172_7529"}, {"internal_id": 65578863, "Award ID": "F32HL142125", "Award Amount": 36646.96, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-05", "CFDA Number": "93.837", "Description": "COMPLEXITY OF COPD CARE AND ADHERENCE (COCOA)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F32HL142125_7529"}, {"internal_id": 48621587, "Award ID": "F32HL141056", "Award Amount": 135042.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-18", "CFDA Number": "93.837", "Description": "PULMONARY BIOENGINEERING: NEW METHODS FOR RECELLULARIZING AND ASSESSING LUNG SCAFFOLDS USING A NOVEL CELL SPRAYER DEVICE AND MRI AIRFLOW MAPPING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_F32HL141056_7529"}, {"internal_id": 48621586, "Award ID": "F32HL140969", "Award Amount": 132284.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-09", "CFDA Number": "93.837", "Description": "CHARACTERIZATION OF THE ROLE OF MESENCHYMAL HOX5 GENES IN ALVEOLOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_F32HL140969_7529"}, {"internal_id": 48621583, "Award ID": "F32HL140868", "Award Amount": 162133.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-15", "CFDA Number": "93.837", "Description": "ROLE OF ILC2S IN LUNG MAINTENANCE AND REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL140868_7529"}, {"internal_id": 62551230, "Award ID": "F32HL140859", "Award Amount": 51542.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-28", "CFDA Number": "93.838", "Description": "GLYCOGEN SYNTHASE KINASE (GSK)-3B INHIBITION MEDIATES LYMPHANGIOGENESIS TO AMELIORATE EXPERIMENTAL FIBROSIS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_F32HL140859_7529"}, {"internal_id": 48621579, "Award ID": "F32HL140821", "Award Amount": 183315.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-09", "CFDA Number": "93.837", "Description": "SYNTHETIC HYDROGEL FOR SATELLITE CELL DELIVERY TO THE DYSTROPHIC DIAPHRAGM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7c481d7-071a-ead9-3bda-e4e7d1e903a7-C", "generated_internal_id": "ASST_NON_F32HL140821_7529"}, {"internal_id": 62420417, "Award ID": "F32HL140729", "Award Amount": 192539.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-05", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISMS FOR E-CIGARETTE VAPOR-INDUCED MUCOCILIARY DYSFUNCTION: ROLE OF NICOTINIC ACETYLCHOLINE AND TRP RECEPTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1a1108fb-0099-a708-6def-aa6d101c8ba8-C", "generated_internal_id": "ASST_NON_F32HL140729_7529"}, {"internal_id": 61613155, "Award ID": "F32HL140685", "Award Amount": 55432.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-19", "CFDA Number": "93.838", "Description": "PREDICTORS, CONSEQUENCES, AND MOTIVATIONS OF BENZODIAZEPINE USE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F32HL140685_7529"}, {"internal_id": 66199211, "Award ID": "F32HL139035", "Award Amount": 34785.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-18", "CFDA Number": "93.838", "Description": "PKA-DEPENDENT REGULATION OF AIRWAY EPITHELIAL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_F32HL139035_7529"}, {"internal_id": 48621568, "Award ID": "F32HL139019", "Award Amount": 128187.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "NEDD9 PROMOTES THROMBOSIS AND VASCULAR REMODELING IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_F32HL139019_7529"}, {"internal_id": 48621566, "Award ID": "F32HL138993", "Award Amount": 125662.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-26", "CFDA Number": "93.838", "Description": "A SIZE ADJUSTABLE PULMONARY VALVE IMPLANT FOR PEDIATRIC APPLICATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_F32HL138993_7529"}, {"internal_id": 48621563, "Award ID": "F32HL138746", "Award Amount": 67884.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-28", "CFDA Number": "93.837", "Description": "INFLUENCE OF ACUTE RESPIRATORY DISTRESS SYNDROME ON HUMAN ALVEOLAR MACROPHAGE POLARITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F32HL138746_7529"}, {"internal_id": 48621561, "Award ID": "F32HL138734", "Award Amount": 101445.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-11", "CFDA Number": "93.837", "Description": "ELECTRONIC CIGARETTES IN YOUTH WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "35c9af52-79d6-b585-258b-ae9342223de1-C", "generated_internal_id": "ASST_NON_F32HL138734_7529"}, {"internal_id": 48621551, "Award ID": "F32HL137273", "Award Amount": 172498.66, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-18", "CFDA Number": "93.837", "Description": "BIOMECHANICS OF MESENCHYMAL REMODELING DURING LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c1ec395-7a2e-ac81-70e3-371cfa83f023-C", "generated_internal_id": "ASST_NON_F32HL137273_7529"}, {"internal_id": 48621550, "Award ID": "F32HL137258", "Award Amount": 108876.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-10", "CFDA Number": "93.837", "Description": "DEGRADATION OF THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (RAGE) - A NOVEL MECHANISM IN LUNG EPITHELIAL CELL INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F32HL137258_7529"}, {"internal_id": 48621547, "Award ID": "F32HL137248", "Award Amount": 115881.17, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-10", "CFDA Number": "93.837", "Description": "REGULATION OF GSK3B DEGRADATION AND ITS ROLE IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F32HL137248_7529"}, {"internal_id": 65579394, "Award ID": "F32HL136225", "Award Amount": 22216.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-12", "CFDA Number": "93.837", "Description": "APOPTOSIS OF RECRUITED MACROPHAGES DURING RESOLUTION OF INNATE LUNG INFLAMMATION REQUIRES SIGLEC-F", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F32HL136225_7529"}, {"internal_id": 48621543, "Award ID": "F32HL136197", "Award Amount": 161724.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-26", "CFDA Number": "93.838", "Description": "ELUCIDATION OF MOLECULAR MECHANISMS AND FUNCTIONAL SIGNIFICANCE OF COOPERATION BETWEEN GLUCOCORTICOID RECEPTOR AND NF-KB IN THE AIRWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd309640-1653-5700-35d0-e048570cf82a-C", "generated_internal_id": "ASST_NON_F32HL136197_7529"}, {"internal_id": 48621530, "Award ID": "F32HL136111", "Award Amount": 119130.33, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-24", "CFDA Number": "93.837", "Description": "A SYSTEMS BIOLOGY APPROACH TO MAPPING AGING IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_F32HL136111_7529"}, {"internal_id": 48621525, "Award ID": "F32HL136062", "Award Amount": 103640.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-09", "CFDA Number": "93.837", "Description": "CELL-BASED CONTROL OF COLLAGEN UPTAKE IN HEALTH AND IN FIBROTIC DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL136062_7529"}, {"internal_id": 48621514, "Award ID": "F32HL134251", "Award Amount": 95841.68, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "IMMUNOMODULATORY IMPLICATIONS OF LYMPHANGIOGENESIS IN ALLERGIC AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_F32HL134251_7529"}, {"internal_id": 48621513, "Award ID": "F32HL134249", "Award Amount": 107377.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-10", "CFDA Number": "93.837", "Description": "EVALUATING MODIFIABLE RISK FACTORS TO ENHANCE THE HEALTH AND SAFETY OF EMS PERSONNEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_F32HL134249_7529"}, {"internal_id": 48621511, "Award ID": "F32HL134243", "Award Amount": 71686.2, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-28", "CFDA Number": "93.837", "Description": "ROLE OF MUC5B IN HONEYCOMB CYST FORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F32HL134243_7529"}, {"internal_id": 48621506, "Award ID": "F32HL134222", "Award Amount": 100057.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-30", "CFDA Number": "93.837", "Description": "THE ROLE OF SIRT3 INDUCERS IN PREVENTING ALVEOLAR EPITHELIAL CELL DEATH AND LUNG FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_F32HL134222_7529"}, {"internal_id": 48621504, "Award ID": "F32HL134217", "Award Amount": 89183.88, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-21", "CFDA Number": "93.837", "Description": "SECRETED PHOSPHOLIPASE A2 GROUP X REGULATION OF TYPE-2 INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F32HL134217_7529"}, {"internal_id": 48621503, "Award ID": "F32HL134207", "Award Amount": 139108.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "THE ROLE OF DBX1-DERIVED MEDULLARY NEURONS FOR RHYTHM GENERATION IN THE INTACT RESPIRATORY NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_F32HL134207_7529"}, {"internal_id": 48621501, "Award ID": "F32HL133772", "Award Amount": 172534.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-15", "CFDA Number": "93.233", "Description": "HYPOCRETINERGIC INTEGRATION OF CIRCADIAN RHYTHMS AND SLEEP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_F32HL133772_7529"}, {"internal_id": 48621500, "Award ID": "F32HL132790", "Award Amount": 103007.72, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-09", "CFDA Number": "93.837", "Description": "THE IMPACT OF SEDATIVE CHOICE AND MANAGEMENT ON THE RISK OF HEALTHCARE-ASSOCIATED INFECTIONS AND COMPLICATIONS OF CRITICAL ILLNESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_F32HL132790_7529"}, {"internal_id": 48621499, "Award ID": "F32HL132586", "Award Amount": 86954.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-22", "CFDA Number": "93.838", "Description": "CONTROL OF THE DIAPHRAGM BY MOTOR CORTICAL AREAS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F32HL132586_7529"}, {"internal_id": 48621498, "Award ID": "F32HL132543", "Award Amount": 124237.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-06", "CFDA Number": "93.837", "Description": "ADAPTIVE REMODELING OF THE RIGHT VENTRICLE IN RESPONSE TO PULMONARY HYPERTENSION: TOWARDS PHYSICAL UNDERSTANDING AND PREDICTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "395e4a2c-bac8-c9f0-4271-75643a4de192-C", "generated_internal_id": "ASST_NON_F32HL132543_7529"}, {"internal_id": 48621496, "Award ID": "F32HL132532", "Award Amount": 173534.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-13", "CFDA Number": "93.838", "Description": "MYOFIBROBLASTS IN PULMONARY FIBROSIS: ORIGIN, CLONES AND KLF4", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_F32HL132532_7529"}, {"internal_id": 48621494, "Award ID": "F32HL132483", "Award Amount": 70495.0, "Award Type": null, "Base Obligation Date": "2016-04-15", "CFDA Number": "93.838", "Description": "HIPPO SIGNALING IN LUNG DEVELOPMENT AND INJURY REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_F32HL132483_7529"}, {"internal_id": 48621487, "Award ID": "F32HL132452", "Award Amount": 172534.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-20", "CFDA Number": "93.838", "Description": "METABOLOMIC PROFILING OF EXPLANTED PULMONARY ARTERIAL HYPERTENSION LUNGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_F32HL132452_7529"}, {"internal_id": 48621468, "Award ID": "F32HL131228", "Award Amount": 121309.48, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-04", "CFDA Number": "93.837", "Description": "PULMONARY VASCULAR CELLULAR RESPONSE TO PATHOLOGIC MATRIX STIFFNESS IN PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_F32HL131228_7529"}, {"internal_id": 48621467, "Award ID": "F32HL131218", "Award Amount": 127101.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-09", "CFDA Number": "93.838", "Description": "GENETIC DETERMINANTS OF VARIATION IN THE HYPOXIC VENTILATORY RESPONSE IN LOW- AND HIGH-ALTITUDE POPULATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_F32HL131218_7529"}, {"internal_id": 48621464, "Award ID": "F32HL131151", "Award Amount": 83222.06, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.837", "Description": "IMPROVING DRUG DELIVERY IN INDIVIDUALS WITH CYSTIC FIBROSIS USING EXERCISE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_F32HL131151_7529"}, {"internal_id": 48621459, "Award ID": "F32HL129815", "Award Amount": 132902.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-17", "CFDA Number": "93.837", "Description": "TREATMENT OF PERSISTENT MRSA INFECTION IN CYSTIC FIBROSIS PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL129815_7529"}, {"internal_id": 48621450, "Award ID": "F32HL129687", "Award Amount": 132099.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-11", "CFDA Number": "93.837", "Description": "DETECTION OF EARLY PULMONARY VASCULAR DISEASE IN SCLERODERMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL129687_7529"}, {"internal_id": 48621444, "Award ID": "F32HL129665", "Award Amount": 107763.04, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-05", "CFDA Number": "93.837", "Description": "TARGETED DRUG DELIVERY FOR ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F32HL129665_7529"}, {"internal_id": 48621434, "Award ID": "F32HL128165", "Award Amount": 130799.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-01", "CFDA Number": "93.838", "Description": "THE ORAL MICROBIOME AND ENTEROSALIVARY CIRCULATION OF NITRIC OXIDE IN HIV.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F32HL128165_7529"}, {"internal_id": 48621419, "Award ID": "F32HL127972", "Award Amount": 111955.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-01", "CFDA Number": "93.837", "Description": "THE ROLE OF LYSOPHOSPHATIDIC ACID SIGNALING IN LUNG ISCHEMIA/REPERFUSION INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F32HL127972_7529"}, {"internal_id": 48621414, "Award ID": "F32HL126522", "Award Amount": 111504.75, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-24", "CFDA Number": "93.837", "Description": "GENETIC MAPPING OF NEURAL CIRCUITS THAT CONTROL BREATHING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_F32HL126522_7529"}, {"internal_id": 48621409, "Award ID": "F32HL126376", "Award Amount": 45735.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-13", "CFDA Number": "93.838", "Description": "ROLE OF GROUP 1 CD1-RESTRICTED T CELLS IN MYCOBACTERIUM TUBERCULOSIS INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_F32HL126376_7529"}, {"internal_id": 48621405, "Award ID": "F32HL126345", "Award Amount": 106151.3, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-02-01", "CFDA Number": "93.837", "Description": "CIGARETTE SMOKE AND THE ACUTE RESPIRATORY DISTRESS SYNDROME: THE ROLE OF ALVEOLAR EPITHELIAL INJURY AND INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL126345_7529"}, {"internal_id": 48621404, "Award ID": "F32HL126333", "Award Amount": 99780.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-01", "CFDA Number": "93.838", "Description": "EXTRACELLULAR RNA AMPLIFIES LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F32HL126333_7529"}, {"internal_id": 48621378, "Award ID": "F32HL124895", "Award Amount": 138913.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-01", "CFDA Number": "93.837", "Description": "INTEGRATING CLINICAL AND MOLECULAR MARKERS FOR RISK PREDICTION IN IDIOPATHIC PULM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL124895_7529"}, {"internal_id": 48621359, "Award ID": "F32HL123267", "Award Amount": 104166.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-07", "CFDA Number": "93.837", "Description": "THE ROLE OF ALPHA-V INTEGRINS ON ACTIVATED FIBROBLASTS IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL123267_7529"}, {"internal_id": 48621327, "Award ID": "F32HL120608", "Award Amount": 161410.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-09-19", "CFDA Number": "93.838", "Description": "DIFFERENTIATION OF HUMAN ENDODERMAL STEM CELLS INTO LUNG LINEAGE CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_F32HL120608_7529"}, {"internal_id": 48621234, "Award ID": "F32HL112498", "Award Amount": 62030.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-29", "CFDA Number": "93.838", "Description": "MICRORNAS IN THE AIRWAY EPITHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F32HL112498_7529"}, {"internal_id": 109189917, "Award ID": "F31HL154777", "Award Amount": 114896.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "CHARACTERIZATION OF PULMONARY PROGENITOR CELL DYSFUNCTION IN COPA SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_F31HL154777_7529"}, {"internal_id": 109190066, "Award ID": "F31HL154758", "Award Amount": 61119.61, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-15", "CFDA Number": "93.837", "Description": "EFFECTS OF POD E-CIGARETTES ON RESPIRATORY MUCOSAL IMMUNE DEFENSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_F31HL154758_7529"}, {"internal_id": 109278420, "Award ID": "F31HL154709", "Award Amount": 89403.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-21", "CFDA Number": "93.837", "Description": "EXPLORING THE EFFECTS OF EXTRACELLULAR FLUID VISCOSITY ON CELL MIGRATION AND CANCER METASTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F31HL154709_7529"}, {"internal_id": 108463268, "Award ID": "F31HL154662", "Award Amount": 138308.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-11", "CFDA Number": "93.837", "Description": "NANOSCALE DRUG CARRIERS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS).", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "867850a1-1693-4b2a-3ff5-034554d322e1-C", "generated_internal_id": "ASST_NON_F31HL154662_7529"}, {"internal_id": 109190208, "Award ID": "F31HL154660", "Award Amount": 104294.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-15", "CFDA Number": "93.837", "Description": "METABOTROPIC CONTRIBUTIONS TO PH-SENSITIVITY AND BREATHING MODULATION BY RTN CHEMORECEPTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_F31HL154660_7529"}, {"internal_id": 108463099, "Award ID": "F31HL154486", "Award Amount": 53398.41, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-07", "CFDA Number": "93.837", "Description": "ROLE OF ORMDL3 AND CERAMIDE IN ASTHMA SEVERITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_F31HL154486_7529"}, {"internal_id": 96557694, "Award ID": "F31HL152650", "Award Amount": 95338.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-15", "CFDA Number": "93.837", "Description": "ELUCIDATING PREMATURE TRANSLATION TERMINATION IN CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_F31HL152650_7529"}, {"internal_id": 97468733, "Award ID": "F31HL152611", "Award Amount": 143308.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-15", "CFDA Number": "93.837", "Description": "PPARG AS A KEY REGULATOR OF SEX-BASED DIFFERENCES IN BRONCHOPULMONARY DYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "88f4772d-e0bd-42e6-ed20-c3144d3bace8-C", "generated_internal_id": "ASST_NON_F31HL152611_7529"}, {"internal_id": 96559947, "Award ID": "F31HL152594", "Award Amount": 91556.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-15", "CFDA Number": "93.837", "Description": "MATERNAL EXPOSURES MODIFY OFFSPRING ALLERGIC AIRWAY DISEASE RISK VIA EPIGENETIC REPROGRAMMING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F31HL152594_7529"}, {"internal_id": 97853079, "Award ID": "F31HL152531", "Award Amount": 110195.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-29", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE OF MESENCHYMAL R-SPONDIN2 DURING HUMAN LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F31HL152531_7529"}, {"internal_id": 96557637, "Award ID": "F31HL152509", "Award Amount": 88063.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-10", "CFDA Number": "93.837", "Description": "DISSECTING THE ROLE OF DDR2 IN THE MODULATION OF ANTIBACTERIAL HOST DEFENSE POST FIBROTIC LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F31HL152509_7529"}, {"internal_id": 100874166, "Award ID": "F31HL152500", "Award Amount": 119123.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-10", "CFDA Number": "93.837", "Description": "ADVANCING LENTIVIRAL GENE THERAPY FOR CYSTIC FIBROSIS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_F31HL152500_7529"}, {"internal_id": 95942963, "Award ID": "F31HL151170", "Award Amount": 85763.46, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-15", "CFDA Number": "93.837", "Description": "THE ROLE OF AIRWAY EPITHELIAL CRAC CHANNELS IN ALLERGIC LUNG INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_F31HL151170_7529"}, {"internal_id": 95942961, "Award ID": "F31HL151111", "Award Amount": 52583.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-15", "CFDA Number": "93.837", "Description": "BRONCHIOLAR DYSPLASIA IN COPD IS GOVERNED BY LOSS OF POLYCOMB REPRESSIVE COMPLEX 2", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_F31HL151111_7529"}, {"internal_id": 109189985, "Award ID": "F31HL151033", "Award Amount": 60794.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-15", "CFDA Number": "93.837", "Description": "INVESTIGATING THE DYNAMICS AND MECHANICS OF CLASP-MEDIATED MICROTUBULE-ACTIN INTERACTIONS BY COMBINING IN VITRO RECONSTITUTION WITH STUDIES IN PRIMARY LUNG FIBROBLASTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4a536007-27e4-2194-a125-f4b8c55294db-C", "generated_internal_id": "ASST_NON_F31HL151033_7529"}, {"internal_id": 95484900, "Award ID": "F31HL151028", "Award Amount": 106374.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-25", "CFDA Number": "93.837", "Description": "NOVEL APPROACHES FOR IDENTIFICATION OF IDIOPATHIC PULMONARY FIBROSIS THERAPY TARGETS USING MICROSCALE COLLAGEN HYDROGELS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_F31HL151028_7529"}, {"internal_id": 83797755, "Award ID": "F31HL149381", "Award Amount": 169651.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-23", "CFDA Number": "93.837", "Description": "DEFINING MOLECULAR SIGNALS THAT INFLUENCE AIRWAY BASAL CELL RENEWAL AND GROWTH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F31HL149381_7529"}, {"internal_id": 83103406, "Award ID": "F31HL149338", "Award Amount": 116936.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-16", "CFDA Number": "93.837", "Description": "ACCOUNTING FOR SURVIVOR BIAS IN LUNG ALLOCATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F31HL149338_7529"}, {"internal_id": 83796343, "Award ID": "F31HL149323", "Award Amount": 126788.74, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-20", "CFDA Number": "93.837", "Description": "CAUSES OF LUNG BARRIER DYSFUNCTION IN A TRANSLATIONAL MODEL OF CHRONIC ALCOHOL INGESTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F31HL149323_7529"}, {"internal_id": 96556891, "Award ID": "F31HL149295", "Award Amount": 108514.66, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-10", "CFDA Number": "93.837", "Description": "ELUCIDATING VIRUS:HOST INTERACTIONS OF HUMAN PARAINFLUENZA VIRUS 3 IN A NOVEL HUMAN LUNG TISSUE EXPLANT MODEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_F31HL149295_7529"}, {"internal_id": 109278239, "Award ID": "F31HL149277", "Award Amount": 69295.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-21", "CFDA Number": "93.837", "Description": "INTEGRATION OF VENTILATION-PERFUSION MATCHING BY HYPOXIC PULMONARY VASOCONSTRICTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F31HL149277_7529"}, {"internal_id": 83103870, "Award ID": "F31HL149268", "Award Amount": 117135.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-16", "CFDA Number": "93.837", "Description": "SPATIOTEMPORAL EVOLUTION OF LUNG INJURY DURING VENTILATOR-INDUCED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F31HL149268_7529"}, {"internal_id": 83115546, "Award ID": "F31HL149232", "Award Amount": 64371.56, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-12", "CFDA Number": "93.837", "Description": "THE SIGNALING ROLE OF ALVEOLAR TYPE 1 CELL-DERIVED WNT LIGANDS DURING ALVEOLOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_F31HL149232_7529"}, {"internal_id": 85590894, "Award ID": "F31HL149156", "Award Amount": 75208.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-10", "CFDA Number": "93.837", "Description": "UNRAVELING NEUROGLIAL INTERACTIONS UNDERLYING THE CENTRAL HYPOXIC RESPONSE AND SIGH GENERATION IN THE PREB?TZINGER COMPLEX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_F31HL149156_7529"}, {"internal_id": 83103738, "Award ID": "F31HL149150", "Award Amount": 103963.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-12", "CFDA Number": "93.837", "Description": "DETERMINING THE ROLE OF MYELOID-DERIVED HB-EGF IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F31HL149150_7529"}, {"internal_id": 80736637, "Award ID": "F31HL147512", "Award Amount": 37600.2, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-07", "CFDA Number": "93.837", "Description": "CYTOTOXIC LUNG ENDOTHELIAL AMYLOIDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06e99475-088f-52e6-67ba-36b42571498a-C", "generated_internal_id": "ASST_NON_F31HL147512_7529"}, {"internal_id": 80736097, "Award ID": "F31HL147500", "Award Amount": 74433.21, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-01", "CFDA Number": "93.837", "Description": "A NOVEL CLASS OF ENZYME SENSORS TO ELUCIDATE THE BIOCHEMICAL RESPONSES OF HUMAN NASAL EPITHELIAL CELLS TO HEAVY METALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_F31HL147500_7529"}, {"internal_id": 80735675, "Award ID": "F31HL147495", "Award Amount": 66480.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-06", "CFDA Number": "93.837", "Description": "BASAL BODY POST-TRANSLATIONAL MODIFICATIONS PROMOTE RESISTANCE TO CILIARY FORCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F31HL147495_7529"}, {"internal_id": 95942934, "Award ID": "F31HL147491", "Award Amount": 57164.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-04", "CFDA Number": "93.837", "Description": "MIXED METHODS APPROACH TO EVALUATING BARRIERS TO NUTRITIONAL ADHERENCE IN ADOLESCENTS WITH CYSTIC FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WV", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "38457ff7-68b1-7220-5dec-347ecba3483d-C", "generated_internal_id": "ASST_NON_F31HL147491_7529"}, {"internal_id": 80735672, "Award ID": "F31HL147431", "Award Amount": 17848.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-06", "CFDA Number": "93.837", "Description": "SYNTHETIC MUCINS FOR STRUCTURAL AND COMPOSITIONAL STUDIES OF MUCUS GELS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_F31HL147431_7529"}, {"internal_id": 78598731, "Award ID": "F31HL147428", "Award Amount": 123233.84, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-28", "CFDA Number": "93.837", "Description": "THE HYPOXIA INDUCIBLE FACTOR: GALECTIN 3 SIGNALING AXIS IN PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_F31HL147428_7529"}, {"internal_id": 79433887, "Award ID": "F31HL147397", "Award Amount": 92010.06, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-23", "CFDA Number": "93.837", "Description": "PNEUMONIA AND ALVEOLAR MACROPHAGE RESILIENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F31HL147397_7529"}, {"internal_id": 78990294, "Award ID": "F31HL147392", "Award Amount": 61539.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-19", "CFDA Number": "93.837", "Description": "THE ROLE OF ATYPICAL CELL WALL BIOLOGY OF MYCOBACTERIUM ABSCESSUS IN PULMONARY INFECTION AND THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F31HL147392_7529"}, {"internal_id": 77189672, "Award ID": "F31HL146178", "Award Amount": 63428.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-01", "CFDA Number": "93.837", "Description": "OPTIMIZATION OF NEXT GENERATION PULMONARY DRY POWDER DELIVERY SYSTEMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "395e4a2c-bac8-c9f0-4271-75643a4de192-C", "generated_internal_id": "ASST_NON_F31HL146178_7529"}, {"internal_id": 77190925, "Award ID": "F31HL146163", "Award Amount": 89351.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-01", "CFDA Number": "93.837", "Description": "YAP/TAZ-NRG1 CROSSTALK IN AIRWAY EPITHELIAL CELL FATE CONTROL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F31HL146163_7529"}, {"internal_id": 76908567, "Award ID": "F31HL146083", "Award Amount": 71127.51, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-10", "CFDA Number": "93.837", "Description": "MUCUS MATTERS: MUCOCILIARY PHYSIOLOGY IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_F31HL146083_7529"}, {"internal_id": 77189780, "Award ID": "F31HL146010", "Award Amount": 89523.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-01", "CFDA Number": "93.837", "Description": "REGULATORY ROLE OF CHROMOSOME 11P13 IN CYSTIC FIBROSIS LUNG DISEASE SEVERITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_F31HL146010_7529"}, {"internal_id": 78990889, "Award ID": "F31HL145991", "Award Amount": 44331.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-14", "CFDA Number": "93.837", "Description": "THE INTERPLAY BETWEEN MESENCHYMAL STEM CELL SECRETOME AND FIBROBLAST DIFFERENTIATION IN THE CONFINED MICROENVIRONMENT OF IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e04c3b49-28c8-efb6-f8ea-b4c853900d6f-C", "generated_internal_id": "ASST_NON_F31HL145991_7529"}, {"internal_id": 78599785, "Award ID": "F31HL145910", "Award Amount": 111051.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-11", "CFDA Number": "93.837", "Description": "CHARACTERIZATION OF ADENINE NUCLEOTIDE TRANSLOCASE (ANT) AND ACTIN-INTERACTING PROTEIN 1 (AIP1) AS PROTECTORS AGAINST CIGARETTE SMOKE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F31HL145910_7529"}, {"internal_id": 83796305, "Award ID": "F31HL144051", "Award Amount": 43117.47, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-22", "CFDA Number": "93.837", "Description": "THE ROLE OF PEROXIREDOXIN 4 IN IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_F31HL144051_7529"}, {"internal_id": 67579351, "Award ID": "F31HL144028", "Award Amount": 80658.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-30", "CFDA Number": "93.837", "Description": "A REAL-TIME COMPUTATIONAL SYSTEM FOR DETECTING ARDS USING VENTILATOR WAVEFORM DATA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_F31HL144028_7529"}, {"internal_id": 67314971, "Award ID": "F31HL143891", "Award Amount": 100921.32, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-10", "CFDA Number": "93.837", "Description": "ELUCIDATING THE ROLE OF MITOCHONDRIAL AND X CHROMOSOME VARIATION ON THE GENETIC ARCHITECTURE OF COMPLEX TRAITS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_F31HL143891_7529"}, {"internal_id": 67314580, "Award ID": "F31HL143873", "Award Amount": 136727.03, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-13", "CFDA Number": "93.837", "Description": "NUCLEAR HEPARAN SULFATE MEDIATES FIBROBLAST ACTIVATION IN INDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F31HL143873_7529"}, {"internal_id": 67833700, "Award ID": "F31HL143863", "Award Amount": 133408.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-13", "CFDA Number": "93.837", "Description": "DETERMINING THE PHYSIOLOGICAL MECHANISM OF CFTR INHIBITION BY SPHINGOMYELINASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F31HL143863_7529"}, {"internal_id": 67314154, "Award ID": "F31HL143853", "Award Amount": 100201.09, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-10", "CFDA Number": "93.837", "Description": "GENETIC AND LONGITUDINAL ANALYSIS OF AIRWAY REMODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_F31HL143853_7529"}, {"internal_id": 66995169, "Award ID": "F31HL143843", "Award Amount": 52327.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-30", "CFDA Number": "93.837", "Description": "PRO-INFLAMMATORY UBIQUITINATION OF SOCS2 BY KIAA0317 AND ITS ROLE IN LUNG INFLAMMATION AND INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F31HL143843_7529"}, {"internal_id": 66199596, "Award ID": "F31HL142313", "Award Amount": 94669.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-04", "CFDA Number": "93.837", "Description": "3D BIOPRINTING FOR TRACHEAL RECONSTRUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_F31HL142313_7529"}, {"internal_id": 65579109, "Award ID": "F31HL142227", "Award Amount": 119133.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-09", "CFDA Number": "93.837", "Description": "ROLE OF P2Y2 IN THE REGULATION OF VASCULAR TONE AND CONTROL OF BREATHING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7d4a874-2ab3-85f8-4c06-002c8728886d-C", "generated_internal_id": "ASST_NON_F31HL142227_7529"}, {"internal_id": 66801012, "Award ID": "F31HL142221", "Award Amount": 54453.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-13", "CFDA Number": "93.837", "Description": "REDOX REGULATION OF SRC KINASE IN ALLERGIC AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_F31HL142221_7529"}, {"internal_id": 65578852, "Award ID": "F31HL142199", "Award Amount": 110190.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-09", "CFDA Number": "93.837", "Description": "LUNG MEMORY B CELL CONTRIBUTIONS TO HETEROTYPIC ANTI-PNEUMOCOCCAL IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F31HL142199_7529"}, {"internal_id": 66487237, "Award ID": "F31HL142197", "Award Amount": 55059.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-25", "CFDA Number": "93.837", "Description": "MECHANISMS OF BASAL CELL DIFFERENTIATION DURING MURINE AND HUMAN LUNG DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F31HL142197_7529"}, {"internal_id": 66486907, "Award ID": "F31HL142189", "Award Amount": 84800.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-30", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF TH17 METABOLIC PATHWAYS THAT CONTRIBUTE TO GLUCOCORTICOID RESISTANCE IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4a536007-27e4-2194-a125-f4b8c55294db-C", "generated_internal_id": "ASST_NON_F31HL142189_7529"}, {"internal_id": 65280282, "Award ID": "F31HL142171", "Award Amount": 59212.35, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-26", "CFDA Number": "93.837", "Description": "EVALUATING THE THERAPEUTIC POTENTIAL OF ELECTROPHILIC FATTY ACID DERIVATIVES FOR INFLUENZA-INDUCED LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F31HL142171_7529"}, {"internal_id": 65579257, "Award ID": "F31HL142170", "Award Amount": 117548.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-11", "CFDA Number": "93.837", "Description": "DETERMINING THE ROLE OF SPAG1 IN THE CYTOPLASMIC ASSEMBLY OF AXONEMAL DYNEIN ARMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_F31HL142170_7529"}, {"internal_id": 66486982, "Award ID": "F31HL142153", "Award Amount": 45857.48, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-30", "CFDA Number": "93.837", "Description": "ENHANCING ELECTRONIC HEALTH RECORD-DERIVED DATA WITH GEOSPATIAL INFORMATION FOR THE STUDY OF ASTHMA EXACERBATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F31HL142153_7529"}, {"internal_id": 67833144, "Award ID": "F31HL142132", "Award Amount": 173212.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-06", "CFDA Number": "93.837", "Description": "EPIGENETIC PROFILING OF SINGLE CELLS BY IN SITU LABELING FOR STUDYING HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F31HL142132_7529"}, {"internal_id": 66800273, "Award ID": "F31HL142124", "Award Amount": 89435.2, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-15", "CFDA Number": "93.837", "Description": "USING A SPATIO-TEMPORAL FRAMEWORK TO UNDERSTAND DISPARITIES IN PEDIATRIC ASTHMA EMERGENCY DEPARTMENT VISITS: A CASE STUDY IN SOUTH CAROLINA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "SC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "04a78f04-ee86-46df-5fbf-c71e46ed8479-C", "generated_internal_id": "ASST_NON_F31HL142124_7529"}, {"internal_id": 48613830, "Award ID": "F31HL140812", "Award Amount": 89399.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-03", "CFDA Number": "93.837", "Description": "DISSECTING THE ROLE OF HOST ENZYME PARP1 IN TUBERCULOSIS INFECTION AND THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F31HL140812_7529"}, {"internal_id": 61613472, "Award ID": "F31HL140795", "Award Amount": 103761.53, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-31", "CFDA Number": "93.837", "Description": "NEW ROLE FOR (AIRWAY) EPITHELIAL PKD IN ANTI-VIRAL IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_F31HL140795_7529"}, {"internal_id": 48613827, "Award ID": "F31HL140785", "Award Amount": 83285.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-15", "CFDA Number": "93.837", "Description": "TEMPORAL AND TRANSCRIPTIONAL CONTROL OF ALVEOLAR EPITHELIAL TYPE 1 CELL FATE AND PLASTICITY DURING DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F31HL140785_7529"}, {"internal_id": 68168148, "Award ID": "F31HL140781", "Award Amount": 107498.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-23", "CFDA Number": "93.837", "Description": "MESOTHELIAL MECHANOTRANSDUCTION AS A KEY REGULATOR OF EMBRYONIC LUNG GROWTH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "88f4772d-e0bd-42e6-ed20-c3144d3bace8-C", "generated_internal_id": "ASST_NON_F31HL140781_7529"}, {"internal_id": 48613823, "Award ID": "F31HL139134", "Award Amount": 141333.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-22", "CFDA Number": "93.837", "Description": "ELUCIDATION OF DNA ENZYME NANOPARTICLES IN REGULATING GENE EXPRESSION IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F31HL139134_7529"}, {"internal_id": 65578838, "Award ID": "F31HL139116", "Award Amount": 57999.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-05", "CFDA Number": "93.837", "Description": "MACROPHAGE REGULATION OF TISSUE REPAIR AND FIBROSIS THROUGH SENSING OF EXTRACELLULAR MATRIX MECHANICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_F31HL139116_7529"}, {"internal_id": 48613820, "Award ID": "F31HL139109", "Award Amount": 130739.03, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-19", "CFDA Number": "93.837", "Description": "IMPACT OF TIGHT JUNCTION REMODELING ON LUNG EPITHELIAL BARRIER FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F31HL139109_7529"}, {"internal_id": 67579381, "Award ID": "F31HL139104", "Award Amount": 89540.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-24", "CFDA Number": "93.838", "Description": "CHARACTERIZATION AND DEVELOPMENT OF GS-BIASED LIGANDS OF BETA2-ADRENERGIC RECEPTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_F31HL139104_7529"}, {"internal_id": 48613818, "Award ID": "F31HL139095", "Award Amount": 93463.05, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-04", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF A KEY TRANSCRIPTIONAL REGULATOR OF AT1 CELL DEVELOPMENT AND MAINTENANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_F31HL139095_7529"}, {"internal_id": 48613813, "Award ID": "F31HL139080", "Award Amount": 116141.13, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-14", "CFDA Number": "93.837", "Description": "INTERPLAY BETWEEN HEME OXYGENASE-1 AND CHITINASE 3-LIKE-1 IN PROTECTION AGAINST NEONATAL HYPEROXIC LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "378fe7f9-e157-cd75-80cc-97cbe1a426db-C", "generated_internal_id": "ASST_NON_F31HL139080_7529"}, {"internal_id": 48613809, "Award ID": "F31HL138832", "Award Amount": 23863.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-25", "CFDA Number": "93.838", "Description": "INTEGRATIVE ANALYSIS OF LUNG DISEASE GENOTYPES AND GENE EXPRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_F31HL138832_7529"}, {"internal_id": 61613034, "Award ID": "F31HL137406", "Award Amount": 72832.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-31", "CFDA Number": "93.838", "Description": "IDENTIFICATION AND CHARACTERIZATION OF OXYGEN-SENSING NEURONS IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_F31HL137406_7529"}, {"internal_id": 48613794, "Award ID": "F31HL137304", "Award Amount": 100647.8, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-30", "CFDA Number": "93.837", "Description": "DETERMINING THE ROLE OF AUTOPHAGY IN REGULATING THE STAPHYLOCOCCUS AUREUS A-TOXIN RECEPTOR ADAM10", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_F31HL137304_7529"}, {"internal_id": 48613793, "Award ID": "F31HL137287", "Award Amount": 105189.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-31", "CFDA Number": "93.838", "Description": "ROLE OF INNATE IMMUNITY IN PNEUMONIC SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07ed9f27-c528-e9d5-e332-90c8b04f48b8-C", "generated_internal_id": "ASST_NON_F31HL137287_7529"}, {"internal_id": 48613783, "Award ID": "F31HL136183", "Award Amount": 44330.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-13", "CFDA Number": "93.837", "Description": "THE EVALUATION OF TLT-1 AS TREATMENT FOR ALI/ARDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4b0f7689-aaf8-396f-d4b3-b944796d133f-C", "generated_internal_id": "ASST_NON_F31HL136183_7529"}, {"internal_id": 48613778, "Award ID": "F31HL136128", "Award Amount": 55323.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-20", "CFDA Number": "93.837", "Description": "DISSECTING THE LINEAGE AND FUNCTION OF THE AIRWAY BRUSH CELL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_F31HL136128_7529"}, {"internal_id": 48613777, "Award ID": "F31HL136126", "Award Amount": 61635.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-25", "CFDA Number": "93.837", "Description": "ORIGIN, MATURATION AND REGENERATION OF PULMONARY LYMPHATIC ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F31HL136126_7529"}, {"internal_id": 48613774, "Award ID": "F31HL136101", "Award Amount": 107002.22, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-26", "CFDA Number": "93.837", "Description": "IDENTIFYING MECHANISMS OF LUNG TISSUE-RESIDENT MEMORY CD8 T CELL DECAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F31HL136101_7529"}, {"internal_id": 48613763, "Award ID": "F31HL134336", "Award Amount": 96345.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.838", "Description": "SINGLE-CELL DYNAMICS OF THE OCT4-GATA6 AXIS IN HUMAN LUNG PROGENITORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_F31HL134336_7529"}, {"internal_id": 48613741, "Award ID": "F31HL134225", "Award Amount": 76070.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-12", "CFDA Number": "93.838", "Description": "THE MECHANISM OF TOBACCO-INDUCED DECREMENTS IN MUCOCILIARY CLEARANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_F31HL134225_7529"}, {"internal_id": 48613737, "Award ID": "F31HL134205", "Award Amount": 62979.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-12", "CFDA Number": "93.838", "Description": "MECHANISMS OF LIVER INJURY AND HEPATOPROTECTION DURING PNEUMONIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F31HL134205_7529"}, {"internal_id": 48613734, "Award ID": "F31HL132645", "Award Amount": 97720.12, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-09", "CFDA Number": "93.837", "Description": "DECONSTRUCTING ROLES OF SENSORY NEURON SUBTYPES IN RESPIRATION AND AIRWAY DEFENSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_F31HL132645_7529"}, {"internal_id": 48613730, "Award ID": "F31HL132560", "Award Amount": 86802.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-07", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF PLEIOTROPIC LOCI FOR ASTHMA AND OBESITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_F31HL132560_7529"}, {"internal_id": 48613723, "Award ID": "F31HL132506", "Award Amount": 137665.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-10", "CFDA Number": "93.838", "Description": "ROLES FOR YAP IN MULTICILIOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F31HL132506_7529"}, {"internal_id": 48613722, "Award ID": "F31HL132501", "Award Amount": 67694.97, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-06", "CFDA Number": "93.837", "Description": "THE GENETIC DISSECTION OF SEAMLESS TUBE SHAPE CONTROL IN THE DROSOPHILA TRACHEA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F31HL132501_7529"}, {"internal_id": 48613717, "Award ID": "F31HL132454", "Award Amount": 114171.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-28", "CFDA Number": "93.838", "Description": "LUBAC MEDIATED EPITHELIAL SIGNALING DURING INFLUENZA A INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_F31HL132454_7529"}, {"internal_id": 48613716, "Award ID": "F31HL132453", "Award Amount": 49492.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-06", "CFDA Number": "93.838", "Description": "THE LUNG EPITHELIUM IS A SOURCE OF LACTATE PRODUCTION IN THE PATHOGENESIS OF PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_F31HL132453_7529"}, {"internal_id": 48613713, "Award ID": "F31HL132425", "Award Amount": 82372.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-31", "CFDA Number": "93.837", "Description": "EXTRACELLULAR VESICLE-MEDIATED INFLAMMASOME SIGNALING IN TRAUMATIC BRAIN INJURY-INDUCED ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_F31HL132425_7529"}, {"internal_id": 48613699, "Award ID": "F31HL131334", "Award Amount": 44254.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-25", "CFDA Number": "93.838", "Description": "ROLE OF PKCBETA AND OXIDANT SIGNALING IN NEONATAL PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a5b5888e-f4b5-655c-bd88-d970f969d7c9-C", "generated_internal_id": "ASST_NON_F31HL131334_7529"}, {"internal_id": 48613693, "Award ID": "F31HL131274", "Award Amount": 87286.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-28", "CFDA Number": "93.837", "Description": "PROVISIONAL MATRIX CITRULLINATION AS AN ACTIVATOR OF FIBROBLASTS IN INTERSTITIAL LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7c481d7-071a-ead9-3bda-e4e7d1e903a7-C", "generated_internal_id": "ASST_NON_F31HL131274_7529"}, {"internal_id": 48613682, "Award ID": "F31HL131076", "Award Amount": 48214.0, "Award Type": null, "Base Obligation Date": "2016-08-19", "CFDA Number": "93.838", "Description": "THE IMPACT OF AGING ON THE PULMONARY VASCULATURE DURING EXERCISE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_F31HL131076_7529"}, {"internal_id": 48613680, "Award ID": "F31HL129777", "Award Amount": 48725.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-21", "CFDA Number": "93.838", "Description": "PLURIPOTENT STEM CELL MODELING OF AIRWAY EPITHELIAL DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F31HL129777_7529"}, {"internal_id": 48613669, "Award ID": "F31HL129681", "Award Amount": 76002.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-12", "CFDA Number": "93.838", "Description": "EFFECTS OF CUMULATIVE RISK ON ASTHMA OUTCOMES IN URBAN CHILDREN AND ADOLESCENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_F31HL129681_7529"}, {"internal_id": 48613667, "Award ID": "F31HL129633", "Award Amount": 107694.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-01", "CFDA Number": "93.233", "Description": "MOLECULAR MECHANISMS AND NEURAL CIRCUITRY THAT REGULATE SLEEP HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_F31HL129633_7529"}, {"internal_id": 48613660, "Award ID": "F31HL128159", "Award Amount": 50767.41, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-06", "CFDA Number": "93.837", "Description": "VGAMMA2VDELTA2 T CELL RECOGNITION OF HIV-INFECTED CELLS IN THE LUNG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_F31HL128159_7529"}, {"internal_id": 48613637, "Award ID": "F31HL127947", "Award Amount": 69059.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-12", "CFDA Number": "93.838", "Description": "METHODS TO IMPROVE THE DETECTION OF TREATMENT EFFECTS IN ARDS CLINICAL TRIALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F31HL127947_7529"}, {"internal_id": 48613629, "Award ID": "F31HL126458", "Award Amount": 71040.22, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-10", "CFDA Number": "93.837", "Description": "A NOVEL MICRORNA IN PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_F31HL126458_7529"}, {"internal_id": 48613628, "Award ID": "F31HL126449", "Award Amount": 52213.4, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-28", "CFDA Number": "93.837", "Description": "TARGETING THE GRANULOMA MICROENVIRONMENT TO IMPROVE TUBERCULOSIS TREATMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7da61d56-2a59-5a83-da02-eb66ecab13f0-C", "generated_internal_id": "ASST_NON_F31HL126449_7529"}, {"internal_id": 48613626, "Award ID": "F31HL126443", "Award Amount": 76171.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-17", "CFDA Number": "93.838", "Description": "A FUNCTION OF THE NEUROENDOCRINE SYSTEM IN MUCOUS HYPERPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_F31HL126443_7529"}, {"internal_id": 48613607, "Award ID": "F31HL123289", "Award Amount": 106114.4, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-15", "CFDA Number": "93.837", "Description": "THE GENETICS OF TRANSCRIPTIONAL RESPONSE TO HUMAN RHINOVIRUS AND ASTHMA RISK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_F31HL123289_7529"}, {"internal_id": 109278306, "Award ID": "F30HL154728", "Award Amount": 153308.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-21", "CFDA Number": "93.837", "Description": "3D PRINTED COLLAGEN TRACHEAL SCAFFOLDS WITH BIOMIMETIC MICROSTRUCTURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c8e3c1b2-847b-fd38-8430-6da62d956103-C", "generated_internal_id": "ASST_NON_F30HL154728_7529"}, {"internal_id": 110024194, "Award ID": "F30HL154674", "Award Amount": 114205.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-26", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE OF B CELLS IN PULMONARY FIBROSIS RESULTING FROM STING GAIN-OF-FUNCTION AUTOINFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_F30HL154674_7529"}, {"internal_id": 108463242, "Award ID": "F30HL154552", "Award Amount": 205486.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-07", "CFDA Number": "93.837", "Description": "UNDERSTANDING THE SYMBIOSIS BETWEEN MEGAKARYOCYTES AND THE LUNG MICROENVIRONMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F30HL154552_7529"}, {"internal_id": 107677356, "Award ID": "F30HL154526", "Award Amount": 200972.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-04", "CFDA Number": "93.837", "Description": "THE ROLE OF INSULIN IN OBESITY-RELATED ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_F30HL154526_7529"}, {"internal_id": 96203622, "Award ID": "F30HL151182", "Award Amount": 206002.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-30", "CFDA Number": "93.837", "Description": "IMMUNE DYSREGULATION IN SARCOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_F30HL151182_7529"}, {"internal_id": 107115344, "Award ID": "F30HL151136", "Award Amount": 166858.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-22", "CFDA Number": "93.837", "Description": "MECHANISTIC INVESTIGATIONS OF GRANZYME A-MEDIATED ?9?2 T CELL TB PROTECTIVE EFFECTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b7dfaba3-c263-11dd-cbe2-5abe1968badc-C", "generated_internal_id": "ASST_NON_F30HL151136_7529"}, {"internal_id": 109278270, "Award ID": "F30HL151085", "Award Amount": 201668.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-20", "CFDA Number": "93.837", "Description": "IRONING OUT MYCOBACTERIAL PERSISTENCE: IRON ACCESS AND UTILIZATION IN CHRONIC MYCOBACTERIAL INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_F30HL151085_7529"}, {"internal_id": 97852503, "Award ID": "F30HL149252", "Award Amount": 75966.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-22", "CFDA Number": "93.837", "Description": "ROLE OF CLEAVED H3 AS A KEY EPIGENETIC REGULATOR OF MACROPHAGES IN IDIOPATHIC PULMONARY FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_F30HL149252_7529"}, {"internal_id": 97470078, "Award ID": "F30HL149151", "Award Amount": 112928.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-06", "CFDA Number": "93.837", "Description": "REGULATION OF T CELL-DERIVED CYTOKINES IN ALLERGIC AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_F30HL149151_7529"}, {"internal_id": 80734479, "Award ID": "F30HL147515", "Award Amount": 30306.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-10", "CFDA Number": "93.838", "Description": "IL-9-SECRETING TISSUE-RESIDENT MEMORY T CELLS IN ALLERGIC AIRWAY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_F30HL147515_7529"}, {"internal_id": 83796058, "Award ID": "F30HL147508", "Award Amount": 57196.72, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-26", "CFDA Number": "93.837", "Description": "PULMONARY FIBROSIS:  NOVEL ROLE FOR DEVELOPMENTAL GENE SIX1 IN ALVEOLAR TYPE II CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_F30HL147508_7529"}, {"internal_id": 83103515, "Award ID": "F30HL147489", "Award Amount": 148823.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-07", "CFDA Number": "93.837", "Description": "THE MITOCHONDRIAL SODIUM/CALCIUM EXCHANGER (NCLX) IN AIRWAY SMOOTH MUSCLE REMODELING DURING ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47ed9961-3300-5ed7-bb62-e5359d99eaf9-C", "generated_internal_id": "ASST_NON_F30HL147489_7529"}, {"internal_id": 95942506, "Award ID": "F30HL147426", "Award Amount": 206002.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-04", "CFDA Number": "93.837", "Description": "PLURIPOTENT STEM CELL-BASED MODELING OF CIGARETTE SMOKE INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F30HL147426_7529"}, {"internal_id": 79433924, "Award ID": "F30HL146174", "Award Amount": 71406.09, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-25", "CFDA Number": "93.837", "Description": "STRUCTURAL ANALYSIS OF SERPINA1 RNA IN A1AT DEFICIENCY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_F30HL146174_7529"}, {"internal_id": 96203803, "Award ID": "F30HL145907", "Award Amount": 40920.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-01", "CFDA Number": "93.837", "Description": "THE FUNCTION OF MHC CLASS II ON LUNG TYPE II ALVEOLAR CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F30HL145907_7529"}, {"internal_id": 83116228, "Award ID": "F30HL145906", "Award Amount": 203324.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-24", "CFDA Number": "93.837", "Description": "AIRWAY SENSORY NERVE CHANGES IN A MOUSE MODEL OF MATERNAL ALLERGEN EXPOSURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_F30HL145906_7529"}, {"internal_id": 80736306, "Award ID": "F30HL143986", "Award Amount": 89507.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-13", "CFDA Number": "93.837", "Description": "INVESTIGATING THE FUNCTION OF A HIGHLY EXPRESSED LNCRNA IN AIRWAY EPITHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68c287e4-398a-6c6b-c0db-5ce9430c6ce3-C", "generated_internal_id": "ASST_NON_F30HL143986_7529"}, {"internal_id": 68565887, "Award ID": "F30HL143911", "Award Amount": 176494.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-03", "CFDA Number": "93.837", "Description": "SOX9 EXPRESSION IDENTIFIES A NOVEL ALVEOLAR STEM CELL POPULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_F30HL143911_7529"}, {"internal_id": 83115977, "Award ID": "F30HL143906", "Award Amount": 103215.04, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-16", "CFDA Number": "93.837", "Description": "REVERSE ENGINEERING THE PULMONARY MICROVASCULATURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_F30HL143906_7529"}, {"internal_id": 68565951, "Award ID": "F30HL143880", "Award Amount": 107283.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-03", "CFDA Number": "93.837", "Description": "REGENERATION OF DISTAL LUNG EPITHELIUM VIA EPITHELIAL-MESENCHYMAL CO-CULTURE AND MODULATION OF WNT SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_F30HL143880_7529"}, {"internal_id": 67580402, "Award ID": "F30HL143879", "Award Amount": 166685.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-26", "CFDA Number": "93.837", "Description": "HIV-INFECTED MACROPHAGES INDUCE ENDOTHELIAL CELL DYSFUNCTION AND METABOLIC REPROGRAMMING TO PROMOTE HIV-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F30HL143879_7529"}, {"internal_id": 65578861, "Award ID": "F30HL142201", "Award Amount": 162169.28, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-19", "CFDA Number": "93.837", "Description": "IDENTIFYING GLI-REGULATED TARGETS DURING TRACHEAL DEVELOPMENT AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_F30HL142201_7529"}, {"internal_id": 66800066, "Award ID": "F30HL142193", "Award Amount": 154254.17, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-07", "CFDA Number": "93.837", "Description": "PLASMALOGEN-DERIVED CHLORINATED LIPIDS: MEDIATORS OF ACUTE LUNG INJURY IN SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b7dfaba3-c263-11dd-cbe2-5abe1968badc-C", "generated_internal_id": "ASST_NON_F30HL142193_7529"}, {"internal_id": 48609247, "Award ID": "F30HL140906", "Award Amount": 147513.09, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-09", "CFDA Number": "93.837", "Description": "ACOUSTIC SYSTEM FOR DIAGNOSIS OF PNEUMONIA AND PNEUMOTHORAX USING TRANSFER FUNCTION ANALYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F30HL140906_7529"}, {"internal_id": 66198942, "Award ID": "F30HL140783", "Award Amount": 125367.7, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-11", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISM OF TMEM16A SURFACE STABILIZATION BY CLCA1", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_F30HL140783_7529"}, {"internal_id": 67833117, "Award ID": "F30HL140756", "Award Amount": 109419.84, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-15", "CFDA Number": "93.837", "Description": "UNRAVELING THE COMPLEXITIES OF COPD: MODELING COPD OUTCOMES AND PHENOTYPE ASSOCIATIONS USING ELECTRONIC HEALTH RECORDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4a536007-27e4-2194-a125-f4b8c55294db-C", "generated_internal_id": "ASST_NON_F30HL140756_7529"}, {"internal_id": 48609246, "Award ID": "F30HL139039", "Award Amount": 321258.29, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-28", "CFDA Number": "93.837", "Description": "MECHANICAL CONTROL OF SMOOTH MUSCLE DIFFERENTIATION DURING MOUSE LUNG BRANCHING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18e10ac5-0c9e-d0fa-8dbc-a56771e0703d-C", "generated_internal_id": "ASST_NON_F30HL139039_7529"}, {"internal_id": 48609245, "Award ID": "F30HL139017", "Award Amount": 199104.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-25", "CFDA Number": "93.837", "Description": "FRATAXIN LOSS INDUCES ENDOTHELIAL DYSFUNCTION TO PROMOTE PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F30HL139017_7529"}, {"internal_id": 62551060, "Award ID": "F30HL137326", "Award Amount": 170726.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-21", "CFDA Number": "93.837", "Description": "ANTISENSE-OLIGONUCLEOTIDE-DIRECTED INHIBITION OF NONSENSE-MEDIATED MRNA DECAY OF CFTR GENE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3313e5e7-fa36-d54b-e36d-0e1e09cc0c30-C", "generated_internal_id": "ASST_NON_F30HL137326_7529"}, {"internal_id": 48609237, "Award ID": "F30HL137309", "Award Amount": 198298.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-14", "CFDA Number": "93.837", "Description": "IRF4+ RESPIRATORY DENDRITIC CELLS IN TYPE 2 INFLAMMATORY RESPONSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_F30HL137309_7529"}, {"internal_id": 48609235, "Award ID": "F30HL137267", "Award Amount": 198549.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-27", "CFDA Number": "93.837", "Description": "HOST-MICROBIOME INTERACTIONS IN SARCOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_F30HL137267_7529"}, {"internal_id": 48609228, "Award ID": "F30HL136195", "Award Amount": 139939.45, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-13", "CFDA Number": "93.837", "Description": "PROTEIN O,O'-DITYROSINE CROSS-LINKING IN LUNG INJURY AND WOUND HEALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_F30HL136195_7529"}, {"internal_id": 48609227, "Award ID": "F30HL136190", "Award Amount": 81402.39, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-17", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF NOVEL ULTRA-SHORT ECHO TIME - MAGNETIC RESONANCE FINGERPRINTING FOR THE ASSESSMENT OF CHRONIC LUNG DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_F30HL136190_7529"}, {"internal_id": 48609225, "Award ID": "F30HL136169", "Award Amount": 120611.31, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-15", "CFDA Number": "93.837", "Description": "ROLE OF TSG-6 MEDIATED HYALURONIC ACID CROSS-LINKING IN ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_F30HL136169_7529"}, {"internal_id": 48609221, "Award ID": "F30HL136001", "Award Amount": 191789.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "PERINATAL ORIGINS OF ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_F30HL136001_7529"}, {"internal_id": 48609220, "Award ID": "F30HL134566", "Award Amount": 118240.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-10", "CFDA Number": "93.837", "Description": "HIV-INDUCED TRANSCRIPTIONAL CHANGES IN ALVEOLAR MACROPHAGES IN SUSCEPTIBILITY TO M. TUBERCULOSIS INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_F30HL134566_7529"}, {"internal_id": 48609214, "Award ID": "F30HL134253", "Award Amount": 137388.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-21", "CFDA Number": "93.837", "Description": "VALIDATING CCL28 AS A TARGET FOR NOVEL ASTHMA THERAPIES USING NMR SPECTROSCOPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_F30HL134253_7529"}, {"internal_id": 48609203, "Award ID": "F30HL132424", "Award Amount": 108240.7, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-16", "CFDA Number": "93.837", "Description": "HEPARAN SULFATE FRAGMENTS AND LUNG REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F30HL132424_7529"}, {"internal_id": 48609202, "Award ID": "F30HL132414", "Award Amount": 197160.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-09", "CFDA Number": "93.838", "Description": "EOSINOPHIL-MEDIATED SENSORY NEUROPLASTICITY IN ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_F30HL132414_7529"}, {"internal_id": 48609195, "Award ID": "F30HL131198", "Award Amount": 66128.0, "Award Type": null, "Base Obligation Date": "2016-08-10", "CFDA Number": "93.838", "Description": "MYELOID CELL REGULATION OF ADULT LUNG ALVEOLOGENESIS POST-PNEUMONECTOMY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F30HL131198_7529"}, {"internal_id": 48609186, "Award ID": "F30HL129656", "Award Amount": 129546.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "TASK-1 MUTATION AS A CAUSE OF PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_F30HL129656_7529"}, {"internal_id": 48609182, "Award ID": "F30HL128034", "Award Amount": 148455.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-01", "CFDA Number": "93.838", "Description": "ROLE OF THE SPHK1/S1P SIGNALING AXIS IN THE PATHOGENESIS OF PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_F30HL128034_7529"}, {"internal_id": 48609176, "Award ID": "F30HL127980", "Award Amount": 88892.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-24", "CFDA Number": "93.838", "Description": "MAPPING QUANTIFICATION OF VENTILATION WITH PROTON MRI: TRANSLATION TO CLINICAL RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_F30HL127980_7529"}, {"internal_id": 48609168, "Award ID": "F30HL126448", "Award Amount": 107467.7, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-04", "CFDA Number": "93.837", "Description": "REGULATION OF CELL PERMEABILITY BY ABL KINASES AND IMPLICATIONS FOR THE TREATING OF ACUTE LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_F30HL126448_7529"}, {"internal_id": 48609167, "Award ID": "F30HL126385", "Award Amount": 122271.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-05", "CFDA Number": "93.838", "Description": "ROLE OF THE PP2A-FOXO1 AXIS IN TREG FUNCTION AND ALLERGIC AIRWAY INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_F30HL126385_7529"}, {"internal_id": 48609165, "Award ID": "F30HL126324", "Award Amount": 128491.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-01", "CFDA Number": "93.837", "Description": "ROLE OF THE MICROBIOME IN REGULATING HOUSE DUST MITE-INDUCED ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68c287e4-398a-6c6b-c0db-5ce9430c6ce3-C", "generated_internal_id": "ASST_NON_F30HL126324_7529"}, {"internal_id": 48609163, "Award ID": "F30HL126280", "Award Amount": 138429.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.838", "Description": "THE INTERSECTION OF SEROTONERGIC AND HEREDITARY PULMONARY ARTERIAL HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4a536007-27e4-2194-a125-f4b8c55294db-C", "generated_internal_id": "ASST_NON_F30HL126280_7529"}, {"internal_id": 48609157, "Award ID": "F30HL123239", "Award Amount": 92718.83, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-01", "CFDA Number": "93.837", "Description": "MECHANISMS CONTROLLING AIRWAY SURFACE LIQUID PH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_F30HL123239_7529"}, {"internal_id": 48609154, "Award ID": "F30HL123109", "Award Amount": 86230.12, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-09", "CFDA Number": "93.837", "Description": "THE ROLE OF ADAPTIVE IMMUNITY IN CHRONIC HYPOXIA-INDUCED PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a5b5888e-f4b5-655c-bd88-d970f969d7c9-C", "generated_internal_id": "ASST_NON_F30HL123109_7529"}, {"internal_id": 48609150, "Award ID": "F30HL122065", "Award Amount": 176198.77, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-02", "CFDA Number": "93.837", "Description": "MECHANOTRANSDUCTORY REGULATION OF TRANSCRIPTION FACTOR ACTIVITY IN FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F30HL122065_7529"}, {"internal_id": 48609142, "Award ID": "F30HL120496", "Award Amount": 82996.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-09", "CFDA Number": "93.838", "Description": "CAPSULAR-INDEPENDENT INHIBITION OF PHAGOCYTOSIS BY CRYPTOCOCCUS NEOFORMANS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_F30HL120496_7529"}, {"internal_id": 48609135, "Award ID": "F30HL118954", "Award Amount": 115300.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-05", "CFDA Number": "93.837", "Description": "THE ROLE OF CXCR6 IN LUNG AIRWAY MEMORY T CELL RECRUITMENT AND MAINTENANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F30HL118954_7529"}, {"internal_id": 85588316, "Award ID": "DP2HL152427", "Award Amount": 2640000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-09", "CFDA Number": "93.838", "Description": "IN UTERO CRISPR-MEDIATED GENE EDITING TO CURE CONGENITAL MONOGENIC DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_DP2HL152427_7529"}, {"internal_id": 48539807, "Award ID": "DP2HL127720", "Award Amount": 2396405.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-20", "CFDA Number": "93.838", "Description": "PROBING THE PHYSICS OF CHRONIC LUNG DISEASE USING MICROPHYSIOLOGICAL BIOMIMICRY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_DP2HL127720_7529"}, {"internal_id": 48539806, "Award ID": "DP2HL123229", "Award Amount": 2256070.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-09-25", "CFDA Number": "93.838", "Description": "INDUCIBLE EPITHELIAL ANTIVIRAL RESISTANCE TO PREVENT ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_DP2HL123229_7529"}, {"internal_id": 138797201, "Award ID": "OT2HL158287", "Award Amount": 137854100.0, "Award Type": "DIRECT PAYMENT FOR SPECIFIED USE, AS A SUBSIDY OR OTHER NON-REIMBURSABLE DIRECT FINANCIAL AID (C)", "Base Obligation Date": "2021-07-30", "CFDA Number": "93.838", "Description": "NHLBI MATERNAL MORBIDITY AND MORTALITY (3M) ADMINISTRATIVE COORDINATING CENTER - OVER THE PAST THREE DECADES, THERE HAVE BEEN ALARMING UPWARD TRENDS IN THE RATES OF MATERNAL MORBIDITY AND MORTALITY IN THE UNITED STATES. OVERALL, THE IDENTIFIED CLINICAL CAUSES OF MATERNAL DEATH ARE: CARDIOVASCULAR CONDITIONS (14%), HEMORRHAGE (13%), INFECTION (11%) EMBOLISM (10%), CARDIOMYOPATHY (95), MENTAL HEALTH CONDITIONS (9%) AND PREECLAMPSIA/ECLAMPSIA (8%) BUT THESE CONDITIONS VARY BY RACE/ETHNICITY. FOR BLACK, NON-HISPANIC WOMEN, THE TWO LEADING CAUSES OF DEATH WERE CARDIOMYOPATHY AND CARDIOVASCULAR CONDITIONS, AND MENTAL CONDITIONS WAS THE LEADING CAUSE AMONG WHITE, NON-HISPANIC WOMEN.1 OBESITY, HYPERTENSION, SMOKING, OPIOID USE AND SLEEP DISORDERS ARE ALSO CONDITIONS AND BEHAVIORS THAT HAVE BEEN FOUND TO BE ASSOCIATED WITH MATERNAL MORBIDITY SUCH AS HEMORRHAGE, PREECLAMPSIA AND CARDIOMYOPATHY. THESE COULD POTENTIALLY BE ADDRESSED IN PRIMARY CARE BEFORE AND BETWEEN PREGNANCIES.2-6 THE NATIONAL HEART, LUNG BLOOD INSTITUTE (NHLBI) IS PARTICIPATING IN A TRANS-NATIONAL INSTITUTES OF HEALTH (NIH) EFFORT TO IMPROVE WOMEN\u2019S HEALTH, PARTICULARLY MATERNAL MORBIDITY AND MORTALITY. A PLAN \u2013 ADVANCING SCIENCE FOR THE HEALTH OF WOMEN, THE TRANS-NIH STRATEGIC PLAN FOR WOMEN\u2019S HEALTH RESEARCH \u2013 WAS DEVELOPED FOR THE PERIOD 2019 \u2013 2023. THIS PLAN PROVIDES A FRAMEWORK THAT RECOGNIZES THE COMPLEX INTERACTIONS OF MULTIPLE FACTORS THAT AFFECT WOMEN\u2019S HEALTH ACROSS THE LIFE COURSE, INCLUDING PREGNANCY. LIFE COURSE THEORY POSITS THAT HEALTH DEVELOPMENT BEGINS BEFORE CONCEPTION AND CONTINUES ACROSS THE LIFE SPAN. IT SUGGESTS THAT A COMPLEX PLAY OF BIOLOGIC, BEHAVIORAL, PSYCHOLOGICAL, AND SOCIAL PROTECTIVE AND RISK FACTORS CONTRIBUTE TO HEALTH OUTCOMES, AND THAT HEALTH STATUS REFLECTS THE CUMULATIVE LIFETIME EXPOSURE TO THESE FACTORS. THE GUIDING PRINCIPLES FOR THIS PLAN ARE CONSIDERATION OF THE COMPLEX FACTORS AFFECTING WOMEN\u2019S HEALTH, THE INCLUSION OF DIVERSE POPULATIONS THAT ARE DISPROPORTIONATELY AFFECTED BY MORBIDITY AND MORTALITY, AND ACTIVE ENGAGEMENT OF A DIVERSE GROUP OF SCIENTISTS.7 THE NIH APPROACH TO REDUCING MATERNAL MORBIDITY AND MORTALITY WILL AIM TO ENHANCE HEALTH DISPARITIES RESEARCH, INCREASE THE UNDERSTANDING OF SOCIAL DETERMINANTS AND OTHER RISK FACTORS (INCLUDING ENVIRONMENTAL RISK FACTORS), IMPROVE CARE (ANTEPARTUM, INTRAPARTUM AND POSTPARTUM) AND MANAGEMENT, PROVIDE INSIGHT TO PSYCHOLOGICAL EXPOSURES SUCH AS STRESS, DISCRIMINATION AND CAREGIVING, UNDERSTAND COPING BEHAVIORS IN FAMILIES AFFECTED BY MATERNAL MORBIDITY OR MORTALITY, AND INVESTIGATE THE ROLE OF IMPLICIT BIAS IN THE HEALTH CARE SYSTEMS REGARDING PREGNANCY.8 WITHIN NHLBI, MATERNAL AND WOMEN\u2019S HEALTH PRIORITIES SPAN ALL OF THE OBJECTIVES OF THE NHLBI STRATEGIC VISION, AND NHLBI HAS SUPPORTED A NUMBER OF MATERNAL HEALTH PROGRAMS LOOKING AT HYPERTENSION, SLEEP DISORDERS, AND OTHER PREGNANCY COMPLICATIONS INCLUDING PRE-ECLAMPSIA, ECLAMPSIA, AND GESTATIONAL DIABETES. THE GOAL OF THE NHLBI 3M ADMINISTRATIVE COORDINATING CENTER (3M ACC) IS TO ENGAGE COMMUNITIES AND NETWORKS IN AREAS THAT EXPERIENCE HIGH LEVELS OF MATERNAL MORBIDITY AND MORTALITY. THE 3M ACC WILL SUPPORT THE PRELIMINARY WORK NECESSARY TO IDENTIFY AND PREPARE A GROUP OF COMMUNITY-BASED ORGANIZATIONS TO RESPOND TO FUTURE FUNDING OPPORTUNITIES. THE 3M ACC WILL DEVELOP THE INFRASTRUCTURE TO SUPPORT THIS GROUP OF MATERNAL MORBIDITY AND MORTALITY REGIONAL COALITIONS (3M RCS) AND PROVIDE SCIENTIFIC SUPPORT AND COORDINATION TO NHLBI ON EMERGING SCIENTIFIC NEEDS. SPECIFICALLY, THE 3M ACC WILL SUPPORT THESE PROGRAMMATIC OBJECTIVES: - IDENTIFY RESEARCH GROUPS AND ORGANIZATIONS WITH EXISTING AND RELEVANT EXPERTISE AND COMMUNITY PARTNERSHIPS. - CONDUCT LANDSCAPE ANALYSES AND COMMUNITY-INFORMED NEEDS ASSESSMENTS. - IDENTIFY WITHIN EACH COMMUNITY IMPLEMENTATION OPPORTUNITIES AND BARRIERS TO IMPROVE DELIVERY OF EVIDENCE-BASED CARE TO REDUCE MATERNAL MORBIDITY AND MORTALITY. - DEVELOP AND CONDUCT EARLY-STAGE TESTS OF I", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": 81202492.0, "Infrastructure Obligations": null, "recipient_id": "1a05eb77-da74-5790-7cc1-11f261fd252e-C", "generated_internal_id": "ASST_NON_OT2HL158287_7529"}, {"internal_id": 149208845, "Award ID": "OT2HL156812", "Award Amount": 502419404.0, "Award Type": "DIRECT PAYMENT FOR SPECIFIED USE, AS A SUBSIDY OR OTHER NON-REIMBURSABLE DIRECT FINANCIAL AID (C)", "Base Obligation Date": "2021-10-14", "CFDA Number": "93.855", "Description": "ACTIV INTEGRATION OF HOST-TARGETING THERAPIES FOR COVID-19 ADMINISTRATIVE COORDINATING CENTER - RTI INTERNATIONAL IS PLEASED TO PROVIDE THIS APPLICATION AS REQUESTED BY THE RESEARCH OPPORTUNITIES ANNOUNCEMENT OTA-20-011 ACTIV INTEGRATION OF HOST-TARGETING THERAPIES FOR COVID-19 FOR THE ROLE OF ADMINISTRATIVE COORDINATING CENTER (ACC). THE TITLE OF OUR APPLICATION IS ACTIV INTEGRATION OF HOST-TARGETING THERAPIES FOR COVID-19 ADMINISTRATIVE COORDINATING CENTER. THE INTEGRATION OF HOST-TARGETING THERAPIES FOR COVID-19 PROGRAM AIMS TO IDENTIFY COVID-19 INTERVENTIONS RELEVANT TO HEART, LUNG, BLOOD, AND CARDIOVASCULAR OUTCOMES THAT CONTRIBUTE TO THE SCIENTIFIC KNOWLEDGE BASE ARE LIKELY TO INFORM CLINICAL PRACTICE. THIS PROGRAM WILL RAPIDLY AND EFFICIENTLY CONDUCT ADAPTIVE PLATFORM TRIALS VIA A COORDINATED EFFORT OF DATA COORDINATING CENTERS AND CLINICAL SITES FROM EXISTING CLINICAL STUDY NETWORKS. THE ACC IS A CRITICAL COMPONENT OF THE PROGRAM. WE WILL COORDINATE WITH NHLBI TO ENSURE COLLABORATION AMONG NETWORKS INCLUDING THE USE OF STANDARDIZED APPROACHES IN CLINICAL TRIAL DESIGN AND CONDUCT, DATA COLLECTION AND VALIDATION, AND STATISTICAL ANALYSIS SUCH THAT STUDIES ARE LAUNCHED, IMPLEMENTED AND ANALYZED SWIFTLY; AND STUDY FINDINGS ARE SCIENTIFICALLY SOUND AND MEET REGULATORY NEEDS FOR MEDICAL THERAPY DEVELOPMENT. AS THE ACC, WE WILL ALSO SERVE THE VITAL ROLE OF FACILITATING COMMUNICATION AND INFORMATION SHARING AMONG ALL RELEVANT STAKE HOLDERS AND HELPING NHLBI IN TRACKING STUDY-SPECIFIC AND PROGRAM-WIDE MILESTONES. SONIA THOMAS, DRPH, WILL LEAD THE ACC AS PRINCIPAL INVESTIGATOR. SHE IS AN EXPERIENCED CC PI AND STATISTICIAN WITH 25 YEARS OF EXPERIENCE IN THE DESIGN, IMPLEMENTATION, AND ANALYSIS OF MULTICENTER NIHAND INDUSTRY-SPONSORED PHASE 2-4 CLINICAL TRIALS OF DRUGS, BIOLOGICS, DEVICES, SURGICAL AND BEHAVIORAL INTERVENTIONS IN MORE THAN A DOZEN THERAPEUTIC INDICATIONS. DR. THOMAS WILL BE SUPPORTED BY TRACY NOLEN, DRPH AS ALTERNATE PI, AN EXPERIENCED CONSORTIUM AND CC PI AND CLINICAL TRIAL STATISTICIAN, AND SUBJECT MATTER EXPERTS STEVE NISSEN, MD, CLEVELAND CLINICAL CHIEF ACADEMIC OFFICER, HEART AND VASCULAR INSTITUTE, SHANNON CARSON, MD, UNIV. OF NORTH CAROLINA CHIEF OF PULMONARY AND CRITICAL CARE MEDICINE, AND ANASTASIA IVANOVA, PHD, UNIV. OF NORTH CAROLINA PROFESSOR OF BIOSTATISTICS UNDER DR THOMAS\u2019S DIRECTION, OUR TEAM WILL LEAD, SUPPORT, AND COLLABORATE WITH PROGRAM NETWORKS THROUGH ORGANIZATION INTO 6 ACC CORES: PROGRAM OPERATIONS, SCIENTIFIC LEADERSHIP AND PRIORITIZATION, INFORMATICS, DATA STANDARDS, STUDY DESIGN, IMPLEMENTATION, & ANALYSIS, AND REGULATORY AND QA. WE HAVE IDENTIFIED MILESTONES FOR THE ESSENTIAL ACTIVITIES OF THE ACC WITHIN EACH OF THESE 6 CORES WITH A DETAILED FOCUS ON THE ACTIVITIES IN THE FIRST 6 MONTHS AS ACTIVITIES COMPLETED DURING THIS TIME ARE MOST IMPORTANT FOR ENSURING THE COORDINATED, EXPEDITED AND EFFICIENT LAUNCH OF THIS PROGRAM. DR. THOMAS, OUR SUBJECT MATTER EXPERTS, SENIOR STATISTICAL SCIENTISTS, AND MANY OF THE CORE LEADS HAVE SUBSTANTIAL EXPERIENCE WITH NHLBI AND THUS UNDERSTAND THE NEEDS AND PRIORITIES OF THE INSTITUTE AND WILL USE THIS KNOWLEDGE TO BETTER COLLABORATE WITH NHLBI AND FURTHER SPEED UP THE LAUNCH OF THIS PROGRAM. WE ARE WILLING TO COLLABORATE WITH ALL INVOLVED ENTITIES AS PART OF THE OVERARCHING TRANS-NIH ACTIV PROGRAM AS IT EVOLVES. WE RECOGNIZE AND ANTICIPATE THAT SWIFT ADAPTATION WILL BE REQUIRED TO RAPIDLY RESPOND TO THE URGENT CLINICAL RESEARCH NEEDS TO ADDRESS THE COVID-19 PANDEMIC. RTI IS UNIQUELY AND SUBSTANTIALLY QUALIFIED FOR THE ACC. WE WILL USE OUR TEAM\u2019S BROAD EXPERIENCE FROM MANY COMPLEX COORDINATING CENTER PROJECTS TO ANTICIPATE THE NEEDS FOR THIS PROGRAM AND \u201cHIT THE GROUND RUNNING\u201d. PROVEN INFORMATICS TECHNOLOGY IN USE BY EXISTING NIH PROGRAMS WILL BE SWIFTLY MODIFIED BY OUR ANALYSTS FOR SPEEDY DEPLOYMENT OF COMMUNICATIONS PLATFORMS. OUR ORGANIZATIONAL SIZE AND FLEXIBILITY WILL ALLOW US TO RAMP UP QUICKLY AND MODIFY PERSONNEL RESOURCES FLEXIBLY. LASTLY, RTI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": 510282783.0, "Infrastructure Obligations": null, "recipient_id": "8303ed9b-9fb4-3e90-ca81-50bbcf400948-C", "generated_internal_id": "ASST_NON_OT2HL156812_7529"}]